<?xml version="1.0" encoding="utf-8"?>
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2021q4" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31" xmlns:us-roles="http://fasb.org/us-roles/2021-01-31" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:country="http://xbrl.sec.gov/country/2021" xmlns:srt="http://fasb.org/srt/2021-01-31" xmlns:AMIH="http://americanii.com/20211231">
<head>
     <title></title>
<meta http-equiv="Content-Type" content="text/html" />
</head>
<!-- Field: Set; Name: xdx; ID: xdx_02A_US%2DGAAP%2D2021 -->
<!-- Field: Set; Name: xdx; ID: xdx_03D_AMIH_americanii.com_20211231 -->
<!-- Field: Set; Name: xdx; ID: xdx_046_20210101_20211231 -->
<!-- Field: Set; Name: xdx; ID: xdx_05D_edei%2D%2DEntityCentralIndexKey_0001300524 -->
<!-- Field: Set; Name: xdx; ID: xdx_059_edei%2D%2DAmendmentFlag_false -->
<!-- Field: Set; Name: xdx; ID: xdx_06B_USD_1_iso4217%2D%2DUSD -->
<!-- Field: Set; Name: xdx; ID: xdx_062_Shares_2_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_06D_USDPShares_3_iso4217%2D%2DUSD_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_069_Pure_4_xbrli%2D%2Dpure -->
<!-- Field: Set; Name: xdx; ID: xdx_061_Integer_0_Integer -->
<body style="font: 10pt Times New Roman, Times, Serif">
<div style="display: none">
<ix:header>
 <ix:hidden>
  <ix:nonNumeric contextRef="From2021-01-01to2021-12-31" name="dei:EntityCentralIndexKey">0001300524</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2021-01-01to2021-12-31" format="ixt:booleanfalse" name="dei:AmendmentFlag">false</ix:nonNumeric>
  <ix:nonFraction name="us-gaap:InventoryNet" contextRef="AsOf2020-12-31" id="xdx2ixbrl0043" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:PrepaidExpenseCurrent" contextRef="AsOf2021-12-31" id="xdx2ixbrl0045" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent" contextRef="AsOf2021-12-31" id="xdx2ixbrl0048" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ConvertibleLongTermNotesPayable" contextRef="AsOf2021-12-31" id="xdx2ixbrl0109" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:DueToRelatedPartiesNoncurrent" contextRef="AsOf2021-12-31" id="xdx2ixbrl0116" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:LiabilitiesNoncurrent" contextRef="AsOf2021-12-31" id="xdx2ixbrl0119" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:PreferredStockValue" contextRef="AsOf2021-12-31" id="xdx2ixbrl0128" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:PreferredStockValue" contextRef="AsOf2020-12-31" id="xdx2ixbrl0129" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:CostOfRevenue" contextRef="From2020-01-012020-12-31" id="xdx2ixbrl0182" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="AMIH:ForgivenessOfLoan" contextRef="From2020-01-012020-12-31" id="xdx2ixbrl0209" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="AMIH:ImpairmentLoss" contextRef="From2021-01-01to2021-12-31" id="xdx2ixbrl0211" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:OtherNonoperatingIncome" contextRef="From2021-01-01to2021-12-31" id="xdx2ixbrl0220" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="From2021-01-01to2021-12-31" id="xdx2ixbrl0229" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="From2020-01-012020-12-31" id="xdx2ixbrl0230" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2019-12-31_us-gaap_SeriesAPreferredStockMember_us-gaap_PreferredStockMember" id="xdx2ixbrl0274" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2019-12-31_us-gaap_SeriesBPreferredStockMember_us-gaap_PreferredStockMember" id="xdx2ixbrl0275" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2019-12-31_us-gaap_SeriesAPreferredStockMember_us-gaap_PreferredStockMember" id="xdx2ixbrl0283" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2019-12-31_us-gaap_SeriesBPreferredStockMember_us-gaap_PreferredStockMember" id="xdx2ixbrl0285" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalOther" contextRef="From2020-01-012020-12-31_us-gaap_SeriesAPreferredStockMember_us-gaap_PreferredStockMember" id="xdx2ixbrl0289" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalOther" contextRef="From2020-01-012020-12-31_us-gaap_SeriesBPreferredStockMember_us-gaap_PreferredStockMember" id="xdx2ixbrl0290" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalOther" contextRef="From2020-01-012020-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0291" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalOther" contextRef="From2020-01-012020-12-31_custom_CommonStockPayableMember" id="xdx2ixbrl0293" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalOther" contextRef="From2020-01-012020-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0294" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalOther" contextRef="From2020-01-012020-12-31_us-gaap_TreasuryStockMember" id="xdx2ixbrl0295" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature" contextRef="From2020-01-012020-12-31_us-gaap_SeriesAPreferredStockMember_us-gaap_PreferredStockMember" id="xdx2ixbrl0298" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature" contextRef="From2020-01-012020-12-31_us-gaap_SeriesBPreferredStockMember_us-gaap_PreferredStockMember" id="xdx2ixbrl0299" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature" contextRef="From2020-01-012020-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0300" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature" contextRef="From2020-01-012020-12-31_custom_CommonStockPayableMember" id="xdx2ixbrl0302" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature" contextRef="From2020-01-012020-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0303" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature" contextRef="From2020-01-012020-12-31_us-gaap_TreasuryStockMember" id="xdx2ixbrl0304" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="AMIH:IssuanceOfPreferredStockForInvestmentValue" contextRef="From2020-01-012020-12-31_us-gaap_SeriesAPreferredStockMember_us-gaap_PreferredStockMember" id="xdx2ixbrl0307" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="AMIH:IssuanceOfPreferredStockForInvestmentValue" contextRef="From2020-01-012020-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0309" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="AMIH:IssuanceOfPreferredStockForInvestmentValue" contextRef="From2020-01-012020-12-31_custom_CommonStockPayableMember" id="xdx2ixbrl0311" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="AMIH:IssuanceOfPreferredStockForInvestmentValue" contextRef="From2020-01-012020-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0312" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="AMIH:IssuanceOfPreferredStockForInvestmentValue" contextRef="From2020-01-012020-12-31_us-gaap_TreasuryStockMember" id="xdx2ixbrl0313" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2020-01-012020-12-31_us-gaap_SeriesAPreferredStockMember_us-gaap_PreferredStockMember" id="xdx2ixbrl0318" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2020-01-012020-12-31_us-gaap_SeriesBPreferredStockMember_us-gaap_PreferredStockMember" id="xdx2ixbrl0319" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2020-01-012020-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0323" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2020-01-012020-12-31_us-gaap_TreasuryStockMember" id="xdx2ixbrl0324" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockRepurchasedDuringPeriodValue" contextRef="From2020-01-012020-12-31_us-gaap_SeriesAPreferredStockMember_us-gaap_PreferredStockMember" id="xdx2ixbrl0329" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockRepurchasedDuringPeriodValue" contextRef="From2020-01-012020-12-31_us-gaap_SeriesBPreferredStockMember_us-gaap_PreferredStockMember" id="xdx2ixbrl0330" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockRepurchasedDuringPeriodValue" contextRef="From2020-01-012020-12-31_custom_CommonStockPayableMember" id="xdx2ixbrl0333" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockRepurchasedDuringPeriodValue" contextRef="From2020-01-012020-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0334" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockRepurchasedDuringPeriodValue" contextRef="From2020-01-012020-12-31" id="xdx2ixbrl0336" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="AMIH:StockIssuedDuringPeriodValueIssuanceOfCommonSharesForNoteSettlement" contextRef="From2020-01-012020-12-31_us-gaap_SeriesAPreferredStockMember_us-gaap_PreferredStockMember" id="xdx2ixbrl0340" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="AMIH:StockIssuedDuringPeriodValueIssuanceOfCommonSharesForNoteSettlement" contextRef="From2020-01-012020-12-31_us-gaap_SeriesBPreferredStockMember_us-gaap_PreferredStockMember" id="xdx2ixbrl0341" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="AMIH:StockIssuedDuringPeriodValueIssuanceOfCommonSharesForNoteSettlement" contextRef="From2020-01-012020-12-31_custom_CommonStockPayableMember" id="xdx2ixbrl0344" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="AMIH:StockIssuedDuringPeriodValueIssuanceOfCommonSharesForNoteSettlement" contextRef="From2020-01-012020-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0345" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="AMIH:StockIssuedDuringPeriodValueIssuanceOfCommonSharesForNoteSettlement" contextRef="From2020-01-012020-12-31_us-gaap_TreasuryStockMember" id="xdx2ixbrl0346" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="AMIH:IssuanceOfSharesForServicesRelatedParties" contextRef="From2020-01-012020-12-31_us-gaap_SeriesAPreferredStockMember_us-gaap_PreferredStockMember" id="xdx2ixbrl0351" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="AMIH:IssuanceOfSharesForServicesRelatedParties" contextRef="From2020-01-012020-12-31_us-gaap_SeriesBPreferredStockMember_us-gaap_PreferredStockMember" id="xdx2ixbrl0352" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="AMIH:IssuanceOfSharesForServicesRelatedParties" contextRef="From2020-01-012020-12-31_custom_CommonStockPayableMember" id="xdx2ixbrl0355" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="AMIH:IssuanceOfSharesForServicesRelatedParties" contextRef="From2020-01-012020-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0356" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="AMIH:IssuanceOfSharesForServicesRelatedParties" contextRef="From2020-01-012020-12-31_us-gaap_TreasuryStockMember" id="xdx2ixbrl0357" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" contextRef="From2020-01-012020-12-31_us-gaap_SeriesAPreferredStockMember_us-gaap_PreferredStockMember" id="xdx2ixbrl0364" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" contextRef="From2020-01-012020-12-31_us-gaap_SeriesBPreferredStockMember_us-gaap_PreferredStockMember" id="xdx2ixbrl0365" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" contextRef="From2020-01-012020-12-31_custom_CommonStockPayableMember" id="xdx2ixbrl0368" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" contextRef="From2020-01-012020-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0369" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" contextRef="From2020-01-012020-12-31_us-gaap_TreasuryStockMember" id="xdx2ixbrl0370" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="AMIH:IssuanceOfCommonSharesForSeriesBPreferredSharesConversion" contextRef="From2020-01-012020-12-31_us-gaap_SeriesAPreferredStockMember_us-gaap_PreferredStockMember" id="xdx2ixbrl0375" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="AMIH:IssuanceOfCommonSharesForSeriesBPreferredSharesConversion" contextRef="From2020-01-012020-12-31_custom_CommonStockPayableMember" id="xdx2ixbrl0379" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="AMIH:IssuanceOfCommonSharesForSeriesBPreferredSharesConversion" contextRef="From2020-01-012020-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0380" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="AMIH:IssuanceOfCommonSharesForSeriesBPreferredSharesConversion" contextRef="From2020-01-012020-12-31_us-gaap_TreasuryStockMember" id="xdx2ixbrl0381" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2020-01-012020-12-31_us-gaap_SeriesAPreferredStockMember_us-gaap_PreferredStockMember" id="xdx2ixbrl0388" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2020-01-012020-12-31_us-gaap_SeriesBPreferredStockMember_us-gaap_PreferredStockMember" id="xdx2ixbrl0389" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2020-01-012020-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0390" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2020-01-012020-12-31_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0391" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2020-01-012020-12-31_custom_CommonStockPayableMember" id="xdx2ixbrl0392" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2020-01-012020-12-31_us-gaap_TreasuryStockMember" id="xdx2ixbrl0394" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2020-12-31_us-gaap_SeriesAPreferredStockMember_us-gaap_PreferredStockMember" id="xdx2ixbrl0397" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2020-12-31_us-gaap_SeriesBPreferredStockMember_us-gaap_PreferredStockMember" id="xdx2ixbrl0398" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2020-12-31_custom_CommonStockPayableMember" id="xdx2ixbrl0401" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2020-12-31_us-gaap_SeriesBPreferredStockMember_us-gaap_PreferredStockMember" id="xdx2ixbrl0408" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2020-12-31_us-gaap_SeriesAPreferredStockMember_us-gaap_PreferredStockMember" id="xdx2ixbrl0412" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2020-12-31_us-gaap_SeriesBPreferredStockMember_us-gaap_PreferredStockMember" id="xdx2ixbrl0413" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2020-12-31_custom_CommonStockPayableMember" id="xdx2ixbrl0416" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2020-12-31_us-gaap_SeriesBPreferredStockMember_us-gaap_PreferredStockMember" id="xdx2ixbrl0423" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2020-12-31_us-gaap_SeriesAPreferredStockMember_us-gaap_PreferredStockMember" id="xdx2ixbrl0427" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2020-12-31_us-gaap_SeriesBPreferredStockMember_us-gaap_PreferredStockMember" id="xdx2ixbrl0428" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2020-12-31_custom_CommonStockPayableMember" id="xdx2ixbrl0431" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2020-12-31_us-gaap_SeriesBPreferredStockMember_us-gaap_PreferredStockMember" id="xdx2ixbrl0438" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalOther" contextRef="From2021-01-012021-12-31_us-gaap_SeriesAPreferredStockMember_us-gaap_PreferredStockMember" id="xdx2ixbrl0442" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalOther" contextRef="From2021-01-012021-12-31_us-gaap_SeriesBPreferredStockMember_us-gaap_PreferredStockMember" id="xdx2ixbrl0443" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalOther" contextRef="From2021-01-012021-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0444" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalOther" contextRef="From2021-01-012021-12-31_custom_CommonStockPayableMember" id="xdx2ixbrl0446" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalOther" contextRef="From2021-01-012021-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0447" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalOther" contextRef="From2021-01-012021-12-31_us-gaap_TreasuryStockMember" id="xdx2ixbrl0448" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature" contextRef="From2021-01-012021-12-31_us-gaap_SeriesAPreferredStockMember_us-gaap_PreferredStockMember" id="xdx2ixbrl0451" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature" contextRef="From2021-01-012021-12-31_us-gaap_SeriesBPreferredStockMember_us-gaap_PreferredStockMember" id="xdx2ixbrl0452" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature" contextRef="From2021-01-012021-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0453" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature" contextRef="From2021-01-012021-12-31_custom_CommonStockPayableMember" id="xdx2ixbrl0455" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature" contextRef="From2021-01-012021-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0456" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature" contextRef="From2021-01-012021-12-31_us-gaap_TreasuryStockMember" id="xdx2ixbrl0457" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="AMIH:StockIssuedDuringPeriodValueNewIssuesOne" contextRef="From2021-01-012021-12-31_us-gaap_SeriesAPreferredStockMember_us-gaap_PreferredStockMember" id="xdx2ixbrl0460" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="AMIH:StockIssuedDuringPeriodValueNewIssuesOne" contextRef="From2021-01-012021-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0462" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="AMIH:StockIssuedDuringPeriodValueNewIssuesOne" contextRef="From2021-01-012021-12-31_custom_CommonStockPayableMember" id="xdx2ixbrl0464" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="AMIH:StockIssuedDuringPeriodValueNewIssuesOne" contextRef="From2021-01-012021-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0465" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="AMIH:StockIssuedDuringPeriodValueNewIssuesOne" contextRef="From2021-01-012021-12-31_us-gaap_TreasuryStockMember" id="xdx2ixbrl0466" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="AMIH:StockIssuedDuringPeriodValuePreferredShareConversion" contextRef="From2021-01-012021-12-31_us-gaap_SeriesAPreferredStockMember_us-gaap_PreferredStockMember" id="xdx2ixbrl0471" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="AMIH:StockIssuedDuringPeriodValuePreferredShareConversion" contextRef="From2021-01-012021-12-31_custom_CommonStockPayableMember" id="xdx2ixbrl0475" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="AMIH:StockIssuedDuringPeriodValuePreferredShareConversion" contextRef="From2021-01-012021-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0476" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="AMIH:StockIssuedDuringPeriodValuePreferredShareConversion" contextRef="From2021-01-012021-12-31_us-gaap_TreasuryStockMember" id="xdx2ixbrl0477" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="AMIH:StockIssuedDuringPeriodValuePreferredShareConversion" contextRef="From2021-01-01to2021-12-31" id="xdx2ixbrl0478" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2021-01-012021-12-31_us-gaap_SeriesAPreferredStockMember_us-gaap_PreferredStockMember" id="xdx2ixbrl0484" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2021-01-012021-12-31_us-gaap_SeriesBPreferredStockMember_us-gaap_PreferredStockMember" id="xdx2ixbrl0485" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2021-01-012021-12-31_custom_CommonStockPayableMember" id="xdx2ixbrl0488" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2021-01-012021-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0489" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2021-01-012021-12-31_us-gaap_TreasuryStockMember" id="xdx2ixbrl0490" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" contextRef="From2021-01-012021-12-31_us-gaap_SeriesAPreferredStockMember_us-gaap_PreferredStockMember" id="xdx2ixbrl0495" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" contextRef="From2021-01-012021-12-31_us-gaap_SeriesBPreferredStockMember_us-gaap_PreferredStockMember" id="xdx2ixbrl0496" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" contextRef="From2021-01-012021-12-31_custom_CommonStockPayableMember" id="xdx2ixbrl0499" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" contextRef="From2021-01-012021-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0500" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" contextRef="From2021-01-012021-12-31_us-gaap_TreasuryStockMember" id="xdx2ixbrl0501" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="AMIH:IssuanceOfSharesForServicesRelatedParties" contextRef="From2021-01-012021-12-31_us-gaap_SeriesAPreferredStockMember_us-gaap_PreferredStockMember" id="xdx2ixbrl0506" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="AMIH:IssuanceOfSharesForServicesRelatedParties" contextRef="From2021-01-012021-12-31_us-gaap_SeriesBPreferredStockMember_us-gaap_PreferredStockMember" id="xdx2ixbrl0507" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="AMIH:IssuanceOfSharesForServicesRelatedParties" contextRef="From2021-01-012021-12-31_custom_CommonStockPayableMember" id="xdx2ixbrl0510" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="AMIH:IssuanceOfSharesForServicesRelatedParties" contextRef="From2021-01-012021-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0511" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="AMIH:IssuanceOfSharesForServicesRelatedParties" contextRef="From2021-01-012021-12-31_us-gaap_TreasuryStockMember" id="xdx2ixbrl0512" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" contextRef="From2021-01-012021-12-31_us-gaap_SeriesAPreferredStockMember_us-gaap_PreferredStockMember" id="xdx2ixbrl0517" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" contextRef="From2021-01-012021-12-31_us-gaap_SeriesBPreferredStockMember_us-gaap_PreferredStockMember" id="xdx2ixbrl0518" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" contextRef="From2021-01-012021-12-31_custom_CommonStockPayableMember" id="xdx2ixbrl0521" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" contextRef="From2021-01-012021-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0522" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" contextRef="From2021-01-012021-12-31_us-gaap_TreasuryStockMember" id="xdx2ixbrl0523" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="AMIH:IssuanceOfCommonSharesForDebtSettlement" contextRef="From2021-01-012021-12-31_us-gaap_SeriesAPreferredStockMember_us-gaap_PreferredStockMember" id="xdx2ixbrl0528" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="AMIH:IssuanceOfCommonSharesForDebtSettlement" contextRef="From2021-01-012021-12-31_us-gaap_SeriesBPreferredStockMember_us-gaap_PreferredStockMember" id="xdx2ixbrl0529" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="AMIH:IssuanceOfCommonSharesForDebtSettlement" contextRef="From2021-01-012021-12-31_custom_CommonStockPayableMember" id="xdx2ixbrl0532" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="AMIH:IssuanceOfCommonSharesForDebtSettlement" contextRef="From2021-01-012021-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0533" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="AMIH:IssuanceOfCommonSharesForDebtSettlement" contextRef="From2021-01-012021-12-31_us-gaap_TreasuryStockMember" id="xdx2ixbrl0534" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2021-01-012021-12-31_us-gaap_SeriesAPreferredStockMember_us-gaap_PreferredStockMember" id="xdx2ixbrl0539" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2021-01-012021-12-31_us-gaap_SeriesBPreferredStockMember_us-gaap_PreferredStockMember" id="xdx2ixbrl0540" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2021-01-012021-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0541" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2021-01-012021-12-31_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0542" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2021-01-012021-12-31_custom_CommonStockPayableMember" id="xdx2ixbrl0543" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2021-01-012021-12-31_us-gaap_TreasuryStockMember" id="xdx2ixbrl0545" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2021-01-012021-12-31_us-gaap_SeriesAPreferredStockMember_us-gaap_PreferredStockMember" id="xdx2ixbrl0548" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2021-01-012021-12-31_us-gaap_SeriesBPreferredStockMember_us-gaap_PreferredStockMember" id="xdx2ixbrl0549" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2021-01-012021-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0550" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2021-01-012021-12-31_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0551" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2021-01-012021-12-31_custom_CommonStockPayableMember" id="xdx2ixbrl0552" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2021-01-012021-12-31_us-gaap_TreasuryStockMember" id="xdx2ixbrl0554" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-12-31_us-gaap_SeriesAPreferredStockMember_us-gaap_PreferredStockMember" id="xdx2ixbrl0557" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-12-31_us-gaap_SeriesBPreferredStockMember_us-gaap_PreferredStockMember" id="xdx2ixbrl0558" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-12-31_custom_CommonStockPayableMember" id="xdx2ixbrl0561" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2021-12-31_us-gaap_SeriesBPreferredStockMember_us-gaap_PreferredStockMember" id="xdx2ixbrl0568" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-12-31_us-gaap_SeriesAPreferredStockMember_us-gaap_PreferredStockMember" id="xdx2ixbrl0572" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-12-31_us-gaap_SeriesBPreferredStockMember_us-gaap_PreferredStockMember" id="xdx2ixbrl0573" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-12-31_custom_CommonStockPayableMember" id="xdx2ixbrl0576" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2021-12-31_us-gaap_SeriesBPreferredStockMember_us-gaap_PreferredStockMember" id="xdx2ixbrl0583" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="AMIH:DerivativesExpenses" contextRef="From2020-01-012020-12-31" id="xdx2ixbrl0606" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="AMIH:ForgivenessOfLoan" contextRef="From2020-01-012020-12-31" id="xdx2ixbrl0609" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="AMIH:ImpairmentOfLoss" contextRef="From2021-01-01to2021-12-31" id="xdx2ixbrl0611" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="AMIH:LossOnDispositionOfAssets" contextRef="From2020-01-012020-12-31" id="xdx2ixbrl0618" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="AMIH:StockIssuedForInProcessResearchAndDevelopment" contextRef="From2020-01-012020-12-31" id="xdx2ixbrl0627" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:IncreaseDecreaseInInventories" contextRef="From2020-01-012020-12-31" id="xdx2ixbrl0633" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" contextRef="From2021-01-01to2021-12-31" id="xdx2ixbrl0665" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" contextRef="From2020-01-012020-12-31" id="xdx2ixbrl0666" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ProceedsFromRelatedPartyDebt" contextRef="From2020-01-012020-12-31" id="xdx2ixbrl0678" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:RepaymentsOfRelatedPartyDebt" contextRef="From2020-01-012020-12-31" id="xdx2ixbrl0681" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:IncomeTaxesPaidNet" contextRef="From2021-01-01to2021-12-31" id="xdx2ixbrl0716" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:IncomeTaxesPaidNet" contextRef="From2020-01-012020-12-31" id="xdx2ixbrl0717" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="AMIH:CancellationOfCommonShares" contextRef="From2021-01-01to2021-12-31" id="xdx2ixbrl0725" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:TransferToInvestments" contextRef="From2021-01-01to2021-12-31" id="xdx2ixbrl0737" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:CapitalLeaseObligationsIncurred" contextRef="From2021-01-01to2021-12-31" id="xdx2ixbrl0740" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="AMIH:RelatedPartysNoteSettledInShares" contextRef="From2021-01-01to2021-12-31" id="xdx2ixbrl0743" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="AMIH:StockPayable" contextRef="From2021-01-01to2021-12-31" id="xdx2ixbrl0749" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:InventoryNet" contextRef="AsOf2020-12-31" id="xdx2ixbrl0796" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:LeaseholdImprovementsGross" contextRef="AsOf2021-12-31_us-gaap_SegmentContinuingOperationsMember" id="xdx2ixbrl0858" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:LeaseholdImprovementsGross" contextRef="AsOf2020-12-31_us-gaap_SegmentContinuingOperationsMember" id="xdx2ixbrl0859" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:FurnitureAndFixturesGross" contextRef="AsOf2021-12-31_us-gaap_SegmentContinuingOperationsMember" id="xdx2ixbrl0861" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:FurnitureAndFixturesGross" contextRef="AsOf2020-12-31_us-gaap_SegmentContinuingOperationsMember" id="xdx2ixbrl0862" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:MachineryAndEquipmentGross" contextRef="AsOf2021-12-31_us-gaap_SegmentDiscontinuedOperationsMember" id="xdx2ixbrl0864" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:MachineryAndEquipmentGross" contextRef="AsOf2020-12-31_us-gaap_SegmentDiscontinuedOperationsMember" id="xdx2ixbrl0865" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2021-12-31_us-gaap_SegmentContinuingOperationsMember" id="xdx2ixbrl0867" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2020-12-31_us-gaap_SegmentContinuingOperationsMember" id="xdx2ixbrl0868" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" contextRef="AsOf2021-12-31_us-gaap_SegmentContinuingOperationsMember" id="xdx2ixbrl0870" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" contextRef="AsOf2020-12-31_us-gaap_SegmentContinuingOperationsMember" id="xdx2ixbrl0871" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="AsOf2021-12-31_us-gaap_SegmentContinuingOperationsMember" id="xdx2ixbrl0873" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="AsOf2020-12-31_us-gaap_SegmentContinuingOperationsMember" id="xdx2ixbrl0874" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:MachineryAndEquipmentGross" contextRef="AsOf2021-12-31_us-gaap_SegmentDiscontinuedOperationsMember" id="xdx2ixbrl0884" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:MachineryAndEquipmentGross" contextRef="AsOf2020-12-31_us-gaap_SegmentDiscontinuedOperationsMember" id="xdx2ixbrl0885" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:DebtInstrumentCarryingAmount" contextRef="AsOf2021-12-31_custom_NotePayableThreeMember" id="xdx2ixbrl1103" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:DebtInstrumentCarryingAmount" contextRef="AsOf2021-12-31_custom_NotePayableFourMember" id="xdx2ixbrl1137" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:DebtInstrumentCarryingAmount" contextRef="AsOf2021-12-31_custom_NotePayableFiveMember" id="xdx2ixbrl1160" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:DebtInstrumentCarryingAmount" contextRef="AsOf2021-12-31_custom_NotePayableEightMember" id="xdx2ixbrl1196" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:DebtInstrumentCarryingAmount" contextRef="AsOf2021-12-31_custom_NotePayableNineMember" id="xdx2ixbrl1220" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:DebtInstrumentCarryingAmount" contextRef="AsOf2021-12-31_custom_NotePayableTenMember" id="xdx2ixbrl1244" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:DebtInstrumentCarryingAmount" contextRef="AsOf2021-12-31_custom_NotePayableElevenMember" id="xdx2ixbrl1272" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:DebtInstrumentCarryingAmount" contextRef="AsOf2021-12-31_custom_NotePayableTwelveMember" id="xdx2ixbrl1300" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:DebtInstrumentCarryingAmount" contextRef="AsOf2021-12-31_custom_NotePayableSeventeenMember" id="xdx2ixbrl1409" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ConvertibleLongTermNotesPayable" contextRef="AsOf2021-12-31" id="xdx2ixbrl1472" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:DeferredTaxAssetsNet" contextRef="AsOf2021-12-31" id="xdx2ixbrl1588" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold" contextRef="From2021-01-01to2021-12-31" id="xdx2ixbrl1739" unitRef="USD" xs:nil="true"></ix:nonFraction>
  </ix:hidden>
 <ix:references>
  <link:schemaRef xlink:href="amih-20211231.xsd" xlink:type="simple" />
  </ix:references>
 <ix:resources>
    <xbrli:context id="From2021-01-01to2021-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001300524</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001300524</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001300524</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001300524</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-12-31_us-gaap_SeriesAPreferredStockMember_us-gaap_PreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001300524</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-12-31_us-gaap_SeriesBPreferredStockMember_us-gaap_PreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001300524</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001300524</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001300524</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-12-31_custom_CommonStockPayableMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001300524</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">AMIH:CommonStockPayableMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001300524</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-12-31_us-gaap_TreasuryStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001300524</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001300524</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_us-gaap_SeriesAPreferredStockMember_us-gaap_PreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001300524</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_us-gaap_SeriesBPreferredStockMember_us-gaap_PreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001300524</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001300524</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001300524</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_custom_CommonStockPayableMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001300524</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">AMIH:CommonStockPayableMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001300524</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_us-gaap_TreasuryStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001300524</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-12-31_us-gaap_SeriesAPreferredStockMember_us-gaap_PreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001300524</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-12-31_us-gaap_SeriesBPreferredStockMember_us-gaap_PreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001300524</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001300524</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001300524</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-12-31_custom_CommonStockPayableMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001300524</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">AMIH:CommonStockPayableMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001300524</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-12-31_us-gaap_TreasuryStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001300524</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_us-gaap_SeriesAPreferredStockMember_us-gaap_PreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001300524</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_us-gaap_SeriesBPreferredStockMember_us-gaap_PreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001300524</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001300524</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001300524</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_custom_CommonStockPayableMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001300524</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">AMIH:CommonStockPayableMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001300524</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_us-gaap_TreasuryStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001300524</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_SeriesAPreferredStockMember_us-gaap_PreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001300524</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_SeriesBPreferredStockMember_us-gaap_PreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001300524</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001300524</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001300524</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_custom_CommonStockPayableMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001300524</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">AMIH:CommonStockPayableMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001300524</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_TreasuryStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001300524</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2018-05-31_custom_AmericanInternationalIndustriesIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001300524</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">AMIH:AmericanInternationalIndustriesIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-05-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-05-302018-05-31_custom_AmericanInternationalIndustriesIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001300524</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">AMIH:AmericanInternationalIndustriesIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-05-30</xbrli:startDate>
        <xbrli:endDate>2018-05-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_custom_AmericanInternationalIndustriesIncMember_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001300524</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">AMIH:AmericanInternationalIndustriesIncMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_custom_AmericanInternationalIndustriesIncMember_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001300524</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">AMIH:AmericanInternationalIndustriesIncMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-04-112019-04-12_custom_ShareExchangeAgreementMember_custom_NovopelleDiamondLLCMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001300524</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">AMIH:ShareExchangeAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">AMIH:NovopelleDiamondLLCMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-04-11</xbrli:startDate>
        <xbrli:endDate>2019-04-12</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-04-12_custom_ShareExchangeAgreementMember_custom_NovopelleDiamondLLCMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001300524</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">AMIH:ShareExchangeAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">AMIH:NovopelleDiamondLLCMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-04-12</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-05-15_custom_SecuritiesPurchaseAgreementMember_custom_GlobalCareerNetworksIncMember_custom_SeriesBConvertiblePreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001300524</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">AMIH:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">AMIH:GlobalCareerNetworksIncMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">AMIH:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-05-15</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-05-142020-05-15_custom_SecuritiesPurchaseAgreementMember_custom_GlobalCareerNetworksIncMember_custom_SeriesBConvertiblePreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001300524</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">AMIH:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">AMIH:GlobalCareerNetworksIncMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">AMIH:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-05-14</xbrli:startDate>
        <xbrli:endDate>2020-05-15</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-05-142020-05-15_custom_SecuritiesPurchaseAgreementMember_custom_GlobalCareerNetworksIncMember_custom_SeriesBConvertiblePreferredStockMember_custom_AgreedToIssueANAdditionalSharesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001300524</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">AMIH:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">AMIH:GlobalCareerNetworksIncMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">AMIH:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">AMIH:AgreedToIssueANAdditionalSharesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-05-14</xbrli:startDate>
        <xbrli:endDate>2020-05-15</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001300524</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001300524</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_srt_MinimumMember_custom_EpiqPawsAndEpiqLuxMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001300524</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">AMIH:EpiqPawsAndEpiqLuxMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_srt_MaximumMember_custom_EpiqPawsAndEpiqLuxMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001300524</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">AMIH:EpiqPawsAndEpiqLuxMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_custom_EPIQMDMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001300524</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">AMIH:EPIQMDMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_srt_MinimumMember_custom_ZipDoctorMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001300524</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">AMIH:ZipDoctorMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_srt_MaximumMember_custom_ZipDoctorMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001300524</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">AMIH:ZipDoctorMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_custom_ZipDoctorMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001300524</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">AMIH:ZipDoctorMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_us-gaap_MachineryAndEquipmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001300524</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_MachineryAndEquipmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001300524</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_us-gaap_FurnitureAndFixturesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001300524</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_FurnitureAndFixturesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001300524</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_us-gaap_ComputerEquipmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001300524</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_ComputerEquipmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001300524</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_us-gaap_SegmentContinuingOperationsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001300524</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementOperatingActivitiesSegmentAxis">us-gaap:SegmentContinuingOperationsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_us-gaap_SegmentDiscontinuedOperationsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001300524</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementOperatingActivitiesSegmentAxis">us-gaap:SegmentDiscontinuedOperationsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_SegmentContinuingOperationsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001300524</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementOperatingActivitiesSegmentAxis">us-gaap:SegmentContinuingOperationsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_us-gaap_SegmentContinuingOperationsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001300524</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementOperatingActivitiesSegmentAxis">us-gaap:SegmentContinuingOperationsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_SegmentDiscontinuedOperationsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001300524</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementOperatingActivitiesSegmentAxis">us-gaap:SegmentDiscontinuedOperationsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_us-gaap_SegmentDiscontinuedOperationsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001300524</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementOperatingActivitiesSegmentAxis">us-gaap:SegmentDiscontinuedOperationsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-10-18_custom_LegendNutritionIncMember_custom_AssetPurchaseAgreementMember_custom_MrMoralesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001300524</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">AMIH:LegendNutritionIncMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">AMIH:AssetPurchaseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">AMIH:MrMoralesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-10-18</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-10-172019-10-18_custom_LegendNutritionIncMember_custom_AssetPurchaseAgreementMember_custom_MrMoralesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001300524</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">AMIH:LegendNutritionIncMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">AMIH:AssetPurchaseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">AMIH:MrMoralesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-10-17</xbrli:startDate>
        <xbrli:endDate>2019-10-18</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_custom_LegendNutritionIncMember_custom_AssetPurchaseAgreementMember_custom_MrMoralesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001300524</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">AMIH:LegendNutritionIncMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">AMIH:AssetPurchaseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">AMIH:MrMoralesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_custom_TexsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001300524</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">AMIH:TexsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-06-262019-06-27_custom_NovoMedSpaAddisonCorpMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001300524</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">AMIH:NovoMedSpaAddisonCorpMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-06-26</xbrli:startDate>
        <xbrli:endDate>2019-06-27</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-06-27_custom_NovoMedSpaAddisonCorpMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001300524</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">AMIH:NovoMedSpaAddisonCorpMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-06-27</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-10-012019-12-31_custom_NovoMedSpaAddisonCorpMember_custom_ExclusiveLicenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001300524</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">AMIH:NovoMedSpaAddisonCorpMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">AMIH:ExclusiveLicenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-10-01</xbrli:startDate>
        <xbrli:endDate>2019-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-05-112020-05-13_custom_NovoMedSpaAddisonCorpMember_custom_ExclusiveLicenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001300524</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">AMIH:NovoMedSpaAddisonCorpMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">AMIH:ExclusiveLicenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-05-11</xbrli:startDate>
        <xbrli:endDate>2020-05-13</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-05-142020-05-15_custom_SecuritiesPurchaseAgreementMember_custom_GlobalCareerNetworksIncMember_custom_SeriesBConvetiblePreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001300524</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">AMIH:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">AMIH:GlobalCareerNetworksIncMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">AMIH:SeriesBConvetiblePreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-05-14</xbrli:startDate>
        <xbrli:endDate>2020-05-15</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-05-142020-05-15_custom_SecuritiesPurchaseAgreementMember_custom_GlobalCareerNetworksIncMember_custom_SeriesBConvetiblePreferredStockMember_custom_AgreedToIssueANAdditionalSharesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001300524</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">AMIH:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">AMIH:GlobalCareerNetworksIncMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">AMIH:SeriesBConvetiblePreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">AMIH:AgreedToIssueANAdditionalSharesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-05-14</xbrli:startDate>
        <xbrli:endDate>2020-05-15</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_custom_WebsiteMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001300524</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">AMIH:WebsiteMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_custom_ThreeHundredCoachesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001300524</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">AMIH:ThreeHundredCoachesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_custom_OneThousandCoachesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001300524</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">AMIH:OneThousandCoachesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_us-gaap_SeriesBPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001300524</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_custom_SharePurchaseAgreementMember_custom_LifeguruIncMember_custom_SeriesBConvetiblePreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001300524</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">AMIH:SharePurchaseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">AMIH:LifeguruIncMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">AMIH:SeriesBConvetiblePreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-10-012020-12-31_custom_SharePurchaseAgreementMember_custom_LifeguruIncMember_custom_SeriesBConvetiblePreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001300524</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">AMIH:SharePurchaseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">AMIH:LifeguruIncMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">AMIH:SeriesBConvetiblePreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-10-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-10-012021-12-31_us-gaap_SeriesBPreferredStockMember_custom_NewIssueWithMilestoneMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001300524</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">AMIH:NewIssueWithMilestoneMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-10-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-10-012021-12-31_us-gaap_SeriesBPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001300524</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-10-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-06-162020-06-17_custom_VendorMember_custom_TwentyFourInstallmentsMember_custom_PurchaseEquipmentAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001300524</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">AMIH:VendorMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">AMIH:TwentyFourInstallmentsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">AMIH:PurchaseEquipmentAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-06-16</xbrli:startDate>
        <xbrli:endDate>2020-06-17</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_custom_VendorMember_custom_TwentyFourInstallmentsMember_custom_PurchaseEquipmentAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001300524</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">AMIH:VendorMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">AMIH:TwentyFourInstallmentsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">AMIH:PurchaseEquipmentAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-06-132020-06-14_custom_VendorMember_custom_TwentyFourInstallmentsMember_custom_PurchaseEquipmentAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001300524</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">AMIH:VendorMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">AMIH:TwentyFourInstallmentsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">AMIH:PurchaseEquipmentAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-06-13</xbrli:startDate>
        <xbrli:endDate>2020-06-14</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-01-02_us-gaap_AccountingStandardsUpdate201602Member_custom_CapitolCitySolutionsUSAIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001300524</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201602Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">AMIH:CapitolCitySolutionsUSAIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-01-02</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-01-02_us-gaap_AccountingStandardsUpdate201602Member_custom_CapitolCitySolutionsUSAIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001300524</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201602Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">AMIH:CapitolCitySolutionsUSAIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-01-02</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-03-082022-03-09_custom_ReleaseAgreementMember_custom_LandlordMember_us-gaap_SubsequentEventMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001300524</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">AMIH:ReleaseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">AMIH:LandlordMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-03-08</xbrli:startDate>
        <xbrli:endDate>2022-03-09</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_custom_CapitolCitySolutionsUSAIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001300524</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">AMIH:CapitolCitySolutionsUSAIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_custom_CapitolCitySolutionsUSAIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001300524</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">AMIH:CapitolCitySolutionsUSAIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-01-02_us-gaap_AccountingStandardsUpdate201602Member_custom_VISSIAMckinneyMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001300524</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201602Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">AMIH:VISSIAMckinneyMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-01-02</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-09-042021-09-05_custom_ReleaseAgreementMember_custom_LandlordMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001300524</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">AMIH:ReleaseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">AMIH:LandlordMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-09-04</xbrli:startDate>
        <xbrli:endDate>2021-09-05</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-09-042021-09-05_custom_ReleaseAgreementMember_us-gaap_FurnitureAndFixturesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001300524</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">AMIH:ReleaseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-09-04</xbrli:startDate>
        <xbrli:endDate>2021-09-05</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-09-042021-09-05_custom_ReleaseAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001300524</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">AMIH:ReleaseAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-09-04</xbrli:startDate>
        <xbrli:endDate>2021-09-05</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_custom_VISSIAMckinneyMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001300524</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">AMIH:VISSIAMckinneyMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_custom_VISSIAMckinneyMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001300524</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">AMIH:VISSIAMckinneyMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-01-02_us-gaap_AccountingStandardsUpdate201602Member_custom_VISSIAWaterwayIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001300524</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201602Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">AMIH:VISSIAWaterwayIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-01-02</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-01-02_custom_VISSIAWaterwayIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001300524</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">AMIH:VISSIAWaterwayIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-01-02</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_custom_VISSIAWaterwayIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001300524</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">AMIH:VISSIAWaterwayIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_custom_VISSIAWaterwayIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001300524</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">AMIH:VISSIAWaterwayIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_custom_VISSIAMckinneyLLCMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001300524</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">AMIH:VISSIAMckinneyLLCMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_custom_JacobCohenMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001300524</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">AMIH:JacobCohenMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_custom_AlanHernandezMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001300524</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">AMIH:AlanHernandezMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_custom_EstebanAlexanderMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001300524</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">AMIH:EstebanAlexanderMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_custom_NotePayableOneMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001300524</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">AMIH:NotePayableOneMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_custom_NotePayableTwoMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001300524</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">AMIH:NotePayableTwoMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_custom_NotePayableThreeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001300524</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">AMIH:NotePayableThreeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_custom_NotePayableThreeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001300524</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">AMIH:NotePayableThreeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_custom_NotePayableFourMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001300524</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">AMIH:NotePayableFourMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_custom_NotePayableFourMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001300524</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">AMIH:NotePayableFourMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_custom_NotePayableFiveMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001300524</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">AMIH:NotePayableFiveMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_custom_NotePayableFiveMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001300524</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">AMIH:NotePayableFiveMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_custom_NotePayableSixMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001300524</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">AMIH:NotePayableSixMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_custom_NotePayableSevenMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001300524</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">AMIH:NotePayableSevenMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_custom_NotePayableEightMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001300524</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">AMIH:NotePayableEightMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_custom_NotePayableEightMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001300524</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">AMIH:NotePayableEightMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_custom_NotePayableNineMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001300524</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">AMIH:NotePayableNineMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_custom_NotePayableNineMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001300524</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">AMIH:NotePayableNineMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_custom_NotePayableTenMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001300524</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">AMIH:NotePayableTenMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_custom_NotePayableTenMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001300524</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">AMIH:NotePayableTenMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_custom_NotePayableElevenMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001300524</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">AMIH:NotePayableElevenMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_custom_NotePayableElevenMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001300524</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">AMIH:NotePayableElevenMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_custom_NotePayableTwelveMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001300524</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">AMIH:NotePayableTwelveMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_custom_NotePayableTwelveMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001300524</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">AMIH:NotePayableTwelveMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_custom_NotePayableThirteenMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001300524</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">AMIH:NotePayableThirteenMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_custom_NotePayableFourteenMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001300524</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">AMIH:NotePayableFourteenMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_custom_NotePayableFourteenMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001300524</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">AMIH:NotePayableFourteenMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_custom_NotePayableFifteenMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001300524</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">AMIH:NotePayableFifteenMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_custom_NotePayableFifteenMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001300524</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">AMIH:NotePayableFifteenMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_custom_NotePayableSixteenMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001300524</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">AMIH:NotePayableSixteenMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_custom_NotePayableSixteenMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001300524</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">AMIH:NotePayableSixteenMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_custom_NotePayableSeventeenMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001300524</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">AMIH:NotePayableSeventeenMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_custom_NotePayableSeventeenMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001300524</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">AMIH:NotePayableSeventeenMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_custom_NotePayableEighteenMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001300524</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">AMIH:NotePayableEighteenMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_custom_NotePayableNineteenMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001300524</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">AMIH:NotePayableNineteenMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_custom_NotePayableTwentyMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001300524</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">AMIH:NotePayableTwentyMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_custom_NotePayableTwentyOneMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001300524</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">AMIH:NotePayableTwentyOneMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_custom_NotePayableTwentyTwoMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001300524</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">AMIH:NotePayableTwentyTwoMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-07-08_custom_NotePayableOneMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001300524</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">AMIH:NotePayableOneMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-07-08</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-07-072019-07-08_custom_NotePayableOneMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001300524</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">AMIH:NotePayableOneMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-07-07</xbrli:startDate>
        <xbrli:endDate>2019-07-08</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-07-07_custom_NotePayableTwoMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001300524</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">AMIH:NotePayableTwoMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-07-07</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-07-062020-07-07_custom_NotePayableTwoMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001300524</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">AMIH:NotePayableTwoMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-07-06</xbrli:startDate>
        <xbrli:endDate>2020-07-07</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-08-05_custom_NotePayableThreeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001300524</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">AMIH:NotePayableThreeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-08-05</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-08-042020-08-05_custom_NotePayableThreeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001300524</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">AMIH:NotePayableThreeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-08-04</xbrli:startDate>
        <xbrli:endDate>2020-08-05</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-03-31_custom_NotePayableThreeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001300524</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">AMIH:NotePayableThreeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-08-11_custom_NotePayableFourMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001300524</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">AMIH:NotePayableFourMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-08-11</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-08-102020-08-11_custom_NotePayableFourMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001300524</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">AMIH:NotePayableFourMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-08-10</xbrli:startDate>
        <xbrli:endDate>2020-08-11</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-03-31_custom_NotePayableFourMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001300524</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">AMIH:NotePayableFourMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-09-14_custom_NotePayableFiveMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001300524</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">AMIH:NotePayableFiveMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-09-14</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-09-132020-09-14_custom_NotePayableFiveMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001300524</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">AMIH:NotePayableFiveMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-09-13</xbrli:startDate>
        <xbrli:endDate>2020-09-14</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-03-31_custom_NotePayableFiveMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001300524</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">AMIH:NotePayableFiveMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-09-11_custom_NotePayableSixMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001300524</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">AMIH:NotePayableSixMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-09-11</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-09-16_custom_NotePayableSevenMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001300524</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">AMIH:NotePayableSevenMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-09-16</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-10-12_custom_NotePayableEightMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001300524</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">AMIH:NotePayableEightMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-10-12</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-10-112020-10-12_custom_NotePayableEightMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001300524</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">AMIH:NotePayableEightMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-10-11</xbrli:startDate>
        <xbrli:endDate>2020-10-12</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-04-012021-06-30_custom_NotePayableEightMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001300524</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">AMIH:NotePayableEightMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-04-01</xbrli:startDate>
        <xbrli:endDate>2021-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-11-13_custom_NotePayableNineMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001300524</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">AMIH:NotePayableNineMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-11-13</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-11-122020-11-13_custom_NotePayableNineMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001300524</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">AMIH:NotePayableNineMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-11-12</xbrli:startDate>
        <xbrli:endDate>2020-11-13</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-03-31_custom_NotePayableNineMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001300524</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">AMIH:NotePayableNineMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-03_custom_NotePayableTenMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001300524</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">AMIH:NotePayableTenMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-03</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-02_custom_NotePayableTenMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001300524</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">AMIH:NotePayableTenMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-02</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-11-292020-12-02_custom_NotePayableTenMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001300524</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">AMIH:NotePayableTenMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-11-29</xbrli:startDate>
        <xbrli:endDate>2020-12-02</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-03-31_custom_NotePayableTenMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001300524</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">AMIH:NotePayableTenMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-01-06_custom_NotePayableElevenMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001300524</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">AMIH:NotePayableElevenMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-01-06</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-042021-01-06_custom_NotePayableElevenMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001300524</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">AMIH:NotePayableElevenMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-04</xbrli:startDate>
        <xbrli:endDate>2021-01-06</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-04-012021-06-30_custom_NotePayableToUnrelatedPartyTenMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001300524</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">AMIH:NotePayableToUnrelatedPartyTenMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-04-01</xbrli:startDate>
        <xbrli:endDate>2021-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-04-012021-06-30_custom_NotePayableElevenMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001300524</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">AMIH:NotePayableElevenMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-04-01</xbrli:startDate>
        <xbrli:endDate>2021-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-01-06_custom_NotePayableTwelveMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001300524</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">AMIH:NotePayableTwelveMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-01-06</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-042021-01-06_custom_NotePayableTwelveMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001300524</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">AMIH:NotePayableTwelveMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-04</xbrli:startDate>
        <xbrli:endDate>2021-01-06</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-04-012021-06-30_custom_NotePayableTwelveMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001300524</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">AMIH:NotePayableTwelveMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-04-01</xbrli:startDate>
        <xbrli:endDate>2021-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-03-30_custom_NotePayableThirteenMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001300524</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">AMIH:NotePayableThirteenMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-03-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-03-272021-03-30_custom_NotePayableThirteenMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001300524</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">AMIH:NotePayableThirteenMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-03-27</xbrli:startDate>
        <xbrli:endDate>2021-03-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-03-30_custom_NotePayableFourteenMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001300524</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">AMIH:NotePayableFourteenMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-03-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-03-272021-03-30_custom_NotePayableFourteenMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001300524</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">AMIH:NotePayableFourteenMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-03-27</xbrli:startDate>
        <xbrli:endDate>2021-03-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-09-30_custom_NotePayableFourteenMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001300524</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">AMIH:NotePayableFourteenMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-07-012021-09-30_custom_NotePayableFourteenMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001300524</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">AMIH:NotePayableFourteenMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-07-01</xbrli:startDate>
        <xbrli:endDate>2021-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-06-24_custom_NotePayableFifteenMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001300524</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">AMIH:NotePayableFifteenMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-06-24</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-06-232021-06-24_custom_NotePayableFifteenMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001300524</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">AMIH:NotePayableFifteenMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-06-23</xbrli:startDate>
        <xbrli:endDate>2021-06-24</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-07-012021-09-30_custom_NotePayableFifteenMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001300524</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">AMIH:NotePayableFifteenMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-07-01</xbrli:startDate>
        <xbrli:endDate>2021-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-10-012021-12-31_custom_NotePayableFifteenMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001300524</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">AMIH:NotePayableFifteenMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-10-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-06-24_custom_NotePayableSixteenMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001300524</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">AMIH:NotePayableSixteenMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-06-24</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-06-232021-06-24_custom_NotePayableSixteenMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001300524</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">AMIH:NotePayableSixteenMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-06-23</xbrli:startDate>
        <xbrli:endDate>2021-06-24</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-09-30_custom_NotePayableSixteenMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001300524</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">AMIH:NotePayableSixteenMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-07-012021-09-30_custom_NotePayableSixteenMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001300524</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">AMIH:NotePayableSixteenMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-07-01</xbrli:startDate>
        <xbrli:endDate>2021-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-10-012021-12-31_custom_NotePayableSixteenMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001300524</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">AMIH:NotePayableSixteenMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-10-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_custom_NotePayableSeventeenMember5567812">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001300524</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">AMIH:NotePayableSeventeenMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-11-22_custom_NotePayableEighteenMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001300524</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">AMIH:NotePayableEighteenMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-11-22</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-11-212021-11-22_custom_NotePayableEighteenMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001300524</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">AMIH:NotePayableEighteenMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-11-21</xbrli:startDate>
        <xbrli:endDate>2021-11-22</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-11-30_custom_NotePayableNineteenMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001300524</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">AMIH:NotePayableNineteenMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-11-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-11-292021-11-30_custom_NotePayableNineteenMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001300524</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">AMIH:NotePayableNineteenMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-11-29</xbrli:startDate>
        <xbrli:endDate>2021-11-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-01_custom_NotePayableTwentyMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001300524</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">AMIH:NotePayableTwentyMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-01</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-11-262021-12-01_custom_NotePayableTwentyMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001300524</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">AMIH:NotePayableTwentyMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-11-26</xbrli:startDate>
        <xbrli:endDate>2021-12-01</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-02_custom_NotePayableTwentyOneMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001300524</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">AMIH:NotePayableTwentyOneMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-02</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-02_custom_NotePayableToUnrelatedPartyEighteenMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001300524</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">AMIH:NotePayableToUnrelatedPartyEighteenMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-02</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-11-262021-12-02_custom_NotePayableTwentyOneMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001300524</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">AMIH:NotePayableTwentyOneMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-11-26</xbrli:startDate>
        <xbrli:endDate>2021-12-02</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_custom_NotePayableTwentyTwoMember5568000">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001300524</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">AMIH:NotePayableTwentyTwoMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_custom_ShortTermDebtConvertibleNotesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001300524</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">AMIH:ShortTermDebtConvertibleNotesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_custom_LongTermDebtConvertibleNotesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001300524</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">AMIH:LongTermDebtConvertibleNotesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_custom_NotesPayableMember_custom_RelatedPartyOneMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001300524</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">AMIH:NotesPayableMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">AMIH:RelatedPartyOneMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_custom_NotesPayableMember_custom_RelatedPartyTwoMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001300524</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">AMIH:NotesPayableMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">AMIH:RelatedPartyTwoMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_custom_NotesPayableMember_custom_RelatedPartyThreeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001300524</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">AMIH:NotesPayableMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">AMIH:RelatedPartyThreeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_custom_NotesPayableMember_custom_RelatedPartiesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001300524</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">AMIH:NotesPayableMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">AMIH:RelatedPartiesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-04-112019-04-12_custom_NotesPayableMember_custom_RelatedPartyOneMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001300524</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">AMIH:NotesPayableMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">AMIH:RelatedPartyOneMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-04-11</xbrli:startDate>
        <xbrli:endDate>2019-04-12</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-04-12_custom_NotesPayableMember_custom_RelatedPartyOneMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001300524</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">AMIH:NotesPayableMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">AMIH:RelatedPartyOneMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-04-12</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-12-31_custom_NotesPayableMember_custom_RelatedPartyOneMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001300524</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">AMIH:NotesPayableMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">AMIH:RelatedPartyOneMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_custom_NotesPayableMember_custom_RelatedPartyOneMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001300524</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">AMIH:NotesPayableMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">AMIH:RelatedPartyOneMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_custom_NotesPayableMember_custom_RelatedPartyOneMember_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001300524</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">AMIH:NotesPayableMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">AMIH:RelatedPartyOneMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_custom_NotesPayableMember_custom_RelatedPartyOneMember_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001300524</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">AMIH:NotesPayableMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">AMIH:RelatedPartyOneMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_MeasurementInputPriceVolatilityMember_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001300524</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_MeasurementInputPriceVolatilityMember_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001300524</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_MeasurementInputPriceVolatilityMember_srt_MinimumMember_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001300524</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_MeasurementInputPriceVolatilityMember_srt_MaximumMember_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001300524</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_MeasurementInputExercisePriceMember_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001300524</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExercisePriceMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_MeasurementInputExercisePriceMember_custom_WarrantOneMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001300524</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExercisePriceMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">AMIH:WarrantOneMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_MeasurementInputExercisePriceMember_custom_WarrantTwoMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001300524</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExercisePriceMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">AMIH:WarrantTwoMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001300524</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_SeriesAPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001300524</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_SeriesBPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001300524</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_us-gaap_SeriesAPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001300524</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-05-142020-05-15_custom_SecuritiesPurchaseAgreementMember_us-gaap_SeriesBPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001300524</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">AMIH:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-05-14</xbrli:startDate>
        <xbrli:endDate>2020-05-15</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-05-15_custom_SecuritiesPurchaseAgreementMember_us-gaap_SeriesBPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001300524</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">AMIH:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-05-15</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-05-142020-05-15_custom_SecuritiesPurchaseAgreementMember_custom_GlobalCareerNetworksIncMember_us-gaap_SeriesBPreferredStockMember_custom_AgreedToIssueANAdditionalSharesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001300524</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">AMIH:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">AMIH:GlobalCareerNetworksIncMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">AMIH:AgreedToIssueANAdditionalSharesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-05-14</xbrli:startDate>
        <xbrli:endDate>2020-05-15</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-05-142020-05-15_custom_SharePurchaseAgreementMember_custom_GlobalCareerNetworksIncMember_us-gaap_SeriesBPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001300524</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">AMIH:SharePurchaseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">AMIH:GlobalCareerNetworksIncMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-05-14</xbrli:startDate>
        <xbrli:endDate>2020-05-15</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-06-022020-06-30_custom_SecuritiesPurchaseAgreementMember_us-gaap_SeriesBPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001300524</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">AMIH:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-06-02</xbrli:startDate>
        <xbrli:endDate>2020-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-05-192020-05-20_us-gaap_SeriesAPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001300524</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-05-19</xbrli:startDate>
        <xbrli:endDate>2020-05-20</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-03-31_us-gaap_SeriesBPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001300524</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_us-gaap_SeriesAPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001300524</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_us-gaap_SeriesBPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001300524</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-102021-01-12_custom_UnrelatedPartyMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001300524</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">AMIH:UnrelatedPartyMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-10</xbrli:startDate>
        <xbrli:endDate>2021-01-12</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-302021-02-02_custom_NonRelatedThirdPartyInvestorMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001300524</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">AMIH:NonRelatedThirdPartyInvestorMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-30</xbrli:startDate>
        <xbrli:endDate>2021-02-02</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-03-31_custom_EmployeeAndNonEmployeeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001300524</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">AMIH:EmployeeAndNonEmployeeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-03-31_custom_InvestorsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001300524</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">AMIH:InvestorsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-03-31_custom_InvestorsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001300524</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">AMIH:InvestorsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-03-31_custom_ThirdPartyMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001300524</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">AMIH:ThirdPartyMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-04-012021-06-30_custom_InvestorsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001300524</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">AMIH:InvestorsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-04-01</xbrli:startDate>
        <xbrli:endDate>2021-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-06-30_custom_InvestorsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001300524</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">AMIH:InvestorsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-07-012021-09-30_custom_EmployeeAndNonEmployeeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001300524</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">AMIH:EmployeeAndNonEmployeeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-07-01</xbrli:startDate>
        <xbrli:endDate>2021-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-07-012021-09-30_custom_InvestorsMember_custom_ConvertibleNoteMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001300524</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">AMIH:InvestorsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">AMIH:ConvertibleNoteMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-07-01</xbrli:startDate>
        <xbrli:endDate>2021-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-09-30_custom_InvestorsMember_custom_ConvertibleNoteMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001300524</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">AMIH:InvestorsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">AMIH:ConvertibleNoteMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-10-012021-12-31_custom_EmployeeAndNonEmployeeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001300524</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">AMIH:EmployeeAndNonEmployeeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-10-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-10-012021-12-31_custom_InvestorsMember_custom_ConvertibleNoteMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001300524</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">AMIH:InvestorsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">AMIH:ConvertibleNoteMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-10-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_custom_InvestorsMember_custom_ConvertibleNoteMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001300524</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">AMIH:InvestorsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">AMIH:ConvertibleNoteMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-10-132019-10-14_custom_RobertHoldenMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001300524</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">AMIH:RobertHoldenMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-10-13</xbrli:startDate>
        <xbrli:endDate>2019-10-14</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-04-102019-04-12_custom_WinfredFieldsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001300524</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">AMIH:WinfredFieldsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-04-10</xbrli:startDate>
        <xbrli:endDate>2019-04-12</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-04-102019-04-12_custom_WinfredFieldsMember_custom_ExchangeAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001300524</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">AMIH:WinfredFieldsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">AMIH:ExchangeAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-04-10</xbrli:startDate>
        <xbrli:endDate>2019-04-12</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-11-11_custom_WinfredFieldsMember_custom_ExchangeAgreementMember_custom_PromissoryNoteMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001300524</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">AMIH:WinfredFieldsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">AMIH:ExchangeAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">AMIH:PromissoryNoteMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-11-11</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-11-132019-11-30_custom_WinfredFieldsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001300524</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">AMIH:WinfredFieldsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-11-13</xbrli:startDate>
        <xbrli:endDate>2019-11-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-08-012021-08-11_custom_AsherParkLLCMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001300524</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">AMIH:AsherParkLLCMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-08-01</xbrli:startDate>
        <xbrli:endDate>2021-08-11</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-242022-01-26_us-gaap_SubsequentEventMember_custom_SettlementAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001300524</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">AMIH:SettlementAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-24</xbrli:startDate>
        <xbrli:endDate>2022-01-26</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-09-012021-09-10_custom_TateMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001300524</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">AMIH:TateMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-09-01</xbrli:startDate>
        <xbrli:endDate>2021-09-10</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-10-012021-11-01_custom_CapitolCitySolutionsUSAIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001300524</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">AMIH:CapitolCitySolutionsUSAIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-10-01</xbrli:startDate>
        <xbrli:endDate>2021-11-01</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-042022-01-05_us-gaap_SubsequentEventMember_custom_FirstFireGlobalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001300524</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">AMIH:FirstFireGlobalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-04</xbrli:startDate>
        <xbrli:endDate>2022-01-05</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-01-05_us-gaap_SubsequentEventMember_custom_FirstFireGlobalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001300524</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">AMIH:FirstFireGlobalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-01-05</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-042022-01-06_us-gaap_SubsequentEventMember_custom_QuickCapitalLlcMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001300524</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">AMIH:QuickCapitalLlcMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-04</xbrli:startDate>
        <xbrli:endDate>2022-01-06</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-01-06_us-gaap_SubsequentEventMember_custom_QuickCapitalLlcMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001300524</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">AMIH:QuickCapitalLlcMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-01-06</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-112022-01-12_us-gaap_SubsequentEventMember_custom_NewEmploymentAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001300524</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">AMIH:NewEmploymentAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-11</xbrli:startDate>
        <xbrli:endDate>2022-01-12</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-242022-01-27_us-gaap_SubsequentEventMember_custom_ConsultingServicesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001300524</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">AMIH:ConsultingServicesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-24</xbrli:startDate>
        <xbrli:endDate>2022-01-27</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-01-27_us-gaap_SubsequentEventMember_custom_ConsultingServicesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001300524</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">AMIH:ConsultingServicesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-01-27</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-302022-02-02_us-gaap_SubsequentEventMember_custom_LoneCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001300524</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">AMIH:LoneCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-30</xbrli:startDate>
        <xbrli:endDate>2022-02-02</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-02-02_us-gaap_SubsequentEventMember_custom_LoneCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001300524</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">AMIH:LoneCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-02-02</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:unit id="USD">
      <xbrli:measure>iso4217:USD</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Shares">
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="USDPShares">
      <xbrli:divide>
        <xbrli:unitNumerator>
          <xbrli:measure>iso4217:USD</xbrli:measure>
        </xbrli:unitNumerator>
        <xbrli:unitDenominator>
          <xbrli:measure>xbrli:shares</xbrli:measure>
        </xbrli:unitDenominator>
      </xbrli:divide>
    </xbrli:unit>
    <xbrli:unit id="Pure">
      <xbrli:measure>xbrli:pure</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Integer">
      <xbrli:measure>AMIH:Integer</xbrli:measure>
    </xbrli:unit>
  </ix:resources>
 </ix:header>
</div>


<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">As
filed with the Securities and Exchange Commission on <span id="xdx_900_edei--DocumentCreationDate_c20210101__20211231_z2EQK3WThzw6"><ix:nonNumeric contextRef="From2021-01-01to2021-12-31" format="ixt:datemonthdayyearen" name="dei:DocumentCreationDate">April
21, 2022</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Registration
No. 333-</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p>

<!-- Field: Rule-Page --><div style="width: 100%"><div style="border-top: Black 4pt solid; font-size: 1pt; border-bottom: Black 1.5pt solid">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 18pt"><b>UNITED
STATES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 18pt"><b>SECURITIES
AND EXCHANGE COMMISSION</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 12pt"><b>WASHINGTON,
D.C. 20549</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 18pt"><b>FORM
<span id="xdx_906_edei--DocumentType_c20210101__20211231_zz2pCWwt9oTc"><ix:nonNumeric contextRef="From2021-01-01to2021-12-31" name="dei:DocumentType">S-1</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>REGISTRATION
STATEMENT</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>UNDER
THE SECURITIES ACT OF 1933</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 18pt"><b><span style="text-decoration: underline"><span id="xdx_909_edei--EntityRegistrantName_c20210101__20211231_zEW8QZ4pwjF1"><ix:nonNumeric contextRef="From2021-01-01to2021-12-31" name="dei:EntityRegistrantName">AMERICAN
INTERNATIONAL HOLDINGS CORP.</ix:nonNumeric></span></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Exact
name of registrant as specified in its charter)</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 32%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_901_edei--EntityIncorporationStateCountryCode_c20210101__20211231_zWZkkwfaI2v5"><ix:nonNumeric contextRef="From2021-01-01to2021-12-31" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode">Nevada</ix:nonNumeric></span></b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 32%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_906_edei--EntityPrimarySicNumber_c20210101__20211231_zZTRxc7i9Nu9" title="Entity Primary SIC Number"><ix:nonNumeric contextRef="From2021-01-01to2021-12-31" name="dei:EntityPrimarySicNumber">8000</ix:nonNumeric></span></b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 32%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_906_edei--EntityTaxIdentificationNumber_c20210101__20211231_zkNDslYFVRW5"><ix:nonNumeric contextRef="From2021-01-01to2021-12-31" name="dei:EntityTaxIdentificationNumber">90-1898207</ix:nonNumeric></span></b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>(State
    or other jurisdiction of</i></span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>incorporation
    or organization)</i></span></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>(Primary
    Standard Industrial</i></span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Classification
    Code Number)</i></span></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>(I.R.S.
    Employer</i></span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Identification
    Number)</i></span></p></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline"><span id="xdx_90D_edei--EntityAddressAddressLine1_c20210101__20211231_zQJPGKw7x9pc" title="Entity Address, Address Line One"><ix:nonNumeric contextRef="From2021-01-01to2021-12-31" name="dei:EntityAddressAddressLine1">7950
Legacy Drive</ix:nonNumeric></span>, <span id="xdx_903_edei--EntityAddressAddressLine2_c20210101__20211231_zP0amSwrgT38" title="Entity Address, Address Line Two"><ix:nonNumeric contextRef="From2021-01-01to2021-12-31" name="dei:EntityAddressAddressLine2">Suite 400</ix:nonNumeric></span></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline"><span id="xdx_907_edei--EntityAddressCityOrTown_c20210101__20211231_zlbBJlTHc933"><ix:nonNumeric contextRef="From2021-01-01to2021-12-31" name="dei:EntityAddressCityOrTown">Plano</ix:nonNumeric></span>,
<span id="xdx_904_edei--EntityAddressStateOrProvince_c20210101__20211231_zBn57n10N75a" title="Entity Address, State or Province"><ix:nonNumeric contextRef="From2021-01-01to2021-12-31" format="ixt-sec:stateprovnameen" name="dei:EntityAddressStateOrProvince">Texas</ix:nonNumeric></span> <span id="xdx_908_edei--EntityAddressPostalZipCode_c20210101__20211231_zPK0yVFgjQsi"><ix:nonNumeric contextRef="From2021-01-01to2021-12-31" name="dei:EntityAddressPostalZipCode">75024</ix:nonNumeric></span></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_900_edei--CityAreaCode_c20210101__20211231_zlBULL99FKKd"><ix:nonNumeric contextRef="From2021-01-01to2021-12-31" name="dei:CityAreaCode">(469)</ix:nonNumeric></span>
<span id="xdx_90D_edei--LocalPhoneNumber_c20210101__20211231_z3tBd22yKXf1" title="Local Phone Number"><ix:nonNumeric contextRef="From2021-01-01to2021-12-31" name="dei:LocalPhoneNumber">963-2644</ix:nonNumeric></span></b><br />
<i>(Address, including zip code, and telephone number,</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>including
area code, of registrant&#8217;s principal executive offices)</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Jacob
D. Cohen<br />
Chief Executive Officer<br />
American International Holdings Corp.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>7950
Legacy Drive, Suite 400</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Plano,
Texas 75024</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(972)
803-5337</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>(Name,
address, including zip code, and telephone number,</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>including
area code, of agent for service of process)</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Copies
To:</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>David
M. Loev, Esq.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>John
S. Gillies, Esq.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>The
Loev Law Firm, PC</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>6300
West Loop South, Suite 280</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Bellaire,
Texas 77401</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Telephone:
(713) 524-4110</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Facsimile:
(713) 524-4122</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Email:
<span style="text-decoration: underline">dloev@loevlaw.com</span>; <span style="text-decoration: underline">john@loevlaw.com</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Approximate
date of commencement of proposed sale to the public: <b>From time to time after this Registration Statement becomes effective.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
any of the securities being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the
Securities Act of 1933 check the following box: &#9746;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
this Form is filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, please check the
following box and list the Securities Act registration statement number of the earlier effective registration statement for the same
offering. &#9744;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
this Form is a post-effective amendment filed pursuant to Rule 462(c) under the Securities Act, check the following box and list the
Securities Act registration statement number of the earlier effective registration statement for the same offering. &#9744;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
this Form is a post-effective amendment filed pursuant to Rule 462(d) under the Securities Act, check the following box and list the
Securities Act registration statement number of the earlier effective registration statement for the same offering. &#9744;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting
company or an emerging growth company. See the definitions of &#8220;<span style="text-decoration: underline">large accelerated filer,</span>&#8221; &#8220;<span style="text-decoration: underline">accelerated filer,</span>&#8221;
&#8220;<span style="text-decoration: underline">smaller reporting company</span>&#8221; and &#8220;<span style="text-decoration: underline">emerging growth company</span>&#8221; in Rule 12b-2 of the Exchange Act.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 60%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Large
    accelerated filer &#9744;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 40%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accelerated
    filer &#9744;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_902_edei--EntityFilerCategory_c20210101__20211231_z02b6clg6qzi"><ix:nonNumeric contextRef="From2021-01-01to2021-12-31" format="ixt-sec:entityfilercategoryen" name="dei:EntityFilerCategory">Non-accelerated
    filer</ix:nonNumeric></span> &#9746;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Smaller
    reporting company <span id="xdx_907_edei--EntitySmallBusiness_c20210101__20211231_zpxUWiI0fTb4"><ix:nonNumeric contextRef="From2021-01-01to2021-12-31" format="ixt:booleantrue" name="dei:EntitySmallBusiness">&#9746;</ix:nonNumeric></span></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Emerging
    growth company <span id="xdx_90E_edei--EntityEmergingGrowthCompany_c20210101__20211231_z7VNqWmryqGk"><ix:nonNumeric contextRef="From2021-01-01to2021-12-31" format="ixt:booleanfalse" name="dei:EntityEmergingGrowthCompany">&#9744;</ix:nonNumeric></span></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided to Section 7(a)(2)(B) of the Securities Act. &#9744;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>The
registrant hereby amends this Registration Statement on such date or dates as may be necessary to delay its effective date until the
registrant shall file a further amendment which specifically states that this Registration Statement shall thereafter become effective
in accordance with Section 8(a) of the Securities Act or until the Registration Statement shall become effective on such date as the
Securities and Exchange Commission acting pursuant to said Section 8(a), may determine.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></p>

<!-- Field: Rule-Page --><div style="width: 100%"><div style="border-top: Black 1.5pt solid; font-size: 1pt; border-bottom: Black 4pt solid">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>


<!-- Field: Page; Sequence: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Red"><b>The
information in this prospectus is not complete and may be changed. The selling shareholders may not sell these securities pursuant to
this prospectus until the registration statement filed with the Securities and Exchange Commission is effective. This prospectus is not
an offer to sell these securities and it is not soliciting an offer to buy these securities in any jurisdiction where the offer or sale
is not permitted.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Red"><b>PRELIMINARY
PROSPECTUS SUBJECT TO COMPLETION, DATED APRIL 21, 2022</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><img src="forms-1_001.jpg" alt="" /></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>42,666,665
Shares of Common Stock</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
prospectus relates to the resale by the selling stockholders named herein of up to 42,666,665 shares of common stock, par value $0.0001
per share, which we refer to as common stock, of American International Holdings Corp., which we refer to as us, we, the Company, the
Registrant or American International, consisting of up to 29,333,333 shares of common stock of the Registrant issuable upon conversion
of the principal and accrued interest at maturity under those certain convertible promissory notes in the aggregate principal amount
of $2,000,000 (the &#8220;<span style="text-decoration: underline">Notes</span>&#8221;), which were sold by the Company between November 22, 2021 and December 2, 2021, at a conversion
rate equal to $0.075 per share, and up to 13,333,332 shares of common stock of the Company issuable upon the exercise of those certain
Common Stock Purchase Warrants (&#8220;<span style="text-decoration: underline">Warrants</span>&#8221;), which were granted by the Company between November 22, 2021 and December
2, 2021, at an exercise price of $0.075 per share. The Notes and Warrants are described in greater detail under &#8220;<a href="#ed_006">Securities Purchase Agreement</a>&#8221;, beginning on page 47.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
shares of common stock being offered by the selling stockholders (which term includes their respective donees, pledgees, transferees,
or other successors-in-interest) have been issued in a private offering transaction between November 22, 2021 and December 2, 2021, as
described in greater detail under &#8220;<a href="#ed_006">Securities Purchase Agreement</a>&#8221;, beginning on page 47. The selling
stockholders are described in greater detail under &#8220;<a href="#ed_011">Selling Stockholders</a>&#8221;, beginning on page 60.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->i<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
shares of common stock described in this prospectus may be offered for sale from time to time by the selling stockholders named herein.
The selling stockholders may offer and sell the shares in a variety of transactions as described under the heading &#8220;<a href="#ed_010">Plan of Distribution</a>&#8221;
beginning on page 57, including transactions on any stock exchange, market or facility on which our common stock may be traded, in privately
negotiated transactions or otherwise at market prices prevailing at the time of sale, at prices related to such market prices or at negotiated
prices. We have no basis for estimating either the number of shares of our common stock that will ultimately be sold by the selling stockholders
or the prices at which such shares will be sold.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are not selling any securities covered by this prospectus and will not receive any of the proceeds from the sale of such shares by
the selling stockholders. However, to the extent that the Warrants are exercised for cash, we will receive the payment of the
exercise price in connection with such exercise (see also &#8220;<a href="#ed_007">Use of Proceeds</a>&#8221; on page 50 below). We
are bearing all of the expenses in connection with the registration of the shares of common stock, but all selling and other
expenses incurred by the selling stockholders, including commissions and discounts, if any, attributable to the sale or disposition
of the shares will be borne by them.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
selling stockholders and intermediaries through whom such securities are sold may be deemed &#8220;<span style="text-decoration: underline">underwriters</span>&#8221; within
the meaning of the Securities Act of 1933, as amended (the &#8220;<span style="text-decoration: underline">Securities Act</span>&#8221;), with respect to the securities offered
hereby, and any profits realized or commissions received may be deemed underwriting compensation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
current prospectus must be in effect at the time of the sale of the shares of common stock discussed above and each selling stockholder
or dealer selling the common stock is required to deliver a current prospectus upon the sale. The selling stockholders will be responsible
for any commissions or discounts due to brokers or dealers. We will pay all of the other offering expenses.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, any securities covered by this prospectus which qualify for sale pursuant to Rule 144 of the Securities Act may be sold under
Rule 144 rather than pursuant to this prospectus.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
common stock is considered a &#8220;<span style="text-decoration: underline">penny stock</span>&#8221;, and subject to the requirements of Rule 15g-9, promulgated under the Exchange
Act of 1934, as amended. &#8220;<span style="text-decoration: underline">Penny stock</span>&#8221; is generally defined as any equity security not traded on an exchange or quoted
on NASDAQ that has a market price of less than $5.00 per share. Under such rule, broker-dealers who recommend low-priced securities to
persons other than established customers and accredited investors must satisfy special sales practice requirements, including a requirement
that they make an individualized written suitability determination for the purchaser and receive the purchaser&#8217;s consent prior
to the transaction. The Securities Enforcement Remedies and Penny Stock Reform Act of 1990, also requires additional disclosure in connection
with any trades involving a stock defined as a penny stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
required penny stock disclosures include the required delivery, prior to any transaction, of a disclosure schedule explaining the penny
stock market and the risks associated with it. Such requirements could severely limit the market liquidity of the securities and the
ability of purchasers to sell their securities in the secondary market. In addition, various state securities laws impose restrictions
on transferring &#8220;<span style="text-decoration: underline">penny stocks</span>&#8221; and as a result, investors in the common stock may have their ability to sell their
shares of the common stock impaired.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 3; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->ii<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Jacob
D. Cohen, our Chief Executive Officer and Chairman, our principal stockholder, currently controls approximately 71.1% of the voting power
of our capital stock (based on shares of common stock outstanding as of the date of this prospectus).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
common stock is quoted on the OTCQB Market under the symbol &#8220;AMIH&#8221;. The closing price for our common stock on April 20,
2022, was $0.041 per share</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Investing
in our securities involves risks. You should carefully consider the &#8220;<a href="#ed_005">risk factors</a>&#8221; beginning on page 16 of this prospectus
and set forth in the documents incorporated by reference herein before making any decision to invest in our securities.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Neither
the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or passed
upon the adequacy or accuracy of this prospectus. Any representation to the contrary is a criminal offense.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>The
date of this prospectus is _____________, 2022.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>


<!-- Field: Page; Sequence: 4; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->iii<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="toc"></span>TABLE
OF CONTENTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>



<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><a href="#ed_001"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">About This Prospectus</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><a href="#ed_002"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cautionary Statement Regarding Forward-Looking Statements</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><a href="#ed_003"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prospectus Summary</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><a href="#ed_004"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">This Offering</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">15</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><a href="#ed_005"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Risk Factors</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">16</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><a href="#ed_006"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Securities Purchase Agreement</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">47</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><a href="#ed_007"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Use of Proceeds</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">50</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><a href="#ed_008"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Determination of Offering Price</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">51</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><a href="#ed_009"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Description of Capital Stock</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">51</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><a href="#ed_010"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Plan of Distribution</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">57</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><a href="#ed_011"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Selling Stockholders</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">60</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><a href="#ed_012"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certain Beneficial Owners and Management</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">63</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><a href="#ed_013"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dividend Policy</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">65</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><a href="#ed_014"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Legal Matters</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">65</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#ed_015">Experts</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">65</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><a href="#ed_016"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Changes in and Disagreements with Accountants on Accounting and Financial Disclosure</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">66</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><a href="#ed_017"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Description of Business</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">66</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><a href="#ed_018"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Description of Property</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">78</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><a href="#ed_019"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Legal Proceedings</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">80</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><a href="#ed_020"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Market for Common Equity and Related Stockholder Matters</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">82</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><a href="#ed_021"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">85</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><a href="#ed_022"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Quantitative and Qualitative Disclosures About Market Risk</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">94</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><a href="#ed_023"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Directors, Executive Officers and Corporate Governance</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">94</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><a href="#ed_024"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Executive and Director Compensation</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">106</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><a href="#ed_025"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certain Relationships and Related Transactions</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">119</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><a href="#ed_026"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Where You Can Find Additional Information</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">123</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><a href="#ed_027"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indemnification of Directors and Officers</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">124</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><a href="#fin"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Index to Financial Statements</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">125</span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 5; Options: NewSection; Value: 4 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: center"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->iv<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%"><a href="#toc" title="Table of Contents" style="font-style: italic">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">&#160;</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-transform: uppercase; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="ed_001"></span>About
This Prospectus</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
prospectus is part of a registration statement that we filed with the Securities and Exchange Commission (the &#8220;<span style="text-decoration: underline">SEC</span>&#8221;
or the &#8220;<span style="text-decoration: underline">Commission</span>&#8221;). This prospectus relates to the resale by the selling stockholders listed in this prospectus
of up to 42,666,665 shares of our common stock. We will not receive any proceeds from the resale of any of the shares by the selling
stockholders. However, to the extent that the Warrants are exercised for cash, we will receive the payment of the exercise price in connection
with such exercise (see also &#8220;<a href="#ed_007">Use of Proceeds</a>&#8221; on page 50 below). We have agreed to pay for the expenses related to the registration
of the shares being offered by the selling stockholders.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">You
should read this prospectus, together with additional information described under &#8220;<a href="#ed_026">Where You Can Find More Information</a>&#8221;,
beginning on page 123, before making an investment decision.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
prospectus does not contain all the information provided in the registration statement we filed with the SEC. For further information
about us or our securities offered hereby, you should refer to that registration statement, which you can obtain from the SEC as described
below under &#8220;<a href="#ed_026">Where You Can Find More Information</a>&#8221;, beginning on page 123.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">You
should rely only on the information contained in this prospectus. We have not authorized any other person to provide you with different
information. If anyone provides you with different or inconsistent information<b>, </b>you should not rely on it. This prospectus is
not an offer to sell or the solicitation of an offer to buy any securities other than the securities to which it relates and is not an
offer to sell or the solicitation of an offer to buy securities in any jurisdiction to any person to whom it is unlawful to make an offer
or solicitation in that jurisdiction.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
will disclose any material changes in our affairs in a post-effective amendment to the registration statement of which this prospectus
is a part, or a prospectus supplement. We do not imply or represent by delivering this prospectus that American International Holdings
Corp., or its business, financial condition or results of operations, are unchanged after the date on the front of this prospectus is
correct at any time after such date, provided that we will amend or supplement this prospectus to disclose any material events which
occur after the date of such prospectus to the extent required by applicable law.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Persons
outside the United States who come into possession of this prospectus must inform themselves about, and observe any restrictions relating
to, the offering of the securities and the distribution of this prospectus outside of the United States.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
logo and some of our trademarks and tradenames are used in this prospectus. This prospectus also includes trademarks, tradenames and
service marks that are the property of others. Solely for convenience, trademarks, tradenames and service marks referred to in this prospectus
may appear without the &#174;, &#8482; and SM symbols. References to our trademarks, tradenames and service marks are not intended to
indicate in any way that we will not assert to the fullest extent under applicable law our rights or the rights of the applicable licensors
if any, nor that respective owners to other intellectual property rights will not assert, to the fullest extent under applicable law,
their rights thereto. We do not intend the use or display of other companies&#8217; trademarks and trade names to imply a relationship
with, or endorsement or sponsorship of us by, any other companies.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 6; Options: NewSection; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%"><a href="#toc" title="Table of Contents" style="font-style: italic">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
market data and certain other statistical information used throughout this prospectus are based on independent industry publications,
reports by market research firms or other independent sources that we believe to be reliable sources. Industry publications and third-party
research, surveys and studies generally indicate that their information has been obtained from sources believed to be reliable, although
they do not guarantee the accuracy or completeness of such information. We are responsible for all of the disclosure contained in this
prospectus, and we believe these industry publications and third-party research, surveys and studies are reliable. While we are not aware
of any misstatements regarding any third-party information presented in this prospectus, their estimates, in particular, as they relate
to projections, involve numerous assumptions, are subject to risks and uncertainties, and are subject to change based on various factors,
including those discussed under the section entitled &#8220;<a href="#ed_005">Risk Factors</a>&#8221; beginning on page 16 of this prospectus. These and other
factors could cause our future performance to differ materially from our assumptions and estimates. Some market and other data included
herein, as well as the data of competitors as they relate to American International Holdings Corp., is also based on our good faith estimates.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unless
the context otherwise requires, references in this prospectus to:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
&#8220;<span style="text-decoration: underline">we,</span>&#8221; &#8220;<span style="text-decoration: underline">us,</span>&#8221; &#8220;<span style="text-decoration: underline">our,</span>&#8221; the &#8220;<span style="text-decoration: underline">Registrant</span>&#8221;, the
&#8220;<span style="text-decoration: underline">Company,</span>&#8221; and &#8220;<span style="text-decoration: underline">American International</span>&#8221;, refer to American International Holdings Corp. and
its subsidiaries;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
&#8220;<span style="text-decoration: underline">Exchange Act</span>&#8221; refers to the Securities Exchange Act of 1934, as amended;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
&#8220;<span style="text-decoration: underline">SEC</span>&#8221; or the &#8220;<span style="text-decoration: underline">Commission</span>&#8221; refers to the United States Securities and Exchange Commission;
and</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
&#8220;<span style="text-decoration: underline">Securities Act</span>&#8221; refers to the Securities Act of 1933, as amended. All dollar amounts in this prospectus are in
U.S. dollars unless otherwise stated. You should read the entire prospectus before making an investment decision to purchase our
securities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-transform: uppercase; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="ed_002"></span>Cautionary
Statement Regarding Forward-Looking Statements</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
prospectus, each prospectus supplement and the information incorporated by reference in this prospectus and each prospectus supplement
contain certain statements that constitute &#8220;<span style="text-decoration: underline">forward-looking statements</span>&#8221; within the meaning of the federal securities
laws, including pursuant to Section 27A of the Securities Act and Section 21E of the Securities Exchange Act. The words &#8220;<span style="text-decoration: underline">believe,</span>&#8221;
&#8220;<span style="text-decoration: underline">may,</span>&#8221; &#8220;<span style="text-decoration: underline">will,</span>&#8221; &#8220;<span style="text-decoration: underline">potentially,</span>&#8221; &#8220;<span style="text-decoration: underline">estimate,</span>&#8221; &#8220;<span style="text-decoration: underline">continue,</span>&#8221;
&#8220;<span style="text-decoration: underline">anticipate,</span>&#8221; &#8220;<span style="text-decoration: underline">intend,</span>&#8221; &#8220;<span style="text-decoration: underline">could,</span>&#8221; &#8220;<span style="text-decoration: underline">would,</span>&#8221; &#8220;<span style="text-decoration: underline">project,</span>&#8221;
&#8220;<span style="text-decoration: underline">plan,</span>&#8221; &#8220;<span style="text-decoration: underline">expect</span>&#8221; and the negative and plural forms of these words and similar expressions are intended
to identify forward-looking statements, but are not the exclusive means of identifying such statements. Those statements appear in this
prospectus, any accompanying prospectus supplement and the documents incorporated herein and therein by reference, particularly in the
sections titled &#8220;<a href="#ed_003">Prospectus Summary</a>&#8221; and &#8220;<a href="#ed_005">Risk Factors,</a>&#8221; and include statements regarding
the intent, belief or current expectations of the Company and management that are subject to known and unknown risks, uncertainties and
assumptions. Examples of forward-looking statements include statements relating to macroeconomic conditions; our expectations regarding
future growth, including future revenue; our expectations regarding new products and market acceptance of current and new products; anticipated
changes in regulations and market acceptance of our products and industry; our growth plans and opportunities, including our strategies
for future acquisitions, future product expansion, potential client marketing and targeting and potential geographic expansion; estimated
returns on future acquisitions; and other statements concerning our plans, objectives, goals, strategies, future events, future revenues
or performance, capital expenditures, financing needs, the competitive landscape for our products, plans or intentions relating to acquisitions
and developments and other information that is not historical information, and our assumptions underlying these expectations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 7 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%"><a href="#toc" title="Table of Contents" style="font-style: italic">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
prospectus, any prospectus supplement and the information incorporated by reference in this prospectus and any prospectus supplement
also contain statements that are based on the current expectations of our Company and management. You are cautioned that any such forward-looking
statements are not guarantees of future performance and involve risks and uncertainties, and that actual results may differ materially
from those projected in the forward-looking statements as a result of various factors.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Because
forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified, you should
not rely upon forward-looking statements as predictions of future events. The events and circumstances reflected in the forward-looking
statements may not be achieved or occur and actual results could differ materially from those projected in the forward-looking statements.
Except as required by applicable law, including the securities laws of the United States and the rules and regulations of the SEC, we
do not plan to publicly update or revise any forward-looking statements contained herein after we distribute this prospectus, whether
as a result of any new information, future events or otherwise.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">You
should also consider carefully the statements under &#8220;<a href="#ed_005">Risk Factors</a>&#8221; and other sections of this prospectus, which address additional
facts that could cause our actual results to differ from those set forth in the forward-looking statements. We caution investors not
to place significant reliance on the forward-looking statements contained in this prospectus.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-transform: uppercase; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="ed_003"></span>Prospectus
Summary</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following summary highlights material information found in more detail elsewhere in the prospectus. It does not contain all of the information
you should consider. As such, before you decide to buy our common stock, in addition to the following summary, we urge you to carefully
read the entire prospectus, especially the risks of investing in our common stock as discussed under &#8220;<a href="#ed_005">Risk Factors.</a>&#8221;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 8 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%"><a href="#toc" title="Table of Contents" style="font-style: italic">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>About
American International Holdings Corp.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company is headquartered in Plano, Texas, and is an investor, developer and asset manager with diversified assets across the healthcare
supply chain. The Company&#8217;s portfolio encompasses telemedicine and other virtual health platforms, subscriber based primary care
and concierge medicine plans, preventative care solutions and wellness related assets such as mental and behavioral health services,
a digital online mail order pharmacy, a men&#8217;s wellness products and services company, as well as its own proprietary life coaching
platform. The Company provides its various services through direct-to-consumer and business-to-business distribution channels and is
focused on developing, acquiring and bringing to market technologies and solutions that we believe can advance the quality of life for
the global community. Additionally, the Company seeks opportunities to acquire and grow businesses that possess strong brand values and
that can generate long-term sustainable free cash flow and attractive returns in order to maximize value for all stakeholders.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company currently is the parent to ten subsidiaries, of which seven are wholly-owned subsidiaries and three (3) are majority-owned subsidiaries.
In 2021, the Company ceased operations of five of its ten subsidiaries in order to focus on the subsidiaries that better aligned with
the purpose of the Company and its ongoing business plan.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>ZIPDOCTOR,
INC. &#8211; 100% OWNED</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
April 28, 2020, the Company incorporated a wholly-owned subsidiary, ZipDoctor, Inc. (&#8220;<span style="text-decoration: underline">ZipDoctor</span>&#8221;) in the state of
Texas. ZipDoctor launched its online, direct-to-consumer subscription-based telemedicine platform <span style="text-decoration: underline">www.ZipDoctor.co </span>in the third
quarter of 2020. ZipDoctor provides its customers with unlimited, 24/7 access to board certified physicians and licensed mental and behavioral
health counselors and therapists via a newly developed, monthly subscription-based online telemedicine platform. ZipDoctor&#8217;s online
telemedicine platform is available to customers across the United States and offers bilingual coverage (English and Spanish), with virtual
visits taking place either via the phone or through a secured video chat platform. ZipDoctor customers subscribe through the website
and are only required to pay a monthly fee, which is determined based on whether they are an individual, a couple, or a family. ZipDoctor
is currently being sold on a direct-to-consumer basis, with an emphasis on digital marketing and advertising.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Digital
Marketing Initiative: </b>The ZipDoctor website was originally designed to be marketed and sold primarily using a digital and social
media advertising campaign. Shortly after the website&#8217;s launch, ZipDoctor began to advertise on Google pay per click (PPC), search
engine optimization (SEO), Facebook and Instagram. Shortly after launching, the Company decided to shift the focus of its marketing to
a direct sales approach, resulting in the formation and launch of EPIQ MD, Inc.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Going
Forward Strategy:</b> With EPIQ MD, Inc. taking over the sales and marketing of the direct-to-consumer telemedicine platform, ZipDoctor
has changed its business plan to focus on developing customized telemedicine solutions for niche, or specialty care, areas of medicine.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Telemedicine
Platform Provider for Pharmacies.</b> ZipDoctor is targeting relationships with specialty compound pharmacies seeking both an online
telemedicine platform and a network of doctors to assist in facilitating patient online visits and to streamline the medical intake,
patient demographics, health insurance verifications and overall prescription process. In exchange, ZipDoctor will receive a monthly
fee on a per-patient per month basis for this customized access to the telemedicine platform. The initial focus will be on Texas based
pharmacies, however, if successful in Texas, ZipDoctor plans to expand its customized telemedicine solution to pharmacies across the
United States.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 9 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%"><a href="#toc" title="Table of Contents" style="font-style: italic">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
August 15, 2021, ZipDoctor entered into a Telemedicine Services Agreement (the &#8220;<span style="text-decoration: underline">Services Agreement</span>&#8221;) with Murphy RX,
LLC (&#8220;<span style="text-decoration: underline">Murphy</span>&#8221;), a Texas-based specialty pharmacy, which has since ceased operations as of January 31, 2022. Pursuant
to the Services Agreement, ZipDoctor agreed to provide Murphy with access to its centralized technology platform, to collect and manage
patient demographics, and access to telemedicine services. Murphy agreed to pay ZipDoctor a monthly fee on a per-patient basis for the
use of the technology platform and for access to primary care telemedicine services. ZipDoctor also agreed to provide continued support
for the ZipDoctor website through the term of the agreement. The Services Agreement is no longer in effect, as Murphy ceased operations
effective as of January 31, 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of the date of this prospectus, ZipDoctor has approximately 100 total members subscribed to its subscription-based telemedicine platform
at <span style="text-decoration: underline">www.ZipDoctor.co</span>. Monthly subscription payments range from $25/month to $45/month, depending on how many family members are
included, and provide members with unlimited, 24/7 access to board certified physicians and licensed mental and behavioral health counselors
and therapists.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>EPIQ
MD, INC. &#8211; 100% OWNED</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
October 23, 2020, the Company incorporated a wholly-owned subsidiary, EPIQ MD, Inc. (&#8220;<span style="text-decoration: underline">EPIQ MD</span>&#8221;) in the state of Nevada.
EPIQ MD is a direct-to-consumer, telemedicine and healthcare company targeting Americans who are uninsured or underinsured. The EPIQ
MD service offering is a convergence of primary care telemedicine, preventative care services and wellness programs &#8211; under the
EPIQ MD brand and on a single platform. EPIQ MD markets and sells its services direct to end-use consumers, as well as through business-to-business
(B2B) efforts, by focusing on employers in the targeted industries.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Products
&amp; Services</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">EPIQ
MD&#8217;s telemedical services revolve around three services (1) primary care, (2) mental health care, and (3) prevention. Using cloud-based
software, EPIQ MD has been able to merge these services under a single platform.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Primary
care with EPIQ MD connects users to board certified doctors and medical professionals who can treat most non-emergency conditions using
telemedicine. Similarly, EPIQ MD&#8217;s mental health services connect users with licensed therapists and counselors. As for EPIQ MD&#8217;s
preventive care, the Company is using data driven technologies (wearables and apps), nutritionist and lab services, to help attempt to
mitigate chronic diseases and the risk factors associated with them. In the future, EPIQ MD plans to add in-home medical devices to record
vital information, offering what we believe to be the ambit of services between patient and doctor via the use of EPIQ MD&#8217;s telemedicine
platform.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 10 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%"><a href="#toc" title="Table of Contents" style="font-style: italic">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">EPIQ
MD also provides its subscribers with an option to participate in two premium add-on services, EPIQ LUX and EPIQ Paws. EPIQ LUX provides
subscribers with discounts to ancillary healthcare related services such as laboratory services, dental and vision discount plans, prescription
drug discounts, and imaging services and EPIQ Paws provides subscribers with access to virtual consultations with licensed veterinarians.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of the date of this prospectus, EPIQ MD has nominal subscribers as it is expanding its marketing initiatives. However, EPIQ MD is currently
registered to do business and is being marketed in <span style="background-color: white">Alaska, Georgia, Illinois, Texas, Arizona, New
Mexico, Colorado, Louisiana, Mississippi, Alabama, Florida, Nevada and Utah.</span> To ensure the highest quality control, it plans to
scale up its full-service coverage incrementally to all 50 U.S. states by year-end 2022, funding permitting.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Marketing
Strategy</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">With
approximately 30 million people uninsured in the United States (according to 2019 Congressional Budget Office estimates) and 45 percent
of U.S. adults between ages of 19 and 64 being inadequately insured (according to a February 2019 Survey Brief by the Commonwealth Fund),
and an estimated 530,000 families turning to bankruptcy each year due to medical expenses (according to a study published in the March
2019 American Public Journal of Health), the Company sees an opportunity to make a positive impact in the lives of these uninsured or
underinsured people. We believe that this is the demographic that the healthcare system has abandoned, ignored and/or left behind and
is what we believe to be a largely underserved group.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
grow its subscriber base, EPIQ MD has implemented its own direct-to-consumer distribution channel referred to as the &#8220;Ambassador
Program&#8221;. The Ambassador Program is intended to allow social influencers, community leaders and entrepreneurial-minded sales agents
to market and sell EPIQ MD&#8217;s services across the nation, on a commission-only basis.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Market
Opportunity</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
previously described above, with approximately 30 million people uninsured in the United States and 45 percent of U.S. adults between
ages of 19 and 64 being inadequately insured, EPIQ MD believes that their service offerings will be instrumental in reaching these Americans
and plans to reach this demographic through its own direct-to-consumer distribution channel, or Ambassador Program, and through its commercial
division <span style="background-color: white">that will target small and medium sized businesses (SMB&#8217;s) and municipalities.</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">According
to a 2020 study by the Kaiser Family Foundation, a leading industry research firm (&#8220;Key Facts About the Uninsured Population&#8221;),
the high cost of insurance is one of the main reasons individuals lack coverage (in 2019, 73.7% of uninsured adults said they were uninsured
because the cost of coverage was too high); and, individuals with income below 200% of the Federal Poverty Level (FPL) are at the highest
risk of being uninsured.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 11 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%"><a href="#toc" title="Table of Contents" style="font-style: italic">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
see a significant opportunity to market to these uninsured and/or underinsured persons, and believe that our low-cost, flat rate, telemedical
services can be an attractive alternative to those persons seeking lower cost health services.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>LIFE
GURU, INC. &#8211; 51% OWNED</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
May 15, 2020, the Company acquired a 51% interest in Life Guru, Inc., a Delaware corporation (&#8220;<span style="text-decoration: underline">Life Guru</span>&#8221;). Life Guru
owns www.LifeGuru.me &#8211; a website dedicated to providing an online platform to connect consumers to a variety of mentors, professionals,
life coaches and career coaches. Upon final launch of the platform, it will include functionality enabling: life coaches from around
the world to access and subscribe to the Life Guru platform; and consumers to filter their life coach options by geographic location,
language and even the type of currency they would like to pay with. While Life Guru is free to consumers, it generates revenues by charging
monthly subscription fees to coaches participating on the platform. Further, and depending on the type of subscription plan the life
coach chooses to participate in, Life Guru receives a percentage of the per session fees generated and earned between the consumer and
the life coach.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Since
the LifeGuru.me website was launched around March 2021, Life Guru has been working to optimize the website for mobile and completing
integration with its merchant account provider to automate monthly payouts to coaches. LifeGuru is currently in the process of marketing
and onboarding coaches onto the platform.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Industry
Trends</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Life
coaching has been the second fastest growing industry in the world for over ten consecutive years, behind the information technology
sector (according to a May 2016 article posted at Forbes.com). The global Personal Development Industry (including market segments from
holistic approaches, motivational speakers, inspirational websites, personal coaching, and other forms of personal development) was valued
at approximately $38.28 billion in 2019 and is expected to grow at a compound annual growth rate (CAGR) of 5.1% from 2020 to 2027 (according
to a July 2020 report by Grand View Research). Moreover, Life Guru believes that improving social skills and focusing on critical areas
for self-awareness, such as emotions, character traits, habits, individual values, and the psychological need that shapes the day-to-day
behavior of individuals are gaining importance.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Operational,
Technological &amp; Cost Advantages</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
anticipate that coaches that subscribe to the Life Guru platform will benefit from Life Guru&#8217;s investment in digital marketing
and promotion, enabling them to reach customers and providing increased visibility. Life Guru has developed a proprietary technology
platform for coaching online, as well as proprietary video conferencing capabilities for coaching interactively. Through our existing
marketing partnerships, Life Guru believes it has access to sales tools which allow the effective marketing of coaches across all major
social media platforms, including and most importantly, LinkedIn. LifeGuru.me is mobile-friendly and can run smoothly on many platforms,
making it highly scalable.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 12 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%"><a href="#toc" title="Table of Contents" style="font-style: italic">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Subscriptions</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Life
Guru offers free membership for all consumers to gain access to the site and search for life coaches. Life Guru&#8217;s model is to charge
coaches, and not members, for the use of its services. The Company currently offers three different subscription levels to life coaches,
with varying levels of promotion on the Life Guru site, prominence of search results, and commissions payable. As of the date of this
prospectus, Life Guru has no members and approximately 100 life coaches have signed up to use the platform.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Growth
Objectives</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition to marketing Life Guru directly to consumers, Life Guru intends to implement packages to be sold to various businesses and corporations,
which can, in turn, be marketed as a corporate benefit by employers. Life Guru calls this &#8220;Life Guru Corporate&#8221;. A recent
survey of 256 companies by the National Alliance of Healthcare Purchaser Coalitions, a nonprofit employer group, found that 53% of employers
are providing special emotional and mental health programs for their workforce in the wake of the pandemic. Life Guru believes that Life
Guru Corporate represents important potential upside in targeting the business and corporate world, and providing services to employees
on an ongoing basis. Life Guru Corporate can only be developed once the platform has achieved a reputable brand and a substantial amount
of high-quality business coaches are engaged, and Life Guru does not anticipate launching Life Guru Corporate with fewer than 200 life
coaches, provided Life Guru&#8217;s projected milestones are met.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>MANGOCEUTICALS,
INC. <i>&#8211; 80% OWNED</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
October 7, 2021, the Company incorporated Mangoceuticals, Inc. (&#8220;<span style="text-decoration: underline">Mangoceuticals</span>&#8221;) in the
state of Texas with the intent of focusing on developing, marketing and selling a variety of men&#8217;s wellness products and services
via a telemedicine platform. To date, the Company has identified men&#8217;s wellness telemedicine services and products as a growing
sector in the most recent years and especially related to the areas of erectile dysfunction and hair loss products. In this regard, Mangoceuticals
is currently in the process of developing and preparing to market a new brand of erectile dysfunction (ED) products that delivers fast
acting results through a proprietary combination of FDA approved ingredients.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mangoceuticals
plans to market and sell this new brand of ED products exclusively online and will require the use of a telemedicine visit, a doctor&#8217;s
prescription and the fulfillment of the prescription by pharmacy licensed in the state in which the customer resides. Mangoceuticals
plans to rely heavily on digital and social media marketing through channels such as Facebook, Instagram, Twitter, Snap Chat and TikTok
and further has plans to use digital marketing with the goal of creating viral marketing campaigns, using social media influencers and
celebrities, funding permitting.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 25.95pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
goal is to eventually sell this new brand of ED products nationwide and to use EPIQ Scripts (described below) as its mail order pharmacy
to fulfill the ED prescriptions. Mangoceuticals is currently in the branding and development stage of this ED product and anticipates
a planned and limited launch in the Texas market in the second quarter of 2022 with the intent of expanding its marketing initiatives
at a pace in which Epiq Scripts obtains additional state licenses across the United States.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 13 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%"><a href="#toc" title="Table of Contents" style="font-style: italic">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subsequent
to incorporation, Mangoceuticals issued 1,000,000 shares of common stock each to Jacob D. Cohen, the Chief Executive Officer of the Company,
and a third party, in consideration for services rendered. As a result, Mangoceuticals is currently 80% owned by the Company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>EPIQ
SCRIPTS, LLC &#8211; 51% OWNED</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
January 24, 2022, the Company formed EPIQ Scripts, LLC (&#8220;<span style="text-decoration: underline">EPIQ Scripts</span>&#8221;) in the state of Texas. EPIQ Scripts has been
established with the intent of operating as a close-door online mail order pharmacy with a specific target and vision to obtain licenses
in all 50 states across the U.S., of which no state licenses have been obtained as of the date of this prospectus. EPIQ Scripts also
plans to seek to become accredited with the most respected and highly recognized authorities in the industry, such as <span style="background-color: white">Utilization
Review Accreditation Commission (</span>URAC), Legit Script, <span style="background-color: white">Accreditation Commission for Health
Care</span> (ACHC), and <span style="background-color: white">National Association of Boards of Pharmacy</span> (NABP) Digital Pharmacy.
EPIQ Scripts also intends to obtain in-network contracts with all major Pharmacy Benefit Managers (PBM) and insurance payors.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Market
Opportunity</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">It
is anticipated that if licenses, accreditations and in-network contracts are secured in all 50 U.S. states, EPIQ Scripts will be able
to market itself to the many up and coming telemedicine companies that have been on the rise since early 2020. Pursuant to a July 9,
2021 article published by McKinsey &amp; Company, according to a study taken by McKinsey &amp; Company, <span style="background-color: white">in
April 2020, overall telehealth utilization for office visits and outpatient care was 78 times higher than in February 2020. Ev</span>en
though telemedicine use has now leveled off as in-person visits have returned, McKinsey &amp; Company is still consistently seeing use
that is 38 times higher than pre-pandemic numbers. Furthermore, a majority of Americans have now tried out telehealth. According to an
article published at Sykes.com, a March 2021 survey of 2,000 U.S. adults undertaken by Sykes.com found that by March 2021, more than
61% of such surveyed individuals had made a telehealth/telemedicine appointment, which is a massive increase from just 19.5% a year prior,
according to Sykes. We further believe that telemedicine use is now widespread across demographics.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
believe the significant increases in demand for telemedicine has created a vacuum for pharmacies that have the capabilities to handle
the prescription volume generated by these platforms. We believe that EPIQ Scripts&#8217; planned mail order pharmacy, which is expected
to have advanced API capabilities and infrastructure and be supported with nationwide licenses and accreditations can position itself
to capitalize on the current market opportunity.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">EPIQ
Scripts has currently filed with the <span style="background-color: white">Utilization Review Accreditation Commission (URAC) to obtain
its pharmacy accreditation and is in the process of obtaining its first state license in the State of Texas, which it anticipates receiving
in April 2022. Once the Texas state license is obtained, EPIQ Scripts will be able to apply for additional state licenses until it has
obtained all 50 state licenses, with some state licenses easier to obtain and quicker to obtain than others. EPIQ Scripts intends to
have licenses to operate in all 50 states by the first quarter of 2023.</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*
* * * * *</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 14 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%"><a href="#toc" title="Table of Contents" style="font-style: italic">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company intends to continue to grow its business both organically and through identifying acquisition targets over the next 12 months
in the telemedicine, life coaching and wellness space, funding permitting. As these opportunities arise, the Company will determine the
best method for financing its growth which may include the issuance of additional debt instruments, common stock, preferred stock, or
a combination thereof, any one or more of which may cause significant dilution to existing shareholders. <span style="background-color: white">The
Company requires approximately $5 million to implement its current business strategy for its different subsidiaries and to support potential
growth. </span>We expect to raise funds in the future through the sale of debt and/or equity in order to allow us to operate for the
next twelve months and may need to raise further additional capital in order to expedite our growth through acquisitions, none of which
are currently planned. There is no assurance that we will be successful in raising such funds and if we do raise funds, this may result
in substantial dilution to current investors.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>DISCONTINUED
OPERATIONS:</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>MEDICAL
SPA AND WELLNESS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company previously operated three wholly-owned subsidiaries that were in the Medical Spa and Wellness Sector (collectively hereinafter
referred to as &#8220;<span style="text-decoration: underline">MedSpa</span>&#8221;, or &#8220;<span style="text-decoration: underline">VISSIA</span>&#8221;), the operations of which were discontinued in October 2020:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>1.</i></b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>VISSIA
    MCKINNEY, LLC (F/K/A NOVOPELLE DIAMOND, LLC) &#8211; 100% OWNED</i></b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.65pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">VISSIA
McKinney was a physician supervised, medical spa and wellness clinic that offered a full menu of wellness services including anti-aging,
weight loss and skin rejuvenation treatments and was located at 5000 Collin McKinney Parkway, Suite 150, McKinney, Texas 75070.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>2.</i></b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>VISSIA
    WATERWAY, INC. (F/K/A NOVOPELLE WATERWAY, INC.) &#8211; 100% OWNED</i></b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.65pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">VISSIA
McKinney was a physician supervised, medical spa and wellness clinic that offered a full menu of wellness services including anti-aging,
weight loss and skin rejuvenation treatments and was located at 25 Waterway, Suite 150, The Woodlands, Texas.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>3.</i></b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>NOVOPELLE
    TYLER, INC. &#8211; 100% OWNED</i></b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
December 3, 2019, the Company formed and organized Novopelle Tyler, Inc. in the State of Texas with the plan to come to terms on a retail
location for a new med spa to be located in Tyler, Texas. The Company no longer intends to open this location and no activity has been
performed under this entity to date.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*
* * * *</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 15 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%"><a href="#toc" title="Table of Contents" style="font-style: italic">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
a result of COVID-19 and &#8216;stay-at-home&#8217; and social distancing orders issued in McKinney and The Woodlands, Texas, we had
to close both of our then operational MedSpas, VISSIA McKinney and VISSIA Waterway, Inc., effective March 10, 2020, and which resulted
in both the loss of income and the loss of substantially all of our MedSpa employees, who had to be let go. VISSIA Waterway, Inc. reopened
effective June 21, 2020 and VISSIA McKinney reopened effective August 8, 2020. However, due to the termination of employees associated
with the shutdown we were forced to expend resources to attract, hire and train completely new staff for preparation of the re-launchings.
Notwithstanding the re-openings, customer traffic and demand at our VISSIA Waterway, Inc. and VISSIA McKinney MedSpa locations failed
to rebound to pre-COVID-19 levels due to COVID-19 and the pandemic&#8217;s effects on the economy, and because we were unable to predict
the length of the pandemic or ultimate outcome thereof, and further due to our limited capital resources, effective on October 25, 2020,
we made the decision to close both our VISSIA Waterway, Inc. and VISSIA McKinney locations. Our former MedSpa operations and assets are
included under discontinued operations in the statement of operations and balance sheet included herein for the year ended December 31,
2021 and for the year ended, December 31, 2020.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>4.</i></b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>CAPITOL
    CITY SOLUTIONS, USA, INC. &#8211; 100% OWNED</i></b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
September 17, 2019, the Company formed and organized Capitol City Solutions USA, Inc. (&#8220;<span style="text-decoration: underline">CCS</span>&#8221;) in the State of Texas
to act as a general contracting and construction company focused on the remodeling, general construction and interior finish of both
the Company&#8217;s then MedSpa locations (which have since been closed) as well as to market to other commercial real estate projects
within the United States. The Company made the decision to cease any further construction-based operations under CCS in July 2021, in
order to focus on the subsidiaries that better aligned with the purpose of the Company and its ongoing business plan in the telehealth
and wellness space.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>5.</i></b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>LEGEND
    NUTRITION, INC. &#8211; 100% OWNED</i></b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
September 23, 2019, the Company formed and organized Legend Nutrition, Inc. (&#8220;<span style="text-decoration: underline">Legend Nutrition</span>&#8221;) in the State of Texas
to act as a new brand of retail vitamin and supplement stores to be branded and marketed as Legend Nutrition. October 18, 2019, Legend
entered into an Asset Purchase Agreement to acquire all of the assets associated with and related to a retail vitamin, supplements and
nutrition store located in McKinney, Texas and previously identified and doing business as &#8220;<span style="text-decoration: underline">Ideal Nutrition.</span>&#8221; Pursuant
to the Asset Purchase Agreement, Legend purchased a variety of assets including software, contracts, bank and merchant accounts, products,
inventory, computers, security systems and other intellectual properties. As Legend Nutrition&#8217;s lease expired in January 2021,
the Company made the decision to cease its operations to focus on the subsidiaries that better aligned with the purpose of the Company
and its ongoing business plan in the telehealth and wellness space.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 16 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%"><a href="#toc" title="Table of Contents" style="font-style: italic">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Government
Regulation</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.65pt; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
health care industry is subject to extensive federal, state and local laws and regulations relating to licensure, conduct of operations,
ownership of facilities, addition of facilities and services, payment for services and prices for services that are extremely complex
and for which, in many instances, the industry does not have the benefit of significant regulatory or judicial interpretation. We will
also be subject to regulation regarding sale of our products online and solicitation of clients thereby, as well as through our general
contractor business and the licensing and code requirements relating thereto.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.65pt; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span style="text-decoration: underline">COVID-19
Outlook and Discontinued Operations</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
outbreak of the 2019 novel coronavirus disease (&#8220;<span style="text-decoration: underline">COVID-19</span>&#8221;), which was declared a global pandemic by the World Health
Organization on March 11, 2020, and the related responses by public health and governmental authorities to contain and combat its outbreak
and spread has severely impacted the U.S. and world economies, the market for health spa services, nutrition supplements and our other
business offerings during the end of the first quarter of 2020, and continuing through the end of 2020 and into 2021. Government mandated
&#8216;stay-at-home&#8217; and similar orders have to date, and may in the future, prevent us from operating. In late 2020, we made the
decision to discontinue operations of our VISSIA Waterway, Inc. and VISSIA McKinney MedSpa locations, due to declines in customers and
issues staffing such facilities, each as a result of the pandemic. Additionally, our Legend Nutrition store saw a deep decline in sales
due to social distancing orders and decreases in customers who are willing to venture out to brick-and-mortar establishments. Legend
Nutrition&#8217;s lease was up January 31, 2021, and the Company chose to not renew the lease, closed the store, and will not continue
in this line of business moving forward. We also decided to cease offering construction services around July 2021.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of the date of this prospectus, our operations are limited, and consist solely of ZipDoctor, Inc., Life Guru, Inc., EPIQ MD, Inc, Mangoceuticals,
Inc., and EPIQ Scripts, LLC.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Moving
forward, economic recessions, including those brought on by the continued COVID-19 outbreak, geopolitical events, including the current
military conflict between Russia and the Ukraine, inflationary pressures, or other events, may have a negative effect on the demand for
our services and our operating results. Any prolonged disruption to our operations or work force available is likely to have a significant
adverse effect on our results of operations, cash flows and ability to meet continuing debt service requirements. All of the above may
be exacerbated in the future as the COVID-19 outbreak and the governmental responses thereto continues.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Summary
Risk Factors</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
business is subject to numerous risks and uncertainties, including those in the section entitled &#8220;Risk Factors&#8221; and elsewhere
in this prospectus. These risks include, but are not limited to, the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
    limited operating history;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 17 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%"><a href="#toc" title="Table of Contents" style="font-style: italic">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
    need for additional funding to support our operations, repay debt and expand our operations;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    continuing effects of COVID-19 on our operations and prospects;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Impairments
    we may be required to assess in connection with our assets and goodwill as a result of such shutdowns and/or otherwise;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Risks
    associated with our telehealth platform, including liability in connection therewith, funding needed to support such operations and
    other risks associated with the operations of the telehealth platform;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Risks
    associated with the launch of our new closed door online digital pharmacy, Epiq Scripts, LLC, including liability in connection therewith,
    ability to obtain state licenses, funding needed to support such operations and other risks associated with the operations of an
    online digital pharmacy;</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Risks
    associated with the development of our new ED product, including liability in connection therewith, funding needed to support such
    operations and other risks associated with the operations of the telehealth platform;</span></td></tr>

<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    ability of Life Guru to sign up enough life coaches to make the commercial launch of such website economic, and the willingness of
    individuals to use such website in the future;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Disruptions
    to our operations or liabilities associated with future acquisitions;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
    ability to continue as a going concern;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
    dependence on our Chief Executive Officer and director, Jacob D. Cohen, including the lack of independent directors, and related
    party transactions affecting the Company;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Competition
    we face;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
    ability to maintain our varied operations, and service our indebtedness;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Material
    weaknesses in our controls and procedures;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
    ability to obtain and maintain adequate insurance;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Legal
    challenges and litigation;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Liability
    associated with our contracting operations;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    terms of Mr. Cohen&#8217;s employment agreement;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 18 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%"><a href="#toc" title="Table of Contents" style="font-style: italic">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dilution
    caused by the conversion of outstanding notes, conversion of preferred stock, exercise of outstanding warrants, and future fund-raising
    activities;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    price of, volatility in, and lack of robust trading market for, our common stock; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    fact that Mr. Cohen, our Chief Executive Officer, has voting control over the Company.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Penny
Stock Rules</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
common stock is considered a &#8220;<span style="text-decoration: underline">penny stock</span>&#8221;, and subject to the requirements of Rule 15g-9, promulgated under the Exchange
Act. &#8220;<span style="text-decoration: underline">Penny stock</span>&#8221; is generally defined as any equity security not traded on an exchange or quoted on NASDAQ that
has a market price of less than $5.00 per share. Under such rule, broker-dealers who recommend low-priced securities to persons other
than established customers and accredited investors must satisfy special sales practice requirements, including a requirement that they
make an individualized written suitability determination for the purchaser and receive the purchaser&#8217;s consent prior to the transaction.
The Securities Enforcement Remedies and Penny Stock Reform Act of 1990, also requires additional disclosure in connection with any trades
involving a stock defined as a penny stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
required penny stock disclosures include the required delivery, prior to any transaction, of a disclosure schedule explaining the penny
stock market and the risks associated with it. Such requirements could severely limit the market liquidity of the securities and the
ability of purchasers to sell their securities in the secondary market. In addition, various state securities laws impose restrictions
on transferring &#8220;<span style="text-decoration: underline">penny stocks</span>&#8221; and as a result, investors in the common stock may have their ability to sell their
shares of the common stock impaired.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Corporate
Information</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
executive offices are located at 7950 Legacy Drive, Suite 400, Plano, Texas 75024 and our telephone number is (469) 963-2644. Our website
address is <span style="text-decoration: underline">https://amihcorp.com</span>. We do not incorporate information on our website into this prospectus or any supplement to this
prospectus and you should not consider any information on, or that can be accessed through, our website as part of this prospectus or
any supplement to this prospectus (other than those filings with the SEC that we specifically incorporate by reference into this prospectus
or any supplement to this prospectus).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Reverse
Stock Split</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have applied to list our common stock and certain warrants to purchase common stock which we plan to sell in the future in a public offering,
on the NASDAQ Capital Market; however, our application to uplist our common stock and certain warrants on the NASDAQ Capital Market may
not be approved and our securities may never trade on the NASDAQ Capital Market.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
July 30, 2021, our board of directors, and on July 30, 2021, stockholders holding a majority of our outstanding voting shares, approved
resolutions authorizing a reverse stock split of the outstanding shares of our common stock in the range from one-for-two (1-for-2) to
one-for-sixty (1-for-60), and provided authority to our board of directors to select the ratio of the reverse stock split in their discretion,
at any time prior to the earlier of July 30, 2022 and the date of our 2022 annual meeting of shareholders. On January 25, 2022, our board
of directors, pursuant to such shareholder authority, approved a one-for-sixty (1-for-60) reverse stock split of the outstanding shares
of our common stock, which is intended to allow us to meet the minimum share price requirement of the NASDAQ Capital Market. Both the
board of directors and Financial Industry Regulatory Authority, Inc. (FINRA) have approved the reverse stock split, which is proposed
in order to increase the trading price of the Company&#8217;s common stock to a level thought to be sufficient to allow an uplisting
of the Company&#8217;s common stock on the Nasdaq Capital Market. Notwithstanding the approvals above, the officers of the Company have
not yet moved forward with the reverse stock split, or filed Articles of Amendment in connection therewith with the Secretary of State
of Nevada. The Company currently does not have an estimated date for when the reverse stock split will be made effective.
Because the Company has not formally affected the reverse stock split, none of the outstanding share amounts set forth below have been
adjusted for such board of directors approved reverse stock split. The board of directors reserves the right to adjust the ratio of the
reverse stock split and/or terminate the authority for such reverse stock split in the future.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Additional
Information</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Additional
information about us can be obtained from the documents described under &#8220;<span style="text-decoration: underline">Where You Can Find More Information.</span>&#8221;</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 19 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%"><a href="#toc" title="Table of Contents" style="font-style: italic">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><b>&#160;</b></span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-transform: uppercase; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="ed_004"></span>This
Offering</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">The
selling stockholders named in this prospectus may offer and sell up to </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">42,666,665
<span style="background-color: white">shares of our common stock, par value $0.0001 per share. Our common stock is currently quoted </span>on
the OTC Markets Group Inc.&#8217;s OTCQB Market (the &#8220;<span style="text-decoration: underline">OTCQB</span>&#8221;) under the trading symbol, &#8220;<span style="text-decoration: underline">AMIH.</span>&#8221;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Shares
    of Common Stock Offered by the Selling Stockholders:</b></span></td>
    <td style="width: 0.1in">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">42,666,665
    shares of common stock, which represents (a) up to 29,333,333 shares of common stock issuable upon conversion of the principal and
    accrued interest at maturity under the $2,000,000 in Notes, issued by the Company to the selling stockholders between November 22,
    2021 and December 2, 2021, at the option of the holders thereof; and (b) up to 13,333,332 shares of the Company&#8217;s common stock
    issuable upon exercise of the Warrants, which Notes and which Warrants, are described in greater detail under &#8220;<a href="#ed_006">Securities Purchase Agreement</a>&#8221;, beginning on page 47.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Shares
    of Common Stock Outstanding Prior to this Offering:</b></span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">97,286,902
    shares of common stock.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Shares
    of Common Stock Outstanding After this Offering<sup>1</sup>:</b></span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">139,953,567
    shares of common stock.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Use
    of Proceeds:</b></span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    will not receive any of the proceeds from the sale or other disposition by the selling stockholders or their transferees of the
    shares of common stock covered hereby. However, to the extent that the Warrants are exercised for cash, we will receive the payment
    of the exercise price in connection with such exercise (see also &#8220;<a href="#ed_007">Use of Proceeds</a>&#8221; on page 50
    below).</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Risk
    factors:</b></span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    purchase of our common stock involves a high degree of risk. The common stock offered in this prospectus is for investment purposes
    only and currently only a limited market exists for our common stock. Please refer to the section entitled &#8220;<a href="#ed_005">Risk Factors</a>&#8221;
    before making an investment in our common stock.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Trading
    symbol:</b></span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
    common stock is quoted on the OTCQB under the trading symbol &#8220;<span style="text-decoration: underline">AMIH</span>&#8221;.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Rule-Page --><div style="width: 25%"><div style="border-top: Black 1pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><sup>1
</sup></i></b><i>Assumes the issuance of all shares of common stock registered in the registration statement, of which this prospectus
forms a part.</i></span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 20 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%"><a href="#toc" title="Table of Contents" style="font-style: italic">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
this prospectus, unless otherwise indicated, the number of shares of our common stock and other capital stock, and the other information
based thereon, is as of April 21, 2022 and excludes:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">warrants
    to purchase 13,333,332 shares of our common stock at an exercise price of $0.075 (including shares of common stock issuable upon
    exercise of the Warrants);</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares
    of common stock issuable upon conversion of $2,000,000 under various convertible promissory notes (including the Notes), with conversion
    prices of $0.075 per share, subject in many cases to adjustments to the conversion prices upon defaults and anti-dilution; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span>&#9679;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">no
    further awards under the Company&#8217;s equity compensation plans.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Additionally,
unless otherwise stated, all information in this prospectus:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">reflects
    all currency in United States dollars.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-transform: uppercase; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="ed_005"></span>Risk
Factors</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>You
should be aware that there are substantial risks for an investment in our common stock. You should carefully consider these risk factors,
along with the other information included in this prospectus, before you decide to invest in our common stock.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>If
any of the following risks were to occur, such as our business, financial condition, results of operations or other prospects, any of
these could materially affect our likelihood of success. If that happens, the market price of our common stock, if any, could decline,
and prospective investors would lose all or part of their investment in our common stock.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Risks
Related to our Business</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.65pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Since
we have a limited operating history, it is difficult for potential investors to evaluate our business.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.65pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.65pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
short operating history in the health and wellness industry and mentoring/life coach industry may hinder our ability to successfully
meet our objectives, and makes it difficult for potential investors to evaluate our business or prospective operations. As an early-stage
company, we are subject to all the risks inherent in the financing, expenditures, operations, complications and delays inherent in a
new business. Accordingly, our business and success face risks from uncertainties faced by developing companies in a competitive environment.
There can be no assurance that our efforts will be successful or that we will ultimately be able to attain profitability.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.65pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.65pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
may not be able to raise capital when needed, if at all, which would force us to delay, reduce or eliminate our service locations and
product development programs or commercialization efforts and could cause our business to fail.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.65pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.65pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company intends to continue to grow its business both organically and by identifying acquisition targets over the next twelve months
in the telemedicine, life coaching and wellness space. We may need to raise additional capital in order to expedite our growth through
acquisitions, provided that none are currently planned. Notwithstanding that, we expect to need substantial additional funding to pursue
additional service locations and product development and commercialize our products and services. There are no assurances that future
funding will be available on favorable terms or at all. The failure to fund our operating and capital requirements could have a material
adverse effect on our business, financial condition and results of operations. If we are unable to raise capital when needed or on attractive
terms, we could be forced to delay, reduce or eliminate our expansion of spa locations and development programs or any future commercialization
efforts. Any of these events could significantly harm our business, financial condition and prospects.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.65pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 21 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%"><a href="#toc" title="Table of Contents" style="font-style: italic">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our
business has been materially and adversely disrupted by COVID-19, and the control response measures that state and local governments
have implemented to address it, and may be impacted by other epidemics or pandemics in the future. We have been forced to close our MedSpas
and have closed our nutrition store.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">An
epidemic, pandemic or similar serious public health issue, and the measures undertaken by governmental authorities to address it, could
significantly disrupt or prevent us from operating our business in the ordinary course for an extended period, and thereby, and/or along
with any associated economic and/or social instability or distress, have a material adverse impact on our consolidated financial statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
March 11, 2020, the World Health Organization characterized the outbreak of COVID-19 as a global pandemic and recommended containment
and mitigation measures. On March 13, 2020, the United States declared a national emergency concerning the outbreak, and several states
and municipalities have declared public health emergencies. Along with these declarations, there were extraordinary and wide-ranging
actions taken by international, federal, state and local public health and governmental authorities to contain and combat the outbreak
and spread of COVID-19 in regions across the United States and the world, including quarantines, &#8220;<span style="text-decoration: underline">stay-at-home</span>&#8221; orders
and similar mandates for many individuals to substantially restrict daily activities and for many businesses to curtail or cease normal
operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
COVID-19 pandemic, and related social distancing requirements, travel bans, stay-at-home orders and closures limited access to our spas
and store and forced us to close our spas and store during the first quarter of 2020 and into the second quarter of 2020 and even though
such stores eventually reopened in June and August 2020, customer traffic and demand at our MedSpa locations failed to rebound to pre-closure
levels due to COVID-19 and the pandemic&#8217;s effects on the economy, and because we were unable to predict the length of the pandemic
or ultimate outcome thereof, and further due to our limited capital resources, effective in October, 2020, we made the decision to discontinue
operations of both our MedSpa locations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">While
our MedSpas were forced to close during the second and third quarters of 2020. Legend Nutrition was able to remain open as an essential
business, as we sold vitamins and other nutritional supplements. Though the store was able to remain open, the store saw a deep decline
in sales due to social distancing orders and decreases in customers who are willing to venture out to brick-and-mortar establishments.
Legend Nutrition&#8217;s lease was up January 31, 2021, and the Company chose to not renew the lease, closed the store, and will not
continue in this line of business moving forward.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
also decided to cease offering construction services around July 2021.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 22 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%"><a href="#toc" title="Table of Contents" style="font-style: italic">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
of the above has, in turn, not only negatively impacted our operations, financial condition and demand for our services, but our overall
ability to react timely to mitigate the impact of this event. Our 2021 financial results were significantly negatively affected by COVID-19
and the closure of our med spas and nutrition store in connection therewith (both due to governmental orders and separately due to our
lack of operating funds) and our decision to cease our construction services; however, the full effect on our business and operation
as a result of COVID-19 is currently unknown. The outbreak of COVID-19 has caused significant disruptions to the Company&#8217;s ability
to generate revenues and cash flows, and uncertainty regarding the length of the disruption may adversely impact our ability to raise
additional capital.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of the date of this prospectus, our operations are limited, and consist solely of ZipDoctor, Inc., Life Guru, Inc., Mangoceuticals, Inc.,
EPIQ Scripts, LLC, and EPIQ MD, Inc., which have been only minimally affected by COVID-19 as they mainly operate through online platforms.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Should
the COVID-19 public health effort intensify to such an extent that we cannot operate, if there are prolonged government restrictions
on our business and our customers, and/or an extended economic recession or significant inflation, we could be unable to produce revenues
and cash flows sufficient to conduct our business; or service our outstanding debt. Such a circumstance could, among other things, exhaust
our available liquidity (and ability to access liquidity sources) and/or trigger an acceleration to pay a significant portion or all
of our then-outstanding debt obligations, which we may be unable to do.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our
business may suffer from the severity or longevity of the Coronavirus/COVID-19 global outbreak.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
demand for our services relies upon, among other things, the ability of our telemedicine platform to provide telemedicine services and
will in the future rely on the operation of our Life Guru website. Economic recessions, including those brought on by the COVID-19 outbreak
may have a negative effect on the demand for our services and our operating results. We have also experienced delays due to the COVID-19
outbreak in receiving products and supplies which we need to operate. All of the above may be exacerbated in the future as the COVID-19
outbreak and the governmental responses thereto continues. All of the above may in the future cause, and have to date caused, a material
adverse effect on our operating results.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
have recently changed our primary business focus from the operation of MedSpas, a nutrition store and construction services, to telemedicine,
life coaching and wellness.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Customer
traffic and demand at our VISSIA Waterway, Inc. and VISSIA McKinney MedSpa locations which were re-opened after mandatory closures associated
with COVID-19 in June and August 2020, respectively, failed to rebound to pre-closure levels due to COVID-19 and the pandemic&#8217;s
effects on the economy, and because we were unable to predict the length of the pandemic or ultimate outcome thereof, and further due
to our limited capital resources, effective in October 2020, we made the decision to close both our VISSIA Waterway, Inc. and VISSIA
McKinney MedSpa locations and discontinue operations. Separately, legend Nutrition&#8217;s lease was up January 31, 2021, and the Company
chose not to renew the lease, closed the store, and not continue in that line of business moving forward. We also decided to cease offering
construction services around July 2021. As such, our current operations consist solely of operations in the telemedicine, life coaching
and wellness industries, which industries we have only a limited history with. Furthermore, the majority of our revenues for the last
two years were generated through our MedSpa, nutrition store and construction services, and as such, our continued ability to generate
revenues and support our operations is unknown.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 23 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%"><a href="#toc" title="Table of Contents" style="font-style: italic">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
may owe significant amounts to a consultant under the terms of a consulting agreement.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
March 8, 2021, we entered into a Consulting Agreement with KBHS, LLC (&#8220;<span style="text-decoration: underline">KBHS</span>&#8221;), whose Chief Executive Officer is Mr.
Kevin Harrington, who was appointed the sole member of our then newly formed Advisory Committee. Pursuant to the Consulting Agreement,
KBHS agreed to provide consulting services to the Company as the Company&#8217;s Brand Ambassador, including providing endorsement services
and advising on marketing, promotions, acquisitions, licensing and business development. KBHS also agreed to up to four webinar appearances
on behalf of the Company per year to support the Company&#8217;s direct sales efforts. The Consulting Agreement has a term of two years,
and can be terminated with ten days prior written notice (subject to applicable cure rights set forth in the Consulting Agreement), in
the event we or KBHS breach any term of the agreement, or we fail to pay any amounts due, become subject to any government regulatory
investigation, certain lawsuits, claims, actions or take certain other actions during the term of the Consulting Agreement. As consideration
for providing the services under the Consulting Agreement, we issued KBHS 1.5 million shares of restricted common stock, which vested
immediately upon issuance, and agreed to pay KBHS $10,000 per month, a 5% finder&#8217;s fee on any new business introduced or developed
by KBHS and 7.5% of the value of any acquisition or merger created or developed exclusively by KBHS, undertaken by the Company, subject
to applicable laws. In the event we fail to pay any consideration due under the Consulting Agreement, such amount accrues interest at
the rate of 1.5% per month until paid in full.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
requirement to pay the finder&#8217;s fees and/or acquisition/merger fee under the agreement could significantly decrease any margin
we would otherwise obtain on any transaction, decrease our cash flows, and could prevent us from completing certain transactions in the
future, all of which could have a material adverse effect on the Company and its securities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
have previously suffered impairment losses, may suffer impairment losses in the future, and may be required to record significant additional
charge to earnings.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Due
to COVID-19&#8217;s effects on the economy, and because we are unable to predict the length of the pandemic or ultimate outcome thereof,
and further due to our limited capital resources, effective on October 25, 2020, we made the decision to close both MedSpa locations,
which are expected to be closed permanently. In accordance with the Generally Accepted Accounting Principles of the United States of
America (&#8220;<span style="text-decoration: underline">GAAP</span>&#8221;), we review our assets for impairment when events or changes in circumstances indicate the carrying
value of the asset may not be recoverable. For example, we had an impairment loss of $605,488 primarily attributable to the investment
in Life Guru, and settlement loss of $1,041,445 in connection with the common shares issued for note settlements in 2020. Other than
a settlement loss of $13,805 for the year ended December 31, 2021, we had no impairment loss nor settlement loss in the year ended December
31, 2021. Goodwill of $29,689 associated with Legend Nutrition was impaired in full during the fourth quarter of 2020. We have other
assets, goodwill and equipment on our balance sheet, which may be impaired in the future. Such impairments may have a significant negative
effect on our balance sheet, results of operations and financial results, and could cause the value of our common stock to decline in
value or become worthless.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 24 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%"><a href="#toc" title="Table of Contents" style="font-style: italic">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
face numerous risks associated with our ZipDoctor and EPIQ MD telehealth platforms which only recently commenced operations.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
2020, the Company incorporated two wholly-owned subsidiaries, ZipDoctor, Inc. in the state of Texas and EPIQ MD, Inc. in the state of
Nevada.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Zip
Doctor&#8217;s telemedicine platform does not require the customer to have an existing insurance plan and does not demand or require
any additional copays. ZipDoctor customers subscribe through the website and are only required to pay a low monthly fee, which is determined
based on if they are an individual, a couple, or a family.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">EPIQ
MD is a direct-to-consumer, telemedicine and healthcare company targeting Americans who are uninsured or underinsured. The EPIQ MD service
offering is a convergence of primary care telemedicine, preventative care services and wellness programs &#8211; under the EPIQ MD brand
and on a single platform.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company launched the ZipDoctor platform in August 2020 and the EPIQ MD platform in September 2021, and has generated nominal subscriptions
and revenues from each platform through their respective soft launch periods. There is no significant operating history upon which to
base any assumption as to the likelihood that either of the ZipDoctor and EPIQ MD telemedicine platforms will prove successful, and we
may never achieve operations or profitable operations through either platform. Each of our telehealth platforms also faces the following
risks, any of which may significantly negatively affect our operations, results of operations, and cash flows and could cause the value
of our common stock to decline in value:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
Our telehealth platforms could be adversely affected by legal challenges or by actions restricting our ability of our health providers
to provide services in certain jurisdictions;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
We will be dependent on the relationships of our partners with health care professionals;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
Evolving government regulations may require increased costs or adversely affect our results of operations;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
The market for telehealth services is new and if it does not develop as we forecast or develops more slowly than we expect our growth
may be harmed;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
The market for telehealth services is competitive and we compete with multiple competitors which have more resources and funding than
we have and a more well-known brand name;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
Economic uncertainty or downturns, particularly as it impacts particular industries, could adversely affect our business and operating
results; and</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
We will be entirely dependent on the infrastructure and operations of our partner to operate our telehealth platforms and such infrastructure
and operations are completely outside of our control.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 25 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%"><a href="#toc" title="Table of Contents" style="font-style: italic">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.65pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our
independent registered public accounting firm has expressed substantial doubt about our ability to continue as a going concern.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.65pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.65pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
historical financial statements have been prepared under the assumption that we will continue as a going concern. Our independent registered
public accounting firm has issued a report on our financial statements for the years ended December 31, 2021 and 2020, that included
an explanatory paragraph referring to our recurring operating losses and expressing substantial doubt in our ability to continue as a
going concern. Our ability to continue as a going concern is dependent upon our ability to obtain additional equity financing or other
capital, attain further operating efficiencies, reduce expenditures, and, ultimately, generate revenue. Our financial statements do not
include any adjustments that might result from the outcome of this uncertainty. However, if adequate funds are not available to us when
we need it, we will be required to curtail our operations which would, in turn, further raise substantial doubt about our ability to
continue as a going concern. The doubt regarding our potential ability to continue as a going concern may adversely affect our ability
to obtain new financing on reasonable terms or at all. Additionally, if we are unable to continue as a going concern, our stockholders
may lose some or all of their investment in the Company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.65pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.65pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
depend heavily on our Chief Executive Officer, and the loss of his services could harm our business.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.65pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.65pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
future business and results of operations depend in significant part upon the continued contributions of our senior management personnel,
particularly our Chief Executive Officer and director, Jacob D. Cohen. If we lose his services or if he fails to perform in his current
position, or if we are not able to attract and retain skilled personnel as needed, our business could suffer. Significant turnover in
our senior management could significantly deplete our institutional knowledge held by our existing senior management team. We depend
on the skills and abilities of these key personnel in managing our operations, product development, marketing and sales aspects of our
business, any part of which could be harmed by turnover in the future.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.65pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.65pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
expect to face intense competition, often from companies with greater resources and experience than we have.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.65pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
health, wellness, and mentoring/life coach industries are highly competitive and subject to rapid change. The industries continue to
expand and evolve as an increasing number of competitors and potential competitors enter the market. Many of these competitors and potential
competitors have substantially greater financial, technological, managerial and research and development resources and experience than
we have. Competitors for our products include Teladoc, PlushCare and Sesamecare. Some of these competitors and potential competitors
have more experience than we have in the development of health and wellness services and products. In addition, our services and products
compete with service and product offerings from large and well-established companies that have greater marketing and sales experience
and capabilities than we or our collaboration partners have. If we are unable to compete successfully, we may be unable to grow and sustain
our revenue.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.65pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 26 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%"><a href="#toc" title="Table of Contents" style="font-style: italic">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.65pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
are growing the size of our organization, and we may experience difficulties in managing any growth we may achieve.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.65pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.65pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of the date of this prospectus, we have twelve full-time employees (two at the parent/ZipDoctor level, eight at the EPIQ MD level, and
two at the Life Guru level). As our development and commercialization plans and strategies develop, we expect to need additional development,
managerial, operational, sales, marketing, financial, accounting, legal, and other resources. Future growth would impose significant
added responsibilities on members of management. Our management may not be able to accommodate those added responsibilities, and our
failure to do so could prevent us from effectively managing future growth, if any, and successfully growing our company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.65pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.65pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
may expend our limited resources to pursue particular products, services or locations and may fail to capitalize on products, locations
or services that may be more profitable or for which there is a greater likelihood of success.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.65pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.65pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Because
we have limited financial and managerial resources, we must focus our efforts on particular service programs, products and locations.
As a result, we may forego or delay pursuit of opportunities with other services, products or locations that later prove to have greater
commercial potential. Our resource allocation decisions may cause us to fail to capitalize on viable commercial products or profitable
market opportunities. Any such failure could result in missed opportunities and/or our focus on products, services or locations with
low market potential, which would harm our business and financial condition.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.65pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.65pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
engage in transactions with related parties and such transactions present possible conflicts of interest that could have an adverse effect
on us.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.65pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.65pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have entered, and may continue to enter, into transactions with related parties for financing, corporate, business development and operational
services, as detailed herein. Such transactions may not have been entered into on an arm&#8217;s-length basis, and we may have achieved
more or less favorable terms because such transactions were entered into with our related parties. This could have a material effect
on our business, results of operations and financial condition. The details of certain of these transactions are set forth under &#8220;<a href="#ed_025">Certain Relationships and Related Transactions</a>&#8221;. Such conflicts could cause an individual in our management to seek to advance his or her
economic interests or the economic interests of certain related parties above ours. Further, the appearance of conflicts of interest
created by related party transactions could impair the confidence of our investors.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 27 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%"><a href="#toc" title="Table of Contents" style="font-style: italic">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
have identified material weaknesses in our disclosure controls and procedures and internal control over financial reporting. If not remediated,
our failure to establish and maintain effective disclosure controls and procedures and internal control over financial reporting could
result in material misstatements in our financial statements and a failure to meet our reporting and financial obligations, each of which
could have a material adverse effect on our financial condition and the trading price of our common stock.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Maintaining
effective internal control over financial reporting and effective disclosure controls and procedures are necessary for us to produce
reliable financial statements. As reported in our Annual Report on Form 10-K for the year ended December 31, 2021, we have determined
that our disclosure controls and procedures and our internal control over financial reporting were not effective at the reasonable assurance
level, primarily due to a lack of segregation of duties in financial reporting, as of December 31, 2021, and continue to be ineffective.
Separately, management assessed the effectiveness of the Company&#8217;s internal control over financial reporting as of December 31,
2021 and determined that such internal control over financial reporting was not effective as a result of such assessment; and further
have not been effective since at least March 31, 2016.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
material weakness is a deficiency, or a combination of deficiencies, in internal control over financial reporting, such that there is
a reasonable possibility that a material misstatement of the Company&#8217;s annual or interim financial statements will not be prevented
or detected on a timely basis. A control deficiency exists when the design or operation of a control does not allow management or employees,
in the normal course of performing their assigned functions, to prevent or detect misstatements on a timely basis.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
recognized the following deficiencies that we believe to be material weaknesses as of December 31, 2021: (a) the Company has not fully
designed, implemented or assessed internal controls over financial reporting and due to the Company being a developing company, management&#8217;s
assessment and conclusion over internal controls were ineffective this year; (b) we recognized the following deficiencies that we believe
to be significant deficiencies: (i) the Company has no formal control process related to the identification and approval of related party
transactions; (ii) we do not have written documentation of our internal control policies and procedures. Written documentation of key
internal controls over financial reporting is a requirement of Section 404 of the Sarbanes-Oxley Act; and (iii) we do not have sufficient
segregation of duties within accounting functions, which is a basic internal control. Due to our size and nature, segregation of all
conflicting duties may not always be possible and may not be economically feasible. However, to the extent possible, the initiation of
transactions, the custody of assets and the recording of transactions should be performed by separate individuals.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
believe we have taken significant steps during and since the year ended December 31, 2021 to correct certain of our disclosure controls
and procedures and internal controls. These steps include the hiring of a third-party CPA firm to assist the Company in resolving the
financial statement preparation and disclosure issues, the establishment of an Audit Committee (discussed under &#8220;Committees of
the Board&#8221;, below), and the hiring of Dr. Craig Hewitt to serve as our full-time Chief Financial Officer effective on March 30,
2022. Nonetheless, until these elements have been fully integrated into our organization and we have established appropriate controls
and internal processes in consultation with our third-party CPA firm and Audit Committee, there is no assurance that our disclosure controls
and procedures and internal controls will in fact be effective.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 28 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%"><a href="#toc" title="Table of Contents" style="font-style: italic">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Maintaining
effective disclosure controls and procedures and effective internal control over financial reporting are necessary for us to produce
reliable financial statements and the Company is committed to remediating its material weaknesses in such controls as promptly as possible.
However, there can be no assurance as to when these material weaknesses will be remediated or that additional material weaknesses will
not arise in the future. Any failure to remediate the material weaknesses, or the development of new material weaknesses in our internal
control over financial reporting, could result in material misstatements in our financial statements and cause us to fail to meet our
reporting and financial obligations, which in turn could have a material adverse effect on our financial condition and the trading price
of our common stock, and/or result in litigation against us or our management. In addition, even if we are successful in strengthening
our controls and procedures, those controls and procedures may not be adequate to prevent or identify irregularities or facilitate the
fair presentation of our financial statements or our periodic reports filed with the SEC.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.65pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>The
employment agreement of Mr. Jacob Cohen, our sole officer and director provides for the payment of certain severance payments upon termination.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mr.
Jacob D. Cohen&#8217;s employment agreement provides that if he is terminated during the term of such agreement by the Company without
cause (as defined in the agreement) or by Mr. Cohen for good reason (as defined in the agreement), Mr. Cohen is due a severance payment.
That severance payment is equal to the compensation (including bonus) earned through the date of termination and three times (one time
if less than one year remains on the employment agreement)(the &#8220;<span style="text-decoration: underline">multiplier</span>&#8221;) the base salary in effect on the date
of the termination plus the average bonus received by Mr. Cohen over the prior two years and Mr. Cohen is also to be paid any bonus which
he would have earned at the end of the fiscal year during which the employment is terminated (pro-rated for days worked), and is to be
paid health insurance for Mr. Cohen and his family for 18 months from the date of termination (the &#8220;<span style="text-decoration: underline">Severance Payments</span>&#8221;).
Also, all equity compensation due to vest in the following 12 months vests immediately. If Mr. Cohen dies while the employment agreement
is in place, or the agreement is terminated due to Mr. Cohen&#8217;s disability, the Company is required to pay Mr. Cohen&#8217;s salary
to his beneficiaries for a period of one year following such death, pay the pro-rated amount of any bonus due, and pay 18 months of health
insurance. If a change in control (as defined in the agreement) occurs and Mr. Cohen is terminated up to one year after such change in
control, Mr. Cohen is due the Severance Payments (based on a 3x multiplier) and all unvested equity awards vest immediately. The payment
of severance fees could have a material adverse effect on our cash flows and results of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Risks
relating to our Telehealth Operations</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.65pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our
telehealth business could be adversely affected by ongoing legal challenges to our business model or by new state actions restricting
our ability to provide the full range of our services in certain states.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.65pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.65pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
ability to conduct planned business operations in each state is dependent upon the state&#8217;s treatment of medicine under such state&#8217;s
laws, and rules and policies governing the practice of physician supervised services, which are subject to changing political, regulatory
and other influences.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.65pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 29 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%"><a href="#toc" title="Table of Contents" style="font-style: italic">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.65pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our
use and disclosure of personally identifiable information, including health information, is subject to federal and state privacy and
security regulations, and our failure to comply with those regulations or to adequately secure the information we hold could result in
significant liability or reputational harm and, in turn, a material adverse effect on our client base and revenue.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.65pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Numerous
state and federal laws and regulations govern the collection, dissemination, use, privacy, confidentiality, security, availability and
integrity of personally identifiable information, or PII, including protected health information, or PHI. These laws and regulations
include the Health Information Portability and Accountability Act of 1996, as amended by the Health Information Technology for Economic
and Clinical Health Act, or HITECH, and their implementing regulations (referred to collectively as HIPAA). HIPAA establishes a set of
basic national privacy and security standards for the protection of PHI. HIPAA requires us to develop and maintain policies and procedures
with respect to PHI that is used or disclosed, including the adoption of administrative, physical and technical safeguards to protect
such information. HIPAA imposes mandatory penalties for certain violations. Penalties for violations of HIPAA and its implementing regulations
start at $100 per violation and are not to exceed $50,000 per violation, subject to a cap of $1.5 million for violations of the same
standard in a single calendar year. However, a single breach incident can result in violations of multiple standards. HIPAA also authorizes
state attorneys general to file suit on behalf of their residents. Courts are able to award damages, costs and attorneys&#8217; fees
related to violations of HIPAA in such cases. While HIPAA does not create a private right of action allowing individuals to sue us in
civil court for violations of HIPAA, its standards have been used as the basis for duty of care in state civil suits such as those for
negligence or recklessness in the misuse or breach of PHI. In addition, HIPAA mandates that the Secretary of Health and Human Services,
or HHS, conduct periodic compliance audits of HIPAA covered entities or business associates for compliance with the HIPAA Privacy and
Security Standards. It also tasks HHS with establishing a methodology whereby harmed individuals who were the victims of breaches of
unsecured PHI may receive a percentage of the Civil Monetary Penalty fine paid by the violator. HIPAA further requires that patients
be notified of any unauthorized acquisition, access, use or disclosure of their unsecured PHI that compromises the privacy or security
of such information, with certain exceptions related to unintentional or inadvertent use or disclosure by employees or authorized individuals.
HIPAA specifies that such notifications must be made &#8220;<span style="text-decoration: underline">without unreasonable delay and in no case later than 60 calendar days
after discovery of the breach.</span>&#8221; If a breach affects 500 patients or more, it must be reported to HHS without unreasonable delay,
and HHS will post the name of the breaching entity on its public web site. Breaches affecting 500 patients or more in the same state
or jurisdiction must also be reported to the local media. If a breach involves fewer than 500 people, the covered entity must record
it in a log and notify HHS at least annually.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.65pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.65pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Numerous
other federal and state laws protect the confidentiality, privacy, availability, integrity and security of PII, including PHI. These
laws in many cases are more restrictive than, and may not be preempted by, the HIPAA rules and may be subject to varying interpretations
by courts and government agencies, creating complex compliance issues for us and our clients and potentially exposing us to additional
expense, adverse publicity and liability.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.65pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 30 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%"><a href="#toc" title="Table of Contents" style="font-style: italic">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.65pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Because
of the extreme sensitivity of the PII we store and transmit, the security features of our technology platform are very important. If
our security measures are breached or fail, unauthorized persons may be able to obtain access to sensitive client data, including HIPAA-regulated
PHI. As a result, our reputation could be severely damaged, adversely affecting client confidence. In addition, we could face litigation,
damages for contract breach, penalties and regulatory actions for violation of HIPAA and other applicable laws or regulations and significant
costs for remediation, notification to individuals and for measures to prevent future occurrences. Any potential security breach could
also result in increased costs associated with liability for stolen assets or information, repairing system damage that may have been
caused by such breaches, incentives offered to clients in an effort to maintain our business relationships after a breach and implementing
measures to prevent future occurrences, including organizational changes, deploying additional personnel and protection technologies,
training employees and engaging third-party experts and consultants.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.65pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.65pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>The
failure of our 3rd party telemedicine services provider to attract and retain physicians and nurse practitioners in a competitive labor
market could limit our ability to execute our growth strategy, resulting in a slower rate of growth.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.65pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.65pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
wellness business depends on our ability of our 3<sup>rd</sup> party telemedicine services provider to continue to recruit and retain
a sufficient number of qualified licensed doctors and nurses. Although we believe such provider has an effective recruitment process,
there is no assurance that such provider will be able to secure arrangements with sufficient numbers of licensed doctors and nurses or
retain the services of such practitioners. If our provider experiences delays or shortages in obtaining access to qualified physicians
and nurses, we would be unable to expand our services and operations, resulting in reduced revenues.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.65pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.65pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>If
the physicians who are available through our telemedicine operations develop a poor reputation, our operations and future revenues would
suffer.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.65pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.65pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
success of our wellness business is dependent upon quality medical services being rendered by the physicians who are provided by our
3<sup>rd</sup> party telemedicine services provider. As the patient-physician relationship involves inherent trust and confidence, any
negative publicity, whether from civil litigation, allegations of criminal misconduct, or forfeiture of medical licenses, with respect
to any physicians made available for our services, and/or our facilities could adversely affect our future results of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.65pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.65pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>If
we fail to comply with government laws and regulations it could have a materially adverse effect on our business.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.65pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.65pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
health care industry is subject to extensive federal, state and local laws and regulations relating to licensure, conduct of operations,
ownership of facilities, addition of facilities and services, payment for services and prices for services that are extremely complex
and for which, in many instances, the industry does not have the benefit of significant regulatory or judicial interpretation. We exercise
care in structuring our arrangements with physicians and other referral sources to comply in all material respects with applicable laws.
We will also take such laws into account when planning future centers, marketing and other activities, and expect that our operations
will be in compliance with applicable law. The laws, rules and regulations described above are complex and subject to interpretation.
In the event of a determination that we are in violation of such laws, rules or regulations, or if further changes in the regulatory
framework occur, any such determination or changes could have a material adverse effect on our business. There can be no assurance however
that we will not be found in noncompliance in any particular situation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.65pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 31 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%"><a href="#toc" title="Table of Contents" style="font-style: italic">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
may not be able to successfully develop, launch and commercialize our planned erectile dysfunction (ED) product or any other potential
future men&#8217;s wellness products.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may not be able to effectively develop and profitably launch and commercialize our planned erectile dysfunction (ED) product or any other
potential future men&#8217;s wellness products. If we are unable to successfully develop, produce, launch and commercialize our planned
erectile dysfunction (ED) product or any other potential future men&#8217;s wellness products, our ability to generate product sales
will be severely limited, which will have a material adverse impact on our business, financial condition, and results of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Changes
to our strategic business plan may cause uncertainty regarding the future of our business, and may adversely impact employee hiring and
retention, our stock price, and our revenue, operating results, and financial condition.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
recent change in our business focus from operating MedSpas, a nutrition store and construction services, to men&#8217;s wellness products
and services and telehealth services, life coaching and other wellness services may cause or result in:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">disruption
    of our business or distraction of our employees and management;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">difficulty
    in recruiting, hiring, motivating and retaining talented and skilled personnel;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">stock
    price volatility; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">difficulty
    in negotiating, maintaining or consummating business or strategic relationships or transactions.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
we are unable to mitigate these or other potential risks, our revenue, operating results and financial condition may be adversely impacted.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
will depend on our partners to manufacture our planned erectile dysfunction (ED) product and other potential future men&#8217;s wellness
products.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
will rely on our planned partners for the manufacture of our planned erectile dysfunction (ED) product and any other potential future
men&#8217;s wellness products and we cannot assure you that they will be successful. This subjects us to a number of risks, including
the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">we
    may not be able to control the commercialization of our products, including the amount, timing and quality of resources that our
    partners may devote to our products;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 32 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%"><a href="#toc" title="Table of Contents" style="font-style: italic">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    partners may experience financial, regulatory or operational difficulties, which may impair their ability to fulfill their contractual
    obligations;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">business
    combinations or significant changes in a partner&#8217;s business strategy may adversely affect a partner&#8217;s willingness or
    ability to perform their obligations under any arrangement;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">legal
    disputes or disagreements may occur with one or more of our partners or between our partners and our suppliers or former partners;
    and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a
    partner could independently move forward with a competing product developed either independently or in collaboration with others,
    including with one of our competitors.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
any of our partners fail to fulfill their contractual obligations, our business may be negatively affected and we may receive limited
or no revenues under our agreements with them.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>If
we are unable to maintain or enter into agreements with suppliers or our suppliers fail to supply us with our planned erectile dysfunction
(ED) product or any other potential future men&#8217;s wellness products, we may experience delays in selling our products.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
cannot guarantee that we will be successful in maintaining or entering into supply agreements on reasonable terms or at all or that we
or our suppliers will be able to obtain or maintain the necessary regulatory approvals or state and federal controlled substances registrations
for current or potential future suppliers in a timely manner or at all. If we are unable to obtain a sufficient quantity of compounds
required to product products, there could be a delay in producing products, which could adversely affect our product sales and operating
results materially, which could significantly harm our business.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
currently do not have any manufacturing facilities and intend to rely on third parties for the supply of the products, as well as for
the supply of materials. However, we cannot be certain that we or our suppliers will be able to obtain or maintain the necessary regulatory
approvals or registrations for these suppliers in a timely manner or at all.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our
ability to gain and increase market acceptance and generate revenues will be subject to a variety of risks, many of which are out of
our control.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
planned erectile dysfunction (ED) product or any other potential future men&#8217;s wellness products may not gain or increase market
acceptance among physicians, patients, healthcare payors or the medical community. We believe that the degree of market acceptance and
our ability to generate revenues from such products will depend on a number of factors, including:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    ability to expand the use of our products through targeted patient and physician education;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">competition
    and timing of market introduction of competitive products;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 33 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%"><a href="#toc" title="Table of Contents" style="font-style: italic">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">quality,
    safety and efficacy in the approved setting;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">prevalence
    and severity of any side effects, including those of the components of our products;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">emergence
    of previously unknown side effects, including those of the generic components of our products;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">potential
    or perceived advantages or disadvantages over alternative treatments;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    convenience and ease of purchasing the product, as perceived by potential patients;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">strength
    of sales, marketing and distribution support;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">price,
    both in absolute terms and relative to alternative treatments;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    effectiveness of any future collaborators&#8217; sales and marketing strategies;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    effect of current and future healthcare laws;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">availability
    of coverage and reimbursement from government and other third-party payors;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">recommendations
    for prescribing physicians to complete certain educational programs for prescribing drugs;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    willingness of patients to pay out-of-pocket in the absence of government or third-party coverage; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">product
    labeling, product insert, or new studies or trial requirements of FDA or other regulatory authorities.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
future products may fail to achieve market acceptance or generate significant revenue to achieve sustainable profitability. In addition,
our efforts to educate the medical community and third-party payors on the safety and benefits of our drugs may require significant resources
and may not be successful.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>If
we become subject to product liability claims, we may be required to pay damages that exceed our insurance coverage, if any.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
future products will be subject to risks for product liability claims due to inherent potential side effects. We may be unable to obtain
or maintain product liability coverage. A product liability claim in excess of, or excluded from, our insurance coverage (if any) would
have to be paid out of cash reserves and could have a material adverse effect upon our business, financial condition and results of operations.
Product liability insurance is expensive even with large self-insured retentions or deductibles, difficult to maintain, and current or
increased coverage may not be available on acceptable terms, if at all.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 34 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%"><a href="#toc" title="Table of Contents" style="font-style: italic">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
we cannot successfully defend ourselves against a product liability claim, we may incur substantial liabilities. Regardless of merit
or eventual outcome, liability claims may result in:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">injury
    to our reputation;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">costs
    of defending the claim and/or related litigation;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">cost
    of any potential adverse verdict;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">substantial
    monetary awards to patients or other claimants; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    inability to commercialize our products.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Damages
awarded in a product liability action could be substantial and could have a negative impact on our financial condition. Whether or not
we were ultimately successful in product liability litigation, such litigation would consume substantial amounts of our financial and
managerial resources, and might result in adverse publicity, all of which would impair our business. In addition, product liability claims
could result in an FDA investigation of the safety or efficacy of our products, our third-party manufacturing processes and facilities,
or our marketing programs. An FDA investigation could also potentially lead to a recall of our future products or more serious enforcement
actions, limitations on the indications for which they may be used, or suspension or withdrawal of approval.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>The
markets in which we operate are highly competitive and we may be unable to compete successfully against new entrants or established companies.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Competition
in the pharmaceutical and medical products industries is intense and is characterized by costly and extensive research efforts and rapid
technological progress. Our competitors may develop technologies and products that are more effective than those we are planning to market.
Such developments could render our planned products less competitive or possibly obsolete.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">New
developments, including the development of other products and technologies occur in the pharmaceutical and medical technology industries
at a rapid pace. These developments may render our products obsolete or noncompetitive. Compared to us, many of our potential competitors
have substantially greater:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">research
    and development resources, including personnel and technology;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">regulatory
    experience;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">experience
    and expertise in exploitation of intellectual property rights; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">access
    to strategic partners and capital resources.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 35 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%"><a href="#toc" title="Table of Contents" style="font-style: italic">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
a result of these factors, our competitors may develop drugs or products that are more effective, more useful and less costly than ours
and may also be more successful in manufacturing and marketing their products. In addition, our competitors may be more effective in
commercializing their products. We currently outsource our manufacturing and therefore rely on third parties for that competitive expertise.
There can be no assurance that we will be able to develop or contract for these capabilities on acceptable economic terms, or at all.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Marketing
activities for our planned erectile dysfunction (ED) products are subject to continued governmental regulation.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">FDA
authorities have the authority to impose significant restrictions on approved products through regulations on advertising, promotional
and distribution activities. If our future products are marketed in contradiction with FDA laws and regulations, FDA may issue warning
letters that require specific remedial measures to be taken, as well as an immediate cessation of the impermissible conduct, resulting
in adverse publicity. FDA may also require that all future promotional materials receive prior agency review and approval before use.
Certain states have also adopted regulations and reporting requirements surrounding the promotion of pharmaceuticals. Failure by us or
any of our collaborators to comply with state requirements may affect our ability to promote or sell future products in certain states.
This, in turn, could have a material adverse impact on our financial results and financial condition and could subject us to significant
liability, including civil and administrative remedies as well as criminal sanctions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Many
of our competitors in the online mail order pharmacy space are better established and have resources significantly greater than we have,
which may make it difficult to fend off competition.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
plan to operate as a close-door online mail order pharmacy with a specific target and vision to obtain licenses in all 50 states across
the U.S. We expect to compete with the three largest drug distributors (McKesson, Cardinal Health and AmerisourceBergen), in addition
to other pharmaceutical distributors, buying groups, software products, and various start-up drug companies. Many of these operations
have substantially greater financial and manufacturer-backed resources, longer operating histories, greater name recognition and more
established relationships in the industry than us. In addition, a number of these competitors may combine or form strategic partnerships.
As a result, our competitors may establish a more favorable footing in the pharmaceutical industry with respect to pricing or other factors.
Our failure to compete successfully with any of these companies would have a material adverse effect on our business and the trading
price of our common stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Additional
restrictive elements exist within the pharmaceutical channels of distribution. For example, a number of the inventory management systems,
either developed by the distributors or third-party vendors, have been developed to require compliance to these restrictive purchasing
agreements. Management anticipates that other existing and prospective competitors will adopt technologies or business plans similar
to ours or seek other means to develop operations competitive with ours, particularly if our development of large-scale production progresses
as scheduled.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 36 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%"><a href="#toc" title="Table of Contents" style="font-style: italic">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
may not receive licenses to operate as an online mail order pharmacy.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
planned operations as a close-door online mail order pharmacy is subject to among other things, our receipt of regulatory approvals and
licenses in the states in which we plan to operate. Our failure to receive regulatory approval or licenses in the states in which we
hope to operate may prohibit us from operating as a close-door online mail order pharmacy, be costly, require us to comply with costly
rules and regulations, and/or subject us to liability, fines and penalties for non-compliance. We may not be able to receive approvals
or licenses to operate in any states and may not be able to undertake any operations as a close-door online mail order pharmacy. Any
of the above may have an adverse effect on our revenues, operations and cash flow, and may require us to abandon altogether our business
plans.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>There
are inherent risks associated with our planned operations within the Pharmaceutical Distribution Market.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
are inherent risks involved with doing business within the pharmaceutical distribution market, any of which may have a material adverse
effect on our planned operations, cash flow and revenues, including:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Improperly
    manufactured products may prove dangerous to the end consumer.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Products
    may become adulterated by improper warehousing methods or modes of shipment.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Counterfeit
    products or products with fake pedigree papers.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unlicensed
    or unlawful participants in the distribution channel.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Risk
    with default and the assumption of credit loss.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Regulatory
    risks.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Risk
    related to the loss of supply, or the loss of a number of suppliers, or in the delay of obtaining the supply of drugs.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Pedigree
tracking laws and regulations could increase our regulatory burdens.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Congress
and state and federal agencies, including state boards of pharmacy and departments of health and the FDA, have made increased efforts
in the past year to regulate the pharmaceutical distribution system in order to prevent the introduction of counterfeit, adulterated
or mislabeled drugs into the pharmaceutical distribution system (otherwise known as &#8220;<span style="text-decoration: underline">pedigree tracking</span>&#8221;). In November
2013, Congress passed (and President Barack Obama signed into law) the Drug Quality and Security Act (the &#8220;<span style="text-decoration: underline">DQSA</span>&#8221;).
The DQSA establishes federal standards requiring supply-chain stakeholders to participate in an electronic, interoperable, lot-level
prescription drug track-and-trace system. The law also preempts state drug pedigree requirements and establishes new requirements for
drug wholesale distributors and third-party logistics providers, including licensing requirements in states that had not previously licensed
such entities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 37 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%"><a href="#toc" title="Table of Contents" style="font-style: italic">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, the Food and Drug Administration Amendments Act of 2007 requires the FDA to establish standards and identify and validate effective
technologies for the purpose of securing the pharmaceutical supply chain against counterfeit drugs. These standards may include track-and-trace
or authentication technologies, such as radio frequency identification devices, 2D data matrix barcodes, and other similar technologies.
On March 26, 2010, the FDA released the Serialized Numerical Identifier (the &#8220;<span style="text-decoration: underline">SNI</span>&#8221;) guidance for manufacturers who
serialize pharmaceutical packaging. We expect to be able to accommodate these SNI regulations in our distribution operations. The DQSA
and other pedigree tracking laws and regulations have increased the overall regulatory burden and costs associated with our planned drug
distribution operations and may have had a material adverse impact on our results of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>It
may be difficult and costly for us to comply with the extensive government regulations to which our business is subject.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
operations are subject to extensive regulation by the U.S. federal and state governments. In addition, as we expand our operations, we
may also become subject to the regulations of foreign jurisdictions, as well as additional regulations relating to environmental matters,
transportation of pharmaceutical products, shipping restrictions, and import and export restrictions. We are also required to comply
with various state pricing gouging laws. Our required compliance, or failure to comply with any of the above rules and regulations, may
adversely affect our cash flow, profitability, and growth.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Regulatory
and Reporting Risks</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.35pt; text-align: justify; text-indent: 35.65pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.35pt; text-align: justify; text-indent: 35.65pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
are subject to the reporting requirements of federal securities laws, which are expensive and subject us to potential liability.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.35pt; text-align: justify; text-indent: 35.65pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.35pt; text-align: justify; text-indent: 35.65pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are a public reporting company in the United States and, accordingly, subject to the information and reporting requirements of the Exchange
Act and other federal securities laws, and the compliance obligations of the Sarbanes-Oxley Act. The costs of preparing and filing annual
and quarterly reports, proxy statements and other information with the SEC and furnishing audited reports to stockholders causes our
expenses to be higher than they would be if we remained a privately-held company. We could also be subject to sanctions or deregistration
if we fail to keep up with or run afoul of our reporting obligations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.35pt; text-align: justify; text-indent: 35.65pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.35pt; text-align: justify; text-indent: 35.65pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our
compliance with the Sarbanes-Oxley Act and SEC rules concerning internal controls is time consuming, difficult and costly.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.35pt; text-align: justify; text-indent: 35.65pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.35pt; text-align: justify; text-indent: 35.65pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Because
we are a reporting company with the SEC, we must comply with Sarbanes-Oxley Act and SEC rules concerning internal controls. It is time
consuming, difficult and costly for us to develop and implement the internal controls and reporting procedures required by the Sarbanes-Oxley
Act. In order to expand our operations, we will need to hire additional financial reporting, internal control, and other finance staff
in order to develop and implement appropriate internal controls and reporting procedures.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 38 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%"><a href="#toc" title="Table of Contents" style="font-style: italic">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Risks
Related to Our Common Stock and Securities</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.65pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Shareholders
who hold unregistered shares of our common stock will be subject to resale restrictions pursuant to Rule 144, if and when available,
due to the fact that we are deemed to be a former &#8220;<span style="text-decoration: underline">shell company</span>&#8221;.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.65pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.65pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to Rule 144 of the Securities Act of 1933, as amended (&#8220;<span style="text-decoration: underline">Rule 144</span>&#8221;), a &#8220;<span style="text-decoration: underline">shell company</span>&#8221; is defined
as a company that has no or nominal operations; and, either no or nominal assets; assets consisting solely of cash and cash equivalents;
or assets consisting of any amount of cash and cash equivalents and nominal other assets. While we do not believe that we are currently
a &#8220;<span style="text-decoration: underline">shell company</span>&#8221;, we were previously a &#8220;<span style="text-decoration: underline">shell company</span>&#8221; and as such are deemed to be a former &#8220;<span style="text-decoration: underline">shell
company</span>&#8221; pursuant to Rule 144, and as such, sales of our securities pursuant to Rule 144 may not be able to be made if we are
not subject to Section 13 or 15(d) of the Exchange Act, and have filed all of our required periodic reports for at least the previous
one year period prior to any sale pursuant to Rule 144; and a period of at least twelve months has elapsed from the date &#8220;<span style="text-decoration: underline">Form
10 information</span>&#8221; has been filed with the Commission reflecting the Company&#8217;s status as a non-&#8221;<span style="text-decoration: underline">shell company</span>&#8221;
(which Form 10 information was filed by the Company in August 2019). Although to date we have complied with the requirement of Rule 144
as related to &#8220;<span style="text-decoration: underline">shell companies</span>&#8221;, our status as a former &#8220;<span style="text-decoration: underline">shell company</span>&#8221; could prevent us from raising
additional funds, engaging consultants, and using our securities to pay for any acquisitions in the future (although none are currently
planned).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
have various outstanding convertible notes which are convertible into shares of our common stock at a discount to market.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">As
of </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the date of this prospectus, and including the Notes<span style="background-color: white">,
we owed approximately $2,648,560 under various convertible promissory notes. The conversion prices of the convertible notes initially
vary from between $0.075 per share (as to the convertible notes issued between November 22 and December 2, 2022), and 25% of the market
value of our common stock (as to our other convertible notes), subject in many cases to adjustments to the conversion prices upon defaults
and anti-dilution and other rights which may result in such conversion prices declining, including in connection with the Notes, discussed
in greater detail below under </span>&#8220;<span style="text-decoration: underline"><a href="#ed_006">Securities Purchase Agreement</a></span>&#8221;, beginning on page 47. <span style="background-color: white">As
a result, any conversion of the convertible notes and sale of shares of common stock issuable in connection with the conversion thereof
may cause the value of our common stock to decline in value, as described in greater detail under the Risk Factors below. Notwithstanding
the above, we hope to repay the convertible notes in full before any conversions take place.</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>The
issuance and sale of common stock upon conversion of the convertible notes may depress the market price of our common stock.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
sequential conversions of the convertible notes and sales of such converted shares take place, the price of our common stock may decline,
and as a result, the holders of the convertible notes will be entitled to receive an increasing number of shares in connection with conversions,
which shares could then be sold in the market, triggering further price declines and conversions for even larger numbers of shares, to
the detriment of our investors. The shares of common stock which the convertible notes are convertible into may be sold without restriction
pursuant to Rule 144. As a result, the sale of these shares may adversely affect the market price, if any, of our common stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 39 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%"><a href="#toc" title="Table of Contents" style="font-style: italic">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, the common stock issuable upon conversion of the convertible notes may represent overhang that may also adversely affect the
market price of our common stock. Overhang occurs when there is a greater supply of a company&#8217;s stock in the market than there
is demand for that stock. When this happens the price of the company&#8217;s stock will decrease, and any additional shares which shareholders
attempt to sell in the market will only further decrease the share price. The convertible notes will be convertible into shares of our
common stock at a discount to market as described above, and such discount to market provides the holders with the ability to sell their
common stock at or below market and still make a profit. In the event of such overhang, the note holders will have an incentive to sell
their common stock as quickly as possible. If the share volume of our common stock cannot absorb the discounted shares, then the value
of our common stock will likely decrease. Notwithstanding the above, we hope to repay the convertible notes in full before any conversions
take place.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>The
issuance of common stock upon conversion of our outstanding convertible notes will cause immediate and substantial dilution.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
issuance of common stock upon conversion of the convertible notes will result in immediate and substantial dilution to the interests
of other stockholders since the holders of the convertible notes may ultimately receive and sell the full number of shares issuable in
connection with the conversion of such convertible notes. Although certain of the convertible notes may not be converted if such conversion
would cause the holders thereof to own more than 4.99% or 9.99% of our outstanding common stock, this restriction does not prevent the
holders of the convertible notes subject to such restrictions from converting some of their holdings, selling those shares, and then
converting the rest of its holdings, while still staying below the 4.99%/9.99% limit. In this way, the holders of the convertible notes
could sell more than any applicable ownership limit while never actually holding more shares than the applicable limits allow. If the
holders of the convertible notes choose to do this, it will cause substantial dilution to the then holders of our common stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>The
continuously adjustable conversion price feature of the convertible notes could require us to issue a substantially greater number of
shares, which may adversely affect the market price of our common stock and cause dilution to our existing stockholders.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
existing stockholders will experience substantial dilution upon any conversion of the convertible notes. The convertible notes are convertible
into shares of common stock at a conversion price equal to a discount to the market value of our common stock as described above. As
a result, the number of shares issuable could prove to be significantly greater in the event of a decrease in the trading price of our
common stock, which decrease would cause substantial dilution to our existing stockholders. As sequential conversions and sales take
place, the price of our common stock may decline, and if so, the holders of the convertible notes would be entitled to receive an increasing
number of shares, which could then be sold, triggering further price declines and conversions for even larger numbers of shares, which
would cause additional dilution to our existing stockholders and would likely cause the value of our common stock to decline.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 40 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%"><a href="#toc" title="Table of Contents" style="font-style: italic">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
could face significant penalties for our failure to comply with the terms of our outstanding convertible notes.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
various convertible notes contain positive and negative covenants and customary events of default including requiring us in many cases
to timely file SEC reports. In the event we fail to timely file our SEC reports in the future, or any other events of defaults occur
under the notes, we could face significant penalties and/or liquidated damages and/or the conversion price of such notes could be adjusted
downward significantly, all of which could have a material adverse effect on our results of operations and financial condition, or cause
any investment in the Company to decline in value or become worthless.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><b><i>Certain
of our outstanding warrants to purchase shares of common stock contain anti-dilution rights and favored nation rights, and certain of
our securities purchase agreements include favored nations rights.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Total
outstanding warrants to purchase 23,253,332 shares of common stock (of which 9,920,000 were originally granted with exercise prices from
between $0.20 and $0.50 per share), include anti-dilution and favored nations rights. Pursuant to such rights, subject to certain exceptions,
in the event we issued securities below the then exercise price, the exercise price of the warrants is reduced to the lower of such dilutive
issuance or the volume weighted average price (VWAP) of our common stock on the next trading day following the first public disclosure
of such dilutive issuance, subject to certain exceptions which may reduce such exercise price further in certain cases, including the
issuance of units. In connection with the grant of the Warrants, the exercise price of all the outstanding warrants with anti-dilution
rights were reduced to $0.075 per share. The Warrants also include anti-dilution rights which provides for a reduction of the exercise
price to match the price per share of any dilutive issuance made while the Warrant is outstanding (other than in connection with stock
plan issuances and other customary exceptions and the Uplist Offering). If in the future we issue securities at prices less than such
$0.075 exercise price, the exercise price of the warrants may be further reduced to such lower amount. Certain of such warrants also
include favored nations provisions which could be triggered in the future and could materially change the terms of the warrants. In the
event any anti-dilution or favored nations provisions of the warrants are triggered, it may cause the terms of such warrants to be materially
amended in favor of the holders thereof, cause significant dilution to existing shareholders, and otherwise have a material adverse effect
on the Company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><b><i>Our
outstanding convertible promissory notes include favored nations rights.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">All
of our outstanding convertible promissory notes, including the Notes, include provisions which provide that, so long as such notes are
outstanding, upon any issuance by the Company (or under certain notes, any of its subsidiaries) of any security, or amendment to a security
that was originally issued, with any term that the holder of such note reasonably believes is more favorable to the holder of such security
or with a term in favor of the holder of such security that the holder reasonably believes was not similarly provided to the holder in
such note, then at the option of the holder, such term may become part of the holder&#8217;s notes. The types of terms contained in another
security that may be more favorable to the holder of such security include, but are not limited to, terms addressing prepayment rate,
interest rates, and original issue discounts. Such favored nations provisions could be triggered in the future and could materially change
the terms of the notes. In the event any favored nations provisions of the notes are triggered, it may cause the terms of such notes
to be materially amended in favor of the holders thereof, cause significant dilution to existing shareholders, and otherwise have a material
adverse effect on the Company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 41 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->36<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%"><a href="#toc" title="Table of Contents" style="font-style: italic">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><b><i>The
issuance and sale of common stock upon exercise of warrants may cause substantial dilution to existing stockholders and may also depress
the market price of our common stock.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of the date of this prospectus, we had a total of 23,253,332 warrants outstanding, of which a) 7,250,000 warrants have an exercise price
of $0.075 per share and mature on January 6, 2026, b) 2,670,000 warrants have an exercise price of $0.075 per share and mature on June
24, 2026, and c) 13,333,332 warrants mature between November 23, 2026 and December 2, 2026 and have an exercise price equal to either
i) in the event of the Company&#8217;s listing on a national exchange by May 23, 2022, at a price equal to 120% of the offering price
upon uplisting, or ii) $0.075 per share. The warrants contain provisions limiting each holder&#8217;s ability to exercise the warrants
if such exercise would cause the holder&#8217;s (or any affiliate of any such holder) holdings in the Company to exceed 9.99% of the
Company&#8217;s issued and outstanding shares of common stock (4.99% in connection with the Warrants). The ownership limitation does
not prevent such holder from exercising some of the warrants, selling those shares, and then exercising the rest of the warrants, while
still staying below the 9.99% limit (4.99% in connection with the Warrants). In this way, the holders of the warrants could sell more
than this limit while never actually holding more shares than this limit allows. If the holders of the warrants choose to do this, it
will cause substantial dilution to the then holders of our common stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
exercises of the warrants and sales of such shares issuable upon exercise thereof take place, the price of our common stock may decline.
In addition, the common stock issuable upon exercise of the warrants may represent overhang that may also adversely affect the market
price of our common stock. Overhang occurs when there is a greater supply of a company&#8217;s stock in the market than there is demand
for that stock. When this happens the price of the company&#8217;s stock will decrease, and any additional shares which shareholders
attempt to sell in the market will only further decrease the share price. If the share volume of our common stock cannot absorb shares
sold by the warrant holders, then the value of our common stock will likely decrease.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><b><i>The
issuance of common stock upon conversion of the Notes will cause immediate and substantial dilution to existing shareholders.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Notes (including accrued and unpaid interest and late fees) making up the $2,000,000 in Notes sold between November 22, 2021 and December
2, 2021 are convertible into shares of the Company&#8217;s common stock at any time, at the option of the holders thereof, at a rate
equal to $0.075 per share; however, if the Company consummates any offering of common stock or common stock equivalents that results
in the immediate listing for trading of the Company&#8217;s common stock on a national stock exchange or Nasdaq, which occurs within
220 days from the date the Notes were issued, referred to as an &#8220;<span style="text-decoration: underline">Uplist Offering</span>&#8221;, the conversion price thereof will
be equal to 80% of the offering price per share of the Company&#8217;s common stock in such Uplist Offering. Each of the Notes provides
for a reduction of the conversion price to match the price per share of any dilutive issuance made while the Note is outstanding (other
than pursuant to certain customary excepted issuances), provided that no adjustment is required unless the Company fails to consummate
an Uplist Offering on or before 220 calendar days after the issuance date of the Note, provided that if such Uplist Offering is not completed
within such 220 calendar day period, the conversion price is adjusted for any dilutive issuance which occurred during such 220 calendar
day period. <span style="background-color: white">Although the Notes may not be converted by a holder if such conversion would cause
the holder to own more than 4.99% of our outstanding common stock, this restriction does not prevent such holder from converting some
of its holdings, selling those shares, and then converting the rest of its holdings, while still staying below the 4.99% limit. In this
way, the holders of the Notes could sell more than this limit while never actually holding more shares than this limit allows. If the
holders of the Notes choose to do this, it will cause substantial dilution to the then holders of our common stock.</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 42 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->37<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%"><a href="#toc" title="Table of Contents" style="font-style: italic">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><b><i>The
issuance and sale of common stock upon conversion of the Notes may depress the market price of our common stock.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">If
conversions of the Notes and sales of such converted shares take place, the price of our common stock may decline. In addition, the common
stock issuable upon conversion of the Notes may represent overhang that may also adversely affect the market price of our common stock.
Overhang occurs when there is a greater supply of a company&#8217;s stock in the market than there is demand for that stock. When this
happens the price of the company&#8217;s stock will decrease, and any additional shares which shareholders attempt to sell in the market
will only further decrease the share price. If the share volume of our common stock cannot absorb converted shares sold by the holders
of the Notes, then the value of our common stock will likely decrease.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
currently owe a significant amount of money under our outstanding convertible notes.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">As
of the date of this prospectus we owe approximately $2,648,560 under outstanding convertible (including the Notes) and non-convertible
promissory notes. We do not have sufficient funds to repay such notes and if we are unable to raise additional funds in the future to
repay such amounts, which may not be available on favorable terms, if at all, such failure could have a material adverse effect on our
financial condition or results of operations and cause any investment in the Company to decline in value or become worthless.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
have established preferred stock which can be designated by the Company&#8217;s Board of Directors without shareholder approval and the
board has established Series A Preferred Stock, which gives the holders majority voting power over the Company.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has 5,000,000 shares of preferred stock authorized. The shares of preferred stock of the Company may be issued from time to time
in one or more series, each of which shall have a distinctive designation or title as shall be determined by the board of directors of
the Company prior to the issuance of any shares thereof. The preferred stock shall have such voting powers, full or limited, or no voting
powers, and such preferences and relative, participating, optional or other special rights and such qualifications, limitations or restrictions
thereof as adopted by the board of directors. In May 2020, we designated three shares of Series A Preferred Stock. The Series A Preferred
Stock have the right, voting in aggregate, to vote on all shareholder matters equal to sixty percent (60%) of the total vote (the &#8220;<span style="text-decoration: underline">Super
Majority Voting Rights</span>&#8221;), so long as such shares are held by directors of the Company. A total of one share of Series A Preferred
Stock is currently outstanding and held by Jacob D. Cohen, our Chief Executive Officer and director, providing him sole voting right
over 60% of our voting shares.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 43 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->38<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%"><a href="#toc" title="Table of Contents" style="font-style: italic">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Because
the board of directors is able to designate the powers and preferences of the preferred stock without the vote of a majority of the Company&#8217;s
shareholders, shareholders of the Company will have no control over what designations and preferences the Company&#8217;s preferred stock
will have. The issuance of shares of preferred stock or the rights associated therewith, could cause substantial dilution to our existing
shareholders. Additionally, the dilutive effect of any preferred stock which we may issue may be exacerbated given the fact that such
preferred stock may have voting rights and/or other rights or preferences which could provide the preferred shareholders with substantial
voting control over us and/or give those holders the power to prevent or cause a change in control, even if that change in control might
benefit our shareholders (similar to the Series A Preferred Stock). As a result, the issuance of shares of preferred stock may cause
the value of our securities to decrease.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.65pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Stockholders
may be diluted significantly through our efforts to obtain financing and satisfy obligations through the issuance of additional shares
of our common stock.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have no committed source of financing. Wherever possible, our board of directors will attempt to use non-cash consideration to satisfy
obligations. In many instances, we believe that the non-cash consideration will consist of restricted shares of our common stock. Our
board of directors has authority, without action or vote of the stockholders, to issue all or part of the authorized but unissued shares
of common stock and designate series of preferred stock. In addition, if a trading market develops for our common stock, we may attempt
to raise capital by selling shares of our common stock (or convertible securities), possibly at a discount to market. These actions will
result in dilution of the ownership interests of existing stockholders, may further dilute common stock book value, and that dilution
may be material. Such issuances may also serve to enhance existing management&#8217;s ability to maintain control of the Company because
the shares may be issued to parties or entities committed to supporting existing management.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.65pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.65pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our
stock price may be volatile, which may result in losses to our stockholders.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.65pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.65pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
stock markets have experienced significant price and trading volume fluctuations, and the market prices of companies quoted on the OTC
Markets&#8217; OTCQB Market, where our shares of common stock are quoted, generally have been very volatile and have experienced sharp
share-price and trading-volume changes. The trading price of our common stock is likely to be volatile and could fluctuate widely in
response to many of the following factors, some of which are beyond our control:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.65pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">variations
    in our operating results;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">changes
    in expectations of our future financial performance, including financial estimates by securities analysts and investors;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 44 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->39<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%"><a href="#toc" title="Table of Contents" style="font-style: italic">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">changes
    in operating and stock price performance of other companies in our industry;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">additions
    or departures of key personnel; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">future
    sales of our common stock.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.65pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.65pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Domestic
and international stock markets often experience significant price and volume fluctuations. These fluctuations, as well as general economic
and political conditions unrelated to our performance, may adversely affect the price of our common stock. In particular, following initial
public offerings, the market prices for stocks of companies often reach levels that bear no established relationship to the operating
performance of these companies. These market prices are generally not sustainable and could vary widely. In the past, following periods
of volatility in the market price of a public company&#8217;s securities, securities class action litigation has often been initiated.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.65pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.65pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our
common shares are thinly-traded, and in the future, may continue to be thinly-traded, and you may be unable to sell at or near ask prices
or at all, if you need to sell your shares to raise money or otherwise desire to liquidate such shares.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.65pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.65pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
cannot predict the extent to which an active public market for our common stock will develop or be sustained due to a number of factors,
including the fact that we are a small company that is relatively unknown to stock analysts, stock brokers, institutional investors,
and others in the investment community that generate or influence sales volume, and that even if we came to the attention of such persons,
they tend to be risk-averse and would be reluctant to follow an unproven company such as ours or purchase or recommend the purchase of
our shares until such time as we became more seasoned and viable. As a consequence, there may be periods of several days or more when
trading activity in our shares is minimal or non-existent, as compared to a seasoned issuer which has a large and steady volume of trading
activity that will generally support continuous sales without an adverse effect on share price. We cannot give you any assurance that
a broader or more active public trading market for our common stock will develop or be sustained, or that current trading levels will
be sustained. You may be unable to sell your common stock at or above your purchase price if at all, which may result in substantial
losses to you. As a consequence of this lack of liquidity, the trading of relatively small quantities of shares by our stockholders may
disproportionately influence the price of those shares in either direction. The price for our shares could, for example, decline precipitously
in the event that a large number of our common shares are sold on the market without commensurate demand, as compared to a seasoned issuer
that could better absorb those sales without adverse impact on its share price. Secondly, an investment in us is a speculative or &#8220;<span style="text-decoration: underline">risky</span>&#8221;
investment due to our lack of revenues or profits to date. As a consequence of this enhanced risk, more risk-adverse investors may, under
the fear of losing all or most of their investment in the event of negative news or lack of progress, be more inclined to sell their
shares on the market more quickly and at greater discounts than would be the case with the stock of a seasoned issuer.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.65pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 45 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->40<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%"><a href="#toc" title="Table of Contents" style="font-style: italic">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.65pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our
common stock is likely to be subject to penny stock rules, which may make it more difficult for our stockholders to sell their common
stock.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.65pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.65pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Broker-dealer
practices in connection with transactions in &#8220;<span style="text-decoration: underline">penny stocks</span>&#8221; are regulated by certain penny stock rules adopted by
the SEC. Penny stocks generally are equity securities with a price of less than $5.00 per share. The penny stock rules require a broker-dealer,
prior to a purchase or sale of a penny stock not otherwise exempt from the rules, to deliver to the customer a standardized risk disclosure
document that provides information about penny stocks and the risks in the penny stock market. The broker-dealer also must provide the
customer with current bid and offer quotations for the penny stock, the compensation of the broker-dealer and its salesperson in the
transaction, and monthly account statements showing the market value of each penny stock held in the customer&#8217;s account. In addition,
the penny stock rules generally require that prior to a transaction in a penny stock the broker-dealer make a special written determination
that the penny stock is a suitable investment for the purchaser and receive the purchaser&#8217;s written agreement to the transaction.
These disclosure requirements may have the effect of reducing the level of trading activity in the secondary market for a stock that
becomes subject to the penny stock rules.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.65pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.65pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our
Chief Executive Officer and director holds majority voting control over the Company.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.65pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.65pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
Chief Executive Officer and director, Jacob D. Cohen, beneficially owns 28.7% of our outstanding common stock and also has the ability
to vote in aggregate, a separate 60% of our voting stock pursuant to his ownership of the one outstanding share of Series A Preferred
Stock, which gives him control over approximately 71.5% of our voting securities. As a result, Mr. Cohen has the ability to influence
matters affecting our stockholders and will therefore exercise control in determining the outcome of all corporate transactions or other
matters, including the election of directors, mergers, consolidations, the sale of all or substantially all of our assets, and also the
power to prevent or cause a change in control. Any investor who purchases shares will be a minority stockholder and as such will have
little to no say in the direction of the Company and the election of directors. Additionally, it will be difficult if not impossible
for investors to remove Mr. Cohen as a director, which will mean he will remain in control of who serves as officers of the Company as
well as whether any changes are made in the board of directors. As a potential investor in the Company, you should keep in mind that
even if you own shares of the Company&#8217;s common stock and wish to vote them at annual or special stockholder meetings, your shares
will likely have little effect on the outcome of corporate decisions. Because Mr. Cohen controls such vote, investors may find it difficult
to replace our management if they disagree with the way our business is being operated. Additionally, the interests of Mr. Cohen may
differ from the interests of the other stockholders and thus result in corporate decisions that are averse to other stockholders.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
currently have limited operations and may not generate significant revenues or be profitable in the future.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.65pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
current operations consist solely of ZipDoctor, Inc., Life Guru, Inc., EPIQ MD, Inc., EPIQ Scripts, LLC, and Mangoceuticals, Inc. We
may not be successful in our planned operations in the future and can make no assurances that we will be able to generate significant
revenues in the future, that we will have sufficient funding to support our operations and pay our expenses, or that we will ever become
profitable. In the event we are unable to generate revenues and/or support our operations, we will be forced to curtail and/or abandon
our current business plan and any investment in the Company could become worthless.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.65pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 46 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->41<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%"><a href="#toc" title="Table of Contents" style="font-style: italic">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Risks
Related to the Planned Reverse Stock Split</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
July 30, 2021, our board of directors, and on July 30, 2021, stockholders holding a majority of our outstanding voting shares, approved
resolutions authorizing a reverse stock split of the outstanding shares of our common stock in the range from one-for-two (1-for-2) to
one-for-sixty (1-for-60), and provided authority to our board of directors to select the ratio of the reverse stock split in their discretion,
at any time prior to the earlier of July 30, 2022 and the date of our 2022 annual meeting of shareholders. On January 25, 2022, our board
of directors, pursuant to such shareholder authority, approved a one-for-sixty (1-for-60) reverse stock split of the outstanding shares
of our common stock, which is intended to allow us to meet the minimum share price requirement of the NASDAQ Capital Market. Both the
board of directors and Financial Industry Regulatory Authority, Inc. (FINRA) have approved the reverse stock split, which is proposed
in order to increase the trading price of the Company&#8217;s common stock to a level thought to be sufficient to allow an uplisting
of the Company&#8217;s common stock on the Nasdaq Capital Market. Notwithstanding the approvals above, the officers of the Company have
not yet moved forward with the reverse stock split, or filed Articles of Amendment in connection therewith with the Secretary of State
of Nevada. The Company currently does not have an estimated date for when the reverse stock split will be made effective. Because
the Company has not formally affected the reverse stock split, none of the outstanding share amounts set forth below have been adjusted
for such board of directors approved reverse stock split. The board of directors reserves the right to adjust the ratio of the reverse
stock split and/or terminate the authority for such reverse stock split in the future.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
anticipate effecting a reverse stock split of our outstanding common stock in the future.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
expect that the reverse stock split will increase the market price of our common stock while our stock is trading and enable us to meet
the minimum market price requirement of the listing rules of the Nasdaq Capital Market. However, the effect of a reverse stock split
upon the market price of our common stock cannot be predicted with certainty, and the results of reverse stock splits by companies in
similar circumstances have been varied. It is possible that the market price of our common stock following the reverse stock split will
not increase sufficiently for us to be in compliance with the minimum market price requirement of the Nasdaq Capital Market, or if it
does, that such price will be sustained. If we are unable to meet the minimum market price requirement, we may be unable to list our
shares on the Nasdaq Capital Market.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Even
if the market price of our common stock increases sufficiently so that we comply with the minimum market price requirement, we cannot
assure you that we will be able to comply with the other standards that we are required to meet in order to be approved for listing on
the Nasdaq Capital Market or maintain a listing of our common stock on the Nasdaq Capital Market. Our failure to meet these requirements
may result in our common stock being unable to be listed on the Nasdaq Capital Market.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 47 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->42<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%"><a href="#toc" title="Table of Contents" style="font-style: italic">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>The
reverse stock split may decrease the liquidity of the shares of our common stock.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
liquidity of the shares of our common stock may be affected adversely by the reverse stock split given the reduced number of shares that
will be outstanding following the reverse stock split. In addition, the reverse stock split may increase the number of stockholders who
own odd lots (less than 100 shares) of our common stock, creating the potential for such stockholders to experience an increase in the
cost of selling their shares and greater difficulty affecting such sales.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>The
reverse stock split may not increase our stock price over the long-term.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
principal purpose of the reverse stock split is to increase the per-share market price of our common stock. It cannot be assured, however,
that the reverse stock split will accomplish this objective for any meaningful period. While it is expected that the reduction in the
number of outstanding shares of common stock will proportionally increase the market price of the Company&#8217;s common stock, it cannot
be assured that the reverse stock split will increase the market price of our common stock by a multiple of the proposed reverse stock
split ratio, or result in any permanent or sustained increase in the market price of our common stock, which is dependent upon many factors,
including our business and financial performance, general market conditions, and prospects for future success. Thus, while our stock
price might meet the initial and continued listing requirements for The Nasdaq Capital Market initially, it cannot be assured that it
will continue to do so.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">General
Risk Factors</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.35pt; text-align: justify; text-indent: 35.65pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
will continue to incur increased costs as a result of being a reporting company, and given our limited capital resources, such additional
costs may have an adverse impact on our profitability.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are an SEC reporting company. The rules and regulations under the Exchange Act require reporting companies to provide periodic reports
with interactive data files, which require that we engage legal, accounting and auditing professionals, and eXtensible Business Reporting
Language (XBRL) and EDGAR (Electronic Data Gathering, Analysis, and Retrieval) service providers. The engagement of such services can
be costly, and we may continue to incur additional losses, which may adversely affect our ability to continue as a going concern. In
addition, the Sarbanes Oxley Act of 2002, as well as a variety of related rules implemented by the SEC, have required changes in corporate
governance practices and generally increased the disclosure requirements of public companies. For example, as a result of being a reporting
company, we are required to file periodic and current reports and other information with the SEC and we have adopted policies regarding
disclosure controls and procedures and regularly evaluate those controls and procedures.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
additional costs we continue to incur in connection with becoming a reporting company (expected to be approximately a hundred thousand
dollars per year) will continue to further stretch our limited capital resources. Due to our limited resources, we have to allocate resources
away from other productive uses in order to continue to comply with our obligations as an SEC reporting company. Further, there is no
guarantee that we will have sufficient resources to continue to meet our reporting and filing obligations with the SEC as they come due.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>


<!-- Field: Page; Sequence: 48 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->43<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%"><a href="#toc" title="Table of Contents" style="font-style: italic">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our
acquisitions may expose us to unknown liabilities.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 21.75pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Because
we have acquired, and expect generally to acquire, all (or a majority of) the outstanding securities of certain of our acquisition targets,
our investment in those companies is or will be subject to all of their liabilities other than their respective debts which we paid or
will pay at the time of the acquisitions. If there are unknown liabilities or other obligations, our business could be materially affected.
We may also experience issues relating to internal controls over financial reporting that could affect our ability to comply with the
Sarbanes-Oxley Act, or that could affect our ability to comply with other applicable laws.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.35pt; text-align: justify; text-indent: 35.65pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
may have difficulty obtaining future funding sources, if needed, and we may have to accept terms that would adversely affect stockholders.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
will need to raise funds from additional financing in the future to complete our business plan and may need to raise additional funding
in the future to support our operations. We have no commitments for any financing and any financing commitments may result in dilution
to our existing stockholders. We may have difficulty obtaining additional funding, and we may have to accept terms that would adversely
affect our stockholders. For example, the terms of any future financings may impose restrictions on our right to declare dividends or
on the manner in which we conduct our business. Additionally, we may raise funding by issuing additional convertible notes, which if
converted into shares of our common stock would dilute our then stockholders&#8217; interests. Lending institutions or private investors
may impose restrictions on a future decision by us to make capital expenditures, acquisitions or significant asset sales. If we are unable
to raise additional funds, we may be forced to curtail or even abandon our business plan.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>If
we make any acquisitions, they may disrupt or have a negative impact on our business.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
we make acquisitions in the future, funding permitting, which may not be available on favorable terms, if at all, we could have difficulty
integrating the acquired company&#8217;s assets, personnel and operations with our own. We do not anticipate that any acquisitions or
mergers we may enter into in the future would result in a change of control of the Company. In addition, the key personnel of the acquired
business may not be willing to work for us. We cannot predict the effect expansion may have on our core business. Regardless of whether
we are successful in making an acquisition, the negotiations could disrupt our ongoing business, distract our management and employees
and increase our expenses. In addition to the risks described above, acquisitions are accompanied by a number of inherent risks, including,
without limitation, the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    difficulty of integrating acquired products, services or operations;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    potential disruption of the ongoing businesses and distraction of our management and the management of acquired companies;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 49 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->44<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%"><a href="#toc" title="Table of Contents" style="font-style: italic">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">difficulties
    in maintaining uniform standards, controls, procedures and policies;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    potential impairment of relationships with employees and customers as a result of any integration of new management personnel;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    potential inability or failure to achieve additional sales and enhance our customer base through cross-marketing of the products
    to new and existing customers;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    effect of any government regulations which relate to the business acquired;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">potential
    unknown liabilities associated with acquired businesses or product lines, or the need to spend significant amounts to retool, reposition
    or modify the marketing and sales of acquired products or operations, or the defense of any litigation, whether or not successful,
    resulting from actions of the acquired company prior to our acquisition; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">potential
    expenses under the labor, environmental and other laws of various jurisdictions.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
business could be severely impaired if and to the extent that we are unable to succeed in addressing any of these risks or other problems
encountered in connection with an acquisition, many of which cannot be presently identified. These risks and problems could disrupt our
ongoing business, distract our management and employees, increase our expenses and adversely affect our results of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.35pt; text-align: justify; text-indent: 35.65pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.35pt; text-align: justify; text-indent: 35.65pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Current
global financial conditions have been characterized by increased volatility which could negatively impact our business, prospects, liquidity
and financial condition.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.35pt; text-align: justify; text-indent: 35.65pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.35pt; text-align: justify; text-indent: 35.65pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Current
global financial conditions and recent market events have been characterized by increased volatility and the resulting tightening of
the credit and capital markets has reduced the amount of available liquidity and overall economic activity. We cannot guaranty that debt
or equity financing, the ability to borrow funds or cash generated by operations will be available or sufficient to meet or satisfy our
initiatives, objectives or requirements. Our inability to access sufficient amounts of capital on terms acceptable to us for our operations
will negatively impact our business, prospects, liquidity and financial condition.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.35pt; text-align: justify; text-indent: 35.65pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our
ability to service our indebtedness will depend on our ability to generate cash in the future.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
ability to make payments on our indebtedness will depend on our ability to generate cash in the future. Our ability to generate cash
is subject to general economic and market conditions and financial, competitive, legislative, regulatory and other factors that are beyond
our control. Our business may not generate sufficient cash to fund our working capital requirements, capital expenditure, debt service
and other liquidity needs, which could result in our inability to comply with financial and other covenants contained in our debt agreements,
our being unable to repay or pay interest on our indebtedness, and our inability to fund our other liquidity needs. If we are unable
to service our debt obligations, fund our other liquidity needs and maintain compliance with our financial and other covenants, we could
be forced to curtail our operations, our creditors could accelerate our indebtedness and exercise other remedies and we could be required
to pursue one or more alternative strategies, such as selling assets or refinancing or restructuring our indebtedness. However, such
alternatives may not be feasible or adequate.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.65pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>


<!-- Field: Page; Sequence: 50 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->45<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%"><a href="#toc" title="Table of Contents" style="font-style: italic">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.65pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our
potential for rapid growth and our entry into new markets make it difficult for us to evaluate our current and future business prospects,
and we may be unable to effectively manage any growth associated with these new markets, which may increase the risk of your investment
and could harm our business, financial condition, results of operations and cash flow.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.35pt; text-align: justify; text-indent: 35.65pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.65pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
entry into the rapidly growing health, wellness and mentoring/life coaching market may place a significant strain on our resources and
increase demands on our executive management, personnel and systems, and our operational, administrative and financial resources may
be inadequate. We may also not be able to effectively manage any expanded operations, or achieve planned growth on a timely or profitable
basis, particularly if the number of customers using our technology significantly increases or their demands and needs change as our
business expands. If we are unable to manage expanded operations effectively, we may experience operating inefficiencies, the quality
of our products and services could deteriorate, and our business and results of operations could be materially adversely affected.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.35pt; text-align: justify; text-indent: 35.65pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.35pt; text-align: justify; text-indent: 35.65pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>If
we are unable to develop and maintain our brand and reputation for our service and product offerings, our business and prospects could
be materially harmed.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.35pt; text-align: justify; text-indent: 35.65pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.35pt; text-align: justify; text-indent: 35.65pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
business and prospects depend, in part, on developing and then maintaining and strengthening our brand and reputation in the markets
we serve. If problems arise with our products or services, our brand and reputation could be diminished. If we fail to develop, promote
and maintain our brand and reputation successfully, our business and prospects could be materially harmed.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.65pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.35pt; text-align: justify; text-indent: 35.65pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
may not maintain sufficient insurance coverage for the risks associated with our business operations.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.35pt; text-align: justify; text-indent: 35.65pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.35pt; text-align: justify; text-indent: 35.65pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Risks
associated with our business and operations include, but are not limited to, claims for wrongful acts committed by our officers, directors,
and other representatives, the loss of intellectual property rights, the loss of key personnel, risks posed by natural disasters and
risks of lawsuits from customers who are injured from or dissatisfied with our services. Any of these risks may result in significant
losses. We cannot provide any assurance that our insurance coverage is sufficient to cover any losses that we may sustain, or that we
will be able to successfully claim our losses under our insurance policies on a timely basis or at all. If we incur any loss not covered
by our insurance policies, or the compensated amount is significantly less than our actual loss or is not timely paid, our business,
financial condition and results of operations could be materially and adversely affected.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.35pt; text-align: justify; text-indent: 35.65pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 51 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->46<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%"><a href="#toc" title="Table of Contents" style="font-style: italic">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.35pt; text-align: justify; text-indent: 35.65pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
do not anticipate paying any cash dividends.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.35pt; text-align: justify; text-indent: 35.65pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.35pt; text-align: justify; text-indent: 35.65pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
presently do not anticipate that we will pay any dividends on any of our capital stock in the foreseeable future. The payment of dividends,
if any, would be contingent upon our revenues and earnings, if any, capital requirements, and general financial condition. The payment
of any dividends will be within the discretion of our board of directors. We presently intend to retain all earnings, if any, to implement
our business plan; accordingly, we do not anticipate the declaration of any dividends in the foreseeable future.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.35pt; text-align: justify; text-indent: 35.65pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.35pt; text-align: justify; text-indent: 35.65pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Any
failure to protect our intellectual property rights could impair our ability to protect our technology and our brand.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.65pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.35pt; text-align: justify; text-indent: 35.65pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
success depends in part on our ability to enforce our intellectual property and other proprietary rights. We rely upon a combination
of trademark and trade secret laws, as well as license and other contractual provisions, to protect our intellectual property and other
proprietary rights. These laws, procedures and restrictions provide only limited protection and any of our intellectual property rights
may be challenged, invalidated, circumvented, infringed or misappropriated. To the extent that our intellectual property and other proprietary
rights are not adequately protected, third parties may gain access to our proprietary information, develop and market solutions similar
to ours or use trademarks similar to ours, each of which could materially harm our business. The failure to adequately protect our intellectual
property and other proprietary rights could have a material adverse effect on our business, financial condition and results of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.65pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>For
all of the foregoing reasons and others set forth herein, an investment in our securities in involves a high degree of risk.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="ed_006"></span>Securities
Purchase AgreementS</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Between
November 22, 2021 and December 2, 2021, we entered into four separate Securities Purchase Agreements (collectively, the &#8220;<span style="text-decoration: underline">Purchase
Agreements</span>&#8221;) with four accredited institutional investors (collectively, the &#8220;<span style="text-decoration: underline">Investors</span>&#8221;), for the sale
of convertible promissory notes in an aggregate principal amount of $2,000,000 (collectively, the &#8220;<span style="text-decoration: underline">Notes</span>&#8221;) and warrants
to purchase an aggregate of 13,333,332 shares of the Company&#8217;s common stock (collectively, the &#8220;<span style="text-decoration: underline">Warrants</span>&#8221;).
The Purchase Agreements, Notes, and Warrants are collectively referred to as the &#8220;<span style="text-decoration: underline">Transaction Documents</span>&#8221;). The Company
and the Investors closed the sale of the Notes and Warrants between November 23, 2021 and December 3, 2021. Gross proceeds of $1,800,000
were raised through the sale of the Notes and Warrants.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">J.H.
Darbie &amp; Co., Inc. acted as placement agent for the offering and was paid a total of $188,000 in placement agent fees of which $98,000
was paid in cash and $90,000 was paid in the form of 1,151,678 shares of restricted common stock from the Company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 52 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->47<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%"><a href="#toc" title="Table of Contents" style="font-style: italic">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">The
Purchase Agreements</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the Purchase Agreements, the Company was required to use the proceeds of the sale of the Notes for business development and not for
the repayment of any indebtedness owed to officers, directors or employees of the Company or their affiliates (except for certain excepted
payments not to exceed $115,000 under certain of the Purchase Agreements); any loan, credit, or advance to any officers, directors, employees,
or affiliates of the Company; the repayment of any debt issued in corporate finance transactions; any loan to or investment in any other
corporation, partnership, enterprise or other person, except in connection with the Company&#8217;s currently existing operations; or
in violation or contravention of any applicable law, rule or regulation. The Company is not permitted to enter into any public or private
offering of the Company&#8217;s securities (including convertible securities) with any other investor that is more favorable in any material
respect than the Investor&#8217;s rights under the Transaction Documents, unless similar terms are granted to the Investor, and is prohibited
from entering into certain &#8220;variable rate transactions&#8221; (including the issuance of convertible securities with a conversion
or exercise price that varies with trading prices of the Company&#8217;s common stock or is contingent upon a future event relating to
the Company&#8217;s business or the market for its common stock, or any agreement to issue securities at a future determined price) for
as long as the Notes are outstanding. The Company is also required to maintain the listing and trading of its common stock on the principal
securities exchange or trading market where such common stock is listed or traded and timely file all required reports with the Securities
and Exchange Commission under the Exchange Act, with a penalty of 1% of the purchase price of the Notes to be paid on the date of any
reporting failure and every thirty days thereafter until such reporting failure is cured. The Company also granted the Investors piggy-back
registration rights (except in connection with underwritten offerings and other customary exceptions) and agreed to indemnify the Investors
in connection with certain violations of the Exchange Act or the Securities Act, in connection with the piggy-back registration rights.
Each Purchase Agreement includes indemnification obligations of the Company and customary representations and warranties of the Buyers
and the Company regarding the purchase and offer and sale of the Notes.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">The
Notes</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Each
Note contains a 10% original issue discount, matures one year from its date of issue, and accrues interest at a rate of 10% per annum
(16% upon the occurrence of an event of default). The Notes also included expense reimbursements of the Investors in the aggregate amount
of $30,000. The Notes do not provide for fixed installment payments, but each Note provides that upon the Company&#8217;s receipt of
cash proceeds from any source, at the Investor&#8217;s option, the Company will immediately apply up to 50% of such proceeds to repay
all or any portion of the outstanding principal amount and interest then due under such Note (or up to 100% of the proceeds of any offering
of common stock or common stock equivalents that results in the immediate listing for trading of the Company&#8217;s common stock on
a national stock exchange or Nasdaq, and occurs within 220 days from the date the Notes are issued, referred to as an &#8220;<span style="text-decoration: underline">Uplist
Offering</span>&#8221;).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Notes (including accrued interest thereon) are convertible into shares of the Company&#8217;s common stock at any time after the occurrence
of an event of default under the Notes, the date that an Uplist Offering has been completed or 10 business days after notice of pre-payment
has been provided to the holders by the Company, at a conversion price equal to $0.075 per share; however, if the Company consummates
any Uplist Offering on or before 220 calendar days from the issuance date of the applicable Note, the conversion price thereof will be
equal to 80% of the offering price per share of the Company&#8217;s common stock in such Uplist Offering. Each Note contains a requirement
for the Company to reserve a number of shares of common stock equal to the greater of: (i) two times the number of shares of common stock
then issuable upon conversion of such Note or (ii) a fixed number of shares of common stock which equal two times the initial number
of shares issuable upon conversion of the Note. Each Note provides for a reduction of the conversion price to match the price per share
of any dilutive issuance made while the Note is outstanding (other than pursuant to certain customary excepted issuances), provided that
no adjustment is required unless the Company fails to consummate an Uplist Offering on or before 220 calendar days after the issuance
date of the Note, provided that if such Uplist Offering is not completed within such 220 calendar day period, the conversion price is
adjusted for any dilutive issuance which occurred during such 220 calendar day period. The conversion price of the Notes may be adjusted
upon the occurrence of certain events, such as a merger, consolidation, exchange of shares, recapitalization, reorganization, or similar
events.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 53 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->48<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%"><a href="#toc" title="Table of Contents" style="font-style: italic">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Notes have priority over all unsecured indebtedness of the Company, and while the Notes are outstanding, the Company is prohibited from
incurring any unsecured indebtedness that is senior to or pari passu with the Notes, paying or declaring any dividend or other distribution
on shares of capital stock other than dividends in kind and distributions pursuant to any shareholders&#8217; rights plan which is approved
by a majority of the Company&#8217;s disinterested directors, selling, leasing or otherwise disposing of any significant portion of its
assets outside the ordinary course of business and from lending money, giving credit, making advances to or entering into any transaction
with any person, firm, joint venture or corporation (other than transactions in existence prior to the issuance of the Notes of which
the Investors have been informed in writing prior to closing, transactions with unaffiliated third parties in the ordinary course of
business, transactions with unaffiliated third parties not in excess of $100,000).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Notes contain penalties for the Company&#8217;s failure to timely deliver shares due upon conversion thereof. The Notes contain provisions
limiting each Investor&#8217;s ability to convert any portion of its individual Note if such conversion would cause the Investor&#8217;s
(or any affiliate of any such Investor&#8217;s) holdings in the Company to exceed 4.99% of the Company&#8217;s issued and outstanding
shares of common stock. The Notes contain customary events of default, which include failure by the Company to maintain a market capitalization
of at least $2,000,000 on any trading day; the suspension, trading halt, or delisting of the Company&#8217;s common stock on the principal
securities exchange or trading market on which the Company&#8217;s common stock is listed or traded; final judgments equal to or greater
than $100,000 rendered against the Company; failure to consummate an Uplist Offering within 220 calendar days after the issue date of
each Note; and the Company&#8217;s failure to comply with the reporting obligations of the Exchange Act. Upon the occurrence of an event
of default, the amount of each Note increases by 125% (including principal and accrued interest) and is immediately due and payable.
The Company has the right to prepay the Notes by paying 110% of the principal and interest thereon at any time (provided we are required
to provide the holders 10 trading days&#8217; prior written notice of such repayment), plus $750 per note holder for administrative fees.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 54 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->49<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%"><a href="#toc" title="Table of Contents" style="font-style: italic">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">The
Warrants</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Warrants have a term of five years, are exercisable beginning 90 days after the issuance date, and have an exercise price of $0.075 per
share; however, if the Company consummates any Uplist Offering on or before 180 calendar days from the grant date of the Warrants, the
exercise price will be equal to 120% of the offering price per share of the Company&#8217;s common stock in such Uplist Offering. If
the exercise price is lower than the highest traded price of the Company&#8217;s common stock during the 150 trading days prior to the
date of exercise and the shares underlying the Warrants are not registered, the Warrants may be exercised via cashless exercise (with
the formula for such cashless exercise being set forth in the Warrants, and based on such highest traded price within the last 150 days).
The exercise price and the number of shares underlying the Warrant will be adjusted to account for any dividend or distribution by the
Company to the holders of its common stock. Each Warrant provides for a reduction of the exercise price to match the price per share
of any dilutive issuance made while the Warrant is outstanding (other than in connection with stock plan issuances and other customary
exceptions). Such reduction of the exercise price will not apply to the Uplist Offering if the Uplist Offering is consummated on or before
180 calendar days after the grant date of the Warrant. The exercise price of the Warrants is subject to customary adjustment upon the
occurrence of certain events, such as a subdivision (by any stock split, stock dividend, recapitalization or otherwise) of the Company&#8217;s
common stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Each
Warrant contains a requirement for the Company to reserve two times the number of shares of common stock issuable upon the exercise of
such Warrant. If the Company undertakes certain fundamental transactions (such as certain mergers, exchanges, or the sale of substantially
all of the Company&#8217;s assets) while the Warrants are outstanding, the Investors will have the right to receive any consideration
received by the record holders of the Company&#8217;s common stock as a result of such fundamental transaction and the exercise price
of the Warrants will be adjusted to account for such additional consideration. The Warrants contain provisions limiting each Investor&#8217;s
ability to exercise the Warrants if such exercise would cause the Investor&#8217;s (or any affiliate of any such Investor) holdings in
the Company to exceed 4.99% of the Company&#8217;s issued and outstanding shares of common stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="ed_007"></span>Use
of Proceeds</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are registering the shares of common stock for the benefit of the selling stockholders. We are not selling any securities under this
prospectus and we will not receive any of the proceeds from the sale or other disposition by the selling stockholders or their transferees
of the shares of common stock covered hereby. However, to the extent that the Warrants are exercised for cash, we will receive up to
$1,000,000 (assuming the exercise price of the Warrants, which is subject to adjustment as discussed above, remains at $0.075 per share)
which amount we plan to use for working capital and general corporate purposes. However, the timing and manner of use of the net proceeds
may vary, depending on the amount of actual proceeds received from the exercise of the Warrants, if any, the timing of the receipt of
such proceeds, our rate of growth and other factors. To the extent that any shares of common stock issuable upon exercise of the Warrants
are not registered under an effective registration statement under the Securities Act, such unregistered Warrants or portion thereof
are exercisable on a cashless basis pursuant to the terms of the Warrant agreements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have agreed to pay all costs, expenses and fees relating to registering the shares of our common stock referenced in this prospectus.
The selling stockholders will pay any underwriting discounts and commissions and expenses incurred by the selling stockholders for brokerage,
accounting, tax or legal services or any other expenses incurred by the selling stockholders in disposing of the shares.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">See
&#8220;<a href="#ed_011">Selling Stockholders</a>&#8221; and &#8220;<a href="#ed_010">Plan of Distribution</a>&#8221; described below.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 55 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->50<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%"><a href="#toc" title="Table of Contents" style="font-style: italic">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><b>&#160;</b></span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="ed_008"></span>Determination
of Offering Price</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
selling stockholders will offer the shares at the prevailing market prices or privately negotiated price. The offering price of our common
stock does not necessarily bear any relationship to our book value, assets, past operating results, financial condition or any other
established criteria of value. Our common stock may not trade at market prices in excess of the offering price as prices for common stock
in any public market will be determined in the marketplace and may be influenced by many factors, including the depth and liquidity.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="ed_009"></span>Description
of Capital Stock</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following information describes our common stock and preferred stock, as well as certain provisions of our Articles of Incorporation
and Bylaws, as amended and restated (the &#8220;<span style="text-decoration: underline">Bylaws</span>&#8221;). This description is only a summary. You should also refer to our
Articles of Incorporation and Bylaws, which have been filed with the SEC as exhibits to our registration statement, of which this prospectus
forms a part.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Description
of Capital Stock</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
authorized capital stock consists of 195,000,000 shares of common stock with a $0.0001 par value per share, and 5,000,000 shares of preferred
stock with a $0.0001 par value per share. As of the date of this prospectus, we have designated three shares of Series A Preferred Stock
and 2,000,000 shares of Series B Preferred Stock. As of the date of this prospectus, there are 97,286,902 shares of common stock issued
and outstanding, one share of Series A Preferred Stock issued and outstanding and no shares of Series B Preferred Stock issued and outstanding.
The following is a summary of the material provisions of the common stock and preferred stock provided for in our Articles of Incorporation
and Bylaws. For additional detail about our capital stock, please refer to our Articles of Incorporation and Bylaws.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline">Common
Stock</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline">Voting
Rights</span></i>. Each share of our common stock is entitled to one vote on all stockholder matters. Shares of our common stock do not
possess any cumulative voting rights.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Except
for the election of directors, if a quorum is present, an action on a matter is approved if it receives the affirmative vote of the holders
of a majority of the voting power of the shares of capital stock present in person or represented by proxy at the meeting and entitled
to vote on the matter, unless otherwise required by applicable law, Nevada law, our Articles of Incorporation, as amended or Bylaws,
as amended. The election of directors will be determined by a plurality of the votes cast in respect of the shares present in person
or represented by proxy at the meeting and entitled to vote, meaning that the nominees with the greatest number of votes cast, even if
less than a majority, will be elected. The rights, preferences and privileges of holders of common stock are subject to, and may be impacted
by, the rights of the holders of shares of any series of preferred stock that we have designated, or may designate and issue in the future.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 56 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->51<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%"><a href="#toc" title="Table of Contents" style="font-style: italic">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline">Dividend
Rights</span></i>. Each share of our common stock is entitled to equal dividends and distributions per share with respect to the common
stock when, as and if declared by our board of directors, subject to any preferential or other rights of any outstanding preferred stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline">Liquidation
and Dissolution Rights</span></i>. Upon liquidation, dissolution or winding up, our common stock will be entitled to receive pro rata on
a share-for-share basis, the assets available for distribution to the stockholders after payment of liabilities and payment of preferential
and other amounts, if any, payable on any outstanding preferred stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline">Fully
Paid Status</span><b>. </b></i>All outstanding shares of the Company&#8217;s common stock are validly issued, fully paid and non-assessable.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline">Other
Matters</span></i>. No holder of any shares of our common stock has a preemptive right to subscribe for any of our securities, nor are any
shares of our common stock subject to redemption or convertible into other securities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Preferred
Stock</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
May 18, 2020, the board of directors of the Company approved the filing of (a) an Amended and Restated Certificate of Designation of
the Company&#8217;s Series A Preferred Stock (the &#8220;<span style="text-decoration: underline">Series A Preferred Stock</span>&#8221; and the &#8220;<span style="text-decoration: underline">Series A Designation</span>&#8221;);
and (b) an Amended and Restated Certificate of Designation of the Company&#8217;s Series B Convertible Preferred Stock (the &#8220;<span style="text-decoration: underline">Series
B Preferred Stock</span>&#8221; and the &#8220;<span style="text-decoration: underline">Series B Designation</span>&#8221;), with the Secretary of State of Nevada, which designations
were filed with, and became effective with, the Secretary of State of Nevada on the same date. The Series A Designation designated three
shares of Series A Preferred Stock and the Series B Designation designated 2,000,000 shares of Series B Preferred Stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Series
A Preferred Stock</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Series A Designation provides for the Series A Preferred Stock to have the following rights:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline">Dividend
Rights</span></i>. The Series A Preferred Stock do not accrue dividends.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline">Liquidation
Preference</span></i>. The Series A Preferred Stock have no liquidation preference.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline">Conversion
Rights</span></i>. The Series A Preferred Stock have no conversion rights.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline">Voting
Rights</span>.</i> For so long as any shares of Series A Preferred Stock remain issued and outstanding, the holders thereof, voting separately
as a class, have the right to vote on all shareholder matters (including, but not limited to at every meeting of the stockholders of
the Company and upon any action taken by stockholders of the Company with or without a meeting) equal to sixty percent (60%) of the total
vote (the &#8220;<span style="text-decoration: underline">Total Series A Vote</span>&#8221; and the &#8220;<span style="text-decoration: underline">Voting Rights</span>&#8221;). For example, if there are 10,000 shares
of the Company&#8217;s common stock issued and outstanding at the time of a shareholder vote, the holders of the Series A Preferred Stock,
voting separately as a class, will have the right to vote an aggregate of 15,000 shares, out of a total number of 25,000 shares voting.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 57 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->52<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%"><a href="#toc" title="Table of Contents" style="font-style: italic">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Additionally,
so long as Series A Preferred Stock is outstanding, the Company shall not, without the affirmative vote of the holders of at least 66-2/3%
of all outstanding shares of Series A Preferred Stock, voting separately as a class (i) amend, alter or repeal any provision of the Articles
of Incorporation or the Bylaws of the Company so as to adversely affect the designations, preferences, limitations and relative rights
of the Series A Preferred Stock, (ii) effect any reclassification of the Series A Preferred Stock, (iii) designate any additional series
of preferred stock, the designation of which adversely effects the rights, privileges, preferences or limitations of the Series A Preferred
Stock; or (iv) amend, alter or repeal any provision of the Series A Designation (except in connection with certain non-material technical
amendments).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notwithstanding
the above, no shares of Series A Preferred Stock held by any person who is not a then member of the board of directors of the Company
(each a &#8220;<span style="text-decoration: underline">Non-Director Holder</span>&#8221;), shall have any Voting Rights and the Voting Rights of all other shares of Series A
Preferred Stock (including, but not limited to the Total Series A Vote) shall be calculated without regard to, and without taking into
account, the shares of Series A Preferred Stock held by such Non-Director Holder.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline">Redemption
Right</span></i>. The Company has the option in its sole discretion, at any time, with the majority consent or approval of the board of
directors of the Company, to redeem any outstanding shares of Series A Preferred Stock of the Company held by any Non-Director Holder,
by paying the Non-Director Holder(s) a redemption price of $1.00 per share for each such Series A Preferred Stock shares redeemed (the
&#8220;<span style="text-decoration: underline">Redemption Amount</span>&#8221;, and each a &#8220;<span style="text-decoration: underline">Redemption</span>&#8221;). The payment by the Company to the Non-Director Holder
(at such Non-Director Holder&#8217;s address of record) of the Redemption Amount in connection with a Redemption automatically results
in the cancellation, termination and invalidation of any outstanding Series A Preferred Stock held by a Non-Director Holder or his, her
or its assigns.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline">Purchase
Right</span></i>. In the event the Company is legally prohibited from exercising the redemption right discussed above, any one or more of
the other holders of the Series A Preferred Stock, other than any Non-Director Holder(s) (the &#8220;<span style="text-decoration: underline">Director Holders</span>&#8221;),
have the option, exercisable in their sole discretion, to purchase their pro rata share of any shares of Series A Preferred Stock held
by any Non-Director Holder(s) for $1.00 per share of Series A Preferred Stock (the &#8220;<span style="text-decoration: underline">Purchase Amount</span>&#8221;, and the &#8220;<span style="text-decoration: underline">Purchase</span>&#8221;).
The payment by the Director Holder(s) of the Series A Preferred Stock to the Non-Director Holder of the Purchase Amount automatically,
and without any required action by the Director Holder(s) or the Non-Director Holder, results in the transfer of the rights to, and ownership
of, such Series A Preferred Stock held by a Non-Director Holder or his, her or its assigns, to the Director Holder(s), pro rata with
their payment of the Purchase Amount.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 58 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->53<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%"><a href="#toc" title="Table of Contents" style="font-style: italic">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36.25pt; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline">Protective
Provisions</span></i>. Subject to the rights of series of preferred stock which may from time to time come into existence, so long as any
shares of Series A Preferred Stock are outstanding, the Company cannot without first obtaining the approval (by written consent, as provided
by law) of the holders of a majority of the then outstanding shares of Series A Preferred Stock, voting together as a class:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
Issue any additional shares of Series A Preferred Stock after the original issuance of shares of Series A Preferred Stock;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
Increase or decrease the total number of authorized or designated shares of Series A Preferred Stock;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)
Effect an exchange, reclassification, or cancellation of all or a part of the Series A Preferred Stock;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)
Effect an exchange, or create a right of exchange, of all or part of the shares of another class of shares into shares of Series A Preferred
Stock; or</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)
Alter or change the rights, preferences or privileges of the shares of Series A Preferred Stock so as to affect adversely the shares
of such series, including the rights set forth in the Series A Designation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 112.25pt; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline">Transfer
Restrictions</span></i>. Each holder of Series A Preferred Stock is prohibited from Transferring any shares of Series A Preferred Stock.
&#8220;<span style="text-decoration: underline">Transfer</span>&#8221; means directly or indirectly (a) offering for sale, selling, pledging, hypothecating, transferring, assigning
or otherwise disposing of (or enter into any transaction or device that is designed to, or could be expected to, result in the sale,
pledge, hypothecation, transfer, assignment or other disposition at any time) (including, without limitation, by operation of law); or
(b) entering into any swap or other derivatives transaction that transfers to another, in whole or in part, any of the benefits or risks
of ownership of the applicable securities, whether any such transaction is to be settled by delivery of securities or other securities,
in cash or otherwise.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
total of one share of Series A Preferred Stock is currently outstanding.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Series
B Convertible Preferred Stock</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Series B Designation provides for the Series B Preferred Stock to have the following rights:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline">Dividend
Rights</span></i>. The Series B Preferred Stock does not accrue any dividends, but the Series B Preferred Stock holders are entitled to
share in dividends paid to the holders of the Company&#8217;s common stock to the same extent that such holders would have received such
dividends had they converted the Series B Preferred Stock into common stock pursuant to the conversion rights discussed below.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 59 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->54<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%"><a href="#toc" title="Table of Contents" style="font-style: italic">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline">Liquidation
Preference</span></i>. In the event of any liquidation, dissolution or winding up of the Company, either voluntary or involuntary (each
a &#8220;<span style="text-decoration: underline">Liquidation Event</span>&#8221;), the holders of Series B Preferred Stock are entitled to receive pari passu with any distribution
of any of the assets of the Company to the holders of the Company&#8217;s common stock, but not prior to any holders of senior securities
(which include holders of capital leases, other preferred stock and debt holders, and banks or others, which hold priority liquidation
preferences over the assets of the Company), which holders of the senior securities have priority to the distribution of any assets of
the Company, an amount per share for each share of Series B Preferred Stock held by them equal to $1.00 per share.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline">Conversion
Rights</span></i>. Each share of Series B Preferred Stock may be converted, at the option of the holder thereof, into that number of shares
of common stock of the Company as equals $1.00 divided by 90% of the average of the volume weighted average prices (&#8220;<span style="text-decoration: underline">VWAP</span>&#8221;)
of the Company&#8217;s common, for the five trading days immediately preceding the date the notice of conversion is received, with any
remainder rounded to the hundredths place. Notwithstanding the above, at no time may the Series B Preferred Stock be converted into shares
of our common stock by any holder, if such conversion would result in such holder thereof and its affiliates owning an aggregate of in
excess of 4.999% of the then outstanding shares of our common stock, which amount may be increased to 9.999% on a per holder basis, upon
61 days&#8217; prior written notice.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline">Voting
Rights</span></i>. The Series B Preferred Stock have no voting rights on general corporate matters, provided that the Series B Designation
does contain customary protective provisions restricting the Company&#8217;s ability to undertake any of the following without the approval
of a majority in interest of such shares of Series B Preferred Stock:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
Increase or decrease (other than by redemption or conversion) the total number of authorized shares of Series B Preferred Stock;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
Re-issue any shares of Series B Preferred Stock converted pursuant to the terms of the Series B Designation;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)
Issue any shares of Series B Preferred Stock other than pursuant to a specified securities purchase agreement;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)
Alter or change the rights, preferences or privileges of the shares of Series B Preferred Stock so as to affect adversely the shares
of such series; or</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)
Amend or waive any provision of the Company&#8217;s Articles of Incorporation or Bylaws relative to the Series B Preferred Stock so as
to affect adversely the shares of Series B Preferred Stock in any material respect as compared to holders of other series of shares.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline">Redemption
Rights</span></i>. The Series B Preferred Stock have no redemption rights.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">No
shares of Series B Preferred Stock are currently outstanding.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 60 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->55<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%"><a href="#toc" title="Table of Contents" style="font-style: italic">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Anti-Takeover
Provisions Under the Nevada Revised Statutes</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Business
Combinations</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sections
78.411 to 78.444 of the Nevada revised statutes (the &#8220;<span style="text-decoration: underline">NRS</span>&#8221;) prohibit a Nevada corporation from engaging in a &#8220;<span style="text-decoration: underline">combination</span>&#8221;
with an &#8220;<span style="text-decoration: underline">interested stockholder</span>&#8221; for three years following the date that such person becomes an interested stockholder
and places certain restrictions on such combinations even after the expiration of the three-year period. With certain exceptions, an
interested stockholder is a person or group that owns 10% or more of the corporation&#8217;s outstanding voting power (including stock
with respect to which the person has voting rights and any rights to acquire stock pursuant to an option, warrant, agreement, arrangement,
or understanding or upon the exercise of conversion or exchange rights) or is an affiliate or associate of the corporation and was the
owner of 10% or more of such voting stock at any time within the previous three years.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
Nevada corporation may elect not to be governed by Sections 78.411 to 78.444 by a provision in its Articles of Incorporation. We do not
have such a provision in our Amended and Restated Articles of Incorporation, as amended, pursuant to which we have elected to opt out
of Sections 78.411 to 78.444; therefore, these sections apply to us.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Control
Shares</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Nevada
law also seeks to impede &#8220;<span style="text-decoration: underline">unfriendly</span>&#8221; corporate takeovers by providing in Sections 78.378 to 78.3793 of the NRS that
an &#8220;<span style="text-decoration: underline">acquiring person</span>&#8221; shall only obtain voting rights in the &#8220;<span style="text-decoration: underline">control shares</span>&#8221; purchased by such
person to the extent approved by the other stockholders at a meeting. With certain exceptions, an acquiring person is one who acquires
or offers to acquire a &#8220;<span style="text-decoration: underline">controlling interest</span>&#8221; in the corporation, defined as one-fifth or more of the voting power.
Control shares include not only shares acquired or offered to be acquired in connection with the acquisition of a controlling interest,
but also all shares acquired by the acquiring person within the preceding 90 days. The statute covers not only the acquiring person but
also any persons acting in association with the acquiring person. The NRS control share statutes only apply to issuers that have 200
or more stockholders of record, at least 100 of whom have had addresses in Nevada appearing on the stock ledger of the corporation at
all times during the 90 days immediately preceding such date; and whom do business in Nevada directly or through an affiliated corporation.
We do not currently meet these requirements and as such these provisions do not apply to us.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
Nevada corporation may elect to opt out of the provisions of Sections 78.378 to 78.3793 of the NRS. We do not have a provision in our
Amended and Restated Articles of Incorporation pursuant to which we have elected to opt out of Sections 78.378 to 78.3793; therefore,
these sections do apply to us.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Removal
of Directors</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section
78.335 of the NRS provides that 2/3rds of the voting power of the issued and outstanding shares of the Company are required to remove
a Director from office. As such, it may be more difficult for stockholders to remove Directors due to the fact the NRS requires greater
than majority approval of the stockholders for such removal.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 61 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->56<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%"><a href="#toc" title="Table of Contents" style="font-style: italic">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Anti-Takeover
Effects of Our Articles of Incorporation and Bylaws</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following provisions of our Articles of Incorporation and Bylaws could have the effect of delaying or discouraging another party from
acquiring control of us and could encourage persons seeking to acquire control of us to first negotiate with our board of directors:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">no
    cumulative voting in the election of directors, which limits the ability of minority stockholders to elect director candidates;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    right of our board of directors to elect a director to fill a vacancy created by the expansion of the board of directors or the resignation,
    death or removal of a director, with our stockholders only allowed to fill such a vacancy if not filled by the board;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    super majority voting rights of our Series A Preferred Stock, to the extent such shares are held by members of our board of directors;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    ability of our board of directors to alter our Bylaws without obtaining stockholder approval; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    requirement that a special meeting of stockholders may be called only by the board of directors, the Chairman of the Board, the President
    or a committee of the board of directors duly designated and whose powers and authority include the power to call meetings may call
    special meetings of the Company.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Listing</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
common stock is traded on the OTCQB Market under the symbol &#8220;<span style="text-decoration: underline">AMIH</span>&#8221;.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Transfer
Agent and Registrar</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
transfer agent and registrar for our common stock is American Stock Transfer &amp; Trust Company, 6201 15th Ave, Brooklyn, NY 11219.
Its telephone number is (800) 937-5449.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="ed_010"></span>Plan
of Distribution</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are registering the shares of common stock covered by the registration statement of which this prospectus is a part, which are issuable
to the selling stockholders upon the conversion of Notes and upon the exercise of Warrants, to permit the resale of these shares of common
stock by the selling stockholders from time to time from after the date of this prospectus.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 62 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->57<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%"><a href="#toc" title="Table of Contents" style="font-style: italic">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Each
selling stockholder may, from time to time, sell any or all of their shares of common stock covered hereby on the over-the-counter market,
any national securities exchange or quotation service on which the shares of our common stock may be listed or quoted at the time of
sale, in the over-the counter market, in privately negotiated transactions, through the writing of options, whether such options are
listed on an options exchange or otherwise, short sales or in a combination of such transactions. These sales may be at fixed prices,
at prevailing market prices at the time of the sale, at varying prices determined at the time of sale, or privately negotiated prices.
A Selling Stockholder may use any one or more of the following methods when selling shares:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ordinary
    brokerage transactions and transactions in which the broker-dealer solicits purchasers&#894;</span></td></tr>

<tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">block
    trades in which the broker-dealer will attempt to sell the shares as agent but may position and resell a portion of the block as
    principal to facilitate the transaction&#894;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">purchases
    by a broker-dealer as principal and resale by the broker-dealer for its account&#894;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">an
    exchange distribution in accordance with the rules of the applicable exchange&#894;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">privately
    negotiated transactions&#894;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">settlement
    of short sales, to the extent permitted by law&#894;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">in
    transactions through broker-dealers that agree with the selling stockholders to sell a specified number of such shares at a stipulated
    price per share&#894;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">through
    the writing or settlement of options or other hedging transactions, whether through an options exchange or otherwise&#894;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a
    combination of any such methods of sale&#894; or</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">any
    other method permitted pursuant to applicable law.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
selling stockholders may pledge or grant a security interest in some or all of the shares of common stock owned by them and, if they
default in the performance of their secured obligations, the pledgees or secured parties may offer and sell the shares of common stock
from time to time pursuant to this prospectus.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
selling stockholders also may transfer and donate the shares of common stock in other circumstances in which case the transferees, donees,
pledgees or other successors in interest will be the selling beneficial owners for purposes of this prospectus.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
selling stockholders may also sell the shares of common stock under Rule 144 under the Securities Act, if available, rather than under
this prospectus.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Broker-dealers
engaged by the selling stockholders may arrange for other brokers-dealers to participate in sales. Broker-dealers may receive commissions
or discounts from the selling stockholders (or, if any broker-dealer acts as agent for the purchaser of shares, from the purchaser) in
amounts to be negotiated, but, except as set forth in a supplement to this prospectus, in the case of an agency transaction not in excess
of a customary brokerage commission in compliance with FINRA Rule 2440&#894; and in the case of a principal transaction a markup or markdown
in compliance with FINRA IM-2440-1.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 63 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->58<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%"><a href="#toc" title="Table of Contents" style="font-style: italic">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
aggregate proceeds to the selling stockholders from the sale of the common stock offered by them will be the purchase price of the common
stock less discounts or commissions, if any. Each of the selling stockholders reserve the right to accept and, together with their agents
from time to time, to reject, in whole or in part, any proposed purchase of common stock to be made directly or through agents. We will
not receive any of the proceeds from the sale by the selling stockholders of the shares of common stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
connection with the sale of the shares of common stock or interests therein, the selling stockholders may enter into hedging transactions
with broker-dealers or other financial institutions, which may in turn engage in short sales of the shares of common stock in the course
of hedging the positions they assume. The selling stockholders may also sell the shares of common stock short and deliver these securities
to close out their short positions or to return borrowed shares in connection with such short sales, or loan or pledge the shares of
common stock to broker-dealers that in turn may sell these securities. The selling stockholders may also enter into option or other transactions
with broker-dealers or other financial institutions or create one or more derivative securities which require the delivery to such broker-dealer
or other financial institution of shares of common stock offered by this prospectus, which shares such broker-dealer or other financial
institution may resell pursuant to this prospectus (as supplemented or amended to reflect such transaction).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
selling stockholders and any broker-dealers or agents that are involved in selling the shares of common stock may be deemed to be &#8220;<span style="text-decoration: underline">underwriters</span>&#8221;
within the meaning of the Securities Act in connection with such sales. In such event, any commissions received by such selling stockholders,
broker-dealers or agents and any profit on the resale of the shares purchased by them may be deemed to be underwriting commissions or
discounts under the Securities Act. Selling stockholders who are &#8220;<span style="text-decoration: underline">underwriters</span>&#8221; within the meaning of Section 2(11)
of the Securities Act will be subject to the prospectus delivery requirements of the Securities Act and may be subject to certain statutory
liabilities of, including but not limited to, Sections 11, 12 and 17 of the Securities Act and Rule 10b-5 under the Exchange Act. Each
selling stockholder has informed us that it is not a registered broker-dealer or an affiliate of a registered broker-dealer.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
the securities laws of some states, the shares of common stock may be sold in such states only through registered or licensed brokers
or dealers. In addition, in some states the shares of common stock may not be sold unless such shares have been registered or qualified
for sale in such state or an exemption from registration or qualification is available and is complied with. There can be no assurance
that any selling stockholder will sell any or all of the shares of common stock registered pursuant to the registration statement, of
which this prospectus forms a part.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are required to pay certain fees and expenses incurred by us incident to the registration of the shares. We have agreed to indemnify
the selling stockholders against certain losses, claims, damages and liabilities, including liabilities under the Securities Act, and
the selling stockholders may be entitled to contribution. We may be indemnified by the selling stockholders against certain losses, claims,
damages and liabilities, including liabilities under the Securities Act that may arise from any written information furnished to us by
the selling stockholders specifically for use in this prospectus, or we may be entitled to contribution.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 64 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->59<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%"><a href="#toc" title="Table of Contents" style="font-style: italic">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
selling stockholders will be subject to the prospectus delivery requirements of the Securities Act including Rule 172 thereunder unless
an exemption therefrom is available.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
applicable rules and regulations under the Exchange Act, any person engaged in the distribution of the shares of common stock may not
simultaneously engage in market making activities with respect to the shares of common stock for the applicable restricted period, as
defined in Regulation M, prior to the commencement of the distribution. In addition, the selling stockholders will be subject to applicable
provisions of the Exchange Act and the rules and regulations thereunder, including Regulation M, which may limit the timing of purchases
and sales of shares of common stock by the selling stockholders or any other person. We will make copies of this prospectus available
to the selling stockholders and have informed them of the need to deliver a copy of this prospectus at or prior to the time of the sale
(including by compliance with Rule 172 under the Securities Act).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
the extent required, the shares of our common stock to be sold, the names of the selling stockholders, the respective purchase prices
and public offering prices, the names of any agents, dealer or underwriter, any applicable commissions or discounts with respect to a
particular offer will be set forth in an accompanying prospectus supplement or, if appropriate, a post-effective amendment to the registration
statement that includes this prospectus.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
selling stockholders may not sell any or all of the shares of common stock we registered on behalf of the selling stockholders pursuant
to the registration statement of which this prospectus forms a part.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Once
sold under the registration statement of which this prospectus forms a part, the shares of common stock registered herein will be freely
tradable in the hands of persons other than our affiliates.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="ed_011"></span>Selling
Stockholders</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
prospectus covers the resale from time to time by the selling stockholders identified in the table below of up to 42,666,665 shares of
common stock through this prospectus, including up to 29,333,333 shares of common stock issuable upon conversion of Notes and 13,333,332
shares of common stock issuable upon exercise of outstanding Warrants, each described in greater detail above under &#8220;<a href="#ed_006">Securities Purchase Agreement</a>&#8221;.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are registering the shares to permit the selling stockholders and any of their pledgees, donees, transferees, assignees and successors-in-interest
to, from time to time, sell any or all of the shares through public or private transactions at prevailing market prices, at prices related
to prevailing market prices or at privately negotiated prices of common stock on any stock exchange, market or trading facility on which
the shares are traded or in private transactions when and as they deem appropriate in the manner described in &#8220;<a href="#ed_010">Plan of Distribution</a>&#8221;.
As of the date of this prospectus, there are 97,286,902 shares of our common stock issued and outstanding.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 65 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->60<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%"><a href="#toc" title="Table of Contents" style="font-style: italic">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table sets forth, as of the date of this prospectus, the name of each selling stockholder, the number and percentage of shares
of our common stock beneficially owned by each selling stockholder prior to the offering for resale of the shares under this prospectus,
the number of shares of our common stock beneficially owned by each selling stockholder that may be offered from time to time under this
prospectus, and the number and percentage of shares of our common stock beneficially owned by the selling stockholder after the offering
of the shares (assuming all of the offered shares are sold by the selling stockholder).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
are no agreements between the Company and any selling stockholder pursuant to which the shares subject to this registration statement
were issued except as discussed above under &#8220;<a href="#ed_006">Securities Purchase Agreement</a>&#8221;. None of the selling stockholders has ever been
an executive officer or director of the Company or has had a material relationship with us at any time within the past three years unless
disclosed in the footnotes below.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Beneficial
ownership is determined in accordance with the rules of the SEC, and includes any shares of common stock as to which a person has sole
or shared voting power or investment power and any shares of common stock which the person has the right to acquire within sixty (60)
days through the exercise of any option, warrant or right, through conversion of any security or pursuant to the automatic termination
of a power of attorney or revocation of a trust, discretionary account or similar arrangement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">Number of Shares of Common Stock Beneficially Owned Prior to this Offering (1)</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">Number of Shares of</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">Beneficial Ownership of Common Stock After Registration Assuming All Shares Are Sold (#)</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">Name of Selling Stockholder</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">Number</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">Percentage</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">Common Stock Being Offered</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">Number</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">Percentage</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; text-align: left">Mast Hill Fund, L.P. (2)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">4,048,335</td><td style="padding-bottom: 1.5pt; text-align: left">(10)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.99</span></td><td style="padding-bottom: 1.5pt; text-align: right">%(10)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">16,000,000</td><td style="padding-bottom: 1.5pt; text-align: left">(6)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#8211;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#8211;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt; text-align: left">Blue Lake Partners, LLC (3)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">4,048,335</td><td style="padding-bottom: 1.5pt; text-align: left">(10)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.99</span></td><td style="padding-bottom: 1.5pt; text-align: right">%(10)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">10,666,666</td><td style="padding-bottom: 1.5pt; text-align: left">(7)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#8211;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#8211;</td><td style="padding-bottom: 1.5pt; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; text-align: left">Talos Victory Fund, LLC (4)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">4,048,335</td><td style="padding-bottom: 1.5pt; text-align: left">(10)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.99</span></td><td style="padding-bottom: 1.5pt; text-align: right">%(10)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">10,666,666</td><td style="padding-bottom: 1.5pt; text-align: left">(8)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#8211;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#8211;</td><td style="padding-bottom: 1.5pt; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt; text-align: left">LGH Investments, LLC (5)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">4,048,335</td><td style="padding-bottom: 1.5pt; text-align: left">(10)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.99</span></td><td style="padding-bottom: 1.5pt; text-align: right">%(10)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">5,333,333</td><td style="padding-bottom: 1.5pt; text-align: left">(9)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#8211;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#8211;</td><td style="padding-bottom: 1.5pt; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 15%; font-weight: bold">&#160;</td><td style="width: 2%; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 13%; font-weight: bold; text-align: right">&#160;</td><td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 2%; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 13%; font-weight: bold; text-align: right">&#160;</td><td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 13%; text-align: right">42,666,665</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 13%; font-weight: bold; text-align: right">&#160;</td><td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 2%; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 13%; font-weight: bold; text-align: right">&#160;</td><td style="width: 1%; font-weight: bold; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*
Less than one percent (1%).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">#
Assumes the sale of all shares offered herein.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 66 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->61<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%"><a href="#toc" title="Table of Contents" style="font-style: italic">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)
&#8220;<span style="text-decoration: underline">Beneficial ownership</span>&#8221; means that a person, directly or indirectly, has or shares voting or investment power with
respect to a security or has the right to acquire such power within 60 days. The percentage is based upon 97,286,902 shares of our common
stock outstanding as of April 21, 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)
Address: 48 Parker Road, Wellesley, MA 02482. Patrick Hassani is the Chief Investment Officer of Mast Hill Fund, L.P. and has voting
and investment power over these securities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)
Address: 3411 Silverside Road, Tatnal Building #104, Wilmington, DE 19810. Craig Kesselman is a managing member of Blue Lake Partners,
LLC. and has voting and investment power over these securities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4)
Address: 348 Cambridge Street #101, Woburn, MA 01801. Thomas Silverman is a managing member of Talos Victory Fund, LLC. and has voting
and investment power over these securities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(5)
Address: 6170 Tiki Ct., San Diego, CA 92130. Lucas Hoppel is a managing member of LGH Investments, LLC. and has voting and investment
power over these securities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(6)
Represents (1) 5,000,000 shares of common stock issuable upon exercise of Common Stock Purchase Warrants granted to the selling stockholder,
providing such selling stockholders the right to purchase 5,000,000 shares of common stock at an exercise price of $0.075 per share,
subject to adjustment; and (2) up to 11,000,000 shares of common stock of the Company issuable, upon conversion of principal and accrued
interest at maturity pursuant to a $750,000 Note acquired by the selling stockholder on November 22, 2021, at the option of the holder
thereof.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(7)
Represents (1) 3,333,333 shares of common stock issuable upon exercise of Common Stock Purchase Warrants granted to the selling stockholder,
providing such selling stockholders the right to purchase 3,333,333 shares of common stock at an exercise price of $0.075 per share,
subject to adjustment; and (2) up to 7,333,333 shares of common stock of the Company issuable, upon conversion of principal and accrued
interest at maturity pursuant to a $500,000 Note acquired by the selling stockholder on December 2, 2021, at the option of the holder
thereof.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(9)
Represents (1) 3,333,333 shares of common stock issuable upon exercise of Common Stock Purchase Warrants granted to the selling stockholder,
providing such selling stockholders the right to purchase 3,333,333 shares of common stock at an exercise price of $0.075 per share,
subject to adjustment; and (2) up to 7,333,333 shares of common stock of the Company issuable, upon conversion of principal and accrued
interest at maturity pursuant to a $500,000 Note acquired by the selling stockholder on November 30, 2021, at the option of the holder
thereof.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(9)
Represents (1) 1,666,666 shares of common stock issuable upon exercise of Common Stock Purchase Warrants granted to the selling stockholder,
providing such selling stockholders the right to purchase 1,666,666 shares of common stock at an exercise price of $0.075 per share,
subject to adjustment; and (2) up to 3,666,667 shares of common stock of the Company issuable, upon conversion of principal and accrued
interest at maturity pursuant to a $250,000 Note acquired by the selling stockholder on December 1, 2021, at the option of the holder
thereof.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 67 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->62<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%"><a href="#toc" title="Table of Contents" style="font-style: italic">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(10)
The Notes and Warrants contain provisions limiting each holder&#8217;s ability to convert/exercise such security, if such conversion/exercise
would cause the holder&#8217;s (or any affiliate of any such holder&#8217;s) holdings in the Company to exceed 4.99% of the Company&#8217;s
issued and outstanding shares of common stock. As such, the number of shares of common stock beneficially owned prior to this offering
represents 4.99% of the Company&#8217;s current outstanding shares of common stock.</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center">&#160;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="ed_012"></span>Certain
Beneficial Owners and Management</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: -0.2in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table sets forth information regarding the beneficial ownership of our common stock as of April [&#160;&#160;], 2022 (the &#8220;<span style="text-decoration: underline">Date
of Determination</span>&#8221;) by (i) each Named Executive Officer, as such term is defined in &#8220;<a href="#ed_024">Executive and Director Compensation</a>&#8221;,
(ii) each member of our board of directors, (iii) each person deemed to be the beneficial owner of more than five percent (5%) of our
common stock or preferred stock, and (iv) all of our executive officers and directors as a group. Unless otherwise indicated, each person
named in the following table is assumed to have sole voting power and investment power with respect to all shares of our stock listed
as owned by such person. The address of each person is deemed to be the address of the Company unless otherwise noted.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Beneficial
ownership is determined in accordance with the rules of the SEC and includes voting and/or investing power with respect to securities.
These rules generally provide that shares of common stock subject to options, warrants or other convertible securities that are currently
exercisable or convertible, or exercisable or convertible within 60 days of the Date of Determination, are deemed to be outstanding and
to be beneficially owned by the person or group holding such options, warrants or other convertible securities for the purpose of computing
the percentage ownership of such person or group, but are not treated as outstanding for the purpose of computing the percentage ownership
of any other person or group. The percentages are based upon 97,286,902 shares of our common stock outstanding as of the Date of Determination.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
our knowledge, except as indicated in the footnotes to this table and pursuant to applicable community property laws, as of the Date
of Determination, (a) the persons named in the table have sole voting and investment power with respect to all shares of common stock
shown as beneficially owned by them, subject to applicable community property laws; and (b) no person owns more than 5% of our common
or preferred stock. Unless otherwise indicated, the address for each of the officers or directors listed in the table below is 7950 Legacy
Drive, Suite 400, Plano, Texas 75024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 68 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->63<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%"><a href="#toc" title="Table of Contents" style="font-style: italic">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"><b>Name and Address of Beneficial Owner</b></td><td style="padding-bottom: 1.5pt; text-align: center"><b>&#160;</b></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><b>Common Shares Beneficially Owned</b></td><td style="padding-bottom: 1.5pt; text-align: center"><b>&#160;</b></td><td style="padding-bottom: 1.5pt; text-align: center"><b>&#160;</b></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><b>Common Ownership Percentage</b></td><td style="padding-bottom: 1.5pt; text-align: center"><b>&#160;</b></td><td style="padding-bottom: 1.5pt; text-align: center"><b>&#160;</b></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><b>Series A Preferred Stock Shares Beneficially Owned</b></td><td style="padding-bottom: 1.5pt; text-align: center"><b>&#160;</b></td><td style="padding-bottom: 1.5pt; text-align: center"><b>&#160;</b></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><b>Series A Preferred Stock Percentage (1)</b></td><td style="padding-bottom: 1.5pt; text-align: center"><b>&#160;</b></td><td style="padding-bottom: 1.5pt; text-align: center"><b>&#160;</b></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><b>Total Voting Percentage (2)</b></td><td style="padding-bottom: 1.5pt; text-align: center"><b>&#160;</b></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; font-style: italic">Officers and Directors</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="width: 35%; text-align: left">Jacob D. Cohen</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">27,500,000</td><td style="width: 1%; text-align: left">(3)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">28.3</td><td style="width: 1%; text-align: left">%</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">1</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">100</td><td style="width: 1%; text-align: left">%</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">71.4</td><td style="width: 1%; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Alejandro Rodriguez</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4,000,000</td><td style="text-align: left">(4)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4.1</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1.7</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Verdie Bowen</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,500,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1.5</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*&#160;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Sultan Haroon</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Maja Matthews</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Peter &#8220;Casey&#8221; Jensen</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">414,112</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*&#160;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">*</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Dr. Kenny Myers</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">163,043</td><td style="text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b></b>*<b>&#160;</b></span></td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">*</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Lorraine D&#8217;Alessio</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">163,043</td><td style="text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b></b>*<b>&#160;</b></span></td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">*</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Dr. Craig Hewitt</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">*</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">All officers and directors as a group</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">33,251,069</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">34.7</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">100</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">73.1</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; font-style: italic; text-align: left">Greater than 5% Shareholders</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Cavalry Fund I LP (5)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5,023,352</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5.0</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2.1</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">L1 Capital Global Opportunities Master Fund (6)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">8,081,267</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">8.1</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3.3</td><td style="text-align: left">%</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*
Less than 1%.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)
The Series A Preferred Stock have the right, voting in aggregate, to vote on all shareholder matters equal to sixty percent (60%) of
the total vote, so long as such shares are held by directors of the Company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)
Based on 240,983,562 total voting shares, including 97,286,902 shares voted by our common stockholders and 143,696,660 voting shares
voted by our Series A Preferred Stock holder, Mr. Cohen (see also footnote 1).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)
The shares of common stock are held in the name of Cohen Enterprises, Inc., which shares Mr. Cohen is deemed to beneficially own due
to his ownership of 100% of Cohen Enterprises and his position as President thereof.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4)
The shares of common stock are held in the name of Landa Rodriguez Holdings, LLC., which shares Mr. Rodriguez is deemed to beneficially
own due to his control position and majority ownership thereof.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(5)
Address: 82 E. Allendale Rd., Ste 5B, Saddle River, NJ 07458. Cavalry Fund I Management LLC, the investment manager of Cavalry Fund I
LP, has voting and investment power over these securities. Thomas Walsh is the managing member of Cavalry Fund I Management LLC, which
is the general partner of Cavalry Fund I LP. Thomas Walsh disclaims beneficial ownership over these securities. Based solely on the Schedule
13G/A filed by Cavalry Fund I LP on February 4, 2022, which we do not know or have reason to believe is not complete or accurate and
on which we are relying pursuant to applicable SEC regulations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 69 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->64<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%"><a href="#toc" title="Table of Contents" style="font-style: italic">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(6)
Address: 161A Shedden Road, 1 Artillery Court, PO Box 10085, Grand Cayman, Cayman Islands KY1-1001. David Feldman and Joel Arber are
the Directors of L1 Capital Global Opportunities Master Fund Ltd. As such, L1 Capital Global Opportunities Master Fund Ltd, Mr. Feldman
and Mr. Arber may be deemed to beneficially own the shares of the Company held by L1 Capital Global Opportunities Master Fund. To the
extent Mr. Feldman and Mr. Arber are deemed to beneficially own such shares, Mr. Feldman and Mr. Arber disclaim beneficial ownership
of these securities for all other purposes. Based solely on the Schedule 13G/A filed by L1 Capital Global Opportunities Master Fund on
February 14, 2022, which we do not know or have reason to believe is not complete or accurate and on which we are relying pursuant to
applicable SEC regulations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Change
of Control</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company is not aware of any arrangements which may at a subsequent date result in a change of control of the Company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="ed_013"></span>Dividend
Policy</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have never paid or declared any cash dividends on our common stock and do not anticipate paying cash dividends in the foreseeable future.
We anticipate that we will retain all of our future earnings for use in the operation of our business and for general corporate purposes.
Any determination to pay dividends in the future will be at the discretion of our board of directors. Accordingly, investors must rely
on sales of their common stock after price appreciation, which may never occur, as the only way to realize any future gains on their
investments.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 20pt; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="ed_014"></span>Legal
Matters</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
validity of the securities offered by this prospectus have been passed upon for us by The Loev Law Firm, PC. David M. Loev, the Managing
Partner of The Loev Law Firm, PC (who is the brother in-law of Jacob Cohen, our Chief Executive Officer), owns 1,000,000 shares of the
Company&#8217;s common stock. The securities are subject to a lock-up agreement (expiring January 22, 2023), preventing the sale or transfer
of such shares without the written approval of the Company, except to affiliates of the holder, who agree to be bound by the same terms.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="ed_015"></span>Experts</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
audited financial statements of American International Holdings Corp. and its subsidiaries as of December 31, 2021 and 2020, and for
the years then ended, included in this prospectus have been audited by M&amp;K CPAS, PLLC, Houston, Texas, independent registered public
accounting firm, as stated in their report date dated March 29, 2022, which is included herein, and has been so incorporated in reliance
upon the report of such firm given upon their authority as experts in accounting and auditing.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">No
expert or counsel named in this prospectus as having prepared or certified any part of this prospectus or having given an opinion upon
the validity of the securities being registered or upon other legal matters in connection with the registration or offering of the common
stock was employed on a contingency basis, or had, or is to receive, any interest, directly or indirectly, in our Company or any of our
parents or subsidiaries, nor was any such person connected with us or any of our parents or subsidiaries, if any, as a promoter, managing
or principal underwriter, voting trustee, director, officer, or employee.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 70 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->65<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%"><a href="#toc" title="Table of Contents" style="font-style: italic">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><b>&#160;</b></span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="ed_016"></span>Changes
in and Disagreements with Accountants on Accounting and Financial Disclosure</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">None.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="ed_017"></span>Description
of Business</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following discussion should be read in conjunction with our financial statements and the related notes and other financial information
appearing elsewhere in this prospectus.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline">Overview</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company is headquartered in Plano, Texas, and is an investor, developer and asset manager with diversified assets across the healthcare
supply chain. The Company&#8217;s portfolio encompasses telemedicine and other virtual health platforms, subscriber based primary care
and concierge medicine plans, preventative care solutions and wellness related assets such as mental and behavioral health services,
as well as its own proprietary life coaching platform. The Company provides its various services through direct-to-consumer and business-to-business
distribution channels and is focused on developing, acquiring and bringing to market technologies and solutions that we believe can advance
the quality of life for the global community. Additionally, the Company seeks opportunities to acquire and grow businesses that possess
strong brand values and that can generate long-term sustainable free cash flow and attractive returns in order to maximize value for
all stakeholders.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline">Corporate
Structure</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.65pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company currently is the parent to ten subsidiaries, of which seven are wholly-owned subsidiaries and three (3) are majority-owned subsidiaries.
In 2021, the Company ceased operations of five of its ten subsidiaries in order to focus on the subsidiaries that better aligned with
the purpose of the Company and its ongoing business plan.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>ZIPDOCTOR,
INC. &#8211; 100% OWNED</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
April 28, 2020, the Company incorporated a wholly-owned subsidiary, ZipDoctor, Inc. (&#8220;<span style="text-decoration: underline">ZipDoctor</span>&#8221;) in the state of
Texas. ZipDoctor launched its online, direct-to-consumer subscription-based telemedicine platform <span style="text-decoration: underline">www.ZipDoctor.co</span> in the third
quarter of 2020. ZipDoctor provides its customers with unlimited, 24/7 access to board certified physicians and licensed mental and behavioral
health counselors and therapists via a newly developed, monthly subscription-based online telemedicine platform. ZipDoctor&#8217;s online
telemedicine platform is available to customers across the United States and offers bilingual coverage (English and Spanish), with virtual
visits taking place either via the phone or through a secured video chat platform. ZipDoctor customers subscribe through the website
and are only required to pay a monthly fee, which is determined based on whether they are an individual, a couple, or a family. ZipDoctor
is currently being sold on a direct-to-consumer basis, with an emphasis on digital marketing and advertising.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 71 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->66<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%"><a href="#toc" title="Table of Contents" style="font-style: italic">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Digital
Marketing Initiative: </b>The ZipDoctor website was originally designed to be marketed and sold primarily using a digital and social
media advertising campaign. Shortly after the website&#8217;s launch, ZipDoctor began to advertise on Google pay per click (PPC), search
engine optimization (SEO), Facebook and Instagram. Shortly after launching, the Company decided to shift the focus of its marketing to
a direct sales approach, resulting in the formation and launch of EPIQ MD, Inc. (discussed below).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Going
Forward Strategy:</b> With EPIQ MD, Inc. taking over the sales and marketing of the direct-to-consumer telemedicine platform, ZipDoctor
has changed its business plan to focus on developing customized telemedicine solutions for niche, or specialty care, areas of medicine.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Telemedicine
Platform Provider for Pharmacies.</b> ZipDoctor is targeting relationships with specialty compound pharmacies seeking both an online
telemedicine platform and a network of doctors to assist in facilitating patient online visits and to streamline the medical intake,
patient demographics, health insurance verifications and overall prescription process. In exchange, ZipDoctor expects to receive a monthly
fee on a per-patient per month basis for this customized access to the telemedicine platform. The initial focus is on Texas based pharmacies,
however, if successful in Texas, ZipDoctor plans to expand its customized telemedicine solution to pharmacies across the United States,
funding permitting.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
August 15, 2021, ZipDoctor entered into a Telemedicine Services Agreement (the &#8220;<span style="text-decoration: underline">Services Agreement</span>&#8221;) with Murphy RX,
LLC (&#8220;<span style="text-decoration: underline">Murphy</span>&#8221;), a Texas-based specialty pharmacy, which has since ceased operations as of January 31, 2022. Pursuant
to the Services Agreement, ZipDoctor agreed to provide Murphy with access to its centralized technology platform, to collect and manage
patient demographics, and access to telemedicine services. Murphy agreed to pay ZipDoctor a monthly fee on a per-patient basis for the
use of the technology platform and for access to primary care telemedicine services. ZipDoctor also agreed to provide continued support
for the ZipDoctor website through the term of the agreement. The Services Agreement is no longer in effect, as Murphy ceased operations
effective as of January 31, 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of the date of this prospectus, ZipDoctor has approximately 100 total members subscribed to its subscription-based telemedicine platform
at www.ZipDoctor.co. Monthly subscription payments range from $25/month to $45/month, depending on how many family members are included,
and provide members with unlimited, 24/7 access to board certified physicians and licensed mental and behavioral health counselors and
therapists.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>EPIQ
MD, INC. &#8211; 100% OWNED</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
October 23, 2020, the Company incorporated a wholly-owned subsidiary, EPIQ MD, Inc. (&#8220;EPIQ MD&#8221;) in the state of Nevada. EPIQ
MD is a direct-to-consumer, telemedicine and healthcare company targeting Americans who are uninsured or underinsured. The EPIQ MD service
offering is a convergence of primary care telemedicine, preventative care services and wellness programs &#8211; under the EPIQ MD brand
and on a single platform. EPIQ MD markets and sells its services direct to end-use consumers, as well as through business-to-business
(B2B) efforts, by focusing on employers in the targeted industries.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 72 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->67<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%"><a href="#toc" title="Table of Contents" style="font-style: italic">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Products
&amp; Services</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">EPIQ
MD&#8217;s telemedical services revolve around three services (1) primary care, (2) mental health care, and (3) prevention. Using cloud-based
software, EPIQ MD has been able to merge these services under a single platform.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Primary
care with EPIQ MD connects users to board certified doctors and medical professionals who can treat most non-emergency conditions using
telemedicine. Similarly, EPIQ MD&#8217;s mental health services connect users with licensed therapists and counselors. As for EPIQ MD&#8217;s
preventive care, the Company is using data driven technologies (wearables and apps), nutritionist and lab services, to help attempt to
mitigate chronic diseases and the risk factors associated with them. In the future, funding permitting, EPIQ MD plans to add in-home
medical devices to record vital information, offering what we believe to be the ambit of services between patient and doctor via the
use of EPIQ MD&#8217;s telemedicine platform.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">EPIQ
MD also provides its subscribers with an option to participate in two premium add-on services, EPIQ LUX and EPIQ Paws. EPIQ LUX provides
subscribers with discounts to ancillary healthcare related services such as laboratory services, dental and vision discount plans, prescription
drug discounts, and imaging services and EPIQ Paws provides subscribers with access to virtual consultations with licensed veterinarians.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of the date of this prospectus, EPIQ MD has nominal subscribers as it is expanding its marketing initiatives. However, EPIQ MD is currently
registered to do business and is being marketed in <span style="background-color: white">Alaska, Georgia, Illinois, Texas, Arizona, New
Mexico, Colorado, Louisiana, Mississippi, Alabama, Florida, Nevada and Utah.</span> To ensure the highest quality control, it plans to
scale up its full-service coverage incrementally to all 50 U.S. states by year-end 2022, funding permitting.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Marketing
Strategy</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">With
approximately 30 million people uninsured in the United States (according to 2019 Congressional Budget Office estimates) and 45 percent
of U.S. adults between ages of 19 and 64 being inadequately insured (according to a February 2019 Survey Brief by the Commonwealth Fund),
and an estimated 530,000 families turning to bankruptcy each year due to medical expenses (according to a study published in the March
2019 American Public Journal of Health), the Company sees an opportunity to make a positive impact in the lives of these uninsured or
underinsured people. We believe that this is the demographic that the healthcare system has abandoned, ignored and/or left behind and
is what we believe to be a largely underserved group.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
grow its subscriber base, EPIQ MD has implemented its own direct-to-consumer distribution channel referred to as the &#8220;Ambassador
Program&#8221;. The Ambassador Program is intended to allow social influencers, community leaders and entrepreneurial-minded sales agents
to market and sell EPIQ MD&#8217;s services across the nation, on a commission-only basis.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 73 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->68<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%"><a href="#toc" title="Table of Contents" style="font-style: italic">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Market
Opportunity</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
previously described above, with approximately 30 million people uninsured in the United States and 45 percent of U.S. adults between
ages of 19 and 64 being inadequately insured, EPIQ MD believes that their service offerings will be instrumental in reaching these Americans
and plans to reach this demographic through its own direct-to-consumer distribution channel, or Ambassador Program, and through its commercial
division <span style="background-color: white">that will target small and medium sized businesses (SMB&#8217;s) and municipalities.</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">According
to a 2020 study by the Kaiser Family Foundation, a leading industry research firm (&#8220;Key Facts About the Uninsured Population&#8221;),
the high cost of insurance is one of the main reasons individuals lack coverage (in 2019, 73.7% of uninsured adults said they were uninsured
because the cost of coverage was too high); and, individuals with income below 200% of the Federal Poverty Level (FPL) are at the highest
risk of being uninsured.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
see a significant opportunity to market to these uninsured and/or underinsured persons, and believe that our low-cost, flat rate, telemedical
services can be an attractive alternative to those persons seeking lower cost health services.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>LIFE
GURU, INC. &#8211; 51% OWNED</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
May 15, 2020, the Company acquired a 51% interest in Life Guru, Inc., a Delaware corporation (&#8220;<span style="text-decoration: underline">Life Guru</span>&#8221;). Life Guru
owns www.LifeGuru.me &#8211; a website dedicated to providing an online platform to connect consumers to a variety of mentors, professionals,
life coaches and career coaches. Upon final launch of the platform, it will include functionality enabling: life coaches from around
the world to access and subscribe to the Life Guru platform; and consumers to filter their life coach options by geographic location,
language and even the type of currency they would like to pay with. While Life Guru is free to consumers, it generates revenues by charging
monthly subscription fees to coaches participating on the platform. Further, and depending on the type of subscription plan the life
coach chooses to participate in, Life Guru receives a percentage of the per session fees generated and earned between the consumer and
the life coach.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Since
the LifeGuru.me website was launched around March 2021, Life Guru has been working to optimize the website for mobile and completing
integration with its merchant account provider to automate monthly payouts to coaches. LifeGuru is currently in the process of marketing
and onboarding coaches onto the platform.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Industry
Trends</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Life
coaching has been the second fastest growing industry in the world for over ten consecutive years, behind the information technology
sector (according to a May 2016 article posted at Forbes.com). The global Personal Development Industry (including market segments from
holistic approaches, motivational speakers, inspirational websites, personal coaching, and other forms of personal development) was valued
at approximately $38.28 billion in 2019 and is expected to grow at a compound annual growth rate (CAGR) of 5.1% from 2020 to 2027 (according
to a July 2020 report by Grand View Research). Moreover, Life Guru believes that improving social skills and focusing on critical areas
for self-awareness, such as emotions, character traits, habits, individual values, and the psychological need that shapes the day-to-day
behavior of individuals are gaining importance.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 74 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->69<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%"><a href="#toc" title="Table of Contents" style="font-style: italic">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Operational,
Technological &amp; Cost Advantages</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
anticipate that coaches that subscribe to the Life Guru platform will benefit from Life Guru&#8217;s investment in digital marketing
and promotion, enabling them to reach customers and providing increased visibility. Life Guru has developed a proprietary technology
platform for coaching online, as well as proprietary video conferencing capabilities for coaching interactively. Through our existing
marketing partnerships, Life Guru believes it has access to sales tools which allow the effective marketing of coaches across all major
social media platforms, including and most importantly, LinkedIn. LifeGuru.me is mobile-friendly and can run smoothly on many platforms,
making it highly scalable.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Subscriptions</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Life
Guru offers free membership for all consumers to gain access to the site and search for life coaches. Life Guru&#8217;s model is to charge
coaches, and not members, for the use of its services. The Company currently offers three different subscription levels to life coaches,
with varying levels of promotion on the Life Guru site, prominence of search results, and commissions payable. As of the date of this
prospectus, Life Guru has no members and approximately 200 total life coaches that have signed up and created profiles on the platform.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Growth
Objectives</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition to marketing Life Guru directly to consumers, Life Guru intends to implement packages to be sold to various businesses and corporations,
which can, in turn, be marketed as a corporate benefit by employers. Life Guru calls this &#8220;Life Guru Corporate&#8221;. A recent
survey of 256 companies by the National Alliance of Healthcare Purchaser Coalitions, a nonprofit employer group, found that 53% of employers
are providing special emotional and mental health programs for their workforce in the wake of the pandemic. Life Guru believes that Life
Guru Corporate represents important potential upside in targeting the business and corporate world, and providing services to employees
on an ongoing basis. Life Guru Corporate can only be developed once the platform has achieved a reputable brand and a substantial amount
of high-quality business coaches are engaged, and Life Guru does not anticipate launching Life Guru Corporate with fewer than 200 life
coaches, provided Life Guru&#8217;s projected milestones are met.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>MANGOCEUTICALS,
INC. <i>&#8211; 80% OWNED</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
October 7, 2021, the Company incorporated Mangoceuticals, Inc. (&#8220;<span style="text-decoration: underline">Mangoceuticals</span>&#8221;) in the
state of Texas with the intent of focusing on developing, marketing and selling a variety of men&#8217;s wellness products and services
via a telemedicine platform. To date, the Company has identified men&#8217;s wellness telemedicine services and products as a growing
sector in the most recent years and especially related to the areas of erectile dysfunction and hair loss products. In this regard, Mangoceuticals
is currently in the process of developing and preparing to market a new brand of erectile dysfunction (ED) products that delivers fast
acting results through a proprietary combination of FDA approved ingredients.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 75 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->70<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%"><a href="#toc" title="Table of Contents" style="font-style: italic">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mangoceuticals
plans to market and sell this new brand of ED products exclusively online and will require the use of a telemedicine visit, a doctor&#8217;s
prescription and the fulfillment of the prescription by pharmacy licensed in the state in which the customer resides. Mangoceuticals
plans to rely heavily on digital and social media marketing through channels such as Facebook, Instagram, Twitter, Snap Chat and TikTok
and further has plans to use digital marketing with the goal of creating viral marketing campaigns, using social media influencers and
celebrities, funding permitting.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 25.95pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
goal is to eventually sell this new brand of ED products nationwide and to use EPIQ Scripts (described below) as its mail order pharmacy
to fulfill the ED prescriptions. Mangoceuticals is currently in the branding and development stage of this ED product and anticipates
a planned and limited launch in the Texas market in the second quarter of 2022 with the intent of expanding its marketing initiatives
at a pace in which Epiq Scripts obtains additional state licenses across the United States.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subsequent
to incorporation, Mangoceuticals issued 1,000,000 shares of common stock each to Jacob D. Cohen, the Chief Executive Officer of the Company,
and a third party, in consideration for services rendered. As a result, Mangoceuticals is currently 80% owned by the Company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>EPIQ
SCRIPTS, LLC &#8211; 51% OWNED</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
January 24, 2022, the Company formed EPIQ Scripts, LLC (&#8220;<span style="text-decoration: underline">EPIQ Scripts</span>&#8221;) in the state of Texas. EPIQ Scripts has been
established with the intent of operating as a close-door online mail order pharmacy with a specific target and vision to obtain licenses
in all 50 states across the U.S., of which no state licenses have been obtained as of the date of this prospectus. EPIQ Scripts also
plans to seek to become accredited with the most respected and highly recognized authorities in the industry, such as <span style="background-color: white">Utilization
Review Accreditation Commission (</span>URAC), Legit Script, <span style="background-color: white">Accreditation Commission for Health
Care</span> (ACHC), and <span style="background-color: white">National Association of Boards of Pharmacy</span> (NABP) Digital Pharmacy.
EPIQ Scripts also intends to obtain in-network contracts with all major Pharmacy Benefit Managers (PBM) and insurance payors.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Market
Opportunity</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">It
is anticipated that if licenses, accreditations and in-network contracts are secured in all 50 U.S. states, EPIQ Scripts will be able
to market itself to the many up and coming telemedicine companies that have been on the rise since early 2020. Pursuant to a July 9,
2021 article published by McKinsey &amp; Company, according to a study taken by McKinsey &amp; Company, <span style="background-color: white">in
April 2020, overall telehealth utilization for office visits and outpatient care was 78 times higher than in February 2020. Ev</span>en
though telemedicine use has now leveled off as in-person visits have returned, McKinsey &amp; Company is still consistently seeing use
that is 38 times higher than pre-pandemic numbers. Furthermore, a majority of Americans have now tried out telehealth. According to an
article published at Sykes.com, a March 2021 survey of 2,000 U.S. adults undertaken by Sykes.com found that by March 2021, more than
61% of such surveyed individuals had made a telehealth/telemedicine appointment, which is a massive increase from just 19.5% a year prior,
according to Sykes. We further believe that telemedicine use is now widespread across demographics.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 76 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->71<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%"><a href="#toc" title="Table of Contents" style="font-style: italic">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
believe the significant increases in demand for telemedicine has created a vacuum for pharmacies that have the capabilities to handle
the prescription volume generated by these platforms. We believe that EPIQ Scripts&#8217; planned mail order pharmacy, which is expected
to have advanced API capabilities and infrastructure and be supported with nationwide licenses and accreditations can position itself
to capitalize on the current market opportunity.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">EPIQ
Scripts has currently filed with the <span style="background-color: white">Utilization Review Accreditation Commission (URAC) to obtain
its pharmacy accreditation and is in the process of obtaining its first state license in the State of Texas, which it anticipates receiving
in April 2022. Once the Texas state license is obtained, EPIQ Scripts will be able to apply for additional state licenses until they
have obtained all 50 state licenses, with some state licenses easier to obtain and quicker to obtain than others. EPIQ Scripts intends
to have licenses to operate in all 50 states by the first quarter of 2023.</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*
* * * * *</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company intends to continue to grow its business both organically and through identifying acquisition targets over the next 12 months
in the telemedicine, life coaching and wellness space, funding permitting. As these opportunities arise, the Company will determine the
best method for financing its growth which may include the issuance of additional debt instruments, common stock, preferred stock, or
a combination thereof, any one or more of which may cause significant dilution to existing shareholders. <span style="background-color: white">The
Company requires approximately $5 million to implement its current business strategy for its different subsidiaries and to support potential
growth. </span>We expect to raise funds in the future through the sale of debt and/or equity in order to allow us to operate for the
next twelve months, and may need to raise further additional capital in order to expedite our growth through acquisitions, none of which
are currently planned. There is no assurance that we will be successful in raising such funds and if we do raise funds, this may result
in substantial dilution to current investors.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>DISCONTINUED
OPERATIONS:</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>MEDICAL
SPA AND WELLNESS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company previously operated three wholly-owned subsidiaries that were in the Medical Spa and Wellness Sector (collectively hereinafter
referred to as &#8220;<span style="text-decoration: underline">MedSpa</span>&#8221;, or &#8220;<span style="text-decoration: underline">VISSIA</span>&#8221;), the operations of which were discontinued in October 2020:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>1.</i></b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>VISSIA
    MCKINNEY, LLC (F/K/A NOVOPELLE DIAMOND, LLC) &#8211; 100% OWNED</i></b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.65pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">VISSIA
McKinney was a physician supervised, medical spa and wellness clinic that offered a full menu of wellness services including anti-aging,
weight loss and skin rejuvenation treatments and was located at 5000 Collin McKinney Parkway, Suite 150, McKinney, Texas 75070.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 77 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->72<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%"><a href="#toc" title="Table of Contents" style="font-style: italic">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>2.</i></b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>VISSIA
    WATERWAY, INC. (F/K/A NOVOPELLE WATERWAY, INC.) &#8211; 100% OWNED</i></b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.65pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">VISSIA
McKinney was a physician supervised, medical spa and wellness clinic that offered a full menu of wellness services including anti-aging,
weight loss and skin rejuvenation treatments and was located at 25 Waterway, Suite 150, The Woodlands, Texas.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>3.</i></b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>NOVOPELLE
    TYLER, INC. &#8211; 100% OWNED</i></b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
December 3, 2019, the Company formed and organized Novopelle Tyler, Inc. in the State of Texas with the plan to come to terms on a retail
location for a new med spa to be located in Tyler, Texas. The Company no longer intends to open this location and no activity has been
performed under this entity to date.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*
* * * *</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
a result of COVID-19 and &#8216;stay-at-home&#8217; and social distancing orders issued in McKinney and The Woodlands, Texas, we had
to close both of our then operational MedSpas, VISSIA McKinney and VISSIA Waterway, Inc., effective March 10, 2020, and which resulted
in both the loss of income and the loss of substantially all of our MedSpa employees, who had to be let go. VISSIA Waterway, Inc. reopened
effective June 21, 2020 and VISSIA McKinney reopened effective August 8, 2020. However, due to the termination of employees associated
with the shutdown we were forced to expend resources to attract, hire and train completely new staff for preparation of the re-launchings.
Notwithstanding the re-openings, customer traffic and demand at our VISSIA Waterway, Inc. and VISSIA McKinney MedSpa locations failed
to rebound to pre-COVID-19 levels due to COVID-19 and the pandemic&#8217;s effects on the economy, and because we were unable to predict
the length of the pandemic or ultimate outcome thereof, and further due to our limited capital resources, effective on October 25, 2020,
we made the decision to close both our VISSIA Waterway, Inc. and VISSIA McKinney locations. Our former MedSpa operations and assets are
included under discontinued operations in the statement of operations and balance sheet included herein for the year ended December 31,
2021 and for the year ended, December 31, 2020.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>4.</i></b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>CAPITOL
    CITY SOLUTIONS, USA, INC. &#8211; 100% OWNED</i></b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
September 17, 2019, the Company formed and organized Capitol City Solutions USA, Inc. (&#8220;<span style="text-decoration: underline">CCS</span>&#8221;) in the State of Texas
to act as a general contracting and construction company focused on the remodeling, general construction and interior finish of both
the Company&#8217;s then MedSpa locations (which have since been closed) as well as to market to other commercial real estate projects
within the United States. The Company made the decision to cease any further construction-based operations under CCS in July 2021, in
order to focus on the subsidiaries that better aligned with the purpose of the Company and its ongoing business plan in the telehealth
and wellness space.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 78 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->73<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%"><a href="#toc" title="Table of Contents" style="font-style: italic">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>5.</i></b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>LEGEND
    NUTRITION, INC. &#8211; 100% OWNED</i></b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
September 23, 2019, the Company formed and organized Legend Nutrition, Inc. (&#8220;<span style="text-decoration: underline">Legend Nutrition</span>&#8221;) in the State of Texas
to act as a new brand of retail vitamin and supplement stores to be branded and marketed as Legend Nutrition. October 18, 2019, Legend
entered into an Asset Purchase Agreement to acquire all of the assets associated with and related to a retail vitamin, supplements and
nutrition store located in McKinney, Texas and previously identified and doing business as &#8220;<span style="text-decoration: underline">Ideal Nutrition.</span>&#8221; Pursuant
to the Asset Purchase Agreement, Legend purchased a variety of assets including software, contracts, bank and merchant accounts, products,
inventory, computers, security systems and other intellectual properties. As Legend Nutrition&#8217;s lease expired in January 2021,
the Company made the decision to cease its operations to focus on the subsidiaries that better aligned with the purpose of the Company
and its ongoing business plan in the telehealth and wellness space.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline">Corporate
History</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>American
International Holdings Corp.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">American
International Holdings Corp. was organized in 1986 and is incorporated in Nevada. The Company has undergone several name changes and
changes of control since its incorporation; however, from 2012 until April 2019, the Company had no operations and nominal assets.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prior
to May 31, 2018, the Company was a 93.2% owned subsidiary of American International Industries, Inc. (&#8220;<span style="text-decoration: underline">American</span>&#8221;,
&#8220;<span style="text-decoration: underline">AMIN</span>&#8221;), a company whose securities are traded on the OTCQB market maintained by OTC Markets under the symbol &#8220;<span style="text-decoration: underline">AMIN</span>&#8221;.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Effective
on May 31, 2018, the Company issued (a) 4,300,000 shares of restricted common stock to Mr. Daniel Dror (the Company&#8217;s former Chief
Executive Officer and President (who resigned from such positions effective on May 31, 2018)); (b) 3,800,000 shares of restricted common
stock to Mr. Robert Holden (who was appointed President, Chief Executive Officer and Director of the Company on May 31, 2018 and resigned
on August 20, 2018); (c) 750,000 shares of restricted common stock to Mr. Everett Bassie (who was appointed as Chief Financial Officer,
Secretary, Treasurer and a member of the board of directors of the Company on May 31, 2018, and resigned from all positions with the
Company); (d) 750,000 shares of restricted common stock to Mr. Winfred Fields (a consultant to the Company); and (e) 500,000 shares of
restricted common stock to Mr. Charles R. Zeller (a then director of the Company), each in consideration for services rendered to the
Company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
a result of the issuance of the shares in May 2018 as discussed above, a change in control occurred. American International Industries,
Inc. ownership decreased from 93.2% to 6.4%.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 79 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->74<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%"><a href="#toc" title="Table of Contents" style="font-style: italic">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.65pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
April 12, 2019, the Company entered into a Share Exchange Agreement (the &#8220;<span style="text-decoration: underline">Share Exchange Agreement</span>&#8221;) with Novopelle
Diamond, LLC, a Texas limited liability company (&#8220;<span style="text-decoration: underline">Novopelle Diamond</span>&#8221; and &#8220;<span style="text-decoration: underline">Novopelle</span>&#8221;) and certain
unitholders of Novopelle Diamond. Pursuant to the terms of the Share Exchange Agreement, the Company acquired 100% of the issued and
outstanding membership interests of Novopelle Diamond by means of a share exchange with the Novopelle Members in exchange for 18,000,000
newly issued shares of the common stock of the Company (the &#8220;<span style="text-decoration: underline">Share Exchange</span>&#8221;). As a result of the Share Exchange,
Novopelle became a 100% owned subsidiary of the Company. The closing of the Share Exchange occurred concurrently with the entry into
the Share Exchange Agreement and resulted in a change of control of the Company. As a result of the Share Exchange, the Company acquired
the business of Novopelle Diamond and all of its assets. Novopelle Diamond is a physician supervised, medical spa and wellness clinic
that offers a full menu of wellness services including anti-aging, weight loss and skin rejuvenation treatments.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.65pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.65pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
three unitholders of Novopelle Diamond who received shares pursuant to the Share Exchange Agreement were (1) Jacob D. Cohen; (2) Esteban
Alexander; and (3) Luis Alan Hernandez, who each received six million shares pursuant to the Share Exchange.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.65pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.65pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Concurrent
with the Share Exchange, the Company entered into individual share exchange agreements and promissory notes with each of Daniel Dror,
Winfred Fields and former directors Everett Bassie and Charles Zeller (the &#8220;<span style="text-decoration: underline">AMIH Shareholders</span>&#8221;) whereby the AMIH Shareholders
agreed to cancel and exchange a total of 4,900,000 shares of their Company common stock for individual promissory notes with an aggregate
principal amount of $350,000 (the &#8220;<span style="text-decoration: underline">Promissory Notes</span>&#8221;). The Promissory Notes had a term of two years and accrue interest
at the rate of 10% per annum (payable at maturity) until paid in full by the Company. The current principal balance of the Promissory
Notes is approximately $110,000 as of the date of this prospectus.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.65pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.65pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
a result of the issuance of the shares in the Share Exchange and the cancellation of the shares held by the AMIH Shareholders, control
of the Company changed to (1) Jacob D. Cohen; (2) Esteban Alexander; and (3) Alan Hernandez, who each owned 26% of the Company&#8217;s
common stock following such transactions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.65pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.65pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Also
effective on April 12, 2019, the directors of the Company changed to Mr. Jacob D. Cohen; Mr. Esteban Alexander; and Mr. Alan Hernandez,
who were also each appointed as the Chief Executive Officer and President of the Company (Mr. Cohen); the Chief Operating Officer and
Treasurer (Mr. Alexander); and the Chief Marketing Officer and Secretary (Mr. Hernandez). Mr. Bassie resigned as a member of the board
of directors of the Company and as the Secretary and Treasurer on April 12, 2019, but remained as the Company&#8217;s Chief Financial
Officer until his passing on May 21, 2020.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.65pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
October 2, 2020, Jacob D. Cohen, the Chief Executive Officer and member of the board of directors of the Company entered into Stock Purchase
Agreements with each of (a) Esteban Alexander, the Chief Operating Officer and member of the board of directors of the Company, and (b)
Luis Alan Hernandez, the Chief Marketing Officer and member of the board of directors of the Company (collectively, the &#8220;<span style="text-decoration: underline">Preferred
Holders</span>&#8221; and the &#8220;<span style="text-decoration: underline">Stock Purchase Agreements</span>&#8221;).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 80 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->75<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%"><a href="#toc" title="Table of Contents" style="font-style: italic">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the Stock Purchase Agreements, Mr. Alexander agreed to sell 7,000,000 shares of common stock of the Company which he held to Mr. Cohen,
which rights to such shares were assigned by Mr. Cohen to Cohen Enterprises, Inc., which entity he controls (&#8220;<span style="text-decoration: underline">Cohen Enterprises</span>&#8221;),
in consideration for an aggregate of $1,500 (which was an arbitrary value agreed to by the parties) as well as for the amount of services
provided by Mr. Cohen to the Company; and Mr. Hernandez agreed to sell 4,000,000 shares of common stock of the Company which he held
to Cohen Enterprises, in consideration for an aggregate of $1,000 as well as for the amount of services provided by Mr. Cohen to the
Company. The sales closed on November 5, 2020.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">One
of the reasons that Mr. Alexander and Mr. Hernandez agreed to the terms of the Stock Purchase Agreements (including the sale of the shares
of common stock of the Company at below market value), is because (a) each of Mr. Cohen, Mr. Alexander, and Mr. Hernandez were all appointed
as officers and directors of the Company at the same time in April 2019, with the intention that such persons would provide a relatively
equal amount of services to the Company in the roles as officers and directors thereof; (b) since such appointment date Mr. Cohen has
been required to provide a disproportionate amount of services to the Company; and (c) each of Mr. Alexander and Mr. Hernandez desired
to provide additional consideration to Mr. Cohen for such disproportionate level of service.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
condition to the Stock Purchase Agreements was that each of Mr. Alexander and Mr. Hernandez resign as a member of the board of directors
of the Company by no later than January 15, 2021, which resignations were effective December 15, 2020.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
further requirement to the terms of the Stock Purchase Agreements was that each of Mr. Alexander and Mr. Hernandez take such actions
necessary and which may be requested from time to time by Mr. Cohen, to affect the cancellation of the one share of Series A Preferred
Stock of the Company held by each of them, for no consideration (including, but not limited to, without the required payment by the Company
of the $1 redemption price described in the designation of such Series A Preferred Stock).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
shares of Series A Preferred Stock held by Mr. Alexander and Mr. Hernandez were canceled on November 6, 2020. The common shares were
also transferred to Mr. Cohen on November 6, 2020, and as such, a change of control occurred on such date, with Mr. Cohen taking over
voting control of the Company, and serving between December 15, 2020 and October 19, 2021, as the sole officer and director of the Company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Effective
on October 19, 2021, the Company <span style="background-color: white">appointed Peter &#8220;<span style="text-decoration: underline">Casey</span>&#8221; Jensen to fill one
of the vacancies on the Board of Directors, as an independent director. Mr. Jensen was also appointed as the sole member of the Company&#8217;s
newly established Audit Committee (discussed under &#8220;Committees of the Board&#8221;, below), and to serve as the Chairperson of
the Audit Committee.</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Effective
on January 13, 2022, the Company <span style="background-color: white">appointed Ms. Lorraine D&#8217;Alessio and Dr. Kenny Myers to
fill two of the vacancies on the Board of Directors, as independent directors. Both Ms. D&#8217;Alessio and Dr. Myers were appointed
as members of the Company&#8217;s Audit Committee upon their appointment to the Board of Directors.</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 81 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->76<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%"><a href="#toc" title="Table of Contents" style="font-style: italic">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>COVID-19
Outlook</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
outbreak of the 2019 novel coronavirus disease (&#8220;<span style="text-decoration: underline">COVID-19</span>&#8221;), which was declared a global pandemic by the World Health
Organization on March 11, 2020, and the related responses by public health and governmental authorities to contain and combat its outbreak
and spread has severely impacted the U.S. and world economies, the market for health spa services, nutrition supplements and our other
business offerings during the end of the first quarter of 2020, and continuing through the end of 2020 and into 2021. Government mandated
&#8216;stay-at-home&#8217; and similar orders have to date, and may in the future, prevent us from operating. As discussed above, we
made the decision to discontinue operations of our VISSIA Waterway, Inc. and VISSIA McKinney MedSpa locations. Additionally, our Legend
Nutrition store saw a deep decline in sales due to social distancing orders and decreases in customers who are willing to venture out
to brick-and-mortar establishments. Legend Nutrition&#8217;s lease was up January 31, 2021, and the Company chose to not renew the lease,
closed the store, and will not continue in this line of business moving forward. We also decided to cease offering construction services
around July 2021.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of the date of this prospectus, our operations are limited, and consist mainly of ZipDoctor, Inc., Life Guru, Inc., EPIQ MD, Inc., EPIQ
Scripts, LLC, and Mangoceuticals, Inc.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Moving
forward, economic recessions, including those brought on by the continued COVID-19 outbreak may have a negative effect on the demand
for our services and our operating results. Any prolonged disruption to our operations or work force available is likely to have a significant
adverse effect on our results of operations, cash flows and ability to meet continuing debt service requirements. All of the above may
be exacerbated in the future as the COVID-19 outbreak and the governmental responses thereto continues.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Employees</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.35pt; text-align: justify; text-indent: 35.65pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of the date of this prospectus, we have fifteen full-time employees (two at the parent/ZipDoctor/Mangoceuticals level, nine at the EPIQ
MD level, two at the EPIQ Scripts level, and two at the Life Guru level). Our compensation programs are designed to align the compensation
of our employees with performance and to provide the proper incentives to attract, retain and motivate employees to achieve superior
results. The structure of our compensation programs balances incentives earnings for both short-term and long-term performance such as
incentive bonuses and flexible schedules. The Company believes that its rich culture of inclusion and diversity enables it to create,
develop and fully leverage the strength of its workforce to exceed customer expectation and meet its growth objectives. The Company places
a high value on diversity and inclusion. We also utilize numerous outside consultants. Our future success will depend partially on our
ability to attract, retain and motivate qualified personnel. We are not a party to any collective bargaining agreements and have not
experienced any strikes or work stoppages. We consider our relations with our employees to be satisfactory.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Government
Regulation</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.65pt; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
health care industry is subject to extensive federal, state and local laws and regulations relating to licensure, conduct of operations,
ownership of facilities, addition of facilities and services, payment for services and prices for services that are extremely complex
and for which, in many instances, the industry does not have the benefit of significant regulatory or judicial interpretation. We will
also be subject to regulation regarding sale of our products online and solicitation of clients thereby, as well as through our general
contractor business and the licensing and code requirements relating thereto.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>


<!-- Field: Page; Sequence: 82 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->77<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%"><a href="#toc" title="Table of Contents" style="font-style: italic">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Available
Information</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are subject to the information and reporting requirements of the Exchange Act, under which we file periodic reports, proxy and information
statements and other information with the Commission. Copies of the reports, proxy statements and other information may be examined without
charge on the Internet at <i>https://www.sec.gov</i>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
file annual, quarterly, and current reports, proxy statements and other information with the SEC. Our SEC filings are available to the
public over the Internet at the SEC&#8217;s website at <span style="text-decoration: underline">www.sec.gov</span> and are available for download, free of charge, soon after
such reports are filed with or furnished to the SEC, on our website at <span style="text-decoration: underline">https://amihcorp.com/investors/</span>. Copies of documents filed
by us with the SEC are also available from us without charge, upon oral or written request to our Secretary, who can be contacted at
7950 Legacy Drive, Suite 400, Plano, Texas 75024. Our website address is <span style="text-decoration: underline">https://amihcorp.com. </span>The information on, or that may
be accessed through, our website is not incorporated by reference into this prospectus and should not be considered a part of this prospectus.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="ed_018"></span>Description
of Property</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><b>EPIQ
MD, INC.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
February 24, 2021, EPIQ MD entered into a short term, six-month lease agreement with Venture X to lease and occupy approximately 1,200
square feet of office space at a rate of $3,500 per month located at 7950 Legacy Drive, Suite 400, Plano, Texas 75024 (the <span style="text-decoration: underline">&#8220;EPIQ
MD Lease</span>&#8221;). The EPIQ MD Lease commenced on March 1, 2021 and was to expire on August 31, 2021, but was renewed on August 19,
2021 for an additional six-month term with a commencement date of September 1, 2021, and expiration date of February 28, 2022. The EPIQ
MD Lease was renewed for an additional six month period and has an expiration date of August 31, 2022. The EPIQ MD Lease contains an
auto renewal feature unless notice of termination is provided ninety (90) days in advance. The Company has deemed this office space to
serve as its corporate headquarters and believes this space to be adequate for the purposes of our operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>VISSIA
MCKINNEY, LLC</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
June 11, 2018, VISSIA McKinney, LLC. (f/k/a Novopelle Diamond, LLC) entered into a Lease Agreement with The Shops at Lake Forest, LLC
to lease and occupy approximately 1,400 square feet of commercial retail space located at 5000 Collin McKinney Parkway, Suite 150, McKinney,
Texas 75070, to operate a MedSpa (the &#8220;<span style="text-decoration: underline">McKinney Lease Agreement</span>&#8221;). On September 5, 2021, VISSIA McKinney entered into
a Release Agreement with the Landlord, whereby the Landlord agreed to release VISSIA McKinney from its remaining obligations under the
McKinney Lease Agreement in exchange for a total of $22,500, of which $10,000 was paid to the Landlord with furniture and fixtures located
at the leased premises and the remaining $12,500 was paid in cash. Accordingly, VISSIA McKinney has ceased operations at the leased premises
and has no further obligations under the McKinney Lease Agreement as of the date of this prospectus.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 83 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->78<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%"><a href="#toc" title="Table of Contents" style="font-style: italic">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>VISSIA
WATERWAY, INC.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
November 6, 2019, VISSIA Waterway, Inc. (f/k/a <span style="text-decoration: underline">Novopelle Waterway</span>, Inc.) entered into a Lease Agreement with 20 &amp; 25 Waterway
Holdings, LLC (the &#8220;<span style="text-decoration: underline">Waterway Landlord</span>&#8221;) to lease and occupy approximately 1,254 square feet of commercial retail space
located at 25 Waterway, Suite 150, The Woodlands, Texas to operate a MedSpa (the &#8220;<span style="text-decoration: underline">Waterway Lease Agreement</span>&#8221;). On December
31, 2021, Vissia Waterway, LLC entered into a Release Agreement with its landlord for the leased premises located at 25 Waterway Avenue,
The Woodlands, Montgomery County, Texas whereby the landlord agreed to release Vissia Waterway from its remaining obligations under the
lease in exchange for a total of $88,679. Accordingly, VISSIA Waterway has ceased operations at the leased premises and has no further
obligations under the Waterway Lease Agreement as of the date of this prospectus.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>CAPITOL
CITY SOLUTIONS USA, INC.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
January 3, 2020, Capitol City Solutions USA, Inc. (&#8220;<span style="text-decoration: underline">CCS</span>&#8221;) entered into a Lease Agreement with Asher Park, LLC (the
&#8220;CCS Landlord&#8221;) to lease and occupy approximately 1,516 square feet of commercial office space located at 1043 Asher Way,
Suite 300, Tyler, TX 75703 to be used for CCS&#8217;s corporate offices and headquarters (the &#8220;CCS Lease Agreement&#8221;). On
March 9, 2022, CCS and the CCS Landlord mutually agreed to terminate the lease for the leased premises and release CCS from its remaining
obligations under the lease in exchange for a total of $18,523. Accordingly, CCS has ceased operations at the leased premises and has
no further obligations under the CCS Lease Agreement as of the date of this prospectus. Total rental expense related to this location
for the year ended December 31, 2021, was $0. The operating lease right-of-use asset net balance on December 31, 2021, related to this
location was $0, which was impaired in full due to discontinued operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>EPIQ
SCRIPTS, LLC</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
February 2, 2022, EPIQ Scripts, LLC entered into a Sublease Agreement with Ideal Xtracare, LLC (the &#8220;Epiq Scripts Landlord&#8221;)
to sublease and occupy approximately 3,080 square feet of commercial office space located at 465 W. President George Bush Fwy, Suite
240, Richardson, TX 75080 to be used for Epiq Scripts&#8217;s corporate offices and pharmacy location (the &#8220;Epiq Scripts Sublease
Agreement&#8221;). The Epiq Scripts Sublease Agreement had an effective date of February 15, 2022 and a term of seventeen (17) months
and sixteen (16) days, terminating on July 31, 2023. The Epiq Scripts Sublease Agreement has base monthly rent of $4,106.67 and includes
an additional $385 electricity expense reimbursement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 84 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->79<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%"><a href="#toc" title="Table of Contents" style="font-style: italic">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><b>&#160;</b></span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="ed_019"></span>Legal
Proceedings</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the ordinary course of business, the Company may become a party to lawsuits involving various matters. The impact and outcome of litigation,
if any, is subject to inherent uncertainties, and an adverse result in these or other matters may arise from time to time that may harm
its business. The Company believes the ultimate resolution of any such current proceeding will not have a material adverse effect on
our continued financial position, results of operations or cash flows.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span style="text-decoration: underline">Robert
Holden vs AMIH</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
October 14, 2019, Robert Holden, the Company&#8217;s former CEO, filed a Petition and Application for Temporary Restraining Order in
the District Court, 152<sup>nd</sup> Judicial District of Harris County, Texas, against the Company stating that the Company is blocking
Mr. Holden&#8217;s legal right to trade his shares in the open market and further attempting to stake his claim that he maintains his
rights to the 3,800,000 shares he received in connection with his acceptance as CEO of the Company on or around May 31, 2018. The Company
is maintaining the position that Mr. Holden does not have the right to those shares as he was in breach of his obligation to convey a
digital marketing business to the Company and subsequently resigned from the Company shortly thereafter, on or around August 15, 2018
and that he procured the shares through fraud. On November 11, 2019, the Company issued a response with a Motion to Dismiss Under the
Texas Citizen&#8217;s Participation Act (TCPA) citing that any declaratory judgment and breach of contract claims be dismissed unless
Mr. Holden can, through &#8220;<span style="text-decoration: underline">clear and specific evidence</span>&#8221;, establish a prima facie case for each essential element of
his claims. After an attempt to remand the case to federal court, the Company filed an amended notice of submission for its TCPA motion
for submission on May 18, 2020, whereby Holden failed to respond to the motion in a timely manner. On May 18, 2020, the Company filed
a response in support of its motion to dismiss under the TCPA, which was denied on June 3, 2020. Immediately thereafter, on June 4, 2020,
the Company filed a notice of accelerated interlocutory appeal to appeal the denial of the motion to dismiss under the TCPA and the trial
court&#8217;s failure to rule on the Company&#8217;s objection to the timeliness of Holden&#8217;s response. The outcome of this action,
and the ultimate outcome of the lawsuit is currently unknown at this time, provided that the Company intends to vehemently defend itself
against the claims made in the lawsuit.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span style="text-decoration: underline">AMIH
vs. Winfred Fields</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
November 11, 2019, the Company filed an original petition and jury demand against Winfred Fields, a shareholder, in the 458<sup>th </sup>Judicial
District Court of Fort Bend County seeking damages related to breach of contract and fraud related charges. The Company executed an exchange
agreement with Mr. Fields on or around April 12, 2019 whereby Mr. Fields was required to tender to the Company a total of 650,000 of
the 750,000 shares of the Company&#8217;s common stock that Mr. Fields then owned (the &#8220;<span style="text-decoration: underline">Exchanged Shares</span>&#8221;) in exchange
for a promissory note with a maturity date of April 12, 2021 payable in the amount of $42,500 (the &#8220;<span style="text-decoration: underline">Fields Note</span>&#8221;).
The Exchange Agreement required that Mr. Fields immediately return the stock certificates for the Exchanged Shares to the Company or
its designated agent for immediate cancellation and for Mr. Fields to retain the remaining 100,000 shares. Mr. Fields agreed in the Exchange
Agreement that these shares would not become unrestricted until such time as Mr. Fields received an opinion of counsel satisfactory to
the Company that the shares were not restricted for trade under SEC regulations. After executing the Exchange Agreement, Mr. Fields&#8212;rather
than return the Exchanged Shares or obtain said opinion of counsel&#8212;attempted to deposit and trade the Exchanged Shares and the
restricted shares, which was a direct violation of the Exchange Agreement. The Company asserts that Mr. Fields knowingly, willingly and
fraudulently attempted to deposit and trade the Exchanged Shares and is seeking damages and equitable relief. Upon several attempts to
serve Mr. Fields, service was perfected on or around February 3, 2020. On March 2, 2020, Mr. Fields filed a response generally denying
all claims. On May 22, 2020, the Company filed its first request for production and request for disclosure and discovery insisting that
Mr. Fields produce all documentation related to the fraudulent transaction and is awaiting a response to these requested discovery items.
The outcome of this action is currently unknown at this time. In November 2019, the Company recovered 650,000 shares from Mr. Fields
which were cancelled in 2019.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 85 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->80<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%"><a href="#toc" title="Table of Contents" style="font-style: italic">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span style="text-decoration: underline">Asher
Park, LLC vs. Novopelle Tyler</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
August 11, 2021, Asher Park, LLC (&#8220;Asher Park&#8221;) filed a petition against the Company and its subsidiary, Novopelle Tyler,
Inc. (&#8220;Novopelle Tyler&#8221;) in the 241<sup>st</sup> Judicial District Court of Smith County, Texas seeking to recover damages
in the amount of $66,651 against that commercial lease and commercial lease guaranty agreement that was signed between the parties on
or around January 8, 2020 to occupy retail premises located at 1058 Asher Way, Suite 100, in Tyler, Texas. As this commercial lease was
executed prior to the COVID-19 pandemic, and due to the uncertainty of the effects on retail establishments during the pandemic, Novopelle
Tyler never officially took possession of the retail premise. On September 23, 2021, the Company and Novopelle Tyler filed an Original
Answer and Affirmative Defense denying the allegations made by Asher Park.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
January 26, 2022, Novopelle Tyler and the Company entered into a Settlement Agreement &amp; Mutual Release with Asher Park whereby Novopelle
Tyler and the Company agreed to pay Asher Park a total of $35,000 in full and final settlement of all of the Asher Park&#8217;s claims.
Accordingly, Asher Park, in consideration for the execution of the Settlement Agreement agreed to dismiss the lawsuit against both Novopelle
Tyler and the Company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Stanley
Tate d/b/a Triangle Cabinets vs. Capitol City Solutions USA, Inc.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
September 10, 2021, Stanley Tate d/b/a Triangle Cabinets (&#8220;Tate&#8221;), a materials supplier and subcontractor that was hired
by the Company&#8217;s subsidiary, Capitol City Solutions USA, Inc. (CCS), filed a petition against the Company, CCS, and CCS&#8217;s
construction client, PC Gateway, LLC (&#8220;PC Gateway&#8221;) in the 136<sup>th</sup> Judicial District Court of Jefferson County,
Texas seeking payment in the amount of $77,681 for services Tate claimed to provide CCS and PC Gateway. The Company and CCS were not
officially served until on or around October 21, 2021. On October 25, 2021, the Company and CCS filed an Original Answer denying the
allegations made by Tate as Tate had failed to provide the services in which they were hired to perform and demanding strict proof by
a preponderance of credible evidence. On December 29, 2021, Tate dismissed all claims against both the Company and CCS.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 86 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->81<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%"><a href="#toc" title="Table of Contents" style="font-style: italic">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Capitol
City Solutions USA, Inc. vs. Peak Living, LLC and PC Gateway, LLC</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
November 1, 2021, the Company&#8217;s subsidiary, Capitol City Solutions USA, Inc. (CCS), filed a petition against PC Gateway and Peak
Living, LLC (&#8220;Peak Living&#8221;) in the 58<sup>th </sup>Judicial District Court of Jefferson County Texas demanding the payment
of the final invoice as delivered to Peak Living in the amount of $2,069,908 representing the balance as owed to CCS for substantial
supplemental charges (including but not limited to dehumidifiers, various material cost and labor increases, code compliance costs, and
additional profit and overhead). Throughout the term of a project completed by CCS for Peak Living, Peak Living instructed CCS to perform
additional work beyond the original scope of the contracted agreement and fully understood that CCS expected to be compensated at the
fair market value for the additional labor and materials. In addition to seeking actual and statutory damages, CCS is seeking to recover
attorney&#8217;s fees, prejudgment and post judgement interest, costs of court and has further placed a constitutional lien on the PC
Gateway property, known as Gateway Village, located at 2825 12th Street, Beaumont, Texas, 77705 and which is the subject of the lawsuit.
CCS is currently reviewing and evaluating all of the discovery items received from Peak in connection with the lawsuit.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="ed_020"></span>Market
for Common Equity and Related Stockholder Matters</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Market
Information</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
common stock is quoted on the OTCQB Market maintained by OTC Markets Group Inc. under the symbol &#8220;<span style="text-decoration: underline">AMIH</span>&#8221;. At present,
there is a very limited market for our common stock. The OTC Market is a network of security dealers who buy and sell stock. The dealers
are connected by a computer network that provides information on current &#8220;<span style="text-decoration: underline">bids</span>&#8221; and &#8220;<span style="text-decoration: underline">asks</span>&#8221;, as
well as volume information. The following table sets forth the range of high and low sales prices for our common stock for each of the
periods indicated as reported by the OTCQB Market. These quotations reflect inter-dealer prices, without retail mark-up, mark-down or
commission and may not necessarily represent actual transactions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">Fiscal 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">Fiscal 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">Fiscal 2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">High</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">Low</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">High</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">Low</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">High</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">Low</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 40%">First Quarter ended March 31</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 6%; text-align: right">0.05</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 6%; text-align: right">0.04</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 6%; text-align: right">0.58</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 6%; text-align: right">0.14</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 6%; text-align: right">0.75</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 6%; text-align: right">0.13</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Second Quarter ended June 30<sup>(1)</sup></span></td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">0.08</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.04</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">0.23</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.10</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">0.39</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.12</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Third Quarter ended September 30</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">0.13</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.05</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">0.33</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.12</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Fourth Quarter ended December 31</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">0.12</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.05</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">0.45</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.06</td><td style="text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span>&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><sup>(1)
</sup>Through April 21, 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Holders</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of April 21, 2022, our shares of common stock were held by approximately 253 stockholders of record.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 87 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->82<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%"><a href="#toc" title="Table of Contents" style="font-style: italic">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Dividends</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have never paid any cash dividends on our common stock. We currently anticipate that we will retain all future earnings for use in our
business. Consequently, we do not anticipate paying any cash dividends in the foreseeable future. The payment of dividends in the future
will depend upon our results of operations, as well as our short-term and long-term cash availability, working capital, working capital
needs, and other factors as determined by our board of directors. Currently, except as may be provided by applicable laws, there are
no contractual or other restrictions on our ability to pay dividends if we were to decide to declare and pay them.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Securities
Authorized for Issuance Under Equity Compensation Plans</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table sets forth information, as of December 31, 2021, with respect to our compensation plans under which common stock is authorized
for issuance.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Plan Category</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Number of securities to be issued upon exercise of outstanding options,<br /> warrants and rights</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted-average exercise price of outstanding options,<br /> warrants and rights</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Number of securities remaining available for future issuance under equity compensation plans (excluding securities reflected in column (a))</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">(a)</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">(b)</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">(c)</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 46%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Equity compensation plans approved by security holders <sup>(1)</sup></span></td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 14%; text-align: right">-</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">-</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 14%; text-align: right">11,100,000</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Equity compensation plans not approved by security holders <sup>(2)</sup></span></td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">7,565,000</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">18,665,000</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">(1)
Represents shares available for awards under the Company&#8217;s </span>2021 Equity Incentive Plan.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">(2)
Represents shares available for awards under the Company&#8217;s 2019 Stock Option and Incentive Plan.</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">2019
Stock Option Plan</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.3pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
July 5, 2019, the board of directors adopted and approved a 2019 Stock Option and Incentive Plan (the &#8220;<span style="text-decoration: underline">Plan</span>&#8221;). The
Plan is intended to promote the interests of the Company by providing eligible persons with the opportunity to acquire a proprietary
interest, or otherwise increase their proprietary interest, in the Company as an incentive for them to remain in the service of the Company.
The maximum number of shares available to be issued under the Plan is currently 10,000,000 shares, subject to adjustments for any stock
splits, stock dividends or other specified adjustments which may take place in the future. The Company has issued 3,535,000 shares of
common stock under the Plan as of the date of this prospectus.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 88 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->83<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%"><a href="#toc" title="Table of Contents" style="font-style: italic">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.3pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Plan is administered by the Company&#8217;s board of directors. Persons eligible to participate in the Plan must: (i) be a natural person,
(ii) provide bona fide services to the Company, and (iii) provide services to the Company that services are not in connection with the
offer or sale of securities in a capital-raising transaction, and do not directly or indirectly promote or maintain a market for the
registrant&#8217;s securities. All grants under the Plan are intended to comply with the requirements under Internal Revenue Code Section
409A and activities under the Plan will be administered accordingly.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.3pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.3pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Options
granted under the Plan are evidenced by agreement between the recipient and the Company, subject to the following general provisions:(i)
a recipient of employee stock option may not exercise any options which would cause him/her/it to hold more than 4.9% of the Company&#8217;s
issued and outstanding common or voting stock, unless such limitation is waived by providing 61 days&#8217; written notice to the Company,
but in no event may exercise options that would cause such recipient to hold more than 9.9% of the Company&#8217;s issued and outstanding
common or voting stock; and (ii) the term of stock options shall be limited to a maximum of two years, unless otherwise approved by the
board of directors.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.3pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">2021
Stock Option Plan</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.3pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Effective
on July 30, 2021, the majority shareholders approved the adoption of the American International Holdings Corp. 2021 Equity Incentive
Plan (the &#8220;<span style="text-decoration: underline">2021 Plan</span>&#8221;), which in accordance with Rule 14c-2 of the Exchange Act, became effective on September 13,
2021, forty days after the date the information statement disclosing the adoption of such 2021 Plan was first made available to shareholders.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.3pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.3pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
2021 Plan provides an opportunity for any employee, officer, director, or consultant of the Company, subject to limitations provided
by federal or state securities laws, to receive (i) incentive stock options (to eligible employees only); (ii) nonqualified stock options;
(iii) restricted stock; (iv) stock awards; (v) shares in performance of services; or (vi) any combination of the foregoing. In making
such determinations, the Board of Directors may take into account the nature of the services rendered by such person, his or her present
and potential contribution to the Company&#8217;s success, and such other factors as the Board of Directors in its discretion shall deem
relevant.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.3pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.3pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subject
to adjustment in connection with the payment of a stock dividend, a stock split or subdivision or combination of the shares of common
stock, or a reorganization or reclassification of the Company&#8217;s common stock, the aggregate number of shares of common stock which
may be issued pursuant to awards under the 2021 Plan is the sum of (i) 11,100,000 shares, and (ii) an annual increase on April 1st of
each calendar year, beginning in 2022 and ending in 2031, in each case subject to the approval of the Board of Directors or the compensation
committee of the Company (if any) on or prior to the applicable date, equal to the lesser of (A) five percent (5%) of the total shares
of common stock of the Company outstanding on the last day of the immediately preceding fiscal year; (B) 10,000,000 shares of common
stock; and (C) such smaller number of shares as determined by the Board of Directors or compensation committee of the of the Company
(if any)(the &#8220;<span style="text-decoration: underline">Share Limit</span>&#8221;), also known as an &#8220;<span style="text-decoration: underline">evergreen</span>&#8221; provision. Notwithstanding the foregoing,
shares added to the Share Limit are available for issuance as incentive stock options only to the extent that making such shares available
for issuance as incentive stock options would not cause any incentive stock option to cease to qualify as such. In the event that the
Board of Directors or the compensation committee (if any) does not take action to affirmatively approve an increase in the Share Limit
on or prior to the applicable date provided for under the plan, the Share Limit remains at its then current level. Notwithstanding the
above, no more than 90,000,000 incentive stock options may be granted pursuant to the terms of the 2021 Plan.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 89 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->84<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%"><a href="#toc" title="Table of Contents" style="font-style: italic">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><b>&#160;</b></span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-transform: uppercase; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="ed_021"></span>Management&#8217;s
Discussion and Analysis of Financial Condition and Results of Operations</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline">Introduction</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations (MD&amp;A) is provided in addition to the
accompanying financial statements and notes to assist readers in understanding our results of operations, financial condition, and cash
flows. MD&amp;A is organized as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Results
    of Operations</i></b>. An analysis of our financial results comparing the years ended December 31, 2021, and 2020.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Liquidity
    and Capital Resources</i></b>. A discussion of our financial condition, including descriptions of balance sheet information and cash
    flows.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Critical
    Accounting Policies and Estimates</i></b>. Critical accounting policies and estimates that we believe are important to understanding
    the assumptions and judgments incorporated in our reported financial results and forecasts.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
references to years relate to the fiscal year ended December 31 of the particular year.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following discussion should be read in conjunction with the American International Holdings Corp. financial statements and accompanying
notes included elsewhere in this prospectus.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline">Results
of Operations</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline">Revenues</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
had revenues of $20,169 and $2,115 for the years ended December 31, 2021 and 2020, respectively. The increase in revenues in 2021 was
due primarily to our change in business strategy. We recognized revenues in accordance with Accounting Standards Codification (ASC) Topic
606. A five-step process has been designed for the individual or pool of contracts to keep financial statements focused on this principle.
Revenues from fixed-price and cost-plus contracts are recognized on the percentage of completion method, whereby revenues on long-term
contracts were recorded on the basis of the Company&#8217;s estimates of the percentage of completion of contracts based on the ratio
of actual cost incurred to total estimated costs. This cost-to-cost method was used because management considered it to be the best available
measure of progress on these contacts. Revenues from cost-plus-fee contracts were recognized on the basis of costs incurred during the
period plus the fee earned, measured on the cost-to-cost method. Revenues from time-and-material and rate chart contracts were recognized
currently as work is performed. During the year ended December 31, 2021, we recognized revenues of $20,169 in connection with membership
income from ZipDoctor. During the year ended December 31, 2020, we recognized revenues of $2,115.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 90 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->85<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%"><a href="#toc" title="Table of Contents" style="font-style: italic">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline">Cost
of Revenues</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
had cost of revenues of $39,738 and $0 during the years ended December 31, 2021 and 2020, respectively. Cost of revenues include all
direct material, sub-contractor, labor and certain other direct costs, as well as those indirect costs related to contract performance,
such as indirect labor and fringe benefits. Selling, general, and administrative costs are charged to expense as incurred.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline">Operating
Expenses</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">General
and administrative expenses were $6,975,654 and $3,711,317 during the years ended December 31, 2021 and 2020, respectively. The increase
in 2021 was due primarily to stock-based compensation in the amount of $4,986,143 (including $4,334,857 in stock issued for services
rendered and $601,852 in stock issued for in process research and development), which totaled $2,860,813 in 2020, stock-and professional
expenses incurred as a public company such as legal expenses in the amount of $242,293 for the year ended December 31, 2021, as compared
to $112,175 for the year ended December 31, 2020, and financial reporting, accounting and auditing compliance expenses in the amount
of $131,608 for the year ended December 31, 2021, as compared to $99,003 for the year ended December 31, 2020.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline">Other
Expenses</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the year ended December 31, 2021, and 2020, we incurred interest expense of $184,589 and $219,202, respectively, of which $1,979 and
$3,345, respectively, were recorded as imputed interest in connection with related party loans.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amortization
of debt discount was $1,958,298 and $777,964 during the years ended December 31, 2021 and 2020, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
had a loss of $1,071,028 and a loss of $107,574 during the year ended December 31, 2021 and 2020, respectively, due to change in derivative
liabilities. See also &#8220;Note 12 &#8211; Derivative Liabilities&#8221;, in the notes to unconsolidated financial statements included
in &#8220;<span style="text-decoration: underline">Index to Financial Statements</span>&#8221;, below, for a more detailed discussion of gain (loss) in derivative liabilities
which is non-cash.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 91 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->86<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%"><a href="#toc" title="Table of Contents" style="font-style: italic">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
had a settlement loss for the year ended December 31, 2021 of $16,359 compared to a settlement loss of $1,041,445 for the year ended
December 31, 2020, each in connection with debt settlements that occurred during the respective periods.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
also had no impairment loss for the year ended December 31, 2021, compared to an impairment loss of $605,488 for the year ended December
31, 2020 in connection with the common shares issued for notes settlement during the applicable period.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline">Discontinued
operations</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 9pt; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Customer
traffic and demand at our VISSIA Waterway, Inc. and VISSIA McKinney MedSpa locations which were re-opened after mandatory closures associated
with COVID-19 in June and August 2020, respectively, failed to rebound to pre-closure levels due to COVID-19 and the pandemic&#8217;s
effects on the economy, and because we are unable to predict the length of the pandemic or ultimate outcome thereof, and further due
to our limited capital resources, effective in October 2020, we made the decision to close both our VISSIA Waterway, Inc. and VISSIA
McKinney locations and discontinued such operations. As such locations are closed, they are not generating any revenue. The continuing
expenses, without corresponding revenues, may have a significant negative affect on our results of operations and cash flows. Separately,
Legend Nutrition&#8217;s lease was up January 31, 2021, and the Company chose not to renew the lease, closed the store, and not continue
in that line of business moving forward.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">VISSIA
Waterway, Inc., VISSIA McKinney LLC Legend Nutrition and Capitol City Solutions USA, Inc. (collectively referred to as &#8220;<span style="text-decoration: underline">Discontinued
Subsidiaries</span>&#8221;) have been presented as discontinued operations in the accompanying consolidated financial statements for the
year ended December 31, 2021, and 2020, and are summarized below:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center">The Years Ended <br />
December 31,</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2021</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2020</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%">Revenue</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">2,530</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">6,107,106</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt">Cost of revenue</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">5,058,373</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Gross profit</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,530</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,048,813</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Operating expenses</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">57,659</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,205,993</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Loss from operations</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(55,130</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(157,180</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Other income (expenses)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">299,716</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(722,057</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Net income (loss)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">244,586</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(879,237</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline">Net
Loss</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
had a net loss of $9,980,911, or $0.14 per share from continuing operations and net income of $244,586 or $0.00 per share from discontinued
operations during the year ended December 31, 2021, for a total net loss of $10,008,362 or $0.14 per share. We had a net loss of $7,339,890,
or $0.18 per share from continuing operations and $879,237 or $0.02 per share from discontinued operations during the year ended December
31, 2020, totaling an aggregate of $7,339,890 or $0.18 per share in total net loss. The increase in net loss in 2021 was primarily attributable
to non-cash expenses in connection with stock-based compensation, amortization of debt discount, the change in derivative values associated
with outstanding convertible debt, settlement loss in connection with the common shares issued for notes settlement, and the decrease
in gross profit and revenues, each as discussed above.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 92 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->87<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%"><a href="#toc" title="Table of Contents" style="font-style: italic">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Liquidity
and Capital Resources</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2021 and 2020, the Company had total assets of $1,213,647 and $38,539, respectively, including $0 and $0 of assets of
discontinued operations, respectively. The main reason for the increase in total assets as of December 31, 2021, compared to December
30, 2020, was due to a $1,184,593 increase in cash, which was mainly due to the proceeds received from the Company&#8217;s financing
activities and issuances of convertible notes, offset by the $208,984 decrease in assets of discontinued operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2021 and 2020, the Company had total liabilities of $5,100,557 and $1,656,529, respectively, which consisted of accounts
payable, accrued interest and accrued compensation in the amount of $252,194 and $211,271, respectively, convertible notes payable (net
of discount) and loans payable to related parties and non-related parties (net of discount) in the amounts of $396,419, $75,000 and $123,473
and $74,827, $55,000 and $135,392 as of December 31, 2021 and 2020, respectively, and derivative liabilities of $4,141,272 and $517,366,
respectively. We also had $112,199 and $669,574 of net liabilities related to discontinued operations. The Company had a total stockholders&#8217;
deficit of $3,869,111 and $1,391,007 as of December 31, 2021 and 2020, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the year ended December 31, 2021, net cash used in operating activities was $2,211,762, compared to net cash used in operating activities
of $2,153,263 for the year ended December 31, 2020. Negative cash flows during the year ended December 31, 2021, were due primarily to
the net loss of $10,225,497 and change in derivative liabilities of $2,469,697, partially offset by non-cash expenses, including stock-based
compensation of $4,334,857, amortization of debt discount of $1,958,298, derivative expense of $3,540,725, loss on loans settlement of
$58,059, and in process research and development of $601,852 Comparatively, negative cash flows during the year ended December 31, 2020,
were due primarily to the net loss of $6,460,653, partially offset by non-cash expenses, including stock-based compensation of $2,860,813,
amortization of debt discount of $777,965, loss on loans settlement by $1,155,685, and impairment loss of $670,280.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the years ended December 31, 2021 and 2020, we had cash provided by investing activities of $10,000 and cash used in investing activities
of $27,392, respectively. The net cash used in investing activities in each year was solely attributable to capital expenditures for
and disposal of property and equipment.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the years ended December 31, 2021 and 2020, net cash flows provided by financing activities were $3,386,335 and $947,180, respectively,
primarily attributable to the proceeds from notes payable to related parties and non-related parties during the respective periods. We
had proceeds of $141,928 from related party borrowings and $3,738,999 from non-related party borrowings in the year ended December 31,
2021, compared to proceeds of $0 from related party borrowings and proceeds of $947,750 from non-related party borrowings in the year
ended December 31, 2020. We made repayments of $141,9289 on related party borrowings and repayments of $427,500 on non-related party
borrowings in the year ended December 31, 2021 compared to repayments of $40,000 on non-related party borrowings and repayments of $0
on related party borrowings in the year ended December 31, 2020. We had proceeds of $100,000 from sales of stock in 2021, which was $46,500
in 2020.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 93 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->88<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%"><a href="#toc" title="Table of Contents" style="font-style: italic">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
had cash of $1,209,737 and a working capital deficit of $3,886,910 as of December 31, 2021. On the short-term basis, we will be required
to raise a significant amount of additional funds over the next 12 months to sustain operations and pay outstanding liabilities. On the
long-term basis, we will potentially need to raise capital to grow and develop our business.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Since
December 31, 2019, we have (a) sold 330,250 shares of our common stock in consideration for $146,500 in cash through our Regulation A
offering, which related to the sale of up to 10,800,000 shares of our common stock at a price of $0.50 per share, which has since been
terminated; and (b) issued 36,236,429 shares of our common stock in exchange for the conversion of $2,832,852 in debt.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
September 27, 2021, October 29, 2021, November 2, 2021, and November 12, 2021, Jacob Cohen, our Chief Executive Officer, advanced the
Company, $50,000, $15,000, $10,000, and $40,000, respectively, which loans are payable upon demand and not bearing interest. This amount
was repaid in November 2021.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">It
is likely that we will require significant additional financing within the next 12 months and if we are unable to raise the needed funds
on an acceptable basis, we may be forced to cease or curtail operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Additional
information regarding the Company&#8217;s (a) accrued compensation for related parties can be found in &#8220;Note 9 &#8211; Accrued
Compensation for Related Parties&#8221;; (b) notes payable can be found in &#8220;Note 10 &#8211; Notes Payable&#8221;; (c) related party
loans can be found in &#8220;Note 11 &#8211; Loans from Related Parties&#8221;; derivative liabilities can be found in &#8220;Note 12
&#8211; Derivative Liabilities&#8221;; in the notes to unconsolidated financial statements included in &#8220;<span style="text-decoration: underline">Index to Financial Statements</span>&#8221;,
below.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline">Critical
Accounting Policies and Estimates</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
discussion and analysis of our financial condition and results of operations are based upon our consolidated financial statements, which
have been prepared in accordance with accounting principles generally accepted in the United States. The preparation of these financial
statements requires us to make estimates and judgments that affect the reported amounts of assets, liabilities, revenues and expenses.
See &#8220;Note 1 &#8211; Summary of Significant Accounting Policies&#8221; to the audited financial statements included under &#8220;<span style="text-decoration: underline">Index
to Financial Statements</span>&#8221;, below.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>


<!-- Field: Page; Sequence: 94 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->89<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%"><a href="#toc" title="Table of Contents" style="font-style: italic">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Revenue
Recognition</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company generates its revenue from monthly membership subscriptions. Revenue is recognized at the time of delivery and includes a delivery
fee for each delivery or a subscription fee on a monthly basis for memberships. Under Accounting Standards Update (&#8220;ASU&#8221;)
No. 2014-09 (Topic 606) &#8220;Revenue from Contracts with Customers&#8221;, revenue from contracts with customers is measured based
on the consideration specified in the contract with the customer, and excludes any sales incentives and amounts collected on behalf of
third parties. A performance obligation is a promise in a contract to transfer a distinct good or service to a customer and is the unit
of account under Topic 606. The Company&#8217;s contracts with its customers do not include multiple performance obligations. The Company
recognizes revenue when a performance obligation is satisfied by transferring control over a product or service to a customer. The amount
of revenue recognized reflects the consideration the Company expects to be entitled to in exchange for such products or services.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s subsidiaries, EPIQ MD, Inc. and ZipDoctor, Inc. both provide its customers with access to its telemedicine platform where
customers have unlimited access to start a doctor visit 24/7. The customers pay a flat fee per month for use of the platform and is not
dependent on the frequency of the doctor visits. Each doctor visit is included in the monthly subscription fee.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">EPIQ
MD: The base monthly subscription fees range from $24.95-$49.95 per month and is dependent on the number of family members included in
the plan. Customers can choose to add additional services, such as Epiq Paws and Epiq Lux, ranging from an additional $4.95-$9.95 per
month.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
customer gains immediate access to the telemedicine platform upon completing the enrollment process and making the first month&#8217;s
payment, at which point the Company recognizes the revenue from that customer. Billing commences on the day that the customer is enrolled
for the Company&#8217;s services and is continued to be billed on the calendar day of each calendar month, in accordance with the original
date of enrollment.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Customer&#8217;s
may cancel their subscription at any time provided that they provide the Company with thirty (30) days advanced written notice of cancellation
with no cancellation fees charged to the customer. In the event a subscriber provides a notice of cancellation within the membership
period, the customer will be billed on their regular billing date at an amount adjusted to reflect an amount due until the cancellation
date.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
avoidance of doubt, if a subscriber is billed $29.95 on the 1st of the month and cancels on the 15th, the subscriber will be billed on
the 1st of the following month at a prorated rate through the 15th, or at a rate of $14.97.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ZipDoctor,
Inc: The base monthly subscription fees range from $25.00-$45.00 per month and is dependent on the number of family members included
in the plan. The customer gains immediate access to the telemedicine platform upon completing the enrollment process and making the first
month&#8217;s payment, at which point the Company recognizes the revenue from that customer. Billing commences on the day that the customer
is enrolled for the Company&#8217;s services and is continued to be billed on the calendar day of each calendar month, in accordance
with the original date of enrollment.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 95 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->90<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%"><a href="#toc" title="Table of Contents" style="font-style: italic">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Customer&#8217;s
may cancel their subscription at any time provided that they provide the Company with thirty (30) days advanced written notice of cancellation
with no cancellation fees charged to the customer. In the event a subscriber provides a notice of cancellation within the membership
period, the customer will be billed on their regular billing date at an amount adjusted to reflect an amount due until the cancellation
date.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
avoidance of doubt, if a subscriber is billed $25.00 on the 1st of the month and cancels on the 15th, the subscriber will be billed on
the 1st of the following month at a prorated rate through the 15th, or at a rate of $12.50.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>LEGEND
NUTRITION &#8211; DISCONTINUED OPERATIONS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company recognizes revenue in according with Accounting Standards Codification (ASC) Topic 606. The underlying principle is that the
Company recognize revenue to depict the transfer of promised goods and services to customers in an amount that they expect to be entitled
to in the exchange for goods and services provided.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s discontinued subsidiary, Legend Nutrition, Inc., operated a retail store in which it sold nutritional and wellness related
products. Legend&#8217;s business was solely based on the sale of retail products and did not offer any non-tangible services.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Revenue
for the entire product sold was recognized when the customer purchased and had control of the product, even if the terms included a right
of return. Legend accounted for any discounts and concessions at the time of sale and accounted for returns and refunds when Legend received
the product back in its possession where in some instances, if the product was unused, would be returned to Legend&#8217;s inventory
or, if used, would be discarded.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Costs
of revenue included the amounts that Legend paid its wholesalers and distributors and recognized the cost of revenue when the products
were sold and transferred to the possession of the customer. The cost of revenue was deducted from Legends open inventory balance upon
sale.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fair
value of financial instruments</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company measures its financial and non-financial assets and liabilities, as well as makes related disclosures, in accordance with FASB
Accounting Standards Codification No. 820, Fair Value Measurement (&#8220;<span style="text-decoration: underline">ASC 820</span>&#8221;), which provides guidance with respect
to valuation techniques to be utilized in the determination of fair value of assets and liabilities. Approaches include, (i) the market
approach (comparable market prices), (ii) the income approach (present value of future income or cash flow), and (iii) the cost approach
(cost to replace the service capacity of an asset or replacement cost). ASC 820 utilizes a fair value hierarchy that prioritizes the
inputs to valuation techniques used to measure fair value into three broad levels. The following is a brief description of those three
levels:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
1: Observable inputs such as quoted prices (unadjusted) in active markets for identical assets or liabilities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 96 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->91<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%"><a href="#toc" title="Table of Contents" style="font-style: italic">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
2: Inputs other than quoted prices that are observable, either directly or indirectly. These include quoted prices for similar assets
or liabilities in active markets and quoted prices for identical or similar assets or liabilities in markets that are not active.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
3: Unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions, such as
valuations derived from valuation techniques in which one or more significant inputs or significant value drivers are unobservable.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
financial instruments include cash, accounts receivable, other receivable, inventories, accounts payable, accrued liabilities, convertible
note payable, and derivative liabilities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
carrying values of the Company&#8217;s cash, accounts receivable, other receivable, inventories, accounts payable, and accrued liabilities
approximate their fair value due to their short-term nature.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s convertible notes payable are measured at amortized cost.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
derivative liabilities are stated at their fair value as a level 3 measurement. The Company used the Lattice Model to determine the fair
values of these derivative liabilities. &#8220;<span style="text-decoration: underline">Note 12 &#8211; Derivative Liabilities</span>&#8221;, to the notes to the financial statements
included herein, under &#8220;<span style="text-decoration: underline">Index to Financial Statements</span>&#8221;, below, for the Company&#8217;s assumptions used in determining
the fair value of these financial instruments.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Convertible
note payable</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company accounts for convertible notes payable in accordance with the Under Financial Accounting Standard Board (&#8220;<span style="text-decoration: underline">FASB</span>&#8221;)
Accounting Standards Codification No. 815, Derivatives and Hedging, since the conversion feature is not indexed to the Company&#8217;s
stock and can&#8217;t be classified in equity. The Company allocates the proceeds received from convertible notes payable between the
liability component and conversion feature component. The conversion feature that is considered embedded derivative liabilities has been
recorded at their fair value as its fair value can be separated from the convertible note and its conversion is independent of the underlying
note value. The Company has also recorded the resulting discount on debt related to the conversion feature and is amortizing the discount
using the effective interest rate method over the life of the debt instruments.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Derivative
liabilities</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company accounts for derivative liabilities in accordance with the FASB Accounting Standards Codification No. 815, Derivatives and Hedging
(&#8220;<span style="text-decoration: underline">ASC 815</span>&#8221;). ASC 815 requires companies to recognize all derivative liabilities in the balance sheet at fair value,
and marks it to market at each reporting date with the resulting gains or losses shown in the Statement of Operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 97 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->92<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%"><a href="#toc" title="Table of Contents" style="font-style: italic">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stock
based compensation</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company recognizes compensation costs to employees under FASB Accounting Standards Codification 718 &#8220;<span style="text-decoration: underline">Compensation - Stock Compensation</span>&#8221;
(&#8220;<span style="text-decoration: underline">ASC 718</span>&#8221;). Under ASC 718, companies are required to measure the compensation costs of share-based compensation arrangements
based on the grant-date fair value and recognize the costs in the financial statements over the period during which employees are required
to provide services. Share based compensation arrangements include stock options and warrants. As such, compensation cost is measured
on the date of grant at their fair value. Such compensation amounts, if any, are amortized over the respective vesting periods of the
option grant.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
July 27, 2018, the inception date, the Company adopted ASU No. 2018-07 &#8220;<span style="text-decoration: underline">Compensation - Stock Compensation (Topic 718): Improvements
to Nonemployee Share-Based Payment Accounting.</span>&#8221; These amendments expand the scope of Topic 718, Compensation - Stock Compensation
(which currently only includes share-based payments to employees) to include share-based payments issued to nonemployees for goods or
services. Consequently, the accounting for share-based payments to nonemployees and employees will be substantially aligned.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Off-Balance
Sheet Arrangements</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2021, we did not have any off-balance sheet arrangements as defined in Item 303(a)(4)(ii) of Regulation S-K promulgated
under the Securities Act of 1934.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 98 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->93<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%"><a href="#toc" title="Table of Contents" style="font-style: italic">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><b>&#160;</b></span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="ed_022"></span>Quantitative
and Qualitative Disclosures About Market Risk</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to Item 305(e) of Regulation S-K (&#167; 229.305(e)), the Company is not required to provide the information required by this Item as
it is a &#8220;<span style="text-decoration: underline">smaller reporting company,</span>&#8221; as defined by Rule 229.10(f)(1).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="ed_023"></span>Directors,
Executive Officers and Corporate Governance</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table sets forth the name, age and position of each director and executive officer of the Company&#160;.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 22%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Name</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 36%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Position</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Age</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 26%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Term
    of Office</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Jacob
    D. Cohen </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">CEO,
    President, Director</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">CEO,
    Director</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mangoceuticals,
    Inc.</span></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">43
    </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">April
    2019 &#8211; Present </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Craig
    A. Hewitt</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Financial Officer</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">54</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">March
    2022 &#8211; Present</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Alejandro
    Rodriguez</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">CEO
    EPIQ MD, Inc. </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">47</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">January
    2021 &#8211; Present </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Verdie
    Bowen </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">COO
    EPIQ MD, Inc. </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">37
    </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">January
    2021 &#8211; Present</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sultan
    Haroon</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dir.
    of Business Operations, EPIQ Scripts, LLC</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">28</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">March
    2022 &#8211; Present</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Maja
    Matthews</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dir.
    of Business Development,</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">EPIQ
    Scripts, LLC</span></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">44</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">March
    2022 &#8211; Present</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Jonathan
    Arango</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">COO,
    President and Director, Mangoceuticals, Inc.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">27</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">April
    2022 &#8211; Present </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Peter
    &#8220;Casey&#8221; Jensen</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">48</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">October
    2021 &#8211; Present </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Lorraine
    D&#8217;Alessio </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director
    </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">42
    </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">January
    2022 &#8211; Present</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dr.
    Kenny Myers</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">55</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">January
    2022 &#8211; Present </span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
directors are elected annually (or as often as we hold meetings of stockholders) and will hold office until our next annual meeting of
the stockholders and until their successors are elected and qualified. Officers will hold their positions at the pleasure of the Board
of Directors, absent any employment agreement. Our officers and directors may receive compensation as determined by us from time to time
by vote of the Board of Directors. Such compensation might be in the form of stock options or other equity. Directors may be reimbursed
by the Company for expenses incurred in attending meetings of the board of directors. Vacancies in the Board are filled by majority vote
of the remaining directors.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 33.75pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following is biographical information on the members of our Board of Directors:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 99 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->94<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%"><a href="#toc" title="Table of Contents" style="font-style: italic">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Jacob
D. Cohen, Chief Executive Officer, President and Director</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.65pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Jacob
Cohen is a serial entrepreneur, corporate finance and executive management professional with over 20 years of investment banking and
capital markets experience having started and growing multiple companies in various industry sectors including marketing, advertising,
healthcare, IT and financial services. Prior to joining the Company, Mr. Cohen was the co-founder and managing partner of several boutique
investment bank and strategic advisory firms where he advised both early and later stage companies in raising capital in the form of
debt and/or equity and in both private and public markets.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.65pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.65pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prior
to his experiences in investment banking, Mr. Cohen served as the Chief Financial Officer of The Renewed Group, Inc. &#8211; a manufacturer,
wholesaler and retailer of eco-friendly and sustainable apparel primarily made from recycled textiles and under the brand name REUSE
JEANS from 2010 through the end of 2013. Further, Mr. Cohen served from 2008 through 2010 as Executive Vice President and Controller
of Metiscan, Inc., a publicly-traded company, and as the President and Chief Executive Officer of one of its subsidiaries, Shoreline
Employment Services, Inc. During his tenure at Metiscan, Mr. Cohen was instrumental in restructuring, reorganizing and operating the
company and its five subsidiaries, and successfully raised over $8 million in equity financing for growth capital. Mr. Cohen also spearheaded
the company&#8217;s financial audit process and managed its various filings with the SEC.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.65pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.65pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">From
2007 through 2008, Mr. Cohen served as the Chief Operating Officer of Artfest International, which he assisted in taking public at the
end of 2007. Throughout his career, Mr. Cohen was involved in starting many new ventures, including The AdvertEyes Network, a digital
signage advertising company where he served as founder and CEO. Other positions include investment advisor and institutional equity research
analyst for Solomon Advisors and Huberman Financial, securities broker-dealers, from 2003 through 2005, and investment banker for Allegiance
Capital, a middle market investment bank specializing on mergers and acquisitions, from 2005-2007. Mr. Cohen holds a Bachelors of Arts
in International Economics and Finance from Brandeis University in Waltham, MA.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.65pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.65pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
believe that Mr. Cohen&#8217;s extensive background in investment banking, public company management, and corporate finance, make him
a strong addition to, and well qualified to serve on, the board of directors.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.65pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Dr.
Craig A. Hewitt, Ph. D, Chief Financial Officer</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dr.
Hewitt, age 54, has served as the Chief Financial Officer of the Company since March 30, 2022. Dr. Hewitt has nearly 20 years of experience
serving in executive management and leadership roles for companies in the health services and business services sectors. Between November
2015 and November 2021, Dr. Hewitt served as Chief Financial Officer of Holston Medical Group, an independent physician group of over
220 primary care physicians, specialists and mid-level providers with over 1,000 employees. Dr. Hewitt was a co-founder of, and Chief
Executive Officer of, Legacy Financial Partners, a business services provider, between 2010 and 2015. From 2005 to 2009, Dr. Hewitt served
as Chief Operating Officer and Interim Chief Executive Officer of Surrex Solutions, a high tech staffing company with over 600 employees
and branch offices in 23 states, while also serving as a member of Surrex&#8217;s Board of Directors, Audit Committee, and Compensation
Committee. Between 2002 and 2005, Dr. Hewitt served as Chief Financial Officer of Accupoll, Inc., a company engaged in the design, development,
and sale of electronic voting systems and related technologies, where he was also a member Board of Directors, Audit Committee, and Compensation
Committee. From 1999 and 2002, Dr. Hewitt served as Chief Financial Officer of Universal Broadband Networks and from 1995 to 1999, Dr.
Hewitt served as Chief Financial Officer of Compreview, Inc.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 100 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->95<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%"><a href="#toc" title="Table of Contents" style="font-style: italic">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
2021, Dr. Hewitt received his Ph.D in Health Science from Trident University, in Cypress California, where he also earned a Master&#8217;s
degree in Healthcare in 2017. Dr. Hewitt received a Master&#8217;s degree in Business Administration from Western Governors University
in Salt Lake City, Utah, in 2015 and a Bachelor&#8217;s degree in Business Administration from California State University, Fullerton
in 1990.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Alejandro
Rodriguez</i></b><span style="background-color: white">, </span><b><i>Chief Executive Officer &#8211; EPIQ MD, Inc.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Alejandro
Rodriguez has served as the Chief Executive Officer of EPIQ MD, Inc. since January 2021. Mr. Rodriguez has 15 years of energy experience
and a total of 20 years of business experience at the C-Level across the energy, telecom and information technology industries. Mr. Rodriguez
is a business development and marketing executive that has successfully launched five different companies that were collectively responsible
for nearly $6 billion in sales revenue over the course of his career in the energy industry. This experience includes but is not limited
to the following private companies SYNRG Marketing (Chief Business Officers &amp; Partner) and Utility Choice Electric (VP of Sales &amp;
Marketing) from 2001 through 2003, AmPro Energy (VP if Business Development) from 2003 through 2004, Stream Energy and Ignite (Founder
&amp; Managing Partner) from 2004 through end of 2009. In August 2004, Mr. Rodriguez co-founded and served as Managing Partner of Stream
Energy, a fast-growing retail energy provider that provided electricity and natural gas services to approximately 400,000 customers and
grossed over $2 billion within the first four years of operation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Upon
his exit from Stream Energy in late 2009, Mr. Rodriguez founded and served as Chairman of NAUP Capital, LP (NAUP Investments, LLC), through
2018. NAUP was an energy holding company and venture development firm with holdings in energy, solar, energy brokerage and energy software
related entities. In his position at NAUP, Mr. Rodriguez founded and grew several companies. Diversegy, LLC and EPIQ Energy, LLC were
among these NAUP projects. Rodriguez served as CEO for these companies and was successful in selling both of these companies to an NYSE
publicly traded energy company (Genie Energy) in December of 2013. Diversegy, LLC is a national energy brokerage company that advises
commercial, industrial and municipal customers regarding their natural gas and power needs.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 101 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->96<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%"><a href="#toc" title="Table of Contents" style="font-style: italic">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Between
February of 2016 and August of 2019, Rodriguez served as a fractional Director and then Chief Executive Officer of a micro-cap company
called The Chron Organization, Inc. (DBA: Zen Home Services &amp; Zenergy). During his tenure with this fledgling upstart, Rodriguez
would develop a national smart home service offering that would automate lights, locks and thermostats for homeowners. Rodriguez resigned
in August of 2019 and formed Essential Sustainability Services (&#8220;Essential&#8221;), where he served as CEO and a board member.
As a result of the Covid-19 pandemic and related shutdowns, Rodriguez, for various personal reasons decided to resign from Essential
as its CEO and to retire from the energy industry altogether to focus on the healthcare industry.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Verdie
Bowen, Chief Operating Officer - EPIQ MD, Inc.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Verdie
Bowen has served as the Chief Operating Officer of EPIQ MD, Inc. since January 2021. Mr. Bowen has spent the past 17 years of his career
focused on information technology, systems and infrastructure development. Over the course of this time period, Verdie Bowen has advised
and consulted with a myriad of Fortune 1000 companies with respect to the design and implementation of various operating systems and
infrastructure assets. In addition to being a well-rounded chief operations executive, Mr. Bowen&#8217;s foundation for his knowledge
base can be attributed to his expertise in Enterprise and Service Provider Network architecture, WAN Architecture, and Data Center Architecture.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prior
to his position at EPIQ MD, Inc,, Mr. Bowen served as a solutions architect for General Datatech (GDT) from November 2010 wherein he&#8217;s
focused on the various business development and design aspects of large IT and Systems-related infrastructure projects for large private
and public sector clientele. Among his flagship clients and projects are the following (not limited to): U.S. Department of Defense&#8217;s
Biometric Fusion Center, the State of Alaska&#8217;s first major IP Telephony deployment, which at the time was the 2<sup>nd</sup> largest
Cisco IPT deployment in the world, General Communication&#8217;s (GCI) ISP core network redesign and implementation, T-Mobile, FiServ,
First Data, US Cellular, HEB, Phillips 66 and Enterprise Partners. From July 2006 to November 2010, Mr. Bowen served as a Lead Engineer
for World Wide Technology, an IT solutions and strategy company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mr.
Bowen is certified in various CISCO specialist programs such as Data Center Storage Networking Design, Firewall, Advanced Wireless Field,
IPS, and Wide Area Application Services for System Engineers. Mr. Bowen holds an AAS in Computer Science focusing on Networking Technology
and a BS in Information Technology Engineering from Charter College.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Sultan
Haroon, Director of Business Operations, EPIQ Scripts, LLC</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Sultan
Haroon started his successful pharmacy career with American Specialty Pharmacy. Taking his knowledge, experience, and research, Sultan
launched a Pharmacy Consulting Company which connected doctors to ancillary services such as pharmacies, labs, and durable medical equipment
companies. Mr. Haroon later went on to establish Whole Health Kinetix (WHK) which specialized in customizing supplements and healthcare
according to a patient&#8217;s blood work and DNA. After its successful launch, WHK was acquired by a group of physicians in the Dallas/Ft
Worth metroplex. Sultan then went on to manage, own and operate five Texas Class-A Pharmacies and was also a co-owner of a Class-G Pharmacy.
Mr. Haroon grew the pharmacies to several millions of dollars in revenue until they were ultimately purchased by a large east-coast based
Venture Capital firm.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 102 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->97<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%"><a href="#toc" title="Table of Contents" style="font-style: italic">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Maja
Matthews, Director of Business Development, EPIQ Scripts, LLC</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Drawing
on her 27 years of experience in health care, Ms. Matthews provides in-depth knowledge in many facets of the Pharmacy/Health Care Industry.
Maja has hands-on experience in management and development of policies &amp; procedures, along with years of experience in credentialing
new pharmacies. This includes State Board, NPI, NCPDP, DEA, URAC, all PBM Contracts, State/Federal Compliance, and out of state licensing.
Ms. Matthews managed and operated five Texas Class-A Pharmacies and was also Co-Owner of a Class-G Pharmacy. Prior to her venturing out
on her own, Maja was District Trainer and Sr. Pharmacy Technician with CVS Pharmacy. She was also Director of Operations and Sr. Technician
at American Specialty Pharmacy (ASP) where she managed and trained hundreds of technicians in the processing of prescriptions, auditing,
and workers compensation. Maja has been a State Certified Pharmacy Technician since 1996.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Peter
&#8220;Casey&#8221; Jensen, Director</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.65pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Peter
&#8220;Casey&#8221; Jensen was appointed as a director of the Company effective October 19, 2021.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Since
September 2019, Mr. Jensen has served as Managing Partner at PHX Global, LLC providing executive management and international business
advisory services. Mr. Jensen worked as a registered investment adviser from December 2018 through October 2019, at Madison Avenue Securities,
LLC/EFC Wealth Management. In February 2013, Mr. Jensen co-founded JPM Capital, a boutique Investment Bank and Strategic Advisory firm,
where he worked until July 2018, and where he assisted in successfully closing over 160 investments in public companies. While serving
as Managing Partner at JPM, Mr. Jensen invested in healthcare start-ups, and he was able to manage investments from seed stage to profitability.
From February 2013 through December 2016, Mr. Jensen served as a partner and investment advisor at Anubis Capital Advisors, Inc.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">From
2000 to 2010, Mr. Jensen worked in investor education and owned a stock brokerage where he managed approximately $100 million in assets
for high net worth and institutional investors. Also, during this period, Mr. Jensen formed Trindax Capital, LLC, an investment firm
focused on commodities and commercial real estate, where he served as CEO. In 2010, Mr. Jensen combined his experience in commercial
finance and investments, and entered private equity. Mr. Jensen became a Managing Director Heartland Capital Markets, where he co-managed
a variety of private equity investments in both seed and growth stage companies from February 2010 to January 2013.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition to being a former Registered Investment Adviser, Mr. Jensen has passed Series 3, 7, 24, 63 and 65 FINRA examinations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 103 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->98<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%"><a href="#toc" title="Table of Contents" style="font-style: italic">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Board of Directors believes that Mr. Jensen is well qualified to serve on the Board of Directors, and as the sole member and Chairperson
of the Company&#8217;s Audit Committee, because of his strong background in finance and securities, and consistent success in several
different roles and industries.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Lorraine
D&#8217;Alessio, Esq., Director</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Lorraine
D&#8217;Alessio was appointed as a director of the Company effective January 13, 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Since
2010, Ms. D&#8217;Alessio has served as CEO and Managing Partner at D&#8217;Alessio Law Group, PLC, a law firm in Beverly Hills, California
which provides immigration and entertainment law services. In that capacity, she has provided counsel to entertainment agencies, unions,
private companies, academic institutions, tech startups, entrepreneurs and enterprises including: Next Models, Food Network, SubPac,
Pepperdine University, ACTRA, New York Film Academy, Plug and Play, Expert Dojo, and 500 Startups.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ms.
D&#8217;Alessio was named the 2017 Leader in Law by the Los Angeles Business Journal and is the recipient of the 2018 Enterprising Woman
Award. Since 2016, Ms. D&#8217;Alessio has also served on the board of directors of Artists for Change, a non-profit organization which
focuses on creating high impact film, television, and multimedia projects to inspire individuals, organizations, and communities to bring
about positive social change.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">From
2005 to 2007, Ms. D&#8217;Alessio served as a policy analyst and advisor for the government of Ontario, Canada.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ms.
D&#8217;Alessio received her Bachelor&#8217;s degree in International Relations from the University of Toronto in 2005; a Master&#8217;s
of Public Policy in Public Policy Administration from Queen&#8217;s University, in Kingston, Ontario in 2006; and a Juris Doctorate degree
from Southwestern Law School in Los Angeles, California in 2010.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Board of Directors believes that Ms. D&#8217;Alessio is well qualified to serve on the Board of Directors because of her extensive business
knowledge and legal expertise.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Dr.
Kenny Myers, Director</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dr.
Kenny Myers was appointed as a director of the Company effective January 13, 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Since
March 2020, Dr. Myers has served as VP of Business Development for Living Fit Nation, Inc., a corporate wellness provider which designs
and implements customized employee health and wellness programs for corporations around the United States. From March 2012 to February
2020, Dr. Myers worked as VP of Business Development at One Health Medical Systems, LLC, an integrated health services provider, where
he was responsible for overseeing the planning, development and execution of the organization&#8217;s marketing and advertising initiatives.
From May 1998 to March 2012, Dr. Myers was CEO of Texas Physicians Network, a healthcare management company where he was responsible
for the marketing and management several urgent care centers, medical clinics and other related healthcare facilities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 104 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->99<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%"><a href="#toc" title="Table of Contents" style="font-style: italic">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dr.
Myers received his Bachelor of Science degree in Microbiology from Oklahoma University in 1989, and a Doctor of Chiropractic Degree from
Parker University in Dallas, Texas in 1996.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Board of Directors believes that Dr. Myers is well qualified to serve on the Board of Directors because of his background in the health
services industry and his experience in business marketing and development.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Corporate
Governance</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company promotes accountability for adherence to honest and ethical conduct; endeavors to provide full, fair, accurate, timely and understandable
disclosure in reports and documents that the Company files with the SEC and in other public communications made by the Company; and strives
to be compliant with applicable governmental laws, rules and regulations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline">Board
Leadership Structure</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
board of directors has the responsibility for selecting the appropriate leadership structure for the Company. In making leadership structure
determinations, the board of directors considers many factors, including the specific needs of the business and what is in the best interests
of the Company&#8217;s stockholders. Our Chief Executive Officer, Mr. Cohen, currently serves as Chairman of the board of directors.
The board of directors believes that this leadership structure is the most effective and efficient for the Company at this time. Mr.
Cohen possesses detailed and in-depth knowledge of the issues, opportunities, and challenges facing the Company. The Board believes that
its programs for overseeing risk, as described below, would be effective under a variety of leadership frameworks and therefore do not
materially affect its choice of structure.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline">Risk
Oversight</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Effective
risk oversight is an important priority of the board of directors. Because risks are considered in virtually every business decision,
the board of directors discusses risk throughout the year generally or in connection with specific proposed actions. The board of directors&#8217;
approach to risk oversight includes understanding the critical risks in the Company&#8217;s business and strategy, evaluating the Company&#8217;s
risk management processes, allocating responsibilities for risk oversight, and fostering an appropriate culture of integrity and compliance
with legal responsibilities. The directors exercise direct oversight of strategic risks to the Company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 105 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->100<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%"><a href="#toc" title="Table of Contents" style="font-style: italic">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline">Family
Relationships</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">None
of our directors are related by blood, marriage, or adoption to any other director, executive officer, or other key employees.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline">Arrangements
between Officers and Directors</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
our knowledge, there is no arrangement or understanding between any of our officers and any other person, including directors, pursuant
to which the officer was selected to serve as an officer.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline">Other
Directorships</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">No
directors of the Company are also directors of issuers with a class of securities registered under Section 12 of the Exchange Act (or
which otherwise are required to file periodic reports under the Exchange Act).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline">Involvement
in Certain Legal Proceedings</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">None
of our executive officers or directors has been involved in any of the following events during the past ten years:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1) any
bankruptcy petition filed by or against any business of which such person was a general partner or executive officer either at the time
of the bankruptcy or within two years prior to that time;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2) any
conviction in a criminal proceeding or being a named subject to a pending criminal proceeding (excluding traffic violations and minor
offenses);</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3) being
subject to any order, judgment, or decree, not subsequently reversed, suspended or vacated, of any court of competent jurisdiction, permanently
or temporarily enjoining, barring, suspending or otherwise limiting his involvement in any type of business, securities or banking activities;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4) being
found by a court of competent jurisdiction (in a civil action), the SEC or the Commodities Futures Trading Commission to have violated
a federal or state securities or commodities law;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(5) being
the subject of, or a party to, any Federal or State judicial or administrative order, judgment, decree, or finding, not subsequently
reversed, suspended or vacated, relating to an alleged violation of (i) any Federal or State securities or commodities law or regulation;
(ii) any law or regulation respecting financial institutions or insurance companies, including, but not limited to, a temporary or permanent
injunction, order of disgorgement or restitution, civil money penalty or temporary or permanent cease-and-desist order, or removal or
prohibition order, or (iii) any law or regulation prohibiting mail or wire fraud or fraud in connection with any business entity; or</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 106 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->101<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%"><a href="#toc" title="Table of Contents" style="font-style: italic">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(6) being
the subject of, or a party to, any sanction or order, not subsequently reversed, suspended or vacated, of any self- regulatory organization
(as defined in Section 3(a)(26) of the Exchange Act), any registered entity (as defined in Section (1)(a)(40) of the Commodity Exchange
Act), or any equivalent exchange, association, entity, or organization that has disciplinary authority over its members or persons associated
with a member.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline">Board
of Directors and Committee Meetings</span></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the fiscal years that ended on December 31, 2021 and 2020, the Board held no meetings, but took various actions via written consent of
the board of directors.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Committees
of the Board</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Board
Committee Membership</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Independent</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Audit</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Committee</b></span></p></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Jacob D. Cohen<sup>(1)</sup></span></td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="width: 60%; text-align: left">Peter &#8220;Casey&#8221; Jensen</td><td style="width: 2%">&#160;</td>
    <td style="width: 18%; text-align: center">X</td><td style="width: 2%">&#160;</td>
    <td style="width: 18%; text-align: center">C</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Lorraine D&#8217;Alessio</td><td>&#160;</td>
    <td style="text-align: center">X</td><td>&#160;</td>
    <td style="text-align: center">M</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Dr. Kenny Myers</td><td>&#160;</td>
    <td style="text-align: center">X</td><td>&#160;</td>
    <td style="text-align: center">M</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>(1)
Chairman of Board of Directors.</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>C
- Chairman of Committee.</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>M
- Member.</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Audit
Committee</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Audit Committee, which is comprised exclusively of an independent director, has been established by the Board to oversee our accounting
and financial reporting processes and the audits of our financial statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Board has selected the members of the Audit Committee based on the Board&#8217;s determination that the members are financially literate
(as required by NASDAQ rules) and qualified to monitor the performance of management and the independent auditors and to monitor our
disclosures so that our disclosures fairly present our business, financial condition and results of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Board has also determined that Mr. Jensen, is an &#8220;<span style="text-decoration: underline">audit committee financial expert</span>&#8221; (as defined in the SEC rules)
because he has the following attributes: (i) an understanding of generally accepted accounting principles in the United States of America
(&#8220;<span style="text-decoration: underline">GAAP</span>&#8221;) and financial statements; (ii) the ability to assess the general application of such principles in connection
with accounting for estimates, accruals and reserves; (iii) experience analyzing and evaluating financial statements that present a breadth
and level of complexity of accounting issues that are generally comparable to the breadth and complexity of issues that can reasonably
be expected to be raised by our financial statements; (iv) an understanding of internal control over financial reporting; and (v) an
understanding of audit committee functions. Mr. Jensen has acquired these attributes as a result of his significant experience serving
on the board of directors of various private and public companies and as an investor and founder of a private equity firm.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 107 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->102<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%"><a href="#toc" title="Table of Contents" style="font-style: italic">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Audit Committee has the sole authority, at its discretion and at our expense, to retain, compensate, evaluate and terminate our independent
auditors and to review, as it deems appropriate, the scope of our annual audits, our accounting policies and reporting practices, our
system of internal controls, our compliance with policies regarding business conduct and other matters. In addition, the Audit Committee
has the authority, at its discretion and at our expense, to retain special legal, accounting or other advisors to advise the Audit Committee.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Other
Committees</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
Company currently does not have nominating or compensation committees or committees performing similar functions, nor does our Company
have a written nominating or compensation committee charter. Our directors believe that it is not necessary to have such committees,
at this time, because the functions of such committees can be adequately performed by our board of directors.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Our
Company does not have any defined policy or procedural requirements for stockholders to submit recommendations or nominations for directors.
Our directors believe that, given the stage of our development, a specific nominating policy would be premature and of little assistance
until our business operations develop to a more advanced level. Our Company does not currently have any specific or minimum criteria
for the election of nominees to the board of directors and we do not have any specific process or procedure for evaluating such nominees.
The board of directors will assess all candidates, whether submitted by management or stockholders, and make recommendations for election
or appointment.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Corporate
Governance</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company promotes accountability for adherence to honest and ethical conduct and strives to be compliant with applicable governmental
laws, rules and regulations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
Audit Committee is responsible for reviewing and making recommendations concerning the selection of outside auditors, reviewing the scope,
results and effectiveness of the annual audit of the Company&#8217;s financial statements and other services provided by the Company&#8217;s
independent public accountants. The Audit Committee reviews the Company&#8217;s internal accounting controls, practices and policies.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 108 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->103<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%"><a href="#toc" title="Table of Contents" style="font-style: italic">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><b>Director
Independence</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
common stock is currently quoted on the OTCQB Market maintained by OTC Markets. The OTCQB Market does not require us to have independent
members of our board of directors. Notwithstanding that, our board of directors has determined that Peter &#8220;Casey&#8221; Jensen,
Lorraine D&#8217;Alessio, and Dr. Kenny Myers are &#8220;independent&#8221; pursuant to the rules of the NASDAQ Capital Market.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
described above, we do not currently have a separately designated nominating or compensation committee.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Stockholder
Communications with the Board</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
stockholders and other interested parties may communicate with members of the Board by submitting such communications in writing to our
Corporate Secretary at 7950 Legacy Drive, Suite 400, Plano, Texas 75024, who, upon receipt of any communication other than one that is
clearly marked &#8220;<span style="text-decoration: underline">Confidential,</span>&#8221; will note the date the communication was received, open the communication, make a copy
of it for our files and promptly forward the communication to the director(s) to whom it is addressed. Upon receipt of any communication
that is clearly marked &#8220;<span style="text-decoration: underline">Confidential,</span>&#8221; our Corporate Secretary will not open the communication, but will note the
date the communication was received and promptly forward the communication to the director(s) to whom it is addressed. If the correspondence
is not addressed to any particular Board member or members, the communication will be forwarded to a Board member to bring to the attention
of the Board.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Code
of Ethics</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
June 24, 2020, our board of directors adopted a Code of Ethical Business Conduct (&#8220;<span style="text-decoration: underline">Code of Ethics</span>&#8221;) that applies to
all of our directors, officers and employees. The Code of Ethics will be available for review in print, without charge, to any stockholder
who requests a copy by writing to us at 7950 Legacy Drive, Suite 400, Plano, Texas 75024, Attention: Investor Relations. Each of our
directors, employees and officers are required to comply with the Code of Ethics.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
intend to disclose any amendments to our Code of Ethics and any waivers with respect to our Code of Ethics granted to our principal executive
officer, our principal financial officer, or any of our other employees performing similar functions on our website at amihcorp.com within
four business days after the amendment or waiver. In such case, the disclosure regarding the amendment or waiver will remain available
on our website for at least 12 months after the initial disclosure. There have been no waivers granted with respect to our Code of Ethics
to any such officers or employees.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 109 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->104<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%"><a href="#toc" title="Table of Contents" style="font-style: italic">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Policy
on Equity Ownership</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company does not have a policy on equity ownership at this time. However, as illustrated in &#8220;<a href="#ed_012">Certain Beneficial Owners and Management</a>&#8221;,
two out of our four current officers and directors are beneficial owners of stock of the Company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Policy
Against Hedging</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company recognizes that hedging against losses in Company shares may disturb the alignment between stockholders and executives that equity
awards are intended to build. Accordingly, the Company discourages &#8216;short sales&#8217; of the Company&#8217;s securities by officers,
directors and employees.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Compensation
Recovery</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
the Sarbanes&#8211;Oxley Act of 2002 (the &#8220;<span style="text-decoration: underline">Sarbanes-Oxley Act</span>&#8221;), in the event of misconduct that results in a financial
restatement that would have reduced a previously paid incentive amount, we can recoup those improper payments from our Chief Executive
Officer and Chief Financial Officer. We plan to implement a clawback policy in the future, although we have not yet implemented such
policy.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Advisory
Board</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
March 17, 2021, the Company formed an Advisory Board to provide guidance to the Board of Directors, regarding business development, marketing,
acquisitions and other growth initiatives, and on such other matters as the board of directors may from time-to-time request input and
guidance on. The Advisory Board has no authority to bind the Company or the board of directors on any matters and was formed only to
provide the director(s) non-binding guidance and advice as requested by the Directors from time to time.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
March 17, 2021, the board of directors appointed Mr. Kevin Harrington to the newly formed Advisory Board. The Advisory Board&#8217;s
mandate is to provide guidance to the Board of Directors regarding business development, marketing, acquisitions, other strategic initiatives
and other matters as may be requested. As of the date of this report, Mr. Harrington is the sole member of the Company&#8217;s Advisory
Board.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Whistleblower
Protection Policy</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company adopted a Whistleblower Protection Policy (&#8220;<span style="text-decoration: underline">Whistleblower Policy</span>&#8221;) that applies to all of its directors, officers,
employees, consultants, contractors and agents of the Company. The Whistleblower Policy has been reviewed and approved by the Board.</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 110 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->105<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%"><a href="#toc" title="Table of Contents" style="font-style: italic">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><b>&#160;</b></span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="ed_024"></span>Executive
and Director Compensation</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table sets forth information concerning the compensation of (i) all individuals serving as our principal executive officer
or acting in a similar capacity during the last completed fiscal year (&#8220;<span style="text-decoration: underline">PEO</span>&#8221;), regardless of compensation level; (ii)
our two most highly compensated executive officers other than the PEO who were serving as executive officers at the end of the last completed
fiscal year, if any; and (iii) up to two additional individuals for whom disclosure would have been provided pursuant to paragraph (ii)
but for the fact that the individual was not serving as an executive officer at the end of the last completed fiscal year (collectively,
the &#8220;<span style="text-decoration: underline">Named Executive Officers</span>&#8221;).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Name and Principal Position</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Fiscal Year Ended<br /> December 31</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Salary ($)(1)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Bonus ($)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Stock Award (s) *</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Option Awards *</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">All Other Compensation(5)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 37%; text-align: left">Jacob D. Cohen, President and CEO</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 5%; text-align: right">2021</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 5%; text-align: right">150,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 5%; text-align: right">&#8212;</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 5%; text-align: right">950,000</td><td style="width: 1%; text-align: left">(4)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 5%; text-align: right">&#8212;</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 5%; text-align: right">18,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 5%; text-align: right">1,118,000</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2020</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">120,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">780,000</td><td style="text-align: left">(3)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">900,000</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Alejandro Rodriguez CEO, EPIQ MD, Inc.</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2021</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">115,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">1,520,000</td><td style="text-align: left">(6)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">1,635,000</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Verdie Bowen COO, EPIQ MD, Inc.</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2021</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">60,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">570,000</td><td style="text-align: left">(7)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">630,000</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Esteban Alexander, Former COO (2)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2020</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">100,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">780,000</td><td style="text-align: left">(3)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">880,000</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Alan Hernandez, Former CMO (2)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2020</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">100,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">100,000</td><td style="text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Does
not include perquisites and other personal benefits, or property, unless the aggregate amount of such compensation is more than $10,000.
No executive officer earned any non-equity incentive plan compensation or nonqualified deferred compensation during the periods reported
above. There have been no changes in the Company&#8217;s compensation policies since December 31, 2021.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*
The fair value of stock issued for services computed in accordance with Financial Accounting Standards Board Accounting Standards Codification
Topic 718 on the date of grant. The fair value of options granted computed in accordance with Financial Accounting Standards Board Accounting
Standards Codification Topic 718 on the date of grant.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)&#8239;$53,500,
$25,000 and $25,000 has been accrued to each of Messrs. Cohen, Alexander and Hernandez, respectively, which remains unpaid as of the
date of this prospectus.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 111 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->106<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%"><a href="#toc" title="Table of Contents" style="font-style: italic">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)
On December 15, 2020, (a) Esteban Alexander, the Chief Operating Officer and member of the board of directors of the Company and (b)
Luis Alan Hernandez, the Chief Marketing Officer and member of the board of directors of the Company, each provided notice to the board
of directors of the Company of their resignation from their respective officer and Board positions, effective December 15, 2020.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)
Represents the value of 3,000,000 shares of common stock issued on May 22, 2020, valued at $0.26 per share, in consideration for services
rendered.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4)
Represents the value of 2,500,000 shares of common stock issued on January 22, 2021, valued at $0.38 per share, in consideration for
services rendered.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(5)
Represents an automobile allowance of $1,500 per month pursuant to the terms of Mr. Cohen&#8217;s employment agreement, dated April 12,
2019.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(6)
Represents the value of 4,000,000 shares of common stock issued on January 22, 2021, valued at $0.38 per share, in consideration for
services rendered.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(7)
Represents the value of 1,500,000 shares of common stock issued on January 22, 2021, valued at $0.38 per share, in consideration for
services rendered.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Employment
Agreements</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Employment
Agreement of Jacob D. Cohen, Chief Executive Officer</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.65pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Concurrent
with the Share Exchange Agreement entered into on April 12, 2019, Jacob D. Cohen (&#8220;<span style="text-decoration: underline">Mr. Cohen</span>&#8221; or the &#8220;<span style="text-decoration: underline">Executive</span>&#8221;)
entered into an Executive Employment Agreement with the Company (the &#8220;<span style="text-decoration: underline">Executive Employment Agreement</span>&#8221;). Effective
on January 12, 2022, the Company entered into a new employment agreement with Mr. Cohen, which replaced and superseded the Executive
Employment Agreement (the &#8220;<span style="text-decoration: underline">New Employment Agreement</span>&#8221;).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.65pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.65pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
New Employment Agreement, which provides for Mr. Cohen to continue to serve as the Company&#8217;s Chief Executive Officer, has a three-year
term expiring January 12, 2025, provided that the New Employment Agreement automatically extends for additional one year terms thereafter
in the event neither party provides the other at least 60 days prior notice of their intention not to renew the terms of the agreement.
The New Employment Agreement also requires the Board, subject to certain exceptions, to nominate Mr. Cohen to serve on the Board at each
stockholders&#8217; meeting which occurs during the term of the New Employment Agreement and to serve as the Chairman of the Board.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.65pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 112 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->107<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%"><a href="#toc" title="Table of Contents" style="font-style: italic">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.65pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the terms of the New Employment Agreement, Mr. Cohen&#8217;s annual compensation package includes (1) a base salary of $180,000 per
year, subject to automatic $60,000 annual increases beginning December 31, 2022 and on each December 31 thereafter, along with such other
increases as may be determined in the sole discretion of the Board from time to time (the &#8220;<span style="text-decoration: underline">Base Salary</span>&#8221;); (2) a yearly
incentive bonus (&#8220;<span style="text-decoration: underline">Incentive Bonus</span>&#8221;) equal to 10% of the net income of the Company and its current and existing and
subsequently acquired or organized subsidiaries, determined annually on a consolidated basis by the Company&#8217;s independent accounting
firm; and (3) an award of 5,000,000 restricted shares of the Company&#8217;s common stock as a signing bonus in consideration of Mr.
Cohen entering into the New Employment Agreement. Mr. Cohen may also receive additional bonuses awarded from time to time in the discretion
of the Board and/or Compensation Committee (if any) in cash, stock or other equity consideration, and the Board of Directors may also
increase Mr. Cohen&#8217;s salary from time to time, with or without amending the New Employment Agreement, in its discretion. Mr. Cohen
is also paid an automobile allowance of $1,500 per month during the term of the New Employment Agreement and is eligible to participate
in our stock option plan and other benefit plans.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.65pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
agreement prohibits Mr. Cohen from competing against us during the term of the agreement and for a period of twelve months after the
termination of the agreement in any state and any other geographic area in which we or our Subsidiaries provide Restricted Services or
Restricted Products, directly or indirectly, during the twelve months preceding the date of the termination of the agreement. &#8220;<span style="text-decoration: underline">Restricted
Services</span>&#8221; means any online, direct-to-consumer subscription-based telemedicine or life-coaching platform, and any other services
that we or our subsidiaries have provided or are researching, developing, performing and/or providing at any time during the two years
immediately preceding the date of termination, or which Mr. Cohen has obtained any trade secret or other confidential information about
at any time during the two years immediately preceding the date of termination of the agreement. &#8220;<span style="text-decoration: underline">Restricted Products</span>&#8221;
means pharmaceutical drugs and other healthcare products and any other product, that we or our subsidiaries have provided or are researching,
developing, manufacturing, distributing, purchasing, selling and/or providing at any time during the two years immediately preceding
the date the agreement is terminated, or which Mr. Cohen obtained any trade secret or other confidential information in connection with
at any time during the two years immediately preceding the date of termination of the agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may terminate Mr. Cohen&#8217;s employment (a) for &#8220;<span style="text-decoration: underline">cause</span>&#8221; (which is defined to include, a material breach of the
agreement by Mr. Cohen, any act of misappropriation of funds or embezzlement by Mr. Cohen, Mr. Cohen committing any act of fraud, or
Mr. Cohen being indicted of, or pleading guilty or nolo contendere with respect to, theft, fraud, a crime involving moral turpitude,
or a felony under federal or applicable state law); (b) in the event Mr. Cohen suffers a physical or mental disability which renders
him unable to perform his duties and obligations for either 90 consecutive days or 180 days in any 12-month period; (c) for any reason
without &#8220;<span style="text-decoration: underline">cause</span>&#8221;; or (d) upon expiration of the initial term of the agreement (or any renewal) upon notice as provided
above. The agreement also automatically terminates upon the death of Mr. Cohen.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 113 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->108<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%"><a href="#toc" title="Table of Contents" style="font-style: italic">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mr.
Cohen may terminate his employment (a) for &#8220;<span style="text-decoration: underline">good reason</span>&#8221; (i.e., (i) if his position or duties are modified to such
an extent that his duties are no longer consistent with the position of CEO of the Company, (ii) there has been a material breach by
us of a material term of the agreement or Mr. Cohen reasonably believes that we are violating any law which would have a material adverse
effect on our operations and such violation continues uncured thirty days after such breach and after notice thereof has been provided
to us by Mr. Cohen, (iii) Mr. Cohen&#8217;s compensation is reduced without his consent, or we fail to pay to Mr. Cohen any compensation
due to him upon five days written notice from Mr. Cohen informing us of such failure, (iv) if the Company&#8217;s headquarters are relocated
to a location more than thirty-five (35) miles from the Company&#8217;s current headquarters in Plano, Texas, without his consent, or
(v) if Mr. Cohen is also then serving as a member of the Board and is not re-nominated by the Board to serve as a member of the Board
at any annual meeting of stockholders of the Company; provided, however, prior to any such termination by Mr. Cohen for &#8220;<span style="text-decoration: underline">good
reason</span>&#8221;, Mr. Cohen must first advise us in writing (within 15 days of the occurrence of such event) and provide us 15 days
to cure (5 days in connection with the reduction of Mr. Cohen&#8217;s salary or the failure to pay amounts owed to him)); (b) for any
reason without &#8220;<span style="text-decoration: underline">good reason</span>&#8221;; and (c) upon expiration of the initial term of the agreement (or any renewal) upon notice
as provided above.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the event that Mr. Cohen&#8217;s employment is terminated for any reason (not including, however, a termination by us for &#8220;cause&#8221;
or a termination as a result of Mr. Cohen&#8217;s death or disability) during the twelve month period following a Change of Control (a
&#8220;<span style="text-decoration: underline">Change of Control Termination</span>&#8221;) or in anticipation of a Change of Control, we are required to pay Mr. Cohen, within
60 days following the later of (i) the date of such Change of Control Termination; and (ii) the date of such Change of Control, a cash
severance payment in a lump sum in an amount equal to 3.0 times the sum of his current base salary and the amount of the last bonus payable
to Mr. Cohen (the &#8220;<span style="text-decoration: underline">Change of Control Payment</span>&#8221;), which amount is due within 60 days of the later of (i) the date of
such Change of Control Termination; and (ii) the date of such Change of Control. If Mr. Cohen&#8217;s employment terminates due to a
Change of Control Termination within six (6) months prior to a Change of Control, it will be deemed to be &#8220;in anticipation of a
Change of Control&#8221; for all purposes. In addition, in the event of a Change of Control, all of Mr. Cohen&#8217;s equity-based compensation
immediately vests to Mr. Cohen and any outstanding stock options held by Mr. Cohen can be exercised by Mr. Cohen until the earlier of
(A) one (1) year from the date of termination and (B) the latest date upon which such stock options would have expired by their original
terms under any circumstances, provided that if Mr. Cohen&#8217;s employment ends in anticipation of a Change of Control and such equity-based
compensation awards or stock options have previously expired pursuant to their terms, the Company is required to pay Mr. Cohen a lump
sum payment, payable on the same date as the Change of Control Payment, equal to the black scholes value of the expired and unexercised
equity compensation awards and stock options held by Mr. Cohen on the date of termination, based on the value of such awards had they
been exercisable through the end of their stated term and had not previously expired. &#8220;<span style="text-decoration: underline">Change of Control</span>&#8221; for the
purposes of the agreement means: (a) any person obtaining beneficial ownership representing more than 50% of the total voting power represented
by our then outstanding voting securities without the approval of not fewer than two-thirds of our Board of Directors; (b) a merger or
consolidation of us whether or not approved by our Board of Directors, other than a merger or consolidation that would result in our
voting securities immediately prior thereto continuing to represent at least 50% of the total voting power outstanding immediately after
such merger or consolidation, (c) our stockholders approving a plan of complete liquidation or an agreement for the sale or disposition
by us of all or substantially all of our assets, or (d) as a result of the election of members to our Board of Directors, a majority
of the Board of Directors consists of persons who are not members of the Board of Directors on January 12, 2022, except in the event
that such slate of directors is proposed by a committee of the Board or the Board; provided that if the definition of &#8220;<span style="text-decoration: underline">Change
of Control</span>&#8221; in our Stock Incentive Plans or Equity Compensation Plans is more favorable than the definition above, then such
definition shall be controlling.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 114 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->109<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%"><a href="#toc" title="Table of Contents" style="font-style: italic">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
Mr. Cohen&#8217;s employment is terminated pursuant to his death or disability, (i) all salary, vacation days, and bonuses accrued through
the termination date will be paid to Mr. Cohen&#8217;s estate or beneficiaries or to Mr. Cohen, as applicable, in cash within 30 days
of the termination date; (ii) 100% of Mr. Cohen&#8217;s then current annual Base Salary, as in effect on the date the agreement is terminated
(the &#8220;<span style="text-decoration: underline">Termination Date</span>&#8221;), will be paid to Mr. Cohen&#8217;s estate or beneficiaries or to Mr. Cohen, as applicable,
in cash when due under Texas law; (iii) the pro rata amount of any discretionary bonus and performance bonus he would have been due for
the year in which the termination date occurred will be paid to Mr. Cohen&#8217;s estate or beneficiaries or to Mr. Cohen, as applicable,
at the time when annual bonuses are paid to the Company&#8217;s other senior executives for that fiscal year; (iv) Mr. Cohen and his
eligible family members will continue to be provided with group health insurance coverage at least equal to that which would have been
provided to them if Mr. Cohen&#8217;s employment had not been terminated (or at the Company&#8217;s election, pay the applicable COBRA
premium for such coverage), subject to certain rights which reduce such obligation if Mr. Cohen is covered by health insurance with a
substantially similar level of insurance as prior to the termination; and (v) any vested benefits which Mr. Cohen is required or eligible
to receive as of the termination date under any plan, contract or agreement of the Company and its affiliates will be paid or provided
to Mr. Cohen&#8217;s estate or beneficiaries or to Mr. Cohen, as applicable, on a timely basis.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
Mr. Cohen&#8217;s employment is terminated pursuant to the end of the initial term (or any renewal term), without &#8220;<span style="text-decoration: underline">good reason</span>&#8221;
by Mr. Cohen, or by us for &#8220;<span style="text-decoration: underline">cause</span>&#8221;, Mr. Cohen is entitled to all salary accrued through the termination date and no
other benefits other than as required under the terms of employee benefit plans in which Mr. Cohen was participating as of the termination
date. Additionally, any unvested stock options or equity compensation held by Mr. Cohen immediately terminate and are forfeited (unless
otherwise provided in the applicable award) and any previously vested stock options (or if applicable equity compensation) are subject
to the terms and conditions set forth in the applicable Stock Incentive Plan or Equity Compensation Plan, or award agreement, as such
may describe the rights and obligations upon termination of employment of Mr. Cohen.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 115 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->110<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%"><a href="#toc" title="Table of Contents" style="font-style: italic">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
Mr. Cohen&#8217;s employment is terminated by Mr. Cohen for &#8220;<span style="text-decoration: underline">good reason</span>&#8221;, or by us without &#8220;<span style="text-decoration: underline">cause</span>&#8221;,
(i) Mr. Cohen will be paid, in two lump sum payments, (a) all salary, vacation days, and bonuses accrued through the termination date,
payable when due under Texas law, and (b) an amount, payable within 60 days after the termination date, equal to 3.0 times (the &#8220;<span style="text-decoration: underline">Severance
Multiple</span>&#8221;) the sum of (1) the Base Salary then in effect plus (2) the average Incentive Bonus and Discretionary Bonus received
by Mr. Cohen for the Company&#8217;s one or two most recent complete fiscal years, as applicable at the time of the termination (or,
if termination occurs during the first year of employment, a prorated amount), provided that, if less than one year remains in the term
of the agreement after the termination date, the Severance Multiple will be 1.0; (ii) the pro rata amount of any discretionary bonus
and performance bonus he would have been due for the year in which the termination date occurred will be paid to Mr. Cohen at the time
when annual bonuses are paid to the Company&#8217;s other senior executives for that fiscal year; and (iii) Mr. Cohen and his eligible
family members will continue to be provided with group health insurance coverage at least equal to that which would have been provided
to them if Mr. Cohen&#8217;s employment had not been terminated (or at the Company&#8217;s election, pay the applicable COBRA premium
for such coverage), subject to certain rights which reduce such obligation if Mr. Cohen is covered by health insurance with a substantially
similar level of insurance as prior to the termination. Additionally, unvested benefits (whether equity or cash benefits and bonuses)
will vest immediately upon such termination and any outstanding stock options previously granted to Mr. Cohen will vest immediately upon
such termination and will be exercisable until the earlier of (A) one year from the date of termination and (B) the latest date upon
which such stock options would have expired by their original terms under any circumstance. Mr. Cohen will also receive any other benefits
payable under any other benefit plans in which he is entitled to participate through the termination date, subject to and in accordance
with the terms of such plans.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
agreement contains standard assignment of inventions, indemnification and confidentiality provisions. Further, Mr. Cohen is subject to
non-solicitation covenants during the term of the agreement and for twelve months thereafter. Although Mr. Cohen will be prohibited from
competing with us while he is employed with us, he will only be prohibited from competing for twelve months after his employment with
us ends pursuant to the agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Employment
Agreement of Dr. Craig Hewitt, Chief Financial Officer</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
February 11, 2022, and effective on March 30, 2022, the Company entered into a Confidential Employment Offer Letter and Summary of Terms
and Conditions with Dr. Craig Hewitt (the &#8220;<span style="text-decoration: underline">Employment Agreement</span>&#8221;).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the Employment Agreement, Dr. Hewitt agreed to serve as Chief Financial Officer (&#8220;<span style="text-decoration: underline">CFO</span>&#8221;) of the Company. In his
role as CFO Dr. Hewitt&#8217;s responsibilities include, but are not limited to, (i) creating, coordinating, and evaluating the financial
programs and supporting information systems of the Company to include budgeting, tax planning, and conservation of assets; (ii) assisting
the Company by providing all information necessary in connection with the Company&#8217;s becoming listed on NASDAQ; (iii) creating investment
related documentation and presenting to prospective investors for both debt and equity financings; (iv) developing an organizational
chart and layout for the Company; (v) assist in the hiring and development of key individuals across the Company and its subsidiaries;
(vi) directing financial audits and providing recommendations for procedural improvements; (vii) approving and coordinating changes and
improvements in automated financial and management information systems for the Company; (viii) ensuring compliance with local, state,
and federal budgetary reporting requirements; (ix) coordinating the preparation of financial statements, financial reports, tax returns,
special analyses, and information reports; (x) developing and implementing finance, accounting, billing, and auditing procedures; (xi)
establishing and maintaining appropriate internal control safeguards; (xii) interacting with other managers to provide consultative support
to planning initiatives through financial and management information analyses, reports, and recommendations; (xiii) ensuring records
systems are maintained in accordance with generally accepted auditing standards; (xiv) developing and directing the implementation of
strategic business and/or operational plans, projects, programs, and systems; (xv) reviewing, analyzing, and structuring all potential
M&amp;A activity for the Company; (xvi) analyzing cash flow, cost controls, and expenses to guide business leaders; (xvii) analyzing
financial statements to pinpoint potential weak areas; (xviii) establishing and implementing short and long-range departmental goals,
objectives, policies, and operating procedures; (xix) serving on planning and policy-making committees; and (xx) representing the Company
externally to media, government agencies, funding agencies, and the general public.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 116 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->111<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%"><a href="#toc" title="Table of Contents" style="font-style: italic">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
consideration for performing such services, which require that Dr. Hewitt allocate his full business efforts to the Company, the Company
agreed to pay Dr. Hewitt a starting salary of $48,000 per year, which will be increased to $120,000 if and when the Company achieves
a successful uplisting to a national exchange (NASDAQ or NYSE). Additionally, Dr. Hewitt will be eligible to participate in other performance
base incentives, benefits, employee stock option plans of the Company. Dr. Hewitt will initially work remotely from his home in Tennessee,
but may be required to relocate to the Dallas-Fort Worth area upon the Company&#8217;s common stock being listed on a national exchange.
Dr. Hewitt&#8217;s employment agreement also contains confidentiality terms and requires Dr. Hewitt to enter into a confidentiality and
non-disclosure agreement with the Company in connection with his employment by the Company. Dr. Hewitt may also receive additional bonuses
awarded from time to time in the discretion of the Board and/or Compensation Committee (if any) in cash, stock or other equity consideration,
and the Board of Directors may also increase Mr. Hewitt&#8217;s salary from time to time, with or without amending the Employment Agreement,
in its discretion.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Employment
Agreement of Alejandro Rodriguez, Chief Executive Officer of EPIQ MD, Inc.</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
January 21, 2021, we entered into an Executive Employment Agreement with Alejandro Rodriguez, pursuant to which Mr. Rodriguez agreed
to serve as the Chief Executive Officer of EPIQ MD, Inc. (&#8220;<span style="text-decoration: underline">EPIQ MD</span>&#8221;), a newly formed wholly-owned Texas subsidiary
of the Company. The agreement has an initial term of three years, beginning on January 1, 2021, provided that the agreement automatically
extends for additional one-year terms thereafter in the event neither party provides the other at least 60 days prior notice of their
intention not to renew the terms of the agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the terms of the agreement, Mr. Rodriguez&#8217;s annual compensation package includes annual base compensation of $90,000 for the
first three months, which increases to an annual base salary of $120,000 commencing April 1, 2021, throughout the initial term of this
agreement, provided that the annual salary increases to $240,000 upon Mr. Rodriguez and EPIQ MD achieving the First Performance Benchmarks
(defined below), and increases to $500,000 upon achieving the Second Performance Benchmark (defined below).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 117 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->112<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%"><a href="#toc" title="Table of Contents" style="font-style: italic">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
&#8220;<span style="text-decoration: underline">First Performance Benchmarks</span>&#8221; are defined as the (a) launch the EPIQ MD Ambassador Program (defined below); (b) EPIQ
MD enrolling 10,000 active customers; (c) EPIQ MD enrolling 50,000 active customers by May 31, 2022; and (d) EPIQ MD enrolling 100,000
active customers by March 31, 2023. The &#8220;<span style="text-decoration: underline">Second Performance Benchmark</span>&#8221; is defined as EPIQ MD enrolling 200,000 active
customers by March 31, 2024. &#8220;<span style="text-decoration: underline">Launching of the Ambassador Program</span>&#8221; means the commencement and implementation of the
direct-sales campaign wherein independent contractors will become sales agents of EPIQ MD for the purposes of soliciting and procuring
end-use customers for EPIQ MD&#8217;s telemedicine services. As of the date of this prospectus, none of the First Performance Benchmarks
or the Second Performance Benchmarks have been achieved.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
additional consideration pursuant to the agreement, the Company agreed to issue Mr. Rodriguez (a) 4,000,000 shares of restricted common
stock, subject to forfeiture and vesting, of which 2,000,000 shares will vest upon the Launching of the Ambassador Program; 1,200,000
shares will vest upon EPIQ MD reaching the 5,000 active customer mark; and the remaining 800,000 shares will vest upon EPIQ MD reaching
the 10,000 active customer mark, provided that all shares vest if the Company uplists its common stock to a higher trading exchange;
and (b) together with other senior executives of EPIQ MD, up to 33% of the ownership of EPIQ MD, due as follows: 10% if Section (a) of
the First Performance Benchmarks are met; 5% if Section (b) of the First Performance Benchmarks are met; 5% if Section (c) of the First
Performance Benchmarks are met; 5% if Section (d) of the First Performance Benchmarks are met; and 8% if the Second Performance Benchmark
is met, which shares shall vest immediately if EPIQ MD completes a spin-off, up-listing and/or a change of control event.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
board of directors and/or Compensation Committee (if any) may also authorize bonuses payable to Mr. Rodriguez from time to time in their
discretion, in cash or securities, and the Board of Directors may also increase Mr. Rodriguez&#8217;s salary from time to time, with
or without amending the employment agreement, in its discretion.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
agreement prohibits Mr. Rodriguez from competing against us during the term of the agreement and for a period of twelve months after
the termination of the agreement in any state and any other geographic area in which we or our subsidiaries provide Nutraceutical products
or services, directly or indirectly, during the twelve months preceding the date of the termination of the agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may terminate Mr. Rodriguez&#8217;s employment (a) for &#8220;<span style="text-decoration: underline">cause</span>&#8221; (which is defined to include, a material breach of
the agreement by Mr. Rodriguez, any act of misappropriation of funds or embezzlement by Mr. Rodriguez, Mr. Rodriguez committing any act
of fraud, or Mr. Rodriguez being indicted of, or pleading guilty or nolo contendere with respect to, theft, fraud, a crime involving
moral turpitude, or a felony under federal or applicable state law); (b) in the event Mr. Rodriguez suffers a physical or mental disability
which renders him unable to perform his duties and obligations for either 90 consecutive days or 180 days in any 12-month period; (c)
for any reason without &#8220;<span style="text-decoration: underline">cause</span>&#8221;; or (d) upon expiration of the initial term of the agreement (or any renewal) upon
notice as provided above. The agreement also automatically terminates upon the death of Mr. Rodriguez.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 118 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->113<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%"><a href="#toc" title="Table of Contents" style="font-style: italic">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mr.
Rodriguez may terminate his employment (a) for &#8220;<span style="text-decoration: underline">good reason</span>&#8221; (i.e., (i) if his position or duties are modified to
such an extent that his duties are no longer consistent with the position of CEO of EPIQ MD, (ii) there has been a material breach by
us of a material term of the agreement or Mr. Rodriguez reasonably believes that we are violating any law which would have a material
adverse effect on our operations and such violation continues uncured thirty days after such breach and after notice thereof has been
provided to us by Mr. Rodriguez, or (iii) Mr. Rodriguez&#8217;s compensation is reduced without his consent, or we fail to pay to Mr.
Rodriguez any compensation due to him upon 15 days written notice from Mr. Rodriguez informing us of such failure); provided, however,
prior to any such termination by Mr. Rodriguez for &#8220;<span style="text-decoration: underline">good reason</span>&#8221;, Mr. Rodriguez must first advise us in writing (within
15 days of the occurrence of such event) and provide us 15 days to cure (15 days in connection with the reduction of Mr. Rodriguez&#8217;s
salary or the failure to pay amounts owed to him)); (b) for any reason without &#8220;<span style="text-decoration: underline">good reason</span>&#8221;; and (c) upon expiration
of the initial term of the agreement (or any renewal) upon notice as provided above.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
Mr. Rodriguez&#8217;s employment is terminated by Mr. Rodriguez for &#8220;<span style="text-decoration: underline">good reason</span>&#8221;, or by us without &#8220;<span style="text-decoration: underline">cause</span>&#8221;,
Mr. Rodriguez is entitled to continue to receive the salary due pursuant to the terms of the agreement at the rate in effect upon the
termination date for six (6) months and we are required to pay 12 months of Mr. Rodriguez&#8217;s COBRA expenses.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
agreement contains standard assignment of inventions, indemnification, confidentiality and arbitration provisions. Further, Mr. Rodriguez
is subject to non-solicitation covenants during the term of the agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Employment
Agreement of Verdie Bowen, President and Chief Operating Officer of EPIQ MD, Inc.</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
January 21, 2021, we entered into an Executive Employment Agreement with Verdie Bowen, pursuant to which Mr. Bowen agreed to serve as
the President and Chief Operating Officer of EPIQ MD. The agreement has an initial term of three years, beginning on January 1, 2021,
provided that the agreement automatically extends for additional one-year terms thereafter in the event neither party provides the other
at least 60 days prior notice of their intention not to renew the terms of the agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the terms of the agreement, Mr. Bowen&#8217;s annual compensation package includes base annual compensation of $60,000 for the first
three months, which increases to an annual base salary of $120,000 commencing April 1, 2021 throughout the initial term of this agreement,
provided that the annual increases to $240,000 upon Mr. Bowen and EPIQ MD achieving 10,000 active customers.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 119 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->114<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%"><a href="#toc" title="Table of Contents" style="font-style: italic">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
additional consideration pursuant to the agreement, the Company agreed to issue Mr. Bowen (a) 1,500,000 shares of restricted Company
common stock, subject to forfeiture and vesting, of which 500,000 shares vest upon the Launching of the Ambassador Program; 500,000 vest
upon EPIQ MD reaching the 5,000 active customer mark; and 500,000 vesting upon EPIQ MD reaching the 10,000 active customer mark, provided
that all shares shall vest if the Company&#8217;s common stock is uplisted to a higher trading exchange; and (b) up to 750,000 shares
of EPIQ MD, upon reaching certain milestones, which vest immediately if EPIQ MD completes a spin-off, up-listing and/or a change of control
event. As of the date of this prospectus, none of these benchmarks have been achieved.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
board of directors and/or Compensation Committee (if any) may also authorize bonuses payable to Mr. Bowen from time to time in their
discretion, in cash or securities, and the Board of Directors may also increase Mr. Bowen&#8217;s salary from time to time, with or without
amending the employment agreement, in its discretion.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
agreement prohibits Mr. Bowen from competing against us during the term of the agreement and for a period of twelve months after the
termination of the agreement in any state and any other geographic area in which we or our subsidiaries provide Nutraceutical products
or services, directly or indirectly, during the twelve months preceding the date of the termination of the agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may terminate Mr. Bowen&#8217;s employment (a) for &#8220;<span style="text-decoration: underline">cause</span>&#8221; (which is defined to include, a material breach of the
agreement by Mr. Bowen, any act of misappropriation of funds or embezzlement by Mr. Bowen, Mr. Bowen committing any act of fraud, or
Mr. Bowen being indicted of, or pleading guilty or nolo contendere with respect to, theft, fraud, a crime involving moral turpitude,
or a felony under federal or applicable state law); (b) in the event Mr. Bowen suffers a physical or mental disability which renders
him unable to perform his duties and obligations for either 90 consecutive days or 180 days in any 12-month period; (c) for any reason
without &#8220;<span style="text-decoration: underline">cause</span>&#8221;; or (d) upon expiration of the initial term of the agreement (or any renewal) upon notice as provided
above. The agreement also automatically terminates upon the death of Mr. Bowen.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mr.
Bowen may terminate his employment (a) for &#8220;<span style="text-decoration: underline">good reason</span>&#8221; (i.e., (i) if his position or duties are modified to such
an extent that his duties are no longer consistent with the position of President and Chief Operating Officer of EPIQ MD, (ii) there
has been a material breach by us of a material term of the agreement or Mr. Bowen reasonably believes that we are violating any law which
would have a material adverse effect on our operations and such violation continues uncured thirty days after such breach and after notice
thereof has been provided to us by Mr. Bowen, or (iii) Mr. Bowen&#8217;s compensation is reduced without his consent, or we fail to pay
to Mr. Bowen any compensation due to him upon 15 days written notice from Mr. Bowen informing us of such failure); provided, however,
prior to any such termination by Mr. Bowen for &#8220;<span style="text-decoration: underline">good reason</span>&#8221;, Mr. Bowen must first advise us in writing (within 15
days of the occurrence of such event) and provide us 15 days to cure (15 days in connection with the reduction of Mr. Bowen&#8217;s salary
or the failure to pay amounts owed to him)); (b) for any reason without &#8220;<span style="text-decoration: underline">good reason</span>&#8221;; and (c) upon expiration of
the initial term of the agreement (or any renewal) upon notice as provided above.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 120 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->115<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%"><a href="#toc" title="Table of Contents" style="font-style: italic">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
Mr. Bowen&#8217;s employment is terminated by Mr. Bowen for &#8220;<span style="text-decoration: underline">good reason</span>&#8221;, or by us without &#8220;<span style="text-decoration: underline">cause</span>&#8221;,
Mr. Bowen is entitled to continue to receive the salary due pursuant to the terms of the agreement at the rate in effect upon the termination
date for six (6) months or otherwise until such obligation ceases and we are required to pay 12 months of Mr. Bowen&#8217;s COBRA expenses.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
agreement contains standard assignment of inventions, indemnification, confidentiality and arbitration provisions. Further, Mr. Bowen
is subject to non-solicitation covenants during the term of the agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Employment
Agreements with Maja Matthews and Sultan Haroon of Epiq Scripts, LLC</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Effective
on March 4, 2022, EPIQ Scripts entered into employment agreements with Maja Matthews and Sultan Haroon (each an &#8220;<span style="text-decoration: underline">Employee</span>&#8221;
or collectively, the &#8220;<span style="text-decoration: underline">Employees</span>&#8221;).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
agreements are substantially identical, except that Mr. Matthews&#8217; agreement provides for Mr. Matthews to serve as EPIQ Scripts&#8217;
Director of Business Development and provides for compensation of $125,000 per year; and Mr. Haroon&#8217;s agreement provides for him
to serve as EPIQ Scripts&#8217; Director of Business Operations and provides for compensation of $100,000 per year.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Each
agreement has a one-year term expiring March 4, 2023, provided that the term of each of the agreements automatically extends on a year-to-year
basis thereafter, in the event neither party provides the other at least 30 days prior notice of their intention not to renew the terms
of the agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
terms of each agreement are discussed below:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
agreement prohibits the Employee from competing against us during the term of the agreement and for a period of twelve months after the
termination of the agreement which generally restricts their ability to compete against us in any state and any other geographic area
in which we or our subsidiaries provide services or products or in connection with any confidential information obtained from the Company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may terminate the Employee&#8217;s employment (a) for &#8220;<span style="text-decoration: underline">cause</span>&#8221; (which is defined to include, a material breach of the
agreement by the Employee (subject to a 20 day cure right), any act of misappropriation of funds or embezzlement by the Employee, the
Employee committing any act of fraud, or the Employee being indicted of, or pleading guilty or nolo contendere with respect to, theft,
fraud, a crime involving moral turpitude, or a felony under federal or applicable state law); (b) in the event the Employee suffers a
physical or mental disability which renders him unable to perform his duties and obligations for either 90 consecutive days or 180 days
in any 12-month period; (c) for any reason without &#8220;<span style="text-decoration: underline">cause</span>&#8221;; or (d) upon expiration of the initial term of the agreement
(or any renewal) upon notice as provided above. The agreement also automatically terminates upon the death of the Employee.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 121 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->116<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%"><a href="#toc" title="Table of Contents" style="font-style: italic">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Employee may terminate his employment (a) for &#8220;<span style="text-decoration: underline">good reason</span>&#8221;, including (i) if there has been a material breach by
the Company of a material term of the agreement or Employee reasonably believes that the Company is violating any law which would have
a material adverse effect on the Company&#8217;s operations and such violation continues uncured following twenty days after such breach
and after notice thereof has been provided to the Company by the Employee, or (ii) Employee&#8217;s compensation is reduced without Employee&#8217;s
consent, or the Company fails to pay to Employee any compensation due to him upon five days written; or (b) for any reason without &#8220;<span style="text-decoration: underline">good
reason</span>&#8221;; and (c) upon expiration of the initial term of the agreement (or any renewal) upon notice as provided above.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
the Employee&#8217;s employment is terminated pursuant to his death, his disability, by the Company for cause, by the Employee without
&#8220;good reason&#8221;, or the end of the initial term or any renewal term, the Employee is entitled to salary accrued through the
dated of termination and no other benefits other than as required under the terms of employee benefit plans in which Employee was participating
as of the termination date.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
the Employee&#8217;s employment is terminated for &#8220;good reason&#8221; or without cause by the Company, the Employee is entitled
to continue to receive the base salary due under the agreement at the rate in effect upon the termination of the agreement, for four
months following such termination, payable in accordance with the Company&#8217;s normal payroll practices and policies, as if Employee&#8217;s
employment had not terminated.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
agreements contain standard assignment of inventions, indemnification and confidentiality provisions. Further, each Employee is subject
to non-solicitation covenants during the term of the agreement and for twelve months thereafter. Although the Employees will be prohibited
from competing with us while they are employed with us, they will only be prohibited from competing for twelve months after their employment
with us ends pursuant to the agreements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Consulting
Agreement</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
March 8, 2021, we entered into a Consulting Agreement with KBHS, LLC (&#8220;<span style="text-decoration: underline">KBHS</span>&#8221;), whose Chief Executive Officer is Mr.
Kevin Harrington, who has been appointed as the sole member of our Advisory Board.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the Consulting Agreement, KBHS agreed to provide consulting services to the Company as the Company&#8217;s Brand Ambassador, including
providing endorsement services and advising on marketing, promotions, acquisitions, licensing and business development. KBHS also agreed
to up to four webinar appearances on behalf of the Company per year to support the Company&#8217;s direct sales efforts. The Consulting
Agreement has a term of two years, and can be terminated with ten days prior written notice (subject to applicable cure rights set forth
in the Consulting Agreement), in the event we or KBHS breach any term of the agreement, or we fail to pay any amounts due, become subject
to any government regulatory investigation, certain lawsuits, claims, actions or take certain other actions during the term of the Consulting
Agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 122 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->117<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%"><a href="#toc" title="Table of Contents" style="font-style: italic">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
consideration for providing the services under the Consulting Agreement, we agreed to issue KBHS 1.5 million shares of restricted common
stock, which vest immediately upon issuance, to pay KBHS $10,000 per month, and agreed to pay KBHS a 5% finder&#8217;s fee on any new
business introduced or developed by KBHS and 7.5% of the value of any acquisition or merger created or developed exclusively by KBHS,
undertaken by the Company, subject to applicable laws. In the event we fail to pay any consideration due under the Consulting Agreement,
such amount accrues interest at the rate of 1.5% per month until paid in full. As of the date of this prospectus, no payments have been
made under the Consulting Agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Director
Summary Compensation Table</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 33.75pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
grant our Board members options from time to time as consideration for their services to the Board. Our executive officers are not paid
any consideration for their service to the Board separate from the consideration they are paid as executive officers of the Company,
as shown above.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 33.75pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table sets forth summary information concerning the compensation we paid to non-executive directors during the year ended December
31, 2021:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Name (1)</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Fees Earned or Paid in Cash ($)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Option Awards ($)(1)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">All Other Compensation ($)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Total ($)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 44%; text-align: justify">Peter &#8220;Casey&#8221; Jensen</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">-</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">-</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">-</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">-</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*
The table above does not include the amount of any expense reimbursements paid to the above directors. No directors received any Stock
Awards, Non-Equity Incentive Plan Compensation, Change in Pension Value and Nonqualified Deferred Compensation Earnings during the period
presented. Does not include perquisites and other personal benefits, or property, unless the aggregate amount of such compensation is
more than $10,000.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)
Represents the fair value of the grant of certain options to purchase shares of our common stock calculated in accordance with Financial
Accounting Standards Board Accounting Standards Codification Topic 718.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Outstanding
Option Equity Awards at 2021 Fiscal Year End</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
were no unvested stock or option awards outstanding at year end held by executive officers.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: -63pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 123 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->118<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%"><a href="#toc" title="Table of Contents" style="font-style: italic">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><b>&#160;</b></span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="ed_025"></span>Certain
Relationships and Related Transactions</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Except
as discussed below or otherwise disclosed above under &#8220;<a href="#ed_024">Executive and Director Compensation</a>&#8221;, which
information is incorporated by reference where applicable in this &#8220;<a href="#ed_025">Certain Relationships and Related Transactions</a>&#8221;
section, the following sets forth a summary of all transactions since the beginning of the fiscal year of 2019, or any currently proposed
transaction, in which the Company was to be a participant and the amount involved exceeded or exceeds the lesser of $120,000 or one percent
of the average of the Company&#8217;s total assets at the fiscal year-end for 2021 and 2020, and in which any related person had or will
have a direct or indirect material interest (other than compensation described above under &#8220;<a href="#ed_024">Executive and Director Compensation</a>&#8221;).
We believe the terms obtained or consideration that we paid or received, as applicable, in connection with the transactions described
below were comparable to terms available or the amounts that would be paid or received, as applicable, in arm&#8217;s-length transactions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Loans
from Related Parties</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 34.95pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
June 21, 2019, the Company issued a promissory note with a principal amount of $40,000 to a related party (the father of the Company&#8217;s
CEO, Jacob Cohen) in exchange for $40,000 in cash. The promissory note is unsecured, has a maturity date of June 21, 2020 and accrues
interest at the rate of 8% per annum until paid in full by the Company. Furthermore, the Company issued 50,000 shares of the Company&#8217;s
common stock to the related party investor as further consideration to enter into the loan with the Company. The Company issued 50,000
shares of common stock valued at $0.10 per share or $5,000, which was accounted for as a discount on the note. This note was repaid in
full in March 2020.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 34.95pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
September 9, 2019, the Company issued a promissory note with a principal amount of $100,000 to a related party (the father of the Company&#8217;s
CEO, Jacob Cohen) in exchange for $100,000 in cash. The promissory note is unsecured, has a maturity date of September 9, 2020 and accrues
interest at the rate of 8% per annum until paid in full by the Company. Furthermore, the Company issued 100,000 shares of the Company&#8217;s
common stock to the related party investor as further consideration to enter into the loan with the Company. The Company issued 100,000
shares of common stock valued at $1.00 per share or $100,000, which was accounted for a discount on the note. This note was repaid in
full in August 2020.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 34.6pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amortization
of the discounts on the note was $30,874 for the 12 months ended December 31, 2019.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 34.95pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2021, the short-term note payable to Kemah Development Texas, LP, a company owned by Dror Family Trust, a former related
party totaled $13,473.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 34.95pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
September 27, 2021, October 29, 2021, November 2, 2021, and November 12, 2021, Jacob Cohen, our Chief Executive Officer, advanced the
Company, $50,000, $15,000, $10,000, and $40,000, respectively, which loans are payable upon demand and not bearing interest. This amount
was repaid in November 2021.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 124 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->119<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%"><a href="#toc" title="Table of Contents" style="font-style: italic">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Long-Term
Debt to Related Parties</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
April 12, 2019 the Company entered into individual share exchange agreements and promissory notes with each of Daniel Dror, Winfred Fields
and former directors Everett Bassie (also the former CFO of the Company) and Charles Zeller (the &#8220;AMIH Shareholders&#8221;), whereby
the AMIH Shareholders agreed to cancel and exchange a total of 5,900,000 shares of their AMIH common stock. The Company issued individual
promissory notes with an aggregate principal balance of $350,000 (the &#8220;Promissory Notes&#8221;) for cancellation of the 5,900,000
shares of common stock. The Promissory Notes have a term of two years and accrue interest at the rate of 10% per annum until paid in
full by the Company. As of December 31, 2019, 4,250,000 shares were returned to Treasury for cancellation, and 1,650,000 shares were
cancelled in 2020. The Company accrued $18,956 and $29,956 of interest on these notes during the years ended December 31, 2020 and 2021,
respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company incurred long term debt in the amount of $37,027 during the year ended December 31, 2019 to purchase equipment used in its operations.
The total purchase price was $37,027, with the Company making a down payment in the amount of $3,000. The note is due in monthly payments
of $1,258.50, including interest at 8%, due in September 2021. Due to the Company&#8217;s discontinued operations of its MedSpas, the
equipment was returned in the third quarter of 2020. As of December 31, 2020 and 2021, the balance of the note was $0.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
December 31, 2021, accrued compensation was $103,500, representing $53,500 as owed to Jacob Cohen, the Company&#8217;s CEO and $25,000
owed to each of Alan Hernandez and Esteban Alexander, the Company&#8217;s former officers and directors.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Additional
Transactions</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.65pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.35pt; text-align: justify; text-indent: 35.65pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
July 5, 2019, our board of directors adopted and approved our 2019 Stock Option and Incentive Plan. The Plan is intended to promote the
interests of our Company by providing eligible person with the opportunity to acquire a proprietary interest, or otherwise increase their
proprietary interest, in the Company as an incentive for them to remain in the service of the Company. The maximum number of shares available
to be issued under the Plan is currently 10,000,000 shares, subject to adjustments for any stock splits, stock dividends or other specified
adjustments which may take place in the future. The Company issued a total of 2,535,000 shares to eligible persons under the Plan and
recorded a total $2,193,550 as Stock Based Compensation against these issuances for the year ended December 31, 2021.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.35pt; text-align: justify; text-indent: 35.65pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.35pt; text-align: justify; text-indent: 35.65pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
January 13, 2020, and with an effective date of December 31, 2019, the Company sold 100% of its interest in YS Brands to its then current
officers and directors, Jacob Cohen, Alan Hernandez and Esteban Alexander, in consideration of $300 in cash.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.65pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 125 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->120<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%"><a href="#toc" title="Table of Contents" style="font-style: italic">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.65pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
May 20, 2020, the Company issued one share of its newly designated shares of Series A Preferred Stock (the rights associated with such
Series A Preferred Stock are described in greater detail under &#8220;Description of Capital Stock&#8212;<span style="text-decoration: underline">Preferred Stock</span>&#8212;<span style="text-decoration: underline">Series
A Preferred Stock</span>&#8221;), to each of the three members of its then board of directors, (1) Jacob D. Cohen, (2) Esteban Alexander
and (3) Alan Hernandez, in consideration for services rendered to the Company as members of the board of directors. Such shares of Series
A Preferred Stock vote in aggregate sixty percent (60%) of the total vote on all shareholder matters, voting separately as a class, as
discussed in greater detail under &#8220;<span style="text-decoration: underline">Description of Capital Stock</span>&#8212;<span style="text-decoration: underline">Preferred Stock</span>&#8212;<span style="text-decoration: underline">Series B Convertible
Preferred Stock</span>&#8221;. Notwithstanding such voting rights, no change in control of the Company was deemed to have occurred in connection
with the issuance since Messrs. Cohen, Alexander and Hernandez, own in aggregate 68% of the Company&#8217;s outstanding common stock
and therefore controlled the Company prior to such issuance.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.65pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
October 2, 2020, Jacob D. Cohen, the Chief Executive Officer and member of the board of directors of the Company entered into Stock Purchase
Agreements with each of (a) Esteban Alexander, the Chief Operating Officer and member of the board of directors of the Company, and (b)
Luis Alan Hernandez, the Chief Marketing Officer and member of the board of directors of the Company (collectively, the &#8220;<span style="text-decoration: underline">Preferred
Holders</span>&#8221; and the &#8220;<span style="text-decoration: underline">Stock Purchase Agreements</span>&#8221;).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the Stock Purchase Agreements, Mr. Alexander agreed to sell 7,000,000 shares of common stock of the Company which he held to Mr. Cohen,
which rights to such shares were assigned by Mr. Cohen to Cohen Enterprises, Inc., which entity he controls (&#8220;<span style="text-decoration: underline">Cohen Enterprises</span>&#8221;),
in consideration for an aggregate of $1,500 as well as for the amount of services provided by Mr. Cohen to the Company; and Mr. Hernandez
agreed to sell 4,000,000 shares of common stock of the Company which he held to Cohen Enterprises, in consideration for an aggregate
of $1,000 as well as for the amount of services provided by Mr. Cohen to the Company. The sales closed on November 5, 2020.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">One
of the reasons that Mr. Alexander and Mr. Hernandez agreed to the terms of the Stock Purchase Agreements (including the sale of the shares
of common stock of the Company at below market value), is because (a) each of Mr. Cohen, Mr. Alexander, and Mr. Hernandez were all appointed
as officers and directors of the Company at the same time in April 2019, with the intention that such persons would provide a relatively
equal amount of services to the Company in the roles as officers and directors thereof; (b) since such appointment date Mr. Cohen has
been required to provide a disproportionate amount of services to the Company; and (c) each of Mr. Alexander and Mr. Hernandez desired
to provide additional consideration to Mr. Cohen for such disproportionate level of service.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
condition to the Stock Purchase Agreements was that each of Mr. Alexander and Mr. Hernandez resign as a member of the board of directors
of the Company by no later than January 15, 2021, which resignations were effective December 15, 2020.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 126 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->121<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%"><a href="#toc" title="Table of Contents" style="font-style: italic">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
further requirement to the terms of the Stock Purchase Agreements was that each of Mr. Alexander and Mr. Hernandez take such actions
necessary and which may be requested from time to time by Mr. Cohen, to affect the cancellation of the one share of Series A Preferred
Stock of the Company held by each of them, for no consideration (including, but not limited to, without the required payment by the Company
of the $1 redemption price described in the designation of such Series A Preferred Stock).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
shares of Series A Preferred Stock held by Mr. Alexander and Mr. Hernandez were canceled on November 6, 2020. The common shares were
also transferred to Mr. Cohen on November 6, 2020, and as such, a change of control occurred on such date, with Mr. Cohen taking over
voting control of the Company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
January 2021, the Company issued Mr. Cohen an aggregate of 2.5 million shares of common stock in consideration for services rendered.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
January 12, 2022, the Company issued an award of 5,000,000 restricted shares of the Company&#8217;s common stock as a signing bonus in
consideration of Mr. Cohen entering into his new Employment Agreement with the Company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
October 7, 2021, the Company incorporated Mangoceuticals, Inc. (&#8220;<span style="text-decoration: underline">Mangoceuticals</span>&#8221;) in the
state of Texas with the intent of focusing on developing, marketing and selling a variety of men&#8217;s wellness products and services
via a telemedicine platform. Subsequent to incorporation, Mangoceuticals issued 1,000,000 shares of common stock each to Jacob D. Cohen,
the Chief Executive Officer of the Company, and a third party, in consideration for services rendered. As a result, Mangoceuticals is
currently 80% owned by the Company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Review,
Approval and Ratification of Related Party Transactions</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Audit Committee of the Board of Directors of the Company is tasked with reviewing and approving any issues relating to conflicts of interests
and all related party transactions of the Company (&#8220;<span style="text-decoration: underline">Related Party Transactions</span>&#8221;). The Audit Committee, in undertaking
such review and will analyze the following factors, in addition to any other factors the Audit Committee deems appropriate, in determining
whether to approve a Related Party Transaction: (1) the fairness of the terms for the Company (including fairness from a financial point
of view); (2) the materiality of the transaction; (3) bids / terms for such transaction from unrelated parties; (4) the structure of
the transaction; (5) the policies, rules and regulations of the U.S. federal and state securities laws; (6) the policies of the Committee;
and (7) interests of each related party in the transaction.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 33.75pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 33.75pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Audit Committee will only approve a Related Party Transaction if the Audit Committee determines that the terms of the Related Party Transaction
are beneficial and fair (including fair from a financial point of view) to the Company and are lawful under the laws of the United States.
In the event multiple members of the Audit Committee are deemed a related party, the Related Party Transaction will be considered by
the disinterested members of the Board of Directors in place of the Committee.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 33.75pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 127 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->122<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%"><a href="#toc" title="Table of Contents" style="font-style: italic">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 33.75pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, our Code of Ethics (described above under &#8220;<span style="text-decoration: underline">Code of Ethics</span>&#8221;), which is applicable to all of our employees,
officers and directors, requires that all employees, officers and directors avoid any conflict, or the appearance of a conflict, between
an individual&#8217;s personal interests and our interests.</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="ed_026"></span>Where
You Can Find Additional Information</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
will provide without charge to each person, including any beneficial owner, to whom this prospectus is delivered, upon his or her written
or oral request, a copy of any or all of the reports or documents referred to above that have been incorporated by reference into this
prospectus, excluding exhibits to those documents unless they are specifically incorporated by reference into those documents. You may
request a copy of these filings, at no cost, by contacting us at our address at 7950 Legacy Drive, Suite 400, Plano, Texas 75024 or by
email at info@amihcorp.com.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
file annual, quarterly, and current reports, proxy statements and other information with the SEC. Our SEC filings are available to the
public over the Internet at the SEC&#8217;s website at <span style="text-decoration: underline">www.sec.gov</span> and are available for download, free of charge, soon after
such reports are filed with or furnished to the SEC, on our website at <span style="text-decoration: underline">https://amihcorp.com/investors/</span>. Our website address is
<span style="text-decoration: underline">https://amihcorp.com</span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
do not incorporate information on our website into this prospectus or any supplement to this prospectus and you should not consider any
information on, or that can be accessed through, our website as part of this prospectus or any supplement to this prospectus (other than
those filings with the SEC that we specifically incorporate by reference into this prospectus or any supplement to this prospectus).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 128 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->123<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%"><a href="#toc" title="Table of Contents" style="font-style: italic">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><b>&#160;</b></span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="ed_027"></span>Indemnification
of Directors and Officers</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
authorized by <span style="text-decoration: underline">Section 78.751</span> of the Nevada Revised Statutes, we may indemnify our officers and directors against expenses incurred
by such persons in connection with any threatened, pending or completed action, suit or proceedings, whether civil, criminal, administrative
or investigative, involving such persons in their capacities as officers and directors, so long as such persons acted in good faith and
in a manner which they reasonably believed to be in our best interests. If the legal proceeding, however, is by or in our right, the
director or officer may not be indemnified in respect of any claim, issue or matter as to which he is adjudged to be liable for negligence
or misconduct in the performance of his duty to us unless a court determines otherwise.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
Nevada law, corporations may also purchase and maintain insurance or make other financial arrangements on behalf of any person who is
or was a director or officer (or is serving at our request as a director or officer of another corporation) for any liability asserted
against such person and any expenses incurred by him in his capacity as a director or officer. These financial arrangements may include
trust funds, self-insurance programs, guarantees and insurance policies.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Additionally,
our Bylaws, as amended and restated (&#8220;<span style="text-decoration: underline">Bylaws</span>&#8221;), state that we shall indemnify every (i) present or former director,
advisory director or officer of us, (ii) any person who while serving in any of the capacities referred to in clause (i) served at our
request as a director, officer, partner, venturer, proprietor, trustee, employee, agent or similar functionary of another foreign or
domestic corporation, partnership, joint venture, trust, employee benefit plan or other enterprise, and (iii) any person nominated or
designated by (or pursuant to authority granted by) the Board of Directors or any committee thereof to serve in any of the capacities
referred to in clauses (i) or (ii) (each an &#8220;<span style="text-decoration: underline">Indemnitee</span>&#8221;).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
Bylaws provide that we shall indemnify an Indemnitee against all judgments, penalties (including excise and similar taxes), fines, amounts
paid in settlement and reasonable expenses actually incurred by the Indemnitee in connection with any proceeding in which he was, is
or is threatened to be named as a defendant or respondent, or in which he was or is a witness without being named a defendant or respondent,
by reason, in whole or in part, of his serving or having served, or having been nominated or designated to serve, if it is determined
that the Indemnitee (a) conducted himself in good faith, (b) reasonably believed, in the case of conduct in his official capacity, that
his conduct was in our best interests and, in all other cases, that his conduct was at least not opposed to our best interests, and (c)
in the case of any criminal proceeding, had no reasonable cause to believe that his conduct was unlawful; provided, however, that in
the event that an Indemnitee is found liable to us or is found liable on the basis that personal benefit was improperly received by the
Indemnitee, the indemnification (i) is limited to reasonable expenses actually incurred by the Indemnitee in connection with the proceeding
and (ii) shall not be made in respect of any proceeding in which the Indemnitee shall have been found liable for willful or intentional
misconduct in the performance of his duty to us.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 129 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->124<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%"><a href="#toc" title="Table of Contents" style="font-style: italic">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Except
as provided above, the Bylaws provide that no indemnification shall be made in respect to any proceeding in which such Indemnitee has
been (a) found liable on the basis that personal benefit was improperly received by him, whether or not the benefit resulted from an
action taken in the Indemnitee&#8217;s official capacity, or (b) found liable to us. The termination of any proceeding by judgment, order,
settlement or conviction, or on a plea of nolo contendere or its equivalent, is not of itself determinative that the Indemnitee did not
meet the requirements set forth in clauses (a) or (b) above. An Indemnitee shall be deemed to have been found liable in respect of any
claim, issue or matter only after the Indemnitee shall have been so adjudged by a court of competent jurisdiction after exhaustion of
all appeals therefrom. Reasonable expenses shall include, without limitation, all court costs and all fees and disbursements of attorneys&#8217;
fees for the Indemnitee. The indemnification provided shall be applicable whether or not negligence or gross negligence of the Indemnitee
is alleged or proven.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Neither
our Bylaws nor our Articles of Incorporation include any specific indemnification provisions for our officers or directors against liability
under the Securities Act. Additionally, insofar as indemnification for liabilities arising under the Securities Act may be permitted
to directors, officers and controlling persons of the Company pursuant to the foregoing provisions, or otherwise, the Company has been
advised that in the opinion of the Securities and Exchange Commission such indemnification is against public policy as expressed in the
Securities Act and is, therefore, unenforceable.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 130 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->125<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%"><a href="#toc" title="Table of Contents" style="font-style: italic">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><b><span id="fin"></span>INDEX TO FINANCIAL STATEMENTS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Contents</b></span></p></td>
    <td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; text-align: center; width: 0.65in"><b>Page(s)</b></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Audited
    Financial Statements for the Years Ended December 2021 and 2020</i></b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#Gv_007">Report
    of Independent Registered Public Accounting Firm</a> PCAOB ID NO: 2738</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-2</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#Gv_008">Consolidated
    Balance Sheets at December 31, 2021 and 2020</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">F-3</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#Gv_009">Consolidated
    Statements of Operations for the Years Ended December 31, 2021 and 2020</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">F-4</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#Gv_010">Consolidated
    Statements of Stockholders&#8217; Equity (Deficit) for the Years Ended December 31, 2021 and 2020</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">F-5</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#Gv_011">Consolidated
    Statements of Cash Flows for the Years Ended December 31, 2021 and 2020</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">F-6</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#Gv_012">Notes
    to Consolidated Financial Statements</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">F-7</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 131; Options: NewSection; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: left"><a href="#fin" title="Table of Contents" style="font-style: italic">Table of Contents</a>&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><img src="forms-1_002.jpg" alt="" /></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span id="Gv_007"></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>REPORT
OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
the Board of Directors and Stockholders of American International Holdings Corp.,</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Opinion
on the Financial Statements</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have audited the accompanying consolidated balance sheets of American International Holdings Corp. (the Company) as of December 31, 2021
and 2020, and the related consolidated statements of operations, changes in stockholders&#8217; deficit, and cash flows for the
two-year period then ended, and the related notes (collectively referred to as the &#8220;financial statements&#8221;).
In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company as of December
31, 2021 and 2020, and the results of its operations and its cash flows for the years then ended in conformity with accounting
principles generally accepted in the United States of America.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Going
Concern</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying financial statements have been prepared assuming that the Company will continue as a going concern. As discussed in Note
15 to the financial statements, the Company has suffered net losses from continuing and discontinued operations, which raises substantial
doubt about its ability to continue as a going concern. Management&#8217;s plans regarding those matters are discussed in Note 15. The
financial statements do not include any adjustments that might result from the outcome of this uncertainty.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Basis
for Opinion</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">These
financial statements are the responsibility of the Company&#8217;s management. Our responsibility is to express an opinion on the Company&#8217;s
financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board
(United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities
laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audits to obtain
reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud.
The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting.
As part of our audits, we are required to obtain an understanding of internal control over financial reporting, but not for the purpose
of expressing an opinion on the effectiveness of the Company&#8217;s internal control over financial reporting. Accordingly, we express
no such opinion.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error
or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence
regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles
used and the significant estimates made by management, as well as evaluating the overall presentation of the financial
statements. We believe our audits provide a reasonable basis for our opinion.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Critical
Audit Matters</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; color: #484849"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
critical audit matter communicated below is a matter arising from the current period audit of the financial statements that were communicated
or required to be communicated to the audit committee and that: (1) relate to accounts or disclosures that are material to the financial
statements and (2) involved our especially challenging, subjective, or complex judgments. The communication of critical audit matters
does not alter in any way our opinion on the financial statements, taken as a whole, and we are not, by communicating the critical audit
matter below, providing separate opinion on the critical audit matter or on the accounts or disclosures to which they relate.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; color: #484849"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
discussed in Note 12, the Company borrows funds through the use of convertible notes payable that contain a conversion price that may
be fixed or fluctuates with the stock price.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; color: #484849"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Auditing
management&#8217;s estimates of the fair value of the derivative liability involves significant judgements and estimates given the embedded
conversion features of the notes.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; color: #484849"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
evaluate the appropriateness of the fluctuation of the conversion price, the embedded conversion feature requires bifurcation from the
host contract and is recorded as a liability subject to market adjustments as of each reporting period. Significant judgment is exercised
by the Company in determining derivative liability values for these convertible note agreements, including the use of a specialist engaged
by management.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; color: #484849"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="margin: 0; text-align: justify">We evaluated management&#8217;s conclusions regarding their derivative liability and reviewed
support for the significant inputs used in the valuation model, as well as assessing the model for reasonableness.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 50%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>/s/
    M&amp;K CPAS, PLLC</i></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 50%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">M&amp;K CPAS, PLLC</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    have served as the Company&#8217;s auditor since 2015</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Houston,
    Texas</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">March 29, <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2022</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>


<!-- Field: Page; Sequence: 132; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: left"><a href="#fin" title="Table of Contents" style="font-style: italic">Table of Contents</a>&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>American
International Holdings Corp.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="Gv_008"></span><b>Consolidated
Balance Sheets</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" id="xdx_30A_111_zgYrDWSaYbxb" summary="xdx: Statement - Consolidated Balance Sheets" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" id="xdx_492_20211231_zZzdKIgghnIh" style="text-align: center">(Audited)</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" id="xdx_493_20201231_z7NdDXSgT62k" style="text-align: center">(Audited)</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">December 31, 2021</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">December 31, 2020</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--AssetsAbstract_iB_zzVFRpvq9k25" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: center">ASSETS</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--AssetsCurrentAbstract_i01B_z3ofaY6wg003" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left">CURRENT ASSETS:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--CashAndCashEquivalentsAtCarryingValue_i02I_pp0p0_maACzKLn_z1LgjLn0RMl5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; width: 64%; text-align: left">Cash and equivalents</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,209,807</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">25,235</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--InventoryNet_i02I_pp0p0_maACzKLn_zTLmkG8RoKb8" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt">Inventory</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:InventoryNet" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">3,840</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl0043">&#160;</span></td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--PrepaidExpenseCurrent_i02I_pp0p0_maACzKLn_z3BzZ2scYb89" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Prepayment and deposits</td><td>&#160;</td>
    <td style="text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl0045">&#160;</span></td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:PrepaidExpenseCurrent" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">3,333</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent_i02I_pp0p0_maACzKLn_zSpTDCiFidWd" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Assets of discontinued operations</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl0048">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">9,971</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--AssetsCurrent_i02TI_pp0p0_mtACzKLn_maAzO7W_zv3Njspja1G4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 20pt; text-align: left">TOTAL CURENT ASSETS</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:AssetsCurrent" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,213,647</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:AssetsCurrent" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">38,539</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--AssetsNoncurrentAbstract_i01B_zu1ruTVi9Ftl" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">NON-CURRENT ASSETS</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--DepositsAssetsNoncurrent_i02I_pp0p0_maANz561_z6vYrFjpvgHc" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Rent deposits</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DepositsAssetsNoncurrent" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">3,599</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DepositsAssetsNoncurrent" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">3,800</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent_i02I_pp0p0_maANz561_zT8g98itnmol" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Assets of discontinued operations</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">14,199</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">223,183</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--AssetsNoncurrent_i02TI_pp0p0_mtANz561_maAzO7W_z7VAE91kA3Xk" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 20pt; text-align: left">NET NON-CURRENT ASSETS</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:AssetsNoncurrent" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">17,798</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:AssetsNoncurrent" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">226,983</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--Assets_i01TI_pp0p0_mtAzO7W_zhHNmw83tOR1" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 20pt; font-weight: bold; text-align: left">TOTAL ASSETS</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:Assets" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,231,445</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:Assets" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">265,522</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--LiabilitiesAndStockholdersEquityAbstract_iB_zyHpWbM6Hb5g" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: center">LIABILITIES AND STOCKHOLDERS&#8217; DEFICIT</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--LiabilitiesCurrentAbstract_i01B_z2eeav1uLQhc" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left">CURRENT LIABILITIES</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--AccountsPayableAndAccruedLiabilitiesCurrent_i02I_pp0p0_maLCzjFL_zzQAYo3dCYIl" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Accounts payable and accrued liabilities</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">54,918</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">14,576</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--InterestPayableCurrent_i02I_pp0p0_maLCzjFL_zwsxLoPIHmj6" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Accrued interest payable</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:InterestPayableCurrent" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">93,776</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:InterestPayableCurrent" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">42,195</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--EmployeeRelatedLiabilitiesCurrent_i02I_pp0p0_maLCzjFL_zjwuaFSbst0a" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Accrued compensation - related parties</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:EmployeeRelatedLiabilitiesCurrent" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">103,500</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:EmployeeRelatedLiabilitiesCurrent" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">154,500</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--ConvertibleDebtCurrent_i02I_pp0p0_maLCzjFL_zbpbTbjBvQtj" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Convertible notes payable, net of debt discount of $<span id="xdx_90E_eus-gaap--DebtInstrumentUnamortizedDiscountCurrent_iI_pp0p0_c20211231_z8fK3NzuoNR5" title="Debt discount, current"><ix:nonFraction name="us-gaap:DebtInstrumentUnamortizedDiscountCurrent" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">2,479,023</ix:nonFraction></span> and $<span id="xdx_903_eus-gaap--DebtInstrumentUnamortizedDiscountCurrent_iI_pp0p0_c20201231_znZybmkcoK17" title="Debt discount, current"><ix:nonFraction name="us-gaap:DebtInstrumentUnamortizedDiscountCurrent" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">370,923</ix:nonFraction></span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ConvertibleDebtCurrent" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">396,419</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ConvertibleDebtCurrent" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">74,827</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--DueToRelatedPartiesCurrent_i02I_pp0p0_maLCzjFL_zzl21HvJaeG5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Loans payable to related parties</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DueToRelatedPartiesCurrent" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">123,473</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DueToRelatedPartiesCurrent" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">13,473</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--LoansPayableCurrent_i02I_pp0p0_maLCzjFL_zXraMJENsep" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Loans payable</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:LoansPayableCurrent" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">75,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:LoansPayableCurrent" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">55,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--DerivativeLiabilitiesCurrent_i02I_pp0p0_maLCzjFL_zCJt7WXaWqt5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Derivative liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DerivativeLiabilitiesCurrent" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">4,141,272</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DerivativeLiabilitiesCurrent" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">517,366</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent_i02I_pp0p0_maLCzjFL_zjGFa9fnbqKh" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Net liabilities of discontinued operations</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">112,199</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">669,574</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--LiabilitiesCurrent_i02TI_pp0p0_mtLCzjFL_maLz7VU_zZIK8YJ7aTD5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 20pt; text-align: left">TOTAL CURRENT LIABILITIES</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesCurrent" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">5,100,557</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesCurrent" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,541,511</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--LiabilitiesNoncurrentAbstract_i01B_zvlw0HtBxPzb" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">LONG-TERM LIABILITIES</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--ConvertibleLongTermNotesPayable_i02I_pp0p0_maLNzk0O_zrEuKctJEReh" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Convertible notes payable, net of debt discount of $<span id="xdx_90B_eus-gaap--DebtInstrumentUnamortizedDiscountNoncurrent_iI_pp0p0_c20211231_zFVE8rgyUWc2" title="Debt discount, noncurrent"><ix:nonFraction name="us-gaap:DebtInstrumentUnamortizedDiscountNoncurrent" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">0</ix:nonFraction></span> and $<span id="xdx_900_eus-gaap--DebtInstrumentUnamortizedDiscountNoncurrent_iI_pp0p0_c20201231_zE4IDTYGcDw3" title="Debt discount, noncurrent"><ix:nonFraction name="us-gaap:DebtInstrumentUnamortizedDiscountNoncurrent" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">78,482</ix:nonFraction></span></td><td>&#160;</td>
    <td style="text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl0109">&#160;</span></td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ConvertibleLongTermNotesPayable" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">5,018</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--DueToRelatedPartiesNoncurrent_i02I_pp0p0_maLNzk0O_zzemMS6Qs1Rc" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Long-term debt - related parties</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl0116">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:DueToRelatedPartiesNoncurrent" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">110,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--LiabilitiesNoncurrent_i02TI_pp0p0_mtLNzk0O_maLz7VU_zbMowc8hRVs4" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 20pt; text-align: left">TOTAL LONG-TERM LIABILITIES</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl0119">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesNoncurrent" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">115,018</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--Liabilities_i01TI_pp0p0_mtLz7VU_maLASEzX5G_zRmFAFDsn4e3" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 20pt; font-weight: bold; text-align: left">TOTAL LIABILITIES</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:Liabilities" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">5,100,557</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:Liabilities" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,656,529</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--StockholdersEquityAbstract_i01B_zaECCSOvBW0i" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left">STOCKHOLDERS&#8217; DEFICIT</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--PreferredStockValue_i02I_pp0p0_maSEz8rw_zxiFE27ypYD" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Preferred stock, (par value $<span id="xdx_902_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_c20211231_ziGyNpwdah5a" title="Preferred stock, par value"><span id="xdx_900_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_c20201231_zlMijAzqtXz3" title="Preferred stock, par value"><ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares"><ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.0001</ix:nonFraction></ix:nonFraction></span></span>, <span id="xdx_90A_eus-gaap--PreferredStockSharesAuthorized_iI_c20211231_zFnitWUIMYD1" title="Preferred stock, share authorized"><span id="xdx_90F_eus-gaap--PreferredStockSharesAuthorized_iI_c20201231_zKigEzEE86G7" title="Preferred stock, share authorized"><ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">5,000,000</ix:nonFraction></ix:nonFraction></span></span> shares authorized, of which <span id="xdx_902_eus-gaap--PreferredStockSharesIssued_iI_c20211231_zUj5102tUyhk" title="Preferred stock, shares issued"><span id="xdx_907_eus-gaap--PreferredStockSharesOutstanding_iI_c20211231_zLuwRoxz3fKe" title="Preferred stock, shares outstanding"><ix:nonFraction name="us-gaap:PreferredStockSharesIssued" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1</ix:nonFraction></ix:nonFraction></span></span> and <span id="xdx_909_eus-gaap--PreferredStockSharesIssued_iI_c20201231_z6GaI9EprGfc" title="Preferred stock, shares issued"><span id="xdx_904_eus-gaap--PreferredStockSharesOutstanding_iI_c20201231_z7PTDQpEKnU" title="Preferred stock, shares outstanding"><ix:nonFraction name="us-gaap:PreferredStockSharesIssued" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1</ix:nonFraction></ix:nonFraction></span></span>
    shares issued and outstanding as of December 31, 2021 and December 31, 2020, respectively)</td><td>&#160;</td>
    <td style="text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl0128">&#160;</span></td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl0129">&#160;</span></td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--CommonStockValue_i02I_pp0p0_maSEz8rw_zeHMCY1qTjZ2" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Common stock (par value $<span id="xdx_90F_eus-gaap--CommonStockParOrStatedValuePerShare_iI_c20211231_zO9JLv4gzv79" title="Common stock, par value"><span id="xdx_90E_eus-gaap--CommonStockParOrStatedValuePerShare_iI_c20201231_zBiyb5mKvYx2" title="Common stock, par value"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="AsOf2021-12-31" decimals="INF" unitRef="USDPShares"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="AsOf2020-12-31" decimals="INF" unitRef="USDPShares">.0001</ix:nonFraction></ix:nonFraction></span></span>,
    <span id="xdx_90F_eus-gaap--CommonStockSharesAuthorized_iI_c20211231_zL47LnVkF9Ph" title="Common stock, shares authorized"><span id="xdx_907_eus-gaap--CommonStockSharesAuthorized_iI_c20201231_zFtfhh5Zc9Hh" title="Common stock, shares authorized"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">195,000,000</ix:nonFraction></ix:nonFraction></span></span> shares authorized, of which
    <span id="xdx_90A_eus-gaap--CommonStockSharesOutstanding_iI_c20211231_zN8YURUDtlgg"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">84,445,067</ix:nonFraction></span> and <span id="xdx_90D_eus-gaap--CommonStockSharesOutstanding_iI_c20201231_z1kJoBE2DG66"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">55,066,855</ix:nonFraction>
    </span>shares issued and outstanding as of December 31, 2021 and December 31, 2020, respectively)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:CommonStockValue" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">8,445</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:CommonStockValue" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">5,507</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--TreasuryStockValue_i02NI_pp0p0_di_msSEz8rw_zGFiBKxVv5ji" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Treasury stock, at cost</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:TreasuryStockValue" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">3,894</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:TreasuryStockValue" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">3,894</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40C_eus-gaap--AdditionalPaidInCapital_i02I_pp0p0_maSEz8rw_ztqY4XRpZ5X2" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Additional paid in capital</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AdditionalPaidInCapital" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">16,666,906</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AdditionalPaidInCapital" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">9,167,038</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--RetainedEarningsAccumulatedDeficit_i02I_pp0p0_maSEz8rw_zZKWXK8TBtI3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Accumulated deficit</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">20,540,569</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">10,559,658</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40E_eus-gaap--StockholdersEquity_i02TI_pp0p0_mtSEz8rw_maLASEzX5G_zSmeeHU41ymj" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 20pt; font-weight: bold; text-align: left">TOTAL STOCKHOLDERS&#8217; DEFICIT</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">3,869,111</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">1,391,007</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--LiabilitiesAndStockholdersEquity_i01TI_pp0p0_mtLASEzX5G_zsOk9WzCwMJ4" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 20pt; font-weight: bold; text-align: left">TOTAL LIABILITIES AND STOCKHOLDERS&#8217; DEFICIT</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,231,445</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">265,522</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying notes are an integral part of these consolidated audited financial statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 133; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: left"><a href="#fin" title="Table of Contents" style="font-style: italic">Table of Contents</a>&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>American
International Holdings Corp.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="Gv_009"></span><b>Consolidated
Statements of Operations</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" id="xdx_306_113_zgAuN8Ajny5a" summary="xdx: Statement - Consolidated Statements of Operations" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" id="xdx_496_20210101__20211231_zanezOAzp183" style="text-align: center">(Audited)</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" id="xdx_491_20200101__20201231_znvfWLodqYQ1" style="text-align: center">(Audited)</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">For The Twelve</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">For The Twelve</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">Months Ended</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">Months Ended</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">December 31, 2021</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">December 31, 2020</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--RevenuesAbstract_iB_zpd1S44tusQ8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold">Revenues</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_maGPz0Sx_zYPViM3c8Hnb" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; width: 64%">Revenues</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">20,169</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,115</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--CostOfRevenue_msGPz0Sx_z0yMobOr3Lfk" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt">Cost of revenues</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:CostOfRevenue" contextRef="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">39,738</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl0182">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--GrossProfit_iT_pp0p0_mtGPz0Sx_maOILzzZ8_zEvImalPlAmh" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 20pt; text-align: left">Gross profit (loss)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:GrossProfit" contextRef="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">19,569</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:GrossProfit" contextRef="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">2,115</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--OperatingExpensesAbstract_iB_zWUbC7MBTpEe" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left">Operating expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--GeneralAndAdministrativeExpense_i01_pp0p0_maOEzs9x_zZEawszF9TBl" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">General and administrative expenses</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">6,975,654</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">3,711,317</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--OperatingExpenses_i01T_pp0p0_mtOEzs9x_msOILzzZ8_zooFx06IhTp9" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left">Total operating expenses</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:OperatingExpenses" contextRef="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">6,975,654</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:OperatingExpenses" contextRef="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">3,711,317</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--OperatingIncomeLoss_iT_pp0p0_mtOILzzZ8_maILFCOz6oh_zfePdIpGT6b1" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left">Income (loss) from operations</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">6,995,223</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">3,709,202</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--NonoperatingIncomeExpenseAbstract_iB_zdsG5Yurkwbc" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left">Other income (expenses)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--AmortizationOfDebtDiscountPremium_i01N_pp0p0_di_msNIEzf5E_zqwPcdf4Y2Tf" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Amortization of debt discount</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:AmortizationOfDebtDiscountPremium" contextRef="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,958,298</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:AmortizationOfDebtDiscountPremium" contextRef="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">777,964</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40F_ecustom--DerivativeGainLossOnDerivativeNetExcludingDerivativeExpense_i01N_pp0p0_di_msNIEzf5E_z3qNEjfxzca5" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Change in derivative liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="AMIH:DerivativeGainLossOnDerivativeNetExcludingDerivativeExpense" contextRef="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,071,028</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="AMIH:DerivativeGainLossOnDerivativeNetExcludingDerivativeExpense" contextRef="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">107,574</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40A_ecustom--ForgivenessOfLoan_i01_pp0p0_maNIEzf5E_zKE8rQetqyb8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Forgiveness of Loan</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="AMIH:ForgivenessOfLoan" contextRef="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">45,500</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl0209">&#160;</span></td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_ecustom--ImpairmentLoss_i01N_pp0p0_di_msNIEzf5E_z9jZFP83ZDog" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Impairment Loss</td><td>&#160;</td>
    <td style="text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl0211">&#160;</span></td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="AMIH:ImpairmentLoss" contextRef="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">605,488</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_401_eus-gaap--InterestExpenseDebtExcludingAmortization_i01N_di_msNIEzf5E_ziAeOq694Fzd" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Interest expense</td><td>&#160;</td>
       <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:InterestExpenseDebtExcludingAmortization" contextRef="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">184,589</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:InterestExpenseDebtExcludingAmortization" contextRef="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">219,280</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40A_ecustom--LossOnSettlementOfDebt_i01N_pp0p0_di_msNIEzf5E_zTFrDaPDasUj" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Settlement loss</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="AMIH:LossOnSettlementOfDebt" contextRef="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">61,859</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="AMIH:LossOnSettlementOfDebt" contextRef="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,041,445</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_404_eus-gaap--OtherNonoperatingIncome_i01_pp0p0_maNIEzf5E_zdLRe6WW0tyb" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Other income</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl0220">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:OtherNonoperatingIncome" contextRef="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">300</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--NonoperatingIncomeExpense_i01T_pp0p0_mtNIEzf5E_maILFCOz6oh_z7AoY5q9EAlh" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left">Total other income (expense)</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NonoperatingIncomeExpense" contextRef="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">3,230,274</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NonoperatingIncomeExpense" contextRef="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">2,751,451</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_iT_pp0p0_mtILFCOz6oh_maILFCOzs2f_z3JfGMh8Fbvg" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left">Income (loss) before income taxes</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">10,225,497</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">6,460,653</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--IncomeTaxExpenseBenefit_msILFCOzs2f_zCd4r72i8IVl" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left">Income taxes</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl0229">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl0230">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_iT_pp0p0_mtILFCOzs2f_maNILzf0g_zaif0F3NSPG9" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left">Net (loss) from continuing operations</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" contextRef="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">10,225,497</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" contextRef="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">6,460,653</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodNetOfTaxAbstract_iB_zDYWZfcGtxCh" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left">Discontinued operations:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax_i01_pp0p0_maILFDOzLNh_zxjP2ZpHLwe" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Income (loss) from discontinued operations</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax" contextRef="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">244,586</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax" contextRef="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">879,237</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40A_eus-gaap--IncomeLossFromDiscontinuedOperationsNetOfTax_i01T_pp0p0_mtILFDOzLNh_maNILzf0g_z6z7H7H4NQEh" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left">Total discontinued operations</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax" contextRef="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">244,586</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax" contextRef="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">879,237</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--NetIncomeLoss_iT_pp0p0_mtNILzf0g_zKKhf4QVXBpe" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left">Net loss</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">9,980,911</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">7,339,890</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--EarningsPerShareAbstract_iB_zp1nSAgQgXNd" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold">Basic income (loss) per share</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--IncomeLossFromContinuingOperationsPerBasicShare_i01_zImmpRxgjBF2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Continuing operations</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsPerBasicShare" contextRef="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares">0.14</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsPerBasicShare" contextRef="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares">0.18</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_406_eus-gaap--DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare_i01_zD6KuHdJ6vKb" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Discontinued operations</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare" contextRef="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.00</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare" contextRef="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares">0.02</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--EarningsPerShareDilutedAbstract_iB_zVToZueptxQk" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold">Diluted income (loss) per share</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--IncomeLossFromContinuingOperationsPerDilutedShare_i01_zOUgDvIRaMf9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Continuing operations</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare" contextRef="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares">0.14</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare" contextRef="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares">0.18</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40C_eus-gaap--DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerDilutedShare_i01_zHfzwU6tnB4k" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Discontinued operations</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerDilutedShare" contextRef="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.00</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerDilutedShare" contextRef="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares">0.02</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_iB_zXedhfRxDXHd" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold">Weighted average number of shares outstanding</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--WeightedAverageNumberOfSharesIssuedBasic_i01_zTUV3ByzEIXd" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt">Basic</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesIssuedBasic" contextRef="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">74,925,101</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesIssuedBasic" contextRef="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">35,462,109</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_i01_z0kcf2BTxhp6" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt">Diluted</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">75,311,586</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">35,456,109</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying notes are an integral part of these consolidated audited financial statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 134; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: left"><a href="#fin" title="Table of Contents" style="font-style: italic">Table of Contents</a>&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>American
International Holdings Corp.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span id="Gv_010"></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Consolidated
Statement of Changes in Stockholders&#8217; Deficit</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline">(Audited)</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" id="xdx_306_114_zG8BSFpBALy7" summary="xdx: Statement - Consolidated Statement of Changes in Stockholders&apos; Deficit" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td colspan="2"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td colspan="2" id="xdx_4BB_us-gaap--StatementClassOfStockAxis_us-gaap--SeriesAPreferredStockMember_us-gaap--StatementEquityComponentsAxis_us-gaap--PreferredStockMember_z6v5oPp3bX8d"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td colspan="2"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td colspan="2" id="xdx_4B8_us-gaap--StatementClassOfStockAxis_us-gaap--SeriesBPreferredStockMember_us-gaap--StatementEquityComponentsAxis_us-gaap--PreferredStockMember_zdUSpmfWepM"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td colspan="2"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td colspan="2" id="xdx_4B6_us-gaap--StatementEquityComponentsAxis_us-gaap--CommonStockMember_zOUVGtjc4Ved"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td colspan="2" id="xdx_4BE_us-gaap--StatementEquityComponentsAxis_us-gaap--AdditionalPaidInCapitalMember_z6jCIKj9g7Ef"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td colspan="2" id="xdx_4B3_us-gaap--StatementEquityComponentsAxis_custom--CommonStockPayableMember_zsvfWs7DAQji"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td colspan="2" id="xdx_4BD_us-gaap--StatementEquityComponentsAxis_us-gaap--RetainedEarningsMember_zsfNpFoIDxnd"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td colspan="2" id="xdx_4BD_us-gaap--StatementEquityComponentsAxis_us-gaap--TreasuryStockMember_zyoI3e1HQ2j2"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td colspan="2" id="xdx_4B8_zwAf7Lp6tibc"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td></tr>
<tr style="vertical-align: bottom">
    <td><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="margin-top: 0; margin-bottom: 0"><span style="font-size: 9pt">Preferred</span></p>
                                                                                <p style="margin-top: 0; margin-bottom: 0"><span style="font-size: 9pt">Stock A</span></p></td><td><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="margin-top: 0; margin-bottom: 0"><span style="font-size: 9pt">Preferred</span></p>
                                                                                <p style="margin-top: 0; margin-bottom: 0"><span style="font-size: 9pt">Stock B</span></p></td><td><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-size: 9pt">Common Stock</span></td><td><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td colspan="2" style="text-align: center"><p style="margin-top: 0; margin-bottom: 0"><span style="font-size: 9pt">Additional</span></p>
                                               <p style="margin-top: 0; margin-bottom: 0"><span style="font-size: 9pt">Paid-in</span></p></td><td><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td colspan="2" style="text-align: center"><p style="margin-top: 0; margin-bottom: 0"><span style="font-size: 9pt">Common</span></p>
                                               <p style="margin-top: 0; margin-bottom: 0"><span style="font-size: 9pt">Stock</span></p></td><td><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td colspan="2" style="text-align: center"><p style="margin-top: 0; margin-bottom: 0"><span style="font-size: 9pt"></span></p>
                                               <p style="margin-top: 0; margin-bottom: 0">Retained<br />
<span style="font-size: 9pt">Earnings</span></p></td><td><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td colspan="2" style="text-align: center"><span style="font-size: 9pt">Treasury</span></td><td><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td colspan="2" style="text-align: center"><p style="margin-top: 0; margin-bottom: 0">Total</p>
                                               <p style="margin-top: 0; margin-bottom: 0"><span style="font-size: 9pt">Stockholders&#8217;<br />
</span></p></td><td><span style="font-size: 9pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-size: 9pt">Shares</span></td><td><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-size: 9pt">Amount</span></td><td><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-size: 9pt">Shares</span></td><td><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-size: 9pt">Amount</span></td><td><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-size: 9pt">Shares</span></td><td><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-size: 9pt">Amount</span></td><td><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-size: 9pt">Capital</span></td><td><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-size: 9pt">Payable</span></td><td><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-size: 9pt">(Deficit)</span></td><td><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-size: 9pt">Stock</span></td><td><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-size: 9pt">(Deficit)</span></td><td><span style="font-size: 9pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td colspan="2"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td colspan="2"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td colspan="2"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td colspan="2"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td colspan="2"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td colspan="2"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td colspan="2"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td colspan="2"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td colspan="2"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td colspan="2"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td colspan="2"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td></tr>
  <tr id="xdx_436_c20200101__20201231_eus-gaap--StockholdersEquity_iS_zFLNM2mJBx37" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 34%"><span style="font-size: 9pt">Balance, December 31, 2019</span></td><td style="width: 1%"><span style="font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left"><span style="font-size: 9pt">&#160;</span></td><td id="xdx_984_eus-gaap--SharesOutstanding_iS_pp0d_c20200101__20201231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zyjiKKt6O2Mh" title="Balance, shares" style="border-bottom: Black 2.5pt double; width: 3%; text-align: right"><span style="font-size: 9pt"><span style="-sec-ix-hidden: xdx2ixbrl0283">-</span></span></td><td style="width: 1%; text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="width: 1%"><span style="font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left"><span style="font-size: 9pt">$</span></td><td style="border-bottom: Black 2.5pt double; width: 3%; text-align: right"><span style="font-size: 9pt"><span style="-sec-ix-hidden: xdx2ixbrl0274">-</span></span></td><td style="width: 1%; text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="width: 1%"><span style="font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left"><span style="font-size: 9pt">&#160;</span></td><td id="xdx_981_eus-gaap--SharesOutstanding_iS_pp0d_c20200101__20201231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zWLIofj6SI55" title="Balance, shares" style="border-bottom: Black 2.5pt double; width: 3%; text-align: right"><span style="font-size: 9pt"><span style="-sec-ix-hidden: xdx2ixbrl0285">-</span></span></td><td style="width: 1%; text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="width: 1%"><span style="font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left"><span style="font-size: 9pt">$</span></td><td style="border-bottom: Black 2.5pt double; width: 3%; text-align: right"><span style="font-size: 9pt"><span style="-sec-ix-hidden: xdx2ixbrl0275">-</span></span></td><td style="width: 1%; text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="width: 1%"><span style="font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left"><span style="font-size: 9pt">&#160;</span></td><td id="xdx_983_eus-gaap--SharesOutstanding_iS_pp0d_c20200101__20201231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zzOaCMMiXZz" title="Balance, shares" style="border-bottom: Black 2.5pt double; width: 3%; text-align: right"><span style="font-size: 9pt"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2019-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">27,208,356</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="width: 1%"><span style="font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left"><span style="font-size: 9pt">$</span></td><td style="border-bottom: Black 2.5pt double; width: 3%; text-align: right"><span style="font-size: 9pt"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2019-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,721</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="width: 1%"><span style="font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left"><span style="font-size: 9pt">$</span></td><td style="border-bottom: Black 2.5pt double; width: 3%; text-align: right"><span style="font-size: 9pt"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2019-12-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,186,651</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="width: 1%"><span style="font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left"><span style="font-size: 9pt">$</span></td><td style="border-bottom: Black 2.5pt double; width: 3%; text-align: right"><span style="font-size: 9pt"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2019-12-31_custom_CommonStockPayableMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">25,000</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="width: 1%"><span style="font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left"><span style="font-size: 9pt">$</span></td><td style="border-bottom: Black 2.5pt double; width: 3%; text-align: right"><span style="font-size: 9pt">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2019-12-31_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">3,219,768</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-size: 9pt">)</span></td><td style="width: 1%"><span style="font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left"><span style="font-size: 9pt">$</span></td><td style="border-bottom: Black 2.5pt double; width: 3%; text-align: right"><span style="font-size: 9pt">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2019-12-31_us-gaap_TreasuryStockMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">103,537</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-size: 9pt">)</span></td><td style="width: 1%"><span style="font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left"><span style="font-size: 9pt">$</span></td><td style="border-bottom: Black 2.5pt double; width: 3%; text-align: right"><span style="font-size: 9pt">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,108,933</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-size: 9pt">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td></tr>
  <tr id="xdx_401_eus-gaap--AdjustmentsToAdditionalPaidInCapitalOther_zMq1K5DO5Ou9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-size: 9pt">Imputed interest</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">-</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt"><span style="-sec-ix-hidden: xdx2ixbrl0289">&#160;</span></span></td><td style="text-align: right"><span style="font-size: 9pt">-</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">-</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt"><span style="-sec-ix-hidden: xdx2ixbrl0290">&#160;</span></span></td><td style="text-align: right"><span style="font-size: 9pt">-</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">-</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt"><span style="-sec-ix-hidden: xdx2ixbrl0291">&#160;</span></span></td><td style="text-align: right"><span style="font-size: 9pt">-</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalOther" contextRef="From2020-01-012020-12-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,345</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt"><span style="-sec-ix-hidden: xdx2ixbrl0293">&#160;</span></span></td><td style="text-align: right"><span style="font-size: 9pt">-</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt"><span style="-sec-ix-hidden: xdx2ixbrl0294">&#160;</span></span></td><td style="text-align: right"><span style="font-size: 9pt">-</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt"><span style="-sec-ix-hidden: xdx2ixbrl0295">&#160;</span></span></td><td style="text-align: right"><span style="font-size: 9pt">-</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalOther" contextRef="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,345</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td></tr>
  <tr id="xdx_408_eus-gaap--AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature_ziT4N8fwLlKe" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-size: 9pt">Reclassification of derivative liabilities due to note conversion</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">-</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt"><span style="-sec-ix-hidden: xdx2ixbrl0298">&#160;</span></span></td><td style="text-align: right"><span style="font-size: 9pt">-</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">-</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt"><span style="-sec-ix-hidden: xdx2ixbrl0299">&#160;</span></span></td><td style="text-align: right"><span style="font-size: 9pt">-</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">-</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt"><span style="-sec-ix-hidden: xdx2ixbrl0300">&#160;</span></span></td><td style="text-align: right"><span style="font-size: 9pt">-</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature" contextRef="From2020-01-012020-12-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">907,551</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt"><span style="-sec-ix-hidden: xdx2ixbrl0302">&#160;</span></span></td><td style="text-align: right"><span style="font-size: 9pt">-</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt"><span style="-sec-ix-hidden: xdx2ixbrl0303">&#160;</span></span></td><td style="text-align: right"><span style="font-size: 9pt">-</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt"><span style="-sec-ix-hidden: xdx2ixbrl0304">&#160;</span></span></td><td style="text-align: right"><span style="font-size: 9pt">-</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature" contextRef="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">907,551</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td></tr>
  <tr id="xdx_403_ecustom--IssuanceOfPreferredStockForInvestmentValue_z91PpZGYdLK2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-size: 9pt">Issuance of Series B preferred shares for investment</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">-</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt"><span style="-sec-ix-hidden: xdx2ixbrl0307">&#160;</span></span></td><td style="text-align: right"><span style="font-size: 9pt">-</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td id="xdx_98B_ecustom--IssuanceOfPreferredStockForInvestmentShares_pp0d_c20200101__20201231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_z6VSUb56yxG5" title="Issuance of Series B preferred shares for investment, shares" style="text-align: right"><span style="font-size: 9pt"><ix:nonFraction name="AMIH:IssuanceOfPreferredStockForInvestmentShares" contextRef="From2020-01-012020-12-31_us-gaap_SeriesBPreferredStockMember_us-gaap_PreferredStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">500,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt"><ix:nonFraction name="AMIH:IssuanceOfPreferredStockForInvestmentValue" contextRef="From2020-01-012020-12-31_us-gaap_SeriesBPreferredStockMember_us-gaap_PreferredStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">50</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">-</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt"><span style="-sec-ix-hidden: xdx2ixbrl0309">&#160;</span></span></td><td style="text-align: right"><span style="font-size: 9pt">-</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt"><ix:nonFraction name="AMIH:IssuanceOfPreferredStockForInvestmentValue" contextRef="From2020-01-012020-12-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">605,438</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt"><span style="-sec-ix-hidden: xdx2ixbrl0311">&#160;</span></span></td><td style="text-align: right"><span style="font-size: 9pt">-</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt"><span style="-sec-ix-hidden: xdx2ixbrl0312">&#160;</span></span></td><td style="text-align: right"><span style="font-size: 9pt">-</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt"><span style="-sec-ix-hidden: xdx2ixbrl0313">&#160;</span></span></td><td style="text-align: right"><span style="font-size: 9pt">-</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt"><ix:nonFraction name="AMIH:IssuanceOfPreferredStockForInvestmentValue" contextRef="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">605,438</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td></tr>
  <tr id="xdx_402_eus-gaap--StockIssuedDuringPeriodValueNewIssues_zlKthEiBIMO" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-size: 9pt">Issuance of common shares under private placement</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">-</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt"><span style="-sec-ix-hidden: xdx2ixbrl0318">&#160;</span></span></td><td style="text-align: right"><span style="font-size: 9pt">-</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">-</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt"><span style="-sec-ix-hidden: xdx2ixbrl0319">&#160;</span></span></td><td style="text-align: right"><span style="font-size: 9pt">-</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td id="xdx_982_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pp0d_c20200101__20201231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zU6Tu5ThYwrk" title="Issuance of common shares under private placement, shares" style="text-align: right"><span style="font-size: 9pt"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2020-01-012020-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">131,250</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2020-01-012020-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">13</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2020-01-012020-12-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">71,487</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">(<ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2020-01-012020-12-31_custom_CommonStockPayableMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">25,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 9pt">)</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt"><span style="-sec-ix-hidden: xdx2ixbrl0323">&#160;</span></span></td><td style="text-align: right"><span style="font-size: 9pt">-</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt"><span style="-sec-ix-hidden: xdx2ixbrl0324">&#160;</span></span></td><td style="text-align: right"><span style="font-size: 9pt">-</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">46,500</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td></tr>
  <tr id="xdx_402_eus-gaap--StockRepurchasedDuringPeriodValue_zDo387pS2eLa" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-size: 9pt">Cancellation of treasury stock</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">-</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt"><span style="-sec-ix-hidden: xdx2ixbrl0329">&#160;</span></span></td><td style="text-align: right"><span style="font-size: 9pt">-</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">-</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt"><span style="-sec-ix-hidden: xdx2ixbrl0330">&#160;</span></span></td><td style="text-align: right"><span style="font-size: 9pt">-</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td id="xdx_981_eus-gaap--StockRepurchasedDuringPeriodShares_pp0d_c20200101__20201231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zMWQSLOFgK97" title="Cancellation of treasury stock, shares" style="text-align: right"><span style="font-size: 9pt">(<ix:nonFraction name="us-gaap:StockRepurchasedDuringPeriodShares" contextRef="From2020-01-012020-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="Shares">1,650,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 9pt">)</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">(<ix:nonFraction name="us-gaap:StockRepurchasedDuringPeriodValue" contextRef="From2020-01-012020-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">165</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 9pt">)</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">(<ix:nonFraction name="us-gaap:StockRepurchasedDuringPeriodValue" contextRef="From2020-01-012020-12-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">99,478</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 9pt">)</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt"><span style="-sec-ix-hidden: xdx2ixbrl0333">&#160;</span></span></td><td style="text-align: right"><span style="font-size: 9pt">-</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt"><span style="-sec-ix-hidden: xdx2ixbrl0334">&#160;</span></span></td><td style="text-align: right"><span style="font-size: 9pt">-</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt"><ix:nonFraction name="us-gaap:StockRepurchasedDuringPeriodValue" contextRef="From2020-01-012020-12-31_us-gaap_TreasuryStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">99,643</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt"><span style="-sec-ix-hidden: xdx2ixbrl0336">&#160;</span></span></td><td style="text-align: right"><span style="font-size: 9pt">-</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td></tr>
  <tr id="xdx_40A_ecustom--StockIssuedDuringPeriodValueIssuanceOfCommonSharesForNoteSettlement_zGG7Nbs8Jrph" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-size: 9pt">Issuance of common shares for note settlement</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">-</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt"><span style="-sec-ix-hidden: xdx2ixbrl0340">&#160;</span></span></td><td style="text-align: right"><span style="font-size: 9pt">-</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">-</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt"><span style="-sec-ix-hidden: xdx2ixbrl0341">&#160;</span></span></td><td style="text-align: right"><span style="font-size: 9pt">-</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td id="xdx_98C_ecustom--StockIssuedDuringPeriodSharesIssuanceOfCommonSharesForNoteSettlement_pp0d_c20200101__20201231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zhqd5i1Pqgk4" title="Issuance of common shares for note settlement, shares" style="text-align: right"><span style="font-size: 9pt"><ix:nonFraction name="AMIH:StockIssuedDuringPeriodSharesIssuanceOfCommonSharesForNoteSettlement" contextRef="From2020-01-012020-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">18,916,774</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt"><ix:nonFraction name="AMIH:StockIssuedDuringPeriodValueIssuanceOfCommonSharesForNoteSettlement" contextRef="From2020-01-012020-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,892</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt"><ix:nonFraction name="AMIH:StockIssuedDuringPeriodValueIssuanceOfCommonSharesForNoteSettlement" contextRef="From2020-01-012020-12-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,632,227</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt"><span style="-sec-ix-hidden: xdx2ixbrl0344">&#160;</span></span></td><td style="text-align: right"><span style="font-size: 9pt">-</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt"><span style="-sec-ix-hidden: xdx2ixbrl0345">&#160;</span></span></td><td style="text-align: right"><span style="font-size: 9pt">-</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt"><span style="-sec-ix-hidden: xdx2ixbrl0346">&#160;</span></span></td><td style="text-align: right"><span style="font-size: 9pt">-</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt"><ix:nonFraction name="AMIH:StockIssuedDuringPeriodValueIssuanceOfCommonSharesForNoteSettlement" contextRef="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,634,119</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td></tr>
  <tr id="xdx_400_ecustom--IssuanceOfSharesForServicesRelatedParties_zrcLeVca6Z55" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-size: 9pt">Issuance of shares for services - related parties</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td id="xdx_984_ecustom--IssuanceOfSharesForServicesRelatedPartiesShares_pp0d_c20200101__20201231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zXtyST0cIUrj" title="Issuance of shares for services - related parties, shares" style="text-align: right"><span style="font-size: 9pt"><ix:nonFraction name="AMIH:IssuanceOfSharesForServicesRelatedPartiesShares" contextRef="From2020-01-012020-12-31_us-gaap_SeriesAPreferredStockMember_us-gaap_PreferredStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">1</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt"><span style="-sec-ix-hidden: xdx2ixbrl0351">&#160;</span></span></td><td style="text-align: right"><span style="font-size: 9pt">-</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">-</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt"><span style="-sec-ix-hidden: xdx2ixbrl0352">&#160;</span></span></td><td style="text-align: right"><span style="font-size: 9pt">-</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td id="xdx_986_ecustom--IssuanceOfSharesForServicesRelatedPartiesShares_pp0d_c20200101__20201231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zTNApXj7jR" title="Issuance of shares for services - related parties, shares" style="text-align: right"><span style="font-size: 9pt"><ix:nonFraction name="AMIH:IssuanceOfSharesForServicesRelatedPartiesShares" contextRef="From2020-01-012020-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">6,000,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt"><ix:nonFraction name="AMIH:IssuanceOfSharesForServicesRelatedParties" contextRef="From2020-01-012020-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">600</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt"><ix:nonFraction name="AMIH:IssuanceOfSharesForServicesRelatedParties" contextRef="From2020-01-012020-12-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,559,400</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt"><span style="-sec-ix-hidden: xdx2ixbrl0355">&#160;</span></span></td><td style="text-align: right"><span style="font-size: 9pt">-</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt"><span style="-sec-ix-hidden: xdx2ixbrl0356">&#160;</span></span></td><td style="text-align: right"><span style="font-size: 9pt">-</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt"><span style="-sec-ix-hidden: xdx2ixbrl0357">&#160;</span></span></td><td style="text-align: right"><span style="font-size: 9pt">-</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt"><ix:nonFraction name="AMIH:IssuanceOfSharesForServicesRelatedParties" contextRef="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,560,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td></tr>
  <tr id="xdx_405_eus-gaap--StockIssuedDuringPeriodValueIssuedForServices_zBFyV3HgZ69e" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-size: 9pt">Issuance of shares for services</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">-</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt"><span style="-sec-ix-hidden: xdx2ixbrl0364">&#160;</span></span></td><td style="text-align: right"><span style="font-size: 9pt">-</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">-</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt"><span style="-sec-ix-hidden: xdx2ixbrl0365">&#160;</span></span></td><td style="text-align: right"><span style="font-size: 9pt">-</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td id="xdx_981_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_pp0d_c20200101__20201231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zNSnqo24aRS" title="Issuance of shares for services, shares" style="text-align: right"><span style="font-size: 9pt"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesIssuedForServices" contextRef="From2020-01-012020-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">2,377,142</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" contextRef="From2020-01-012020-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">238</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" contextRef="From2020-01-012020-12-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,300,575</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt"><span style="-sec-ix-hidden: xdx2ixbrl0368">&#160;</span></span></td><td style="text-align: right"><span style="font-size: 9pt">-</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt"><span style="-sec-ix-hidden: xdx2ixbrl0369">&#160;</span></span></td><td style="text-align: right"><span style="font-size: 9pt">-</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt"><span style="-sec-ix-hidden: xdx2ixbrl0370">&#160;</span></span></td><td style="text-align: right"><span style="font-size: 9pt">-</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" contextRef="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,300,813</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td></tr>
  <tr id="xdx_403_ecustom--IssuanceOfCommonSharesForSeriesBPreferredSharesConversion_i_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-size: 9pt">Issuance of common shares for Series B preferred shares conversion</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">-</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt"><span style="-sec-ix-hidden: xdx2ixbrl0375">&#160;</span></span></td><td style="text-align: right"><span style="font-size: 9pt">-</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td id="xdx_980_ecustom--IssuanceOfCommonSharesForSeriesBPreferredSharesConversionShares_pp0d_c20200101__20201231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zLNvFcLcA7Bf" title="Issuance of common shares for Series B preferred shares conversion, shares" style="text-align: right"><span style="font-size: 9pt">(<ix:nonFraction name="AMIH:IssuanceOfCommonSharesForSeriesBPreferredSharesConversionShares" contextRef="From2020-01-012020-12-31_us-gaap_SeriesBPreferredStockMember_us-gaap_PreferredStockMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="Shares">500,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 9pt">)</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">(<ix:nonFraction name="AMIH:IssuanceOfCommonSharesForSeriesBPreferredSharesConversion" contextRef="From2020-01-012020-12-31_us-gaap_SeriesBPreferredStockMember_us-gaap_PreferredStockMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">50</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 9pt">)</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td id="xdx_983_ecustom--IssuanceOfCommonSharesForSeriesBPreferredSharesConversionShares_pp0d_c20200101__20201231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zJOEAtjkDjfd" title="Issuance of common shares for Series B preferred shares conversion, shares" style="text-align: right"><span style="font-size: 9pt"><ix:nonFraction name="AMIH:IssuanceOfCommonSharesForSeriesBPreferredSharesConversionShares" contextRef="From2020-01-012020-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">2,083,333</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt"><ix:nonFraction name="AMIH:IssuanceOfCommonSharesForSeriesBPreferredSharesConversion" contextRef="From2020-01-012020-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">208</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">(<ix:nonFraction name="AMIH:IssuanceOfCommonSharesForSeriesBPreferredSharesConversion" contextRef="From2020-01-012020-12-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">158</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 9pt">)</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt"><span style="-sec-ix-hidden: xdx2ixbrl0379">&#160;</span></span></td><td style="text-align: right"><span style="font-size: 9pt">-</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt"><span style="-sec-ix-hidden: xdx2ixbrl0380">&#160;</span></span></td><td style="text-align: right"><span style="font-size: 9pt">-</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt"><span style="-sec-ix-hidden: xdx2ixbrl0381">&#160;</span></span></td><td style="text-align: right"><span style="font-size: 9pt">-</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt"><ix:nonFraction name="AMIH:IssuanceOfCommonSharesForSeriesBPreferredSharesConversion" contextRef="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">50</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td></tr>
  <tr id="xdx_405_eus-gaap--NetIncomeLoss_zi9n2RvRUIV7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-size: 9pt">Net (loss)</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<span style="font-size: 9pt">-</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<span style="-sec-ix-hidden: xdx2ixbrl0388">&#8239;</span><span style="font-size: 9pt">-</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 9pt">-</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<span style="-sec-ix-hidden: xdx2ixbrl0389">&#8239;</span><span style="font-size: 9pt">-</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 9pt">-</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 9pt"><span style="-sec-ix-hidden: xdx2ixbrl0390">&#160;</span></span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 9pt">-</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 9pt"><span style="-sec-ix-hidden: xdx2ixbrl0391">&#160;</span></span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 9pt">-</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 9pt"><span style="-sec-ix-hidden: xdx2ixbrl0392">&#160;</span></span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 9pt">-</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 9pt">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2020-01-012020-12-31_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">7,339,890</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 9pt">)</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 9pt"><span style="-sec-ix-hidden: xdx2ixbrl0394">&#160;</span></span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 9pt">-</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 9pt">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">7,339,890</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 9pt">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td></tr>
  <tr id="xdx_438_c20200101__20201231_eus-gaap--StockholdersEquity_iE_z00lAIl1Xjcj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-size: 9pt">Balance, December 31, 2020</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-size: 9pt">&#160;</span></td><td id="xdx_98B_eus-gaap--SharesOutstanding_iE_pp0d_c20200101__20201231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zVvaSVVYya85" title="Balance, shares" style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-size: 9pt"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2020-12-31_us-gaap_SeriesAPreferredStockMember_us-gaap_PreferredStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">1</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-size: 9pt">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-size: 9pt"><span style="-sec-ix-hidden: xdx2ixbrl0397">-</span></span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-size: 9pt">&#160;</span></td><td id="xdx_988_eus-gaap--SharesOutstanding_iE_pp0d_c20200101__20201231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zZDPPt8eB4J2" title="Balance, shares" style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-size: 9pt"><span style="-sec-ix-hidden: xdx2ixbrl0408">-</span></span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-size: 9pt">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-size: 9pt"><span style="-sec-ix-hidden: xdx2ixbrl0398">-</span></span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-size: 9pt">&#160;</span></td><td id="xdx_981_eus-gaap--SharesOutstanding_iE_pp0d_c20200101__20201231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zf7nWF0TxrDa" title="Balance, shares" style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-size: 9pt"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2020-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">55,066,855</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-size: 9pt">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-size: 9pt"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2020-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,507</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-size: 9pt">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-size: 9pt"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2020-12-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">9,167,038</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-size: 9pt">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-size: 9pt"><span style="-sec-ix-hidden: xdx2ixbrl0401">-</span></span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-size: 9pt">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-size: 9pt">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2020-12-31_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">10,559,658</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 9pt">)</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-size: 9pt">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-size: 9pt">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2020-12-31_us-gaap_TreasuryStockMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">3,894</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 9pt">)</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-size: 9pt">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-size: 9pt">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,391,007</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 9pt">)</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-size: 9pt">Shares</span></td><td><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: center">&#160;</td>
    <td id="xdx_4BC_us-gaap--StatementClassOfStockAxis_us-gaap--SeriesAPreferredStockMember_us-gaap--StatementEquityComponentsAxis_us-gaap--PreferredStockMember_zw18mElYBIv1" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-size: 9pt">Amount</span></td><td><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-size: 9pt">Shares</span></td><td><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: center">&#160;</td>
    <td id="xdx_4B2_us-gaap--StatementClassOfStockAxis_us-gaap--SeriesBPreferredStockMember_us-gaap--StatementEquityComponentsAxis_us-gaap--PreferredStockMember_zkUkH9JjLXma" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-size: 9pt">Amount</span></td><td><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-size: 9pt">Shares</span></td><td><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td colspan="2" id="xdx_4BF_us-gaap--StatementEquityComponentsAxis_us-gaap--CommonStockMember_z7WUVUVp5a91" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-size: 9pt">Amount</span></td><td><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td colspan="2" id="xdx_4BA_us-gaap--StatementEquityComponentsAxis_us-gaap--AdditionalPaidInCapitalMember_zNdO3WlFLbdl" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-size: 9pt">Capital</span></td><td><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td colspan="2" id="xdx_4B7_us-gaap--StatementEquityComponentsAxis_custom--CommonStockPayableMember_zOeVlUMYIzu6" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-size: 9pt">Payable</span></td><td><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td colspan="2" id="xdx_4BA_us-gaap--StatementEquityComponentsAxis_us-gaap--RetainedEarningsMember_zGUS6GxSgdza" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-size: 9pt">(Deficit)</span></td><td><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td colspan="2" id="xdx_4BD_us-gaap--StatementEquityComponentsAxis_us-gaap--TreasuryStockMember_zj6DNgLPF2Vk" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-size: 9pt">Stock</span></td><td><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td colspan="2" id="xdx_4B6_zFLXyGr0w0h5" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-size: 9pt">(Deficit)</span></td><td><span style="font-size: 9pt">&#160;</span></td></tr>
<tr style="vertical-align: bottom">
    <td><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="margin-top: 0; margin-bottom: 0"><span style="font-size: 9pt">Preferred</span></p>
                                                                                <p style="margin-top: 0; margin-bottom: 0"><span style="font-size: 9pt">Stock A</span></p></td><td><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="margin-top: 0; margin-bottom: 0"><span style="font-size: 9pt">Preferred</span></p>
                                                                                <p style="margin-top: 0; margin-bottom: 0"><span style="font-size: 9pt">Stock B</span></p></td><td><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-size: 9pt">Common Stock</span></td><td><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td colspan="2" style="text-align: center"><p style="margin-top: 0; margin-bottom: 0"><span style="font-size: 9pt">Additional</span></p>
                                               <p style="margin-top: 0; margin-bottom: 0"><span style="font-size: 9pt">Paid-in</span></p></td><td><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td colspan="2" style="text-align: center"><p style="margin-top: 0; margin-bottom: 0">Common</p>
                                               <p style="margin-top: 0; margin-bottom: 0"><span style="font-size: 9pt">Stock</span></p></td><td><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td colspan="2" style="text-align: center"><p style="margin-top: 0; margin-bottom: 0">Retained</p>
                                               <p style="margin-top: 0; margin-bottom: 0"><span style="font-size: 9pt">Earnings</span></p></td><td><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td colspan="2" style="text-align: center"><span style="font-size: 9pt">Treasury</span></td><td><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td colspan="2" style="text-align: center"><p style="margin-top: 0; margin-bottom: 0"><span style="font-size: 9pt">Total</span></p>
                                               <p style="margin-top: 0; margin-bottom: 0"><span style="font-size: 9pt">Stockholders&#8217;<br />
</span></p></td><td><span style="font-size: 9pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-size: 9pt">Shares</span></td><td><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-size: 9pt">Amount</span></td><td><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-size: 9pt">Shares</span></td><td><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-size: 9pt">Amount</span></td><td><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-size: 9pt">Shares</span></td><td><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-size: 9pt">Amount</span></td><td><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-size: 9pt">Capital</span></td><td><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-size: 9pt">Payable</span></td><td><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-size: 9pt">(Deficit)</span></td><td><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-size: 9pt">Stock</span></td><td><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-size: 9pt">(Deficit)</span></td><td><span style="font-size: 9pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td colspan="2"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td colspan="2"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td colspan="2"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td colspan="2"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td colspan="2"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td colspan="2"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td colspan="2"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td colspan="2"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td colspan="2"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td colspan="2"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td colspan="2"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td></tr>
  <tr id="xdx_43D_c20210101__20211231_eus-gaap--StockholdersEquity_iS_zYdef80Gf87i" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 34%"><span style="font-size: 9pt">Balance, December 31, 2020</span></td><td style="width: 1%"><span style="font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left"><span style="font-size: 9pt">&#160;</span></td><td id="xdx_988_eus-gaap--SharesOutstanding_iS_pp0d_c20210101__20211231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zppYd40d1rta" title="Balance, shares" style="border-bottom: Black 2.5pt double; width: 3%; text-align: right"><span style="font-size: 9pt"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2020-12-31_us-gaap_SeriesAPreferredStockMember_us-gaap_PreferredStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">1</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="width: 1%"><span style="font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left"><span style="font-size: 9pt">$</span></td><td style="border-bottom: Black 2.5pt double; width: 3%; text-align: right"><span style="font-size: 9pt"><span style="-sec-ix-hidden: xdx2ixbrl0412">-</span></span></td><td style="width: 1%; text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="width: 1%"><span style="font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left"><span style="font-size: 9pt">&#160;</span></td><td id="xdx_982_eus-gaap--SharesOutstanding_iS_pp0d_c20210101__20211231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zHCiNKTIfyPh" title="Balance, shares" style="border-bottom: Black 2.5pt double; width: 3%; text-align: right"><span style="font-size: 9pt"><span style="-sec-ix-hidden: xdx2ixbrl0423">-</span></span></td><td style="width: 1%; text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="width: 1%"><span style="font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left"><span style="font-size: 9pt">$</span></td><td style="border-bottom: Black 2.5pt double; width: 3%; text-align: right"><span style="font-size: 9pt"><span style="-sec-ix-hidden: xdx2ixbrl0413">-</span></span></td><td style="width: 1%; text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="width: 1%"><span style="font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left"><span style="font-size: 9pt">&#160;</span></td><td id="xdx_98A_eus-gaap--SharesOutstanding_iS_pp0d_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zI84rExeK39l" title="Balance, shares" style="border-bottom: Black 2.5pt double; width: 3%; text-align: right"><span style="font-size: 9pt"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2020-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">55,066,855</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="width: 1%"><span style="font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left"><span style="font-size: 9pt">$</span></td><td style="border-bottom: Black 2.5pt double; width: 3%; text-align: right"><span style="font-size: 9pt"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2020-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,507</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="width: 1%"><span style="font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left"><span style="font-size: 9pt">$</span></td><td style="border-bottom: Black 2.5pt double; width: 3%; text-align: right"><span style="font-size: 9pt"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2020-12-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">9,167,038</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="width: 1%"><span style="font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left"><span style="font-size: 9pt">$</span></td><td style="border-bottom: Black 2.5pt double; width: 3%; text-align: right"><span style="font-size: 9pt"><span style="-sec-ix-hidden: xdx2ixbrl0416">-</span></span></td><td style="width: 1%; text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="width: 1%"><span style="font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left"><span style="font-size: 9pt">$</span></td><td style="border-bottom: Black 2.5pt double; width: 3%; text-align: right"><span style="font-size: 9pt">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2020-12-31_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">10,559,658</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-size: 9pt">)</span></td><td style="width: 1%"><span style="font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left"><span style="font-size: 9pt">$</span></td><td style="border-bottom: Black 2.5pt double; width: 3%; text-align: right"><span style="font-size: 9pt">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2020-12-31_us-gaap_TreasuryStockMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">3,894</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-size: 9pt">)</span></td><td style="width: 1%"><span style="font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left"><span style="font-size: 9pt">$</span></td><td style="border-bottom: Black 2.5pt double; width: 3%; text-align: right"><span style="font-size: 9pt">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,391,007</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-size: 9pt">)</span></td></tr>
  <tr id="xdx_435_c20210101__20211231_eus-gaap--StockholdersEquity_iS_zhL4YWc9Onyc" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-size: 9pt">Balance</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-size: 9pt">&#160;</span></td><td id="xdx_98A_eus-gaap--SharesOutstanding_iS_pp0d_c20210101__20211231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zoi8bpGydqqk" title="Balance, shares" style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-size: 9pt"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2020-12-31_us-gaap_SeriesAPreferredStockMember_us-gaap_PreferredStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">1</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-size: 9pt">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-size: 9pt"><span style="-sec-ix-hidden: xdx2ixbrl0427">-</span></span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-size: 9pt">&#160;</span></td><td id="xdx_989_eus-gaap--SharesOutstanding_iS_pp0d_c20210101__20211231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_znF2i8wjYiY6" title="Balance, shares" style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-size: 9pt"><span style="-sec-ix-hidden: xdx2ixbrl0438">-</span></span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-size: 9pt">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-size: 9pt"><span style="-sec-ix-hidden: xdx2ixbrl0428">-</span></span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-size: 9pt">&#160;</span></td><td id="xdx_98A_eus-gaap--SharesOutstanding_iS_pp0d_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zE6s92eWFNml" title="Balance, shares" style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-size: 9pt"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2020-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">55,066,855</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-size: 9pt">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-size: 9pt"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2020-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,507</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-size: 9pt">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-size: 9pt"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2020-12-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">9,167,038</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-size: 9pt">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-size: 9pt"><span style="-sec-ix-hidden: xdx2ixbrl0431">-</span></span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-size: 9pt">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-size: 9pt">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2020-12-31_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">10,559,658</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 9pt">)</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-size: 9pt">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-size: 9pt">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2020-12-31_us-gaap_TreasuryStockMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">3,894</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 9pt">)</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-size: 9pt">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-size: 9pt">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,391,007</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 9pt">)</span></td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td></tr>
  <tr id="xdx_40D_eus-gaap--AdjustmentsToAdditionalPaidInCapitalOther_zTClzpDy94B1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-size: 9pt">Imputed interest</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">-</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt"><span style="-sec-ix-hidden: xdx2ixbrl0442">-</span></span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">-</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt"><span style="-sec-ix-hidden: xdx2ixbrl0443">-</span></span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">-</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt"><span style="-sec-ix-hidden: xdx2ixbrl0444">&#160;</span></span></td><td style="text-align: right"><span style="font-size: 9pt">-</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalOther" contextRef="From2021-01-012021-12-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,979</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt"><span style="-sec-ix-hidden: xdx2ixbrl0446">&#160;</span></span></td><td style="text-align: right"><span style="font-size: 9pt">-</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt"><span style="-sec-ix-hidden: xdx2ixbrl0447">&#160;</span></span></td><td style="text-align: right"><span style="font-size: 9pt">-</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt"><span style="-sec-ix-hidden: xdx2ixbrl0448">&#160;</span></span></td><td style="text-align: right"><span style="font-size: 9pt">-</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalOther" contextRef="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,979</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td></tr>
  <tr id="xdx_401_eus-gaap--AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature_zs7dFgaKFyJd" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-size: 9pt">Reclassification of derivative liabilities due to note conversion</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">-</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt"><span style="-sec-ix-hidden: xdx2ixbrl0451">-</span></span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">-</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt"><span style="-sec-ix-hidden: xdx2ixbrl0452">-</span></span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">-</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt"><span style="-sec-ix-hidden: xdx2ixbrl0453">&#160;</span></span></td><td style="text-align: right"><span style="font-size: 9pt">-</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature" contextRef="From2021-01-012021-12-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,116,122</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt"><span style="-sec-ix-hidden: xdx2ixbrl0455">&#160;</span></span></td><td style="text-align: right"><span style="font-size: 9pt">-</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt"><span style="-sec-ix-hidden: xdx2ixbrl0456">&#160;</span></span></td><td style="text-align: right"><span style="font-size: 9pt">-</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt"><span style="-sec-ix-hidden: xdx2ixbrl0457">&#160;</span></span></td><td style="text-align: right"><span style="font-size: 9pt">-</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature" contextRef="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,116,122</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td></tr>
  <tr id="xdx_406_ecustom--StockIssuedDuringPeriodValueNewIssuesOne_zjXISHaZfxtl" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">Issuance
    of Series B preferred shares for In Process Research and Development</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">-</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt"><span style="-sec-ix-hidden: xdx2ixbrl0460">-</span></span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td id="xdx_984_ecustom--StockIssuedDuringPeriodSharesNewIssuesOne_c20210101__20211231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_z8D7Nz4zNzea" title="Issuance of Series B preferred shares for In Process Research and Development, shares" style="text-align: right"><span style="font-size: 9pt"><ix:nonFraction name="AMIH:StockIssuedDuringPeriodSharesNewIssuesOne" contextRef="From2021-01-012021-12-31_us-gaap_SeriesBPreferredStockMember_us-gaap_PreferredStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">500,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt"><ix:nonFraction name="AMIH:StockIssuedDuringPeriodValueNewIssuesOne" contextRef="From2021-01-012021-12-31_us-gaap_SeriesBPreferredStockMember_us-gaap_PreferredStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">50</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">-</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt"><span style="-sec-ix-hidden: xdx2ixbrl0462">&#160;</span></span></td><td style="text-align: right"><span style="font-size: 9pt">-</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt"><ix:nonFraction name="AMIH:StockIssuedDuringPeriodValueNewIssuesOne" contextRef="From2021-01-012021-12-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">601,802</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt"><span style="-sec-ix-hidden: xdx2ixbrl0464">&#160;</span></span></td><td style="text-align: right"><span style="font-size: 9pt">-</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt"><span style="-sec-ix-hidden: xdx2ixbrl0465">&#160;</span></span></td><td style="text-align: right"><span style="font-size: 9pt">-</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt"><span style="-sec-ix-hidden: xdx2ixbrl0466">&#160;</span></span></td><td style="text-align: right"><span style="font-size: 9pt">-</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt"><ix:nonFraction name="AMIH:StockIssuedDuringPeriodValueNewIssuesOne" contextRef="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">601,852</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_ecustom--StockIssuedDuringPeriodValuePreferredShareConversion_zzhE88musgue" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-size: 9pt">Issuance of common shares for Series B preferred shares conversion</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">-</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt"><span style="-sec-ix-hidden: xdx2ixbrl0471">-</span></span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td id="xdx_980_ecustom--StockIssuedDuringPeriodSharesPreferredShareConversion_pid_c20210101__20211231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zyh6OErp4Yx4" title="Issuance of common shares for Series B preferred shares conversion, shares" style="text-align: right">(<ix:nonFraction name="AMIH:StockIssuedDuringPeriodSharesPreferredShareConversion" contextRef="From2021-01-012021-12-31_us-gaap_SeriesBPreferredStockMember_us-gaap_PreferredStockMember" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="Shares">500,000</ix:nonFraction></td><td style="text-align: left">)<span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right">(<ix:nonFraction name="AMIH:StockIssuedDuringPeriodValuePreferredShareConversion" contextRef="From2021-01-012021-12-31_us-gaap_SeriesBPreferredStockMember_us-gaap_PreferredStockMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">50</ix:nonFraction></td><td style="text-align: left">)<span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td id="xdx_987_ecustom--StockIssuedDuringPeriodSharesPreferredShareConversion_pp0d_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zp3laCRJYJZ5" title="Issuance of common shares for series B preferred shares conversion, shares" style="text-align: right"><span style="font-size: 9pt"><ix:nonFraction name="AMIH:StockIssuedDuringPeriodSharesPreferredShareConversion" contextRef="From2021-01-012021-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">2,057,613</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt"><ix:nonFraction name="AMIH:StockIssuedDuringPeriodValuePreferredShareConversion" contextRef="From2021-01-012021-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">206</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">(<ix:nonFraction name="AMIH:StockIssuedDuringPeriodValuePreferredShareConversion" contextRef="From2021-01-012021-12-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">156</ix:nonFraction></span></td><td style="text-align: left">)<span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt"><span style="-sec-ix-hidden: xdx2ixbrl0475">&#160;</span></span></td><td style="text-align: right"><span style="font-size: 9pt">-</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt"><span style="-sec-ix-hidden: xdx2ixbrl0476">&#160;</span></span></td><td style="text-align: right"><span style="font-size: 9pt">-</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt"><span style="-sec-ix-hidden: xdx2ixbrl0477">&#160;</span></span></td><td style="text-align: right"><span style="font-size: 9pt">-</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt"><span style="-sec-ix-hidden: xdx2ixbrl0478">&#160;</span></span></td><td style="text-align: right"><span style="font-size: 9pt">-</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td></tr>
  <tr id="xdx_40F_eus-gaap--StockIssuedDuringPeriodValueNewIssues_zowDxo3kd1ag" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-size: 9pt">Issuance of common shares under private placement</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">-</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt"><span style="-sec-ix-hidden: xdx2ixbrl0484">-</span></span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">-</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt"><span style="-sec-ix-hidden: xdx2ixbrl0485">-</span></span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td id="xdx_98E_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pp0d_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zSS553oI12Th" title="Issuance of common shares under private placement, shares" style="text-align: right"><span style="font-size: 9pt"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2021-01-012021-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">200,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2021-01-012021-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">20</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2021-01-012021-12-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">99,980</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt"><span style="-sec-ix-hidden: xdx2ixbrl0488">&#160;</span></span></td><td style="text-align: right"><span style="font-size: 9pt">-</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt"><span style="-sec-ix-hidden: xdx2ixbrl0489">&#160;</span></span></td><td style="text-align: right"><span style="font-size: 9pt">-</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt"><span style="-sec-ix-hidden: xdx2ixbrl0490">&#160;</span></span></td><td style="text-align: right"><span style="font-size: 9pt">-</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">100,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td></tr>
  <tr id="xdx_40C_eus-gaap--StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_zkGqemkPCPl5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-size: 9pt">Issuance of common shares for note conversion and settlement</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">-</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt"><span style="-sec-ix-hidden: xdx2ixbrl0495">-</span></span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">-</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt"><span style="-sec-ix-hidden: xdx2ixbrl0496">-</span></span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td id="xdx_983_eus-gaap--StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_pid_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zPN8niXRt14b" title="Issuance of common shares for note conversion and settlement, shares" style="text-align: right"><span style="font-size: 9pt"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" contextRef="From2021-01-012021-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">12,545,171</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" contextRef="From2021-01-012021-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,255</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" contextRef="From2021-01-012021-12-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,227,216</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt"><span style="-sec-ix-hidden: xdx2ixbrl0499">&#160;</span></span></td><td style="text-align: right"><span style="font-size: 9pt">-</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt"><span style="-sec-ix-hidden: xdx2ixbrl0500">&#160;</span></span></td><td style="text-align: right"><span style="font-size: 9pt">-</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt"><span style="-sec-ix-hidden: xdx2ixbrl0501">&#160;</span></span></td><td style="text-align: right"><span style="font-size: 9pt">-</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" contextRef="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,228,471</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td></tr>
  <tr id="xdx_404_ecustom--IssuanceOfSharesForServicesRelatedParties_zTYnHHIOt4O5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-size: 9pt">Issuance of shares for services - related parties</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">-</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt"><span style="-sec-ix-hidden: xdx2ixbrl0506">-</span></span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">-</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt"><span style="-sec-ix-hidden: xdx2ixbrl0507">-</span></span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td id="xdx_98D_ecustom--IssuanceOfSharesForServicesRelatedPartiesShares_pid_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zAjt0teOVqpd" title="Issuance of shares for services - related parties, shares" style="text-align: right"><span style="font-size: 9pt"><ix:nonFraction name="AMIH:IssuanceOfSharesForServicesRelatedPartiesShares" contextRef="From2021-01-012021-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">6,500,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt"><ix:nonFraction name="AMIH:IssuanceOfSharesForServicesRelatedParties" contextRef="From2021-01-012021-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">650</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt"><ix:nonFraction name="AMIH:IssuanceOfSharesForServicesRelatedParties" contextRef="From2021-01-012021-12-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,510,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt"><span style="-sec-ix-hidden: xdx2ixbrl0510">&#160;</span></span></td><td style="text-align: right"><span style="font-size: 9pt">-</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt"><span style="-sec-ix-hidden: xdx2ixbrl0511">&#160;</span></span></td><td style="text-align: right"><span style="font-size: 9pt">-</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt"><span style="-sec-ix-hidden: xdx2ixbrl0512">&#160;</span></span></td><td style="text-align: right"><span style="font-size: 9pt">-</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt"><ix:nonFraction name="AMIH:IssuanceOfSharesForServicesRelatedParties" contextRef="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,510,650</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td></tr>
  <tr id="xdx_400_eus-gaap--StockIssuedDuringPeriodValueIssuedForServices_zTHse5BpGZA8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-size: 9pt">Issuance of shares for services</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">-</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt"><span style="-sec-ix-hidden: xdx2ixbrl0517">-</span></span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">-</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt"><span style="-sec-ix-hidden: xdx2ixbrl0518">-</span></span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td id="xdx_983_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_pid_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zM1ZjPLtk33k" title="Issuance of shares for services, shares" style="text-align: right"><span style="font-size: 9pt"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesIssuedForServices" contextRef="From2021-01-012021-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">7,366,678</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" contextRef="From2021-01-012021-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">736</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" contextRef="From2021-01-012021-12-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,823,471</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt"><span style="-sec-ix-hidden: xdx2ixbrl0521">&#160;</span></span></td><td style="text-align: right"><span style="font-size: 9pt">-</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt"><span style="-sec-ix-hidden: xdx2ixbrl0522">&#160;</span></span></td><td style="text-align: right"><span style="font-size: 9pt">-</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt"><span style="-sec-ix-hidden: xdx2ixbrl0523">&#160;</span></span></td><td style="text-align: right"><span style="font-size: 9pt">-</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" contextRef="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,824,207</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td></tr>
  <tr id="xdx_40C_ecustom--IssuanceOfCommonSharesForDebtSettlement_zOHyxjjrhZY1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-size: 9pt">Issuance of common shares for debt settlement</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">-</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt"><span style="-sec-ix-hidden: xdx2ixbrl0528">-</span></span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">-</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt"><span style="-sec-ix-hidden: xdx2ixbrl0529">-</span></span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td id="xdx_981_ecustom--IssuanceOfCommonSharesForDebtSettlementShares_pid_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zswgET9dBM0a" title="Issuance of common shares for debt settlement, shares" style="text-align: right"><span style="font-size: 9pt"><ix:nonFraction name="AMIH:IssuanceOfCommonSharesForDebtSettlementShares" contextRef="From2021-01-012021-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">708,750</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt"><ix:nonFraction name="AMIH:IssuanceOfCommonSharesForDebtSettlement" contextRef="From2021-01-012021-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">71</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt"><ix:nonFraction name="AMIH:IssuanceOfCommonSharesForDebtSettlement" contextRef="From2021-01-012021-12-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">119,454</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt"><span style="-sec-ix-hidden: xdx2ixbrl0532">&#160;</span></span></td><td style="text-align: right"><span style="font-size: 9pt">-</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt"><span style="-sec-ix-hidden: xdx2ixbrl0533">&#160;</span></span></td><td style="text-align: right"><span style="font-size: 9pt">-</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt"><span style="-sec-ix-hidden: xdx2ixbrl0534">&#160;</span></span></td><td style="text-align: right"><span style="font-size: 9pt">-</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt"><ix:nonFraction name="AMIH:IssuanceOfCommonSharesForDebtSettlement" contextRef="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">119,525</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td></tr>
  <tr id="xdx_404_eus-gaap--NetIncomeLoss_zQQfTFzsQ4n5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-size: 9pt">Net income</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<span style="font-size: 9pt">-</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 9pt"><span style="-sec-ix-hidden: xdx2ixbrl0539">-</span></span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<span style="font-size: 9pt">-</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 9pt"><span style="-sec-ix-hidden: xdx2ixbrl0540">-</span></span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 9pt">-</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 9pt"><span style="-sec-ix-hidden: xdx2ixbrl0541">&#160;</span></span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 9pt">-</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 9pt"><span style="-sec-ix-hidden: xdx2ixbrl0542">&#160;</span></span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 9pt">-</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 9pt"><span style="-sec-ix-hidden: xdx2ixbrl0543">&#160;</span></span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 9pt">-</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 9pt">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2021-01-012021-12-31_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">9,980,911</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 9pt">)</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 9pt"><span style="-sec-ix-hidden: xdx2ixbrl0545">&#160;</span></span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 9pt">-</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 9pt">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">9,980,911</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 9pt">)</span></td></tr>
<tr id="xdx_40E_eus-gaap--NetIncomeLoss_zWodncpIKnve" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-size: 9pt">Net income (Loss)</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">-</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt"><span style="-sec-ix-hidden: xdx2ixbrl0548">-</span></span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">-</span></td><td style="text-align: left"><span style="font-size: 9pt"></span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt"><span style="-sec-ix-hidden: xdx2ixbrl0549">-</span></span></td><td style="text-align: left"><span style="font-size: 9pt"></span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">-</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt"><span style="-sec-ix-hidden: xdx2ixbrl0550">&#160;</span></span></td><td style="text-align: right"><span style="font-size: 9pt">-</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt"><span style="-sec-ix-hidden: xdx2ixbrl0551">&#160;</span></span></td><td style="text-align: right">-</td><td style="text-align: left"><span style="font-size: 9pt"></span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt"><span style="-sec-ix-hidden: xdx2ixbrl0552">&#160;</span></span></td><td style="text-align: right"><span style="font-size: 9pt">-</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2021-01-012021-12-31_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">9,980,911</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 9pt">)</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt"><span style="-sec-ix-hidden: xdx2ixbrl0554">&#160;</span></span></td><td style="text-align: right"><span style="font-size: 9pt">-</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">9,980,911</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 9pt">)</span></td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td></tr>
  <tr id="xdx_436_c20210101__20211231_eus-gaap--StockholdersEquity_iE_zQCoQiBCkET" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-size: 9pt">Balance, December 31, 2021</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-size: 9pt">&#160;</span></td><td id="xdx_986_eus-gaap--SharesOutstanding_iE_pid_c20210101__20211231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_z7GTvbeFOkV6" title="Balance, shares" style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-size: 9pt"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2021-12-31_us-gaap_SeriesAPreferredStockMember_us-gaap_PreferredStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-size: 9pt">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-size: 9pt"><span style="-sec-ix-hidden: xdx2ixbrl0557">-</span></span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-size: 9pt">&#160;</span></td><td id="xdx_984_eus-gaap--SharesOutstanding_iE_pid_c20210101__20211231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zHHBgQXqw575" title="Balance, shares" style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-size: 9pt"><span style="-sec-ix-hidden: xdx2ixbrl0568">-</span></span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-size: 9pt">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-size: 9pt"><span style="-sec-ix-hidden: xdx2ixbrl0558">-</span></span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-size: 9pt">&#160;</span></td><td id="xdx_98E_eus-gaap--SharesOutstanding_iE_pid_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zULUImxXOo42" title="Balance, shares" style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-size: 9pt"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2021-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">84,445,067</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-size: 9pt">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-size: 9pt"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">8,445</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-size: 9pt">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-size: 9pt"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-12-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">16,666,906</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-size: 9pt">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-size: 9pt"><span style="-sec-ix-hidden: xdx2ixbrl0561">-</span></span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-size: 9pt">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-size: 9pt">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-12-31_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">20,540,569</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 9pt">)</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-size: 9pt">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-size: 9pt">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-12-31_us-gaap_TreasuryStockMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">3,894</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 9pt">)</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-size: 9pt">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-size: 9pt">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">3,869,111</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 9pt">)</span></td></tr>
  <tr id="xdx_437_c20210101__20211231_eus-gaap--StockholdersEquity_iE_zD81PCOs6pWh" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-size: 9pt">Balance</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-size: 9pt">&#160;</span></td><td id="xdx_98E_eus-gaap--SharesOutstanding_iE_pid_c20210101__20211231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zZb48chmlkk5" title="Balance, shares" style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-size: 9pt"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2021-12-31_us-gaap_SeriesAPreferredStockMember_us-gaap_PreferredStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-size: 9pt">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-size: 9pt"><span style="-sec-ix-hidden: xdx2ixbrl0572">-</span></span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-size: 9pt">&#160;</span></td><td id="xdx_980_eus-gaap--SharesOutstanding_iE_pid_c20210101__20211231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zL0aTduAZDI" title="Balance, shares" style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-size: 9pt"><span style="-sec-ix-hidden: xdx2ixbrl0583">-</span></span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-size: 9pt">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-size: 9pt"><span style="-sec-ix-hidden: xdx2ixbrl0573">-</span></span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-size: 9pt">&#160;</span></td><td id="xdx_982_eus-gaap--SharesOutstanding_iE_pid_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zvxutRZC2uyd" title="Balance, shares" style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-size: 9pt"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2021-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">84,445,067</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-size: 9pt">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-size: 9pt"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">8,445</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-size: 9pt">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-size: 9pt"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-12-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">16,666,906</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-size: 9pt">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-size: 9pt"><span style="-sec-ix-hidden: xdx2ixbrl0576">-</span></span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-size: 9pt">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-size: 9pt">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-12-31_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">20,540,569</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 9pt">)</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-size: 9pt">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-size: 9pt">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-12-31_us-gaap_TreasuryStockMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">3,894</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 9pt">)</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-size: 9pt">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-size: 9pt">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">3,869,111</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 9pt">)</span></td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying notes are an integral part of these audited consolidated financial statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 135; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: left"><a href="#fin" title="Table of Contents" style="font-style: italic">Table of Contents</a>&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>AMERICAN
INTERNATIONAL HOLDINGS CORP.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="Gv_011"></span>Consolidated
Statements of Cash Flows</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" id="xdx_305_112_zKsuLFjgk4Oe" summary="xdx: Statement - Consolidated Statements of Cash Flows" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" id="xdx_497_20210101__20211231_zDTytOlGNLvh" style="text-align: center">For the Year Ended</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" id="xdx_49F_20200101__20201231_z4PemhBDvVZd" style="text-align: center">For the Year Ended</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">December 31, 2021</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">December 31, 2020</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--NetCashProvidedByUsedInOperatingActivitiesAbstract_iB_zHazdyLZ0Qx" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">CASH FLOWS FROM OPERATING ACTIVITIES:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_i01_pp0p0_maNCPBUzx42_zQPhUcm992P7" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; width: 60%; text-align: left">Net income (loss)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" contextRef="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">10,225,497</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" contextRef="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">6,460,653</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td></tr>
  <tr id="xdx_40A_eus-gaap--IncomeLossFromDiscontinuedOperationsNetOfTax_i01_pp0p0_maNCPBUzx42_zlgniHelIuEd" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Net loss from discontinued operations</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax" contextRef="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">244,586</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax" contextRef="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">879,237</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_407_eus-gaap--AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_i01B_zW3BlykYr4ok" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Adjustments to reconcile net income (loss) to net cash (used in) operating activities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--AmortizationOfDebtDiscountPremium_i02_pp0p0_maNCPBUzx42_zsyX7OpJCpP3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 30pt; text-align: left">Amortization of debt discount</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AmortizationOfDebtDiscountPremium" contextRef="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,958,298</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AmortizationOfDebtDiscountPremium" contextRef="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">777,964</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_ecustom--ChangeInDerivativeLiabilities_i02N_pp0p0_di_msNCPBUzx42_zdl6gmKI6Y3h" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 30pt; text-align: left">Change in derivative liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="AMIH:ChangeInDerivativeLiabilities" contextRef="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">2,469,697</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="AMIH:ChangeInDerivativeLiabilities" contextRef="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">107,574</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_ecustom--DerivativesExpenses_i02_pp0p0_maNCPBUzx42_zGS87oiLTdf9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 30pt; text-align: left">Derivatives expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="AMIH:DerivativesExpenses" contextRef="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">3,540,725</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl0606">&#160;</span></td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_ecustom--ForgivenessOfLoan_i02N_pp0p0_di_msNCPBUzx42_zEniwYPveLp" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 30pt">Forgiveness of Loan</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="AMIH:ForgivenessOfLoan" contextRef="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">45,500</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl0609">&#160;</span></td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_ecustom--ImpairmentOfLoss_i02_pp0p0_maNCPBUzx42_z17CQRnSZ9va" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 30pt; text-align: left">Impairment loss</td><td>&#160;</td>
    <td style="text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl0611">&#160;</span></td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="AMIH:ImpairmentOfLoss" contextRef="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">670,280</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_ecustom--ImputedInterestExpense_i02_pp0p0_maNCPBUzx42_zwnrCo3O9p85" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 30pt; text-align: left">Imputed interest expense</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="AMIH:ImputedInterestExpense" contextRef="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,979</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="AMIH:ImputedInterestExpense" contextRef="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">3,345</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_ecustom--LossOnDispositionOfAssets_i02_pp0p0_maNCPBUzx42_zig7ZQEevYvc" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 30pt; text-align: left">Loss on disposal</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="AMIH:LossOnDispositionOfAssets" contextRef="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">3,800</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl0618">&#160;</span></td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_ecustom--LossOnLoansSettlement_i02_pp0p0_maNCPBUzx42_zKY4pM3PGf2k" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 30pt; text-align: left">Loss on loans settlement</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="AMIH:LossOnLoansSettlement" contextRef="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">58,059</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="AMIH:LossOnLoansSettlement" contextRef="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,155,685</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--IssuanceOfStockAndWarrantsForServicesOrClaims_i02_pp0p0_maNCPBUzx42_zSXb7pQg3ylf" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 30pt; text-align: left">Stock issued for services rendered</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims" contextRef="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">4,334,857</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims" contextRef="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">2,860,813</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_ecustom--StockIssuedForInProcessResearchAndDevelopment_i02_pp0p0_maNCPBUzx42_z1TJ29eHyMUl" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 30pt; text-align: left">Stock issued for in process research and development</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="AMIH:StockIssuedForInProcessResearchAndDevelopment" contextRef="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">601,852</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl0627">&#160;</span></td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--IncreaseDecreaseInOperatingAssetsAbstract_i02B_zZbgCTGZD6Dh" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">(Increase) decrease in operating assets:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--IncreaseDecreaseInInventories_i03N_pp0p0_di_msNCPBUzx42_zO4VVIqmLlzb" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 30pt">Inventory</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInInventories" contextRef="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">3,840</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl0633">&#160;</span></td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--IncreaseDecreaseInPrepaidExpense_i03N_pp0p0_di_msNCPBUzx42_z8emAsXb4YX" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 30pt; text-align: left">Prepaid expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInPrepaidExpense" contextRef="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">3,333</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInPrepaidExpense" contextRef="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">3,333</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_409_eus-gaap--IncreaseDecreaseInDepositOtherAssets_i03N_pp0p0_di_msNCPBUzx42_ziTQkf351i7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 30pt; text-align: left">Rent Deposit</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInDepositOtherAssets" contextRef="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">3,599</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInDepositOtherAssets" contextRef="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">3,800</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_400_eus-gaap--IncreaseDecreaseInOperatingLiabilitiesAbstract_i02B_zy1ThXZK7Z8a" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">(Decrease) increase in operating liabilities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--IncreaseDecreaseInAccountsPayable_i03_pp0p0_maNCPBUzx42_znu8oOw8UvBj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 30pt; text-align: left">Accounts payable</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsPayable" contextRef="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">40,342</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsPayable" contextRef="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">13,389</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--IncreaseDecreaseInInterestPayableNet_i03_pp0p0_maNCPBUzx42_zxl5ygXD6EUj" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 30pt; text-align: left">Accrued interest payable</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInInterestPayableNet" contextRef="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">77,296</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInInterestPayableNet" contextRef="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">213,430</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--IncreaseDecreaseInEmployeeRelatedLiabilities_i03_pp0p0_maNCPBUzx42_zQAMo9cQQYZe" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 30pt; text-align: left">Accrued compensation - related parties</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities" contextRef="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">5,500</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities" contextRef="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">96,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_i01T_pp0p0_mtNCPBUzx42_maNCPBUzc4v_zcXdO75KxLd7" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 20pt; font-weight: bold; text-align: left">NET CASH (USED IN) OPERATING ACTIVITIES OF CONTINUING OPERATIONS</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" contextRef="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">1,888,506</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" contextRef="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">1,448,542</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_402_eus-gaap--CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations_i01_pp0p0_maNCPBUzc4v_zeB73CEWnLF6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 20pt; font-weight: bold; text-align: left">NET CASH (USED IN) OPERATING ACTIVITIES OF DISCONTINUED OPERATIONS</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations" contextRef="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">323,256</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations" contextRef="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">704,721</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40F_eus-gaap--NetCashProvidedByUsedInOperatingActivities_i01T_pp0p0_mtNCPBUzc4v_maCCERCznd0_zoYIMuar5xxg" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 20pt; font-weight: bold; text-align: left">NET CASH (USED IN) OPERATING ACTIVITIES</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">2,211,762</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">2,153,263</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--NetCashProvidedByUsedInInvestingActivitiesAbstract_iB_zf96Jd2zru8" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left">CASH FLOWS FROM INVESTING ACTIVITIES:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_i01_maNCPBUz6o2_zQwIjnFXXRG6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 20pt; font-weight: bold; text-align: left">NET CASH (USED IN) INVESTING ACTIVITIES OF CONTINUING OPERATIONS</td><td>&#160;</td>
    <td style="text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl0665">&#160;</span></td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl0666">&#160;</span></td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations_i01_maNCPBUz6o2_zzdC5ClWIq9i" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 20pt; font-weight: bold; text-align: left">NET CASH PROVIDED BY (USED IN) INVESTING ACTIVITIES OF DISCONTINUED OPERATIONS</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations" contextRef="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">10,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations" contextRef="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">27,392</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_400_eus-gaap--NetCashProvidedByUsedInInvestingActivities_i01T_mtNCPBUz6o2_maCCERCznd0_zcc0chtN3mii" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 20pt; font-weight: bold; text-align: left">NET CASH PROVIDED BY (USED IN) INVESTING ACTIVITIES OF DISCONTINUED OPERATIONS</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">10,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">27,392</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--NetCashProvidedByUsedInFinancingActivitiesAbstract_iB_z532QZmzgEUg" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">CASH FLOWS FROM FINANCING ACTIVITIES:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--ProceedsFromRelatedPartyDebt_i01_pp0p0_maNCPBUzhD8_zwObhXSF2uS" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Proceeds from borrowings - related parties</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ProceedsFromRelatedPartyDebt" contextRef="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">141,928</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl0678">&#160;</span></td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--RepaymentsOfRelatedPartyDebt_i01N_pp0p0_di_msNCPBUzhD8_zPr8ZEuuG7R4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">(Repayment) to borrowings - related parties</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:RepaymentsOfRelatedPartyDebt" contextRef="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">141,928</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl0681">&#160;</span></td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--ProceedsFromIssuanceOfMediumTermNotes_i01_pp0p0_maNCPBUzhD8_zlEWneqdIrbi" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Proceeds from borrowings</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfMediumTermNotes" contextRef="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">3,738,999</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfMediumTermNotes" contextRef="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">947,750</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--RepaymentsOfDebt_i01N_pp0p0_di_msNCPBUzhD8_ztWvgLgIGYW" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">(Repayment) to borrowings</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:RepaymentsOfDebt" contextRef="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">427,500</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:RepaymentsOfDebt" contextRef="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">40,000</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_409_eus-gaap--ProceedsFromIssuanceOfCommonStock_i01_pp0p0_maNCPBUzhD8_zkFcIH9a5ck9" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Proceeds from sales of stock</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">100,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">46,500</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--NetCashProvidedByUsedInFinancingActivitiesContinuingOperations_i01T_pp0p0_mtNCPBUzhD8_maNCPBUzpsG_z63VmnGu8ILf" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 20pt; font-weight: bold; text-align: left">NET CASH PROVIDED BY FINANCING ACTIVITIES OF CONTINUING OPERATIONS</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" contextRef="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">3,411,499</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" contextRef="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">954,250</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations_i01_pp0p0_maNCPBUzpsG_zjCKeryH1fb9" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 20pt; font-weight: bold; text-align: left">NET CASH (USED IN) FINANCING ACTIVITIES OF DISCONTINUED OPERATIONS</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations" contextRef="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">25,164</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations" contextRef="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">7,070</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_409_eus-gaap--NetCashProvidedByUsedInFinancingActivities_i01T_pp0p0_mtNCPBUzpsG_maCCERCznd0_zm2SXOXYMQl8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 20pt; font-weight: bold; text-align: left">NET CASH PROVIDED BY FINANCING ACTIVITIES</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">3,386,335</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">947,180</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_iT_pp0p0_mtCCERCznd0_zD3i30XtYnld" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" contextRef="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,184,572</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" contextRef="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">1,233,475</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--CashAndCashEquivalentsAbstract_iB_zktzRAx2L53d" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">CASH AND CASH EQUIVALENTS:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_iS_pp0p0_zsVOtTefm6pj" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt">Beginning of period</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">25,235</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,258,710</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_iE_pp0p0_z53yRNTLF628" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt">End of period</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,209,807</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">25,235</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--SupplementalCashFlowInformationAbstract_iB_zULCAPIHXqP6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Supplemental disclosure of cash flow information:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--IncomeTaxesPaidNet_i01_pp0p0_z9aChVZv88t" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Cash paid for income taxes</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0716">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0717">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--InterestPaidNet_i01_pp0p0_zUOesgF2fyUa" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Cash paid for interest</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:InterestPaidNet" contextRef="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">106,677</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:InterestPaidNet" contextRef="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">2,674</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--NoncashInvestingAndFinancingItemsAbstract_iB_z2F6v6SrIBf6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Non-cash transactions:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_ecustom--CancellationOfCommonShares_i01_pp0p0_znf4cYEupZ51" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt">Cancellation of common shares</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0725">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="AMIH:CancellationOfCommonShares" contextRef="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">99,643</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_ecustom--CommonSharesIssuedForNotesConversion_i01_pp0p0_zic1icYPPYbg" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Common shares issued for notes conversion</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="AMIH:CommonSharesIssuedForNotesConversion" contextRef="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,228,471</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="AMIH:CommonSharesIssuedForNotesConversion" contextRef="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,282,386</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--StockIssued1_i01_pp0p0_ztJYlHah2T5c" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Common shares issued for loan settlement</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockIssued1" contextRef="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">111,466</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockIssued1" contextRef="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">86,771</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_ecustom--DiscountsOnConvertibleNotes_i01_pp0p0_zBtPMXBdfZO1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Discounts on convertible notes</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="AMIH:DiscountsOnConvertibleNotes" contextRef="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">3,756,000</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="AMIH:DiscountsOnConvertibleNotes" contextRef="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">876,098</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--TransferToInvestments_i01_pp0p0_zlpNolWaklFh" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Issuance of Series B for Investment</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0737">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:TransferToInvestments" contextRef="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">605,488</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--CapitalLeaseObligationsIncurred_i01_pp0p0_zOpZDcRLate2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Lease Inception</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0740">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:CapitalLeaseObligationsIncurred" contextRef="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">348,279</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_ecustom--RelatedPartysNoteSettledInShares_i01_pp0p0_zOWevUlrJtE8" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Related party&#8217;s note settled in shares</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0743">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="AMIH:RelatedPartysNoteSettledInShares" contextRef="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">109,278</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_ecustom--SettlementOfDerivativeLiabilities_i01_pp0p0_zaL2H5sMZf66" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Settlement of derivative liabilities</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="AMIH:SettlementOfDerivativeLiabilities" contextRef="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,116,122</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="AMIH:SettlementOfDerivativeLiabilities" contextRef="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">907,551</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_ecustom--StockPayable_i01_pp0p0_zrfHoJMBSse7" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Stock Payable</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0749">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="AMIH:StockPayable" contextRef="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">25,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying notes are an integral part of these audited consolidated financial statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 136; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: left"><a href="#fin" title="Table of Contents" style="font-style: italic">Table of Contents</a>&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>AMERICAN
INTERNATIONAL HOLDINGS CORP.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span id="Gv_012"></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notes
to Consolidated Financial Statements</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Year
Ended December 31, 2021</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Audited)</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2021-01-01to2021-12-31" escape="true" name="us-gaap:SignificantAccountingPoliciesTextBlock"><p id="xdx_80C_eus-gaap--SignificantAccountingPoliciesTextBlock_zOTmlMlDIB7j" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
1 &#8211; <span id="xdx_82A_zORiBEVOfe3e">Summary of Significant Accounting Policies</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<ix:nonNumeric contextRef="From2021-01-01to2021-12-31" escape="true" name="AMIH:OrganizationOwnershipAndBusinessPolicyTextBlock"><p id="xdx_84D_ecustom--OrganizationOwnershipAndBusinessPolicyTextBlock_z7a2yHVrz3hi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86E_zwecXsUc9Pcj">Organization,
Ownership and Business</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prior
to May 31, 2018, the Company was a <span id="xdx_90E_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_uPure_c20180531__dei--LegalEntityAxis__custom--AmericanInternationalIndustriesIncMember_zukA6FisnYS1" title="Equity method investment ownership percentage"><ix:nonFraction name="us-gaap:EquityMethodInvestmentOwnershipPercentage" contextRef="AsOf2018-05-31_custom_AmericanInternationalIndustriesIncMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">93.2</ix:nonFraction></span>% owned subsidiary of American International Industries, Inc. (&#8220;<span style="text-decoration: underline">American</span>&#8221; or
&#8220;<span style="text-decoration: underline">AMIN</span>&#8221;) (OTCQB: AMIN). Effective May 31, 2018, the Company issued <span id="xdx_90C_eus-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardGross_c20180530__20180531__dei--LegalEntityAxis__custom--AmericanInternationalIndustriesIncMember_z0T0rGfBUSM1" title="Stock issued during period shares restricted stock award gross"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross" contextRef="From2018-05-302018-05-31_custom_AmericanInternationalIndustriesIncMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">10,100,000</ix:nonFraction></span> shares of restricted common stock. As
a result of the issuance of the common shares, a change in control occurred. American International Industries, Inc. ownership decreased
from <span id="xdx_907_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_uPure_c20211231__dei--LegalEntityAxis__custom--AmericanInternationalIndustriesIncMember__srt--RangeAxis__srt--MaximumMember_zi0tWYcQJSg1" title="Equity method investment ownership percentage"><ix:nonFraction name="us-gaap:EquityMethodInvestmentOwnershipPercentage" contextRef="AsOf2021-12-31_custom_AmericanInternationalIndustriesIncMember_srt_MaximumMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">93.2</ix:nonFraction></span>% to <span id="xdx_90E_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_c20211231__dei--LegalEntityAxis__custom--AmericanInternationalIndustriesIncMember__srt--RangeAxis__srt--MinimumMember_zpVKCwwv1Bah" title="Equity method investment ownership percentage"><ix:nonFraction name="us-gaap:EquityMethodInvestmentOwnershipPercentage" contextRef="AsOf2021-12-31_custom_AmericanInternationalIndustriesIncMember_srt_MinimumMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">6.4</ix:nonFraction></span>%. No one individual or entity owns at least 50% of the outstanding shares of the Company. Effective April 12, 2019,
the Company changed its business focus to the services of medical spas.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
April 12, 2019, the Company entered into a Share Exchange Agreement (the &#8220;<span style="text-decoration: underline">Agreement</span>&#8221;) with Novopelle Diamond, LLC
(&#8220;<span style="text-decoration: underline">Novopelle</span>&#8221;) and all three members of Novopelle, pursuant to which the Company issued <span id="xdx_904_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20190411__20190412__us-gaap--TypeOfArrangementAxis__custom--ShareExchangeAgreementMember__dei--LegalEntityAxis__custom--NovopelleDiamondLLCMember_zNPne3MgMXX5" title="Number of shares issued"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2019-04-112019-04-12_custom_ShareExchangeAgreementMember_custom_NovopelleDiamondLLCMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">18,000,000</ix:nonFraction></span> shares of the Company
common stock to the members (three individuals) of Novopelle Diamond, LLC (&#8220;<span style="text-decoration: underline">Novopelle</span>&#8221;), a Texas limited company,
to acquire <span id="xdx_90B_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_dp_uPure_c20190412__us-gaap--TypeOfArrangementAxis__custom--ShareExchangeAgreementMember__dei--LegalEntityAxis__custom--NovopelleDiamondLLCMember_zaA2RnUQbs0f" title="Equity method investment ownership percentage"><ix:nonFraction name="us-gaap:EquityMethodInvestmentOwnershipPercentage" contextRef="AsOf2019-04-12_custom_ShareExchangeAgreementMember_custom_NovopelleDiamondLLCMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">100</ix:nonFraction></span>% of the membership interests of Novopelle. The issuance of these shares represents a change in control of the Company.
Concurrent with the issuance, Jacob Cohen, Esteban Alexander and Alan Hernandez, representing the three former members of Novopelle,
were elected to the board of directors and to the office of Chief Executive Officer, Chief Operating Officer and Chief Marketing officer
of the Company, respectively. Everett Bassie and Charles Zeller resigned as board members of the Company. This transaction was treated
as a reverse acquisition for accounting purposes, with the Company remaining the parent company and Novopelle (which has since been renamed
VISSIA McKinney, LLC) becoming a wholly-owned subsidiary of the Company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
April 28, 2020, the Company incorporated a wholly-owned subsidiary, ZipDoctor, Inc. (&#8220;<span style="text-decoration: underline">ZipDoctor</span>&#8221;) in the State of
Texas. ZipDoctor plans to provide its customers with unlimited, 24/7 access to board certified physicians and licensed mental and behavioral
health counselors and therapists via a newly developed, monthly subscription based online telemedicine platform. ZipDoctor was launched
in August 2020 and has generated nominal revenues through the year ended December 31, 2021.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
May 15, 2020, the Company entered into a Securities Purchase Agreement (the &#8220;<span style="text-decoration: underline">SPA</span>&#8221;) with Global Career Networks Inc,
a Delaware corporation (the &#8220;<span style="text-decoration: underline">GCN</span>&#8221;), the sole owner of Life Guru, Inc., a Delaware corporation (&#8220;<span style="text-decoration: underline">Life Guru</span>&#8221;).
Pursuant to the SPA, the Company acquired a <span id="xdx_90D_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_dp_uPure_c20200515__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__dei--LegalEntityAxis__custom--GlobalCareerNetworksIncMember__us-gaap--StatementClassOfStockAxis__custom--SeriesBConvertiblePreferredStockMember_zT8EhM67LUD5" title="Equity method investment ownership percentage"><ix:nonFraction name="us-gaap:EquityMethodInvestmentOwnershipPercentage" contextRef="AsOf2020-05-15_custom_SecuritiesPurchaseAgreementMember_custom_GlobalCareerNetworksIncMember_custom_SeriesBConvertiblePreferredStockMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">51</ix:nonFraction></span>% interest in Life Guru from GCN. As consideration for the purchase of the 51% ownership
interest in Life Guru, the Company issued to GCN <span id="xdx_90D_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20200514__20200515__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__dei--LegalEntityAxis__custom--GlobalCareerNetworksIncMember__us-gaap--StatementClassOfStockAxis__custom--SeriesBConvertiblePreferredStockMember_z6LbCqW5xkvi" title="Stock issued during period shares new issues"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2020-05-142020-05-15_custom_SecuritiesPurchaseAgreementMember_custom_GlobalCareerNetworksIncMember_custom_SeriesBConvertiblePreferredStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">500,000</ix:nonFraction></span> shares of its newly designated Series B Convertible Preferred Stock, which had
an agreed upon value of $<span id="xdx_90F_eus-gaap--StockIssuedDuringPeriodValueNewIssues_pp0p0_c20200514__20200515__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__dei--LegalEntityAxis__custom--GlobalCareerNetworksIncMember__us-gaap--StatementClassOfStockAxis__custom--SeriesBConvertiblePreferredStockMember_zNTUa5nIXBdf" title="Stock issued during period value new issues"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2020-05-142020-05-15_custom_SecuritiesPurchaseAgreementMember_custom_GlobalCareerNetworksIncMember_custom_SeriesBConvertiblePreferredStockMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">500,000</ix:nonFraction></span> ($<span id="xdx_905_eus-gaap--SharesIssuedPricePerShare_iI_c20200515__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__dei--LegalEntityAxis__custom--GlobalCareerNetworksIncMember__us-gaap--StatementClassOfStockAxis__custom--SeriesBConvertiblePreferredStockMember_zCUJArcSLuM1" title="Shares issued, price per share"><ix:nonFraction name="us-gaap:SharesIssuedPricePerShare" contextRef="AsOf2020-05-15_custom_SecuritiesPurchaseAgreementMember_custom_GlobalCareerNetworksIncMember_custom_SeriesBConvertiblePreferredStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.00</ix:nonFraction></span> per share), and agreed to issue GCN up to an additional <span id="xdx_903_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20200514__20200515__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__dei--LegalEntityAxis__custom--GlobalCareerNetworksIncMember__us-gaap--StatementClassOfStockAxis__custom--SeriesBConvertiblePreferredStockMember__srt--StatementScenarioAxis__custom--AgreedToIssueANAdditionalSharesMember_zbYARnGU9QVj" title="Number of shares issued"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2020-05-142020-05-15_custom_SecuritiesPurchaseAgreementMember_custom_GlobalCareerNetworksIncMember_custom_SeriesBConvertiblePreferredStockMember_custom_AgreedToIssueANAdditionalSharesMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,500,000</ix:nonFraction></span> shares of Series B Convertible
Preferred Stock (with an agreed upon value of $<span id="xdx_901_eus-gaap--StockIssuedDuringPeriodValueNewIssues_pp0p0_c20200514__20200515__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__dei--LegalEntityAxis__custom--GlobalCareerNetworksIncMember__us-gaap--StatementClassOfStockAxis__custom--SeriesBConvertiblePreferredStockMember__srt--StatementScenarioAxis__custom--AgreedToIssueANAdditionalSharesMember_zXZ1VvaVb0T8" title="Number of value of common stock shares"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2020-05-142020-05-15_custom_SecuritiesPurchaseAgreementMember_custom_GlobalCareerNetworksIncMember_custom_SeriesBConvertiblePreferredStockMember_custom_AgreedToIssueANAdditionalSharesMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,500,000</ix:nonFraction></span>) upon reaching certain milestones.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Impact
of COVID-19 Pandemic on Consolidated Financial Statements.</i> The outbreak of the 2019 novel coronavirus disease (&#8220;<span style="text-decoration: underline">COVID-19</span>&#8221;),
which was declared a global pandemic by the World Health Organization on March 11, 2020, and the related responses by public health and
governmental authorities to contain and combat its outbreak and spread has severely impacted the U.S. and world economies, the market
for health spa services, nutrition supplements and our other business offerings during the end of the first quarter of 2020, and continuing
through the end of 2020 and into 2021. Government mandated &#8216;stay-at-home&#8217; and similar orders have to date, and may in the
future, prevent us from staffing our spas and construction services, and prohibited us from operating. In late 2020, we made the decision
to discontinue operations of our VISSIA Waterway, Inc. and VISSIA McKinney MedSpa locations due to declines in customers and issues staffing
such facilities, each as a result of the pandemic. Additionally, our Legend Nutrition store saw a deep decline in sales due to social
distancing orders and decreases in customers who were willing to venture out to brick-and-mortar establishments during 2020. Legend Nutrition&#8217;s
lease was up January 31, 2021, and the Company chose to not renew the lease, closed the store, and will not continue in this line of
business moving forward. We also decided to cease offering construction services around July 2021.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 137; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: left"><a href="#fin" title="Table of Contents" style="font-style: italic">Table of Contents</a>&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of the date of this Report, our operations are limited, and consist mainly of ZipDoctor, Inc., Life Guru, Inc., EPIQ Scripts, LLC, EPIQ
MD, Inc. and Mangoceuticals, Inc.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Moving
forward, economic recessions, including those brought on by the continued COVID-19 outbreak may have a negative effect on the demand
for our services and our operating results. Any prolonged disruption to our operations or work force availability is likely to have a
significant adverse effect on our results of operations, cash flows and ability to meet continuing debt service requirements. All of
the above may be exacerbated in the future as the COVID-19 outbreak and the governmental responses thereto continues.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2021-01-01to2021-12-31" escape="true" name="us-gaap:ConsolidationPolicyTextBlock"><p id="xdx_84F_eus-gaap--ConsolidationPolicyTextBlock_z1Byyg2QFBGc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_865_zIOSiSR7NhKj">Principles
of Consolidation</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
consolidated financial statements include the accounts of AMIH and its subsidiaries: VISSIA McKinney, LLC (f/k/a Novopelle Diamond, LLC),
VISSIA Waterway, Inc. (f/k/a Novopelle Waterway, Inc.), Legend Nutrition, Inc., Capitol City Solutions USA, Inc. ZipDoctor, Inc., LifeGuru,
Inc., Mangoceuticals, Inc., and EPIQ MD, Inc.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">VISSIA
Waterway, Inc., VISSIA McKinney LLC, Capitol City Solutions USA, Inc. and Legend Nutrition, Inc. (collectively referred to as &#8220;Discontinued
Subsidiaries&#8221;) have been presented as discontinued operations in the accompanying consolidated financial statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
significant intercompany transactions and balances have been eliminated in consolidation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2021-01-01to2021-12-31" escape="true" name="us-gaap:PriorPeriodReclassificationAdjustmentDescription"><p id="xdx_842_eus-gaap--PriorPeriodReclassificationAdjustmentDescription_zmk2dez3ssMh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_868_z4Y0zU7oOLK2">Reclassifications</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certain
reclassifications have been made to amounts in prior periods to conform to the current period presentation. All reclassifications have
been applied consistently to the periods presented.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2021-01-01to2021-12-31" escape="true" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock"><p id="xdx_848_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zwGh3YWUWhR5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86E_zmEW5AuBzjOl">Cash
Equivalents</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Highly
liquid investments with original maturities of three months or less are considered cash equivalents. There are <span id="xdx_90E_eus-gaap--CashEquivalentsAtCarryingValue_iI_pdp0_do_c20211231_z9mtmuN8qTkc" title="Cash equivalents"><span id="xdx_90E_eus-gaap--CashEquivalentsAtCarryingValue_iI_pdp0_do_c20201231_zDk6K5Ptnohd" title="Cash equivalents"><ix:nonFraction name="us-gaap:CashEquivalentsAtCarryingValue" contextRef="AsOf2021-12-31" format="ixt-sec:numwordsen" decimals="0" scale="0" unitRef="USD"><ix:nonFraction name="us-gaap:CashEquivalentsAtCarryingValue" contextRef="AsOf2020-12-31" format="ixt-sec:numwordsen" decimals="0" scale="0" unitRef="USD">no</ix:nonFraction></ix:nonFraction></span></span> cash equivalents at
December 31, 2021 and December 31, 2020.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company maintains the majority of its cash accounts at a commercial bank. The total cash balance is insured by the Federal Deposit Insurance
Corporation (&#8220;FDIC&#8221;) up to $<span id="xdx_903_eus-gaap--CashFDICInsuredAmount_iI_pp0p0_c20211231_zyAdbJukAMnj" title="FDIC insured amount"><ix:nonFraction name="us-gaap:CashFDICInsuredAmount" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">250,000</ix:nonFraction></span> per commercial bank. From time to time, cash in deposit accounts may exceed the FDIC
limits, the excess would be at risk of loss for purposes of the statement of cash flows.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2021-01-01to2021-12-31" escape="true" name="us-gaap:InventoryPolicyTextBlock"><p id="xdx_848_eus-gaap--InventoryPolicyTextBlock_zAsiqrhdyG4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_868_zHoYfp0Abrea">Inventory</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inventory
consists of finished goods purchased, which are valued at the lower of cost or market value, with cost being determined on the first-in,
first-out method. The Company periodically reviews historical sales activity to determine potentially obsolete items and also evaluates
the impact of any anticipated changes in future demand. The Company had $<span id="xdx_90E_eus-gaap--InventoryNet_iI_pdp0_c20211231_zHa7sr9VpYb" title="Inventory"><ix:nonFraction name="us-gaap:InventoryNet" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">3,840</ix:nonFraction>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">and $<span id="xdx_90F_eus-gaap--InventoryNet_iI_pdp0_dxL_c20201231_zzso8dNLuJhd" title="Inventory::XDX::-"><span style="-sec-ix-hidden: xdx2ixbrl0796">0
</span></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">inventory from continuing operations as of December
31, 2021 and 2020, respectively. <span id="xdx_90D_eus-gaap--InventoryNetOfAllowancesCustomerAdvancesAndProgressBillings_iI_pdp0_do_c20211231_zD7JWrE9wpdd"><span id="xdx_906_eus-gaap--InventoryNetOfAllowancesCustomerAdvancesAndProgressBillings_iI_pdp0_do_c20201231_z2h3VBzDVTKb" title="Inventory allowances, net"><ix:nonFraction name="us-gaap:InventoryNetOfAllowancesCustomerAdvancesAndProgressBillings" contextRef="AsOf2021-12-31" format="ixt-sec:numwordsen" decimals="0" scale="0" unitRef="USD"><ix:nonFraction name="us-gaap:InventoryNetOfAllowancesCustomerAdvancesAndProgressBillings" contextRef="AsOf2020-12-31" format="ixt-sec:numwordsen" decimals="0" scale="0" unitRef="USD">No</ix:nonFraction></ix:nonFraction></span>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">allowance was necessary as of December 31, 2021
and 2020.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2021-01-01to2021-12-31" escape="true" name="us-gaap:EarningsPerSharePolicyTextBlock"><p id="xdx_84E_eus-gaap--EarningsPerSharePolicyTextBlock_zOrFD12FCkg8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86F_zmzXRIl4wMc3">Net
Loss Per Common Share</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
compute net income (loss) per share in accordance with ASC 260, <i>Earning per Share</i>. ASC 260 requires presentation of both basic
and diluted earnings per share (EPS) on the face of the income statement. Basic EPS is computed by dividing net income (loss) available
to common shareholders (numerator) by the weighted average number of shares outstanding (denominator) during the period. Diluted EPS
gives effect to all dilutive potential common shares outstanding during the period using the treasury stock method and convertible preferred
stock using the if-converted method. In computing Diluted EPS, the average stock price for the period is used in determining the number
of shares assumed to be purchased from the exercise of stock options or warrants. Diluted EPS excludes all dilutive potential shares
if their effect is anti-dilutive. The Company issued dilutive securities in the form of convertible notes and warrants during the year
ended December 31, 2021.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>


<ix:exclude><!-- Field: Page; Sequence: 138; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: left"><a href="#fin" title="Table of Contents" style="font-style: italic">Table of Contents</a>&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2021-01-01to2021-12-31" escape="true" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock"><p id="xdx_840_eus-gaap--PropertyPlantAndEquipmentPolicyTextBlock_zWXR2PbouVX3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_866_zSB4f6AdoZP1">Property,
Plant, Equipment, Depreciation, Amortization and Long-Lived Assets</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Long-lived
assets include:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Property,
Plant and Equipment &#8211; Assets acquired in the normal course of business are recorded at original cost and may be adjusted for any
additional significant improvements after purchase. We depreciate the cost evenly over the assets&#8217; estimated useful lives from
the date on which they become fully operational and after taking into account their estimated residual values:</span></p>

<ix:nonNumeric contextRef="From2021-01-01to2021-12-31" escape="true" name="AMIH:ScheduleOfEstimatedUsefulLivesOfPropertyPlantAndEquipmentTableTextBlock"><p id="xdx_890_ecustom--ScheduleOfEstimatedUsefulLivesOfPropertyPlantAndEquipmentTableTextBlock_zjmO5QaPbfo3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B3_z7MkbdgiW67j" style="display: none">Schedule of Estimated Useful Lives of Property, Plant and Equipment</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 50%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: center">Depreciable life</td><td>&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Residual value</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left">Machinery and Equipment</td><td style="width: 2%">&#160;</td>
    <td style="width: 16%"><span id="xdx_90F_eus-gaap--PropertyPlantAndEquipmentUsefulLife_c20210101__20211231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--MachineryAndEquipmentMember_zNU11906hfk4" title="Property, plant and equipment estimated useful lives"><ix:nonNumeric contextRef="From2021-01-012021-12-31_us-gaap_MachineryAndEquipmentMember" format="ixt-sec:durwordsen" name="us-gaap:PropertyPlantAndEquipmentUsefulLife">5 years</ix:nonNumeric></span></td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right"><span id="xdx_907_eus-gaap--PropertyPlantAndEquipmentSalvageValuePercentage_iI_dp_uPure_c20211231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--MachineryAndEquipmentMember_zf479m9BqfU" title="Residual value"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentSalvageValuePercentage" contextRef="AsOf2021-12-31_us-gaap_MachineryAndEquipmentMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">0</ix:nonFraction></span></td><td style="width: 1%; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Furniture and fixture</td><td>&#160;</td>
    <td><span id="xdx_905_eus-gaap--PropertyPlantAndEquipmentUsefulLife_c20210101__20211231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember_ztEf3jINTB7e" title="Property, plant and equipment estimated useful lives"><ix:nonNumeric contextRef="From2021-01-012021-12-31_us-gaap_FurnitureAndFixturesMember" format="ixt-sec:durwordsen" name="us-gaap:PropertyPlantAndEquipmentUsefulLife">7 years</ix:nonNumeric></span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_908_eus-gaap--PropertyPlantAndEquipmentSalvageValuePercentage_iI_dp_uPure_c20211231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember_zYg7MzczNeBh" title="Residual value"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentSalvageValuePercentage" contextRef="AsOf2021-12-31_us-gaap_FurnitureAndFixturesMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">0</ix:nonFraction></span></td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Computer and software</td><td>&#160;</td>
    <td><span id="xdx_904_eus-gaap--PropertyPlantAndEquipmentUsefulLife_c20210101__20211231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ComputerEquipmentMember_zDVzpuESoyn3" title="Property, plant and equipment estimated useful lives"><ix:nonNumeric contextRef="From2021-01-012021-12-31_us-gaap_ComputerEquipmentMember" format="ixt-sec:durwordsen" name="us-gaap:PropertyPlantAndEquipmentUsefulLife">3 years</ix:nonNumeric></span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_902_eus-gaap--PropertyPlantAndEquipmentSalvageValuePercentage_iI_dp_uPure_c20211231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ComputerEquipmentMember_zWUND5gxE002" title="Residual value"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentSalvageValuePercentage" contextRef="AsOf2021-12-31_us-gaap_ComputerEquipmentMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">0</ix:nonFraction></span></td><td style="text-align: left">%</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8AC_zJVXR9Tgy91g" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Upon
retirement or sale, the cost of the assets disposed of and the related accumulated depreciation are removed from the accounts, with any
resultant gain or loss being recognized as a component of other income or expense.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Identifiable
intangible assets &#8211; These assets are recorded at acquisition cost. Intangible assets with finite lives are amortized evenly over
their estimated useful lives.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
least annually, we review all long-lived assets for impairment. When necessary, we record changes for impairments of long-lived assets
for the amount by which the present value of future cash flows, or some other fair value measure, is less than the carrying value of
these assets.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
the carrying amount of a reporting unit exceeds its fair value, we measure the possible goodwill impairment based upon an allocation
of the estimate of fair value of the reporting unit to all of the underlying assets and liabilities of the reporting unit, including
any previously unrecognized intangible assets (Step Two Analysis). The excess of the fair value of a reporting unit over the amounts
assigned to its assets and liabilities (&#8220;carrying amount&#8221;) is the implied fair value of goodwill.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Goodwill
and indefinite-lived brands are not amortized, but are evaluated for impairment annually or when indicators of a potential impairment
are present. Our impairment testing of goodwill is performed separately from our impairment testing of indefinite-lived intangibles.
The annual evaluation for impairment of goodwill and indefinite-lived intangibles is based on valuation models that incorporate assumptions
and internal projections of expected future cash flows and operating plans. The Company believe such assumptions are also comparable
to those that would be used by other marketplace participants.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2021-01-01to2021-12-31" escape="true" name="us-gaap:FairValueOfFinancialInstrumentsPolicy"><p id="xdx_842_eus-gaap--FairValueOfFinancialInstrumentsPolicy_zetnXEnqcMMc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_866_zxq5qOGQciRj">Fair
value of financial instruments</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company measures its financial and non-financial assets and liabilities, as well as makes related disclosures, in accordance with FASB
Accounting Standards Codification No. 820, Fair Value Measurement (&#8220;ASC 820&#8221;), which provides guidance with respect to valuation
techniques to be utilized in the determination of fair value of assets and liabilities. Approaches include, (i) the market approach (comparable
market prices), (ii) the income approach (present value of future income or cash flow), and (iii) the cost approach (cost to replace
the service capacity of an asset or replacement cost). ASC 820 utilizes a fair value hierarchy that prioritizes the inputs to valuation
techniques used to measure fair value into three broad levels. The following is a brief description of those three levels:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
1: Observable inputs such as quoted prices (unadjusted) in active markets for identical assets or liabilities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
2: Inputs other than quoted prices that are observable, either directly or indirectly. These include quoted prices for similar assets
or liabilities in active markets and quoted prices for identical or similar assets or liabilities in markets that are not active.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
3: Unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions, such as
valuations derived from valuation techniques in which one more significant inputs or significant value drivers are unobservable.</span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 139; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: left"><a href="#fin" title="Table of Contents" style="font-style: italic">Table of Contents</a>&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
financial instruments include cash, inventories, prepayment and deposits, accounts payable, accrued liabilities, accrued interest payable,
accrued compensation, convertible note payable, loans payable, derivative liabilities and billing in excess of costs and estimated earnings.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
carrying values of the Company&#8217;s cash, inventories, prepayment and deposits, accounts payable, accrued liabilities, accrued interest
payable, accrued compensation, convertible note payable, short-term loans payable, derivative liabilities and billing in excess of costs
and estimated earnings approximate their fair value due to their short-term nature.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s convertible note payable are measured at amortized cost.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
derivative liabilities are stated at their fair value as a level 3 measurement. The Company used the Lattice Model to determine the fair
values of these derivative liabilities. See Note 12 for the Company&#8217;s assumptions used in determining the fair value of these financial
instruments.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2021-01-01to2021-12-31" escape="true" name="us-gaap:DebtPolicyTextBlock"><p id="xdx_840_eus-gaap--DebtPolicyTextBlock_ze4giLGMqWPi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_868_zShzIbambaok">Convertible
notes payable</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company accounts for convertible notes payable in accordance with the FASB Accounting Standards Codification No. 815, Derivatives and
Hedging, since the conversion feature is not indexed to the Company&#8217;s stock and can&#8217;t be classified in equity. The Company
allocates the proceeds received from convertible notes payable between the liability component and conversion feature component. The
conversion feature that is considered embedded derivative liabilities has been recorded at their fair value as its fair value can be
separated from the convertible note and its conversion is independent of the underlying note value. The Company has also recorded the
resulting discount on debt related to the conversion feature and is amortizing the discount using the effective interest rate method
over the life of the debt instruments.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2021-01-01to2021-12-31" escape="true" name="us-gaap:DerivativesPolicyTextBlock"><p id="xdx_84E_eus-gaap--DerivativesPolicyTextBlock_zyNoTtvsTdLe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86B_zLfJ4PWkCa0d">Derivative
liabilities</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company accounts for derivative liabilities in accordance with the FASB Accounting Standards Codification No. 815, Derivatives and Hedging
(&#8220;ASC 815&#8221;). ASC 815 requires companies to recognize all derivative liabilities in the balance sheet at fair value, and marks
it to market at each reporting date with the resulting gains or losses shown in the Statement of Operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2021-01-01to2021-12-31" escape="true" name="us-gaap:UseOfEstimates"><p id="xdx_843_eus-gaap--UseOfEstimates_ztQeobqcruQ8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_863_zzOsIpvVtFUf">Management&#8217;s
Estimates and Assumptions</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates
and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date
of the financial statements, and the reported amounts of revenues and expenses. Actual results could differ from these estimates.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2021-01-01to2021-12-31" escape="true" name="us-gaap:ConcentrationRiskCreditRisk"><p id="xdx_84F_eus-gaap--ConcentrationRiskCreditRisk_zUBhURyWchKg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86F_zXhJbqKkFa3g">Concentration
and Risks</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s operations are subject to risks including financial, operational, regulatory and other risks including the potential
risk of business failure.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
the year ended December 31, 2021, the Company had no significant revenue from continuing or discounted operations which were derived
from a single or a few major customers.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 140; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: left"><a href="#fin" title="Table of Contents" style="font-style: italic">Table of Contents</a>&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2021-01-01to2021-12-31" escape="true" name="us-gaap:RevenueFromContractWithCustomerPolicyTextBlock"><p id="xdx_844_eus-gaap--RevenueFromContractWithCustomerPolicyTextBlock_zcvkHTE7E40k" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86E_zp0WA4KZ6JRi">Revenue
Recognition</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company generates its revenue from monthly membership subscriptions. Revenue is recognized at the time of delivery and includes a delivery
fee for each delivery or a subscription fee on a monthly basis for memberships. Under Accounting Standards Update (&#8220;ASU&#8221;)
No. 2014-09 (Topic 606) &#8220;Revenue from Contracts with Customers&#8221;, revenue from contracts with customers is measured based
on the consideration specified in the contract with the customer, and excludes any sales incentives and amounts collected on behalf of
third parties. A performance obligation is a promise in a contract to transfer a distinct good or service to a customer and is the unit
of account under Topic 606. The Company&#8217;s contracts with its customers do not include multiple performance obligations. The Company
recognizes revenue when a performance obligation is satisfied by transferring control over a product or service to a customer. The amount
of revenue recognized reflects the consideration the Company expects to be entitled to in exchange for such products or services.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s subsidiaries, EPIQ MD, Inc. and ZipDoctor, Inc. both provide its customers with access to its telemedicine platform where
customers have unlimited access to start a doctor visit 24/7. The customers pay a flat fee per month for use of the platform and is not
dependent on the frequency of the doctor visits. Each doctor visit is included in the monthly subscription fee.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">EPIQ
MD: The base monthly subscription fees range from $<span id="xdx_90D_ecustom--SubscriptionFees_c20210101__20211231__srt--RangeAxis__srt--MinimumMember_zHLoR0q0lTmc" title="Subscription fees"><ix:nonFraction name="AMIH:SubscriptionFees" contextRef="From2021-01-012021-12-31_srt_MinimumMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">24.95</ix:nonFraction></span>-$<span id="xdx_90D_ecustom--SubscriptionFees_c20210101__20211231__srt--RangeAxis__srt--MaximumMember_z5B760GE4Pp2" title="Subscription fees"><ix:nonFraction name="AMIH:SubscriptionFees" contextRef="From2021-01-012021-12-31_srt_MaximumMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">49.95</ix:nonFraction></span> per month and is dependent on the number of family members included in
the plan. Customers can choose to add additional services, such as Epiq Paws and Epiq Lux, ranging from an additional $<span id="xdx_906_ecustom--SubscriptionFees_c20210101__20211231__srt--RangeAxis__srt--MinimumMember__us-gaap--RelatedPartyTransactionAxis__custom--EpiqPawsAndEpiqLuxMember_zysWjxYVMUrl" title="Subscription fees"><ix:nonFraction name="AMIH:SubscriptionFees" contextRef="From2021-01-012021-12-31_srt_MinimumMember_custom_EpiqPawsAndEpiqLuxMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">4.95</ix:nonFraction></span>-$<span id="xdx_903_ecustom--SubscriptionFees_c20210101__20211231__srt--RangeAxis__srt--MaximumMember__us-gaap--RelatedPartyTransactionAxis__custom--EpiqPawsAndEpiqLuxMember_zjhAzwZYCLCj" title="Subscription fees"><ix:nonFraction name="AMIH:SubscriptionFees" contextRef="From2021-01-012021-12-31_srt_MaximumMember_custom_EpiqPawsAndEpiqLuxMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">9.95</ix:nonFraction></span> per
month.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
customer gains immediate access to the telemedicine platform upon completing the enrollment process and making the first month&#8217;s
payment, at which point the Company recognizes the revenue from that customer. Billing commences on the day that the customer is enrolled
for the Company&#8217;s services and is continued to be billed on the calendar day of each calendar month, in accordance with the original
date of enrollment.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Customer&#8217;s
may cancel their subscription at any time provided that they provide the Company with thirty (30) days advanced written notice of cancellation
with no cancellation fees charged to the customer. In the event a subscriber provides a notice of cancellation within the membership
period, the customer will be billed on their regular billing date at an amount adjusted to reflect an amount due until the cancellation
date.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
avoidance of doubt, <span id="xdx_90A_ecustom--SubscriberBilledDiscription_c20210101__20211231__dei--LegalEntityAxis__custom--EPIQMDMember_zbSiV9qAc1cl" title="Subscriber billed discription"><ix:nonNumeric contextRef="From2021-01-012021-12-31_custom_EPIQMDMember" name="AMIH:SubscriberBilledDiscription">if a subscriber is billed $29.95 on the 1st of the month and cancels on the 15th, the subscriber will be billed on
the 1st of the following month at a prorated rate through the 15th, or at a rate of $14.97</ix:nonNumeric></span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ZipDoctor,
Inc</b>: The base monthly subscription fees range from $<span id="xdx_90F_ecustom--SubscriptionFees_c20210101__20211231__srt--RangeAxis__srt--MinimumMember__dei--LegalEntityAxis__custom--ZipDoctorMember_zNBmSGfOscO" title="Subscription fees"><ix:nonFraction name="AMIH:SubscriptionFees" contextRef="From2021-01-012021-12-31_srt_MinimumMember_custom_ZipDoctorMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">25.00</ix:nonFraction></span>-$<span id="xdx_90E_ecustom--SubscriptionFees_c20210101__20211231__srt--RangeAxis__srt--MaximumMember__dei--LegalEntityAxis__custom--ZipDoctorMember_zQAQ0RAHxqT4" title="Subscription fees"><ix:nonFraction name="AMIH:SubscriptionFees" contextRef="From2021-01-012021-12-31_srt_MaximumMember_custom_ZipDoctorMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">45.00</ix:nonFraction></span> per month and is dependent on the number of family members included
in the plan. The customer gains immediate access to the telemedicine platform upon completing the enrollment process and making the first
month&#8217;s payment, at which point the Company recognizes the revenue from that customer. Billing commences on the day that the customer
is enrolled for the Company&#8217;s services and is continued to be billed on the calendar day of each calendar month, in accordance
with the original date of enrollment.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Customer&#8217;s
may cancel their subscription at any time provided that they provide the Company with thirty (30) days advanced written notice of cancellation
with no cancellation fees charged to the customer. In the event a subscriber provides a notice of cancellation within the membership
period, the customer will be billed on their regular billing date at an amount adjusted to reflect an amount due until the cancellation
date.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
avoidance of doubt, <span id="xdx_906_ecustom--SubscriberBilledDiscription_c20210101__20211231__dei--LegalEntityAxis__custom--ZipDoctorMember_zOxHm2pbFpza"><ix:nonNumeric contextRef="From2021-01-012021-12-31_custom_ZipDoctorMember" name="AMIH:SubscriberBilledDiscription">if a subscriber is billed $25.00 on the 1st of the month and cancels on the 15th, the subscriber will be billed on
the 1st of the following month at a prorated rate through the 15th, or at a rate of $12.50</ix:nonNumeric></span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>LEGEND
NUTRITION &#8211; DISCONTINUED OPERATIONS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company recognizes revenue in according with Accounting Standards Codification (ASC) Topic 606. The underlying principle is that the
Company recognize revenue to depict the transfer of promised goods and services to customers in an amount that they expect to be entitled
to in the exchange for goods and services provided.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s discontinued subsidiary, Legend Nutrition, Inc., operated a retail store in which it sold nutritional and wellness related
products. Legend&#8217;s business was solely based on the sale of retail products and did not offer any non-tangible services.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 141; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: left"><a href="#fin" title="Table of Contents" style="font-style: italic">Table of Contents</a>&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Revenue
for the entire product sold was recognized when the customer purchased and had control of the product, even if the terms included a right
of return. Legend accounted for any discounts and concessions at the time of sale and accounted for returns and refunds when Legend received
the product back in its possession where in some instances, if the product was unused, would be returned to Legend&#8217;s inventory
or, if used, would be discarded.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Costs
of revenue included the amounts that Legend paid its wholesalers and distributors and recognized the cost of revenue when the products
were sold and transferred to the possession of the customer. The cost of revenue was deducted from Legends open inventory balance upon
sale.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2021-01-01to2021-12-31" escape="true" name="us-gaap:CompensationRelatedCostsPolicyTextBlock"><p id="xdx_84E_eus-gaap--CompensationRelatedCostsPolicyTextBlock_zhTZlb2KNmIe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86D_zUdihJpsgIq2">Stock
based compensation</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company recognizes compensation costs to employees under FASB Accounting Standards Codification 718 &#8220;Compensation - Stock Compensation&#8221;
(&#8220;ASC 718&#8221;). Under ASC 718, companies are required to measure the compensation costs of share-based compensation arrangements
based on the grant-date fair value and recognize the costs in the financial statements over the period during which employees are required
to provide services. Share based compensation arrangements include stock options and warrants. As such, compensation cost is measured
on the date of grant at their fair value. Such compensation amounts, if any, are amortized over the respective vesting periods of the
option grant.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
July 27, 2018, the inception date, the Company adopted ASU No. 2018-07 &#8220;Compensation - Stock Compensation (Topic 718): Improvements
to Nonemployee Share-Based Payment Accounting.&#8221; These amendments expand the scope of Topic 718, Compensation - Stock Compensation
(which currently only includes share-based payments to employees) to include share-based payments issued to nonemployees for goods or
services. Consequently, the accounting for share-based payments to nonemployees and employees will be substantially aligned.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2021-01-01to2021-12-31" escape="true" name="us-gaap:IncomeTaxPolicyTextBlock"><p id="xdx_84E_eus-gaap--IncomeTaxPolicyTextBlock_zMBQxHSwOLXk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86E_zMUwlVgZStga">Income
Taxes</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company is a taxable entity and recognizes deferred tax assets and liabilities for the future tax consequences attributable to differences
between the financial statement carrying amounts of existing assets and liabilities and their respective tax basis. Deferred tax assets
and liabilities are measured using enacted tax rates expected to be in effect when the temporary differences reverse. The effect on the
deferred tax assets and liabilities of a change in tax rates is recognized in income in the year that includes the enactment date of
the rate change. A valuation allowance is used to reduce deferred tax assets to the amount that is more likely than not to be realized.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2021-01-01to2021-12-31" escape="true" name="AMIH:RelatedPartiesPolicyTextBlock"><p id="xdx_84E_ecustom--RelatedPartiesPolicyTextBlock_zkOuj45oor25" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86C_zY8syYEsxxuk">Related
Parties</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company follows subtopic 850-10 of the FASB Accounting Standards Codification for the identification of related parties and disclosure
of related party transactions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to Section 850-10-20 the related parties include a. affiliates of the Company; b. Entities for which investments in their equity securities
would be required, absent the election of the fair value option under the Fair Value Option Subsection of Section 825&#8211;10&#8211;15,
to be accounted for by the equity method by the investing entity; c. trusts for the benefit of employees, such as pension and profit-sharing
trusts that are managed by or under the trusteeship of management; d. principal owners of the Company; e. management of the Company;
f. other parties with which the Company may deal if one party controls or can significantly influence the management or operating policies
of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests; and
g. Other parties that can significantly influence the management or operating policies of the transacting parties or that have an ownership
interest in one of the transacting parties and can significantly influence the other to an extent that one or more of the transacting
parties might be prevented from fully pursuing its own separate interests.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
consolidated financial statements shall include disclosures of material related party transactions, other than compensation arrangements,
expense allowances, and other similar items in the ordinary course of business. However, disclosure of transactions that are eliminated
in the preparation of consolidated or combined financial statements is not required in those statements. The disclosures shall include:
a. the nature of the relationship(s) involved; b. a description of the transactions, including transactions to which no amounts or nominal
amounts were ascribed, for each of the periods for which income statements are presented, and such other information deemed necessary
to an understanding of the effects of the transactions on the financial statements; c. the dollar amounts of transactions for each of
the periods for which income statements are presented and the effects of any change in the method of establishing the terms from that
used in the preceding period; and d. amounts due from or to related parties as of the date of each balance sheet presented and, if not
otherwise apparent, the terms and manner of settlement. A material related party transaction has been identified in Note 11 in the financial
statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 142; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: left"><a href="#fin" title="Table of Contents" style="font-style: italic">Table of Contents</a>&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2021-01-01to2021-12-31" escape="true" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock"><p id="xdx_846_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zFWQyjFK9sx4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_861_zlcbCJvR29Fh">Recently
Issued Accounting Pronouncements</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">From
time to time, new accounting pronouncements are issued by the Financial Accounting Standard Board (&#8220;<span style="text-decoration: underline">FASB</span>&#8221;) or other
standard setting bodies that are adopted by the Company as of the specified effective date. Unless otherwise discussed, the Company believes
that the effect of recently issued standards that are not yet effective will not have a material effect on its consolidated financial
position or results of operations upon adoption.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
December 2019, the FASB issued ASU No. 2019-12, &#8220;Simplifying the Accounting for Income Taxes (Topic 740)&#8221;. This standard
simplifies the accounting for income taxes. This standard is effective for fiscal years beginning after December 15, 2020, including
interim periods within those fiscal years. Early adoption is permitted for all entities. The Company adopted ASU 2019-12 effective on
January 1, 2021, and it did not have an effect on the Company&#8217;s consolidated financial statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
August 2020, the FASB issued ASU 2020-06, <i>&#8220;<span style="text-decoration: underline">Debt &#8211; Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives
and Hedging &#8211; Contracts in Entity&#8217;s Own Equity (Subtopic 815 &#8211; 40)</span>&#8221; </i>(&#8220;<span style="text-decoration: underline">ASU 2020-06</span>&#8221;).
ASU 2020-06 simplifies the accounting for certain financial instruments with characteristics of liabilities and equity, including convertible
instruments and contracts on an entity&#8217;s own equity. The ASU is part of the FASB&#8217;s simplification initiative, which aims
to reduce unnecessary complexity in U.S. GAAP. The ASU&#8217;s amendments are effective for fiscal years beginning after December 15,
2023, and interim periods within those fiscal years. The Company is currently evaluating the impact of ASU 2020-06 on its financial statements.</span></p>

</ix:nonNumeric><p id="xdx_857_zESPmQpfE3n8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2021-01-01to2021-12-31" escape="true" name="us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock"><p id="xdx_808_eus-gaap--PropertyPlantAndEquipmentDisclosureTextBlock_zCjTXWqUBjh4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
2 &#8211; <span id="xdx_824_zdRcGX0RxdQ7">Property and Equipment</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<ix:nonNumeric contextRef="From2021-01-012021-12-31_us-gaap_SegmentContinuingOperationsMember" escape="true" name="us-gaap:PropertyPlantAndEquipmentTextBlock"><p id="xdx_890_eus-gaap--PropertyPlantAndEquipmentTextBlock_hus-gaap--StatementOperatingActivitiesSegmentAxis__us-gaap--SegmentContinuingOperationsMember_zigQbfHysjmg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Property
and equipment from continuing operations were as follows at December 31, 2021 and 2020:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8BD_zlw3v0mc1iH6" style="display: none">Schedule of Property and Equipment</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: center">&#160;</td><td id="xdx_495_20211231_zYHSlgDqRHB8" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>December 31,</b></span></td><td style="font-weight: bold; text-align: center">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: center">&#160;</td><td id="xdx_492_20201231_zi8u2Yzx6fVi" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>December 31,</b></span></td><td style="font-weight: bold; text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: center">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: center">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: center">2020</td><td style="padding-bottom: 1.5pt; text-align: center">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--LeaseholdImprovementsGross_iI_hus-gaap--StatementOperatingActivitiesSegmentAxis__us-gaap--SegmentContinuingOperationsMember_maPPAEGzdRo_zItK1naqjDsg" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left">Leasehold improvements</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 14%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0858">-</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 14%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0859">-</span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--FurnitureAndFixturesGross_iI_hus-gaap--StatementOperatingActivitiesSegmentAxis__us-gaap--SegmentContinuingOperationsMember_maPPAEGzdRo_zYdX8xgIPTUc" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Furniture &amp; fixtures</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0861">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0862">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--MachineryAndEquipmentGross_iI_hus-gaap--StatementOperatingActivitiesSegmentAxis__us-gaap--SegmentDiscontinuedOperationsMember_maPPAEGzdRo_zqtfHmPAviC1" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1.5pt">Equipment</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0864">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0865">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
<tr id="xdx_407_eus-gaap--PropertyPlantAndEquipmentGross_iTI_hus-gaap--StatementOperatingActivitiesSegmentAxis__us-gaap--SegmentContinuingOperationsMember_mtPPAEGzdRo_maPPAENzidY_zyVZ4q5nNzT2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Gross property and equipment</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0867">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0868">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iI_hus-gaap--StatementOperatingActivitiesSegmentAxis__us-gaap--SegmentContinuingOperationsMember_msPPAENzidY_zBGc9uvxl6yb" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Less accumulated depreciation and amortization</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0870">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0871">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--PropertyPlantAndEquipmentNet_iTI_hus-gaap--StatementOperatingActivitiesSegmentAxis__us-gaap--SegmentContinuingOperationsMember_mtPPAENzidY_z6oodJd6RAc5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Net property and equipment</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0873">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0874">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

</ix:nonNumeric><p id="xdx_8AC_zPA8g8dpRBtb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2021-01-012021-12-31_us-gaap_SegmentDiscontinuedOperationsMember" escape="true" name="us-gaap:PropertyPlantAndEquipmentTextBlock"><p id="xdx_89C_eus-gaap--PropertyPlantAndEquipmentTextBlock_hus-gaap--StatementOperatingActivitiesSegmentAxis__us-gaap--SegmentDiscontinuedOperationsMember_zE31ZAjSXZn2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Property
and equipment from discontinued operations were as follows at December 31, 2021 and 2020:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B8_zkJSkzKrP15g" style="display: none">Schedule of Property and Equipment</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_49A_20211231_zdzlKkhMRN28" style="font-weight: bold; text-align: center">December 31,</td><td style="text-align: center; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_494_20201231_z7nxJdFBeLwb" style="font-weight: bold; text-align: center">December 31,</td><td style="text-align: center; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--LeaseholdImprovementsGross_iI_hus-gaap--StatementOperatingActivitiesSegmentAxis__us-gaap--SegmentDiscontinuedOperationsMember_maPPAEGzI8f_zOoY9kZcyZZ5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: justify">Leasehold improvements</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right"><ix:nonFraction name="us-gaap:LeaseholdImprovementsGross" contextRef="AsOf2021-12-31_us-gaap_SegmentDiscontinuedOperationsMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,262</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right"><ix:nonFraction name="us-gaap:LeaseholdImprovementsGross" contextRef="AsOf2020-12-31_us-gaap_SegmentDiscontinuedOperationsMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,262</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--FurnitureAndFixturesGross_iI_hus-gaap--StatementOperatingActivitiesSegmentAxis__us-gaap--SegmentDiscontinuedOperationsMember_maPPAEGzI8f_zcDa4NUeVKQj" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Furniture &amp; fixtures</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:FurnitureAndFixturesGross" contextRef="AsOf2021-12-31_us-gaap_SegmentDiscontinuedOperationsMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">18,830</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:FurnitureAndFixturesGross" contextRef="AsOf2020-12-31_us-gaap_SegmentDiscontinuedOperationsMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">29,902</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--MachineryAndEquipmentGross_iI_hus-gaap--StatementOperatingActivitiesSegmentAxis__us-gaap--SegmentDiscontinuedOperationsMember_maPPAEGzI8f_zefQ8jL9F66" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1.5pt">Equipment</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl0884">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl0885">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--PropertyPlantAndEquipmentGross_iTI_hus-gaap--StatementOperatingActivitiesSegmentAxis__us-gaap--SegmentDiscontinuedOperationsMember_mtPPAEGzI8f_maPPAENzYkq_zTpTGtLChk5f" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Gross property and equipment</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2021-12-31_us-gaap_SegmentDiscontinuedOperationsMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">23,092</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2020-12-31_us-gaap_SegmentDiscontinuedOperationsMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">118,083</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iI_hus-gaap--StatementOperatingActivitiesSegmentAxis__us-gaap--SegmentDiscontinuedOperationsMember_msPPAENzYkq_ziaPU5t55qEf" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1.5pt">Less accumulated depreciation and amortization</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" contextRef="AsOf2021-12-31_us-gaap_SegmentDiscontinuedOperationsMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">8,823</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" contextRef="AsOf2020-12-31_us-gaap_SegmentDiscontinuedOperationsMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">10,422</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--PropertyPlantAndEquipmentNet_iTI_hus-gaap--StatementOperatingActivitiesSegmentAxis__us-gaap--SegmentDiscontinuedOperationsMember_mtPPAENzYkq_z1FvMqjvYx65" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 2.5pt">Net property and equipment</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="AsOf2021-12-31_us-gaap_SegmentDiscontinuedOperationsMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">14,199</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="AsOf2020-12-31_us-gaap_SegmentDiscontinuedOperationsMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">107,661</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>


</ix:nonNumeric><p id="xdx_8A4_zsPkdGbzlBIk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
a result of discontinued operations, the leasing equipment of $<span id="xdx_904_ecustom--LeaseEquipmentReturned_pp0p0_c20210101__20211231_zE3ZxwnmTWhj" title="Lease equipment returned"><ix:nonFraction name="AMIH:LeaseEquipmentReturned" contextRef="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">67,336</ix:nonFraction></span> was returned in the first quarter of 2021 and the related liabilities
were released.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 143; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: left"><a href="#fin" title="Table of Contents" style="font-style: italic">Table of Contents</a>&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Depreciation
and amortization expense from continuing operations for the years ended December 31, 2021 and 2020 was $<span id="xdx_905_eus-gaap--DepreciationAndAmortization_pp0p0_c20210101__20211231_zBKQBMZnrAAh" title="Depreciation and amortization, continuing operations"><ix:nonFraction name="us-gaap:DepreciationAndAmortization" contextRef="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">0</ix:nonFraction></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">and
$<span id="xdx_909_eus-gaap--DepreciationAndAmortization_pp0p0_c20200101__20201231_z93ZI7TH8cP8" title="Depreciation and amortization, continuing operations"><ix:nonFraction name="us-gaap:DepreciationAndAmortization" contextRef="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">0</ix:nonFraction></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">,
respectively. Depreciation and amortization expense from discontinued operations for the years ended December 31, 2021 and 2020 was $<span id="xdx_90B_eus-gaap--DepreciationAndAmortizationDiscontinuedOperations_pp0p0_c20210101__20211231_zoUOkF0iEuS8" title="Depreciation and amortization, discontinued operations"><ix:nonFraction name="us-gaap:DepreciationAndAmortizationDiscontinuedOperations" contextRef="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">8,823</ix:nonFraction>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">and $<span id="xdx_900_eus-gaap--DepreciationAndAmortizationDiscontinuedOperations_pp0p0_c20200101__20201231_zSioKMgKaAB1" title="Depreciation and amortization, discontinued operations"><ix:nonFraction name="us-gaap:DepreciationAndAmortizationDiscontinuedOperations" contextRef="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">10,422</ix:nonFraction></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">,
respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2021-01-01to2021-12-31" escape="true" name="AMIH:AssetPurchaseAgreementTextBlock"><p id="xdx_80F_ecustom--AssetPurchaseAgreementTextBlock_z3pe7SNALm6k" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
3 &#8211; <span id="xdx_822_zF3CFMH4RB85">Asset Purchase Agreement</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
October 18, 2019, Legend Nutrition, Inc. (&#8220;Legend&#8221;), a wholly owned subsidiary of the Company entered into an Asset Purchase
Agreement with David Morales (the &#8220;Asset Purchase Agreement&#8221;) to acquire all of the assets associated with and related to
a retail vitamin, supplements and nutrition store located in Mckinney, TX previously doing business as &#8220;Ideal Nutrition&#8221;.
Pursuant to the Asset Purchase Agreement, Legend purchased a variety of assets including software, contracts, bank and merchant accounts,
products, inventory, computers, security systems and other intellectual properties (the &#8220;Assets&#8221;). For consideration of the
Assets, Legend issued to Mr. Morales a promissory note in the amount of Seventy-Five Thousand US Dollars ($<span id="xdx_90C_eus-gaap--NotesPayable_iI_pp0p0_c20191018__dei--LegalEntityAxis__custom--LegendNutritionIncMember__us-gaap--TypeOfArrangementAxis__custom--AssetPurchaseAgreementMember__srt--TitleOfIndividualAxis__custom--MrMoralesMember_zmY5JvmxyQp4" title="Promissory note"><ix:nonFraction name="us-gaap:NotesPayable" contextRef="AsOf2019-10-18_custom_LegendNutritionIncMember_custom_AssetPurchaseAgreementMember_custom_MrMoralesMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">75,000</ix:nonFraction></span>) bearing an interest
rate of five percent (<span id="xdx_90D_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_dp_uPure_c20191018__dei--LegalEntityAxis__custom--LegendNutritionIncMember__us-gaap--TypeOfArrangementAxis__custom--AssetPurchaseAgreementMember__srt--TitleOfIndividualAxis__custom--MrMoralesMember_zY8RH1Hw5PU" title="Interest rate"><ix:nonFraction name="us-gaap:DebtInstrumentInterestRateStatedPercentage" contextRef="AsOf2019-10-18_custom_LegendNutritionIncMember_custom_AssetPurchaseAgreementMember_custom_MrMoralesMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">5</ix:nonFraction></span>%) per annum and with a <span id="xdx_90E_eus-gaap--DebtInstrumentMaturityDateDescription_c20191017__20191018__dei--LegalEntityAxis__custom--LegendNutritionIncMember__us-gaap--TypeOfArrangementAxis__custom--AssetPurchaseAgreementMember__srt--TitleOfIndividualAxis__custom--MrMoralesMember_z97K4B9Fkjze" title="Maturity date, description"><ix:nonNumeric contextRef="From2019-10-172019-10-18_custom_LegendNutritionIncMember_custom_AssetPurchaseAgreementMember_custom_MrMoralesMember" name="us-gaap:DebtInstrumentMaturityDateDescription">maturity date of one year</ix:nonNumeric></span> (the &#8220;Promissory Note&#8221;). As of December 31, 2020,
the promissory note is fully converted. During 2021, the Company discontinued operation of Legend. The assets acquired pursuant to the
Asset Purchase Agreement, such as property and equipment of $<span id="xdx_906_eus-gaap--AssetImpairmentCharges_pp0p0_c20210101__20211231__dei--LegalEntityAxis__custom--LegendNutritionIncMember__us-gaap--TypeOfArrangementAxis__custom--AssetPurchaseAgreementMember__srt--TitleOfIndividualAxis__custom--MrMoralesMember_zZICbKIm5HW9" title="Impairment of property and equipment"><ix:nonFraction name="us-gaap:AssetImpairmentCharges" contextRef="From2021-01-012021-12-31_custom_LegendNutritionIncMember_custom_AssetPurchaseAgreementMember_custom_MrMoralesMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">16,303</ix:nonFraction></span> and goodwill of $<span id="xdx_90A_eus-gaap--GoodwillImpairmentLoss_pp0p0_c20210101__20211231__dei--LegalEntityAxis__custom--LegendNutritionIncMember__us-gaap--TypeOfArrangementAxis__custom--AssetPurchaseAgreementMember__srt--TitleOfIndividualAxis__custom--MrMoralesMember_z9svZYFkOj42" title="Impairment of goodwill"><ix:nonFraction name="us-gaap:GoodwillImpairmentLoss" contextRef="From2021-01-012021-12-31_custom_LegendNutritionIncMember_custom_AssetPurchaseAgreementMember_custom_MrMoralesMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">29,689</ix:nonFraction></span>, have been fully impaired.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2021-01-01to2021-12-31" escape="true" name="us-gaap:GoodwillDisclosureTextBlock"><p id="xdx_80C_eus-gaap--GoodwillDisclosureTextBlock_z1wZR0cp2DQ5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
4 &#8211; <span id="xdx_820_zZcAYMiHmYfl">Goodwill</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2021, the goodwill in connection with the acquisition of the assets in October 2019 associated with and related to a
retail vitamin, supplements and nutrition store located in McKinney, Texas was $<span id="xdx_907_eus-gaap--Goodwill_iI_c20211231__srt--StatementGeographicalAxis__custom--TexsMember_zdGMsVKPHzHh" title="Goodwill"><ix:nonFraction name="us-gaap:Goodwill" contextRef="AsOf2021-12-31_custom_TexsMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">0</ix:nonFraction></span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Goodwill
is not amortized, but is evaluated for impairment annually or when indicators of a potential impairment are present. The annual evaluation
for impairment of goodwill is based on valuation models that incorporate assumptions and internal projections of expected future cash
flows and operating plans. The Company believes such assumptions are also comparable to those that would be used by other marketplace
participants. The Company determined impairment adjustment was necessary for the year ended December 31, 2020, since the goodwill was
not substantiating a future cash flow. Hence, goodwill of $<span id="xdx_90C_eus-gaap--Goodwill_iI_pp0p0_c20211231_zXL0BvWCPawh" title="Goodwill"><ix:nonFraction name="us-gaap:Goodwill" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">29,689</ix:nonFraction></span> was impaired in full during the fourth quarter of 2020.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2021-01-01to2021-12-31" escape="true" name="AMIH:LicensingAgreementDisclosureTextBlock"><p id="xdx_801_ecustom--LicensingAgreementDisclosureTextBlock_z6f9atdQGrba" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
5 &#8211; <span id="xdx_823_zAsZVjE3Nicc">Licensing Agreement</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
June 27<sup>th</sup>, 2019, the Company executed an exclusive license agreement with Novo MedSpa Addison Corp (&#8220;<span style="text-decoration: underline">Novo Medspa</span>&#8221;)
providing the Company with the exclusive rights to the Novopelle brand and to establish new Novopelle branded MedSpa locations on a worldwide
basis (the &#8220;<span style="text-decoration: underline">Exclusive License</span>&#8221;). In consideration for the Exclusive License, the Company paid Novo MedSpa a one-time
cash payment of $<span id="xdx_90C_eus-gaap--PaymentsToAcquireInterestInJointVenture_pp0p0_c20190626__20190627__dei--LegalEntityAxis__custom--NovoMedSpaAddisonCorpMember_zJXemaNQYlbf" title="One time cash payment"><ix:nonFraction name="us-gaap:PaymentsToAcquireInterestInJointVenture" contextRef="From2019-06-262019-06-27_custom_NovoMedSpaAddisonCorpMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">40,000</ix:nonFraction></span> and issued to Novo MedSpa <span id="xdx_907_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20190626__20190627__dei--LegalEntityAxis__custom--NovoMedSpaAddisonCorpMember_zJY5eACqouC1" title="Number of shares issued during period, shares"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2019-06-262019-06-27_custom_NovoMedSpaAddisonCorpMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">250,000</ix:nonFraction></span> shares of the Company&#8217;s common stock. The <span id="xdx_905_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20190626__20190627__dei--LegalEntityAxis__custom--NovoMedSpaAddisonCorpMember_zhxbsyaeYtr4" title="Number of shares issued during period, shares"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2019-06-262019-06-27_custom_NovoMedSpaAddisonCorpMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">250,000</ix:nonFraction></span> shares of the Company&#8217;s
common stock were valued at $<span id="xdx_907_eus-gaap--SharesIssuedPricePerShare_iI_c20190627__dei--LegalEntityAxis__custom--NovoMedSpaAddisonCorpMember_zg2MYuDfg3f8" title="Shares issued, price per share"><ix:nonFraction name="us-gaap:SharesIssuedPricePerShare" contextRef="AsOf2019-06-27_custom_NovoMedSpaAddisonCorpMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.10</ix:nonFraction></span> per share or $<span id="xdx_900_eus-gaap--StockIssuedDuringPeriodValueNewIssues_pp0p0_c20190626__20190627__dei--LegalEntityAxis__custom--NovoMedSpaAddisonCorpMember_zj2qOgElJs2b" title="Number of shares issued during period, values"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2019-06-262019-06-27_custom_NovoMedSpaAddisonCorpMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">25,000</ix:nonFraction></span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the fourth quarter of 2019, the Company opened a new MedSpa location and paid Novo MedSpa a one-time cash payment of $<span id="xdx_909_eus-gaap--PaymentsToAcquireInterestInJointVenture_pp0p0_c20191001__20191231__dei--LegalEntityAxis__custom--NovoMedSpaAddisonCorpMember__srt--StatementScenarioAxis__custom--ExclusiveLicenseMember_zZGrlz2SN396" title="One time cash payment"><ix:nonFraction name="us-gaap:PaymentsToAcquireInterestInJointVenture" contextRef="From2019-10-012019-12-31_custom_NovoMedSpaAddisonCorpMember_custom_ExclusiveLicenseMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">30,000</ix:nonFraction></span> as a new
location fee pursuant to the exclusive license agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
May 13, 2020, the Company provided Novo Medspa with notice to terminate the June 27, 2019 License Agreement in pursuit of the Company&#8217;s
desire to establish and develop its own brand and have the flexibility to offer additional products and services that are not currently
available at Novopelle branded locations, which was effective immediately. Accordingly, the license of $<span id="xdx_905_eus-gaap--AssetImpairmentCharges_pp0p0_c20200511__20200513__dei--LegalEntityAxis__custom--NovoMedSpaAddisonCorpMember__srt--StatementScenarioAxis__custom--ExclusiveLicenseMember_zmUOsVntMWa6" title="Impairment of license"><ix:nonFraction name="us-gaap:AssetImpairmentCharges" contextRef="From2020-05-112020-05-13_custom_NovoMedSpaAddisonCorpMember_custom_ExclusiveLicenseMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">95,000</ix:nonFraction></span> was impaired in full during
the second quarter of 2020.</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2021-01-01to2021-12-31" escape="true" name="us-gaap:OtherAssetsDisclosureTextBlock"><p id="xdx_80D_eus-gaap--OtherAssetsDisclosureTextBlock_zD7VggUH3OVc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
6 &#8211; <span id="xdx_824_zFGgUzKZV5tl">Other assets</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
May 15, 2020, the Company executed a securities purchase agreement with Global Career Networks Inc, a Delaware corporation (the &#8220;<span style="text-decoration: underline">Seller</span>&#8221;),
<span id="xdx_900_eus-gaap--EquityMethodInvestmentDescriptionOfPrincipalActivities_c20200514__20200515__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__dei--LegalEntityAxis__custom--GlobalCareerNetworksIncMember__us-gaap--StatementClassOfStockAxis__custom--SeriesBConvetiblePreferredStockMember_zrjyq7x725Ak" title="Equity method investment, description of principal activities"><ix:nonNumeric contextRef="From2020-05-142020-05-15_custom_SecuritiesPurchaseAgreementMember_custom_GlobalCareerNetworksIncMember_custom_SeriesBConvetiblePreferredStockMember" name="us-gaap:EquityMethodInvestmentDescriptionOfPrincipalActivities">the
sole owner of Life Guru, pursuant to which the Company purchased from the Seller, a 51% interest in the capital stock of Life Guru, representing
an aggregate of 2,040 shares of Life Guru&#8217;s common stock. LifeGuru owns and operates the LifeGuru.me website which is currently
in development and is anticipated to be fully launched in the second quarter of 2022. In consideration for the purchase,
the Company agreed to issue the Seller <span id="xdx_90F_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20200514__20200515__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__dei--LegalEntityAxis__custom--GlobalCareerNetworksIncMember__us-gaap--StatementClassOfStockAxis__custom--SeriesBConvetiblePreferredStockMember_zU4Fq7Kl3hX"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2020-05-142020-05-15_custom_SecuritiesPurchaseAgreementMember_custom_GlobalCareerNetworksIncMember_custom_SeriesBConvetiblePreferredStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">500,000</ix:nonFraction></span> shares of the Company&#8217;s Series B Preferred Stock at closing, which occurred on May
15, 2020</ix:nonNumeric></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">. An additional up to <span id="xdx_905_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20200514__20200515__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__dei--LegalEntityAxis__custom--GlobalCareerNetworksIncMember__us-gaap--StatementClassOfStockAxis__custom--SeriesBConvetiblePreferredStockMember__srt--StatementScenarioAxis__custom--AgreedToIssueANAdditionalSharesMember_ztXrSwkjlZr7"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2020-05-142020-05-15_custom_SecuritiesPurchaseAgreementMember_custom_GlobalCareerNetworksIncMember_custom_SeriesBConvetiblePreferredStockMember_custom_AgreedToIssueANAdditionalSharesMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,500,000</ix:nonFraction>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Series B Preferred Stock shares will be issuable
to the Seller upon the following milestones, provided that such milestones are met prior to the earlier of (i) one (1) year after closing;
and (ii) thirty (30) days after the Company has provided the Seller written notice of a breach by the Seller of any provision of the
SPA, which breach has not been reasonably cured within such thirty (30) day period (such earlier date of (i) and (ii), the &#8220;<span style="text-decoration: underline">Milestone
Termination Date</span>&#8221;):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
<span id="xdx_904_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20210101__20211231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--WebsiteMember_ziu7PrIYfPH5" title="Number of shares issued"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2021-01-012021-12-31_custom_WebsiteMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">500,000</ix:nonFraction></span> Series B Preferred Stock shares upon completion of the fully operational LifeGuru.me website;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 144; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: left"><a href="#fin" title="Table of Contents" style="font-style: italic">Table of Contents</a>&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
<span id="xdx_903_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20210101__20211231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--ThreeHundredCoachesMember_z4DnCQr7LFzc" title="Number of shares issued"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2021-01-012021-12-31_custom_ThreeHundredCoachesMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">500,000</ix:nonFraction></span> Series B Preferred Stock shares upon such time as 300 coaches have signed up at LifeGuru.me; and</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)
<span id="xdx_90D_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20210101__20211231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--OneThousandCoachesMember_zIYBOTqgJvfe" title="Number of shares issued"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2021-01-012021-12-31_custom_OneThousandCoachesMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">500,000</ix:nonFraction></span> Series B Preferred Stock shares upon such time as 1,000 coaches have signed up at LifeGuru.me.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
fair value of <span id="xdx_90F_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20210101__20211231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zdTUthbDZJlk"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2021-01-012021-12-31_us-gaap_SeriesBPreferredStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">500,000</ix:nonFraction></span> shares of the Company&#8217;s Series B Preferred Stock issued at closing, valued on such grant date was $<span id="xdx_90C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardValueOptionsGrantsInPeriodGross_c20210101__20211231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zfxWaSeA5zHf" title="Number of value for granted shares"><ix:nonFraction name="AMIH:ShareBasedCompensationArrangementByShareBasedPaymentAwardValueOptionsGrantsInPeriodGross" contextRef="From2021-01-012021-12-31_us-gaap_SeriesBPreferredStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">605,488</ix:nonFraction></span>,
which equaled the market price per common share on the grant multiplied by the equivalent number of common shares which would be issuable
upon conversion of Series B Preferred Stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company did not recognize any liabilities related to the milestone shares due to the uncertainty surrounding such milestones.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
<span id="xdx_902_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_dp_c20211231__us-gaap--TypeOfArrangementAxis__custom--SharePurchaseAgreementMember__dei--LegalEntityAxis__custom--LifeguruIncMember__us-gaap--StatementClassOfStockAxis__custom--SeriesBConvetiblePreferredStockMember_zsVOjJ4hhxqg" title="Percentage of subsidiary owned"><ix:nonFraction name="us-gaap:EquityMethodInvestmentOwnershipPercentage" contextRef="AsOf2021-12-31_custom_SharePurchaseAgreementMember_custom_LifeguruIncMember_custom_SeriesBConvetiblePreferredStockMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">51</ix:nonFraction></span>% owned subsidiary is a consolidated entity which requires the presentation of noncontrolling interest in the consolidated statements
of operations for the year ended December 31, 2021. As there was no activity for the entity as of December 31, 2021, no assets, liabilities
or noncontrolling interest were presented at the period ended December 31, 2020. Since the asset is not substantiating a future cash
flow, the Company determined an impairment adjustment was necessary for the periods presented. Investment in LifeGuru of $<span id="xdx_906_eus-gaap--EquityMethodInvestmentOtherThanTemporaryImpairment_c20201001__20201231__us-gaap--TypeOfArrangementAxis__custom--SharePurchaseAgreementMember__dei--LegalEntityAxis__custom--LifeguruIncMember__us-gaap--StatementClassOfStockAxis__custom--SeriesBConvetiblePreferredStockMember_zA4sGY3bLr9j" title="Impairment of investment"><ix:nonFraction name="us-gaap:EquityMethodInvestmentOtherThanTemporaryImpairment" contextRef="From2020-10-012020-12-31_custom_SharePurchaseAgreementMember_custom_LifeguruIncMember_custom_SeriesBConvetiblePreferredStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">605,488</ix:nonFraction></span> was
impaired in full during the fourth quarter of 2020.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the first quarter of 2021, the Company issued <span id="xdx_902_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20211001__20211231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember__srt--StatementScenarioAxis__custom--NewIssueWithMilestoneMember_zIyyE2vzaXc9"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2021-10-012021-12-31_us-gaap_SeriesBPreferredStockMember_custom_NewIssueWithMilestoneMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">500,000</ix:nonFraction>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Series B Preferred Stock shares for reaching
the first milestone (milestone (a)). The fair value of <span id="xdx_90D_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20211001__20211231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zYktVua1XKWj"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2021-10-012021-12-31_us-gaap_SeriesBPreferredStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">500,000</ix:nonFraction>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares of the Company&#8217;s Series B Preferred
Stock issued at closing, valued on such grant date was $<span id="xdx_904_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20211001__20211231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zJbx8qsT7Le9"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2021-10-012021-12-31_us-gaap_SeriesBPreferredStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">601,852</ix:nonFraction></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">,
which equaled the market price per common share on the grant multiplied by the equivalent number of common shares which would be issuable
upon conversion of Series B Preferred Stock. This amount was expensed as in process research and development.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">The
Company did not recognize any liabilities related to the milestone shares due to the uncertainty surrounding such milestones.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Since
more than one year has elapsed since closing, the right of the Seller to earn the milestone shares set forth in (b) and (c) above
has expired.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2021-01-01to2021-12-31" escape="true" name="us-gaap:LesseeFinanceLeasesTextBlock"><p id="xdx_805_eus-gaap--LesseeFinanceLeasesTextBlock_zeZnWvKtZzyb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
7 &#8211; <span id="xdx_820_zWCoo678Yh92">Capital lease</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
June 17, 2020, the Company entered into an agreement with a vendor to purchase equipment used in its spa operations. Pursuant to the
agreement, the Company agreed to pay a total amount of $<span id="xdx_904_eus-gaap--FinanceLeasePrincipalPayments_pp0p0_c20200616__20200617__us-gaap--RelatedPartyTransactionAxis__custom--VendorMember__us-gaap--AwardTypeAxis__custom--TwentyFourInstallmentsMember__us-gaap--TypeOfArrangementAxis__custom--PurchaseEquipmentAgreementMember_zfxf8wjOJluk"><ix:nonFraction name="us-gaap:FinanceLeasePrincipalPayments" contextRef="From2020-06-162020-06-17_custom_VendorMember_custom_TwentyFourInstallmentsMember_custom_PurchaseEquipmentAgreementMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">44,722</ix:nonFraction></span> in 24 installments, or $<span id="xdx_908_eus-gaap--PaymentsForRent_pp0p0_c20200616__20200617__us-gaap--RelatedPartyTransactionAxis__custom--VendorMember__us-gaap--AwardTypeAxis__custom--TwentyFourInstallmentsMember__us-gaap--TypeOfArrangementAxis__custom--PurchaseEquipmentAgreementMember_zOijErXydPQg" title="Payments for rent"><ix:nonFraction name="us-gaap:PaymentsForRent" contextRef="From2020-06-162020-06-17_custom_VendorMember_custom_TwentyFourInstallmentsMember_custom_PurchaseEquipmentAgreementMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,819</ix:nonFraction></span> per month plus tax. The outstanding balance
of this capital lease was $<span id="xdx_900_eus-gaap--FinanceLeaseLiability_iI_pp0p0_c20211231__us-gaap--RelatedPartyTransactionAxis__custom--VendorMember__us-gaap--AwardTypeAxis__custom--TwentyFourInstallmentsMember__us-gaap--TypeOfArrangementAxis__custom--PurchaseEquipmentAgreementMember_z7jHBZXMs16b" title="Capital lease obligations"><ix:nonFraction name="us-gaap:FinanceLeaseLiability" contextRef="AsOf2021-12-31_custom_VendorMember_custom_TwentyFourInstallmentsMember_custom_PurchaseEquipmentAgreementMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">0</ix:nonFraction></span> as of December 31, 2021. Due to the discontinued operation, the Company returned equipment in the first
quarter of 2021.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
July 14, 2020, the Company entered into an agreement with a vendor to purchase equipment used in its spa operations. Pursuant to the
agreement, the Company agreed to pay a total amount of $<span id="xdx_906_eus-gaap--FinanceLeasePrincipalPayments_pp0p0_c20200613__20200614__us-gaap--RelatedPartyTransactionAxis__custom--VendorMember__us-gaap--AwardTypeAxis__custom--TwentyFourInstallmentsMember__us-gaap--TypeOfArrangementAxis__custom--PurchaseEquipmentAgreementMember_ziriVzcwvHaj" title="Finance lease, payments"><ix:nonFraction name="us-gaap:FinanceLeasePrincipalPayments" contextRef="From2020-06-132020-06-14_custom_VendorMember_custom_TwentyFourInstallmentsMember_custom_PurchaseEquipmentAgreementMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">44,722</ix:nonFraction></span> in 24 installments, or $<span id="xdx_907_eus-gaap--PaymentsForRent_pp0p0_c20200613__20200614__us-gaap--RelatedPartyTransactionAxis__custom--VendorMember__us-gaap--AwardTypeAxis__custom--TwentyFourInstallmentsMember__us-gaap--TypeOfArrangementAxis__custom--PurchaseEquipmentAgreementMember_z48NNFMhbHa9"><ix:nonFraction name="us-gaap:PaymentsForRent" contextRef="From2020-06-132020-06-14_custom_VendorMember_custom_TwentyFourInstallmentsMember_custom_PurchaseEquipmentAgreementMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,819</ix:nonFraction></span> per month plus tax. The outstanding balance
of this capital lease was $<span id="xdx_903_eus-gaap--FinanceLeaseLiability_iI_pp0p0_c20211231__us-gaap--RelatedPartyTransactionAxis__custom--VendorMember__us-gaap--AwardTypeAxis__custom--TwentyFourInstallmentsMember__us-gaap--TypeOfArrangementAxis__custom--PurchaseEquipmentAgreementMember_zImbNp1vDlkf"><ix:nonFraction name="us-gaap:FinanceLeaseLiability" contextRef="AsOf2021-12-31_custom_VendorMember_custom_TwentyFourInstallmentsMember_custom_PurchaseEquipmentAgreementMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">0</ix:nonFraction></span> as of December 31, 2021. Due to the discontinued operation, the Company returned equipment in the first
quarter of 2021.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2021-01-01to2021-12-31" escape="true" name="us-gaap:LesseeOperatingLeasesTextBlock"><p id="xdx_801_eus-gaap--LesseeOperatingLeasesTextBlock_z3xo8fPOFCf1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
8 &#8211; <span id="xdx_82A_zsMaTDl3ZhU9">Operating Right-of-Use Lease Liability</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
January 1, 2019, the Company adopted Accounting Standards Update No. 2016-2, Leases (Topic 842), as amended, which supersedes the lease
accounting guidance under Topic 840, and generally requires lessees to recognize operating and financing lease liabilities and corresponding
right-of-use (ROU) assets on the balance sheet and to provide enhanced disclosure surrounding the amount, timing and uncertainty of cash
flows arising from leasing arrangements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 145; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: left"><a href="#fin" title="Table of Contents" style="font-style: italic">Table of Contents</a>&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2021, the Company had three (3) leasing agreements subject to Accounting Standards Codification (ASC) 842.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Location
1 &#8211; Capitol City Solutions USA, Inc.</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
January 1, 2020, the Company recognized an operating right-of-use asset in the amount of $<span id="xdx_909_eus-gaap--OperatingLeaseRightOfUseAsset_c20200102__us-gaap--AdjustmentsForNewAccountingPronouncementsAxis__us-gaap--AccountingStandardsUpdate201602Member__dei--LegalEntityAxis__custom--CapitolCitySolutionsUSAIncMember_pp0p0"><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="AsOf2020-01-02_us-gaap_AccountingStandardsUpdate201602Member_custom_CapitolCitySolutionsUSAIncMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">113,794</ix:nonFraction>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">and an operating lease liability in the amount
of $<span id="xdx_900_eus-gaap--OperatingLeaseLiability_iI_pp0p0_c20200102__us-gaap--AdjustmentsForNewAccountingPronouncementsAxis__us-gaap--AccountingStandardsUpdate201602Member__dei--LegalEntityAxis__custom--CapitolCitySolutionsUSAIncMember_z5A0i6uR7Dfl"><ix:nonFraction name="us-gaap:OperatingLeaseLiability" contextRef="AsOf2020-01-02_us-gaap_AccountingStandardsUpdate201602Member_custom_CapitolCitySolutionsUSAIncMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">113,794</ix:nonFraction>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">in connection with Location 1. The lease term
is sixty-one (<span id="xdx_90D_eus-gaap--LesseeOperatingLeaseTermOfContract_iI_dtM_c20200102__us-gaap--AdjustmentsForNewAccountingPronouncementsAxis__us-gaap--AccountingStandardsUpdate201602Member__dei--LegalEntityAxis__custom--CapitolCitySolutionsUSAIncMember_z7w4wk9L97Ni"><ix:nonNumeric contextRef="AsOf2020-01-02_us-gaap_AccountingStandardsUpdate201602Member_custom_CapitolCitySolutionsUSAIncMember" format="ixt-sec:durmonth" name="us-gaap:LesseeOperatingLeaseTermOfContract">61</ix:nonNumeric></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)
months and <span id="xdx_904_eus-gaap--LesseeOperatingLeaseOptionToExtend_c20200101__20200102__us-gaap--AdjustmentsForNewAccountingPronouncementsAxis__us-gaap--AccountingStandardsUpdate201602Member__dei--LegalEntityAxis__custom--CapitolCitySolutionsUSAIncMember_zZJbsp5flyCc"><ix:nonNumeric contextRef="From2020-01-012020-01-02_us-gaap_AccountingStandardsUpdate201602Member_custom_CapitolCitySolutionsUSAIncMember" name="us-gaap:LesseeOperatingLeaseOptionToExtend">expires
in January 2025</ix:nonNumeric></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&#160;</p>

<ix:nonNumeric contextRef="From2021-01-012021-12-31_custom_CapitolCitySolutionsUSAIncMember" escape="true" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock"><p id="xdx_89C_eus-gaap--LesseeOperatingLeaseLiabilityMaturityTableTextBlock_hdei--LegalEntityAxis__custom--CapitolCitySolutionsUSAIncMember_zK0wetJRBsC4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following is a schedule, by year, of maturities of lease liabilities as of December 31, 2021:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B6_zW1EXNwmXoFl" style="display: none">Schedule
of Maturities of Lease Liabilities</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_49C_20211231__dei--LegalEntityAxis__custom--CapitolCitySolutionsUSAIncMember_zgiNHWuKs396" style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_pp0p0_maLOLLPznkz_zNivitMBp8P5" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">2021</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_408_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_iI_pp0p0_maLOLLPznkz_z32dgMYYg7i1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 80%; text-align: left">2022</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" contextRef="AsOf2021-12-31_custom_CapitolCitySolutionsUSAIncMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">27,288</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearThree_iI_pp0p0_maLOLLPznkz_zyUYm6XrmHo4" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">2023</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" contextRef="AsOf2021-12-31_custom_CapitolCitySolutionsUSAIncMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">27,288</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearFour_iI_pp0p0_maLOLLPznkz_zQZr3m2vCjSi" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">2024</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour" contextRef="AsOf2021-12-31_custom_CapitolCitySolutionsUSAIncMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">27,288</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearFive_iI_pp0p0_maLOLLPznkz_zsjKqmShXzqe" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">2025</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive" contextRef="AsOf2021-12-31_custom_CapitolCitySolutionsUSAIncMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">2,274</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iTI_pp0p0_mtLOLLPznkz_zLkO4ztlC0Zk" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Total undiscounted cash flows</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" contextRef="AsOf2021-12-31_custom_CapitolCitySolutionsUSAIncMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">84,138</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_iNI_di_z0i5cvMSVN0i" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Less imputed interest (<span id="xdx_903_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_pid_dp_uPure_c20211231__dei--LegalEntityAxis__custom--CapitolCitySolutionsUSAIncMember_zhbGX9ZqVCT" class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE1hdHVyaXRpZXMgb2YgTGVhc2UgTGlhYmlsaXRpZXMgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_"><ix:nonFraction name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" contextRef="AsOf2021-12-31_custom_CapitolCitySolutionsUSAIncMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">8</ix:nonFraction></span>%)</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" contextRef="AsOf2021-12-31_custom_CapitolCitySolutionsUSAIncMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">20,623</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40F_eus-gaap--OperatingLeaseLiability_iI_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Present value of lease liability</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseLiability" contextRef="AsOf2021-12-31_custom_CapitolCitySolutionsUSAIncMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">63,515</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8AE_zYiwpHLXit9b" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
March 9,</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> 2022, Capitol City Solutions USA, Inc.
entered into a Release Agreement with its landlord for the leased premises located at 1043 Asher Way, Suite 300, Tyler, TX 75703 whereby
the landlord agreed to release CCS from its remaining obligations under the lease in exchange for a total of $<span id="xdx_909_eus-gaap--OperatingLeasePayments_c20220308__20220309__us-gaap--TypeOfArrangementAxis__custom--ReleaseAgreementMember__srt--TitleOfIndividualAxis__custom--LandlordMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zgZKw9zFM505"><ix:nonFraction name="us-gaap:OperatingLeasePayments" contextRef="From2022-03-082022-03-09_custom_ReleaseAgreementMember_custom_LandlordMember_us-gaap_SubsequentEventMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">18,523</ix:nonFraction></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">.
Total rental expense related to this location for the year ended December 31, 2021, was $<span id="xdx_90C_eus-gaap--PaymentsForRent_pp0p0_c20210101__20211231__dei--LegalEntityAxis__custom--CapitolCitySolutionsUSAIncMember_zxIJYXYdYmCb"><ix:nonFraction name="us-gaap:PaymentsForRent" contextRef="From2021-01-012021-12-31_custom_CapitolCitySolutionsUSAIncMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">0</ix:nonFraction></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">.
The operating lease right-of-use asset net balance on December 31, 2021, related to this location was $<span id="xdx_901_eus-gaap--OperatingLeaseRightOfUseAsset_iI_pp0p0_c20211231__dei--LegalEntityAxis__custom--CapitolCitySolutionsUSAIncMember_zVVB26fT2Ljb"><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="AsOf2021-12-31_custom_CapitolCitySolutionsUSAIncMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">0</ix:nonFraction></span></span>,
which was impaired in full due to discontinued operations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Location
2 &#8211; VISSIA Mckinney, LLC</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
January 1, 2019, the Company recognized an operating right-of-use asset in the amount of $<span id="xdx_900_eus-gaap--OperatingLeaseRightOfUseAsset_iI_pp0p0_c20200102__us-gaap--AdjustmentsForNewAccountingPronouncementsAxis__us-gaap--AccountingStandardsUpdate201602Member__dei--LegalEntityAxis__custom--VISSIAMckinneyMember_z5DIbWEdeFlg"><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="AsOf2020-01-02_us-gaap_AccountingStandardsUpdate201602Member_custom_VISSIAMckinneyMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">287,206</ix:nonFraction></span> and an operating lease liability in
the amount of $<span id="xdx_903_eus-gaap--OperatingLeaseLiability_iI_pp0p0_c20200102__us-gaap--AdjustmentsForNewAccountingPronouncementsAxis__us-gaap--AccountingStandardsUpdate201602Member__dei--LegalEntityAxis__custom--VISSIAMckinneyMember_zuv4rVsV7Goa"><ix:nonFraction name="us-gaap:OperatingLeaseLiability" contextRef="AsOf2020-01-02_us-gaap_AccountingStandardsUpdate201602Member_custom_VISSIAMckinneyMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">294,774</ix:nonFraction></span> in connection with Location 1. The lease term is eighty-four (<span id="xdx_908_eus-gaap--LesseeOperatingLeaseTermOfContract_iI_dtM_c20200102__us-gaap--AdjustmentsForNewAccountingPronouncementsAxis__us-gaap--AccountingStandardsUpdate201602Member__dei--LegalEntityAxis__custom--VISSIAMckinneyMember_zDITLOj61GAc" title="Lease term"><ix:nonNumeric contextRef="AsOf2020-01-02_us-gaap_AccountingStandardsUpdate201602Member_custom_VISSIAMckinneyMember" format="ixt-sec:durmonth" name="us-gaap:LesseeOperatingLeaseTermOfContract">84</ix:nonNumeric></span>) months and expires in November 2025.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2021-01-012021-12-31_custom_VISSIAMckinneyLLCMember" escape="true" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock"><p id="xdx_891_eus-gaap--LesseeOperatingLeaseLiabilityMaturityTableTextBlock_hdei--LegalEntityAxis__custom--VISSIAMckinneyLLCMember_zFwdNRKVaJR8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following is a schedule, by year, of maturities of lease liabilities as of December 31, 2021:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8BE_zQaWVUZG17re" style="display: none">Schedule
of Maturities of Lease Liabilities</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_49B_20211231__dei--LegalEntityAxis__custom--VISSIAMckinneyMember_zGwAKOnvpfxb" style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_pp0p0_zWFakH6LCgbg" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 80%; text-align: left">2021</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" contextRef="AsOf2021-12-31_custom_VISSIAMckinneyMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">54,951</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_iI_pp0p0_zKnd8Wi2sIz4" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">2022</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" contextRef="AsOf2021-12-31_custom_VISSIAMckinneyMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">55,854</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearThree_iI_pp0p0_zsdzYyinYbFf" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">2023</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" contextRef="AsOf2021-12-31_custom_VISSIAMckinneyMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">56,776</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearFour_iI_pp0p0_zbOrIJrzHBjg" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">2024</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour" contextRef="AsOf2021-12-31_custom_VISSIAMckinneyMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">57,715</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearFive_iI_pp0p0_zR3IOc9G4fdf" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">2025</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive" contextRef="AsOf2021-12-31_custom_VISSIAMckinneyMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">53,828</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iTI_pp0p0_zcluFXy6XRf1" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Total undiscounted cash flows</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" contextRef="AsOf2021-12-31_custom_VISSIAMckinneyMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">279,124</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_iNI_di_zXvOrh27L7J1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Less imputed interest (<span id="xdx_904_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_pid_dp_uPure_c20211231__dei--LegalEntityAxis__custom--VISSIAMckinneyMember_zL7gpZb3gTv8" title="Imputed interest" class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE1hdHVyaXRpZXMgb2YgTGVhc2UgTGlhYmlsaXRpZXMgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_"><ix:nonFraction name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" contextRef="AsOf2021-12-31_custom_VISSIAMckinneyMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">8</ix:nonFraction></span>%)</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" contextRef="AsOf2021-12-31_custom_VISSIAMckinneyMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">83,144</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_405_eus-gaap--OperatingLeaseLiability_iI_pp0p0_zcKcXbtnW4zg" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Present value of lease liability</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseLiability" contextRef="AsOf2021-12-31_custom_VISSIAMckinneyMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">195,980</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A1_zA39WCRytXpd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
September 5, 2021, Vissia Mckinney, LLC entered into a Release Agreement with its landlord for the leased premises located at 5000 Collin
Mckinney Parkway, Mckinney, Texas 75070 whereby the landlord agreed to release Vissia Mckinney from its remaining obligations under the
lease in exchange for a total of $<span id="xdx_90D_eus-gaap--OperatingLeasePayments_c20210904__20210905__us-gaap--TypeOfArrangementAxis__custom--ReleaseAgreementMember__srt--TitleOfIndividualAxis__custom--LandlordMember_zAOIsgRUxB18"><ix:nonFraction name="us-gaap:OperatingLeasePayments" contextRef="From2021-09-042021-09-05_custom_ReleaseAgreementMember_custom_LandlordMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">22,500</ix:nonFraction></span>, of which $<span id="xdx_908_eus-gaap--OperatingLeasePayments_c20210904__20210905__us-gaap--TypeOfArrangementAxis__custom--ReleaseAgreementMember__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember_zw8qfIKCiNQl"><ix:nonFraction name="us-gaap:OperatingLeasePayments" contextRef="From2021-09-042021-09-05_custom_ReleaseAgreementMember_us-gaap_FurnitureAndFixturesMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">10,000</ix:nonFraction></span> was paid to the landlord with furniture and fixtures located at the property
and the remaining $<span id="xdx_907_eus-gaap--OperatingLeasePayments_c20210904__20210905__us-gaap--TypeOfArrangementAxis__custom--ReleaseAgreementMember_zce9dXwBI0d4"><ix:nonFraction name="us-gaap:OperatingLeasePayments" contextRef="From2021-09-042021-09-05_custom_ReleaseAgreementMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">12,500</ix:nonFraction></span> was paid in full with cash. Total rental expense related to this location for the year ended December 31, 2021,
was $<span id="xdx_900_eus-gaap--PaymentsForRent_pp0p0_c20210101__20211231__dei--LegalEntityAxis__custom--VISSIAMckinneyMember_zVqNpDYtANE1" title="Rental expenses"><ix:nonFraction name="us-gaap:PaymentsForRent" contextRef="From2021-01-012021-12-31_custom_VISSIAMckinneyMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">0</ix:nonFraction></span>. The operating lease right-of-use asset net balance on December 31, 2021, related to this location was $<span id="xdx_902_eus-gaap--OperatingLeaseRightOfUseAsset_iI_pp0p0_c20211231__dei--LegalEntityAxis__custom--VISSIAMckinneyMember_zzqsvzP5ILji"><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="AsOf2021-12-31_custom_VISSIAMckinneyMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">0</ix:nonFraction></span>, which was impaired
in full due to discontinued operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Location
3 &#8211; VISSIA Waterway, Inc.</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
January 1, 2020, the Company recognized an operating right-of-use asset in the amount of $<span id="xdx_903_eus-gaap--OperatingLeaseRightOfUseAsset_iI_pp0p0_c20200102__us-gaap--AdjustmentsForNewAccountingPronouncementsAxis__us-gaap--AccountingStandardsUpdate201602Member__dei--LegalEntityAxis__custom--VISSIAWaterwayIncMember_zLZaojXOXZbi" title="Operating right-of-use asset"><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="AsOf2020-01-02_us-gaap_AccountingStandardsUpdate201602Member_custom_VISSIAWaterwayIncMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">234,485</ix:nonFraction></span> and an operating lease liability in
the amount of $<span id="xdx_90F_eus-gaap--OperatingLeaseLiability_iI_pp0p0_c20200102__us-gaap--AdjustmentsForNewAccountingPronouncementsAxis__us-gaap--AccountingStandardsUpdate201602Member__dei--LegalEntityAxis__custom--VISSIAWaterwayIncMember_z1cm2KT5Tchg" title="Operating lease liability"><ix:nonFraction name="us-gaap:OperatingLeaseLiability" contextRef="AsOf2020-01-02_us-gaap_AccountingStandardsUpdate201602Member_custom_VISSIAWaterwayIncMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">234,485</ix:nonFraction></span> in connection with Location 2. The lease term is sixty (<span id="xdx_904_eus-gaap--LesseeOperatingLeaseTermOfContract_iI_dtM_c20200102__us-gaap--AdjustmentsForNewAccountingPronouncementsAxis__us-gaap--AccountingStandardsUpdate201602Member__dei--LegalEntityAxis__custom--VISSIAWaterwayIncMember_zfxvV1D84zkg" title="Lease term"><ix:nonNumeric contextRef="AsOf2020-01-02_us-gaap_AccountingStandardsUpdate201602Member_custom_VISSIAWaterwayIncMember" format="ixt-sec:durmonth" name="us-gaap:LesseeOperatingLeaseTermOfContract">60</ix:nonNumeric></span>) months and expires in December 2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2021-01-012021-12-31_custom_VISSIAWaterwayIncMember" escape="true" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock"><p id="xdx_891_eus-gaap--LesseeOperatingLeaseLiabilityMaturityTableTextBlock_hdei--LegalEntityAxis__custom--VISSIAWaterwayIncMember_z43NfpJ54exk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following is a schedule, by year, of maturities of lease liabilities as of December 31, 2020:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B5_zzkhdp7VviE4" style="display: none">Schedule
of Maturities of Lease Liabilities</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_499_20201231__dei--LegalEntityAxis__custom--VISSIAWaterwayIncMember_z3gGXBhx4gQk" style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_pp0p0_zbnpxP117TP9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 80%; text-align: left">2021</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" contextRef="AsOf2020-12-31_custom_VISSIAWaterwayIncMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">55,540</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_iI_pp0p0_zfLb2vMWY0bk" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">2022</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" contextRef="AsOf2020-12-31_custom_VISSIAWaterwayIncMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">57,206</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearThree_iI_pp0p0_zEtuCO1Lr05a" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">2023</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" contextRef="AsOf2020-12-31_custom_VISSIAWaterwayIncMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">58,922</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearFour_iI_pp0p0_zU2TJp1bFhq9" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">2024</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour" contextRef="AsOf2020-12-31_custom_VISSIAWaterwayIncMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">60,690</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iTI_pp0p0_zc7ikDDp8i91" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Total undiscounted cash flows</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" contextRef="AsOf2020-12-31_custom_VISSIAWaterwayIncMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">232,358</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_iNI_di_zTDOw1Kl4r69" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Less imputed interest (<span id="xdx_90B_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_pid_dp_uPure_c20201231__dei--LegalEntityAxis__custom--VISSIAWaterwayIncMember_zMnaXFj08Hl3" title="Imputed interest" class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE1hdHVyaXRpZXMgb2YgTGVhc2UgTGlhYmlsaXRpZXMgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_"><ix:nonFraction name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" contextRef="AsOf2020-12-31_custom_VISSIAWaterwayIncMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">8</ix:nonFraction></span>%)</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" contextRef="AsOf2020-12-31_custom_VISSIAWaterwayIncMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">49,529</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_402_eus-gaap--OperatingLeaseLiability_iI_pp0p0_zJo9JIM2OrLc" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Present value of lease liability</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseLiability" contextRef="AsOf2020-12-31_custom_VISSIAWaterwayIncMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">182,829</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A2_zQ2YWrtVeAqi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
December 31, 2021, Vissia Waterway, LLC entered into a Release Agreement with its landlord for the leased premises located at 25 Waterway
Avenue, The Woodlands, Montgomery County, Texas whereby the landlord agreed to release Vissia Waterway from its remaining obligations
under the lease in exchange for a total of $<span id="xdx_90A_eus-gaap--OperatingLeasePayments_pp0p0_c20200101__20200102__dei--LegalEntityAxis__custom--VISSIAWaterwayIncMember_z9kWSRVAkKHk" title="Operating lease payments"><ix:nonFraction name="us-gaap:OperatingLeasePayments" contextRef="From2020-01-012020-01-02_custom_VISSIAWaterwayIncMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">88,679</ix:nonFraction></span>. Total rental expense related to this location for the year ended December 31, 2021,
was $<span id="xdx_909_eus-gaap--PaymentsForRent_pp0p0_c20210101__20211231__dei--LegalEntityAxis__custom--VISSIAWaterwayIncMember_zCVIkEVFPiE6" title="Rent expenses"><ix:nonFraction name="us-gaap:PaymentsForRent" contextRef="From2021-01-012021-12-31_custom_VISSIAWaterwayIncMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">0</ix:nonFraction></span>. The operating lease right-of-use asset net balance on December 31, 2021, related to this location was $<span id="xdx_904_eus-gaap--OperatingLeaseRightOfUseAsset_iI_pp0p0_c20201231__dei--LegalEntityAxis__custom--VISSIAWaterwayIncMember_zKs8DP4gaSQb" title="Operating right-of-use asset"><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="AsOf2020-12-31_custom_VISSIAWaterwayIncMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">0</ix:nonFraction></span>, which was impaired
in full due to discontinued operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2021-01-01to2021-12-31" escape="true" name="us-gaap:CompensationRelatedCostsGeneralTextBlock"><p id="xdx_80E_eus-gaap--CompensationRelatedCostsGeneralTextBlock_zWN2luLBBBNh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
9 &#8211; <span id="xdx_821_zvHxS05Q564j">Accrued Compensation for Related Parties</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
December 31, 2021, accrued compensation was $<span id="xdx_90C_eus-gaap--EmployeeRelatedLiabilitiesCurrent_iI_pp0p0_c20211231_zvdE4uSVGLbj" title="Accrued compensation"><ix:nonFraction name="us-gaap:EmployeeRelatedLiabilitiesCurrent" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">103,500</ix:nonFraction></span>, representing $<span id="xdx_90F_eus-gaap--EmployeeRelatedLiabilitiesCurrent_iI_pp0p0_c20211231__srt--TitleOfIndividualAxis__custom--JacobCohenMember_zd4oEMQEWnxc"><ix:nonFraction name="us-gaap:EmployeeRelatedLiabilitiesCurrent" contextRef="AsOf2021-12-31_custom_JacobCohenMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">53,500</ix:nonFraction></span> owed to Jacob Cohen, the Company&#8217;s CEO and $<span id="xdx_908_eus-gaap--EmployeeRelatedLiabilitiesCurrent_iI_pp0p0_c20211231__srt--TitleOfIndividualAxis__custom--AlanHernandezMember_zWSlJKC3DQSl"><span id="xdx_907_eus-gaap--EmployeeRelatedLiabilitiesCurrent_iI_pp0p0_c20211231__srt--TitleOfIndividualAxis__custom--EstebanAlexanderMember_zUPvvTDao0M" title="Accrued compensation"><ix:nonFraction name="us-gaap:EmployeeRelatedLiabilitiesCurrent" contextRef="AsOf2021-12-31_custom_AlanHernandezMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD"><ix:nonFraction name="us-gaap:EmployeeRelatedLiabilitiesCurrent" contextRef="AsOf2021-12-31_custom_EstebanAlexanderMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">25,000</ix:nonFraction></ix:nonFraction></span></span> owed
to each of Alan Hernandez and Esteban Alexander, the Company&#8217;s former officers and directors.</span></p>
<!-- Field: Split-Segment; Name: 001 -->
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 146; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: left"><a href="#fin" title="Table of Contents" style="font-style: italic">Table of Contents</a>&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2021-01-01to2021-12-31" escape="true" name="us-gaap:DebtDisclosureTextBlock"><p id="xdx_807_eus-gaap--DebtDisclosureTextBlock_zpqGum8EmuJd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
10 &#8211; <span id="xdx_825_zHojju5lXX84">Notes Payable</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2021-01-01to2021-12-31" escape="true" name="us-gaap:ScheduleOfDebtTableTextBlock"><p id="xdx_899_eus-gaap--ScheduleOfDebtTableTextBlock_zn2RUJH4DCpa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notes
payable represents the following at December 31, 2021:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B6_z6scqPDGIVVa" style="display: none">Schedule of Notes
Payable&#160;</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom; background-color: #CCEEFF">
    <td style="text-align: justify">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td id="xdx_49D_20211231_zPEP9AA9cHW5" style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
<tr id="xdx_404_eus-gaap--DebtInstrumentCarryingAmount_iI_hus-gaap--ShortTermDebtTypeAxis__custom--NotePayableOneMember_z0aiCamOzC9d" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Note payable .</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DebtInstrumentCarryingAmount" contextRef="AsOf2021-12-31_custom_NotePayableOneMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">40,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_402_eus-gaap--DebtInstrumentCarryingAmount_iI_hus-gaap--ShortTermDebtTypeAxis__custom--NotePayableOneMember_zZ7q2LffoCrh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 80%; text-align: justify">Note payable to an individual dated July 8, 2019 for $<span id="xdx_904_eus-gaap--DebtInstrumentFaceAmount_iI_c20190708__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableOneMember_zvghw8IliLXd" class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE5vdGVzIFBheWFibGUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_"><ix:nonFraction name="us-gaap:DebtInstrumentFaceAmount" contextRef="AsOf2019-07-08_custom_NotePayableOneMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">40,000</ix:nonFraction></span>, with interest at <span id="xdx_90C_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_dp_uPure_c20190708__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableOneMember_zZoFMbqNi04h" class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE5vdGVzIFBheWFibGUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_"><ix:nonFraction name="us-gaap:DebtInstrumentInterestRateStatedPercentage" contextRef="AsOf2019-07-08_custom_NotePayableOneMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">8</ix:nonFraction></span>% per annum and due on <span id="xdx_904_eus-gaap--DebtInstrumentMaturityDate_c20190707__20190708__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableOneMember_zhHkNDROnMP6" class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE5vdGVzIFBheWFibGUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_"><ix:nonNumeric contextRef="From2019-07-072019-07-08_custom_NotePayableOneMember" format="ixt:datemonthdayyearen" name="us-gaap:DebtInstrumentMaturityDate">July 8, 2020</ix:nonNumeric></span>. The Note is currently past due.</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:DebtInstrumentCarryingAmount" contextRef="AsOf2021-12-31_custom_NotePayableOneMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">40,000</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--DebtInstrumentCarryingAmount_iI_hus-gaap--ShortTermDebtTypeAxis__custom--NotePayableTwoMember_zny88y8bNaJ" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Note payable dated July 7, 2020 for $<span id="xdx_909_eus-gaap--DebtInstrumentFaceAmount_iI_pp0p0_c20200707__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableTwoMember_z6jS61zKwtwh" title="Debt instrument, face amount" class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE5vdGVzIFBheWFibGUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_"><ix:nonFraction name="us-gaap:DebtInstrumentFaceAmount" contextRef="AsOf2020-07-07_custom_NotePayableTwoMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">50,000</ix:nonFraction></span>, with interest at <span id="xdx_90A_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_dp_c20200707__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableTwoMember_zHoEwh06W2Ma" title="Debt instrument, interest rate" class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE5vdGVzIFBheWFibGUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_"><ix:nonFraction name="us-gaap:DebtInstrumentInterestRateStatedPercentage" contextRef="AsOf2020-07-07_custom_NotePayableTwoMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">5</ix:nonFraction></span>% per annum and due on <span id="xdx_904_eus-gaap--DebtInstrumentMaturityDate_c20200706__20200707__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableTwoMember_zB6qvKYDDkl4" title="Debt instrument, maturity date" class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE5vdGVzIFBheWFibGUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_"><ix:nonNumeric contextRef="From2020-07-062020-07-07_custom_NotePayableTwoMember" format="ixt:datemonthdayyearen" name="us-gaap:DebtInstrumentMaturityDate">July 7, 2021</ix:nonNumeric></span>. The Note is unsecured. The Note is currently past due.</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DebtInstrumentCarryingAmount" contextRef="AsOf2021-12-31_custom_NotePayableTwoMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">50,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_ecustom--NotesPayableBeforeReductionOfPartialConversion_iI_hus-gaap--ShortTermDebtTypeAxis__custom--NotePayableThreeMember_zmmJH705kD8f" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Note payable of $<span id="xdx_90F_eus-gaap--NotesPayable_iI_pp0p0_c20200805__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableThreeMember_z7LnK3OIILog" class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE5vdGVzIFBheWFibGUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_"><ix:nonFraction name="us-gaap:NotesPayable" contextRef="AsOf2020-08-05_custom_NotePayableThreeMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">53,000</ix:nonFraction></span> dated August 5, 2020 for cash of $<span id="xdx_901_eus-gaap--DebtInstrumentFaceAmount_iI_pp0p0_c20200805__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableThreeMember_zxCoasqW3PFd" class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE5vdGVzIFBheWFibGUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_"><ix:nonFraction name="us-gaap:DebtInstrumentFaceAmount" contextRef="AsOf2020-08-05_custom_NotePayableThreeMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">53,000</ix:nonFraction></span>, with interest at <span id="xdx_90D_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20200805__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableThreeMember_zjktWT9vnWh4" class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE5vdGVzIFBheWFibGUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_"><ix:nonFraction name="us-gaap:DebtInstrumentInterestRateStatedPercentage" contextRef="AsOf2020-08-05_custom_NotePayableThreeMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">8</ix:nonFraction></span>% per annum and due on <span id="xdx_902_eus-gaap--DebtInstrumentMaturityDate_c20200804__20200805__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableThreeMember_zyJzul9ep5V7" class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE5vdGVzIFBheWFibGUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_"><ix:nonNumeric contextRef="From2020-08-042020-08-05_custom_NotePayableThreeMember" format="ixt:datemonthdayyearen" name="us-gaap:DebtInstrumentMaturityDate">November 5, 2021</ix:nonNumeric></span>. The annual interest rate will increase to <span id="xdx_908_eus-gaap--DebtInstrumentInterestRateIncreaseDecrease_pid_dp_uPure_c20200804__20200805__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableThreeMember_z9E54praINGa" class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE5vdGVzIFBheWFibGUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_"><ix:nonFraction name="us-gaap:DebtInstrumentInterestRateIncreaseDecrease" contextRef="From2020-08-042020-08-05_custom_NotePayableThreeMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">22</ix:nonFraction></span>% if in default. The Note is a convertible promissory note. The conversion price equals <span id="xdx_90D_ecustom--DebtInstrumentConvertibleStockPriceTriggerPercentage_pid_dp_uPure_c20200804__20200805__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableThreeMember_zy26NhKZwB8h" class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE5vdGVzIFBheWFibGUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_"><ix:nonFraction name="AMIH:DebtInstrumentConvertibleStockPriceTriggerPercentage" contextRef="From2020-08-042020-08-05_custom_NotePayableThreeMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">61</ix:nonFraction></span>% of the lowest daily volume weighted average price (VWAP) for the common stock during the ten (<span id="xdx_907_eus-gaap--DebtInstrumentConvertibleThresholdTradingDays_uInteger_c20200804__20200805__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableThreeMember_zMYylRj44VPh" class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE5vdGVzIFBheWFibGUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_"><ix:nonFraction name="us-gaap:DebtInstrumentConvertibleThresholdTradingDays" contextRef="From2020-08-042020-08-05_custom_NotePayableThreeMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Integer">10</ix:nonFraction></span>) trading day period prior to the conversion date, representing a discount rate of <span id="xdx_90A_eus-gaap--DebtConversionConvertedInstrumentRate_pid_dp_uPure_c20200804__20200805__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableThreeMember_zCFP0U6kRami" title="Debt discount rate" class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE5vdGVzIFBheWFibGUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_"><ix:nonFraction name="us-gaap:DebtConversionConvertedInstrumentRate" contextRef="From2020-08-042020-08-05_custom_NotePayableThreeMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">39</ix:nonFraction></span>%. The note, accrued interest and early payment penalty totaling $<span id="xdx_902_eus-gaap--DebtConversionOriginalDebtAmount1_pp0p0_c20210101__20210331__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableThreeMember_zbrWimnvunJ3" title="Principal and accrued interest" class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE5vdGVzIFBheWFibGUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_"><ix:nonFraction name="us-gaap:DebtConversionOriginalDebtAmount1" contextRef="From2021-01-012021-03-31_custom_NotePayableThreeMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">70,736</ix:nonFraction></span> was paid during the three months ended March 31, 2021.</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="AMIH:NotesPayableBeforeReductionOfPartialConversion" contextRef="AsOf2021-12-31_custom_NotePayableThreeMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">53,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Less: Repayment</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_981_eus-gaap--RepaymentsOfDebt_iN_pp0p0_di_c20210101__20211231__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableThreeMember_z60fE3r60mOj" title="Repayment" style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:RepaymentsOfDebt" contextRef="From2021-01-012021-12-31_custom_NotePayableThreeMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">53,000</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_404_eus-gaap--DebtInstrumentCarryingAmount_iI_hus-gaap--ShortTermDebtTypeAxis__custom--NotePayableThreeMember_zvQGYzLBqlh7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1103">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_ecustom--NotesPayableBeforeReductionOfPartialConversion_iI_hus-gaap--ShortTermDebtTypeAxis__custom--NotePayableFourMember_zK80dhnCiPc4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Note payable of $<span id="xdx_90D_eus-gaap--NotesPayable_iI_pp0p0_c20200811__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableFourMember_zvJSLMkY6Qp5" class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE5vdGVzIFBheWFibGUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_"><ix:nonFraction name="us-gaap:NotesPayable" contextRef="AsOf2020-08-11_custom_NotePayableFourMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">105,000</ix:nonFraction></span> dated August 11, 2020 for cash of $<span id="xdx_902_eus-gaap--DebtInstrumentFaceAmount_iI_pp0p0_c20200811__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableFourMember_zHxR3M57VuX1" title="Debt instrument, face amount" class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE5vdGVzIFBheWFibGUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_"><ix:nonFraction name="us-gaap:DebtInstrumentFaceAmount" contextRef="AsOf2020-08-11_custom_NotePayableFourMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">100,000</ix:nonFraction></span>, net of original issue discount of $<span id="xdx_90E_eus-gaap--DebtInstrumentUnamortizedDiscountCurrent_iI_pp0p0_c20200811__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableFourMember_zxpit2dSY4E6" title="Original issue of discount" class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE5vdGVzIFBheWFibGUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_"><ix:nonFraction name="us-gaap:DebtInstrumentUnamortizedDiscountCurrent" contextRef="AsOf2020-08-11_custom_NotePayableFourMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">5,000</ix:nonFraction></span>, with one-time interest charge of <span id="xdx_90E_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20200811__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableFourMember_zFLLRhbP5Hye" title="Debt instrument, interest rate" class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE5vdGVzIFBheWFibGUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_"><ix:nonFraction name="us-gaap:DebtInstrumentInterestRateStatedPercentage" contextRef="AsOf2020-08-11_custom_NotePayableFourMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">8</ix:nonFraction></span>% payable and due on May 11, 2021. The outstanding balance of the Note will be increase by <span id="xdx_900_eus-gaap--DebtInstrumentInterestRateIncreaseDecrease_pid_dp_uPure_c20200810__20200811__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableFourMember_zyU8NB9YExS1" title="Increase decrease in debt percentage" class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE5vdGVzIFBheWFibGUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_"><ix:nonFraction name="us-gaap:DebtInstrumentInterestRateIncreaseDecrease" contextRef="From2020-08-102020-08-11_custom_NotePayableFourMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">135</ix:nonFraction></span>% if in default. The Note is a convertible promissory note. The conversion price equals the lower of $<span id="xdx_90A_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_c20200811__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableFourMember_zkcCLE2I3xjb" title="Debt conversion price" class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE5vdGVzIFBheWFibGUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_"><ix:nonFraction name="us-gaap:DebtInstrumentConvertibleConversionPrice1" contextRef="AsOf2020-08-11_custom_NotePayableFourMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.50</ix:nonFraction></span> per share or <span id="xdx_90F_ecustom--DebtInstrumentConvertibleStockPriceTriggerPercentage_pid_dp_uPure_c20200810__20200811__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableFourMember_z6n1GvV5NNYk" title="Trading price percentage" class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE5vdGVzIFBheWFibGUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_"><ix:nonFraction name="AMIH:DebtInstrumentConvertibleStockPriceTriggerPercentage" contextRef="From2020-08-102020-08-11_custom_NotePayableFourMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">60</ix:nonFraction></span>% of the lowest daily volume weighted average price (VWAP) for the common stock during the ten (<span id="xdx_906_eus-gaap--DebtInstrumentConvertibleThresholdTradingDays_uInteger_c20200810__20200811__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableFourMember_ztaDJgAcC2m6" title="Trading days" class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE5vdGVzIFBheWFibGUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_"><ix:nonFraction name="us-gaap:DebtInstrumentConvertibleThresholdTradingDays" contextRef="From2020-08-102020-08-11_custom_NotePayableFourMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Integer">10</ix:nonFraction></span>) trading day period prior to the conversion date, representing a discount rate of <span id="xdx_906_eus-gaap--DebtConversionConvertedInstrumentRate_pid_dp_uPure_c20200810__20200811__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableFourMember_zHNIgV3LYqo3" title="Debt discount rate" class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE5vdGVzIFBheWFibGUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_"><ix:nonFraction name="us-gaap:DebtConversionConvertedInstrumentRate" contextRef="From2020-08-102020-08-11_custom_NotePayableFourMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">40</ix:nonFraction></span>%. The note and accrued interest totaling $<span id="xdx_90C_eus-gaap--DebtConversionOriginalDebtAmount1_pp0p0_c20200810__20200811__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableFourMember_zOIPemHOv7Bl" class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE5vdGVzIFBheWFibGUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_"><ix:nonFraction name="us-gaap:DebtConversionOriginalDebtAmount1" contextRef="From2020-08-102020-08-11_custom_NotePayableFourMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">111,466</ix:nonFraction></span> was settled by the issuance of <span id="xdx_90B_eus-gaap--StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_c20200810__20200811__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableFourMember_zpt57LSLDal6" title="Convertible shares" class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE5vdGVzIFBheWFibGUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" contextRef="From2020-08-102020-08-11_custom_NotePayableFourMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">708,750</ix:nonFraction></span> common shares of the Company and $<span id="xdx_90E_eus-gaap--Cash_iI_pp0p0_c20200811__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableFourMember_zrP1yQ5DwF1g" title="Cash" class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE5vdGVzIFBheWFibGUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_"><ix:nonFraction name="us-gaap:Cash" contextRef="AsOf2020-08-11_custom_NotePayableFourMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">50,000</ix:nonFraction></span> in cash. The note and accrued interest were converted at $<span id="xdx_90C_ecustom--DebtInstrumentConvertibleConversionPrice_iI_c20200811__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableFourMember_zEGXxOKcKQ58" title="Debt conversion price" class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE5vdGVzIFBheWFibGUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_"><ix:nonFraction name="AMIH:DebtInstrumentConvertibleConversionPrice" contextRef="AsOf2020-08-11_custom_NotePayableFourMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.1614</ix:nonFraction></span> per share and settled with additional shares valued at $<span id="xdx_902_eus-gaap--SharePrice_iI_c20200811__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableFourMember_zUSxbsT7McD5" title="Additional shares price per share" class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE5vdGVzIFBheWFibGUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_"><ix:nonFraction name="us-gaap:SharePrice" contextRef="AsOf2020-08-11_custom_NotePayableFourMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.45</ix:nonFraction></span> per shares. Accordingly, the Company recorded a loss on loan settlement of $<span id="xdx_90B_eus-gaap--GainsLossesOnExtinguishmentOfDebt_pp0p0_c20210101__20210331__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableFourMember_zQ2FFY52TvW3" title="Loss on settlement of debt" class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE5vdGVzIFBheWFibGUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_"><ix:nonFraction name="us-gaap:GainsLossesOnExtinguishmentOfDebt" contextRef="From2021-01-012021-03-31_custom_NotePayableFourMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">58,059</ix:nonFraction></span> during the three months ended March 31, 2021.</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="AMIH:NotesPayableBeforeReductionOfPartialConversion" contextRef="AsOf2021-12-31_custom_NotePayableFourMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">105,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Less: Repayment</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_983_eus-gaap--RepaymentsOfDebt_iN_pp0p0_di_c20210101__20211231__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableFourMember_zoDG7BSirhv2" title="Repayment" style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:RepaymentsOfDebt" contextRef="From2021-01-012021-12-31_custom_NotePayableFourMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">105,000</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_406_eus-gaap--DebtInstrumentCarryingAmount_iI_hus-gaap--ShortTermDebtTypeAxis__custom--NotePayableFourMember_zelvUAtPpBG8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1137">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_ecustom--NotesPayableBeforeReductionOfPartialConversion_iI_hus-gaap--ShortTermDebtTypeAxis__custom--NotePayableFiveMember_zz4NMYcQ0Ssa" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Note payable of $<span id="xdx_900_eus-gaap--NotesPayable_iI_pp0p0_c20200914__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableFiveMember_zqnRcPWMkAu9" class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE5vdGVzIFBheWFibGUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_"><ix:nonFraction name="us-gaap:NotesPayable" contextRef="AsOf2020-09-14_custom_NotePayableFiveMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">53,000</ix:nonFraction></span> dated September 14, 2020 for cash of $<span id="xdx_907_eus-gaap--DebtInstrumentFaceAmount_iI_pp0p0_c20200914__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableFiveMember_za2ygkkgSF3k" title="Debt instrument, face amount" class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE5vdGVzIFBheWFibGUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_"><ix:nonFraction name="us-gaap:DebtInstrumentFaceAmount" contextRef="AsOf2020-09-14_custom_NotePayableFiveMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">53,000</ix:nonFraction></span>, with interest at <span id="xdx_906_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_c20200914__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableFiveMember_zj0Go8PlqCp2" title="Debt instrument, interest rate" class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE5vdGVzIFBheWFibGUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_"><ix:nonFraction name="us-gaap:DebtInstrumentInterestRateStatedPercentage" contextRef="AsOf2020-09-14_custom_NotePayableFiveMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">8</ix:nonFraction></span>% per annum and due on <span id="xdx_904_eus-gaap--DebtInstrumentMaturityDate_c20200913__20200914__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableFiveMember_zMYfbEdhbpC8" title="Debt instrument, maturity date" class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE5vdGVzIFBheWFibGUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_"><ix:nonNumeric contextRef="From2020-09-132020-09-14_custom_NotePayableFiveMember" format="ixt:datemonthdayyearen" name="us-gaap:DebtInstrumentMaturityDate">December 14, 2021</ix:nonNumeric></span>. The annual interest rate will increase to <span id="xdx_90A_eus-gaap--DebtInstrumentInterestRateIncreaseDecrease_pid_dp_uPure_c20200913__20200914__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableFiveMember_z2SXmNGx2VFa" title="Increase decrease in debt percentage" class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE5vdGVzIFBheWFibGUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_"><ix:nonFraction name="us-gaap:DebtInstrumentInterestRateIncreaseDecrease" contextRef="From2020-09-132020-09-14_custom_NotePayableFiveMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">22</ix:nonFraction></span>% if in default. The Note is a convertible promissory note. The conversion price equals <span id="xdx_903_ecustom--DebtInstrumentConvertibleStockPriceTriggerPercentage_pid_dp_uPure_c20200913__20200914__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableFiveMember_zoPDfyLwgwe5" title="Trading price percentage" class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE5vdGVzIFBheWFibGUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_"><ix:nonFraction name="AMIH:DebtInstrumentConvertibleStockPriceTriggerPercentage" contextRef="From2020-09-132020-09-14_custom_NotePayableFiveMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">61</ix:nonFraction></span>% of the lowest daily volume weighted average price (VWAP) for the common stock during the ten (<span id="xdx_90F_eus-gaap--DebtInstrumentConvertibleThresholdTradingDays_uInteger_c20200913__20200914__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableFiveMember_zxqNztRFR8D1" title="Trading days" class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE5vdGVzIFBheWFibGUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_"><ix:nonFraction name="us-gaap:DebtInstrumentConvertibleThresholdTradingDays" contextRef="From2020-09-132020-09-14_custom_NotePayableFiveMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Integer">10</ix:nonFraction></span>) trading day period prior to the conversion date, representing a discount rate of <span id="xdx_90A_eus-gaap--DebtConversionConvertedInstrumentRate_pid_dp_uPure_c20200913__20200914__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableFiveMember_z5E4VB3qrbd7" title="Debt discount rate" class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE5vdGVzIFBheWFibGUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_"><ix:nonFraction name="us-gaap:DebtConversionConvertedInstrumentRate" contextRef="From2020-09-132020-09-14_custom_NotePayableFiveMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">39</ix:nonFraction></span>%. The note, accrued interest and early payment penalty totaling $<span id="xdx_90E_eus-gaap--DebtConversionOriginalDebtAmount1_pp0p0_c20210101__20210331__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableFiveMember_zM72oNOgsF9f" title="Principal and accrued interest" class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE5vdGVzIFBheWFibGUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_"><ix:nonFraction name="us-gaap:DebtConversionOriginalDebtAmount1" contextRef="From2021-01-012021-03-31_custom_NotePayableFiveMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">70,736</ix:nonFraction></span> was paid during the three months ended March 31, 2021.</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="AMIH:NotesPayableBeforeReductionOfPartialConversion" contextRef="AsOf2021-12-31_custom_NotePayableFiveMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">53,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Less: Repayment</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--RepaymentsOfDebt_iN_pp0p0_di_c20210101__20211231__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableFiveMember_zxGBNa3lbXR7" title="Repayment" style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:RepaymentsOfDebt" contextRef="From2021-01-012021-12-31_custom_NotePayableFiveMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">53,000</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40D_eus-gaap--DebtInstrumentCarryingAmount_iI_hus-gaap--ShortTermDebtTypeAxis__custom--NotePayableFiveMember_z2D6YG9MFbwe" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1160">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--DebtInstrumentCarryingAmount_iI_hus-gaap--ShortTermDebtTypeAxis__custom--NotePayableSixMember_zDTxxreyohp6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Note payable to an unrelated party dated September 11, 2020 for $<span id="xdx_906_eus-gaap--DebtInstrumentFaceAmount_iI_pp0p0_c20200911__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableSixMember_zsxPktDwCWSa" title="Debt instrument, face amount" class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE5vdGVzIFBheWFibGUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_"><ix:nonFraction name="us-gaap:DebtInstrumentFaceAmount" contextRef="AsOf2020-09-11_custom_NotePayableSixMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">4,000</ix:nonFraction></span>, with no interest and due on demand.</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DebtInstrumentCarryingAmount" contextRef="AsOf2021-12-31_custom_NotePayableSixMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--DebtInstrumentCarryingAmount_iI_hus-gaap--ShortTermDebtTypeAxis__custom--NotePayableSevenMember_zutz1KQ2tZBc" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Note payable to an unrelated party dated September 16, 2020 for $<span id="xdx_90A_eus-gaap--DebtInstrumentFaceAmount_iI_pp0p0_c20200916__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableSevenMember_zq62o2ZV7p33" title="Debt instrument, face amount" class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE5vdGVzIFBheWFibGUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_"><ix:nonFraction name="us-gaap:DebtInstrumentFaceAmount" contextRef="AsOf2020-09-16_custom_NotePayableSevenMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">5,000</ix:nonFraction></span>, with no interest and due on demand.</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DebtInstrumentCarryingAmount" contextRef="AsOf2021-12-31_custom_NotePayableSevenMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_ecustom--NotesPayableBeforeReductionOfPartialConversion_iI_hus-gaap--ShortTermDebtTypeAxis__custom--NotePayableEightMember_zyHrR4Nr1KXh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Note payable of $<span id="xdx_90B_eus-gaap--NotesPayable_iI_pp0p0_c20201012__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableEightMember_zZB4jQ1K72Fj" title="Notes payable" class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE5vdGVzIFBheWFibGUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_"><ix:nonFraction name="us-gaap:NotesPayable" contextRef="AsOf2020-10-12_custom_NotePayableEightMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">56,750</ix:nonFraction></span> dated October 12, 2020, for cash of $<span id="xdx_90F_eus-gaap--DebtInstrumentFaceAmount_iI_pp0p0_c20201012__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableEightMember_zuY6DFZUYad7" title="Debt instrument, face amount" class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE5vdGVzIFBheWFibGUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_"><ix:nonFraction name="us-gaap:DebtInstrumentFaceAmount" contextRef="AsOf2020-10-12_custom_NotePayableEightMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">52,750</ix:nonFraction></span>, with interest at <span id="xdx_90E_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20201012__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableEightMember_zjXZBIs3L2W4" title="Debt instrument, interest rate" class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE5vdGVzIFBheWFibGUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_"><ix:nonFraction name="us-gaap:DebtInstrumentInterestRateStatedPercentage" contextRef="AsOf2020-10-12_custom_NotePayableEightMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">8</ix:nonFraction></span>% per annum and due on <span id="xdx_901_eus-gaap--DebtInstrumentMaturityDate_c20201011__20201012__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableEightMember_z7ChFeKZHnBe" title="Debt instrument, maturity date" class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE5vdGVzIFBheWFibGUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_"><ix:nonNumeric contextRef="From2020-10-112020-10-12_custom_NotePayableEightMember" format="ixt:datemonthdayyearen" name="us-gaap:DebtInstrumentMaturityDate">October 12, 2021</ix:nonNumeric></span>. The annual interest rate will increase to <span id="xdx_908_eus-gaap--DebtInstrumentInterestRateIncreaseDecrease_pid_dp_uPure_c20201011__20201012__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableEightMember_zhOumb2tBIL4" title="Increase decrease in debt percentage" class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE5vdGVzIFBheWFibGUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_"><ix:nonFraction name="us-gaap:DebtInstrumentInterestRateIncreaseDecrease" contextRef="From2020-10-112020-10-12_custom_NotePayableEightMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">24</ix:nonFraction></span>% if in default. The Note is a convertible promissory note. The conversion price equals the lessor of $<span id="xdx_905_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_c20201012__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableEightMember_zc8oaoYJzX9a" title="Debt conversion price" class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE5vdGVzIFBheWFibGUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_"><ix:nonFraction name="us-gaap:DebtInstrumentConvertibleConversionPrice1" contextRef="AsOf2020-10-12_custom_NotePayableEightMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.50</ix:nonFraction></span> per share or <span id="xdx_901_ecustom--DebtInstrumentConvertibleStockPriceTriggerPercentage_pid_dp_uPure_c20201011__20201012__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableEightMember_z5neHIjuxDL9" title="Trading price percentage" class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE5vdGVzIFBheWFibGUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_"><ix:nonFraction name="AMIH:DebtInstrumentConvertibleStockPriceTriggerPercentage" contextRef="From2020-10-112020-10-12_custom_NotePayableEightMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">60</ix:nonFraction></span>% of the lowest daily volume weighted average price (VWAP) for the common stock during the ten (<span id="xdx_902_eus-gaap--DebtInstrumentConvertibleThresholdTradingDays_uInteger_c20201011__20201012__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableEightMember_z4qIMFBsa51" title="Trading days" class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE5vdGVzIFBheWFibGUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_"><ix:nonFraction name="us-gaap:DebtInstrumentConvertibleThresholdTradingDays" contextRef="From2020-10-112020-10-12_custom_NotePayableEightMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Integer">10</ix:nonFraction></span>) trading day period prior to the conversion date, representing a discount rate of <span id="xdx_90F_eus-gaap--DebtConversionConvertedInstrumentRate_pid_dp_uPure_c20201011__20201012__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableEightMember_zhTJH4eRwSDh" title="Debt discount rate" class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE5vdGVzIFBheWFibGUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_"><ix:nonFraction name="us-gaap:DebtConversionConvertedInstrumentRate" contextRef="From2020-10-112020-10-12_custom_NotePayableEightMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">40</ix:nonFraction></span>%. The Note and accrued interest totaling $<span id="xdx_903_eus-gaap--DebtConversionOriginalDebtAmount1_pp0p0_c20201011__20201012__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableEightMember_zAJq1aRsHiBd" title="Principal and accrued interest" class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE5vdGVzIFBheWFibGUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_"><ix:nonFraction name="us-gaap:DebtConversionOriginalDebtAmount1" contextRef="From2020-10-112020-10-12_custom_NotePayableEightMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">56,750</ix:nonFraction></span> was converted into <span id="xdx_901_eus-gaap--StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_c20210401__20210630__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableEightMember_zx79cwG2JCDf" title="Convertible shares" class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE5vdGVzIFBheWFibGUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" contextRef="From2021-04-012021-06-30_custom_NotePayableEightMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">760,928</ix:nonFraction></span> common shares of the Company within the terms of the note during the quarter ended June 30, 2021.</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="AMIH:NotesPayableBeforeReductionOfPartialConversion" contextRef="AsOf2021-12-31_custom_NotePayableEightMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">56,750</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Less: Repayment</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_989_eus-gaap--RepaymentsOfDebt_iN_pp0p0_di_c20210101__20211231__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableEightMember_zaXX6AGyJh08" title="Repayment" style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:RepaymentsOfDebt" contextRef="From2021-01-012021-12-31_custom_NotePayableEightMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">56,750</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40F_eus-gaap--DebtInstrumentCarryingAmount_iI_hus-gaap--ShortTermDebtTypeAxis__custom--NotePayableEightMember_zpzL81P8aVH1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1196">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_ecustom--NotesPayableBeforeReductionOfPartialConversion_iI_hus-gaap--ShortTermDebtTypeAxis__custom--NotePayableNineMember_z3CTLitu0Dvj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Note payable of $<span id="xdx_90A_eus-gaap--NotesPayable_iI_pp0p0_c20201113__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableNineMember_zdWvY3Yhh4X6" title="Debt instrument, face amount" class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE5vdGVzIFBheWFibGUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_"><ix:nonFraction name="us-gaap:NotesPayable" contextRef="AsOf2020-11-13_custom_NotePayableNineMember" format="ixt:numunitdecimalin" decimals="0" scale="0" unitRef="USD">138,00</ix:nonFraction></span> dated November 13, 2020 for cash of $<span id="xdx_902_eus-gaap--DebtInstrumentFaceAmount_iI_pp0p0_c20201113__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableNineMember_zwpSCAIfOIA" title="Debt instrument, face amount" class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE5vdGVzIFBheWFibGUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_"><ix:nonFraction name="us-gaap:DebtInstrumentFaceAmount" contextRef="AsOf2020-11-13_custom_NotePayableNineMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">138,000</ix:nonFraction></span>, with interest at <span id="xdx_90D_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20201113__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableNineMember_zbY0FUoPBEu9" title="Debt instrument, interest rate" class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE5vdGVzIFBheWFibGUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_"><ix:nonFraction name="us-gaap:DebtInstrumentInterestRateStatedPercentage" contextRef="AsOf2020-11-13_custom_NotePayableNineMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">8</ix:nonFraction></span>% per annum and due on <span id="xdx_906_eus-gaap--DebtInstrumentMaturityDate_c20201112__20201113__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableNineMember_zSsOZpMpLLs7" title="Debt instrument, maturity date" class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE5vdGVzIFBheWFibGUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_"><ix:nonNumeric contextRef="From2020-11-122020-11-13_custom_NotePayableNineMember" format="ixt:datemonthdayyearen" name="us-gaap:DebtInstrumentMaturityDate">November 13, 2021</ix:nonNumeric></span>. The annual interest rate will increase to <span id="xdx_90B_eus-gaap--DebtInstrumentInterestRateIncreaseDecrease_pid_dp_uPure_c20201112__20201113__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableNineMember_zpk6A7RsUSOa" title="Increase decrease in debt percentage" class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE5vdGVzIFBheWFibGUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_"><ix:nonFraction name="us-gaap:DebtInstrumentInterestRateIncreaseDecrease" contextRef="From2020-11-122020-11-13_custom_NotePayableNineMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">18</ix:nonFraction></span>% if in default. The Note is a convertible promissory note. The conversion price equals <span id="xdx_905_ecustom--DebtInstrumentConvertibleStockPriceTriggerPercentage_pid_dp_uPure_c20201112__20201113__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableNineMember_zkM09JvqxS4a" title="Trading price percentage" class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE5vdGVzIFBheWFibGUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_"><ix:nonFraction name="AMIH:DebtInstrumentConvertibleStockPriceTriggerPercentage" contextRef="From2020-11-122020-11-13_custom_NotePayableNineMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">61</ix:nonFraction></span>% of the lowest daily volume weighted average price (VWAP) for the common stock during the ten (<span id="xdx_90B_eus-gaap--DebtInstrumentConvertibleThresholdTradingDays_uInteger_c20201112__20201113__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableNineMember_z0XGr0p2ctC" title="Trading days" class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE5vdGVzIFBheWFibGUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_"><ix:nonFraction name="us-gaap:DebtInstrumentConvertibleThresholdTradingDays" contextRef="From2020-11-122020-11-13_custom_NotePayableNineMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Integer">10</ix:nonFraction></span>) trading day period prior to the conversion date, representing a discount rate of <span id="xdx_90F_eus-gaap--DebtConversionConvertedInstrumentRate_pid_dp_uPure_c20201112__20201113__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableNineMember_z1ZV5bJkJdE" title="Debt discount rate" class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE5vdGVzIFBheWFibGUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_"><ix:nonFraction name="us-gaap:DebtConversionConvertedInstrumentRate" contextRef="From2020-11-122020-11-13_custom_NotePayableNineMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">39</ix:nonFraction></span>%. The note, accrued interest and early payment penalty totaling $<span id="xdx_906_eus-gaap--DebtConversionOriginalDebtAmount1_pp0p0_c20210101__20210331__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableNineMember_zYo7oS9A49E9" title="Principal and accrued interest" class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE5vdGVzIFBheWFibGUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_"><ix:nonFraction name="us-gaap:DebtConversionOriginalDebtAmount1" contextRef="From2021-01-012021-03-31_custom_NotePayableNineMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">183,483</ix:nonFraction></span> was paid during the three months ended March 31, 2021.</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="AMIH:NotesPayableBeforeReductionOfPartialConversion" contextRef="AsOf2021-12-31_custom_NotePayableNineMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">138,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Less: Repayment</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_983_eus-gaap--RepaymentsOfDebt_iN_pp0p0_di_c20210101__20211231__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableNineMember_zR4XDyGjxX12" title="Repayment" style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:RepaymentsOfDebt" contextRef="From2021-01-012021-12-31_custom_NotePayableNineMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">138,000</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_408_eus-gaap--DebtInstrumentCarryingAmount_iI_hus-gaap--ShortTermDebtTypeAxis__custom--NotePayableNineMember_zUX61VYrOKV6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1220">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_ecustom--NotesPayableBeforeReductionOfPartialConversion_iI_hus-gaap--ShortTermDebtTypeAxis__custom--NotePayableTenMember_zUiLQxqPV6S7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Note payable of $<span id="xdx_909_eus-gaap--NotesPayable_iI_pp0p0_c20201203__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableTenMember_zb2dFyVuU0Oh" title="Debt instrument, face amount" class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE5vdGVzIFBheWFibGUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_"><ix:nonFraction name="us-gaap:NotesPayable" contextRef="AsOf2020-12-03_custom_NotePayableTenMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">83,500</ix:nonFraction></span> dated December 2, 2020 for cash of $<span id="xdx_902_eus-gaap--DebtInstrumentFaceAmount_iI_pp0p0_c20201202__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableTenMember_zFiAYSTQPsTc" title="Debt instrument, face amount" class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE5vdGVzIFBheWFibGUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_"><ix:nonFraction name="us-gaap:DebtInstrumentFaceAmount" contextRef="AsOf2020-12-02_custom_NotePayableTenMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">83,500</ix:nonFraction></span>, with interest at <span id="xdx_902_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20201202__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableTenMember_zRTErDwaCeHg" title="Debt instrument, interest rate" class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE5vdGVzIFBheWFibGUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_"><ix:nonFraction name="us-gaap:DebtInstrumentInterestRateStatedPercentage" contextRef="AsOf2020-12-02_custom_NotePayableTenMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">8</ix:nonFraction></span>% per annum and due on <span id="xdx_905_eus-gaap--DebtInstrumentMaturityDate_c20201129__20201202__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableTenMember_zLmmQISgTMP9" title="Debt instrument, maturity date" class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE5vdGVzIFBheWFibGUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_"><ix:nonNumeric contextRef="From2020-11-292020-12-02_custom_NotePayableTenMember" format="ixt:datemonthdayyearen" name="us-gaap:DebtInstrumentMaturityDate">March 2, 2022</ix:nonNumeric></span>. The annual interest rate will increase to <span id="xdx_90E_eus-gaap--DebtInstrumentInterestRateIncreaseDecrease_pid_dp_uPure_c20201129__20201202__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableTenMember_zibkZRGYhYPl" title="Increase decrease in debt percentage" class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE5vdGVzIFBheWFibGUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_"><ix:nonFraction name="us-gaap:DebtInstrumentInterestRateIncreaseDecrease" contextRef="From2020-11-292020-12-02_custom_NotePayableTenMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">22</ix:nonFraction></span>% if in default. The Note is a convertible promissory note. The conversion price equals <span id="xdx_902_ecustom--DebtInstrumentConvertibleStockPriceTriggerPercentage_pid_dp_uPure_c20201129__20201202__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableTenMember_z2Ui6aaV79g7" title="Trading price percentage" class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE5vdGVzIFBheWFibGUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_"><ix:nonFraction name="AMIH:DebtInstrumentConvertibleStockPriceTriggerPercentage" contextRef="From2020-11-292020-12-02_custom_NotePayableTenMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">61</ix:nonFraction></span>% of the lowest daily volume weighted average price (VWAP) for the common stock during the ten (<span id="xdx_907_eus-gaap--DebtInstrumentConvertibleThresholdTradingDays_uInteger_c20201129__20201202__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableTenMember_zQeQpCevFT43" title="Trading days" class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE5vdGVzIFBheWFibGUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_"><ix:nonFraction name="us-gaap:DebtInstrumentConvertibleThresholdTradingDays" contextRef="From2020-11-292020-12-02_custom_NotePayableTenMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Integer">10</ix:nonFraction></span>) trading day period prior to the conversion date, representing a discount rate of <span id="xdx_905_eus-gaap--DebtConversionConvertedInstrumentRate_pid_dp_uPure_c20201129__20201202__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableTenMember_zB6eytBO0CLh" title="Debt discount rate" class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE5vdGVzIFBheWFibGUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_"><ix:nonFraction name="us-gaap:DebtConversionConvertedInstrumentRate" contextRef="From2020-11-292020-12-02_custom_NotePayableTenMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">39</ix:nonFraction></span>%. The note, accrued interest and early payment penalty totaling $<span id="xdx_906_eus-gaap--DebtConversionOriginalDebtAmount1_pp0p0_c20210101__20210331__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableTenMember_zJyJOTPlQkvd" title="Principal and accrued interest" class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE5vdGVzIFBheWFibGUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_"><ix:nonFraction name="us-gaap:DebtConversionOriginalDebtAmount1" contextRef="From2021-01-012021-03-31_custom_NotePayableTenMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">104,527</ix:nonFraction></span> was paid during the three months ended March 31, 2021.</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="AMIH:NotesPayableBeforeReductionOfPartialConversion" contextRef="AsOf2021-12-31_custom_NotePayableTenMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">83,500</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Less: Repayment</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_982_eus-gaap--RepaymentsOfDebt_iN_pp0p0_di_c20210101__20211231__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableTenMember_zIYknJ5q5I77" title="Repayment" style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:RepaymentsOfDebt" contextRef="From2021-01-012021-12-31_custom_NotePayableTenMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">83,500</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40F_eus-gaap--DebtInstrumentCarryingAmount_iI_hus-gaap--ShortTermDebtTypeAxis__custom--NotePayableTenMember_zKJn38iDGeme" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1244">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_ecustom--NotesPayableBeforeReductionOfPartialConversion_iI_hus-gaap--ShortTermDebtTypeAxis__custom--NotePayableElevenMember_zucVtXw34g21" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Note payable of $<span id="xdx_90D_eus-gaap--NotesPayable_iI_pp0p0_c20210106__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableElevenMember_z2BXss2deRWd" title="Notes payable" class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE5vdGVzIFBheWFibGUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_"><ix:nonFraction name="us-gaap:NotesPayable" contextRef="AsOf2021-01-06_custom_NotePayableElevenMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">425,000</ix:nonFraction></span> dated January 6, 2021 for cash of $<span id="xdx_903_eus-gaap--DebtInstrumentFaceAmount_iI_pp0p0_c20210106__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableElevenMember_z3xkTxC2J8we" title="Debt instrument, face amount" class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE5vdGVzIFBheWFibGUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_"><ix:nonFraction name="us-gaap:DebtInstrumentFaceAmount" contextRef="AsOf2021-01-06_custom_NotePayableElevenMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">400,000</ix:nonFraction></span>, with interest at <span id="xdx_905_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20210106__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableElevenMember_zSDmexd7yjPd" title="Debt instrument, interest rate" class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE5vdGVzIFBheWFibGUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_"><ix:nonFraction name="us-gaap:DebtInstrumentInterestRateStatedPercentage" contextRef="AsOf2021-01-06_custom_NotePayableElevenMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">6</ix:nonFraction></span>% per annum and due on <span id="xdx_907_eus-gaap--DebtInstrumentMaturityDate_c20210104__20210106__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableElevenMember_zILPRxtnoPn9" title="Debt instrument, maturity date" class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE5vdGVzIFBheWFibGUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_"><ix:nonNumeric contextRef="From2021-01-042021-01-06_custom_NotePayableElevenMember" format="ixt:datemonthdayyearen" name="us-gaap:DebtInstrumentMaturityDate">January 7, 2022</ix:nonNumeric></span>. The annual interest rate will increase to <span id="xdx_908_eus-gaap--DebtInstrumentInterestRateIncreaseDecrease_pid_dp_uPure_c20210104__20210106__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableElevenMember_zEuVekJYIlNj" title="Increase decrease in debt percentage" class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE5vdGVzIFBheWFibGUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_"><ix:nonFraction name="us-gaap:DebtInstrumentInterestRateIncreaseDecrease" contextRef="From2021-01-042021-01-06_custom_NotePayableElevenMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">15</ix:nonFraction></span>% if in default. The Note is a convertible promissory note. The conversion price equals the lessor of $<span id="xdx_905_eus-gaap--DebtInstrumentConvertibleStockPriceTrigger_c20210104__20210106__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableElevenMember_zQYg6LC5y0Bb" title="Trading price" class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE5vdGVzIFBheWFibGUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_"><ix:nonFraction name="us-gaap:DebtInstrumentConvertibleStockPriceTrigger" contextRef="From2021-01-042021-01-06_custom_NotePayableElevenMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.50</ix:nonFraction></span> or <span id="xdx_90F_ecustom--DebtInstrumentConvertibleStockPriceTriggerPercentage_pid_dp_uPure_c20210104__20210106__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableElevenMember_zjzfZKlaU7D6" title="Trading price percentage" class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE5vdGVzIFBheWFibGUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_"><ix:nonFraction name="AMIH:DebtInstrumentConvertibleStockPriceTriggerPercentage" contextRef="From2021-01-042021-01-06_custom_NotePayableElevenMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">75</ix:nonFraction></span>% of the lowest daily volume weighted average price (VWAP) for the common stock during the seven (<span id="xdx_907_eus-gaap--DebtInstrumentConvertibleThresholdTradingDays_uInteger_c20210104__20210106__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableElevenMember_zntMmS6gtuRj" title="Trading days" class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE5vdGVzIFBheWFibGUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_"><ix:nonFraction name="us-gaap:DebtInstrumentConvertibleThresholdTradingDays" contextRef="From2021-01-042021-01-06_custom_NotePayableElevenMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Integer">7</ix:nonFraction></span>) trading day period prior to the conversion date, representing a discount rate of <span id="xdx_90B_eus-gaap--DebtConversionConvertedInstrumentRate_pid_dp_uPure_c20210104__20210106__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableElevenMember_zYndIN0FKD33" title="Debt discount rate" class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE5vdGVzIFBheWFibGUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_"><ix:nonFraction name="us-gaap:DebtConversionConvertedInstrumentRate" contextRef="From2021-01-042021-01-06_custom_NotePayableElevenMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">25</ix:nonFraction></span>%. The note and accrued interest totaling $<span id="xdx_907_eus-gaap--DebtConversionOriginalDebtAmount1_pp0p0_c20210401__20210630__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableToUnrelatedPartyTenMember_ztaygnc5HyT4" title="Principal and accrued interest" class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE5vdGVzIFBheWFibGUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_"><ix:nonFraction name="us-gaap:DebtConversionOriginalDebtAmount1" contextRef="From2021-04-012021-06-30_custom_NotePayableToUnrelatedPartyTenMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">437,359</ix:nonFraction></span> was converted into <span id="xdx_90B_eus-gaap--StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_c20210401__20210630__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableElevenMember_z685ezZuayYj" title="Convertible shares" class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE5vdGVzIFBheWFibGUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" contextRef="From2021-04-012021-06-30_custom_NotePayableElevenMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,549,999</ix:nonFraction></span> common shares of the Company within the terms of the note during the quarter ended June 30, 2021.</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="AMIH:NotesPayableBeforeReductionOfPartialConversion" contextRef="AsOf2021-12-31_custom_NotePayableElevenMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">425,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Less: Conversion</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--DebtConversionConvertedInstrumentAmount1_iN_pp0p0_di_c20210101__20211231__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableElevenMember_z8Kin4qc9NFe" title="Less: conversion" style="text-align: right">(<ix:nonFraction name="us-gaap:DebtConversionConvertedInstrumentAmount1" contextRef="From2021-01-012021-12-31_custom_NotePayableElevenMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">425,000</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_404_eus-gaap--DebtInstrumentCarryingAmount_iI_hus-gaap--ShortTermDebtTypeAxis__custom--NotePayableElevenMember_zAgeFlVSsOkh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1272">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_ecustom--NotesPayableBeforeReductionOfPartialConversion_iI_hus-gaap--ShortTermDebtTypeAxis__custom--NotePayableTwelveMember_zk8oXUwP9TKf" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Note payable of $<span id="xdx_909_eus-gaap--NotesPayable_iI_pp0p0_c20210106__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableTwelveMember_zwV3XzTn286c" title="Notes payable" class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE5vdGVzIFBheWFibGUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_"><ix:nonFraction name="us-gaap:NotesPayable" contextRef="AsOf2021-01-06_custom_NotePayableTwelveMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">425,000</ix:nonFraction></span> dated January 6, 2021 for cash of $<span id="xdx_902_eus-gaap--DebtInstrumentFaceAmount_iI_pp0p0_c20210106__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableTwelveMember_zpJWLFvyrXpg" title="Debt instrument, face amount" class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE5vdGVzIFBheWFibGUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_"><ix:nonFraction name="us-gaap:DebtInstrumentFaceAmount" contextRef="AsOf2021-01-06_custom_NotePayableTwelveMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">400,000</ix:nonFraction></span>, with interest at <span id="xdx_90D_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20210106__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableTwelveMember_zKfBrb3s9vT8" title="Debt instrument, interest rate" class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE5vdGVzIFBheWFibGUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_"><ix:nonFraction name="us-gaap:DebtInstrumentInterestRateStatedPercentage" contextRef="AsOf2021-01-06_custom_NotePayableTwelveMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">6</ix:nonFraction></span>% per annum and due on <span id="xdx_90B_eus-gaap--DebtInstrumentMaturityDate_dd_c20210104__20210106__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableTwelveMember_zWnC1yvOWzb5" title="Debt instrument, maturity date" class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE5vdGVzIFBheWFibGUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_"><ix:nonNumeric contextRef="From2021-01-042021-01-06_custom_NotePayableTwelveMember" format="ixt:datemonthdayyearen" name="us-gaap:DebtInstrumentMaturityDate">January 7, 2022</ix:nonNumeric></span>. The annual interest rate will increase to <span id="xdx_901_eus-gaap--DebtInstrumentInterestRateIncreaseDecrease_pid_dp_uPure_c20210104__20210106__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableTwelveMember_zfxFoBoqGUa9" title="Increase decrease in debt percentage" class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE5vdGVzIFBheWFibGUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_"><ix:nonFraction name="us-gaap:DebtInstrumentInterestRateIncreaseDecrease" contextRef="From2021-01-042021-01-06_custom_NotePayableTwelveMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">15</ix:nonFraction></span>% if in default. The Note is a convertible promissory note. The conversion price equals the lessor of $<span id="xdx_90F_eus-gaap--DebtInstrumentConvertibleStockPriceTrigger_c20210104__20210106__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableTwelveMember_zdh8Lvbvpbaf" title="Trading price" class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE5vdGVzIFBheWFibGUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_"><ix:nonFraction name="us-gaap:DebtInstrumentConvertibleStockPriceTrigger" contextRef="From2021-01-042021-01-06_custom_NotePayableTwelveMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.50</ix:nonFraction></span> or <span id="xdx_904_ecustom--DebtInstrumentConvertibleStockPriceTriggerPercentage_pid_dp_uPure_c20210104__20210106__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableTwelveMember_zOZtAQt231mk" title="Trading price percentage" class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE5vdGVzIFBheWFibGUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_"><ix:nonFraction name="AMIH:DebtInstrumentConvertibleStockPriceTriggerPercentage" contextRef="From2021-01-042021-01-06_custom_NotePayableTwelveMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">75</ix:nonFraction></span>% of the lowest daily volume weighted average price (VWAP) for the common stock during the seven (<span id="xdx_90D_eus-gaap--DebtInstrumentConvertibleThresholdTradingDays_uInteger_c20210104__20210106__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableTwelveMember_zZa85eBuK3Z7" title="Trading days" class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE5vdGVzIFBheWFibGUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_"><ix:nonFraction name="us-gaap:DebtInstrumentConvertibleThresholdTradingDays" contextRef="From2021-01-042021-01-06_custom_NotePayableTwelveMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Integer">7</ix:nonFraction></span>) trading day period prior to the conversion date, representing a discount rate of <span id="xdx_903_eus-gaap--DebtConversionConvertedInstrumentRate_pid_dp_uPure_c20210104__20210106__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableTwelveMember_zWK97wV0OGZc" title="Debt discount rate" class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE5vdGVzIFBheWFibGUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_"><ix:nonFraction name="us-gaap:DebtConversionConvertedInstrumentRate" contextRef="From2021-01-042021-01-06_custom_NotePayableTwelveMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">25</ix:nonFraction></span>%. The note and accrued interest totaling $<span id="xdx_902_eus-gaap--DebtConversionOriginalDebtAmount1_pp0p0_c20210401__20210630__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableTwelveMember_zM5TKhAPZgmh" title="Principal and accrued interest" class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE5vdGVzIFBheWFibGUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_"><ix:nonFraction name="us-gaap:DebtConversionOriginalDebtAmount1" contextRef="From2021-04-012021-06-30_custom_NotePayableTwelveMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">437,297</ix:nonFraction></span> was converted into <span id="xdx_90F_eus-gaap--StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_c20210401__20210630__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableTwelveMember_zsPOFkSV3U7k" title="Convertible shares" class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE5vdGVzIFBheWFibGUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" contextRef="From2021-04-012021-06-30_custom_NotePayableTwelveMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">3,220,515</ix:nonFraction></span> common shares of the Company within the terms of the note during the quarter ended June 30, 2021.</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="AMIH:NotesPayableBeforeReductionOfPartialConversion" contextRef="AsOf2021-12-31_custom_NotePayableTwelveMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">425,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Less: Conversion</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_987_eus-gaap--DebtConversionConvertedInstrumentAmount1_iN_pp0p0_di_c20210101__20211231__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableTwelveMember_zBIilBwc8cl" title="Less: conversion" style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:DebtConversionConvertedInstrumentAmount1" contextRef="From2021-01-012021-12-31_custom_NotePayableTwelveMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">425,000</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_404_eus-gaap--DebtInstrumentCarryingAmount_iI_hus-gaap--ShortTermDebtTypeAxis__custom--NotePayableTwelveMember_zhFr4U5a4Wz7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1300">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--DebtInstrumentCarryingAmount_iI_hus-gaap--ShortTermDebtTypeAxis__custom--NotePayableThirteenMember_zjhYzCii3Sp6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Note payable of $<span id="xdx_90F_eus-gaap--NotesPayable_iI_pp0p0_c20210330__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableThirteenMember_z5m04mnHtWta" title="Notes payable" class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE5vdGVzIFBheWFibGUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_"><ix:nonFraction name="us-gaap:NotesPayable" contextRef="AsOf2021-03-30_custom_NotePayableThirteenMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">300,000</ix:nonFraction></span> dated March 30, 2021 for cash of $<span id="xdx_90A_eus-gaap--DebtInstrumentFaceAmount_iI_pp0p0_c20210330__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableThirteenMember_zmiwdde9HRi2" title="Debt instrument, face amount" class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE5vdGVzIFBheWFibGUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_"><ix:nonFraction name="us-gaap:DebtInstrumentFaceAmount" contextRef="AsOf2021-03-30_custom_NotePayableThirteenMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">282,000</ix:nonFraction></span>, with interest at <span id="xdx_906_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_uPure_c20210330__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableThirteenMember_zYSGuVxyJief" title="Debt instrument, interest rate" class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE5vdGVzIFBheWFibGUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_"><ix:nonFraction name="us-gaap:DebtInstrumentInterestRateStatedPercentage" contextRef="AsOf2021-03-30_custom_NotePayableThirteenMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Pure">6</ix:nonFraction></span>% per annum
    and due on <span id="xdx_905_eus-gaap--DebtInstrumentMaturityDate_c20210327__20210330__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableThirteenMember_zavlzYLzo11c" title="Debt instrument, maturity date" class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE5vdGVzIFBheWFibGUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_"><ix:nonNumeric contextRef="From2021-03-272021-03-30_custom_NotePayableThirteenMember" format="ixt:datemonthdayyearen" name="us-gaap:DebtInstrumentMaturityDate">March 30, 2022</ix:nonNumeric></span>. The annual interest rate will increase to <span id="xdx_907_eus-gaap--DebtInstrumentInterestRateIncreaseDecrease_pid_dp_uPure_c20210327__20210330__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableThirteenMember_zCRMhN3aU9o9" title="Increase decrease in debt percentage" class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE5vdGVzIFBheWFibGUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_"><ix:nonFraction name="us-gaap:DebtInstrumentInterestRateIncreaseDecrease" contextRef="From2021-03-272021-03-30_custom_NotePayableThirteenMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">15</ix:nonFraction></span>% if in default. The Note is a convertible promissory note.
    The conversion price equals the lessor of $<span id="xdx_907_eus-gaap--DebtInstrumentConvertibleStockPriceTrigger_c20210327__20210330__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableThirteenMember_zn6OudqxSsta" title="Trading price" class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE5vdGVzIFBheWFibGUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_"><ix:nonFraction name="us-gaap:DebtInstrumentConvertibleStockPriceTrigger" contextRef="From2021-03-272021-03-30_custom_NotePayableThirteenMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.2437</ix:nonFraction></span> or <span id="xdx_900_ecustom--DebtInstrumentConvertibleStockPriceTriggerPercentage_pid_dp_uPure_c20210327__20210330__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableThirteenMember_zWC1G6sCCBW6" title="Trading price percentage" class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE5vdGVzIFBheWFibGUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_"><ix:nonFraction name="AMIH:DebtInstrumentConvertibleStockPriceTriggerPercentage" contextRef="From2021-03-272021-03-30_custom_NotePayableThirteenMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">75</ix:nonFraction></span>% of the lowest daily volume weighted average price (VWAP) for the common
    stock during the seven (<span id="xdx_90E_eus-gaap--DebtInstrumentConvertibleThresholdTradingDays_uInteger_c20210327__20210330__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableThirteenMember_znsyDjSCM4Bf" title="Trading days" class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE5vdGVzIFBheWFibGUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_"><ix:nonFraction name="us-gaap:DebtInstrumentConvertibleThresholdTradingDays" contextRef="From2021-03-272021-03-30_custom_NotePayableThirteenMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Integer">7</ix:nonFraction></span>) trading day period prior to the conversion date, representing a discount rate of <span id="xdx_907_eus-gaap--DebtConversionConvertedInstrumentRate_pid_dp_uPure_c20210327__20210330__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableThirteenMember_zxjV90oebuqj" title="Debt discount rate" class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE5vdGVzIFBheWFibGUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_"><ix:nonFraction name="us-gaap:DebtConversionConvertedInstrumentRate" contextRef="From2021-03-272021-03-30_custom_NotePayableThirteenMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">25</ix:nonFraction></span>%.</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DebtInstrumentCarryingAmount" contextRef="AsOf2021-12-31_custom_NotePayableThirteenMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">300,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_ecustom--NotesPayableBeforeReductionOfPartialConversion_iI_hus-gaap--ShortTermDebtTypeAxis__custom--NotePayableFourteenMember_zC5NEqJsifle" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Note payable of $<span id="xdx_90D_eus-gaap--NotesPayable_iI_pp0p0_c20210330__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableFourteenMember_zHwPK9OSgH52" title="Notes payable" class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE5vdGVzIFBheWFibGUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_"><ix:nonFraction name="us-gaap:NotesPayable" contextRef="AsOf2021-03-30_custom_NotePayableFourteenMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">300,000</ix:nonFraction></span> dated March 30, 2021 for cash of $<span id="xdx_90F_eus-gaap--DebtInstrumentFaceAmount_iI_pp0p0_c20210330__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableFourteenMember_zxX8TLaMUigc" title="Debt instrument, face amount" class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE5vdGVzIFBheWFibGUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_"><ix:nonFraction name="us-gaap:DebtInstrumentFaceAmount" contextRef="AsOf2021-03-30_custom_NotePayableFourteenMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">282,000</ix:nonFraction></span>, with interest at <span id="xdx_900_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20210330__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableFourteenMember_zkIPLkyxD20j" title="Debt instrument, interest rate" class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE5vdGVzIFBheWFibGUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_"><ix:nonFraction name="us-gaap:DebtInstrumentInterestRateStatedPercentage" contextRef="AsOf2021-03-30_custom_NotePayableFourteenMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">6</ix:nonFraction></span>% per annum
    and due on <span id="xdx_905_eus-gaap--DebtInstrumentMaturityDate_c20210327__20210330__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableFourteenMember_z0CZRyhntPEa" title="Debt instrument, maturity date" class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE5vdGVzIFBheWFibGUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_"><ix:nonNumeric contextRef="From2021-03-272021-03-30_custom_NotePayableFourteenMember" format="ixt:datemonthdayyearen" name="us-gaap:DebtInstrumentMaturityDate">March 30, 2022</ix:nonNumeric></span>. The annual interest rate will increase to <span id="xdx_90B_eus-gaap--DebtInstrumentInterestRateIncreaseDecrease_pid_dp_uPure_c20210327__20210330__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableFourteenMember_zMFnXRr10RQe" title="Increase decrease in debt percentage" class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE5vdGVzIFBheWFibGUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_"><ix:nonFraction name="us-gaap:DebtInstrumentInterestRateIncreaseDecrease" contextRef="From2021-03-272021-03-30_custom_NotePayableFourteenMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">15</ix:nonFraction></span>% if in default. The Note is a convertible promissory note.
    The conversion price equals the lessor of $<span id="xdx_900_eus-gaap--DebtInstrumentConvertibleStockPriceTrigger_c20210327__20210330__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableFourteenMember_zTkWVho712Re" title="Trading price" class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE5vdGVzIFBheWFibGUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_"><ix:nonFraction name="us-gaap:DebtInstrumentConvertibleStockPriceTrigger" contextRef="From2021-03-272021-03-30_custom_NotePayableFourteenMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.2437</ix:nonFraction></span> or <span id="xdx_900_ecustom--DebtInstrumentConvertibleStockPriceTriggerPercentage_pid_dp_uPure_c20210327__20210330__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableFourteenMember_zZGWekwXnZhi" title="Trading price percentage" class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE5vdGVzIFBheWFibGUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_"><ix:nonFraction name="AMIH:DebtInstrumentConvertibleStockPriceTriggerPercentage" contextRef="From2021-03-272021-03-30_custom_NotePayableFourteenMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">75</ix:nonFraction></span>% of the lowest daily volume weighted average price (VWAP) for the common
    stock during the seven (<span id="xdx_90A_eus-gaap--DebtInstrumentConvertibleThresholdTradingDays_uInteger_c20210327__20210330__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableFourteenMember_zNTHjnNVzb4f" title="Trading days" class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE5vdGVzIFBheWFibGUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_"><ix:nonFraction name="us-gaap:DebtInstrumentConvertibleThresholdTradingDays" contextRef="From2021-03-272021-03-30_custom_NotePayableFourteenMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Integer">7</ix:nonFraction></span>) trading day period prior to the conversion date, representing a discount rate of <span id="xdx_904_eus-gaap--DebtConversionConvertedInstrumentRate_pid_dp_uPure_c20210327__20210330__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableFourteenMember_zzXmn5iQJnGa" title="Debt discount rate" class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE5vdGVzIFBheWFibGUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_"><ix:nonFraction name="us-gaap:DebtConversionConvertedInstrumentRate" contextRef="From2021-03-272021-03-30_custom_NotePayableFourteenMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">25</ix:nonFraction></span>%. A partial conversion
    of the Note and accrued interest totaling $<span id="xdx_900_eus-gaap--InterestPayableCurrentAndNoncurrent_iI_c20210930__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableFourteenMember_zsRjYdo0CfUf" class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE5vdGVzIFBheWFibGUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_"><ix:nonFraction name="us-gaap:InterestPayableCurrentAndNoncurrent" contextRef="AsOf2021-09-30_custom_NotePayableFourteenMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">51,116</ix:nonFraction></span> was converted into <span id="xdx_907_eus-gaap--StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_c20210701__20210930__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableFourteenMember_zoYuD5exuKml" class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE5vdGVzIFBheWFibGUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" contextRef="From2021-07-012021-09-30_custom_NotePayableFourteenMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">881,310</ix:nonFraction></span> common shares of the Company within the terms of the
    note during the quarter ended September 30, 2021.</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="AMIH:NotesPayableBeforeReductionOfPartialConversion" contextRef="AsOf2021-12-31_custom_NotePayableFourteenMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">300,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Less: Conversion</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--DebtConversionConvertedInstrumentAmount1_iN_pp0p0_di_c20210101__20211231__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableFourteenMember_zZ6vtYNmNhN9" style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:DebtConversionConvertedInstrumentAmount1" contextRef="From2021-01-012021-12-31_custom_NotePayableFourteenMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">50,000</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40F_eus-gaap--DebtInstrumentCarryingAmount_iI_hus-gaap--ShortTermDebtTypeAxis__custom--NotePayableFourteenMember_zNb2cUIp7ZLb" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DebtInstrumentCarryingAmount" contextRef="AsOf2021-12-31_custom_NotePayableFourteenMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">250,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_ecustom--NotesPayableBeforeReductionOfPartialConversion_iI_hus-gaap--ShortTermDebtTypeAxis__custom--NotePayableFifteenMember_zRylLXH5fcx6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Note payable of $<span id="xdx_909_eus-gaap--NotesPayable_iI_pp0p0_c20210624__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableFifteenMember_zXXVSKNdxu12" title="Notes payable" class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE5vdGVzIFBheWFibGUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_"><ix:nonFraction name="us-gaap:NotesPayable" contextRef="AsOf2021-06-24_custom_NotePayableFifteenMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">265,958</ix:nonFraction></span> dated June 24, 2021 for cash of $<span id="xdx_90D_eus-gaap--DebtInstrumentFaceAmount_iI_pp0p0_c20210624__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableFifteenMember_zryz4QRutOX7" title="Debt instrument, face amount" class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE5vdGVzIFBheWFibGUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_"><ix:nonFraction name="us-gaap:DebtInstrumentFaceAmount" contextRef="AsOf2021-06-24_custom_NotePayableFifteenMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">250,000</ix:nonFraction></span>, with interest at <span id="xdx_903_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20210624__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableFifteenMember_zzDNEQLMvyJ2" title="Debt instrument, interest rate" class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE5vdGVzIFBheWFibGUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_"><ix:nonFraction name="us-gaap:DebtInstrumentInterestRateStatedPercentage" contextRef="AsOf2021-06-24_custom_NotePayableFifteenMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">6</ix:nonFraction></span>% per annum
    and due on <span id="xdx_90F_eus-gaap--DebtInstrumentMaturityDate_c20210623__20210624__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableFifteenMember_zSTV4NAD9M4i" class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE5vdGVzIFBheWFibGUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_"><ix:nonNumeric contextRef="From2021-06-232021-06-24_custom_NotePayableFifteenMember" format="ixt:datemonthdayyearen" name="us-gaap:DebtInstrumentMaturityDate">June 24, 2022</ix:nonNumeric></span>. The annual interest rate will increase to <span id="xdx_903_eus-gaap--DebtInstrumentInterestRateIncreaseDecrease_pid_dp_uPure_c20210623__20210624__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableFifteenMember_z57nxPgYnRyf" title="Increase decrease in debt percentage" class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE5vdGVzIFBheWFibGUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_"><ix:nonFraction name="us-gaap:DebtInstrumentInterestRateIncreaseDecrease" contextRef="From2021-06-232021-06-24_custom_NotePayableFifteenMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">15</ix:nonFraction></span>% if in default. The Note is a convertible promissory note.
    The conversion price equals the lessor of $<span id="xdx_903_eus-gaap--DebtInstrumentConvertibleStockPriceTrigger_c20210623__20210624__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableFifteenMember_zG0kjAU6jVQ1" title="Trading price" class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE5vdGVzIFBheWFibGUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_"><ix:nonFraction name="us-gaap:DebtInstrumentConvertibleStockPriceTrigger" contextRef="From2021-06-232021-06-24_custom_NotePayableFifteenMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.2437</ix:nonFraction></span> or <span id="xdx_909_ecustom--DebtInstrumentConvertibleStockPriceTriggerPercentage_pid_dp_uPure_c20210623__20210624__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableFifteenMember_zMSvdlVKHUaj" title="Trading price percentage" class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE5vdGVzIFBheWFibGUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_"><ix:nonFraction name="AMIH:DebtInstrumentConvertibleStockPriceTriggerPercentage" contextRef="From2021-06-232021-06-24_custom_NotePayableFifteenMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">75</ix:nonFraction></span>% of the lowest daily volume weighted average price (VWAP) for the common
    stock during the seven (<span id="xdx_903_eus-gaap--DebtInstrumentConvertibleThresholdTradingDays_uInteger_c20210623__20210624__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableFifteenMember_zu7z3fRGwkD5" title="Trading days" class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE5vdGVzIFBheWFibGUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_"><ix:nonFraction name="us-gaap:DebtInstrumentConvertibleThresholdTradingDays" contextRef="From2021-06-232021-06-24_custom_NotePayableFifteenMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Integer">7</ix:nonFraction></span>) trading day period prior to the conversion date, representing a discount rate of <span id="xdx_900_eus-gaap--DebtConversionConvertedInstrumentRate_pid_dp_uPure_c20210623__20210624__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableFifteenMember_zJN6n8RBrbud" title="Debt discount rate" class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE5vdGVzIFBheWFibGUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_"><ix:nonFraction name="us-gaap:DebtConversionConvertedInstrumentRate" contextRef="From2021-06-232021-06-24_custom_NotePayableFifteenMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">25</ix:nonFraction></span>%.A partial conversion
    of the Note totaling $<span id="xdx_901_eus-gaap--StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_pp0p0_c20210701__20210930__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableFifteenMember_zW8j2KrfPtpf" class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE5vdGVzIFBheWFibGUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_"><span id="xdx_905_eus-gaap--StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_pp0p0_c20211001__20211231__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableFifteenMember_zhFt11LhZYGl" class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE5vdGVzIFBheWFibGUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" title="Number of value converion of shares"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" contextRef="From2021-07-012021-09-30_custom_NotePayableFifteenMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" contextRef="From2021-10-012021-12-31_custom_NotePayableFifteenMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">118,668</ix:nonFraction></ix:nonFraction></span></span> was converted into <span id="xdx_906_eus-gaap--StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_pp0p0_c20210701__20210930__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableFifteenMember_zB0d4FNHFLBb" class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE5vdGVzIFBheWFibGUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_"><span id="xdx_904_eus-gaap--StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_pp0p0_c20211001__20211231__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableFifteenMember_zP1q6kLd1Bq3" class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE5vdGVzIFBheWFibGUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" title="Number of converion of shares"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" contextRef="From2021-07-012021-09-30_custom_NotePayableFifteenMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="Shares"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" contextRef="From2021-10-012021-12-31_custom_NotePayableFifteenMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="Shares">2,390,000</ix:nonFraction></ix:nonFraction></span></span> common shares of the Company within the terms of the note during the quarter
    ended September 30, 2021 and fourth quarter ended December 31, 2021.</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="AMIH:NotesPayableBeforeReductionOfPartialConversion" contextRef="AsOf2021-12-31_custom_NotePayableFifteenMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">265,958</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Less: Conversion</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_982_eus-gaap--DebtConversionConvertedInstrumentAmount1_iN_pp0p0_di_c20210101__20211231__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableFifteenMember_zbpDIBFeev56" style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:DebtConversionConvertedInstrumentAmount1" contextRef="From2021-01-012021-12-31_custom_NotePayableFifteenMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">118,668</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40D_eus-gaap--DebtInstrumentCarryingAmount_iI_hus-gaap--ShortTermDebtTypeAxis__custom--NotePayableFifteenMember_zNhe5mZW7bi1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DebtInstrumentCarryingAmount" contextRef="AsOf2021-12-31_custom_NotePayableFifteenMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">147,290</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_ecustom--NotesPayableBeforeReductionOfPartialConversion_iI_hus-gaap--ShortTermDebtTypeAxis__custom--NotePayableSixteenMember_zMfOjXcmvZ82" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Note payable of $<span id="xdx_905_eus-gaap--NotesPayable_iI_pp0p0_c20210624__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableSixteenMember_zxTQhe6oq6li" title="Notes payable" class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE5vdGVzIFBheWFibGUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_"><ix:nonFraction name="us-gaap:NotesPayable" contextRef="AsOf2021-06-24_custom_NotePayableSixteenMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">271,958</ix:nonFraction></span> dated June 24, 2021 for cash of $<span id="xdx_900_eus-gaap--DebtInstrumentFaceAmount_iI_pp0p0_c20210624__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableSixteenMember_zSXl052a88vl" title="Debt instrument, face amount" class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE5vdGVzIFBheWFibGUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_"><ix:nonFraction name="us-gaap:DebtInstrumentFaceAmount" contextRef="AsOf2021-06-24_custom_NotePayableSixteenMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">256,000</ix:nonFraction></span>, with interest at <span id="xdx_90B_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20210624__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableSixteenMember_zPYNAGZzJZK3" title="Debt instrument, interest rate" class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE5vdGVzIFBheWFibGUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_"><ix:nonFraction name="us-gaap:DebtInstrumentInterestRateStatedPercentage" contextRef="AsOf2021-06-24_custom_NotePayableSixteenMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">6</ix:nonFraction></span>% per annum
    and due on <span id="xdx_907_eus-gaap--DebtInstrumentMaturityDate_c20210623__20210624__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableSixteenMember_zx84p4HDkNy4" class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE5vdGVzIFBheWFibGUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_"><ix:nonNumeric contextRef="From2021-06-232021-06-24_custom_NotePayableSixteenMember" format="ixt:datemonthdayyearen" name="us-gaap:DebtInstrumentMaturityDate">June 24, 2022</ix:nonNumeric></span>. The annual interest rate will increase to <span id="xdx_90A_eus-gaap--DebtInstrumentInterestRateIncreaseDecrease_pid_dp_uPure_c20210623__20210624__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableSixteenMember_ziZCM6q9fsXf" title="Increase decrease in debt percentage" class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE5vdGVzIFBheWFibGUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_"><ix:nonFraction name="us-gaap:DebtInstrumentInterestRateIncreaseDecrease" contextRef="From2021-06-232021-06-24_custom_NotePayableSixteenMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">15</ix:nonFraction></span>% if in default. The Note is a convertible promissory note.
    The conversion price equals the lessor of $<span id="xdx_90B_eus-gaap--DebtInstrumentConvertibleStockPriceTrigger_c20210623__20210624__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableSixteenMember_zROJSskqozWe" title="Trading price" class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE5vdGVzIFBheWFibGUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_"><ix:nonFraction name="us-gaap:DebtInstrumentConvertibleStockPriceTrigger" contextRef="From2021-06-232021-06-24_custom_NotePayableSixteenMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.2437</ix:nonFraction></span> or <span id="xdx_909_ecustom--DebtInstrumentConvertibleStockPriceTriggerPercentage_pid_dp_uPure_c20210623__20210624__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableSixteenMember_zCznAVK9hRB2" title="Trading price percentage" class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE5vdGVzIFBheWFibGUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_"><ix:nonFraction name="AMIH:DebtInstrumentConvertibleStockPriceTriggerPercentage" contextRef="From2021-06-232021-06-24_custom_NotePayableSixteenMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">75</ix:nonFraction></span>% of the lowest daily volume weighted average price (VWAP) for the common
    stock during the seven (<span id="xdx_904_eus-gaap--DebtInstrumentConvertibleThresholdTradingDays_uInteger_c20210623__20210624__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableSixteenMember_zuPMlfqiLWr6" title="Trading days" class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE5vdGVzIFBheWFibGUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_"><ix:nonFraction name="us-gaap:DebtInstrumentConvertibleThresholdTradingDays" contextRef="From2021-06-232021-06-24_custom_NotePayableSixteenMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Integer">7</ix:nonFraction></span>) trading day period prior to the conversion date, representing a discount rate of <span id="xdx_906_eus-gaap--DebtConversionConvertedInstrumentRate_pid_dp_uPure_c20210623__20210624__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableSixteenMember_zazobT0Yd6Il" title="Debt discount rate" class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE5vdGVzIFBheWFibGUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_"><ix:nonFraction name="us-gaap:DebtConversionConvertedInstrumentRate" contextRef="From2021-06-232021-06-24_custom_NotePayableSixteenMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">25</ix:nonFraction></span>%. A partial conversion
    of the Note and accrued interest totaling $<span id="xdx_904_eus-gaap--InterestPayableCurrentAndNoncurrent_iI_c20210930__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableSixteenMember_zz0xQF98ZYnk" class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE5vdGVzIFBheWFibGUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_"><span id="xdx_90B_eus-gaap--InterestPayableCurrentAndNoncurrent_iI_c20211231__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableSixteenMember_z6Jgr87D8NFb" class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE5vdGVzIFBheWFibGUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_"><ix:nonFraction name="us-gaap:InterestPayableCurrentAndNoncurrent" contextRef="AsOf2021-09-30_custom_NotePayableSixteenMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD"><ix:nonFraction name="us-gaap:InterestPayableCurrentAndNoncurrent" contextRef="AsOf2021-12-31_custom_NotePayableSixteenMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">140,000</ix:nonFraction></ix:nonFraction></span></span> was converted into <span id="xdx_902_eus-gaap--StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_c20210701__20210930__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableSixteenMember_zm9Zs641YI41" class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE5vdGVzIFBheWFibGUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_"><span id="xdx_902_eus-gaap--StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_c20211001__20211231__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableSixteenMember_zR5WdEMw4Zn4" class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE5vdGVzIFBheWFibGUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" contextRef="From2021-07-012021-09-30_custom_NotePayableSixteenMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" contextRef="From2021-10-012021-12-31_custom_NotePayableSixteenMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,742,419</ix:nonFraction></ix:nonFraction></span></span> common shares of the Company within the terms of
    the note during the quarter ended September 30, 2021 and fourth quarter ended December 31, 2021.</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="AMIH:NotesPayableBeforeReductionOfPartialConversion" contextRef="AsOf2021-12-31_custom_NotePayableSixteenMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">271,958</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Less: Conversion</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_988_eus-gaap--DebtConversionConvertedInstrumentAmount1_iN_pp0p0_di_c20210101__20211231__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableSixteenMember_zPVtiX3kz7yl" title="Less: Conversion" style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:DebtConversionConvertedInstrumentAmount1" contextRef="From2021-01-012021-12-31_custom_NotePayableSixteenMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">133,806</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_407_eus-gaap--DebtInstrumentCarryingAmount_iI_hus-gaap--ShortTermDebtTypeAxis__custom--NotePayableSixteenMember_zeYDRtHLLN2d" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:DebtInstrumentCarryingAmount" contextRef="AsOf2021-12-31_custom_NotePayableSixteenMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">138,152</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_ecustom--NotesPayableBeforeReductionOfPartialConversion_iI_hus-gaap--ShortTermDebtTypeAxis__custom--NotePayableSeventeenMember_zYJNrt5I7i0i" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">As of December 31, 2021 the Company had a short-term Advance payable in amount of $<span id="xdx_901_eus-gaap--ShortTermBorrowings_iI_pp0p0_c20211231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--NotePayableSeventeenMember_zvJHXXA8wpIj" title="Short term borrowings" class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE5vdGVzIFBheWFibGUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_"><ix:nonFraction name="us-gaap:ShortTermBorrowings" contextRef="AsOf2021-12-31_custom_NotePayableSeventeenMember5567812" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">50,000</ix:nonFraction></span> to a unrelated party, with no interest and due on demand.</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="AMIH:NotesPayableBeforeReductionOfPartialConversion" contextRef="AsOf2021-12-31_custom_NotePayableSeventeenMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">50,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_ecustom--NotesPayableBeforeReductionOfPartialConversion_iI_hus-gaap--ShortTermDebtTypeAxis__custom--NotePayableSeventeenMember_zJJfPeKx6Zk" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Notes payable, before conversion</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="AMIH:NotesPayableBeforeReductionOfPartialConversion" contextRef="AsOf2021-12-31_custom_NotePayableSeventeenMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">50,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Less: Repayment</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_982_eus-gaap--RepaymentsOfDebt_iN_pp0p0_di_c20210101__20211231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--NotePayableSeventeenMember_zx67k5Fu4Rud" style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:RepaymentsOfDebt" contextRef="From2021-01-012021-12-31_custom_NotePayableSeventeenMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">50,000</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_401_eus-gaap--DebtInstrumentCarryingAmount_iI_hus-gaap--ShortTermDebtTypeAxis__custom--NotePayableSeventeenMember_zkFsmbOsZrqc" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1409">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--DebtInstrumentCarryingAmount_iI_hus-gaap--ShortTermDebtTypeAxis__custom--NotePayableEighteenMember_z6DvlCnzhYC7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Note payable of $<span id="xdx_902_eus-gaap--NotesPayable_iI_pp0p0_c20211122__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableEighteenMember_zUVt0w22RBoi" title="Notes payable" class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE5vdGVzIFBheWFibGUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_"><ix:nonFraction name="us-gaap:NotesPayable" contextRef="AsOf2021-11-22_custom_NotePayableEighteenMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">750,000</ix:nonFraction></span> dated November 22, 2021 for cash of $<span id="xdx_908_eus-gaap--DebtInstrumentFaceAmount_iI_pp0p0_c20211122__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableEighteenMember_zCwJ5N6Fui9a" title="Debt instrument, face amount" class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE5vdGVzIFBheWFibGUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_"><ix:nonFraction name="us-gaap:DebtInstrumentFaceAmount" contextRef="AsOf2021-11-22_custom_NotePayableEighteenMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">750,000</ix:nonFraction></span>, with interest at <span id="xdx_903_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20211122__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableEighteenMember_z0XzuroJ8Ma8" title="Debt instrument, interest rate" class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE5vdGVzIFBheWFibGUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_"><ix:nonFraction name="us-gaap:DebtInstrumentInterestRateStatedPercentage" contextRef="AsOf2021-11-22_custom_NotePayableEighteenMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">10</ix:nonFraction></span>% per annum and due on <span id="xdx_90D_eus-gaap--DebtInstrumentMaturityDate_c20211121__20211122__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableEighteenMember_zOdPk8JACrg2" title="Debt instrument, maturity date" class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE5vdGVzIFBheWFibGUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_"><ix:nonNumeric contextRef="From2021-11-212021-11-22_custom_NotePayableEighteenMember" format="ixt:datemonthdayyearen" name="us-gaap:DebtInstrumentMaturityDate">June 24, 2022</ix:nonNumeric></span>. The annual interest rate will increase to <span id="xdx_900_eus-gaap--DebtInstrumentInterestRateIncreaseDecrease_pid_dp_uPure_c20211121__20211122__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableEighteenMember_zcMR46NX0QTe" title="Increase decrease in debt percentage" class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE5vdGVzIFBheWFibGUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_"><ix:nonFraction name="us-gaap:DebtInstrumentInterestRateIncreaseDecrease" contextRef="From2021-11-212021-11-22_custom_NotePayableEighteenMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">16</ix:nonFraction></span>% or the maximum amount permitted by law if in default. The Note is a convertible promissory note. The conversion price equals the lessor of $<span id="xdx_90B_eus-gaap--DebtInstrumentConvertibleStockPriceTrigger_c20211121__20211122__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableEighteenMember_zwVKUHKIKImg" title="Trading price" class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE5vdGVzIFBheWFibGUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_"><ix:nonFraction name="us-gaap:DebtInstrumentConvertibleStockPriceTrigger" contextRef="From2021-11-212021-11-22_custom_NotePayableEighteenMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.075</ix:nonFraction></span> or <span id="xdx_90B_ecustom--DebtInstrumentConvertibleStockPriceTriggerPercentage_pid_dp_uPure_c20211121__20211122__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableEighteenMember_z44xIekqsYyg" title="Trading price percentage" class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE5vdGVzIFBheWFibGUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_"><ix:nonFraction name="AMIH:DebtInstrumentConvertibleStockPriceTriggerPercentage" contextRef="From2021-11-212021-11-22_custom_NotePayableEighteenMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">80</ix:nonFraction></span>% of the offering price per share of Common Stock at which the Company offers shares of Common Stock in a public offering which results in the Common Stock being uplisted on a national stock exchange or Nasdaq, that occurs within 220 days from the date the Notes are issued (an &#8220;Uplist Offering&#8221;).</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DebtInstrumentCarryingAmount" contextRef="AsOf2021-12-31_custom_NotePayableEighteenMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">750,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--DebtInstrumentCarryingAmount_iI_hus-gaap--ShortTermDebtTypeAxis__custom--NotePayableNineteenMember_zJqqnoNojZk8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Note payable of $<span id="xdx_901_eus-gaap--NotesPayable_iI_pp0p0_c20211130__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableNineteenMember_zJuMiIQZygSg" class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE5vdGVzIFBheWFibGUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_"><ix:nonFraction name="us-gaap:NotesPayable" contextRef="AsOf2021-11-30_custom_NotePayableNineteenMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">500,000</ix:nonFraction></span> dated November 30, 2021 for cash of $<span id="xdx_908_eus-gaap--DebtInstrumentFaceAmount_iI_pp0p0_c20211130__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableNineteenMember_zJxTVRJBqPB4" title="Debt instrument, face amount" class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE5vdGVzIFBheWFibGUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_"><ix:nonFraction name="us-gaap:DebtInstrumentFaceAmount" contextRef="AsOf2021-11-30_custom_NotePayableNineteenMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">500,000</ix:nonFraction></span>, with interest at <span id="xdx_90D_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20211130__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableNineteenMember_z70pU6ABHzxi" class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE5vdGVzIFBheWFibGUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_"><ix:nonFraction name="us-gaap:DebtInstrumentInterestRateStatedPercentage" contextRef="AsOf2021-11-30_custom_NotePayableNineteenMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">10</ix:nonFraction></span>% per annum and due on<span id="xdx_909_eus-gaap--DebtInstrumentMaturityDate_c20211129__20211130__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableNineteenMember_zqrgWRArAfOg" class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE5vdGVzIFBheWFibGUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_"> <ix:nonNumeric contextRef="From2021-11-292021-11-30_custom_NotePayableNineteenMember" format="ixt:datemonthdayyearen" name="us-gaap:DebtInstrumentMaturityDate">November 30, 2022</ix:nonNumeric></span>. The annual interest rate will increase to <span id="xdx_90C_eus-gaap--DebtInstrumentInterestRateIncreaseDecrease_pid_dp_uPure_c20211129__20211130__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableNineteenMember_zUVeBXWFQVw4" class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE5vdGVzIFBheWFibGUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_"><ix:nonFraction name="us-gaap:DebtInstrumentInterestRateIncreaseDecrease" contextRef="From2021-11-292021-11-30_custom_NotePayableNineteenMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">16</ix:nonFraction></span>% or the maximum amount permitted by law if in default. The Note is a convertible promissory note. The conversion price equals the lessor of $<span id="xdx_903_eus-gaap--DebtInstrumentConvertibleStockPriceTrigger_c20211129__20211130__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableNineteenMember_zOasKWRMuuVh" title="Trading price" class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE5vdGVzIFBheWFibGUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_"><ix:nonFraction name="us-gaap:DebtInstrumentConvertibleStockPriceTrigger" contextRef="From2021-11-292021-11-30_custom_NotePayableNineteenMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.075</ix:nonFraction></span> or <span id="xdx_904_ecustom--DebtInstrumentConvertibleStockPriceTriggerPercentage_pid_dp_uPure_c20211129__20211130__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableNineteenMember_zP06dPqy88hl" title="Trading price percentage" class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE5vdGVzIFBheWFibGUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_"><ix:nonFraction name="AMIH:DebtInstrumentConvertibleStockPriceTriggerPercentage" contextRef="From2021-11-292021-11-30_custom_NotePayableNineteenMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">80</ix:nonFraction></span>% of the offering price per share of Common Stock at which the Uplist Offering is made.</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DebtInstrumentCarryingAmount" contextRef="AsOf2021-12-31_custom_NotePayableNineteenMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">500,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--DebtInstrumentCarryingAmount_iI_hus-gaap--ShortTermDebtTypeAxis__custom--NotePayableTwentyMember_zYnAHPtYPZE7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Note payable of $<span id="xdx_906_eus-gaap--NotesPayable_iI_pp0p0_c20211201__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableTwentyMember_zOcmzGkcifr2" class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE5vdGVzIFBheWFibGUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_"><ix:nonFraction name="us-gaap:NotesPayable" contextRef="AsOf2021-12-01_custom_NotePayableTwentyMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">250,000</ix:nonFraction></span> dated December 1, 2021 for cash of $<span id="xdx_90E_eus-gaap--DebtInstrumentFaceAmount_iI_pp0p0_c20211201__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableTwentyMember_zrQJtaKanWE4" class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE5vdGVzIFBheWFibGUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_"><ix:nonFraction name="us-gaap:DebtInstrumentFaceAmount" contextRef="AsOf2021-12-01_custom_NotePayableTwentyMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">250,000</ix:nonFraction></span>, with interest at <span id="xdx_908_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20211201__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableTwentyMember_zXuWieQ5iDqh" class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE5vdGVzIFBheWFibGUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_"><ix:nonFraction name="us-gaap:DebtInstrumentInterestRateStatedPercentage" contextRef="AsOf2021-12-01_custom_NotePayableTwentyMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">10</ix:nonFraction></span>% per annum and due on <span id="xdx_907_eus-gaap--DebtInstrumentMaturityDate_c20211126__20211201__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableTwentyMember_zKW3xTuBlIId" class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE5vdGVzIFBheWFibGUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_"><ix:nonNumeric contextRef="From2021-11-262021-12-01_custom_NotePayableTwentyMember" format="ixt:datemonthdayyearen" name="us-gaap:DebtInstrumentMaturityDate">December 1, 2022</ix:nonNumeric></span>. The annual interest rate will increase to <span id="xdx_904_eus-gaap--DebtInstrumentInterestRateIncreaseDecrease_pid_dp_uPure_c20211126__20211201__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableTwentyMember_zNBhGI2vXda5" class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE5vdGVzIFBheWFibGUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_"><ix:nonFraction name="us-gaap:DebtInstrumentInterestRateIncreaseDecrease" contextRef="From2021-11-262021-12-01_custom_NotePayableTwentyMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">16</ix:nonFraction></span>% or the maximum amount permitted by law if in default. The Note is a convertible promissory note. The conversion price equals the lessor of $<span id="xdx_90E_eus-gaap--DebtInstrumentConvertibleStockPriceTrigger_c20211126__20211201__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableTwentyMember_zBvpSJfdynRi" class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE5vdGVzIFBheWFibGUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_"><ix:nonFraction name="us-gaap:DebtInstrumentConvertibleStockPriceTrigger" contextRef="From2021-11-262021-12-01_custom_NotePayableTwentyMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.075</ix:nonFraction></span> or <span id="xdx_90A_ecustom--DebtInstrumentConvertibleStockPriceTriggerPercentage_pid_dp_uPure_c20211126__20211201__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableTwentyMember_ztpMjpVQyij1" class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE5vdGVzIFBheWFibGUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_"><ix:nonFraction name="AMIH:DebtInstrumentConvertibleStockPriceTriggerPercentage" contextRef="From2021-11-262021-12-01_custom_NotePayableTwentyMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">80</ix:nonFraction></span>% of the offering price per share of Common Stock at which the Uplist Offering is made.</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DebtInstrumentCarryingAmount" contextRef="AsOf2021-12-31_custom_NotePayableTwentyMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">250,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--DebtInstrumentCarryingAmount_iI_hus-gaap--ShortTermDebtTypeAxis__custom--NotePayableTwentyOneMember_zs6YKww3m882" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Note payable of $<span id="xdx_904_eus-gaap--NotesPayable_iI_pp0p0_c20211202__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableTwentyOneMember_zphznwLE7OWk" class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE5vdGVzIFBheWFibGUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_"><ix:nonFraction name="us-gaap:NotesPayable" contextRef="AsOf2021-12-02_custom_NotePayableTwentyOneMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">500,000</ix:nonFraction></span> dated December 2, 2021 for cash of $<span id="xdx_904_eus-gaap--DebtInstrumentFaceAmount_iI_pp0p0_c20211202__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableTwentyOneMember_zpKeqCK0KTB3" class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE5vdGVzIFBheWFibGUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_"><ix:nonFraction name="us-gaap:DebtInstrumentFaceAmount" contextRef="AsOf2021-12-02_custom_NotePayableTwentyOneMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">5000,000</ix:nonFraction></span>, with interest at <span id="xdx_90C_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20211202__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableToUnrelatedPartyEighteenMember_zmggBoCSY2o7" class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE5vdGVzIFBheWFibGUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_"><ix:nonFraction name="us-gaap:DebtInstrumentInterestRateStatedPercentage" contextRef="AsOf2021-12-02_custom_NotePayableToUnrelatedPartyEighteenMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">10</ix:nonFraction></span>% per annum and due on <span id="xdx_90C_eus-gaap--DebtInstrumentMaturityDate_c20211126__20211202__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableTwentyOneMember_zc3ADkzBEVYe" class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE5vdGVzIFBheWFibGUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_"><ix:nonNumeric contextRef="From2021-11-262021-12-02_custom_NotePayableTwentyOneMember" format="ixt:datemonthdayyearen" name="us-gaap:DebtInstrumentMaturityDate">December 2, 2022</ix:nonNumeric></span>. The annual interest rate will increase to <span id="xdx_905_eus-gaap--DebtInstrumentInterestRateIncreaseDecrease_pid_dp_uPure_c20211126__20211202__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableTwentyOneMember_zo4ModDO1NLc" class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE5vdGVzIFBheWFibGUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_"><ix:nonFraction name="us-gaap:DebtInstrumentInterestRateIncreaseDecrease" contextRef="From2021-11-262021-12-02_custom_NotePayableTwentyOneMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">16</ix:nonFraction></span>% or the maximum amount permitted by law if in default. The Note is a convertible promissory note. The conversion price equals the lessor of $<span id="xdx_90C_eus-gaap--DebtInstrumentConvertibleStockPriceTrigger_c20211126__20211202__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableTwentyOneMember_zxELiIfY9NZf" class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE5vdGVzIFBheWFibGUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_"><ix:nonFraction name="us-gaap:DebtInstrumentConvertibleStockPriceTrigger" contextRef="From2021-11-262021-12-02_custom_NotePayableTwentyOneMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.075</ix:nonFraction></span> or <span id="xdx_902_ecustom--DebtInstrumentConvertibleStockPriceTriggerPercentage_pid_dp_uPure_c20211126__20211202__us-gaap--ShortTermDebtTypeAxis__custom--NotePayableTwentyOneMember_zwzZ1HIlkXT8" class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE5vdGVzIFBheWFibGUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_"><ix:nonFraction name="AMIH:DebtInstrumentConvertibleStockPriceTriggerPercentage" contextRef="From2021-11-262021-12-02_custom_NotePayableTwentyOneMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">80</ix:nonFraction></span>% of the offering price per share of Common Stock at which the Uplist Offering is made.</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DebtInstrumentCarryingAmount" contextRef="AsOf2021-12-31_custom_NotePayableTwentyOneMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">500,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--DebtInstrumentCarryingAmount_iI_hus-gaap--ShortTermDebtTypeAxis__custom--NotePayableTwentyTwoMember_zvtVgwT2L8r6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">As of December 31, 2021 the Company had a short-term Advance payable in amount of $<span id="xdx_90A_eus-gaap--ShortTermBorrowings_iI_pp0p0_c20211231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--NotePayableTwentyTwoMember_zvNY7WSLu8Fi" class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE5vdGVzIFBheWFibGUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_"><ix:nonFraction name="us-gaap:ShortTermBorrowings" contextRef="AsOf2021-12-31_custom_NotePayableTwentyTwoMember5568000" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">20,000</ix:nonFraction></span> to a unrelated party, with no interest and due on demand.</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DebtInstrumentCarryingAmount" contextRef="AsOf2021-12-31_custom_NotePayableTwentyTwoMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">20,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--DebtInstrumentCarryingAmount_iI_zPVkq6uxbJ02" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Notes payable, gross</span></td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DebtInstrumentCarryingAmount" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,950,442</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--DebtInstrumentUnamortizedDiscount_iNI_di_zlW5m1LZCgIe" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: justify">Less: unamortized discount</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:DebtInstrumentUnamortizedDiscount" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,479,023</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_409_ecustom--NotePayables_iI_z9h9FVrNOs5e" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: justify">Total</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="AMIH:NotePayables" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">471,419</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--ConvertibleNotesPayableCurrent_iI_zsPbm1E2jjT7" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: justify">Short term convertible notes, net of discount of $<span id="xdx_903_eus-gaap--DebtInstrumentUnamortizedDiscount_iI_pp0p0_c20211231__us-gaap--DebtInstrumentAxis__custom--ShortTermDebtConvertibleNotesMember_zogKwOiwM8Ik" title="Original issue of discount" class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE5vdGVzIFBheWFibGUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_"><ix:nonFraction name="us-gaap:DebtInstrumentUnamortizedDiscount" contextRef="AsOf2021-12-31_custom_ShortTermDebtConvertibleNotesMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">2,479,023</ix:nonFraction></span></td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:ConvertibleNotesPayableCurrent" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">396,419</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: justify">Long-term convertible notes, net of discount of $<span id="xdx_905_eus-gaap--DebtInstrumentUnamortizedDiscount_iI_pp0p0_c20211231__us-gaap--DebtInstrumentAxis__custom--LongTermDebtConvertibleNotesMember_zV9AzDBNnsJk" title="Original issue of discount" class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE5vdGVzIFBheWFibGUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_"><ix:nonFraction name="us-gaap:DebtInstrumentUnamortizedDiscount" contextRef="AsOf2021-12-31_custom_LongTermDebtConvertibleNotesMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">0</ix:nonFraction></span></td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_987_eus-gaap--ConvertibleLongTermNotesPayable_iI_pp0p0_dxL_c20211231_zt8ApbEDwNd3" title="Long-term convertible notes, net of discount::XDX::-" style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1472">0</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_ecustom--LoansPayableCurrentContinuingOperations_iI_zVpCj42Ip1jg" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: justify">Short-term non-convertible notes &#8211; continuing operations</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="AMIH:LoansPayableCurrentContinuingOperations" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">75,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_ecustom--LoansPayableCurrentDiscontinuedOperations_iI_zJyObiP0nS49" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: justify">Short-term non-convertible notes &#8211; discontinued operations</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="AMIH:LoansPayableCurrentDiscontinuedOperations" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--LongTermLoansPayable_iI_zhzFMzDLwEG8" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: justify">Long-term non-convertible notes</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:LongTermLoansPayable" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">0</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A7_zJJrdo5o7P35" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>


<ix:exclude><!-- Field: Page; Sequence: 147; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: left"><a href="#fin" title="Table of Contents" style="font-style: italic">Table of Contents</a>&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2021-01-01to2021-12-31" escape="true" name="us-gaap:RelatedPartyTransactionsDisclosureTextBlock"><p id="xdx_805_eus-gaap--RelatedPartyTransactionsDisclosureTextBlock_znDheqbG81Hh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="Naa_002"></span>Note
11 &#8211; <span id="xdx_824_zDR1ZJJhJiUd">Loans from Related Parties</span></b></span></p>

<ix:nonNumeric contextRef="From2021-01-01to2021-12-31" escape="true" name="us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock"><p id="xdx_890_eus-gaap--ScheduleOfRelatedPartyTransactionsTableTextBlock_z86uzz07cexb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;<span id="xdx_8BA_zwXGy512Pswd" style="display: none">Schedule of Loans from Related Parties</span></span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_493_20211231_zGkcw1z0OGz1" style="text-align: right">1</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_405_ecustom--LoansFromRelatedPartiesBeforeConversion_iI_pp0p0_hus-gaap--DebtInstrumentAxis__custom--NotesPayableMember__us-gaap--RelatedPartyTransactionAxis__custom--RelatedPartyOneMember_zSLrVFqkYX56" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 80%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On April 12, 2019, the Company entered into individual share exchange agreements and promissory notes with each of Daniel Dror, Winfred Fields and former Directors Everett Bassie and Charles Zeller (the &#8220;<span style="text-decoration: underline">AMIH Shareholders</span>&#8221;), whereby the AMIH Shareholders agreed to cancel and exchange a total of <span id="xdx_900_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20190411__20190412__us-gaap--DebtInstrumentAxis__custom--NotesPayableMember__us-gaap--RelatedPartyTransactionAxis__custom--RelatedPartyOneMember_zWpMvUs6s4Ke" title="Number of shares issued during period, shares" class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIExvYW5zIGZyb20gUmVsYXRlZCBQYXJ0aWVzIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2019-04-112019-04-12_custom_NotesPayableMember_custom_RelatedPartyOneMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">5,900,000</ix:nonFraction></span> shares of their AMIH common stock. The Company issued individual promissory notes with an aggregate principal amount of $<span id="xdx_909_eus-gaap--DebtInstrumentFaceAmount_iI_pp0p0_c20190412__us-gaap--DebtInstrumentAxis__custom--NotesPayableMember__us-gaap--RelatedPartyTransactionAxis__custom--RelatedPartyOneMember_zSxiep62ecDj" title="Debt instrument, face amount" class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIExvYW5zIGZyb20gUmVsYXRlZCBQYXJ0aWVzIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA"><ix:nonFraction name="us-gaap:DebtInstrumentFaceAmount" contextRef="AsOf2019-04-12_custom_NotesPayableMember_custom_RelatedPartyOneMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">350,000</ix:nonFraction></span> (the &#8220;<span style="text-decoration: underline">Promissory Notes</span>&#8221;) for cancellation of the <span id="xdx_901_eus-gaap--StockRepurchasedAndRetiredDuringPeriodShares_c20190411__20190412__us-gaap--DebtInstrumentAxis__custom--NotesPayableMember__us-gaap--RelatedPartyTransactionAxis__custom--RelatedPartyOneMember_zFrRBO6uTwyi" title="Cancellation of common shares for long-term debt, shares" class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIExvYW5zIGZyb20gUmVsYXRlZCBQYXJ0aWVzIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA"><ix:nonFraction name="us-gaap:StockRepurchasedAndRetiredDuringPeriodShares" contextRef="From2019-04-112019-04-12_custom_NotesPayableMember_custom_RelatedPartyOneMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">5,900,000</ix:nonFraction></span> common shares. The Promissory Notes have a term of two years and accrue interest at the rate of <span id="xdx_903_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_dp_uPure_c20190412__us-gaap--DebtInstrumentAxis__custom--NotesPayableMember__us-gaap--RelatedPartyTransactionAxis__custom--RelatedPartyOneMember_zZOxwxZuVe75" title="Debt instrument, interest rate" class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIExvYW5zIGZyb20gUmVsYXRlZCBQYXJ0aWVzIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA"><ix:nonFraction name="us-gaap:DebtInstrumentInterestRateStatedPercentage" contextRef="AsOf2019-04-12_custom_NotesPayableMember_custom_RelatedPartyOneMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">10</ix:nonFraction></span>% per annum until paid in full by the Company. The Company recorded interest of $<span id="xdx_90A_eus-gaap--InterestExpense_pp0p0_c20200101__20201231__us-gaap--DebtInstrumentAxis__custom--NotesPayableMember__us-gaap--RelatedPartyTransactionAxis__custom--RelatedPartyOneMember_zYGUySamFCQ2" title="Interest expense" class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIExvYW5zIGZyb20gUmVsYXRlZCBQYXJ0aWVzIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA"><ix:nonFraction name="us-gaap:InterestExpense" contextRef="From2020-01-012020-12-31_custom_NotesPayableMember_custom_RelatedPartyOneMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">7,506</ix:nonFraction></span> on these notes during the year ended December 31, 2020. The accrued interest on these notes was $<span id="xdx_90B_eus-gaap--InterestPayableCurrentAndNoncurrent_iI_pp0p0_c20201231__us-gaap--DebtInstrumentAxis__custom--NotesPayableMember__us-gaap--RelatedPartyTransactionAxis__custom--RelatedPartyOneMember_za8cxj050ZWk" title="Accrued interest" class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIExvYW5zIGZyb20gUmVsYXRlZCBQYXJ0aWVzIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA"><ix:nonFraction name="us-gaap:InterestPayableCurrentAndNoncurrent" contextRef="AsOf2020-12-31_custom_NotesPayableMember_custom_RelatedPartyOneMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">18,982</ix:nonFraction></span> as of December 31, 2020. The Note and accrued interest totaling $<span id="xdx_907_eus-gaap--StockIssuedDuringPeriodValueNewIssues_pp0p0_c20200101__20201231__us-gaap--DebtInstrumentAxis__custom--NotesPayableMember__us-gaap--RelatedPartyTransactionAxis__custom--RelatedPartyOneMember_zKYRORIoQesd" title="Number of shares issued during period, values" class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIExvYW5zIGZyb20gUmVsYXRlZCBQYXJ0aWVzIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2020-01-012020-12-31_custom_NotesPayableMember_custom_RelatedPartyOneMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">280,108</ix:nonFraction></span> was settled by the issuance of <span id="xdx_90B_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20200101__20201231__us-gaap--DebtInstrumentAxis__custom--NotesPayableMember__us-gaap--RelatedPartyTransactionAxis__custom--RelatedPartyOneMember_zwAMNKfwAF0d" title="Number of shares issued during period, shares" class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIExvYW5zIGZyb20gUmVsYXRlZCBQYXJ0aWVzIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2020-01-012020-12-31_custom_NotesPayableMember_custom_RelatedPartyOneMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">3,476,495</ix:nonFraction></span> common shares of the Company. The shares were valued at $<span id="xdx_90B_eus-gaap--SharesIssuedPricePerShare_c20201231__us-gaap--DebtInstrumentAxis__custom--NotesPayableMember__us-gaap--RelatedPartyTransactionAxis__custom--RelatedPartyOneMember__srt--RangeAxis__srt--MaximumMember_pdd" title="Shares issued, price per share" class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIExvYW5zIGZyb20gUmVsYXRlZCBQYXJ0aWVzIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA"><ix:nonFraction name="us-gaap:SharesIssuedPricePerShare" contextRef="AsOf2020-12-31_custom_NotesPayableMember_custom_RelatedPartyOneMember_srt_MaximumMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.31</ix:nonFraction></span> and $<span id="xdx_905_eus-gaap--SharesIssuedPricePerShare_c20201231__us-gaap--DebtInstrumentAxis__custom--NotesPayableMember__us-gaap--RelatedPartyTransactionAxis__custom--RelatedPartyOneMember__srt--RangeAxis__srt--MinimumMember_pdd" title="Shares issued, price per share" class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIExvYW5zIGZyb20gUmVsYXRlZCBQYXJ0aWVzIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA"><ix:nonFraction name="us-gaap:SharesIssuedPricePerShare" contextRef="AsOf2020-12-31_custom_NotesPayableMember_custom_RelatedPartyOneMember_srt_MinimumMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.27</ix:nonFraction></span> per share based on the market price at the settlement date. Accordingly, the Company recorded a loss on loan settlement of $<span id="xdx_90A_eus-gaap--GainsLossesOnExtinguishmentOfDebt_pp0p0_c20200101__20201231__us-gaap--DebtInstrumentAxis__custom--NotesPayableMember__us-gaap--RelatedPartyTransactionAxis__custom--RelatedPartyOneMember_z21RSOOdNPcl" title="Loss on loan settlement" class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIExvYW5zIGZyb20gUmVsYXRlZCBQYXJ0aWVzIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA"><ix:nonFraction name="us-gaap:GainsLossesOnExtinguishmentOfDebt" contextRef="From2020-01-012020-12-31_custom_NotesPayableMember_custom_RelatedPartyOneMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">758,601</ix:nonFraction></span> during the year ended December 31, 2020.</span></td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right"><ix:nonFraction name="AMIH:LoansFromRelatedPartiesBeforeConversion" contextRef="AsOf2021-12-31_custom_NotesPayableMember_custom_RelatedPartyOneMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">350,000</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_ecustom--LoansFromRelatedPartiesBeforeConversion_iI_pp0p0_hus-gaap--DebtInstrumentAxis__custom--NotesPayableMember__us-gaap--RelatedPartyTransactionAxis__custom--RelatedPartyOneMember_zc6XlKAVXjyd" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Loans from related
    parties, before conversion</span></td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="AMIH:LoansFromRelatedPartiesBeforeConversion" contextRef="AsOf2021-12-31_custom_NotesPayableMember_custom_RelatedPartyOneMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">350,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_409_ecustom--Conversion_iNI_pp0p0_di_hus-gaap--DebtInstrumentAxis__custom--NotesPayableMember__us-gaap--RelatedPartyTransactionAxis__custom--RelatedPartyOneMember_zMy6mjnN84d4" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Less: Conversion</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="AMIH:Conversion" contextRef="AsOf2021-12-31_custom_NotesPayableMember_custom_RelatedPartyOneMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">240,000</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40E_ecustom--LoansAndLeasesReceivableRelatedPartiesGross_iI_pp0p0_hus-gaap--DebtInstrumentAxis__custom--NotesPayableMember__us-gaap--RelatedPartyTransactionAxis__custom--RelatedPartyOneMember_zxcymdVY3Tn7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="AMIH:LoansAndLeasesReceivableRelatedPartiesGross" contextRef="AsOf2021-12-31_custom_NotesPayableMember_custom_RelatedPartyOneMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">110,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_ecustom--LoansAndLeasesReceivableRelatedPartiesGross_iI_pp0p0_hus-gaap--DebtInstrumentAxis__custom--NotesPayableMember__us-gaap--RelatedPartyTransactionAxis__custom--RelatedPartyTwoMember_znREH5jI9OCk" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">As of December 31, 2021, the Company had a short-term note payable in the amount of $<span id="xdx_902_eus-gaap--NotesPayableCurrent_iI_pp0p0_c20211231__us-gaap--DebtInstrumentAxis__custom--NotesPayableMember__us-gaap--RelatedPartyTransactionAxis__custom--RelatedPartyTwoMember_zqZlfoUzTmT9" title="Short term notes payable" class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIExvYW5zIGZyb20gUmVsYXRlZCBQYXJ0aWVzIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA"><ix:nonFraction name="us-gaap:NotesPayableCurrent" contextRef="AsOf2021-12-31_custom_NotesPayableMember_custom_RelatedPartyTwoMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">13,473</ix:nonFraction></span> to Kemah Development Texas, LP, a company owned by Dror Family Trust, a related party.</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="AMIH:LoansAndLeasesReceivableRelatedPartiesGross" contextRef="AsOf2021-12-31_custom_NotesPayableMember_custom_RelatedPartyTwoMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">13,473</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_ecustom--LoansAndLeasesReceivableRelatedPartiesGross_iI_pp0p0_hus-gaap--DebtInstrumentAxis__custom--NotesPayableMember__us-gaap--RelatedPartyTransactionAxis__custom--RelatedPartyThreeMember_zEhufwy6Epj2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">As of December 31, 2021, outstanding loan balances payable to the Company&#8217;s CEO and board member, Jacob Cohen, were $<span id="xdx_900_eus-gaap--LoansPayable_iI_pp0p0_c20211231__us-gaap--DebtInstrumentAxis__custom--NotesPayableMember__us-gaap--RelatedPartyTransactionAxis__custom--RelatedPartyThreeMember_zrRUKwr9PLa4" title="Loan payable" class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIExvYW5zIGZyb20gUmVsYXRlZCBQYXJ0aWVzIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA"><ix:nonFraction name="us-gaap:LoansPayable" contextRef="AsOf2021-12-31_custom_NotesPayableMember_custom_RelatedPartyThreeMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">50</ix:nonFraction></span> with no interest and due on demand</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="AMIH:LoansAndLeasesReceivableRelatedPartiesGross" contextRef="AsOf2021-12-31_custom_NotesPayableMember_custom_RelatedPartyThreeMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">50</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_400_ecustom--LoansAndLeasesReceivableRelatedPartiesGross_iI_pp0p0_hus-gaap--DebtInstrumentAxis__custom--NotesPayableMember__us-gaap--RelatedPartyTransactionAxis__custom--RelatedPartiesMember_zmIBqZKIampl" style="vertical-align: bottom; background-color: White">
    <td><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Loans from related parties, gross</span></td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="AMIH:LoansAndLeasesReceivableRelatedPartiesGross" contextRef="AsOf2021-12-31_custom_NotesPayableMember_custom_RelatedPartiesMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">123,523</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--DebtInstrumentUnamortizedDiscount_iNI_pp0p0_di_hus-gaap--DebtInstrumentAxis__custom--NotesPayableMember__us-gaap--RelatedPartyTransactionAxis__custom--RelatedPartiesMember_zcFsnWblRawe" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Less: unamortized discount</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:DebtInstrumentUnamortizedDiscount" contextRef="AsOf2021-12-31_custom_NotesPayableMember_custom_RelatedPartiesMember" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">0</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--LoansAndLeasesReceivableRelatedParties_iI_pp0p0_hus-gaap--DebtInstrumentAxis__custom--NotesPayableMember__us-gaap--RelatedPartyTransactionAxis__custom--RelatedPartiesMember_zN99Y4qgOWO6" style="vertical-align: bottom; background-color: White">
    <td>Total</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:LoansAndLeasesReceivableRelatedParties" contextRef="AsOf2021-12-31_custom_NotesPayableMember_custom_RelatedPartiesMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">123,523</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--DueToRelatedPartiesNoncurrent_iI_pp0p0_hus-gaap--DebtInstrumentAxis__custom--NotesPayableMember__us-gaap--RelatedPartyTransactionAxis__custom--RelatedPartiesMember_zREwjzcHVwU2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Long-term loan from related parties</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:DueToRelatedPartiesNoncurrent" contextRef="AsOf2021-12-31_custom_NotesPayableMember_custom_RelatedPartiesMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">0</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_ecustom--DueToRelatedPartiesContinuingOperations_iI_pp0p0_hus-gaap--DebtInstrumentAxis__custom--NotesPayableMember__us-gaap--RelatedPartyTransactionAxis__custom--RelatedPartiesMember_zZVJPtJ0FMO1" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Short-term loan from related parties &#8211; continuing operations</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="AMIH:DueToRelatedPartiesContinuingOperations" contextRef="AsOf2021-12-31_custom_NotesPayableMember_custom_RelatedPartiesMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">123,473</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_ecustom--DueToRelatedPartiesDiscontinuedOperations_iI_pp0p0_hus-gaap--DebtInstrumentAxis__custom--NotesPayableMember__us-gaap--RelatedPartyTransactionAxis__custom--RelatedPartiesMember_zffY6u7Q0zPc" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Short-term loan from related parties &#8211; discontinued operations</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="AMIH:DueToRelatedPartiesDiscontinuedOperations" contextRef="AsOf2021-12-31_custom_NotesPayableMember_custom_RelatedPartiesMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">50</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A3_zoZbGE7lm1pf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>


<ix:exclude><!-- Field: Page; Sequence: 148; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: left"><a href="#fin" title="Table of Contents" style="font-style: italic">Table of Contents</a>&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2021-01-01to2021-12-31" escape="true" name="us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock"><p id="xdx_800_eus-gaap--DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock_zFWeyISHj9H5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
12&#8211;<span id="xdx_821_zIV8TfoP0cDk"> Derivative Liabilities</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notes
that are convertible at a discount to market are considered embedded derivatives.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
Financial Accounting Standard Board (&#8220;<span style="text-decoration: underline">FASB</span>&#8221;), U.S. GAAP, Accounting Standards Codification, &#8220;<span style="text-decoration: underline">Derivatives
and Hedging</span>&#8221;, ASC Topic 815 (&#8220;<span style="text-decoration: underline">ASC 815</span>&#8221;) requires that all derivative financial instruments be recorded on
the balance sheet at fair value. Fair values for exchange traded securities and derivatives are based on quoted market prices. Where
market prices are not readily available, fair values are determined using market-based pricing models incorporating readily observable
market data and requiring judgment and estimates.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s convertible note has been evaluated with respect to the terms and conditions of the conversion features contained in
the note to determine whether they represent embedded or freestanding derivative instruments under the provisions of ASC 815. The Company
determined that the conversion features contained in the notes totaled $<span id="xdx_909_eus-gaap--DebtInstrumentConvertibleBeneficialConversionFeature_c20210101__20211231_zze5zcpQcQjc" title="Debt instrument beneficial conversion"><ix:nonFraction name="us-gaap:DebtInstrumentConvertibleBeneficialConversionFeature" contextRef="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,575,083</ix:nonFraction></span> and represent a freestanding derivative instrument
that meets the requirements for liability classification under ASC 815. As a result, the fair value of the derivative financial instrument
in the note is reflected in the Company&#8217;s balance sheet as a liability. The fair value of the derivative financial instrument of
the convertible note was measured using the Lattice Model at the inception date of the note and will do so again on each subsequent balance
sheet date. Any changes in the fair value of the derivative financial instruments are recorded as non-operating, non-cash income or expense
at each balance sheet date. The derivative liabilities will be reclassified into additional paid in capital upon conversion.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2021-01-01to2021-12-31" escape="true" name="us-gaap:ConvertibleDebtTableTextBlock"><p id="xdx_898_eus-gaap--ConvertibleDebtTableTextBlock_z0uZ3gVDEmR8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Convertible Note derivatives were valued as of December 31, 2020, at issuance, at conversion and at December 31, 2021 as set forth in
the table below.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B0_zcVmmlHQxZql" style="display: none">Schedule of Convertible Note Derivatives</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_494_20210101__20211231_zeWj9AsHimxd" style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_40A_eus-gaap--DerivativeLiabilities_iS_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 80%">Derivative liabilities as of December 31, 2020</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:DerivativeLiabilities" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">517,366</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_402_ecustom--InitialDerivativeLiabilitiesAtNewNoteIssuance_zb3DLYPumJW5" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Initial derivative liabilities at new note issuance</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="AMIH:InitialDerivativeLiabilitiesAtNewNoteIssuance" contextRef="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">7,209,723</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--DerivativeLossOnDerivative_iN_pp0p0_di_zasopXPJDfdb" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Initial loss</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:DerivativeLossOnDerivative" contextRef="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">0</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40A_ecustom--ConversionOfDerivativeLiabilities_iN_pp0p0_di_z4SKAdfUJ9Gg" style="vertical-align: bottom; background-color: White">
    <td>Conversion</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="AMIH:ConversionOfDerivativeLiabilities" contextRef="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,116,124</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40F_ecustom--ConvertibleNoteDerivativesMarketChanges_i_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Mark to market changes</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="AMIH:ConvertibleNoteDerivativesMarketChanges" contextRef="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">2,469,693</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--DerivativeLiabilities_iE_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Derivative liabilities as of December 31, 2021</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:DerivativeLiabilities" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">4,141,272</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A3_zRS6C3HyYs8a" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2021, the Company had derivative liabilities of $<span id="xdx_908_eus-gaap--DerivativeLiabilitiesCurrent_iI_c20211231_zOaL757jTOg2" title="Derivative liabilities"><ix:nonFraction name="us-gaap:DerivativeLiabilitiesCurrent" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,141,272</ix:nonFraction></span>, and recorded changes in derivative liabilities in the amount
of $<span id="xdx_906_eus-gaap--GainLossOnSaleOfDerivatives_c20210101__20211231_zWpvh9x7gQ53" title="Changes in derivative liabilities"><ix:nonFraction name="us-gaap:GainLossOnSaleOfDerivatives" contextRef="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,171,028</ix:nonFraction></span> during the year ended December 31, 2021.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 149; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: left"><a href="#fin" title="Table of Contents" style="font-style: italic">Table of Contents</a>&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following assumptions were used for the valuation of the derivative liability related to the Notes:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    stock price would fluctuate with the Company&#8217;s projected volatility;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    projected volatility curve from an annualized analysis for each valuation period was based on the historical volatility of the Company
    and the term remaining for each note ranged from <span id="xdx_908_eus-gaap--DerivativeLiabilityMeasurementInput_iI_pid_uPure_c20211231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__srt--RangeAxis__srt--MinimumMember_z4BvChh1Hn07" title="Derivative Liability, Measurement Input"><ix:nonFraction name="us-gaap:DerivativeLiabilityMeasurementInput" contextRef="AsOf2021-12-31_us-gaap_MeasurementInputPriceVolatilityMember_srt_MinimumMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Pure">116</ix:nonFraction></span>% through <span id="xdx_908_eus-gaap--DerivativeLiabilityMeasurementInput_iI_pid_uPure_c20211231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__srt--RangeAxis__srt--MaximumMember_zm6stZS0IB28" title="Derivative liability, measurement input"><ix:nonFraction name="us-gaap:DerivativeLiabilityMeasurementInput" contextRef="AsOf2021-12-31_us-gaap_MeasurementInputPriceVolatilityMember_srt_MaximumMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Pure">206</ix:nonFraction></span>% at issuance, conversion, and quarters ends;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    Company would not redeem the notes;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_902_eus-gaap--DebtInstrumentDescription_c20210101__20211231" title="Derivative liability, description"><ix:nonNumeric contextRef="From2021-01-01to2021-12-31" name="us-gaap:DebtInstrumentDescription">An
    event of default adjusting the interest rate would occur initially 0% of the time for all notes with increases 1% per month to a
    maximum of 10% with the corresponding penalty</ix:nonNumeric></span>;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    Company would raise capital quarterly at market, which could trigger a reset event; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    Holder would convert the note monthly if the Company was not in default.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following assumptions were used for the valuation of the warrant derivative liability related to the Notes:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    stock price would fluctuate with the Company&#8217;s projected volatility;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    projected volatility curve from an annualized analysis for each valuation period was based on the historical volatility of the Company
    and the term remaining for each note ranged from <span id="xdx_901_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20211231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__srt--RangeAxis__srt--MinimumMember__us-gaap--FinancialInstrumentAxis__us-gaap--WarrantMember_zMDvjmOFPUG" title="Warrants and Rights Outstanding, Measurement Input"><ix:nonFraction name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" contextRef="AsOf2021-12-31_us-gaap_MeasurementInputPriceVolatilityMember_srt_MinimumMember_us-gaap_WarrantMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Pure">166</ix:nonFraction></span>% through <span id="xdx_90C_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20211231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__srt--RangeAxis__srt--MaximumMember__us-gaap--FinancialInstrumentAxis__us-gaap--WarrantMember_zCTNsbh1z6Le" title="Warrants and Rights Outstanding, Measurement Input"><ix:nonFraction name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" contextRef="AsOf2021-12-31_us-gaap_MeasurementInputPriceVolatilityMember_srt_MaximumMember_us-gaap_WarrantMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Pure">166.9</ix:nonFraction></span>% at issuance, conversion, and quarters ends.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    Warrants with the fixed $<span id="xdx_906_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20211231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExercisePriceMember__us-gaap--FinancialInstrumentAxis__us-gaap--WarrantMember_zpkTumUmbbf1" title="Warrants and Rights Outstanding, Measurement Input"><ix:nonFraction name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" contextRef="AsOf2021-12-31_us-gaap_MeasurementInputExercisePriceMember_us-gaap_WarrantMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Pure">0.20</ix:nonFraction></span>, $<span id="xdx_90A_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20211231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExercisePriceMember__us-gaap--FinancialInstrumentAxis__custom--WarrantOneMember_z7y6ZUbY3Bc7" title="Warrants and Rights Outstanding, Measurement Input"><ix:nonFraction name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" contextRef="AsOf2021-12-31_us-gaap_MeasurementInputExercisePriceMember_custom_WarrantOneMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Pure">0.35</ix:nonFraction></span>, and $<span id="xdx_901_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20211231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExercisePriceMember__us-gaap--FinancialInstrumentAxis__custom--WarrantTwoMember_z7RMYOEkdq28" title="Warrants and rights outstanding, measurement input"><ix:nonFraction name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" contextRef="AsOf2021-12-31_us-gaap_MeasurementInputExercisePriceMember_custom_WarrantTwoMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Pure">0.50</ix:nonFraction></span> exercise prices are subject to full ratchet reset provisions;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    Company would raise capital quarterly at market, which could trigger a reset event;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    cash flows are discounted to net present values using risk free rates; discount rates were based on risk free rates in effect based
    on the remaining term.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_906_eus-gaap--DerivativeLiabilityMeasurementDifferenceDescription_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember" title="Derivative liability measurement description"><ix:nonNumeric contextRef="From2021-01-012021-12-31_us-gaap_WarrantMember" name="us-gaap:DerivativeLiabilityMeasurementDifferenceDescription">The
    occurrence of a fundamental transaction by a public company was estimated at 2.5% after 2.5 years and 5% prior to maturity; and</ix:nonNumeric></span></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    Holder would hold the warrant to maturity (<span id="xdx_908_ecustom--WarrantsMaturityTerm_dtY_c20210101__20211231_zXQYrCLKTLG1" title="Warrants maturity term"><ix:nonNumeric contextRef="From2021-01-01to2021-12-31" format="ixt-sec:duryear" name="AMIH:WarrantsMaturityTerm">5</ix:nonNumeric></span>-year terms) at which point it could exercise the warrant if the warrant were in the
    money.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2021-01-01to2021-12-31" escape="true" name="us-gaap:IncomeTaxDisclosureTextBlock"><p id="xdx_80D_eus-gaap--IncomeTaxDisclosureTextBlock_zXuMISRD4Y51" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
13 &#8211; <span id="xdx_823_zyqP0NOZD3ya">Income Taxes</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has current net operating loss carryforwards in excess of $<span id="xdx_904_eus-gaap--OperatingLossCarryforwards_iI_c20211231_zpBNviZpaaZ2" title="Operating loss carryforwards"><ix:nonFraction name="us-gaap:OperatingLossCarryforwards" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">20,540,569</ix:nonFraction></span> as of December 31, 2021, to offset future taxable income,
which expire beginning <span id="xdx_904_eus-gaap--IncomeTaxExaminationYearUnderExamination_c20210101__20211231_z3f8a1RHSqAi" title="Operating loss expiration year"><ix:nonNumeric contextRef="From2021-01-01to2021-12-31" name="us-gaap:IncomeTaxExaminationYearUnderExamination">2029</ix:nonNumeric></span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Deferred
taxes are determined based on the temporary differences between the financial statement and income tax bases of assets and liabilities
as measured by the enacted tax rates, which will be in effect when these differences reverse. The components of deferred income tax assets
are as follows:</span></p>

<ix:nonNumeric contextRef="From2021-01-01to2021-12-31" escape="true" name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"><p id="xdx_898_eus-gaap--ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_zYVPt5SpZSEc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_8B9_zHZdBiVGHbei" style="display: none">Schedule
of Income Taxes</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; text-align: justify">December 31, 2021</td><td>&#160;</td>
    <td colspan="2" id="xdx_49A_20211231_zlgPfls7ROV8" style="text-align: justify">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Deferred Tax Asset:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_iI_maDTANzNWW_zngRXyAEqKih" style="vertical-align: bottom; background-color: White">
    <td style="width: 80%; text-align: justify">Net Operating Loss</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">9,980,911</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--DeferredTaxAssetsValuationAllowance_iNI_di_msDTANzNWW_znnB67IRCN96" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Valuation Allowance</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:DeferredTaxAssetsValuationAllowance" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">9,980,911</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_400_eus-gaap--DeferredTaxAssetsNet_iTI_mtDTANzNWW_zSRXW9kO1b59" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Net Deferred Asset</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1588">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8AB_zr8Ny5R3d1G7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
December 31, 2021, the Company provided a <span id="xdx_902_eus-gaap--EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_pid_dp_uPure_c20210101__20211231_znjOu7nMS83k" title="Valuation allowances"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" contextRef="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">100</ix:nonFraction></span>% valuation allowance for the deferred tax asset because it could not be determined whether
it was more likely than not that the deferred tax asset/(liability) would be realized.</span></p>
<!-- Field: Split-Segment; Name: 002 -->
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2021-01-01to2021-12-31" escape="true" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock"><p id="xdx_80D_eus-gaap--StockholdersEquityNoteDisclosureTextBlock_zuMdaaBAv6D" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
14 &#8211; <span id="xdx_82A_zTl9ezB5GnH3">Capital Stock</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Preferred
Stock</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company is authorized to issue up to <span id="xdx_902_eus-gaap--PreferredStockSharesAuthorized_iI_c20211231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zpuqhmF8NsAi" title="Preferred stock, shares authorized"><ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="AsOf2021-12-31_us-gaap_SeriesAPreferredStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">5,000,000</ix:nonFraction></span> shares of preferred stock, $<span id="xdx_904_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_c20211231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_z7XF7hRExL8i" title="Preferred stock, par value"><ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="AsOf2021-12-31_us-gaap_SeriesAPreferredStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.0001</ix:nonFraction></span> par value, of which three shares were designated as
Series A Preferred Stock and <span id="xdx_906_eus-gaap--PreferredStockSharesAuthorized_iI_c20211231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zzAyNvOQKd8l" title="Preferred stock, shares authorized"><ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="AsOf2021-12-31_us-gaap_SeriesBPreferredStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,000,000</ix:nonFraction></span> were designated as Series B Preferred stock, the balance of <span id="xdx_901_ecustom--UndesignatedPreferredStockAuthorized_iI_c20211231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_z8w0FfHX1v8g" title="Undesignated preferred stock authorized"><ix:nonFraction name="AMIH:UndesignatedPreferredStockAuthorized" contextRef="AsOf2021-12-31_us-gaap_SeriesBPreferredStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,999,997</ix:nonFraction></span> shares of preferred stock
were undesignated as of December 31, 2021.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 150; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: left"><a href="#fin" title="Table of Contents" style="font-style: italic">Table of Contents</a>&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
holders of Series A Preferred Stock have no dividend rights, liquidation preference and conversion rights. As long as any shares of Series
A Preferred Stock remain issued and outstanding, the holders of Series A Preferred Stock have the right to vote on all shareholder matters
equal to sixty percent (60%) of the total vote. At the option of the Company, Series A Preferred Stock is redeemable at $<span id="xdx_90D_ecustom--RedeemableValuePerShare_iI_c20211231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zT80zf3wmCN7" title="Redeemable value per share"><ix:nonFraction name="AMIH:RedeemableValuePerShare" contextRef="AsOf2021-12-31_us-gaap_SeriesAPreferredStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.00</ix:nonFraction></span> per share.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90D_ecustom--PreferredStockIssuanceDescription_c20210101__20211231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_z17zO3MxuOzb" title="Preferred stock issuance description"><ix:nonNumeric contextRef="From2021-01-012021-12-31_us-gaap_SeriesAPreferredStockMember" name="AMIH:PreferredStockIssuanceDescription">The
holders of Series B Preferred Stock have the same dividend rights as common stockholders on a fully converted basis, are entitled to
receive pari passu with any distribution of any of the assets of the Company to the holders of the Company&#8217;s common stock, but
not prior to any holders of senior securities. Each share of Series B Preferred Stock may be converted, at the option of the holder thereof,
into that number of shares of common stock of the Company as equals $1.00 divided by 90% of the average of the volume weighted average
prices (&#8220;</ix:nonNumeric><span style="text-decoration: underline">VWAP</span>&#8221;) of the Company&#8217;s common stock, for the five trading days immediately preceding the date the
notice of conversion is received, subject to the limit of 4.999% of the Company&#8217;s outstanding shares of common stock. The holders
of Series B Preferred Stock have no voting rights.</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
May 15, 2020, the Company entered into a Securities Purchase Agreement with GCN as described in greater detail in &#8220;Note 1 Summary
of Significant Account Policies &#8211; Organization, Ownership and Business&#8221;. Pursuant to the SPA, the Company acquired a 51%
interest in Life Guru from GCN in consideration for <span id="xdx_907_eus-gaap--StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_c20200514__20200515__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zfUtmtihORe6" title="Conversion of common stock"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" contextRef="From2020-05-142020-05-15_custom_SecuritiesPurchaseAgreementMember_us-gaap_SeriesBPreferredStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">500,000</ix:nonFraction></span> shares of Series B Convertible Preferred Stock, which had an agreed upon
value of $<span id="xdx_905_eus-gaap--StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_c20200514__20200515__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zwtado1Ymmf9" title="Conversion of common stock"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" contextRef="From2020-05-142020-05-15_custom_SecuritiesPurchaseAgreementMember_us-gaap_SeriesBPreferredStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">500,000</ix:nonFraction></span> ($<span id="xdx_90C_eus-gaap--SharesIssuedPricePerShare_iI_pid_c20200515__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_z35DBAM99aG4" title="Shares issued price per share"><ix:nonFraction name="us-gaap:SharesIssuedPricePerShare" contextRef="AsOf2020-05-15_custom_SecuritiesPurchaseAgreementMember_us-gaap_SeriesBPreferredStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.00</ix:nonFraction></span> per share), and agreed to issue GCN up to an additional <span id="xdx_908_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20200514__20200515__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__dei--LegalEntityAxis__custom--GlobalCareerNetworksIncMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember__srt--StatementScenarioAxis__custom--AgreedToIssueANAdditionalSharesMember_z5hXYJDpEn1b" title="Number of shares issued during period, shares"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2020-05-142020-05-15_custom_SecuritiesPurchaseAgreementMember_custom_GlobalCareerNetworksIncMember_us-gaap_SeriesBPreferredStockMember_custom_AgreedToIssueANAdditionalSharesMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,500,000</ix:nonFraction></span> shares of Series B Convertible Preferred Stock
(with an agreed upon value of $<span id="xdx_90E_eus-gaap--StockIssuedDuringPeriodValueNewIssues_pp0p0_c20200514__20200515__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__dei--LegalEntityAxis__custom--GlobalCareerNetworksIncMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember__srt--StatementScenarioAxis__custom--AgreedToIssueANAdditionalSharesMember_zcBDvcMbvFWl" title="Number of shares issued during period, values"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2020-05-142020-05-15_custom_SecuritiesPurchaseAgreementMember_custom_GlobalCareerNetworksIncMember_us-gaap_SeriesBPreferredStockMember_custom_AgreedToIssueANAdditionalSharesMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,500,000</ix:nonFraction></span>) upon reaching certain milestones. The fair value of the first <span id="xdx_909_eus-gaap--StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_c20200514__20200515__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zE8edtxtnxo7"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" contextRef="From2020-05-142020-05-15_custom_SecuritiesPurchaseAgreementMember_us-gaap_SeriesBPreferredStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">500,000</ix:nonFraction></span> shares of the Company&#8217;s
Series B Preferred Stock at grant date was $<span id="xdx_908_eus-gaap--StockIssuedDuringPeriodValueNewIssues_pp0p0_c20200514__20200515__us-gaap--TypeOfArrangementAxis__custom--SharePurchaseAgreementMember__dei--LegalEntityAxis__custom--GlobalCareerNetworksIncMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zzpy6ypj3lQ6" title="Number of shares issued during period, values"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2020-05-142020-05-15_custom_SharePurchaseAgreementMember_custom_GlobalCareerNetworksIncMember_us-gaap_SeriesBPreferredStockMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">605,488</ix:nonFraction></span>, a result of market price per common share at the grant date times the equivalent
number of common shares after the conversion of Series B Preferred Stock. Such <span id="xdx_904_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20200602__20200630__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zT4YDlrWdN28" title="Shares acquired"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2020-06-022020-06-30_custom_SecuritiesPurchaseAgreementMember_us-gaap_SeriesBPreferredStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">500,000</ix:nonFraction></span> initial shares of Series B Preferred Stock were
subsequently converted to common stock in June 2020, as discussed below.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90C_eus-gaap--DebtInstrumentDescription_c20200519__20200520__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zkQtjSAAlVTa" title="Debt instrument, description"><ix:nonNumeric contextRef="From2020-05-192020-05-20_us-gaap_SeriesAPreferredStockMember" name="us-gaap:DebtInstrumentDescription">On
May 20, 2020, the Company issued one share of its newly designated shares of Series A Preferred Stock to each of the three members of
its then Board of Directors, (1) Jacob D. Cohen, (2) Esteban Alexander and (3) Luis Alan Hernandez, in consideration for services rendered
to the Company as members of the Board of Directors. Such shares of Series A Preferred Stock vote in aggregate sixty percent (60%) of
the total vote on all shareholder matters, voting separately as a class. Notwithstanding such voting rights, no change in control of
the Company was deemed to have occurred in connection with the issuance since Messrs. Cohen, Alexander and Hernandez, own in aggregate
68% of the Company&#8217;s outstanding common stock and therefore controlled the Company prior to such issuance</ix:nonNumeric></span>. The shares of Series
A Preferred Stock held by Mr. Alexander and Mr. Hernandez were cancelled on November 6, 2020 pursuant to the Stock Purchase Agreements
dated October 2, 2020, and as such, a change of control occurred on such date, with Mr. Cohen taking over voting control of the Company,
and serving between December 15, 2020 and October 19, 2021, as the sole officer and director of the Company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">During the first quarter of 2021, the Company
issued <span id="xdx_906_eus-gaap--StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_pp0p0_c20210101__20210331__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_z2Qoe4aKiU77" title="Conversion of common stock"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" contextRef="From2021-01-012021-03-31_us-gaap_SeriesBPreferredStockMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="Shares">500,000</ix:nonFraction></span> Series B Preferred Stock shares for reaching the first milestone (milestone (a)). The fair value of <span id="xdx_907_eus-gaap--StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_pp0p0_c20210101__20210331__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zYU6ExBYFJEe" title="Conversion of common stock"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" contextRef="From2021-01-012021-03-31_us-gaap_SeriesBPreferredStockMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">500,000</ix:nonFraction></span> shares of
the Company&#8217;s Series B Preferred Stock issued at closing, valued on such grant date was $<span id="xdx_908_eus-gaap--StockIssuedDuringPeriodValueNewIssues_pp0p0_c20210101__20210331__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zZV96famM2Jf" title="Number of shares issued during period, values"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2021-01-012021-03-31_us-gaap_SeriesBPreferredStockMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">601,852</ix:nonFraction></span>, which equaled the market price
per common share on the grant multiplied by the equivalent number of common shares which would be issuable upon conversion of Series
B Preferred Stock. This amount was expensed as in process research and development. The shareholder then elected to convert the Series
B Preferred Stock to <span id="xdx_90A_eus-gaap--ConversionOfStockSharesConverted1_c20210101__20210331__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zkIjlfRqd5o7" title="Shares converted, shares"><ix:nonFraction name="us-gaap:ConversionOfStockSharesConverted1" contextRef="From2021-01-012021-03-31_us-gaap_SeriesBPreferredStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,057,613</ix:nonFraction></span> shares of common stock.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2021 and December 31, 2020, there was <span id="xdx_902_eus-gaap--PreferredStockSharesOutstanding_iI_pid_dc_uShares_c20211231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zR0nWn606Ugd" title="Preferred stock shares outstanding"><span id="xdx_905_eus-gaap--PreferredStockSharesOutstanding_iI_pid_dc_uShares_c20201231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zFTfxQSH3MO5" title="Preferred stock shares outstanding"><ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" contextRef="AsOf2021-12-31_us-gaap_SeriesAPreferredStockMember" format="ixt-sec:numwordsen" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" contextRef="AsOf2020-12-31_us-gaap_SeriesAPreferredStockMember" format="ixt-sec:numwordsen" decimals="INF" unitRef="Shares">one</ix:nonFraction></ix:nonFraction></span></span> share of Series A Preferred Stock and <span id="xdx_90F_eus-gaap--PreferredStockSharesIssued_iI_pid_do_c20211231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_z1rllBPpXXHa" title="Preferred stock shares issued"><span id="xdx_902_eus-gaap--PreferredStockSharesOutstanding_iI_pid_do_c20201231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zRxvQdmdwM9j" title="Preferred stock shares outstanding"><ix:nonFraction name="us-gaap:PreferredStockSharesIssued" contextRef="AsOf2021-12-31_us-gaap_SeriesBPreferredStockMember" format="ixt-sec:numwordsen" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" contextRef="AsOf2020-12-31_us-gaap_SeriesBPreferredStockMember" format="ixt-sec:numwordsen" decimals="INF" unitRef="Shares">no</ix:nonFraction></ix:nonFraction></span></span> shares of Series B Preferred Stock
issued and outstanding.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Common
Stock</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company is authorized to issue up to <span id="xdx_906_eus-gaap--CommonStockSharesAuthorized_iI_c20201231_zb0MbdlM97uk" title="Common stock, shares authorized"><span id="xdx_906_eus-gaap--CommonStockSharesAuthorized_iI_c20211231_zx2ICNsTq7Ah" title="Common stock, shares authorized"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">195,000,000</ix:nonFraction></ix:nonFraction></span></span> shares of common stock, $<span id="xdx_905_eus-gaap--CommonStockParOrStatedValuePerShare_iI_pid_c20201231_zAif4d0Oyes4" title="Common stock, par value"><span id="xdx_90F_eus-gaap--CommonStockParOrStatedValuePerShare_iI_pid_c20211231_z7st8kPOJwki" title="Common stock, par value"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.0001</ix:nonFraction></ix:nonFraction></span></span> par value, of which <span id="xdx_900_eus-gaap--CommonStockSharesOutstanding_iI_c20211231_zDmfnN5t4lqi" title="Common stock, shares outstanding"><span id="xdx_904_eus-gaap--CommonStockSharesIssued_iI_c20211231_z36WP23Ky7Pd" title="Common stock, shares issued"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">84,445,067</ix:nonFraction></ix:nonFraction></span></span> shares were issued and
outstanding at December 31, 2021 and <span id="xdx_909_eus-gaap--CommonStockSharesOutstanding_iI_c20201231_z4HYaA1n00Q8" title="Common stock, shares outstanding"><span id="xdx_907_eus-gaap--CommonStockSharesIssued_iI_c20201231_zrypCovCnfkh" title="Common stock, shares issued"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">55,066,855</ix:nonFraction></ix:nonFraction></span></span> were issued and outstanding at December 31, 2020.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
January 12, 2021, the Company issued <span id="xdx_903_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20210110__20210112__us-gaap--DebtInstrumentAxis__custom--UnrelatedPartyMember_zAAqGdafLiik" title="Number of shares issued during period, shares"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2021-01-102021-01-12_custom_UnrelatedPartyMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">708,750</ix:nonFraction></span> common shares and paid $<span id="xdx_90B_eus-gaap--StockIssuedDuringPeriodValueNewIssues_pp0p0_c20210110__20210112__us-gaap--DebtInstrumentAxis__custom--UnrelatedPartyMember_zStVwa4K72El" title="Number of shares issued during period, values"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2021-01-102021-01-12_custom_UnrelatedPartyMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">50,000</ix:nonFraction></span> to settle a note with an unrelated party, dated August 11,
2020, under the terms and conditions of convertible notes as issued. The Company recorded a loss on loan settlement of $<span id="xdx_908_eus-gaap--GainsLossesOnExtinguishmentOfDebt_pp0p0_c20210110__20210112__us-gaap--DebtInstrumentAxis__custom--UnrelatedPartyMember_zAOcvoZhXZO2" title="Gain (Loss) on Extinguishment of Debt"><ix:nonFraction name="us-gaap:GainsLossesOnExtinguishmentOfDebt" contextRef="From2021-01-102021-01-12_custom_UnrelatedPartyMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">58,059</ix:nonFraction></span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
February 2, 2021, the Company issued <span id="xdx_908_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20210130__20210202__us-gaap--DebtInstrumentAxis__custom--NonRelatedThirdPartyInvestorMember_zfZ6xVjifPmg" title="Number of shares issued during period, shares"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2021-01-302021-02-02_custom_NonRelatedThirdPartyInvestorMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">200,000</ix:nonFraction></span> shares of the Company&#8217;s common stock to a non-related third-party investor in exchange
for $<span id="xdx_90A_eus-gaap--StockIssuedDuringPeriodValueNewIssues_pp0p0_c20210130__20210202__us-gaap--DebtInstrumentAxis__custom--NonRelatedThirdPartyInvestorMember_z2ZCdizT46Q9" title="Number of shares issued during period, values"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2021-01-302021-02-02_custom_NonRelatedThirdPartyInvestorMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">100,000</ix:nonFraction></span> in cash.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the first quarter of 2021, the Company issued <span id="xdx_90F_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_c20210101__20210331__srt--TitleOfIndividualAxis__custom--EmployeeAndNonEmployeeMember_zmcpmfwzq8C4" title="Stock Issued During Period, Shares, Issued for Services"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesIssuedForServices" contextRef="From2021-01-012021-03-31_custom_EmployeeAndNonEmployeeMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">11,800,000</ix:nonFraction></span> shares of the Company&#8217;s common stock in consideration for services performed
by employees and non-employee consultants. The shares were valued at $<span id="xdx_905_eus-gaap--StockIssuedDuringPeriodValueIssuedForServices_pp0p0_c20210101__20210331__srt--TitleOfIndividualAxis__custom--EmployeeAndNonEmployeeMember_zuttP0NfFi43" title="Stock Issued During Period, Value, Issued for Services"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" contextRef="From2021-01-012021-03-31_custom_EmployeeAndNonEmployeeMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">4,223,390</ix:nonFraction></span> based on the market price on the date of agreements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 151; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: left"><a href="#fin" title="Table of Contents" style="font-style: italic">Table of Contents</a>&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the first quarter of 2021, the Company issued <span id="xdx_90D_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20210101__20210331__srt--TitleOfIndividualAxis__custom--InvestorsMember_z3CwNm2NTEif" title="Number of shares issued during period, shares"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2021-01-012021-03-31_custom_InvestorsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,730,548</ix:nonFraction></span> common shares to investors in exchange for $<span id="xdx_907_eus-gaap--DebtInstrumentFaceAmount_iI_pp0p0_c20210331__srt--TitleOfIndividualAxis__custom--InvestorsMember_zjWFVTI4vdb3" title="Debt face amount"><ix:nonFraction name="us-gaap:DebtInstrumentFaceAmount" contextRef="AsOf2021-03-31_custom_InvestorsMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">502,050</ix:nonFraction></span> of principal and accrued
interest owed under the terms and conditions of convertible notes as issued.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the first quarter of 2021, the Company issued <span id="xdx_90C_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20210101__20210331__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ThirdPartyMember_zGsbCD1QJZN8" title="Number of shares issued during period, shares"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2021-01-012021-03-31_custom_ThirdPartyMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">500,000</ix:nonFraction></span> shares of Series B Preferred Shares to a third party for services related to research
and development. The shares were subsequently converted into <span id="xdx_902_eus-gaap--ConversionOfStockSharesConverted1_c20210101__20210331__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ThirdPartyMember_zp8GSLkbvvMd" title="Shares converted, shares"><ix:nonFraction name="us-gaap:ConversionOfStockSharesConverted1" contextRef="From2021-01-012021-03-31_custom_ThirdPartyMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,057,613</ix:nonFraction></span> shares of common stock. The shares were valued at $<span id="xdx_90A_eus-gaap--ConversionOfStockAmountConverted1_pp0p0_c20210101__20210331__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ThirdPartyMember_z22MgdgbLJy8" title="Shares converted, amount"><ix:nonFraction name="us-gaap:ConversionOfStockAmountConverted1" contextRef="From2021-01-012021-03-31_custom_ThirdPartyMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">601,582</ix:nonFraction></span>,
under the terms and conditions of agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the second quarter of 2021, the Company issued <span id="xdx_909_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20210401__20210630__srt--TitleOfIndividualAxis__custom--InvestorsMember_zJHkHJdZWgm9" title="Number of shares issued during period, shares"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2021-04-012021-06-30_custom_InvestorsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">3,800,894</ix:nonFraction></span> common shares to investors in exchange for $<span id="xdx_904_eus-gaap--DebtInstrumentFaceAmount_iI_pp0p0_c20210630__srt--TitleOfIndividualAxis__custom--InvestorsMember_zXFoiVDMt6k7" title="Debt face amount"><ix:nonFraction name="us-gaap:DebtInstrumentFaceAmount" contextRef="AsOf2021-06-30_custom_InvestorsMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">416,636</ix:nonFraction></span> of principal and accrued
interest owed under the terms and conditions of convertible notes as issued.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the third quarter of 2021, the Company issued <span id="xdx_90A_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_c20210701__20210930__srt--TitleOfIndividualAxis__custom--EmployeeAndNonEmployeeMember_zSbgcgWzwHW8" title="Stock Issued During Period, Shares, Issued for Services"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesIssuedForServices" contextRef="From2021-07-012021-09-30_custom_EmployeeAndNonEmployeeMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">915,000</ix:nonFraction></span> shares of the Company&#8217;s common stock in consideration for services performed
by employees and non-employee consultants. The shares were valued at $<span id="xdx_908_eus-gaap--StockIssuedDuringPeriodValueIssuedForServices_pp0p0_c20210701__20210930__srt--TitleOfIndividualAxis__custom--EmployeeAndNonEmployeeMember_zrtkjSa8gTHh" title="Stock Issued During Period, Value, Issued for Services"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" contextRef="From2021-07-012021-09-30_custom_EmployeeAndNonEmployeeMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">68,609</ix:nonFraction></span> based on the market price on the date of agreements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the third quarter of 2021, the Company issued <span id="xdx_908_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20210701__20210930__srt--TitleOfIndividualAxis__custom--InvestorsMember__us-gaap--DebtInstrumentAxis__custom--ConvertibleNoteMember_z5AeuibepS52" title="Number of shares issued during period, shares"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2021-07-012021-09-30_custom_InvestorsMember_custom_ConvertibleNoteMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">3,049,304</ix:nonFraction></span> common shares to investors in exchange for $<span id="xdx_903_eus-gaap--DebtInstrumentFaceAmount_iI_pp0p0_c20210930__srt--TitleOfIndividualAxis__custom--InvestorsMember__us-gaap--DebtInstrumentAxis__custom--ConvertibleNoteMember_z3C92pldDOBc" title="Debt face amount"><ix:nonFraction name="us-gaap:DebtInstrumentFaceAmount" contextRef="AsOf2021-09-30_custom_InvestorsMember_custom_ConvertibleNoteMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">156,204</ix:nonFraction></span> of principal and accrued
interest owed under the terms and conditions of convertible notes outstanding.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the fourth quarter, the Company issued <span id="xdx_90C_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_c20211001__20211231__srt--TitleOfIndividualAxis__custom--EmployeeAndNonEmployeeMember_zOaSBBQCvwtg" title="Number of shares issued for services"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesIssuedForServices" contextRef="From2021-10-012021-12-31_custom_EmployeeAndNonEmployeeMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,151,678</ix:nonFraction></span> shares of the Company&#8217;s common stock in consideration for services performed by
employees and non-employee consultants. The shares were valued at $<span id="xdx_90A_eus-gaap--StockIssuedDuringPeriodValueIssuedForServices_pp0p0_c20211001__20211231__srt--TitleOfIndividualAxis__custom--EmployeeAndNonEmployeeMember_zLX2oolmlqPa" title="Number of shares issued for services, value"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" contextRef="From2021-10-012021-12-31_custom_EmployeeAndNonEmployeeMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">92,293</ix:nonFraction></span> based on the market price on the date of agreements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the fourth quarter of 2021, the Company issued <span id="xdx_90A_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20211001__20211231__srt--TitleOfIndividualAxis__custom--InvestorsMember__us-gaap--DebtInstrumentAxis__custom--ConvertibleNoteMember_z89k18dLQHXg" title="Number of shares issued during period"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2021-10-012021-12-31_custom_InvestorsMember_custom_ConvertibleNoteMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,964,425</ix:nonFraction></span> common shares to investors in exchange for $<span id="xdx_904_eus-gaap--DebtInstrumentFaceAmount_iI_pp0p0_c20211231__srt--TitleOfIndividualAxis__custom--InvestorsMember__us-gaap--DebtInstrumentAxis__custom--ConvertibleNoteMember_zRGP60PWU0Lc" title="Debt face amount"><ix:nonFraction name="us-gaap:DebtInstrumentFaceAmount" contextRef="AsOf2021-12-31_custom_InvestorsMember_custom_ConvertibleNoteMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">153,580</ix:nonFraction></span> of principal and accrued
interest owed under the terms and conditions of convertible notes outstanding.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2021-01-01to2021-12-31" escape="true" name="us-gaap:SubstantialDoubtAboutGoingConcernTextBlock"><p id="xdx_80B_eus-gaap--SubstantialDoubtAboutGoingConcernTextBlock_zAkRagsAPGTj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
15 &#8211; <span id="xdx_82D_z3JrnSMJvnzi">Going Concern</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">These
consolidated financial statements have been prepared assuming that the Company will continue as a going concern, which contemplates the
realization of assets and the discharge of liabilities in the normal course of business for the foreseeable future.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
reflected in the accompanying financial statements, the Company has a net loss from continuing operation of $<span id="xdx_900_eus-gaap--IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_iN_pp0p0_di_uUSD_c20210101__20211231_zCCiV30rIW2k" title="Net loss from continuing operation"><ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" contextRef="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">10,225,497</ix:nonFraction></span>
and $<span id="xdx_90F_eus-gaap--IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_iN_pp0p0_di_uUSD_c20200101__20201231_zqobHr6Cssfa" title="Net loss from continuing operation"><ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" contextRef="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">6,460,653</ix:nonFraction></span>
for the year ended December 31, 2021 and 2020 respectively, a gain of $<span id="xdx_900_eus-gaap--IncomeLossFromDiscontinuedOperationsNetOfTax_pp0p0_c20210101__20211231_zxtQ2x3d6k7h" title="Income loss from discontinued operations"><ix:nonFraction name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax" contextRef="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">244,586</ix:nonFraction></span>
and a net loss from discontinued operation of $<span id="xdx_90F_eus-gaap--IncomeLossFromDiscontinuedOperationsNetOfTax_iN_pp0p0_di_c20200101__20201231_zREuaRj1PTQ6" title="Income loss from discontinued operations"><ix:nonFraction name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax" contextRef="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">879,237</ix:nonFraction></span>
for the year ended December 31, 2021 and 2020 respectively, and an accumulated deficit of $<span id="xdx_906_eus-gaap--RetainedEarningsAccumulatedDeficit_iNI_pp0p0_di_c20211231_z1J87WhoN7Ul" title="Accumulated deficit"><ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">20,540,569</ix:nonFraction></span>
as of December 31, 2021. The ability to continue as a going concern is dependent upon the Company generating profitable operations
in the future and/or to obtain the necessary financing to meet its obligations and repay its liabilities arising from normal
business operations when they come due. These financials do not include any adjustments relating to the recoverability and
reclassification of recorded asset amounts, or amounts and classifications of liabilities that might result from this uncertainty.
There can be no assurance that the Company will become commercially viable without additional financing, the availability and terms
of which are uncertain. If the Company cannot secure necessary capital when needed on commercially reasonable terms, its business,
condition (financial and otherwise) and commercial viability may be harmed. Although management believes that it will be able to
successfully execute its business plan, which includes third party financing and the raising of capital to meet the Company&#8217;s
future liquidity needs, there can be no assurances in this regard. These matters raise substantial doubt about the Company&#8217;s
ability to continue as a going concern.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2021-01-01to2021-12-31" escape="true" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock"><p id="xdx_800_eus-gaap--CommitmentsAndContingenciesDisclosureTextBlock_zzmDCVJX0ouf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note
16 &#8211; <span id="xdx_828_z9KI68JpgqLd">Commitments and Contingencies</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the ordinary course of business, the Company may become a party to lawsuits involving various matters. The impact and outcome of litigation,
if any, is subject to inherent uncertainties, and an adverse result in these or other matters may arise from time to time that may harm
its business. The Company believes the ultimate resolution of any such current proceeding will not have a material adverse effect on
our continued financial position, results of operations or cash flows.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 152; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: left"><a href="#fin" title="Table of Contents" style="font-style: italic">Table of Contents</a>&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
October 14, 2019, Robert Holden, the Company&#8217;s former CEO, filed a Petition and Application for Temporary Restraining Order in
the District Court, 152<sup>nd</sup> Judicial District of Harris County, Texas, against the Company stating that the Company is blocking
Mr. Holden&#8217;s legal right to trade his shares in the open market and further attempting to stake his claim that he maintains his
rights to the <span id="xdx_907_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20191013__20191014__srt--TitleOfIndividualAxis__custom--RobertHoldenMember_zNTXg5nu9551" title="Number of common stock shares issued"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2019-10-132019-10-14_custom_RobertHoldenMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">3,800,000</ix:nonFraction></span> shares he received in connection with his acceptance as CEO of the Company on or around May 31, 2018. The Company
is maintaining the position that Mr. Holden does not have the right to those shares as he was in breach of his obligation to convey a
digital marketing business to the Company and subsequently resigned from the Company shortly thereafter, on or around August 15, 2018
and that he procured the shares through fraud. On November 11, 2019, the Company issued a response with a Motion to Dismiss Under the
Texas Citizen&#8217;s Participation Act (TCPA) citing that any declaratory judgment and breach of contract claims be dismissed unless
Mr. Holden can, through &#8220;<span style="text-decoration: underline">clear and specific evidence</span>&#8221;, establish a prima facie case for each essential element of
his claims. After an attempt to remand the case to federal court, the Company filed an amended notice of submission for its TCPA motion
for submission on May 18, 2020, whereby Holden failed to respond to the motion in a timely manner. On May 18, 2020, the Company filed
a response in support of its motion to dismiss under the TCPA, which was denied on June 3, 2020. Immediately thereafter, on June 4, 2020,
the Company filed a notice of accelerated interlocutory appeal to appeal the denial of the motion to dismiss under the TCPA and the trial
court&#8217;s failure to rule on the Company&#8217;s objection to the timeliness of Holden&#8217;s response. The outcome of this action,
and the ultimate outcome of the lawsuit is currently unknown at this time, provided that the Company intends to vehemently defend itself
against the claims made in the lawsuit.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span style="text-decoration: underline">AMIH
vs. Winfred Fields</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
November 11, 2019, the Company filed an Original Petition and Jury Demand in the 458<sup>th</sup> Judicial District Court of Fort Bend
County, Texas against Winfred Fields, a shareholder, in the 458<sup>th </sup>Judicial District Court of Fort Bend County seeking damages
related to breach of contract and fraud related charges. The Company executed an exchange agreement with Mr. Fields on or around April
12, 2019 whereby Mr. Fields was required to tender to the Company a total of <span id="xdx_90B_ecustom--StockIssuedDuringPeriodSharesExchanged_c20190410__20190412__srt--TitleOfIndividualAxis__custom--WinfredFieldsMember_zaWpDe1o7R4e" title="Number of common stock shares exchanged"><ix:nonFraction name="AMIH:StockIssuedDuringPeriodSharesExchanged" contextRef="From2019-04-102019-04-12_custom_WinfredFieldsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">650,000</ix:nonFraction></span> of the <span id="xdx_909_ecustom--StockIssuedDuringPeriodSharesExchanged_c20190410__20190412__srt--TitleOfIndividualAxis__custom--WinfredFieldsMember__us-gaap--TypeOfArrangementAxis__custom--ExchangeAgreementMember_zPwqu0et92B7" title="Number of common stock shares exchanged"><ix:nonFraction name="AMIH:StockIssuedDuringPeriodSharesExchanged" contextRef="From2019-04-102019-04-12_custom_WinfredFieldsMember_custom_ExchangeAgreementMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">750,000</ix:nonFraction></span> shares of the Company&#8217;s common
stock that Mr. Fields then owned (the &#8220;<span style="text-decoration: underline">Exchanged Shares</span>&#8221;) in exchange for a promissory note with a maturity date of
April 12, 2021 payable in the amount of $<span id="xdx_901_eus-gaap--NotesPayable_iI_pp0p0_c20191111__srt--TitleOfIndividualAxis__custom--WinfredFieldsMember__us-gaap--TypeOfArrangementAxis__custom--ExchangeAgreementMember__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteMember_z8fyY8H6OCgk" title="Notes Payable"><ix:nonFraction name="us-gaap:NotesPayable" contextRef="AsOf2019-11-11_custom_WinfredFieldsMember_custom_ExchangeAgreementMember_custom_PromissoryNoteMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">42,500</ix:nonFraction></span> (the &#8220;<span style="text-decoration: underline">Fields Note</span>&#8221;) (see also &#8220;Note 11 &#8211; Loans from Related
Parties&#8221;). The Exchange Agreement required that Mr. Fields immediately return the stock certificates for the Exchanged Shares to
the Company or its designated agent for immediate cancellation and for Mr. Fields to retain the remaining <span id="xdx_903_ecustom--StockIssuedDuringPeriodSharesRemaining_c20190410__20190412__srt--TitleOfIndividualAxis__custom--WinfredFieldsMember_zlmZvHpwlz8i" title="Remaining number of shares"><ix:nonFraction name="AMIH:StockIssuedDuringPeriodSharesRemaining" contextRef="From2019-04-102019-04-12_custom_WinfredFieldsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">100,000</ix:nonFraction></span> shares. Mr. Fields
agreed in the Exchange Agreement that these shares would not become unrestricted until such time as Mr. Fields received an opinion of
counsel satisfactory to the Company that the shares were not restricted for trade under SEC regulations. After executing the Exchange
Agreement, Mr. Fields&#8212;rather than return the Exchanged Shares or obtain said opinion of counsel&#8212;attempted to deposit and
trade the Exchanged Shares and the restricted shares, which was a direct violation of the Exchange Agreement. The Company asserts that
Mr. Fields knowingly, willingly and fraudulently attempted to deposit and trade the Exchanged Shares and is seeking damages and equitable
relief. Upon several attempts to serve Mr. Fields, service was perfected on or around February 3, 2020. On March 2, 2020, Mr. Fields
filed a response generally denying all claims. On May 22, 2020, the Company filed its first request for production and request for disclosure
and discovery insisting that Mr. Fields produce all documentation related to the fraudulent transaction and is awaiting a response to
these requested discovery items. The outcome of this action is currently unknown at this time. In November 2019, the Company recovered
<span id="xdx_90F_eus-gaap--StockIssuedDuringPeriodSharesShareBasedCompensationForfeited_c20191113__20191130__srt--TitleOfIndividualAxis__custom--WinfredFieldsMember_zZAE1IDZI9w8" title="Number of shares forfeited"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensationForfeited" contextRef="From2019-11-132019-11-30_custom_WinfredFieldsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">650,000</ix:nonFraction></span> shares from Mr. Fields which were cancelled in 2019.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Asher
Park, LLC vs. Novopelle Tyler</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
August 11, 2021, Asher Park, LLC (&#8220;Asher Park&#8221;) filed a petition against the Company and its subsidiary, Novopelle Tyler,
Inc. (&#8220;Novopelle Tyler&#8221;) in the 241<sup>st</sup> Judicial District Court of Smith County, Texas seeking to recover damages
in the amount of $<span id="xdx_90D_eus-gaap--LossContingencyDamagesSoughtValue_pp0p0_c20210801__20210811__dei--LegalEntityAxis__custom--AsherParkLLCMember_zyHtkBxjtPPg" title="Damages sought value"><ix:nonFraction name="us-gaap:LossContingencyDamagesSoughtValue" contextRef="From2021-08-012021-08-11_custom_AsherParkLLCMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">66,651</ix:nonFraction></span> against that commercial lease and commercial lease guaranty agreement that was signed between the parties on
or around January 8, 2020 to occupy retail premises located at 1058 Asher Way, Suite 100, in Tyler, Texas. As this commercial lease was
executed prior to the COVID-19 pandemic, and due to the uncertainty of the effects on retail establishments during the pandemic, Novopelle
Tyler never officially took possession of the retail premise. On September 23, 2021, the Company and Novopelle Tyler filed an Original
Answer and Affirmative Defense denying the allegations made by Asher Park.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
January 26, 2022, Novopelle Tyler and the Company entered into a Settlement Agreement &amp; Mutual Release with Asher Park whereby Novopelle
Tyler and the Company agreed to pay Asher Park a total of $<span id="xdx_903_eus-gaap--LitigationSettlementExpense_c20220124__20220126__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--TypeOfArrangementAxis__custom--SettlementAgreementMember_z03jKOVVgWD4" title="Litigation settlement expense"><ix:nonFraction name="us-gaap:LitigationSettlementExpense" contextRef="From2022-01-242022-01-26_us-gaap_SubsequentEventMember_custom_SettlementAgreementMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">35,000</ix:nonFraction>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">in full and final settlement of all of the Asher
Park&#8217;s claims. Accordingly, Asher Park, in consideration for the execution of the Settlement Agreement agreed to dismiss the lawsuit
against both Novopelle Tyler and the Company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 153; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: left"><a href="#fin" title="Table of Contents" style="font-style: italic">Table of Contents</a>&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Stanley Tate d/b/a Triangle Cabinets vs. Capitol
City Solutions USA, Inc.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On September 10, 2021, Stanley Tate d/b/a Triangle
Cabinets (&#8220;Tate&#8221;), a materials supplier and subcontractor that was hired by the Company&#8217;s subsidiary, Capitol City Solutions
USA, Inc. (CCS), filed a petition against the Company, CCS, and CCS&#8217;s construction client, PC Gateway, LLC (&#8220;PC Gateway&#8221;)
in the 136<sup>th</sup> Judicial District Court of Jefferson County, Texas seeking payment in the amount of $<span id="xdx_90A_eus-gaap--LossContingencyDamagesSoughtValue_pp0p0_c20210901__20210910__dei--LegalEntityAxis__custom--TateMember_zkmz4A8cgvzj" title="Damages sought value"><ix:nonFraction name="us-gaap:LossContingencyDamagesSoughtValue" contextRef="From2021-09-012021-09-10_custom_TateMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">77,681</ix:nonFraction></span> for services Tate
claimed to provide CCS and PC Gateway. The Company and CCS were not officially served until on or around October 21, 2021. On October
25, 2021, the Company and CCS filed an Original Answer denying the allegations made by Tate as Tate had failed to provide the services
in which they were hired to perform and demanding strict proof by a preponderance of credible evidence.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On December 29, 2021, Tate dismissed all claims against
both the Company and CCS.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Capitol City Solutions USA, Inc. vs. Peak Living,
LLC and PC Gateway, LLC</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On November 1, 2021, the Company&#8217;s subsidiary,
Capitol City Solutions USA, Inc. (CCS), filed a petition against PC Gateway and Peak Living, LLC (&#8220;Peak Living&#8221;) in the 58<sup>th
</sup>Judicial District Court of Jefferson County Texas demanding the payment of the final invoice as delivered to Peak Living in the
amount of $<span id="xdx_908_eus-gaap--LossContingencyDamagesSoughtValue_pp0p0_c20211001__20211101__dei--LegalEntityAxis__custom--CapitolCitySolutionsUSAIncMember_zEdlbVnK5oG"><ix:nonFraction name="us-gaap:LossContingencyDamagesSoughtValue" contextRef="From2021-10-012021-11-01_custom_CapitolCitySolutionsUSAIncMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">2,069,908</ix:nonFraction>
</span>representing the balance as owed to CCS for substantial supplemental charges (including but not limited to dehumidifiers, various
material cost and labor increases, code compliance costs, and additional profit and overhead). Throughout the term of a project completed
by CCS for Peak Living, Peak Living instructed CCS to perform additional work beyond the original scope of the contracted agreement and
fully understood that CCS expected to be compensated at the fair market value for the additional labor and materials. In addition to
seeking actual and statutory damages, CCS is seeking to recover attorney&#8217;s fees, prejudgment and post judgement interest, costs
of court and has further placed a constitutional lien on the PC Gateway property, known as Gateway Village, located at 2825 12th Street,
Beaumont, Texas, 77705 and which is the subject of the lawsuit. CCS is currently reviewing and evaluating all of the discovery
items received from Peak in connection with the lawsuit.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&#160;</b></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2021-01-01to2021-12-31" escape="true" name="us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock"><p id="xdx_80D_eus-gaap--DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock_z2bxGIPTHJx8" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><span id="Naa_005"></span>Note 17 &#8211; <span id="xdx_823_ztDQJC2jnGs6">Discontinued Operations</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">During 2020 and 2021, the Company decided to discontinue
the operation of its VISSIA McKinney, VISSIA Waterway, Legend Nutrition and Capitol City Solutions USA, Inc. VISSIA McKinney, VISSIA Waterway,
Legend Nutrition and Capitol City Solutions have been presented as discontinued operations in the accompanying consolidated financial
statements. The operating results for VISSIA McKinney, VISSIA Waterway, Legend Nutrition and Capitol City Solutions have been presented
in the accompanying consolidated statement of operations for the years ended December 31, 2021 and December 31, 2020 as discontinued operations
and are summarized below:</p>

<ix:nonNumeric contextRef="From2021-01-01to2021-12-31" escape="true" name="us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock"><p id="xdx_89F_eus-gaap--ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock_zQiJMxx9dBb8" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span id="xdx_8BB_zRzl0iB9Lj75" style="font: 10pt Times New Roman, Times, Serif; display: none">Schedule
of Discontinued Operations</span>&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto">
  <tr style="display: none; vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" id="xdx_49D_20210101__20211231_zBRHGwIQaBOh" style="border-bottom: Black 1.5pt solid; text-align: center">2021</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" id="xdx_495_20200101__20201231_zGzGmuTrbzoi" style="border-bottom: Black 1.5pt solid; text-align: center">2020</td><td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center">The Years Ended <br />
December 31,</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2021</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2020</td><td>&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--DisposalGroupIncludingDiscontinuedOperationRevenue_maDGIDOzLpN_ztxO1tLjQ8le" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 68%">Revenue</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right"><ix:nonFraction name="us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue" contextRef="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,530</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right"><ix:nonFraction name="us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue" contextRef="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,107,106</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold_msDGIDOzLpN_zpNs2Uax4mxd" style="vertical-align: bottom; background-color: White">
    <td>Cost of revenue</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl1739">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold" contextRef="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,058,373</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--DisposalGroupIncludingDiscontinuedOperationGrossProfitLoss_iT_pp0p0_mtDGIDOzLpN_maDGIDOz7Yi_zAdtPLPSOWo6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Gross profit</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DisposalGroupIncludingDiscontinuedOperationGrossProfitLoss" contextRef="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">2,530</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DisposalGroupIncludingDiscontinuedOperationGrossProfitLoss" contextRef="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,048,813</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--DisposalGroupIncludingDiscontinuedOperationOperatingExpense_msDGIDOz7Yi_zUllHCcDmM05" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Operating expenses</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingExpense" contextRef="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">57,659</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingExpense" contextRef="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,205,993</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss_iT_pp0p0_mtDGIDOz7Yi_maILFDOziuP_z0jryJvLqDm8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Loss from operations</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss" contextRef="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">55,130</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss" contextRef="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">157,180</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40D_ecustom--DisposalGroupIncludingDiscontinuedOperationOtherIncomeExpense_pp0p0_msILFDOziuP_zZI5GELhsyo2" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Other income (expenses)</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="AMIH:DisposalGroupIncludingDiscontinuedOperationOtherIncomeExpense" contextRef="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">299,716</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="AMIH:DisposalGroupIncludingDiscontinuedOperationOtherIncomeExpense" contextRef="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">722,057</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40B_eus-gaap--IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_iT_pp0p0_mtILFDOziuP_ziSlRnOLhV18" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Net loss</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" contextRef="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">244,586</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" contextRef="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">879,237</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A6_zJxWei4TK7Zd" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2021-01-01to2021-12-31" escape="true" name="us-gaap:SubsequentEventsTextBlock"><p id="xdx_80A_eus-gaap--SubsequentEventsTextBlock_z9rwkaGwvJh3" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Note 18 &#8211; <span id="xdx_822_zvnpImXCf4Z4">Subsequent Events</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">On January 5, 2022, the Company
issued <span id="xdx_907_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20220104__20220105__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__dei--LegalEntityAxis__custom--FirstFireGlobalMember_zcouyvetxQCe" title="Shares issued"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2022-01-042022-01-05_us-gaap_SubsequentEventMember_custom_FirstFireGlobalMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,200,000</ix:nonFraction></span> shares of common stock to a note holder in exchange for $<span id="xdx_90D_eus-gaap--DebtInstrumentFaceAmount_iI_pid_c20220105__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__dei--LegalEntityAxis__custom--FirstFireGlobalMember_zwPm9J96AvS4" title="Debt instrument face amount"><ix:nonFraction name="us-gaap:DebtInstrumentFaceAmount" contextRef="AsOf2022-01-05_us-gaap_SubsequentEventMember_custom_FirstFireGlobalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">50,688</ix:nonFraction></span> of principal and accrued interest owed under the terms
and conditions of the <span id="xdx_903_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20220105__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__dei--LegalEntityAxis__custom--FirstFireGlobalMember_zKvxWCXiEUUe" title="Debt interest rate"><ix:nonFraction name="us-gaap:DebtInstrumentInterestRateStatedPercentage" contextRef="AsOf2022-01-05_us-gaap_SubsequentEventMember_custom_FirstFireGlobalMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">6</ix:nonFraction>%</span> convertible promissory note as issued to FirstFire Global, dated June 24, 2021.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On January 6, 2022, the Company issued <span id="xdx_909_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20220104__20220106__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__dei--LegalEntityAxis__custom--QuickCapitalLlcMember_zvNqlnZXoZb" title="Shares issued"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2022-01-042022-01-06_us-gaap_SubsequentEventMember_custom_QuickCapitalLlcMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">710,227</ix:nonFraction></span> common
shares to a note holder in exchange for $<span id="xdx_90D_eus-gaap--DebtInstrumentFaceAmount_iI_pid_c20220106__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__dei--LegalEntityAxis__custom--QuickCapitalLlcMember_zNbCNCr7u8ql" title="Debt instrument face amount"><ix:nonFraction name="us-gaap:DebtInstrumentFaceAmount" contextRef="AsOf2022-01-06_us-gaap_SubsequentEventMember_custom_QuickCapitalLlcMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">30,000</ix:nonFraction></span> of principal owed under the terms and conditions of that <span id="xdx_909_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20220106__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__dei--LegalEntityAxis__custom--QuickCapitalLlcMember_zRgjDxpfnMra"><ix:nonFraction name="us-gaap:DebtInstrumentInterestRateStatedPercentage" contextRef="AsOf2022-01-06_us-gaap_SubsequentEventMember_custom_QuickCapitalLlcMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">6</ix:nonFraction></span>% convertible promissory note
as issued to Quick Capital, LLC, dated June 24, 2021.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On January 12, 2022, the Company issued an award of
<span id="xdx_90B_eus-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_c20220111__20220112__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--TypeOfArrangementAxis__custom--NewEmploymentAgreementMember_zhfk4v6UrfDh" title="Restricted shares"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" contextRef="From2022-01-112022-01-12_us-gaap_SubsequentEventMember_custom_NewEmploymentAgreementMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">5,000,000</ix:nonFraction></span> restricted shares of the Company&#8217;s common stock as a signing bonus in consideration of Mr. Cohen entering into the New
Employment Agreement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">On January 27, 2022, the
Company issued <span id="xdx_90C_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_c20220124__20220127__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__srt--TitleOfIndividualAxis__custom--ConsultingServicesMember_zgwC9yUyGvw" title="Shares issued for services"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesIssuedForServices" contextRef="From2022-01-242022-01-27_us-gaap_SubsequentEventMember_custom_ConsultingServicesMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,260,000</ix:nonFraction></span> shares of the Company&#8217;s common stock in consideration for consulting services. The shares were valued at
$<span id="xdx_903_eus-gaap--SharesIssuedPricePerShare_iI_c20220127__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__srt--TitleOfIndividualAxis__custom--ConsultingServicesMember_z1GsyPqcm4ff" title="Shares issued price per share"><ix:nonFraction name="us-gaap:SharesIssuedPricePerShare" contextRef="AsOf2022-01-27_us-gaap_SubsequentEventMember_custom_ConsultingServicesMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.0625</ix:nonFraction></span> per share, or $<span id="xdx_902_eus-gaap--StockIssuedDuringPeriodValueIssuedForServices_c20220124__20220127__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__srt--TitleOfIndividualAxis__custom--ConsultingServicesMember_zgVrXsO1NuFc" title="Value issued for services"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" contextRef="From2022-01-242022-01-27_us-gaap_SubsequentEventMember_custom_ConsultingServicesMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">78,687</ix:nonFraction></span> based on the market price on the date of issuance.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On February 2, 2022, the Company issued <span id="xdx_905_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20220130__20220202__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__dei--LegalEntityAxis__custom--LoneCapitalMember_z8v6LZ3Rbnk2" title="Debt conversion, shares issued"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2022-01-302022-02-02_us-gaap_SubsequentEventMember_custom_LoneCapitalMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">3,182,479</ix:nonFraction></span>
shares of common stock to a note holder in exchange for $<span id="xdx_90F_eus-gaap--DebtInstrumentFaceAmount_iI_c20220202__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__dei--LegalEntityAxis__custom--LoneCapitalMember_zygym2UZ33k" title="Debt instrument face amount"><ix:nonFraction name="us-gaap:DebtInstrumentFaceAmount" contextRef="AsOf2022-02-02_us-gaap_SubsequentEventMember_custom_LoneCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">124,117</ix:nonFraction></span> of principal and accrued interest owed under the terms and conditions
of that <span id="xdx_90B_eus-gaap--DebtInstrumentInterestRateDuringPeriod_pid_c20220130__20220202__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__dei--LegalEntityAxis__custom--LoneCapitalMember_zHt4CNsTQbyb" title="Debt interest rate"><ix:nonFraction name="us-gaap:DebtInstrumentInterestRateDuringPeriod" contextRef="From2022-01-302022-02-02_us-gaap_SubsequentEventMember_custom_LoneCapitalMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">6</ix:nonFraction>%</span> convertible promissory note as issued to L1 Capital, dated March 30, 2021.</p>

</ix:nonNumeric><p id="xdx_810_zxSBh6LxDBWf" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>


<!-- Field: Page; Sequence: 154; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: left"><a href="#fin" title="Table of Contents" style="font-style: italic">Table of Contents</a>&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><img src="forms-1_001.jpg" alt="" /></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>42,666,665
SHARES OF COMMON STOCK</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>PROSPECTUS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>______________,
2022</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Neither
we nor the selling stockholders have authorized any dealer, salesperson or other person to give any information or to make any representations
not contained in this prospectus or any prospectus supplement. You must not rely on any unauthorized information. This prospectus is
not an offer to sell these securities in any jurisdiction where an offer or sale is not permitted. The information in this prospectus
is current as of the date of this prospectus. You should not assume that this prospectus is accurate as of any other date.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 155; Options: NewSection; Value: 126 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->126<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: left"><a href="#fin" title="Table of Contents" style="font-style: italic">Table of Contents</a>&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="S_002"></span>PART
II</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>INFORMATION
NOT REQUIRED IN PROSPECTUS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="S_003"></span>ITEM
13. OTHER EXPENSES OF ISSUANCE AND DISTRIBUTION</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table sets forth an estimate of the registrant&#8217;s expenses, other than any sales commissions or discounts, in connection
with the issuance and distribution of the securities being registered hereby. All amounts are estimates except the SEC registration fee.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 80%; text-align: left">Securities and Exchange Commission registration fee</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">[&#160;&#160;]</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Accounting fees and expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,000.00</td><td style="text-align: left">*</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Legal fees and expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">[&#160;&#160;]</td><td style="text-align: left">*</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt">Miscellaneous</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">[&#160;&#160;]</td><td style="padding-bottom: 1.5pt; text-align: left">*</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold">Total</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">[&#160;&#160;]</td><td style="text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicates
    expenses that have been estimated for filing purposes only.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="S_004"></span>ITEM
14. INDEMNIFICATION OF DIRECTORS AND OFFICERS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
authorized by <span style="text-decoration: underline">Section 78.751</span> of the Nevada Revised Statutes, we may indemnify our officers and directors against expenses incurred
by such persons in connection with any threatened, pending or completed action, suit or proceedings, whether civil, criminal, administrative
or investigative, involving such persons in their capacities as officers and directors, so long as such persons acted in good faith and
in a manner which they reasonably believed to be in our best interests. If the legal proceeding, however, is by or in our right, the
director or officer may not be indemnified in respect of any claim, issue or matter as to which he is adjudged to be liable for negligence
or misconduct in the performance of his duty to us unless a court determines otherwise.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
Nevada law, corporations may also purchase and maintain insurance or make other financial arrangements on behalf of any person who is
or was a director or officer (or is serving at our request as a director or officer of another corporation) for any liability asserted
against such person and any expenses incurred by him in his capacity as a director or officer. These financial arrangements may include
trust funds, self-insurance programs, guarantees and insurance policies.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Additionally,
our Bylaws, as amended and restated (&#8220;<span style="text-decoration: underline">Bylaws</span>&#8221;), state that we shall indemnify every (i) present or former director,
advisory director or officer of us, (ii) any person who while serving in any of the capacities referred to in clause (i) served at our
request as a director, officer, partner, venturer, proprietor, trustee, employee, agent or similar functionary of another foreign or
domestic corporation, partnership, joint venture, trust, employee benefit plan or other enterprise, and (iii) any person nominated or
designated by (or pursuant to authority granted by) the Board of Directors or any committee thereof to serve in any of the capacities
referred to in clauses (i) or (ii) (each an &#8220;<span style="text-decoration: underline">Indemnitee</span>&#8221;).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 156; Options: NewSection; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: center">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: left"><a href="#toc" title="Table of Contents" style="font-style: italic">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
Bylaws provide that we shall indemnify an Indemnitee against all judgments, penalties (including excise and similar taxes), fines, amounts
paid in settlement and reasonable expenses actually incurred by the Indemnitee in connection with any proceeding in which he was, is
or is threatened to be named as a defendant or respondent, or in which he was or is a witness without being named a defendant or respondent,
by reason, in whole or in part, of his serving or having served, or having been nominated or designated to serve, if it is determined
that the Indemnitee (a) conducted himself in good faith, (b) reasonably believed, in the case of conduct in his official capacity, that
his conduct was in our best interests and, in all other cases, that his conduct was at least not opposed to our best interests, and (c)
in the case of any criminal proceeding, had no reasonable cause to believe that his conduct was unlawful; provided, however, that in
the event that an Indemnitee is found liable to us or is found liable on the basis that personal benefit was improperly received by the
Indemnitee, the indemnification (i) is limited to reasonable expenses actually incurred by the Indemnitee in connection with the proceeding
and (ii) shall not be made in respect of any proceeding in which the Indemnitee shall have been found liable for willful or intentional
misconduct in the performance of his duty to us.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Except
as provided above, the Bylaws provide that no indemnification shall be made in respect to any proceeding in which such Indemnitee has
been (a) found liable on the basis that personal benefit was improperly received by him, whether or not the benefit resulted from an
action taken in the Indemnitee&#8217;s official capacity, or (b) found liable to us. The termination of any proceeding by judgment, order,
settlement or conviction, or on a plea of nolo contendere or its equivalent, is not of itself determinative that the Indemnitee did not
meet the requirements set forth in clauses (a) or (b) above. An Indemnitee shall be deemed to have been found liable in respect of any
claim, issue or matter only after the Indemnitee shall have been so adjudged by a court of competent jurisdiction after exhaustion of
all appeals therefrom. Reasonable expenses shall include, without limitation, all court costs and all fees and disbursements of attorneys&#8217;
fees for the Indemnitee. The indemnification provided shall be applicable whether or not negligence or gross negligence of the Indemnitee
is alleged or proven.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Neither
our Bylaws nor our Articles of Incorporation include any specific indemnification provisions for our officers or directors against liability
under the Securities Act. Additionally, insofar as indemnification for liabilities arising under the Securities Act may be permitted
to directors, officers and controlling persons of the Company pursuant to the foregoing provisions, or otherwise, the Company has been
advised that in the opinion of the Securities and Exchange Commission such indemnification is against public policy as expressed in the
Securities Act and is, therefore, unenforceable.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 157; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: center">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: left"><a href="#toc" title="Table of Contents" style="font-style: italic">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="S_005"></span>ITEM
15. RECENT SALES OF UNREGISTERED SECURITIES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
April 12, 2019, the Company issued 18,000,000 shares of the Company common stock to the members of Novopelle Diamond, LLC (&#8220;<span style="text-decoration: underline">Novopelle</span>&#8221;),
a Texas limited company, to acquire 100% of the membership interests of Novopelle. The three members of Novopelle Diamond who received
shares pursuant to the Share Exchange Agreement were (1) Jacob D. Cohen; (2) Esteban Alexander; and (3) Luis Alan Hernandez, who each
received six million shares pursuant to the Share Exchange.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
May 3, 2019, the Company issued 100,000 shares of the Company&#8217;s common stock to a non-related third-party investor in exchange
for $10,000 in cash.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
June 21, 2019, the Company issued a promissory note with a principal amount of $40,000 to a related party (the father of the Company&#8217;s
CEO, Jacob D. Cohen) in exchange for $40,000 in cash. The promissory note is unsecured, has a maturity date of June 21, 2020 and accrues
interest at the rate of 8% per annum until paid in full by the Company. Furthermore, the Company issued 50,000 shares of the Company&#8217;s
restricted common stock to the related party investor as further consideration to enter into the loan with the Company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
June 24, 2019, the issued 250,000 shares of the Company&#8217;s common stock as part consideration of an exclusive licensing agreement.
The shares were valued at $0.10 per share or $25,000 based on recent sales of common stock to the third party.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
June 27, 2019, the Company executed an exclusive license agreement with Novo MedSpa Addison Corp (&#8220;<span style="text-decoration: underline">Novo MedSpa</span>&#8221;) providing
the Company with the exclusive rights to the Novopelle brand and to establish new Novopelle branded MedSpa locations on a worldwide basis
(the &#8220;<span style="text-decoration: underline">Exclusive License</span>&#8221;). In consideration for the Exclusive License, the Company paid Novo MedSpa a one-time cash
payment of $40,000 and issued to Novo MedSpa 250,000 shares of the Company&#8217;s restricted common stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
July 8, 2019, the Company issued a convertible promissory note with a principal amount of $40,000 to a non-related third party in exchange
for $40,000 in cash. The promissory note is unsecured, has a maturity date of July 8, 2020 and accrues interest at the rate of 8% per
annum until paid in full by the Company. In the event that the Company filed, and had qualified by the SEC, an offering Statement under
Regulation A (&#8220;<span style="text-decoration: underline">Offering Statement</span>&#8221;) of the Securities Act in order to sell shares of its common stock, the holder
of the note had the right to convert all or any portion of the principal amount and interest due on the note into shares of common stock
through the Offering Statement during the term of the Offering Statement, which Offering Statement has been qualified.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
August 23, 2019, the Company issued 100,000 shares of the Company&#8217;s common stock in consideration for consulting services. The
shares were valued at $1.50 per share or $150,000 based on the market price on the date of issuance.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
September 9, 2019, the Company issued 100,000 shares of common stock as part consideration of a loan agreement. The shares were valued
at $1.00 per share or $100,000 based on the market price on the date of issuance.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 158; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: center">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: left"><a href="#toc" title="Table of Contents" style="font-style: italic">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
October 1, 2019, the Company entered into an Employment Agreement with Jesse L. Dickens, Jr. to serve as the Chief Executive Officer
of the Company&#8217;s newly formed wholly owned subsidiary, Capitol City Solutions USA, Inc. (&#8220;<span style="text-decoration: underline">CCS</span>&#8221;). Pursuant to
the Employment Agreement, Mr. Dickens will receive an annual base salary of $120,000 and shall receive an equity grant in the amount
of 1,000,000 shares of the Company&#8217;s common stock (the &#8220;<span style="text-decoration: underline">Equity Shares</span>&#8221;) pursuant to a vesting period of one-year,
of which: 500,000 shares on January 1, 2020, 250,000 shares on May 22, 2020, and 250,000 shares on July 1, 2020.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
October 11, 2019, the Company issued 10,000 shares of common stock as part consideration of a loan agreement. The shares were valued
at $1.16 per share or $11,600 based on the market price on the date of issuance.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
November 1, 2019, the Company issued 300,000 shares of the Company&#8217;s common stock to eligible persons under the Plan.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
November 11, 2019, the Company issued 30,000 shares of the Company&#8217;s common stock to eligible persons under the Plan.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
February 24, 2020, the Company entered into a Securities Purchase Agreement with Adar Alef, LLC, an accredited investor (&#8220;<span style="text-decoration: underline">Adar
Alef</span>&#8221;), pursuant to which the Company sold Adar Alef a convertible promissory note in the principal amount of $157,500, representing
a purchase price of $150,000 and an original issue discount of $7,500, in exchange for $150,000 in cash (less $7,500 of Adar Alef&#8217;s
legal fees as discussed below)(the &#8220;<span style="text-decoration: underline">Adar Alef Note</span>&#8221;). The Adar Alef Note accrues interest at a rate of 8% per annum
(24% upon the occurrence of an event of default) and has a maturity date of February 24, 2021. Adar Alef may in its option, convert the
outstanding principal and interest on the Adar Alef Note into shares of our common stock at a conversion price per share equal to 60%
of the lowest daily volume weighted average price (&#8220;<span style="text-decoration: underline">VWAP</span>&#8221;) of our common stock during the 10 days trading days prior
to, and including, the date of conversion. The 40% discount discussed above is automatically increased to 50% in the event we experience
a depository trust company &#8216;chill&#8217; on our common stock. Additionally, in the event that we are not &#8216;current&#8217;
in our filings with the Securities and Exchange Commission, six months after the date of the note, the conversion price decreases to
the lowest closing bid price of our common stock during the delinquency period, less the applicable percentage discount discussed above.
The conversion discount, look back period and other terms of the Adar Alef Note are adjustable on a ratchet basis if the Company offers
any more favorable terms to any other note holder after the date of the Adar Alef Note. At no time may the Adar Alef Note be converted
into shares of our common stock if such conversion would result in Adar Alef and its affiliates owning an aggregate of in excess of 4.99%
of the then outstanding shares of our common stock, which amount may be increased to 9.9% upon 60 days&#8217; prior written notice.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 159; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: center">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: left"><a href="#toc" title="Table of Contents" style="font-style: italic">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
January 13, 2020, the Company executed a Data Delivery and Ancillary Services Agreement with a third party, pursuant to which the Company
issued 357,142 shares of the Company&#8217;s restricted common stock to the third party in exchange of sector-specific consumer records
and data to be utilized for marketing purposes provided by the third party and the ancillary advisory services such as data cleaning,
data emailing, lead generation campaigns, social media management. The shares were valued at $0.56 per share or $200,000 based on the
market price at the grant date.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
January 17, 2020, the Company issued 62,500 shares of restricted common stock to an investor in exchange for $25,000 in cash and $25,000
of principal and interest due under that certain convertible promissory note between the Company and the investor dated August 26, 2019.
The Company received cash of $25,000 on November 26, 2019 which was recorded as common stock payable as of December 31, 2019. The shares
issued to the investor are part of the 10,000,000 shares qualified and registered in connection with the Company, Regulation A offering,
in which the Company offered for sale up to 10,000,000 shares of common stock at $0.50 per share (the &#8220;<span style="text-decoration: underline">Offering Statement</span>&#8221;).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
January 24, 2020, the Company issued 400,000 shares of the Company&#8217;s common stock to eligible persons under the Plan. The shares
were valued at $0.30 per share or $120,000.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
February 28, 2020, the Company issued 160,000 common shares to an investor in exchange for $46,500 in cash, net of offering costs, and
$30,000 of principal and interest due under that certain convertible promissory note between the Company and the investor dated August
26, 2019. The shares issued to the investor are part of the 10,000,000 Shares offered and registered by the Company under the Offering
Statement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
March 11, 2020, the Company issued 100,000 shares of the Company&#8217;s common stock to eligible persons under the Plan. The shares
were valued at $0.40 per share or $40,000.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
April 1, 2020, the Company issued 40,000 common shares to an investor in exchange for $20,000 of principal and interest due under that
certain convertible promissory note between the Company and the investor dated October 10, 2019.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
April 2, 2020, the Company issued 40,000 shares of common stock to an investor in exchange for $20,000 of principal and interest due
under that certain convertible promissory note between the Company and the investor dated October 10, 2019. The shares issued to the
investor are part of the 10,000,000 Shares offered and registered by the Company under the Offering Statement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
April 20, 2020, the Company entered into a Securities Purchase Agreement with Geneva Roth Remark Holdings, Inc. (&#8220;<span style="text-decoration: underline">Geneva Roth</span>&#8221;),
an accredited investor, pursuant to which the Company sold Geneva Roth a convertible promissory note in the principal amount of $88,000
(the &#8220;<span style="text-decoration: underline">Geneva Roth Note</span>&#8221;). The Geneva Roth Note accrues interest at a rate of 8% per annum (22% upon the occurrence
of an event of default) and has a maturity date of April 20, 2021. Geneva Roth may in its option, at any time beginning 180 days after
the date of the note, convert the outstanding principal and interest on the Geneva Roth Note into shares of our common stock at a conversion
price per share equal to 61% of the lowest daily volume weighted average price (&#8220;<span style="text-decoration: underline">VWAP</span>&#8221;) of our common stock during
the 10 days trading days prior to the date of conversion. We agreed to reserve a number of shares of our common stock equal to 6 times
the number of shares of common stock which may be issuable upon conversion of the Geneva Roth Note at all times. At no time may the Geneva
Roth Note be converted into shares of our common stock if such conversion would result in Geneva Roth and its affiliates owning an aggregate
of in excess of 4.99% of the then outstanding shares of our common stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"></p>

<!-- Field: Page; Sequence: 160; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: center">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: left"><a href="#toc" title="Table of Contents" style="font-style: italic">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
April 30, 2020, we entered into a Securities Purchase Agreement with FirstFire Global Opportunities Fund, LLC, an accredited investor
(&#8220;<span style="text-decoration: underline">FirstFire</span>&#8221;), pursuant to which the Company sold FirstFire a convertible promissory note in the principal amount
of $105,000, representing a purchase price of $100,000 and an original issue discount of $5,000 (the &#8220;<span style="text-decoration: underline">FirstFire Note</span>&#8221;).
The FirstFire Note accrues interest at a rate of 8% per annum (15% upon the occurrence of an event of default) and has a maturity date
of April 30, 2021. FirstFire may in its option, at any time, convert the outstanding principal and interest on the FirstFire Note into
shares of our common stock at a conversion price per share equal to $0.50 per share for the first 180 days that the FirstFire Note is
outstanding and the lower of (a) $0.50 per share; and (b) 60% of the lowest VWAP of our common stock during the 10 days trading days
prior to the date of conversion (the &#8220;<span style="text-decoration: underline">Variable Conversion Rate</span>&#8221;), thereafter, subject to adjustment in the case of
certain fundamental transactions. In the event we have a DTC &#8220;<span style="text-decoration: underline">Chill</span>&#8221; on our shares, an additional discount of 10%
will apply to the Variable Conversion Rate while that &#8220;<span style="text-decoration: underline">Chill</span>&#8221; is in effect. The FirstFire Note includes anti-dilution
protection such that if we, at any time while the note is outstanding, issue any shares or are deemed to have issued any shares at a
price per share less than the applicable conversion price of such FirstFire Note, then FirstFire has the option to reduce such conversion
price to such lower price, subject to certain exceptions. The conversion discount of the Variable Conversion Rate of the FirstFire Note
is adjustable upward by 15% (cumulative for the occurrence of each such event) upon the occurrence of certain events described in the
FirstFire Note including in the event (a) our common stock cannot be delivered via DWAC; (b) we cease to report with the Securities and
Exchange Commission; (c) we fail to maintain DTC eligibility; (d) the conversion price is below $0.01 per share; (e) we do not have sufficient
authorized shares to allow for any conversion; and (f) certain other events described in the FirstFire Note occur. In addition, upon
the occurrence of any events described in the immediately preceding sentence (and after each such event), FirstFire can increase the
amount of the FirstFire Note by $10,000. At no time may the FirstFire Note be converted into shares of our common stock if such conversion
would result in FirstFire and its affiliates owning an aggregate of in excess of 4.99% of the then outstanding shares of our common stock,
which amount may be increased to 9.9% upon 60 days&#8217; prior written notice.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
May 15, 2020, the Company entered into a Securities Purchase Agreement (the &#8220;<span style="text-decoration: underline">SPA</span>&#8221;) with Global Career Networks Inc,
a Delaware corporation (the &#8220;<span style="text-decoration: underline">Seller</span>&#8221;), the sole owner of Life Guru, Inc., a Delaware corporation (&#8220;<span style="text-decoration: underline">Life Guru</span>&#8221;).
Pursuant to the SPA, the Company acquired a 51% interest in Life Guru from the Seller. Life Guru owns the website www.LifeGuru.me &#8211;
a website dedicated to providing an online platform to connect consumers to a variety of mentors, professionals, life coaches and career
coaches, which was under development. As consideration for the purchase of the 51% ownership interest in Life Guru, the Company issued
the Seller 500,000 shares of its newly designated Series B Convertible Preferred Stock, which had an agreed upon value of $500,000 ($1.00
per share), and agreed to issue the Seller up to an additional 1,500,000 shares of Series B Convertible Preferred Stock (with an agreed
upon value of $1,500,000) upon the following milestones, provided that such milestones are met prior to the earlier of (i) May 15, 2021;
and (ii) thirty (30) days after the Company has provided the Seller written notice of a breach by the Seller of any provision of the
SPA, which breach has not been reasonably cured within a thirty (30) day period:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
500,000 Series B Convertible Preferred Stock shares upon completion of the fully operational LifeGuru.me website;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 161; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: center">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: left"><a href="#toc" title="Table of Contents" style="font-style: italic">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
500,000 Series B Convertible Preferred Stock shares upon such time as 300 coaches have signed up at LifeGuru.me; and</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)
500,000 Series B Convertible Preferred Stock shares upon such time as 1,000 coaches have signed up at LifeGuru.me.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Each
share of Series B Preferred Stock may be converted, at the option of the holder thereof, into that number of shares of common stock of
the Company as equals $1.00 divided by 90% of the average of the volume weighted average prices of the Company&#8217;s common, for the
five trading days immediately preceding the date the notice of conversion is received, with any remainder rounded to the hundredths place.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notwithstanding
the above, at no time may the Series B Preferred Stock be converted into shares of our common stock by any holder, if such conversion
would result in such holder thereof and its affiliates owning an aggregate of in excess of 4.999% of the then outstanding shares of our
common stock, which amount may be increased to 9.999% on a per holder basis, upon 61 days&#8217; prior written notice.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
May 20, 2020, the Company issued one share of its newly designated shares of Series A Preferred Stock, to each of the three members of
its then board of directors, (1) Jacob D. Cohen, (2) Esteban Alexander and (3) Luis Alan Hernandez, in consideration for services rendered
to the Company as members of the board of directors. Such shares of Series A Preferred Stock vote in aggregate sixty percent (60%) of
the total vote on all shareholder matters, voting separately as a class. Notwithstanding such voting rights, no change in control of
the Company was deemed to have occurred in connection with the issuance since Messrs. Cohen, Alexander and Hernandez, owned in aggregate
68% of the Company&#8217;s outstanding common stock prior to such issuance, and therefore controlled the Company prior to such issuance.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
May 19, 2020, the Company entered into a Securities Purchase Agreement with Geneva Roth, pursuant to which the Company sold Geneva Roth
a convertible promissory note in the principal amount of $53,000 (the &#8220;<span style="text-decoration: underline">Geneva Roth Note #2</span>&#8221;). The Geneva Roth Note
#2 accrues interest at a rate of 8% per annum (22% upon the occurrence of an event of default) and has a maturity date of May 19, 2021.
Geneva Roth may in its option, at any time beginning 180 days after the date of the note, convert the outstanding principal and interest
on the Geneva Roth Note #2 into shares of our common stock at a conversion price per share equal to 61% of the lowest daily volume weighted
average price of our common stock during the 10 days trading days prior to the date of conversion. At no time may the Geneva Roth Note
#2 be converted into shares of our common stock if such conversion would result in Geneva Roth and its affiliates owning an aggregate
of in excess of 4.99% of the then outstanding shares of our common stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"></p>

<!-- Field: Page; Sequence: 162; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: center">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: left"><a href="#toc" title="Table of Contents" style="font-style: italic">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
May 22, 2020, (a) in consideration for Mr. Jacob D. Cohen&#8217;s past services rendered as President and Chief Executive Officer of
the Company, and in further consideration of the liability he has incurred in his capacity as President and Chief Executive Officer of
the Company, and (b) in consideration for Mr. Esteban Alexander&#8217;s past services rendered as Chief Operating Officer of the Company,
and in further consideration of the liability he has incurred in his capacity as Chief Operating Officer of the Company, the Company
issued Mr. Cohen and Mr. Alexander each a one-time bonus of 3,000,000 shares of the Company&#8217;s restricted common stock (6,000,000
in total), which shares vested immediately.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
June 2, 2020, the Company issued 2,083,333 shares of the Company&#8217;s common stock to Global Career Networks Inc, a Delaware corporation
(the &#8220;<span style="text-decoration: underline">GCN</span>&#8221;) in connection with the conversion of 500,000 shares of Series B Convertible Preferred stock into common
stock. The shares were valued at $0.24 per share or $500,000.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
June 4, 2020, the Company issued 50,000 common shares to an investor in exchange for $6,600 of principal and interest due under that
certain convertible promissory note between the Company and the investor dated October 28, 2019.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
June 8, 2020, the Company issued 125,000 shares of the Company&#8217;s common stock to eligible persons under the Plan. The shares were
valued at $0.27 per share or $33,750.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
July 27, 2020, the Company issued 1,030,808 restricted common shares to an investor in exchange for $77,929 of principal and accrued
interest owed under the terms and conditions of that convertible note as issued to Fourth Man, LLC dated October 28, 2019. After this
conversion, the balance owed under the convertible note is $0.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
July 27, 2020, the Company issued 1,119,309 restricted common shares to an investor in exchange for $84,620 of principal and accrued
interest owed under the terms and conditions of that convertible note as issued to Armada Capital Partners, LLC dated October 28, 2019.
After this conversion, the balance owed under the convertible note is $0.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
July 27, 2020, the Company issued 1,119,309 restricted common shares to an investor in exchange for $84,620 of principal and accrued
interest owed under the terms and conditions of that convertible note as issued to BHP Capital NY, Inc. dated October 28, 2019. After
this conversion, the balance owed under the convertible note is $0.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 163; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: center">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: left"><a href="#toc" title="Table of Contents" style="font-style: italic">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
June 8, 2020, the Company issued 125,000 shares of the Company&#8217;s common stock to eligible persons under the 2019 Stock Option and
Incentive Plan (the &#8220;<span style="text-decoration: underline">Plan</span>&#8221;). The shares were valued at $0.27 per share or $33,750.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
August 5, 2020, we entered into a Securities Purchase Agreement with Geneva Roth Remark Holdings, Inc., an accredited investor, pursuant
to which the Company sold Geneva Roth a convertible promissory note in the principal amount of $53,000 (the &#8220;<span style="text-decoration: underline">Geneva Roth Note
#3</span>&#8221;). The Geneva Roth Note #3 accrues interest at a rate of 8% per annum (22% upon the occurrence of an event of default) and
has a maturity date of November 5, 2021. Geneva Roth may in its option, at any time beginning 180 days after the date of the note, convert
the outstanding principal and interest on the Geneva Roth Note #3 into shares of our common stock at a conversion price per share equal
to 61% of the lowest daily volume weighted average price of our common stock during the 10 days trading days prior to the date of conversion.
We agreed to reserve a number of shares of our common stock equal to the number of shares of common stock which may be issuable upon
conversion of the Geneva Roth Note #3 at all times. At no time may the Geneva Roth Note #3 be converted into shares of our common stock
if such conversion would result in Geneva Roth and its affiliates owning an aggregate of in excess of 4.99% of the then outstanding shares
of our common stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
August 11, 2020, we sold LGH Investments, LLC (&#8220;<span style="text-decoration: underline">LGH</span>&#8221;) a convertible promissory note in the principal amount of $105,000
(the &#8220;<span style="text-decoration: underline">LGH Note</span>&#8221;). The LGH Note included a $5,000 originally issuance discount. The LGH Note accrues interest at a
rate of 8% per annum (22% upon the occurrence of an event of default) and has a maturity date of May 11, 2021. LGH may in its option,
at any time convert the outstanding principal and interest on the LGH Note into shares of our common stock at a conversion price per
share equal to the lesser of (a) $0.50 per share; and (b) 60% of the lowest daily volume weighted average price of the Company&#8217;s
common stock on the ten trading days prior to the date of conversion. We agreed to reserve a number of shares of our common stock equal
to three times the number of shares of common stock which may be issuable upon conversion of the LGH Note at all times. At no time may
the LGH Note be converted into shares of our common stock if such conversion would result in LGH and its affiliates owning an aggregate
of in excess of 4.99% of the then outstanding shares of our common stock, provided that such percentage automatically increases to 9.99%
if our market capitalization falls below $2.5 million.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
August 21, 2020, the Company issued 330,689 common shares to an investor in exchange for $25,000 of principal and accrued interest owed
under the terms and conditions of that convertible note as issued to GHS Investments, LLC dated October 10, 2019.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
August 24, 2020, the Company issued 895,722 common shares to an investor in exchange for $109,278 of principal and accrued interest owed
under the terms and conditions of that promissory note as issued to Isaak Cohen (the father of our Chief Executive Officer and director,
Jacob D. Cohen), dated September 9, 2019. After this conversion, the balance owed under the promissory note is $0.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 164; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: center">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: left"><a href="#toc" title="Table of Contents" style="font-style: italic">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
August 26, 2020, the Company issued 242,407 common shares to an investor in exchange for $31,792 of principal and accrued interest owed
under the terms and conditions of that promissory note as issued to Bradley Stewart, dated May 17, 2019. After this conversion, the balance
owed under the promissory note is $0.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
August 28, 2020, the Company issued 895,722 common shares to settle a Note with an unrelated party. The shares were valued at $0.33 per
share based on the market price at the settlement date.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
September 8, 2020, the Company issued 330,689 common shares to an investor in exchange for $25,000 of principal and accrued interest
owed under the terms and conditions of that convertible note, dated October 15, 2019. After this conversion, the balance owed under the
convertible note is $33,888.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
September 14, 2020, the Company entered into a Securities Purchase Agreement with Geneva Roth, pursuant to which the Company sold Geneva
Roth a convertible promissory note in the principal amount of $53,000 (the &#8220;<span style="text-decoration: underline">Geneva Roth Note #4</span>&#8221;). The Geneva Roth
Note #4 accrues interest at a rate of 8% per annum (22% upon the occurrence of an event of default) and has a maturity date of December
14, 2021. Geneva Roth may in its option, at any time beginning 180 days after the date of the note, convert the outstanding principal
and interest on the Geneva Roth Note #4 into shares of our common stock at a conversion price per share equal to 61% of the average of
the two lowest daily volume weighted average prices of our common stock during the 10 days trading days prior to the date of conversion.
At no time may the Geneva Roth Note #4 be converted into shares of our common stock if such conversion would result in Geneva Roth and
its affiliates owning an aggregate of in excess of 4.99% of the then outstanding shares of our common stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
October 8, 2020, the Company issued 125,000 shares of the Company&#8217;s common stock to eligible persons under the Plan. The shares
were valued at $0.27 per share or $33,750.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
October 12, 2020, the Company issued 136,687 common shares to an investor in exchange for $12,818 of principal and accrued interest owed
under the terms and conditions of that convertible note as issued to Adar Alef, LLC, dated February 24, 2020.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 165; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: center">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: left"><a href="#toc" title="Table of Contents" style="font-style: italic">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
October 12, 2020, the Company entered into a Securities Purchase Agreement with Quick Capital LLC an accredited investor (&#8220;<span style="text-decoration: underline">Quick
Capital</span>&#8221;), pursuant to which the Company sold Quick Capital a convertible promissory note in the principal amount of $56,750
(the &#8220;<span style="text-decoration: underline">Quick Capital Note</span>&#8221;) in consideration for a $52,750 payment. The principal amount of the Quick Capital Note
includes an advancement of legal fees equal to Quick Capital of $2,750 and carries a lump-sum interest payment for the entire twelve
(12) months of the note, at eight percent (8%) per annum, equal to $4,000 which was capitalized upon the entry into the note. The Quick
Capital Note has a maturity date of October 12, 2021. Among other requirements, the Securities Purchase Agreement requires us to cause
the par value of our common stock to be reduced below $0.00001, if the closing bid price of our common stock shall ever fall below $0.0001
per share. Upon an event of default, the Quick Capital Note accrues interest at the lesser of 24% per annum and the highest rate provided
by law. Quick Capital may in its option, at any time after the date of the note, convert the outstanding principal and interest on the
Quick Capital Note into shares of our common stock at a conversion price per share equal to the lesser of a) $0.50 per share, b) 60%
(the &#8220;<span style="text-decoration: underline">Discount</span>&#8221;) of the lowest daily volume weighted average price per share of our common stock during the 10 days
trading days prior to the date of conversion; and c) 60% of the lowest daily VWAP of our common stock during the 10 days trading days
prior to the date of the Quick Capital Note. The conversion price is adjustable downward if within three business days of the date of
any conversion notice, the Company&#8217;s common stock has a closing bid price 5% or lower than the conversion rate set forth in the
notice of conversion. The Discount decreases by 10% in the event the Company&#8217;s common stock is not eligible to be delivered via
DWAC and decreases by an additional 15% if the Company&#8217;s common stock is &#8216;chilled&#8217; by the DTC system (while such &#8216;chill
is in place&#8217;). Separately, if the Company ceases to be a reporting company or the note cannot be converted into free trading shares
181 days after the date of the note, the Discount decreases by an additional 15%. Quick Capital can deduct $750 from each conversion
amount to cover its deposit fees. The conversion rate is also subject to a favored nations provision (subject to certain exceptions),
allowing Quick Capital to use any more favorable conversion terms of other parties converting securities of the Company. The conversion
rate is also further adjustable in the event of the occurrence of certain major transaction announcements. In the event the conversion
price falls below $0.01 per share at any time, the Discount is lowered to 40% and $15,000 is added to the principal amount of the note.
We are also required to pay certain penalties in the event we fail to timely deliver stock upon conversion of the Quick Capital Note.
At no time may the Quick Capital Note be converted into shares of our common stock if such conversion would result in Quick Capital and
its affiliates owning an aggregate of in excess of 4.99% of the then outstanding shares of our common stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
October 12, 2020, the Company issued 136,687 common shares to an investor in exchange for $12,818 of principal and accrued interest owed
under the terms and conditions of that convertible note as issued to Adar Alef, LLC, dated February 24, 2020.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
October 19, 2020, the Company issued 323,322 common shares to an investor in exchange for $18,682 of principal and accrued interest owed
under the terms and conditions of that convertible note as issued to Adar Alef, LLC, dated February 24, 2020.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
October 21, 2020, the Company issued 416,667 common shares to an investor in exchange for $30,000 of principal and accrued interest owed
under the terms and conditions of that convertible note as issued to GHS Investments, LLC, dated October 10, 2020.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
October 26, 2020, the Company issued 340,716 common shares to an investor in exchange for $20,000 of principal and accrued interest owed
under the terms and conditions of that convertible note as issued to Geneva Roth Remark Holdings, Inc., dated April 20, 2020.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 166; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: center">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: left"><a href="#toc" title="Table of Contents" style="font-style: italic">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
November 3, 2020, the Company issued 520,833 common shares to an investor in exchange for $26,000 of principal and accrued interest owed
under the terms and conditions of that convertible note as issued to Adar Alef, LLC, dated February 24, 2020.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
November 3, 2020, the Company issued 492,126 common shares to an investor in exchange for $20,000 of principal and accrued interest owed
under the terms and conditions of that convertible note as issued to Geneva Roth, dated April 20, 2020.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
November 9, 2020, the Company issued 688,976 common shares to an investor in exchange for $20,000 of principal and accrued interest owed
under the terms and conditions of that convertible note as issued to Geneva Roth, dated April 20, 2020.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
November 10, 2020, the Company issued 721,154 common shares to an investor in exchange for $36,000 of principal and accrued interest
owed under the terms and conditions of that convertible note as issued to Adar Alef, LLC, dated February 24, 2020.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
November 13, 2020, the Company issued 480,769 common shares to an investor in exchange for $24,000 of principal and accrued interest
owed under the terms and conditions of that convertible note as issued to Adar Alef, LLC, dated February 24, 2020.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
November 22, 2020, the Company issued 480,000 common shares to an investor in exchange for $25,000 of principal and accrued interest
owed under the terms and conditions of that certain convertible note as issued to FirstFire Global Opportunities Fund LLC, dated April
30, 2020.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
December 2, 2020, the Company entered into a Securities Purchase Agreement with Geneva Roth, pursuant to which the Company sold Geneva
Roth a convertible promissory note in the principal amount of $83,000 (the &#8220;<span style="text-decoration: underline">Geneva Roth Note #5</span>&#8221;). The Geneva Roth
Note #5 accrues interest at a rate of 8% per annum (22% upon the occurrence of an event of default) and has a maturity date of March
2, 2022. Geneva Roth may in its option, at any time beginning 180 days after the date of the note, convert the outstanding principal
and interest on the Geneva Roth Note #5 into shares of our common stock at a conversion price per share equal to 61% of the average of
the two lowest daily volume weighted average prices of our common stock during the 10 days trading days prior to the date of conversion.
At no time may the Geneva Roth Note #5 be converted into shares of our common stock if such conversion would result in Geneva Roth and
its affiliates owning an aggregate of in excess of 4.99% of the then outstanding shares of our common stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
December 2, 2020, the Company issued 716,527 common shares to an investor in exchange for $35,769 of principal and accrued interest owed
under the terms and conditions of that convertible note as issued to GHS Investments, LLC, dated October 10, 2020.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 167; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: center">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: left"><a href="#toc" title="Table of Contents" style="font-style: italic">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
December 2, 2020, the Company issued 889,054 common shares to an investor in exchange for $40,000 of principal and accrued interest owed
under the terms and conditions of that convertible note as issued to Adar Alef, LLC, dated February 24, 2020.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
December 2, 2020, the Company issued 622,000 common shares to an investor in exchange for $31,100 of principal and accrued interest owed
under the terms and conditions of that convertible note as issued to GreenTree Financial Group, Inc., dated August 26, 2019.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
December 2, 2020, the Company issued 1,031,000 common shares to an investor in exchange for $84,200 of principal and accrued interest
owed under the terms and conditions of that convertible note as issued to FirstFire Global Opportunities Fund LLC, dated April 30, 2020.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
December 12, 2020, the Company issued 2,501,378 common shares to an investor in exchange for $195,108 of principal and accrued interest
owed under the terms and conditions of that promissory note as issued to Daniel Dror, dated April 12, 2019.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
December 12, 2020, the Company issued 412,580 common shares to an investor in exchange for $35,000 of principal and accrued interest
owed under the terms and conditions of that convertible note as issued to Geneva Roth, dated April 20, 2020.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
December 18, 2020, the Company issued 297,900 common shares to an investor in exchange for $25,968 of principal and accrued interest
owed under the terms and conditions of that convertible note as issued to Geneva Roth, dated April 20, 2020.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
December 18, 2020, the Company issued 975,117 common shares to an investor in exchange for $85,000 of principal and accrued interest
owed under the terms and conditions of that promissory note as issued to Daniel Dror, dated April 12, 2019.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
December 18, 2020, the Company issued 500,000 shares of the Company&#8217;s common stock in consideration for consulting services. The
shares were valued at $0.08 per share, or $40,000 based on the market price on the date of issuance.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
December 30, 2020, the Company issued 683,791 common shares to an investor in exchange for $86,217 of principal and accrued interest
owed under the terms and conditions of that convertible note as issued to Geneva Roth, dated May 19, 2020.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
December 30, 2020, the Company issued 889,979 common shares to an investor in exchange for $72,657 of principal and accrued interest
owed under the terms and conditions of that promissory note as issued to David Morales, dated October 18, 2019.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 168; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: center">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: left"><a href="#toc" title="Table of Contents" style="font-style: italic">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
December 30, 2020, the Company issued 376,704 common shares to an investor in exchange for $30,777 of principal and accrued interest
owed under the terms and conditions of that promissory note as issued to Asia Pacific Partners, Inc., dated June 24, 2020.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
January 6, 2021 (the &#8220;<span style="text-decoration: underline">Closing Date</span>&#8221;), the Company closed the transactions contemplated by a Securities Purchase Agreement
dated January 6, 2021 (the &#8220;<span style="text-decoration: underline">Purchase Agreement</span>&#8221;), which was entered into with a group of accredited institutional
investors (collectively, the &#8220;<span style="text-decoration: underline">Investors</span>&#8221;), for the sale of convertible promissory notes. Pursuant to the Purchase
Agreement, the Company agreed to sell 6% Original Issue Discount Senior Secured Convertible Promissory Notes in an aggregate principal
amount of $1,450,000 (the &#8220;<span style="text-decoration: underline">Notes</span>&#8221;) and warrants to purchase up to an aggregate of 6,750,000 shares of the Company&#8217;s
common stock (the &#8220;<span style="text-decoration: underline">Warrants</span>&#8221;) to the Investors and entered into a Security Agreement, a Guaranty Agreement, a Pledge
Agreement, and a Registration Rights Agreement (the foregoing, collectively with the Purchase Agreement, Notes and Warrant, the &#8220;<span style="text-decoration: underline">Transaction
Documents</span>&#8221;). The Purchase Agreement includes indemnification obligations of the Company, requirements for the Company to reserve
three times the number of shares of common stock issuable upon conversion of the Notes and exercise of the Warrants, the right of the
Investors to participate up to 30% in any future equity or debt offering made by the Company in the 12 months after the Closing Date,
a prohibition on the Company selling any shares of common stock or common stock equivalents until 30 days after the Closing Date, subject
to certain exceptions, a one year prohibition on the Company entering into any equity line transaction or variable rate transaction (including
convertible notes with adjustable conversion prices), and a one year prohibition, without the approval of the Investors, of a reverse
or forward stock split.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
total of $850,000 in Notes (the &#8220;<span style="text-decoration: underline">First Tranche Notes</span>&#8221;) were sold on the Closing Date, and a total of $600,000 in Notes
(the &#8220;<span style="text-decoration: underline">Second Tranche Notes</span>&#8221;), were sold on March 30, 2021. In connection with the sale of the First Tranche Notes,
the Company paid $25,000 of the Investors&#8217; legal fees and certain other amounts in expense reimbursements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
First Tranche Notes mature on January 7, 2022, and the Second Tranche Notes mature on March 30, 2022, and accrue interest at a rate of
6% per annum (15% upon the occurrence of an event of default) payable to the Investors in cash on a calendar quarterly basis (which changes
to monthly upon the occurrence of an event of default). Each of the Notes contained a 6% original issue discount.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
First Tranche Notes, Second Tranche Notes and Warrants are described in greater detail in the prospectus which forms a part of this Registration
Statement under Greentree &#8220;Securities Purchase Agreement&#8221;, beginning on page 2.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
January 12, 2021, the Company issued 708,750 common shares to an investor in exchange for $114,392 of principal and accrued interest
owed under the terms and conditions of that promissory note as issued to LGH Investments, LLC., dated August 11, 2020.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"></p>

<!-- Field: Page; Sequence: 169; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: center">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: left"><a href="#toc" title="Table of Contents" style="font-style: italic">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
January 13, 2021, the Company issued 105,000 shares of the Company&#8217;s common stock to eligible persons under the Plan. The shares
were valued at $0.40 per share or $40,000.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
January 21, 2021, the Company agreed to issue 4,000,000 shares of common stock to Mr. Rodriquez under the terms of his employment agreement,
1,500,000 million shares of common stock to Mr. Bowen under the terms of his employment agreement and 1,000,000 shares to the Company&#8217;s
legal counsel under the terms of the reduced fee agreement. The securities issued to the Company&#8217;s legal counsel are subject to
a two-year lock-up agreement, preventing the sale or transfer of such shares without the written approval of the Company, except to affiliates
of the holder, who agree to be bound by the same terms.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
January 22, 2021, Mr. Jacob D. Cohen, as the sole member of the Board of Directors of the Company, approved the issuance to himself,
in consideration for services rendered as the sole officer and director of the Company, of 2,500,000 shares of restricted common stock.
The securities are subject to a two-year lock-up agreement, preventing the sale or transfer of such shares without the written approval
of the Company, except to affiliates of the holder, who agree to be bound by the same terms.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
January 22, 2021, the Company issued 400,000 shares of the Company&#8217;s common stock in consideration for consulting services. The
shares were valued at $0.38 per share, or $152,000 based on the market price on the date of issuance.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
January 22, 2021, the Company issued 200,000 common shares to an investor in exchange for $94,500 in cash, net of offering costs. The
shares issued to the investor are part of the 10,000,000 Shares offered and registered by the Company under the Offering Statement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
February 8, 2021, the Company issued 217,640 common shares to an investor in exchange for $50,275 of principal and accrued interest owed
under the terms and conditions of that 6% convertible promissory note as issued to L1 Capital Global Opportunities Master Fund (&#8220;<span style="text-decoration: underline">L1
Capital</span>&#8221;), dated January 7, 2021.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
February 12, 2021, the Company issued 224,921 common shares to an investor in exchange for $50,000 of principal and accrued interest
owed under the terms and conditions of that 6% convertible promissory note as issued to Cavalry Fund 1, LP (&#8220;<span style="text-decoration: underline">Cavalry</span>&#8221;),
dated January 7, 2021.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
February 26, 2021, the Company issued 500,000 shares of the Company&#8217;s common stock in consideration for consulting services. The
shares were valued at $0.08 per share, or $142,600 based on the market price on the date of issuance.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
March 5, 2021, the Company issued 409,333 common shares to an investor in exchange for $75,000 of principal and accrued interest owed
under the terms and conditions of that 6% convertible promissory note as issued to Cavalry, dated January 7, 2021.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 170; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: center">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: left"><a href="#toc" title="Table of Contents" style="font-style: italic">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
March 8, 2021, the Company issued to GCN an additional 500,000 shares of Series B Convertible Preferred Stock, which had an agreed upon
value of $500,000 ($1.00 per share) in connection with milestones achieved pursuant to a Securities Purchase Agreement as executed with
GCN on May 15, 2020. Immediately upon issuance, GCN elected to convert the 500,000 shares of Series B Convertible Preferred Stock into
2,057,613 shares of the Company&#8217;s common stock, at a price of $0.24 per share.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
March 8, 2021, the Company issued 1,500,000 shares of the Company&#8217;s common stock in consideration for consulting services. The
shares were valued at $0.27 per share, or $405,000 based on the market price on the date of issuance.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
March 9, 2021, the Company issued 200,000 shares of the Company&#8217;s common stock in consideration for consulting services. The shares
were valued at $0.22 per share, or $44,000 based on the market price on the date of issuance.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
March 18, 2021, the Company issued 451,060 common shares to an investor in exchange for $75,000 of principal and accrued interest owed
under the terms and conditions of that 6% convertible promissory note as issued to Cavalry, dated January 7, 2021.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
March 19, 2021, the Company issued 872,270 common shares to an investor in exchange for $151,175 of principal and accrued interest owed
under the terms and conditions of that 6% convertible promissory note as issued to L1 Capital, dated January 7, 2021.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
March 22, 2021, the Company issued 100,000 shares of the Company&#8217;s common stock in consideration for consulting services. The shares
were valued at $0.28 per share, or $28,000 based on the market price on the date of issuance.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
March 24, 2021, the Company issued 555,324 common shares to an investor in exchange for $100,000 of principal and accrued interest owed
under the terms and conditions of that 6% convertible promissory note as issued to Cavalry, dated January 7, 2021.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
April 8, 2021, the Company issued 909,361 common shares to an investor in exchange for $129,925 of principal and accrued interest owed
under the terms and conditions of that 6% convertible promissory note as issued to Cavalry, dated January 7, 2021.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
April 21, 2021, the Company issued 403,769 common shares to an investor in exchange for $50,875 of principal and accrued interest owed
under the terms and conditions of that 6% convertible promissory note as issued to L1 Capital, dated January 7, 2021.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 171; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: center">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: left"><a href="#toc" title="Table of Contents" style="font-style: italic">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
April 28, 2021, the Company issued 485,079 common shares to an investor in exchange for $61,120 of principal and accrued interest owed
under the terms and conditions of that 6% convertible promissory note as issued to L1 Capital, dated January 7, 2021.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
May 3, 2021, the Company issued 760,928 common shares to an investor in exchange for $56,750 of principal and accrued interest owed under
the terms and conditions of that 8% convertible promissory note as issued to Quick Capital, LLC, dated October 20, 2020.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
June 24, 2021 (the &#8220;<span style="text-decoration: underline">Closing Date</span>&#8221;), American International Holdings Corp (the &#8220;<span style="text-decoration: underline">Company</span>&#8221;, &#8220;<span style="text-decoration: underline">we</span>&#8221;
and &#8220;<span style="text-decoration: underline">us</span>&#8221;) closed the transactions contemplated by a Securities Purchase Agreement dated June 24, 2021 (the &#8220;<span style="text-decoration: underline">Purchase
Agreement</span>&#8221;), which was entered into with two accredited institutional investors (collectively, the &#8220;<span style="text-decoration: underline">Investors</span>&#8221;),
for the sale of convertible promissory notes.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
May 25, 2021, the Company issued 538,505 common shares to an investor in exchange for $51,158 of principal and accrued interest owed
under the terms and conditions of that 6% convertible promissory note as issued to L1 Capital, dated January 7, 2021.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
June 22, 2021, the Company issued 703,252 common shares to an investor in exchange for $66,809 of principal and accrued interest owed
under the terms and conditions of that 6% convertible promissory note as issued to L1 Capital, dated January 7, 2021.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
June 24, 2021, the <span style="text-decoration: underline">Company</span> closed the transactions contemplated by a Securities Purchase Agreement dated June 24, 2021 (the &#8220;<span style="text-decoration: underline">Purchase
Agreement</span>&#8221;), which was entered into with two accredited institutional investors (collectively, the &#8220;<span style="text-decoration: underline">Investors</span>&#8221;),
for the sale of convertible promissory notes.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the Purchase Agreement, the Company agreed to sell 6% Original Issue Discount Senior Secured Convertible Promissory Notes in an aggregate
principal amount of $537,916 (the &#8220;<span style="text-decoration: underline">Notes</span>&#8221;) and warrants to purchase up to an aggregate of 2,670,000 shares of the
Company&#8217;s common stock (the &#8220;<span style="text-decoration: underline">Warrants</span>&#8221;) to the Investors and entered into a Registration Rights Agreement (the
foregoing, collectively with the Purchase Agreement, Notes and Warrant, the &#8220;<span style="text-decoration: underline">Transaction Documents</span>&#8221;). The Purchase
Agreement includes indemnification obligations of the Company, requirements for the Company to reserve three times the number of shares
of common stock issuable upon conversion of the Notes and exercise of the Warrants, the right of the Investors to participate up to 30%
in any future equity or debt offering made by the Company in the 12 months after the Closing Date, a prohibition on the Company selling
any shares of common stock or common stock equivalents until 30 days after the Closing Date, subject to certain exceptions, a one year
prohibition on the Company entering into any equity line transaction or variable rate transaction (including convertible notes with adjustable
conversion prices), and a one year prohibition, without the approval of the Investors, of a reverse or forward stock split. A total of
$537,916 in Notes (the &#8220;<span style="text-decoration: underline">Notes</span>&#8221;) were sold on the Closing Date.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 172; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: center">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: left"><a href="#toc" title="Table of Contents" style="font-style: italic">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
July 6, 2021, the Company issued 165,000 shares of the Company&#8217;s common stock in consideration for consulting services. The shares
were valued at $0.11 per share, or $18,150 based on the market price on the date of issuance.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
July 29, 2021, the Company issued 750,000 shares of the Company&#8217;s common stock in consideration for consulting services. The shares
were valued at $0.10 per share, or $75,000 based on the market price on the date of issuance.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
August 11, 2021, the Company issued 881,310 common shares to an investor in exchange for $51,116 of principal and accrued interest owed
under the terms and conditions of that 6% convertible promissory note as issued to L1 Capital, dated March 30, 2021.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
August 23, 2021, the Company issued 490,000 common shares to an investor in exchange for $25,088 of principal and accrued interest owed
under the terms and conditions of that 6% convertible promissory note as issued to FirstFire Global, dated June 24, 2021.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
September 1, 2021, the Company issued 607,903 common shares to an investor in exchange for $30,000 of principal owed under the terms
and conditions of that 6% convertible promissory note as issued to Quick Capital, LLC, dated June 24, 2021.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
September 17, 2021, the Company issued 1,070,091 common shares to an investor in exchange for $50,000 of principal owed under the terms
and conditions of that 6% convertible promissory note as issued to Quick Capital, LLC, dated June 24, 2021.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Between
November 22, 2021 and December 2, 2021, we entered into four separate Securities Purchase Agreements with four accredited institutional
investors, for the sale of convertible promissory notes in an aggregate principal amount of $2,000,000 and warrants to purchase an aggregate
of 13,333,332 shares of the Company&#8217;s common stock. J.H. Darbie &amp; Co., Inc. acted as placement agent for the offering and was
paid a total of $188,000 in placement agent fees of which $98,000 was paid in cash and $90,000 was paid in the form of 1,151,678 shares
of restricted common stock issued by the Company between November 22, 2021 and December 3, 2021.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
November 29, 2021, the Company issued 476,190 shares of common stock to a note holder in exchange for $30,000 of principal owed under
the terms and conditions of that 6% convertible promissory note as issued to Quick Capital, LLC, dated June 24, 2021.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
November 30, 2021, the Company issued 600,000 shares of common stock to a note holder in exchange for $37,800 of principal and accrued
interest owed under the terms and conditions of the 6% convertible promissory note as issued to FirstFire Global, dated June 24, 2021.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"></p>

<!-- Field: Page; Sequence: 173; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: center">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: left"><a href="#toc" title="Table of Contents" style="font-style: italic">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
December 7, 2021, the Company issued 588,235 shares of common stock to a note holder in exchange for $30,000 of principal owed under
the terms and conditions of that 6% convertible promissory note as issued to Quick Capital, LLC, dated June 24, 2021.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
January 5, 2022, the Company issued 1,200,000 shares of common stock to a note holder in exchange for $50,688 of principal and accrued
interest owed under the terms and conditions of the 6% convertible promissory note as issued to FirstFire Global, dated June 24, 2021.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
January 6, 2022, the Company issued 710,227 common shares to a note holder in exchange for $30,000 of principal owed under the terms
and conditions of that 6% convertible promissory note as issued to Quick Capital, LLC, dated June 24, 2021.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
January 27, 2022, the Company issued 1,260,000 shares of the Company&#8217;s restricted common stock in consideration for consulting
services. The shares were valued at $0.0625 per share, or $78,687 based on the market price on the date of issuance.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
February 2, 2022, the Company issued 3,182,479 shares of common stock to a note holder in exchange for $124,117 of principal and accrued
interest owed under the terms and conditions of that 6% convertible promissory note as issued to L1 Capital, dated March 30, 2021.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
March 31, 2022, the Company issued 163,043 shares of common stock to Peter Casey Jensen at a price of $.046 per share, or $7,500 based
on the market price on the date of issuance. The shares were issued as consideration for his services as an independent member of the
board of directors for the quarter ended March 31, 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
March 31, 2022, the Company issued 163,043 shares of common stock to Dr. Kenny Myers at a price of $.046 per share, or $7,500 based on
the market price on the date of issuance. The shares were issued as consideration for his services as an independent member of the board
of directors for the quarter ended March 31, 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
March 31, 2022, the Company issued 163,043 shares of common stock to Loraine D&#8217;Alessio at a price of $.046 per share, or $7,500
based on the market price on the date of issuance. The shares were issued as consideration for her services as an independent member
of the board of directors for the quarter ended March 31, 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
April 15, 2022, the Company issued 1,000,000 shares of the Company&#8217;s common stock to eligible persons under the Plan. The shares
were valued at $0.04 per share or $40,000.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*
* * * * * *</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 174; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: center">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: left"><a href="#toc" title="Table of Contents" style="font-style: italic">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
use of proceeds associated with the above listed sales of unregistered securities was for general working capital purposes.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
issuances and grants described above, except as otherwise disclosed, or set forth below, were exempt from registration pursuant to Section
4(a)(2), Rule 506 of Regulation D and/or Regulation S of the Securities Act, since the foregoing issuances and grants did not involve
a public offering, the recipients took the securities for investment and not resale, we took take appropriate measures to restrict transfer,
and the recipients were (a) &#8220;<span style="text-decoration: underline">accredited investors</span>&#8221;; (b) had access to similar documentation and information as would
be required in a Registration Statement under the Securities Act; (c) were non U.S. persons; and/or (d) were officers or directors of
the Company. The securities are subject to transfer restrictions, and the certificates evidencing the securities contain an appropriate
legend stating that such securities have not been registered under the Securities Act and may not be offered or sold absent registration
or pursuant to an exemption therefrom. The securities were not registered under the Securities Act and such securities may not be offered
or sold in the United States absent registration or an exemption from registration under the Securities Act and any applicable state
securities laws.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
claim an exemption from registration afforded by Section 3(a)(9) of the Securities Act, for the above conversions, as the securities
were exchanged by the Company with its existing security holders exclusively in transactions where no commission or other remuneration
was paid or given directly or indirectly for soliciting such exchange.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="S_006"></span>ITEM
16. EXHIBITS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exhibits
                                            Pursuant to Item 601 of Regulation S-K:</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>EXHIBIT
INDEX</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: justify">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td colspan="7" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; text-align: center"><span style="font-size: 10pt"><b>Incorporated by Reference</b></span></td>
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="border-bottom: Black 1.5pt solid; width: 10%; text-align: center"><span style="font-size: 10pt"><b>Exhibit No.</b></span></td>
    <td style="padding-bottom: 1.5pt; width: 1%; text-align: center"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; width: 35%; text-align: justify"><span style="font-size: 10pt"><b>Description</b></span></td>
    <td style="padding-bottom: 1.5pt; width: 1%; text-align: center"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; width: 8%; text-align: center"><span style="font-size: 10pt"><b>Form</b></span></td>
    <td style="padding-bottom: 1.5pt; width: 1%; text-align: center"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; width: 8%; text-align: center"><span style="font-size: 10pt"><b>File No.</b></span></td>
    <td style="padding-bottom: 1.5pt; width: 1%; text-align: center"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; width: 8%; text-align: center"><span style="font-size: 10pt"><b>Exhibit</b></span></td>
    <td style="padding-bottom: 1.5pt; width: 1%; text-align: center"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; width: 14%; text-align: center"><span style="font-size: 10pt"><b>Filing Date</b></span></td>
    <td style="padding-bottom: 1.5pt; width: 1%; text-align: center"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; width: 11%; text-align: center"><span style="font-size: 10pt"><b>Filed Herewith</b></span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-align: center"><span style="font-size: 10pt">2.1</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1300524/000149315219008843/ex2-1.htm"><span style="font-size: 10pt">Share Exchange Agreement, dated as of April 12, 2019 by and among American Holdings International Corp., Novopelle Diamond, LLC and the Novopelle Members</span></a></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">8-K</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">000-50912</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">2.1</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">6/7/2019</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-align: center"><span style="font-size: 10pt">2.2</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1300524/000149315220009594/ex2-1.htm"><span style="font-size: 10pt">Securities Purchase Agreement dated May 15, 2020, by and between American International Holdings Corp., as purchaser and Global Career Networks Inc, as seller, relating to the sale of 51% of Life Guru, Inc.</span></a></td>
    <td style="text-align: center"><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">8-K</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">000-50912</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">2.1</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">5/21/2020</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
</table>

<p style="margin: 0">&#160;</p>

<p style="margin: 0"></p>

<!-- Field: Page; Sequence: 175; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: center">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: left"><a href="#toc" title="Table of Contents" style="font-style: italic">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page -->

<p style="margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top; background-color: White">
    <td style="text-align: center; width: 10%"><span style="font-size: 10pt">3.1</span></td>
    <td style="text-align: center; width: 1%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify; width: 35%"><a href="https://www.sec.gov/Archives/edgar/data/1300524/000149315220011951/ex3-1.htm"><span style="font-size: 10pt">Articles of Incorporation, as amended</span></a></td>
    <td style="text-align: center; width: 1%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: center; width: 8%"><span style="font-size: 10pt">10-K</span></td>
    <td style="text-align: center; width: 1%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: center; width: 8%"><span style="font-size: 10pt">000-50912</span></td>
    <td style="text-align: center; width: 1%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: center; width: 8%"><span style="font-size: 10pt">3.1</span></td>
    <td style="text-align: center; width: 1%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: center; width: 14%"><span style="font-size: 10pt">6/26/2020</span></td>
    <td style="text-align: center; width: 1%">&#160;</td>
    <td style="text-align: center; width: 11%">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-align: center"><span style="font-size: 10pt">3.2</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1300524/000149315220009594/ex3-1.htm"><span style="font-size: 10pt">Amended and Restated Certificate of Designations of American International Holdings Corp. Establishing the Designations, Preferences, Limitations and Relative Rights of Its Series A Preferred Stock, filed with the Secretary of State of Nevada on May 18, 2020</span></a></td>
    <td style="text-align: center"><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">8-K</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">000-50912</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">3.1</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">5/21/2020</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-align: center"><span style="font-size: 10pt">3.3</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1300524/000149315220009594/ex3-2.htm"><span style="font-size: 10pt">Amended and Restated Certificate of Designation of American International Holdings Corp. Establishing the Designation, Preferences, Limitations and Relative Rights of Its Series B Convertible Preferred Stock, filed with the Secretary of State of Nevada on May 18, 2020</span></a></td>
    <td style="text-align: center"><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">8-K</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">000-50912</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">3.2</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">5/21/2020</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-align: center"><span style="font-size: 10pt">3.4</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1300524/000121478204000342/doc1.txt"><span style="font-size: 10pt">Bylaws of Unlimited Coatings Corporation</span></a></td>
    <td style="text-align: center"><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">10-SB/12G</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">000-50912</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">3(ii)</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">8/18/04</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-align: center"><span style="font-size: 10pt">4.1</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1300524/000149315222008013/ex4-1.htm"><span style="font-size: 10pt">Description of Securities of the Registrant</span></a></td>
    <td style="text-align: center"><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">10-K</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">000-50912</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">4.1</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">3/29/2022</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-align: center"><span style="font-size: 10pt">5.1</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><a href="ex5-1.htm"><span style="font-size: 10pt">Opinion and consent of The Loev Law Firm, PC re: the legality of the securities being registered</span></a></td>
    <td style="text-align: center"><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">X</span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-align: center"><span style="font-size: 10pt">10.1</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1300524/000149315219010304/ex1-1.htm"><span style="font-size: 10pt">Exclusive License Agreement, dated as of June 27, 2019 by and among American Holdings International Corp., and Novo MedSpa Addison Corporation</span></a></td>
    <td style="text-align: center"><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">8-K</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">000-50912</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">1.1</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">7/05/2019</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-align: center"><span style="font-size: 10pt">&#160;10.2***</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1300524/000149315219010339/ex1-1.htm"><span style="font-size: 10pt">American Holdings International Corp. 2019 Employee Stock Option Plan, dated July 5, 2019</span></a></td>
    <td style="text-align: center"><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">8-K</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">000-50912</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">1.1</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">7/8/2019</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-align: center"><span style="font-size: 10pt">10.3***</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1300524/000149315219015197/ex1-1.htm"><span style="font-size: 10pt">Employment Agreement, dated as of October 1, 2019 by and among American Holdings International Corp., and Jesse L. Dickens, Jr.</span></a></td>
    <td style="text-align: center"><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">8-K</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">000-50912</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">1.1</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">10/8/2019</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">&#160;</span></td></tr>
</table>

<p style="margin: 0">&#160;</p>

<p style="margin: 0"></p>

<!-- Field: Page; Sequence: 176; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: center">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: left"><a href="#toc" title="Table of Contents" style="font-style: italic">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page -->

<p style="margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top; background-color: White">
    <td style="text-align: center; width: 10%"><span style="font-size: 10pt">10.4</span></td>
    <td style="text-align: center; width: 1%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify; width: 35%"><a href="https://www.sec.gov/Archives/edgar/data/1300524/000149315219016949/ex1-1.htm"><span style="font-size: 10pt">Asset Purchase Agreement and Promissory Note, dated as of October 18, 2019 by and among Legend Nutrition, Inc. and David Morales.</span></a></td>
    <td style="text-align: center; width: 1%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: center; width: 8%"><span style="font-size: 10pt">8-K</span></td>
    <td style="text-align: center; width: 1%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: center; width: 8%"><span style="font-size: 10pt">000-50912</span></td>
    <td style="text-align: center; width: 1%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: center; width: 8%"><span style="font-size: 10pt">1.1</span></td>
    <td style="text-align: center; width: 1%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: center; width: 14%"><span style="font-size: 10pt">11/13/2019</span></td>
    <td style="text-align: center; width: 1%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: center; width: 11%"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-align: center"><span style="font-size: 10pt">10.5***</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1300524/000149315219016949/ex1-2.htm"><span style="font-size: 10pt">Employment Agreement, dated as of October 18, 2019 by and among Legend Nutrition, Inc. and Michael Ladner</span></a></td>
    <td style="text-align: center"><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">8-K</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">000-50912</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">1.2</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">11/13/2019</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-align: center"><span style="font-size: 10pt">10.6</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1300524/000149315219017650/ex1-1.htm"><span style="font-size: 10pt">Lease Agreement, dated as of November 6, 2019 by and among Novopelle Waterway, Inc. and 20 &amp; 25 Waterway Holdings, LLC</span></a></td>
    <td style="text-align: center"><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">8-K</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">000-50912</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">1.1</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">11/15/2019</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-align: center"><span style="font-size: 10pt">10.7</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1300524/000149315219008843/ex10-1.htm"><span style="font-size: 10pt">Share Exchange Agreement and Promissory Note, dated as of April 12, 2019, by and between American Holdings International Corp. and Daniel Dror</span></a></td>
    <td style="text-align: center"><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">8-K</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">000-50912</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">10.1</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">6/7/2019</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-align: center"><span style="font-size: 10pt">10.8</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1300524/000149315219008843/ex10-2.htm"><span style="font-size: 10pt">Share Exchange Agreement and Promissory Note, dated as of April 12, 2019, by and between American Holdings International Corp. and Winfred Fields</span></a></td>
    <td style="text-align: center"><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">8-K</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">000-50912</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">10.2</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">6/7/2019</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-align: center"><span style="font-size: 10pt">10.9</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1300524/000149315219008843/ex10-3.htm"><span style="font-size: 10pt">Share Exchange Agreement and Promissory Note, dated as of April 12, 2019, by and between American Holdings International Corp. and Everett Bassie</span></a></td>
    <td style="text-align: center"><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">8-K</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">000-50912</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">10.3</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">6/7/2019</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-align: center"><span style="font-size: 10pt">10.10</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1300524/000149315219008843/ex10-4.htm"><span style="font-size: 10pt">Share Exchange Agreement and Promissory Note, dated as of April 12, 2019, by and between American Holdings International Corp. and Charles Zeller</span></a></td>
    <td style="text-align: center"><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">8-K</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">000-50912</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">10.4</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">6/7/2019</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-align: center"><span style="font-size: 10pt">10.11***</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1300524/000149315219008843/ex10-5.htm"><span style="font-size: 10pt">Executive Employment Agreement, dated as of April 12, 2019, by and between American Holdings International Corp. and Jacob D. Cohen</span></a></td>
    <td style="text-align: center"><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">8-K</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">000-50912</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">10.5</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">6/7/2019</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
</table>

<p style="margin: 0">&#160;</p>

<p style="margin: 0"></p>

<!-- Field: Page; Sequence: 177; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: center">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: left"><a href="#toc" title="Table of Contents" style="font-style: italic">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page -->

<p style="margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top; background-color: White">
    <td style="text-align: center; width: 10%"><span style="font-size: 10pt">10.12***</span></td>
    <td style="text-align: center; width: 1%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify; width: 35%"><a href="https://www.sec.gov/Archives/edgar/data/1300524/000149315219008843/ex10-6.htm"><span style="font-size: 10pt">Executive Employment Agreement, dated as of April 12, 2019, by and between American Holdings International Corp. and Esteban Alexander</span></a></td>
    <td style="text-align: center; width: 1%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: center; width: 8%"><span style="font-size: 10pt">8-K</span></td>
    <td style="text-align: center; width: 1%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: center; width: 8%"><span style="font-size: 10pt">000-50912</span></td>
    <td style="text-align: center; width: 1%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: center; width: 8%"><span style="font-size: 10pt">10.6</span></td>
    <td style="text-align: center; width: 1%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: center; width: 14%"><span style="font-size: 10pt">6/7/2019</span></td>
    <td style="text-align: center; width: 1%">&#160;</td>
    <td style="text-align: center; width: 11%">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-align: center"><span style="font-size: 10pt">10.13***</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1300524/000149315219008843/ex10-7.htm"><span style="font-size: 10pt">Executive Employment Agreement, dated as of April 12, 2019, by and between American Holdings International Corp. and Alan Hernandez</span></a></td>
    <td style="text-align: center"><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">8-K</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">000-50912</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">10.7</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">6/7/2019</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-align: center"><span style="font-size: 10pt">10.14***</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1300524/000149315219012724/ex10-8.htm"><span style="font-size: 10pt">Financial and Accounting Consulting Agreement, dated as of May 3, 2019, by and between American Holdings International Corp. and Everett Bassie</span></a></td>
    <td style="text-align: center"><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">8-K/A</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">000-50912</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">10.8</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">8/15/2019</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="background-color: White">
    <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt">10.15***</span></td>
    <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1300524/000149315219010579/ex4-2.htm"><span style="font-size: 10pt">Sample Stock Option Award and Stock Option Agreement under 2019 Employee Stock Option Plan</span></a></td>
    <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt">S-8</span></td>
    <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt">333-232638</span></td>
    <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt">4.2</span></td>
    <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt">7/12/2020</span></td>
    <td style="vertical-align: top; text-align: center">&#160;</td>
    <td style="vertical-align: top; text-align: center">&#160;</td></tr>
  <tr style="background-color: White">
    <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt">10.16</span></td>
    <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1300524/000149315219019250/ex6-11.htm"><span style="font-size: 10pt">$78,750 Convertible Promissory Note dated October 28, 2019 payable to Armada Capital Partners LLC</span></a></td>
    <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt">1-A Pos</span></td>
    <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt">024-11080</span></td>
    <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt">6.11</span></td>
    <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt">12/16/2019</span></td>
    <td style="vertical-align: top; text-align: center">&#160;</td>
    <td style="vertical-align: top; text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-align: center"><span style="font-size: 10pt">&#160;10.17</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1300524/000149315219019250/ex6-11.htm"><span style="font-size: 10pt">$78,750 Convertible Promissory Note dated October 28, 2019 payable to Fourth Man LLC</span></a></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">1-A Pos</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">024-11080</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">6.11</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">12/16/2019</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-align: center"><span style="font-size: 10pt">10.18</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1300524/000149315219019250/ex6-11.htm"><span style="font-size: 10pt">$78,750 Convertible Promissory Note dated October 28, 2019 payable to BHP Capital NY Inc.</span></a></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">1-A Pos</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">024-11080</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">6.11</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">&#160;12/16/2019</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-align: center"><span style="font-size: 10pt">10.19</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1300524/000149315219015197/ex1-1.htm"><span style="font-size: 10pt">Jesse L. Dickens, Jr. employment agreement with Capitol City Solutions USA, Inc. dated October 1, 2019</span></a></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">8-K</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">024-11080</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">1.1</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">10/8/2019</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-align: center"><span style="font-size: 10pt">10.20</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1300524/000149315219016949/ex1-1.htm"><span style="font-size: 10pt">Legend Nutrition, Inc. Asset Acquisition Agreement and Related Promissory Note dated October 18, 2019</span></a></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">8-K</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">000-50912</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">1.1</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">11/13/2019</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-align: center"><span style="font-size: 10pt">10.21***</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1300524/000149315219016949/ex1-2.htm"><span style="font-size: 10pt">Employment Agreement between Legend Nutrition, Inc. and Michael Ladner dated October 18, 2019</span></a></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">8-K</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">000-50912</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">1.2</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">11/13/2019</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
</table>

<p style="margin: 0">&#160;</p>

<p style="margin: 0"></p>

<!-- Field: Page; Sequence: 178; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: center">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: left"><a href="#toc" title="Table of Contents" style="font-style: italic">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page -->

<p style="margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top; background-color: White">
    <td style="text-align: center; width: 10%"><span style="font-size: 10pt">10.22</span></td>
    <td style="width: 1%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify; width: 35%"><a href="https://www.sec.gov/Archives/edgar/data/1300524/000149315219019250/ex6-15.htm"><span style="font-size: 10pt">$75,000 Promissory Note Issued October 11, 2019, evidencing amounts owed to GHS Investments, LLC</span></a></td>
    <td style="width: 1%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: center; width: 8%"><span style="font-size: 10pt">1-A Pos</span></td>
    <td style="width: 1%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 8%"><span style="font-size: 10pt">024-11080</span></td>
    <td style="width: 1%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: center; width: 8%"><span style="font-size: 10pt">6.15</span></td>
    <td style="width: 1%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: center; width: 14%"><span style="font-size: 10pt">12/16/2019</span></td>
    <td style="text-align: center; width: 1%">&#160;</td>
    <td style="text-align: center; width: 11%">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-align: center"><span style="font-size: 10pt">10.23</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1300524/000149315220000380/ex6-17.htm"><span style="font-size: 10pt">Services Agreement and Promissory Note dated August 26, 2019 with Greentree Financial Group, Inc.</span></a></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">1-A Pos</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">024-11080</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">6.17</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">1/9/2019</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-align: center"><span style="font-size: 10pt">10.24</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1300524/000149315220000380/ex6-18.htm"><span style="font-size: 10pt">$40,000 Promissory Note with Isaak Cohen dated June 21, 2019</span></a></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">1-A Pos</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">024-11080</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">6.18</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">1/9/2019</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-align: center"><span style="font-size: 10pt">10.25</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1300524/000149315220000380/ex6-19.htm"><span style="font-size: 10pt">$40,000 Promissory Note with Megan Amason dated July 8, 2019</span></a></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">1-A Pos</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">024-11080</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">6.19</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">1/9/2019</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-align: center"><span style="font-size: 10pt">10.26</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1300524/000149315219014415/ex4-1.htm"><span style="font-size: 10pt">Form of Subscription Agreement for the Company&#8217;s Regulation A Offering</span></a></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">1-A</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">024-11080</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">4.1</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">9/23/2019</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-align: center"><span style="font-size: 10pt">10.27</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1300524/000149315220003319/ex10-1.htm"><span style="font-size: 10pt">Securities Purchase Agreement between Adar Alef, LLC and American International Holdings Corp., dated February 24, 2020</span></a></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">8-K</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">000-50912</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">10.1</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">3/4/2020</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-align: center"><span style="font-size: 10pt">10.28</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1300524/000149315220003319/ex10-2.htm"><span style="font-size: 10pt">Convertible Promissory Note between Adar Alef, LLC and American International Holdings Corp., dated February 24, 2020</span></a></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">8-K</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">000-50912</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">10.2</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">3/4/2020</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-align: center"><span style="font-size: 10pt">10.29</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1300524/000149315220009290/ex10-1.htm"><span style="font-size: 10pt">Securities Purchase Agreement between Geneva Roth Remark Holdings, Inc. and American International Holdings Corp., dated April 20, 2020</span></a></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">8-K</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">000-50912</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">10.1</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">5/18/2020</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-align: center"><span style="font-size: 10pt">10.30</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1300524/000149315220009290/ex10-2.htm"><span style="font-size: 10pt">$88,000 Convertible Promissory Note between Geneva Roth Remark Holdings, Inc. and American International Holdings Corp., dated April 20, 2020</span></a></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">8-K</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">000-50912</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">10.2</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">5/18/2020</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-align: center"><span style="font-size: 10pt">10.31</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1300524/000149315220009290/ex10-3.htm"><span style="font-size: 10pt">Securities Purchase Agreement between FirstFire Global Opportunities Fund LLC and American International Holdings Corp., dated April 30, 2020</span></a></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">8-K</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">000-50912</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">10.3</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">5/18/2020</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
</table>

<p style="margin: 0">&#160;</p>

<p style="margin: 0"></p>

<!-- Field: Page; Sequence: 179; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: center">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: left"><a href="#toc" title="Table of Contents" style="font-style: italic">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page -->

<p style="margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top; background-color: White">
    <td style="text-align: center; width: 10%"><span style="font-size: 10pt">10.32</span></td>
    <td style="width: 1%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify; width: 35%"><a href="https://www.sec.gov/Archives/edgar/data/1300524/000149315220009290/ex10-4.htm"><span style="font-size: 10pt">$105,000 Convertible Promissory Note between FirstFire Global Opportunities Fund LLC and American International Holdings Corp., dated April 30, 2020</span></a></td>
    <td style="width: 1%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: center; width: 8%"><span style="font-size: 10pt">8-K</span></td>
    <td style="width: 1%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 8%"><span style="font-size: 10pt">000-50912</span></td>
    <td style="width: 1%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: center; width: 8%"><span style="font-size: 10pt">10.4</span></td>
    <td style="width: 1%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: center; width: 14%"><span style="font-size: 10pt">5/18/2020</span></td>
    <td style="text-align: center; width: 1%">&#160;</td>
    <td style="text-align: center; width: 11%">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-align: center"><span style="font-size: 10pt">10.33</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1300524/000149315220013965/ex10-8.htm"><span style="font-size: 10pt">Data Delivery and Ancillary Services Agreement between American International Holdings Corp. and Cicero Transact Group, Inc., dated January 13, 2020</span></a></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">10-Q</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">000-50912</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">10.8</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">7/24/2020</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-align: center"><span style="font-size: 10pt">10.34</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1300524/000149315220016301/ex10-9.htm"><span style="font-size: 10pt">Securities Purchase Agreement between Geneva Roth Remark Holdings, Inc. and American International Holdings Corp., dated August 5, 2020</span></a></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">10-Q</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">000-50912</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">10.9</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">8/19/2020</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-align: center"><span style="font-size: 10pt">10.35</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1300524/000149315220016301/ex10-10.htm"><span style="font-size: 10pt">$53,000 Convertible Promissory Note between Geneva Roth Remark Holdings, Inc. and American International Holdings Corp., dated August 5, 2020</span></a></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">10-Q</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">000-50912</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">10.10</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">8/19/2020</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-align: center"><span style="font-size: 10pt">10.36</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1300524/000149315220016301/ex10-11.htm"><span style="font-size: 10pt">$105,000 Convertible Promissory Note between LGH Investments, LLC and American International Holdings Corp., dated August 11, 2020</span></a></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">10-Q</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">000-50912</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">10.11</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">8/19/2020</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-align: center"><span style="font-size: 10pt">10.37</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1300524/000149315220018885/ex10-1.htm"><span style="font-size: 10pt">Securities Purchase Agreement between Geneva Roth Remark Holdings, Inc. and American International Holdings Corp., dated September 14, 2020</span></a></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">8-K</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">000-50912</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">10.1</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">10/5/2020</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-align: center"><span style="font-size: 10pt">10.38</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1300524/000149315220018885/ex10-2.htm"><span style="font-size: 10pt">$53,000 Convertible Promissory Note between Geneva Roth Remark Holdings, Inc. and American International Holdings Corp., dated September 14, 2020</span></a></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">8-K</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">000-50912</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">10.2</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">10/5/2020</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-align: center"><span style="font-size: 10pt">10.39</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1300524/000149315220021833/ex10-1.htm"><span style="font-size: 10pt">Stock Purchase Agreement dated October 2, 2020, by and between Jacob Cohen and Luis Alan Hernandez</span></a></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">8-K</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">000-50912</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">10.1</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">11/17/2020</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-align: center"><span style="font-size: 10pt">10.40</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1300524/000149315220021833/ex10-2.htm"><span style="font-size: 10pt">Stock Purchase Agreement dated October 2, 2020, by and between Jacob Cohen and Estaban Alexander</span></a></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">8-K</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">000-50912</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">10.2</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">10/5/2020</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
</table>

<p style="margin: 0">&#160;</p>

<p style="margin: 0"></p>

<!-- Field: Page; Sequence: 180; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: center">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: left"><a href="#toc" title="Table of Contents" style="font-style: italic">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page -->

<p style="margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top; background-color: White">
    <td style="text-align: center; width: 10%"><span style="font-size: 10pt">10.41</span></td>
    <td style="width: 1%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify; width: 35%"><a href="https://www.sec.gov/Archives/edgar/data/1300524/000149315220021833/ex10-3.htm"><span style="font-size: 10pt">Securities Purchase Agreement between Quick Capital, LLC and American International Holdings Corp., dated October 12, 2020</span></a></td>
    <td style="width: 1%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: center; width: 8%"><span style="font-size: 10pt">8-K</span></td>
    <td style="width: 1%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 8%"><span style="font-size: 10pt">000-50912</span></td>
    <td style="width: 1%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 8%"><span style="font-size: 10pt">10.3</span></td>
    <td style="width: 1%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: center; width: 14%"><span style="font-size: 10pt">11/17/2020</span></td>
    <td style="text-align: center; width: 1%">&#160;</td>
    <td style="text-align: center; width: 11%">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-align: center"><span style="font-size: 10pt">10.42</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1300524/000149315220021833/ex10-4.htm"><span style="font-size: 10pt">$56,750 Convertible Promissory Note between Quick Capital, LLC and American International Holdings Corp., dated October 12, 2020</span></a></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">8-K</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">000-50912</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">10.4</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">11/17/2020</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-align: center"><span style="font-size: 10pt">10.43</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1300524/000149315220022084/ex10-18.htm"><span style="font-size: 10pt">$138,000 Convertible Promissory Note between JSJ Investments, Inc. and American International Holdings Corp., dated November 13, 2020</span></a></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">10-Q</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">000-50912</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">10.18</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">11/20/2020</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-align: center"><span style="font-size: 10pt">10.44#</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1300524/000149315221000822/ex10-1.htm"><span style="font-size: 10pt">Securities Purchase Agreement dated January 6, 2021, by and between American International Holdings Corp., and the Investors party thereto</span></a></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">8-K</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">000-50912</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">10.1</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">1/12/2021</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-align: center"><span style="font-size: 10pt">10.45</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1300524/000149315221000822/ex10-2.htm"><span style="font-size: 10pt">Form of 6% Original Issue Discount Secured Convertible Promissory Note dated January 6, 2021, by American International Holdings Corp. in favor of the holders thereof</span></a></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">8-K</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">000-50912</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">10.2</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">1/12/2021</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-align: center"><span style="font-size: 10pt">10.46</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1300524/000149315221000822/ex10-3.htm"><span style="font-size: 10pt">Form of Warrant to Purchase Common Stock dated January 6, 2021, by American International Holdings Corp. in favor of the holders thereof</span></a></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">8-K</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">000-50912</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">10.3</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">1/12/2021</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-align: center"><span style="font-size: 10pt">10.47#</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1300524/000149315221000822/ex10-4.htm"><span style="font-size: 10pt">Security Agreement date January 6, 2021, between American International Holdings Corp., VISSIA McKinney, LLC, VISSIA Waterway, Inc., EPIQ MD, Inc., Legend Nutrition, Inc., Life Guru, Inc and ZipDoctor, Inc., and in favor of the debtors named therein and collateral agent set forth therein</span></a></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">8-K</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">000-50912</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">10.4</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">1/12/2021</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
</table>

<p style="margin: 0">&#160;</p>

<p style="margin: 0"></p>

<!-- Field: Page; Sequence: 181; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: center">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: left"><a href="#toc" title="Table of Contents" style="font-style: italic">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page -->

<p style="margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top; background-color: White">
    <td style="text-align: center; width: 10%"><span style="font-size: 10pt">10.48#</span></td>
    <td style="width: 1%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify; width: 35%"><a href="https://www.sec.gov/Archives/edgar/data/1300524/000149315221000822/ex10-5.htm"><span style="font-size: 10pt">Pledge Agreement dated January 6, 2021, by American International Holdings Corp. in favor of the collateral agent set forth thereof</span></a></td>
    <td style="width: 1%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: center; width: 8%"><span style="font-size: 10pt">8-K</span></td>
    <td style="width: 1%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 8%"><span style="font-size: 10pt">000-50912</span></td>
    <td style="width: 1%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 8%"><span style="font-size: 10pt">10.5</span></td>
    <td style="width: 1%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: center; width: 14%"><span style="font-size: 10pt">1/12/2021</span></td>
    <td style="text-align: center; width: 1%">&#160;</td>
    <td style="text-align: center; width: 11%">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-align: center"><span style="font-size: 10pt">10.49#</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1300524/000149315221000822/ex10-6.htm"><span style="font-size: 10pt">Registration Rights Agreement dated January 6, 2021, by American International Holdings Corp. in favor of the investors named thereof</span></a></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">8-K</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">000-50912</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">10.6</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">1/12/2021</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-align: center"><span style="font-size: 10pt">10.50#</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1300524/000149315221000822/ex10-7.htm"><span style="font-size: 10pt">Subsidiary Guaranty Agreement between American International Holdings Corp., VISSIA McKinney, LLC, VISSIA Waterway, Inc., EPIQ MD, Inc., Legend Nutrition, Inc., Life Guru, Inc and ZipDoctor, Inc., and in favor of the purchasers named therein and collateral agent set forth therein</span></a></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">8-K</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">000-50912</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">10.7</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">1/12/2021</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-align: center"><span style="font-size: 10pt">10.51***</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1300524/000149315221001671/ex10-1.htm"><span style="font-size: 10pt">January 21, 2021 Employment Agreement between American International Holdings Corp. and Alejandro Rodriquez</span></a></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">8-K</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">000-50912</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">10.1</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">1/26/2021</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-align: center"><span style="font-size: 10pt">10.52***</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1300524/000149315221001671/ex10-2.htm"><span style="font-size: 10pt">January 21, 2021 Employment Agreement between American International Holdings Corp. and Verdie Bowen</span></a></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">8-K</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">000-50912</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">10.2</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">1/26/2021</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-align: center"><span style="font-size: 10pt">10.53</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1300524/000149315221001671/ex10-3.htm"><span style="font-size: 10pt">Reduced Fee Agreement between American International Holdings Corp. and The Loev Law Firm, PC dated January 22, 2021</span></a></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">8-K</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">000-50912</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">10.3</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">1/26/2021</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-align: center"><span style="font-size: 10pt">10.54</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1300524/000149315221001671/ex10-4.htm"><span style="font-size: 10pt">Lock-Up Agreement dated January 22, 2021, between American International Holdings Corp. and the shareholders party thereto</span></a></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">8-K</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">000-50912</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">10.4</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">1/26/2021</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-align: center"><span style="font-size: 10pt">10.55</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1300524/000149315221001853/ex10-5.htm"><span style="font-size: 10pt">Securities Purchase Agreement dated December 2, 2020, between American International Holdings Corp. and Geneva Roth Remark Holdings, Inc.</span></a></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">8-K/A</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">000-50912</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">10.5</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">1/27/2021</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">&#160;</span></td></tr>
</table>

<p style="margin: 0">&#160;</p>

<p style="margin: 0"></p>

<!-- Field: Page; Sequence: 182; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: center">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: left"><a href="#toc" title="Table of Contents" style="font-style: italic">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page -->

<p style="margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top; background-color: White">
    <td style="text-align: center; width: 10%"><span style="font-size: 10pt">10.56</span></td>
    <td style="width: 1%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify; width: 35%"><a href="https://www.sec.gov/Archives/edgar/data/1300524/000149315221001853/ex10-6.htm"><span style="font-size: 10pt">$83,000 Convertible Promissory Note date dated December 2, 2020, issued by American International Holdings Corp. to Geneva Roth Remark Holdings, Inc.</span></a></td>
    <td style="width: 1%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: center; width: 8%"><span style="font-size: 10pt">8-K/A</span></td>
    <td style="width: 1%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 8%"><span style="font-size: 10pt">000-50912</span></td>
    <td style="width: 1%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 8%"><span style="font-size: 10pt">10.6</span></td>
    <td style="width: 1%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: center; width: 14%"><span style="font-size: 10pt">1/27/2021</span></td>
    <td style="width: 1%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: center; width: 11%"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-align: center"><span style="font-size: 10pt">10.57</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1300524/000149315221006319/ex10-1.htm"><span style="font-size: 10pt">March 8, 2021, Consulting Agreement between American International Holdings Corp. and KBHS, LLC</span></a></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">8-K</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">000-50912</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">10.1</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">3/18/2021</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-align: center"><span style="font-size: 10pt">10.58</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><a href="https://www.sec.gov/Archives/edgar/data/1300524/000149315221008089/ex10-3.htm"><span style="font-size: 10pt">Form of 6% Original Issue Discount Secured Convertible Promissory Note dated January 6, 2021, by American International Holdings Corp. in favor of the holders thereof</span></a></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">8-K</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">000-50912</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">10.3</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">4/6/2021</span></td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-align: center"><span style="font-size: 10pt">10.59#</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1300524/000149315221016724/ex10-1.htm"><span style="font-size: 10pt">Securities Purchase Agreement dated June 24, 2021, by and between American International Holdings Corp., and the Investors party thereto</span></a></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">8-K</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">000-50912</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">10.1</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">7/13/2021</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-align: center"><span style="font-size: 10pt">10.60</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1300524/000149315221016724/ex10-2.htm"><span style="font-size: 10pt">Form of 6% Original Issue Discount Secured Convertible Promissory Note dated June 24, 2021, by American International Holdings Corp. in favor of the holders thereof</span></a></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">8-K</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">000-50912</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">10.2</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">7/13/2021</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-align: center"><span style="font-size: 10pt">10.61</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1300524/000149315221016724/ex10-3.htm"><span style="font-size: 10pt">Form of Warrant to Purchase Common Stock dated June 24, 2021, by American International Holdings Corp. in favor of the holders thereof</span></a></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">8-K</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">000-50912</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">10.3</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">7/13/2021</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-align: center"><span style="font-size: 10pt">10.62#</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1300524/000149315221016724/ex10-4.htm"><span style="font-size: 10pt">Registration Rights Agreement dated June 24, 2021, by American International Holdings Corp. in favor of the investors named therein</span></a></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">8-K</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">000-50912</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">10.4</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">7/13/2021</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-align: center"><span style="font-size: 10pt">10.63***</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1300524/000149315221018550/ex10-1.htm"><span style="font-size: 10pt">American International Holdings Corp. 2021 Equity Incentive Plan</span></a></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">8-K</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">000-50912</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">10.1</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">8/4/2021</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">&#160;</span></td></tr>
</table>

<p style="margin: 0">&#160;</p>

<p style="margin: 0"></p>

<!-- Field: Page; Sequence: 183; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: center">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: left"><a href="#toc" title="Table of Contents" style="font-style: italic">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page -->

<p style="margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top; background-color: White">
    <td style="text-align: center"><span style="font-size: 10pt">10.64</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1300524/000149315221021320/ex10-1.htm"><span style="font-size: 10pt">Telemedicine Services Agreement dated August 15, 2021, by and between ZipDoctor, Inc. and Murphy RX, LLC</span></a></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">8-K</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">000-50912</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">10.1</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">8/26/2021</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-align: center"><span style="font-size: 10pt">10.65</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1300524/000149315221030819/ex10-1.htm"><span style="font-size: 10pt">Form of Securities Purchase Agreement by and between American International Holdings Corp., and each Investor party thereto (November 2021 Offering)</span></a></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">8-K</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">000-50912</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">10.1</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">12/8/2021</span></td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-align: center"><span style="font-size: 10pt">10.66</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1300524/000149315221030819/ex10-2.htm"><span style="font-size: 10pt">Form of Promissory Note by American International Holdings Corp. in favor of the holders thereof (November 2021 Offering)</span></a></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">8-K</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">000-50912</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">10.2</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">12/8/2021</span></td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-align: center"><span style="font-size: 10pt">10.67</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1300524/000149315221030819/ex10-3.htm"><span style="font-size: 10pt">Form of Common Stock Purchase Warrant by American International Holdings Corp. in favor of the holders thereof (November 2021 Offering)</span></a></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">8-K</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">000-50912</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">10.3</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">12/8/2021</span></td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>

<tr style="vertical-align: top; background-color: White">
    <td style="width: 10%; text-align: center"><span style="font-size: 10pt">10.68***</span></td>
    <td style="width: 1%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 35%; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1300524/000149315222001452/ex10-1.htm"><span style="font-size: 10pt; background-color: white">January 12, 2022 Executive Employment Agreement between American International Holdings Corp. and Jacob D. Cohen</span></a></td>
    <td style="width: 1%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 8%; text-align: center"><span style="font-size: 10pt">8-K</span></td>
    <td style="width: 1%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 8%"><span style="font-size: 10pt">000-50912</span></td>
    <td style="width: 1%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 8%; text-align: center"><span style="font-size: 10pt">10.1</span></td>
    <td style="width: 1%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 14%; text-align: center"><span style="font-size: 10pt">1/18/2022</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 11%; text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-align: center"><span style="font-size: 10pt">10.69***</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1300524/000149315222004868/ex10-1.htm"><span style="font-size: 10pt">Confidential Employment Offer Letter and Summary of Terms and Conditions dated February 11, 2022, by and between American International Holdings Corp and Craig Hewitt</span></a></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">8-K</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">000-50912</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">10.1</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">2/17/2022</span></td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-align: center"><span style="font-size: 10pt">10.70***</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1300524/000149315222006290/ex10-1.htm"><span style="font-size: 10pt">Employment Agreement between American International Holdings Corp. and Maja Matthews dated March 4, 2022</span></a></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">8-K</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">000-50912</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">10.1</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">3/08/2022</span></td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-align: center"><span style="font-size: 10pt">10.71***</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1300524/000149315222006290/ex10-2.htm"><span style="font-size: 10pt">Employment Agreement between American International Holdings Corp. and Sultan Haroon dated March 4, 2022</span></a></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">8-K</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">000-50912</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">10.2</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">3/08/2022</span></td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>

</table>

<p style="margin: 0">&#160;</p>

<p style="margin: 0"></p>

<!-- Field: Page; Sequence: 184; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: center">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: left"><a href="#toc" title="Table of Contents" style="font-style: italic">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page -->

<p style="margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top; background-color: White">
    <td style="text-align: center; width: 10%"><span style="font-size: 10pt">23.1*</span></td>
    <td style="width: 1%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify; width: 35%"><a href="ex23-1.htm"><span style="font-size: 10pt">Consent of Independent Registered Public Accounting Firm</span></a></td>
    <td style="width: 1%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: center; width: 8%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 1%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 8%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 1%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: center; width: 8%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 1%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: center; width: 14%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 1%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: center; width: 11%"><span style="font-size: 10pt">X</span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-align: center"><span style="font-size: 10pt">23.2#</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><a href="ex5-1.htm"><span style="font-size: 10pt">Consent of The Loev Law Firm, PC (included in Exhibit 5.1)</span></a></td>
    <td style="text-align: center"><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-align: center"><span style="font-size: 10pt">24.1*</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><a href="#S_001"><span style="font-size: 10pt">Power of Attorney (included on signature page)</span></a></td>
    <td style="text-align: center"><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">X</span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-align: center"><span style="font-size: 10pt">107*</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: justify"><a href="ex107.htm"><span style="font-size: 10pt">Filing Fee Table</span></a></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">X</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Filed
    herewith.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">***</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicates
    management contract or compensatory plan or arrangement.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">#
Certain schedules and exhibits have been omitted pursuant to Item 601(a)(5) of Regulation S-K. A copy of any omitted schedule or Exhibit
will be furnished supplementally to the Securities and Exchange Commission upon request; provided, however that American International
Holdings Corp. may request confidential treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended, for any
schedule or Exhibit so furnished.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="S_007"></span>ITEM
17. UNDERTAKINGS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
undersigned registrant hereby undertakes:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)
To file, during any period in which offers or sales are being made, a post-effective amendment to this registration statement to:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)
Include any prospectus required by Section 10(a)(3) of the Securities Act;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)
Reflect in the prospectus any facts or events arising after the effective date of the registration statement (or the most recent post-effective
amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in the registration
statement. Notwithstanding the foregoing, any increase or decrease in volume of securities offered (if the total dollar value of securities
offered would not exceed that which was registered) and any deviation from the low or high end of the estimated maximum offering range
may be reflected in the form of prospectus filed with the Commission pursuant to Rule 424(b) if, in the aggregate, the changes in volume
and price represent no more than a 20% change in the maximum aggregate offering price set forth in the &#8220;<span style="text-decoration: underline">Calculation of Registration
Fee</span>&#8221; table in the effective registration statement; and</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.4in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iii)
Include any material information with respect to the plan of distribution not previously disclosed in the registration statement or any
material change to such information in the registration statement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)
That, for the purpose of determining any liability under the Securities Act of 1933, each such post-effective amendment shall be deemed
to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall
be deemed to be the initial bona fide offering thereof.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 185; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: center">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: left"><a href="#toc" title="Table of Contents" style="font-style: italic">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)
To remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the
termination of the offering.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4)
That, for the purpose of determining liability under the Securities Act of 1933 to any purchaser each prospectus filed by the registrant
pursuant to Rule 424(b)(3) shall be deemed to be part of the registration statement as of the date the filed prospectus was deemed part
of and included in the registration statement; and each prospectus required to be filed pursuant to Rule 424(b)(2), (b)(5), or (b)(7)
as part of a registration statement in reliance on Rule 430B relating to an offering made pursuant to Rule 415(a)(1)(i), (vii), or (x)
for the purpose of providing the information required by section 10(a) of the Securities Act of 1933 shall be deemed to be part of and
included in the registration statement as of the earlier of the date such form of prospectus is first used after effectiveness or the
date of the first contract of sale of securities in the offering described in the prospectus. As provided in Rule 430B, for liability
purposes of the issuer and any person that is at that date an underwriter, such date shall be deemed to be a new effective date of the
registration statement relating to the securities in the registration statement to which that prospectus relates, and the offering of
such securities at that time shall be deemed to be the initial bona fide offering thereof. Provided, however, that no statement made
in a registration statement or prospectus that is part of the registration statement or made in a document incorporated or deemed incorporated
by reference into the registration statement or prospectus that is part of the registration statement will, as to a purchaser with a
time of contract of sale prior to such effective date, supersede or modify any statement that was made in the registration statement
or prospectus that was part of the registration statement or made in any such document immediately prior to such effective date.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(5)
Insofar as indemnification for liabilities arising under the Securities Act of 1933 may be permitted to directors, officers and controlling
persons of the registrant pursuant to the foregoing provisions, or otherwise, the registrant has been advised that in the opinion of
the Securities and Exchange Commission such indemnification is against public policy as expressed in the Act and is, therefore, unenforceable.
In the event that a claim for indemnification against such liabilities (other than the payment by the registrant of expenses incurred
or paid by a director, officer or controlling person of the registrant in the successful defense of any action, suit or proceeding) is
asserted by such director, officer or controlling person in connection with the securities being registered, the registrant will, unless
in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the
question whether such indemnification by it is against public policy as expressed in the Act and will be governed by the final adjudication
of such issue.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>


<!-- Field: Page; Sequence: 186; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: center">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: left"><a href="#toc" title="Table of Contents" style="font-style: italic">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="S_001"></span>SIGNATURES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the requirements of the Securities Act of 1933, the registrant has duly caused this registration statement to be signed on its behalf
by the undersigned, thereunto duly authorized, in the city of Plano, State of Texas on the 21<sup>st</sup> day of April 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>AMERICAN
    INTERNATIONAL HOLDINGS CORP.</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 50%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 3%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 47%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>/s/
    Jacob D. Cohen</i></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Jacob
    D. Cohen, Chief Executive Officer, President, Director (Principal Executive Officer)</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">KNOW
ALL MEN BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints Mr. Jacob D. Cohen with full power
of substitution and authority to act in the absence of the other, as his or her true and lawful attorneys-in-fact and agents, with full
power of substitution and re-substitution for him or her and in his or her name, place and stead, in any and all capacities, to sign
any and all amendments (including post-effective amendments) to this Registration Statement, and to file the same, with all exhibits
thereto, and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact
and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done
in and about the premises, as fully to all intents and purposes as he might or could do in person, hereby ratifying and confirming all
that each of said attorney-in-fact or his substitute or substitutes, may lawfully do or cause to be done by virtue hereof.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the requirements of the Securities Act of 1933, this Registration Statement has been signed by the following persons in the capacities
and on the dates indicated.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 32%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Signature</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 32%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Title</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 32%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Date</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>/s/
    Jacob D. Cohen</i></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Executive Officer, President, </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">April
    21,</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> 2022</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Jacob
    D. Cohen</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director
    (Principal Executive Officer)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>/s/
    Craig A. Hewitt</i></b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Financial Officer</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">April
    21,</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> 2022</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Craig
    A. Hewitt</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Principal
    Financial/Accounting Officer)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>/s/
    Peter &#8220;Casey&#8221; Jensen</i></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">April
    21,</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> 2022</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Peter
                                            &#8220;Casey&#8221; Jensen</span></p>
</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>/s/
    Kenny Myers</i></b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">April
    21,</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> 2022</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Kenny
    Myers</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>/s/
    <b>Lorraine D&#8217;Alessio</b></i></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">April
    21,</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> 2022</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Lorraine
    D&#8217;Alessio</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 187; Options: Last -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: center">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></td></tr></table></div>
    <!-- Field: /Page -->
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>



















































</body>
</html>
<!-- Field: Set; Name: xdx; ID: xdx_08B_extensions -->
<!-- eJzNW21z47YR/gX5Dxh/amdcx/Il0/a+ybJ9cSu/xNbddZrJB4iEZMxRBAOQspV/1H/ZXYAvIAiAlNMPzdzkTtxnXwgsdhcL8OTk9OSTuOEZk+Rfl09LsmK7IqMlI09swyTLEwaIxe0/PxL4+4ltuSolzUv9s2FcCOBhwPPj2ewDBYKG7rli6Udy/sP3s79+f3FBzv/+cfY3Mr87+Q7pC5FveMryktOM0Dwlj1IUkrOSyoORsKJvIhe7g1b1hUnFRf6RzM7ODfk/5OJ8dkHuxZ6+CvlNkeVycfLdqf7vu5NPUlQFqqlUKXbkOmM70KUMa/dHm5JozMdnllSSl5ypx0omL1Sx+VYyzXfHdmsmATo7vwCtczShg5MGT1oG8oth+fUYoGvQp0ysabagAJX3rNRveZsnPmMMlBgsacAE0LaCaajhuMC0qEuYsD0r+TpjjxJdQ7L0uRTJN//YIAu5JJpJai7SshHN1x+i4/CuiXo405W4Vapi8/t5msJ4i5xmzy/wrspnomEhpSCaCVyQdGzE8Nkqj8UPRhER0xwLkWM+NQHjWrDkG7atZBVwISR/ArLrDqHnrvgvLE+F9Ek2FJt3+MSVtnqFtznciEre5qqkWaaXbyv9vJN+8QOxIbbQCMnV1wzl9W8VLxA9nCJLZzvwLdw/BVNxrjVXsB72tOR79onyfCmUesi7Z7Bwr9+SrEp5vu2eXr8VLFcYrSEsgqHnP8A/OzLZgiSSgSgicpJ2z3NWEtaIswnMCDzzR0uI+TuR65X5SA8UFqxvoAyqXsA1zn7xMbqrFdcehZz0sOkHoRsBfrJnqsSR/UKzCscBhqEZh4aPiA0p2riitNoNeCJvmckeuQMvrXXp9Z9eQUzPt48wXCLVCjvT6qHRIQEMuxcle2ZlaVJQ3y7z4lxLJKkWSQot09ihSY3hiRksZWINmp2DaKJa2QGrO8tamyDg7nnC1BPDXJ8+Uon5KTxmlk5VsxJpeElhmEeVO8NSp5VuHjXBJABM9WFjhuOgmvxhza2hJq28UfsiHmVsa137/MfjXMrY8kdnZ8yICXM01ZIjp2rMsvdNWNzYwFI0pkxfi5bFkbVY2/a/WIzalEvICSlWzRBgKZYQcwlF9VbzXR46CEREnYteqTRB5qFAtPqEJTjUguadodZVevS75VLjyBaBLD12wq/YuuwP09SVmAKnNQh/SO/xbuVor0l+I7rUqOrUqeOfL3eqJhcGRIHlW4DlDPL0ZimoE7ssMpqdGYBvXHZFBbN1C1MGZpddRresqjEQXgxoJE1by0RHNNhlQVyAyKIYhdpknqdXbM8yUTS5aebPTSaiwXLV7BBXDL/euaWdhFCxQAteimzBy8OzyCrtm5+f53YlahcNBk0QTlo8AYZTLELPegXEEdihVeBIWaYXYN8V+/Nn4wZ+F62O2mCkRx+DTzDBLXrObI06hhU7LAa8matEVBAUHnJrD6U19vW0QCwDE2u7pfUE5s9KRAfVxVDwVN94PVlJ56DsuIhuOxLW28X7sOkW4JLTNc/4sEbp4DgxVvGadRyxlVGXnL6irDCkUOjcFZRLVLysg29vidY0XW8HJHy5fX6+nd8l33ies8NyufAtBQMiDeoUmxy9jdQI3VX6ILc0578bl3/NwaNeeAFB4LJSHOPTo8h4clixt/Iyg0FojVlg7DXMql4HDbcOAeuan/xiJJASRBAt41f/6893MFkJzXWwy6nZR9/mKVCxNAhsUhsu0mMjHd9w1b+DxbX1K1srXno3ODXJ5vY88hYBsId7waQ/oRnQQGPNgDjGteBe7EUBQY1dcQpxJ7X9z1LfwkiNG3jYOMJVvXoB+36q8lRiDUSTF+bd1384Pyc12ZYWeDyMI13TSv6fdq0ecrZ6EZWCBRQZh9m5/41Dz10tS2a3NZ5YWcmcpf1UrzGEtU0KWaPOIjR/mmDe7pb1OjXG76VR4uDFYNwyIVOflobWa2R5nvmD8ldIX/KVHgL1SR10G9QwfowCBt4Kk5hWGRTE16rkO8yenxXbVNkSq0/cmsIag2T6mEE5D+G6nc4VpqhAuG6EYmZkjVhSabmQH7Gs1VtXI5oUKFsH826uf9HyyWosmD9Xa5VIrjcdN8yq2S8XaIhFJRsWzMjXBf/tkb4qfEH457J6840+kgjCtK36FyDt0R1HuJr/zYsrkZRW+9JSCERiqLYI/9NI4YTnCrHs+uRs1ZtMOjr4cwXF1aCzHNCiwaRo+pK0W2hTJxne9JJDvE+xkqxntdUx+7GbbwCStUZCYdZCQ3P/ePvz3ZV3voFC7q56Ezx85Mr7B03EeiFeWO6TqalEk20hgccDW1XJ1jSfZ+wNHIx5nabGkBbUsz9GHIQ5nsD+jufbdmpx4KGwrGRo5WcNizW/acs0Yarv2avetXzl5csdzyB6iNxb/gCwPg95BShpsb0KYQJmUCOwN28yxOc2n/t7uP5SeH8MYrp98sikLpa00FkTnzoQ0SgCMHOiE3DWfinRtCSuWGA9PDrdwaaNdOqui0lA33TBDqveyTwE5gn3YE1//cGZnwjN1YQNGjxSkRU6lVX3mN0UFNpsJfl2yySMIThhSbd6c2WSweUJdlXWJewCGxG9Lah56wKlkNKIIa2Ysz/CHBg0Vb/2JYOdNgM/qBLTDNABm2bOZn3W1Euat9khnpK1ZofKqObXedVIcBrQ72KMz/jqVfgrd5jVWhEBzGDGA7SYJizcx3UhKqzNpUb04enfqDoEBbW5xJgyKIjGlWFrIajMIUaUPfO3UV2ACapyaDFNbG+lwKAuRIW1uVRXX7+VMaGPEWlhxHeOXJomlDc3IJVoci9F+B9Hxuyab1+8m/HeqGhUcMwG1Ii+e56Pux6CgtpcYmwRi8+5tNp5qwnuUQrSMtUjuYr4yzjcta9vks8eV6AlLEIajkNel9mdK5lTPv/NBcD/panLNcdfjIqGpz8E07GuXde7IhMHxmDnA2KaXz6LGhoBKEGV7QO7vpwCcm1o7PTelmmJtgTvQ1fskm0ZvFVVSn1XJrClNijSwk4Ht1DGAK5e/67Ip9tsieJ3aaZgXAvu5J2QNPN3de7kGanJtozA46Ef7yHpp88FxTtISuQLIQt/3bcXxCBJDSWIdTt4Y5iBw+KFEaU787jV8NacLYbUoJ6LxoiuNudEw+egdgtOB6PeJZMwLRYpJ0TGWBgciXlPAgjlTyJL/XtUQycG0GuShQiuhq8830BpecNZlnpXdQ0gBtHrYQcpHk8Y72LHe9PHda4fpdjBxkjIQ8gXOsRguiOkmCe8smxCdWhgkULbJcdUQgYp2RQPrIGRinsIiCjGknmS4gYYLb6PUcw30/QaXKQMH9BdrVdcFULRTF8ShjxSX6XDk9G85HnF0oeCSXNIVr4wCRCxY97j+EYU2aIs2Ju2F+ksaUQ04ohAeQgDgWNH9y9Clismd7jrdQ91fcOkGQhyEL1RduNebx0fBR4kdZFvRy2z0zvgja6omokw15rPecoU3+a6gOy1ZuZVCa/Jf9enFabjo2+R2ByDy1u0ZQpMjN05CLmr8t1mDBIGucGqhh/8m4OnXs07c05RQqRhlQTuCLhvgfNnTUdB39xTvTBl4MftGX20DLOO8gPX6ON0V+2K+k9s8Xlvf0in5wFn76Q3ecyfvntdtdVwR9TwBjtxE3ki5j7zt0nW1bigJR56TCt2C6bpbZBhzT5ERPfkCRkd/SOHGjfgkxQ3wKBiH8BVfMOlKuF/zHzQ4VOqIQQxpP7qw5IXJbrKfq548k1fs6LZMvPu3jSE1BgCIFtelDgYUvZq9qqj4QJPFTqoPyRMwQxTG83VDZSJ/aM70yHu94NnbT9YM5ENcLk3btseb78PfBSDx8qgIUypj64u51noped5qs/61RNLGN+jN/bHoLlnaum7ERK/hKmg7KFK8Q2HFwF/0jc0IUGw8hTeb5OxpFQEKh+SUCkP+mBqh5fQsN9d5QXlqb4VWT9VJK2Yd3AILbWYngqSAmT84hr3F012suT9OiNCcvV8pXiBtwzk6prqHq4EHgdkB/r8jRCnjR94HJCt7miJ36gdsPhq5c8uO0GKNBBdoJ0FKR4ltznHEw3v
     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 -->
[{"type": "S-1", "sequence": "1", "filename": "forms-1.htm", "secsgml_size_bytes": 2456709}]
{"company-data": {"conformed-name": "AMERICAN INTERNATIONAL HOLDINGS CORP.", "cik": "0001300524", "assigned-sic": "8000", "irs-number": "901898207", "fiscal-year-end": "1231"}, "filing-values": {"form-type": "S-1", "act": "33", "file-number": "333-264411", "film-number": "22841144"}, "business-address": {"street1": "7950 LEGACY DRIVE", "street2": "SUITE 400", "city": "PLANO", "state": "TX", "zip": "75024", "phone": "(469) 963-2644"}, "mail-address": {"street1": "7950 LEGACY DRIVE", "street2": "SUITE 400", "city": "PLANO", "state": "TX", "zip": "75024"}, "former-company": [{"former-conformed-name": "Delta Seaboard International, Inc.", "date-changed": "20100518"}, {"former-conformed-name": "Hammonds Industries, Inc.", "date-changed": "20070515"}, {"former-conformed-name": "International American Technologies, Inc.", "date-changed": "20050310"}]}
As
filed with the Securities and Exchange Commission on
April
21, 2022
Registration
No. 333-
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
WASHINGTON,
D.C. 20549
FORM
S-1
REGISTRATION
STATEMENT
UNDER
THE SECURITIES ACT OF 1933
AMERICAN
INTERNATIONAL HOLDINGS CORP.
(Exact
name of registrant as specified in its charter)
Nevada
8000
90-1898207
(State
    or other jurisdiction of
incorporation
    or organization)
(Primary
    Standard Industrial
Classification
    Code Number)
(I.R.S.
    Employer
Identification
    Number)
7950
Legacy Drive
,
Suite 400
Plano
,
Texas
75024
(469)
963-2644
(Address, including zip code, and telephone number,
including
area code, of registrant's principal executive offices)
Jacob
D. Cohen
Chief Executive Officer
American International Holdings Corp.
7950
Legacy Drive, Suite 400
Plano,
Texas 75024
(972)
803-5337
(Name,
address, including zip code, and telephone number,
including
area code, of agent for service of process)
Copies
To:
David
M. Loev, Esq.
John
S. Gillies, Esq.
The
Loev Law Firm, PC
6300
West Loop South, Suite 280
Bellaire,
Texas 77401
Telephone:
(713) 524-4110
Facsimile:
(713) 524-4122
Email:
dloev@loevlaw.com
;
john@loevlaw.com
Approximate
date of commencement of proposed sale to the public:
From time to time after this Registration Statement becomes effective.
If
any of the securities being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the
Securities Act of 1933 check the following box: ☒
If
this Form is filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, please check the
following box and list the Securities Act registration statement number of the earlier effective registration statement for the same
offering. ☐
If
this Form is a post-effective amendment filed pursuant to Rule 462(c) under the Securities Act, check the following box and list the
Securities Act registration statement number of the earlier effective registration statement for the same offering. ☐
If
this Form is a post-effective amendment filed pursuant to Rule 462(d) under the Securities Act, check the following box and list the
Securities Act registration statement number of the earlier effective registration statement for the same offering. ☐
Indicate
by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting
company or an emerging growth company. See the definitions of "
large accelerated filer,
" "
accelerated filer,
"
"
smaller reporting company
" and "
emerging growth company
" in Rule 12b-2 of the Exchange Act.
Large
    accelerated filer ☐
Accelerated
    filer ☐
Non-accelerated
    filer
☒
Smaller
    reporting company
☒
Emerging
    growth company
☐
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided to Section 7(a)(2)(B) of the Securities Act. ☐
The
registrant hereby amends this Registration Statement on such date or dates as may be necessary to delay its effective date until the
registrant shall file a further amendment which specifically states that this Registration Statement shall thereafter become effective
in accordance with Section 8(a) of the Securities Act or until the Registration Statement shall become effective on such date as the
Securities and Exchange Commission acting pursuant to said Section 8(a), may determine.
The
information in this prospectus is not complete and may be changed. The selling shareholders may not sell these securities pursuant to
this prospectus until the registration statement filed with the Securities and Exchange Commission is effective. This prospectus is not
an offer to sell these securities and it is not soliciting an offer to buy these securities in any jurisdiction where the offer or sale
is not permitted.
PRELIMINARY
PROSPECTUS SUBJECT TO COMPLETION, DATED APRIL 21, 2022
42,666,665
Shares of Common Stock
This
prospectus relates to the resale by the selling stockholders named herein of up to 42,666,665 shares of common stock, par value $0.0001
per share, which we refer to as common stock, of American International Holdings Corp., which we refer to as us, we, the Company, the
Registrant or American International, consisting of up to 29,333,333 shares of common stock of the Registrant issuable upon conversion
of the principal and accrued interest at maturity under those certain convertible promissory notes in the aggregate principal amount
of $2,000,000 (the "
Notes
"), which were sold by the Company between November 22, 2021 and December 2, 2021, at a conversion
rate equal to $0.075 per share, and up to 13,333,332 shares of common stock of the Company issuable upon the exercise of those certain
Common Stock Purchase Warrants ("
Warrants
"), which were granted by the Company between November 22, 2021 and December
2, 2021, at an exercise price of $0.075 per share. The Notes and Warrants are described in greater detail under "
Securities Purchase Agreement
", beginning on page 47.
The
shares of common stock being offered by the selling stockholders (which term includes their respective donees, pledgees, transferees,
or other successors-in-interest) have been issued in a private offering transaction between November 22, 2021 and December 2, 2021, as
described in greater detail under "
Securities Purchase Agreement
", beginning on page 47. The selling
stockholders are described in greater detail under "
Selling Stockholders
", beginning on page 60.
i
The
shares of common stock described in this prospectus may be offered for sale from time to time by the selling stockholders named herein.
The selling stockholders may offer and sell the shares in a variety of transactions as described under the heading "
Plan of Distribution
"
beginning on page 57, including transactions on any stock exchange, market or facility on which our common stock may be traded, in privately
negotiated transactions or otherwise at market prices prevailing at the time of sale, at prices related to such market prices or at negotiated
prices. We have no basis for estimating either the number of shares of our common stock that will ultimately be sold by the selling stockholders
or the prices at which such shares will be sold.
We
are not selling any securities covered by this prospectus and will not receive any of the proceeds from the sale of such shares by
the selling stockholders. However, to the extent that the Warrants are exercised for cash, we will receive the payment of the
exercise price in connection with such exercise (see also "
Use of Proceeds
" on page 50 below). We
are bearing all of the expenses in connection with the registration of the shares of common stock, but all selling and other
expenses incurred by the selling stockholders, including commissions and discounts, if any, attributable to the sale or disposition
of the shares will be borne by them.
The
selling stockholders and intermediaries through whom such securities are sold may be deemed "
underwriters
" within
the meaning of the Securities Act of 1933, as amended (the "
Securities Act
"), with respect to the securities offered
hereby, and any profits realized or commissions received may be deemed underwriting compensation.
A
current prospectus must be in effect at the time of the sale of the shares of common stock discussed above and each selling stockholder
or dealer selling the common stock is required to deliver a current prospectus upon the sale. The selling stockholders will be responsible
for any commissions or discounts due to brokers or dealers. We will pay all of the other offering expenses.
In
addition, any securities covered by this prospectus which qualify for sale pursuant to Rule 144 of the Securities Act may be sold under
Rule 144 rather than pursuant to this prospectus.
Our
common stock is considered a "
penny stock
", and subject to the requirements of Rule 15g-9, promulgated under the Exchange
Act of 1934, as amended. "
Penny stock
" is generally defined as any equity security not traded on an exchange or quoted
on NASDAQ that has a market price of less than $5.00 per share. Under such rule, broker-dealers who recommend low-priced securities to
persons other than established customers and accredited investors must satisfy special sales practice requirements, including a requirement
that they make an individualized written suitability determination for the purchaser and receive the purchaser's consent prior
to the transaction. The Securities Enforcement Remedies and Penny Stock Reform Act of 1990, also requires additional disclosure in connection
with any trades involving a stock defined as a penny stock.
The
required penny stock disclosures include the required delivery, prior to any transaction, of a disclosure schedule explaining the penny
stock market and the risks associated with it. Such requirements could severely limit the market liquidity of the securities and the
ability of purchasers to sell their securities in the secondary market. In addition, various state securities laws impose restrictions
on transferring "
penny stocks
" and as a result, investors in the common stock may have their ability to sell their
shares of the common stock impaired.
ii
Jacob
D. Cohen, our Chief Executive Officer and Chairman, our principal stockholder, currently controls approximately 71.1% of the voting power
of our capital stock (based on shares of common stock outstanding as of the date of this prospectus).
Our
common stock is quoted on the OTCQB Market under the symbol "AMIH". The closing price for our common stock on April 20,
2022, was $0.041 per share
Investing
in our securities involves risks. You should carefully consider the "
risk factors
" beginning on page 16 of this prospectus
and set forth in the documents incorporated by reference herein before making any decision to invest in our securities.
Neither
the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or passed
upon the adequacy or accuracy of this prospectus. Any representation to the contrary is a criminal offense.
The
date of this prospectus is _____________, 2022.
iii
TABLE
OF CONTENTS
About This Prospectus
1
Cautionary Statement Regarding Forward-Looking Statements
2
Prospectus Summary
3
This Offering
15
Risk Factors
16
Securities Purchase Agreement
47
Use of Proceeds
50
Determination of Offering Price
51
Description of Capital Stock
51
Plan of Distribution
57
Selling Stockholders
60
Certain Beneficial Owners and Management
63
Dividend Policy
65
Legal Matters
65
Experts
65
Changes in and Disagreements with Accountants on Accounting and Financial Disclosure
66
Description of Business
66
Description of Property
78
Legal Proceedings
80
Market for Common Equity and Related Stockholder Matters
82
Management's Discussion and Analysis of Financial Condition and Results of Operations
85
Quantitative and Qualitative Disclosures About Market Risk
94
Directors, Executive Officers and Corporate Governance
94
Executive and Director Compensation
106
Certain Relationships and Related Transactions
119
Where You Can Find Additional Information
123
Indemnification of Directors and Officers
124
Index to Financial Statements
125
iv
Table of Contents
About
This Prospectus
This
prospectus is part of a registration statement that we filed with the Securities and Exchange Commission (the "
SEC
"
or the "
Commission
"). This prospectus relates to the resale by the selling stockholders listed in this prospectus
of up to 42,666,665 shares of our common stock. We will not receive any proceeds from the resale of any of the shares by the selling
stockholders. However, to the extent that the Warrants are exercised for cash, we will receive the payment of the exercise price in connection
with such exercise (see also "
Use of Proceeds
" on page 50 below). We have agreed to pay for the expenses related to the registration
of the shares being offered by the selling stockholders.
You
should read this prospectus, together with additional information described under "
Where You Can Find More Information
",
beginning on page 123, before making an investment decision.
This
prospectus does not contain all the information provided in the registration statement we filed with the SEC. For further information
about us or our securities offered hereby, you should refer to that registration statement, which you can obtain from the SEC as described
below under "
Where You Can Find More Information
", beginning on page 123.
You
should rely only on the information contained in this prospectus. We have not authorized any other person to provide you with different
information. If anyone provides you with different or inconsistent information
,
you should not rely on it. This prospectus is
not an offer to sell or the solicitation of an offer to buy any securities other than the securities to which it relates and is not an
offer to sell or the solicitation of an offer to buy securities in any jurisdiction to any person to whom it is unlawful to make an offer
or solicitation in that jurisdiction.
We
will disclose any material changes in our affairs in a post-effective amendment to the registration statement of which this prospectus
is a part, or a prospectus supplement. We do not imply or represent by delivering this prospectus that American International Holdings
Corp., or its business, financial condition or results of operations, are unchanged after the date on the front of this prospectus is
correct at any time after such date, provided that we will amend or supplement this prospectus to disclose any material events which
occur after the date of such prospectus to the extent required by applicable law.
Persons
outside the United States who come into possession of this prospectus must inform themselves about, and observe any restrictions relating
to, the offering of the securities and the distribution of this prospectus outside of the United States.
Our
logo and some of our trademarks and tradenames are used in this prospectus. This prospectus also includes trademarks, tradenames and
service marks that are the property of others. Solely for convenience, trademarks, tradenames and service marks referred to in this prospectus
may appear without the ®, ™ and SM symbols. References to our trademarks, tradenames and service marks are not intended to
indicate in any way that we will not assert to the fullest extent under applicable law our rights or the rights of the applicable licensors
if any, nor that respective owners to other intellectual property rights will not assert, to the fullest extent under applicable law,
their rights thereto. We do not intend the use or display of other companies' trademarks and trade names to imply a relationship
with, or endorsement or sponsorship of us by, any other companies.
1
Table of Contents
The
market data and certain other statistical information used throughout this prospectus are based on independent industry publications,
reports by market research firms or other independent sources that we believe to be reliable sources. Industry publications and third-party
research, surveys and studies generally indicate that their information has been obtained from sources believed to be reliable, although
they do not guarantee the accuracy or completeness of such information. We are responsible for all of the disclosure contained in this
prospectus, and we believe these industry publications and third-party research, surveys and studies are reliable. While we are not aware
of any misstatements regarding any third-party information presented in this prospectus, their estimates, in particular, as they relate
to projections, involve numerous assumptions, are subject to risks and uncertainties, and are subject to change based on various factors,
including those discussed under the section entitled "
Risk Factors
" beginning on page 16 of this prospectus. These and other
factors could cause our future performance to differ materially from our assumptions and estimates. Some market and other data included
herein, as well as the data of competitors as they relate to American International Holdings Corp., is also based on our good faith estimates.
Unless
the context otherwise requires, references in this prospectus to:
●
"
we,
" "
us,
" "
our,
" the "
Registrant
", the
"
Company,
" and "
American International
", refer to American International Holdings Corp. and
its subsidiaries;
●
"
Exchange Act
" refers to the Securities Exchange Act of 1934, as amended;
●
"
SEC
" or the "
Commission
" refers to the United States Securities and Exchange Commission;
and
●
"
Securities Act
" refers to the Securities Act of 1933, as amended. All dollar amounts in this prospectus are in
U.S. dollars unless otherwise stated. You should read the entire prospectus before making an investment decision to purchase our
securities.
Cautionary
Statement Regarding Forward-Looking Statements
This
prospectus, each prospectus supplement and the information incorporated by reference in this prospectus and each prospectus supplement
contain certain statements that constitute "
forward-looking statements
" within the meaning of the federal securities
laws, including pursuant to Section 27A of the Securities Act and Section 21E of the Securities Exchange Act. The words "
believe,
"
"
may,
" "
will,
" "
potentially,
" "
estimate,
" "
continue,
"
"
anticipate,
" "
intend,
" "
could,
" "
would,
" "
project,
"
"
plan,
" "
expect
" and the negative and plural forms of these words and similar expressions are intended
to identify forward-looking statements, but are not the exclusive means of identifying such statements. Those statements appear in this
prospectus, any accompanying prospectus supplement and the documents incorporated herein and therein by reference, particularly in the
sections titled "
Prospectus Summary
" and "
Risk Factors,
" and include statements regarding
the intent, belief or current expectations of the Company and management that are subject to known and unknown risks, uncertainties and
assumptions. Examples of forward-looking statements include statements relating to macroeconomic conditions; our expectations regarding
future growth, including future revenue; our expectations regarding new products and market acceptance of current and new products; anticipated
changes in regulations and market acceptance of our products and industry; our growth plans and opportunities, including our strategies
for future acquisitions, future product expansion, potential client marketing and targeting and potential geographic expansion; estimated
returns on future acquisitions; and other statements concerning our plans, objectives, goals, strategies, future events, future revenues
or performance, capital expenditures, financing needs, the competitive landscape for our products, plans or intentions relating to acquisitions
and developments and other information that is not historical information, and our assumptions underlying these expectations.
2
Table of Contents
This
prospectus, any prospectus supplement and the information incorporated by reference in this prospectus and any prospectus supplement
also contain statements that are based on the current expectations of our Company and management. You are cautioned that any such forward-looking
statements are not guarantees of future performance and involve risks and uncertainties, and that actual results may differ materially
from those projected in the forward-looking statements as a result of various factors.
Because
forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified, you should
not rely upon forward-looking statements as predictions of future events. The events and circumstances reflected in the forward-looking
statements may not be achieved or occur and actual results could differ materially from those projected in the forward-looking statements.
Except as required by applicable law, including the securities laws of the United States and the rules and regulations of the SEC, we
do not plan to publicly update or revise any forward-looking statements contained herein after we distribute this prospectus, whether
as a result of any new information, future events or otherwise.
You
should also consider carefully the statements under "
Risk Factors
" and other sections of this prospectus, which address additional
facts that could cause our actual results to differ from those set forth in the forward-looking statements. We caution investors not
to place significant reliance on the forward-looking statements contained in this prospectus.
Prospectus
Summary
The
following summary highlights material information found in more detail elsewhere in the prospectus. It does not contain all of the information
you should consider. As such, before you decide to buy our common stock, in addition to the following summary, we urge you to carefully
read the entire prospectus, especially the risks of investing in our common stock as discussed under "
Risk Factors.
"
3
Table of Contents
About
American International Holdings Corp.
The
Company is headquartered in Plano, Texas, and is an investor, developer and asset manager with diversified assets across the healthcare
supply chain. The Company's portfolio encompasses telemedicine and other virtual health platforms, subscriber based primary care
and concierge medicine plans, preventative care solutions and wellness related assets such as mental and behavioral health services,
a digital online mail order pharmacy, a men's wellness products and services company, as well as its own proprietary life coaching
platform. The Company provides its various services through direct-to-consumer and business-to-business distribution channels and is
focused on developing, acquiring and bringing to market technologies and solutions that we believe can advance the quality of life for
the global community. Additionally, the Company seeks opportunities to acquire and grow businesses that possess strong brand values and
that can generate long-term sustainable free cash flow and attractive returns in order to maximize value for all stakeholders.
The
Company currently is the parent to ten subsidiaries, of which seven are wholly-owned subsidiaries and three (3) are majority-owned subsidiaries.
In 2021, the Company ceased operations of five of its ten subsidiaries in order to focus on the subsidiaries that better aligned with
the purpose of the Company and its ongoing business plan.
ZIPDOCTOR,
INC. – 100% OWNED
On
April 28, 2020, the Company incorporated a wholly-owned subsidiary, ZipDoctor, Inc. ("
ZipDoctor
") in the state of
Texas. ZipDoctor launched its online, direct-to-consumer subscription-based telemedicine platform
www.ZipDoctor.co
in the third
quarter of 2020. ZipDoctor provides its customers with unlimited, 24/7 access to board certified physicians and licensed mental and behavioral
health counselors and therapists via a newly developed, monthly subscription-based online telemedicine platform. ZipDoctor's online
telemedicine platform is available to customers across the United States and offers bilingual coverage (English and Spanish), with virtual
visits taking place either via the phone or through a secured video chat platform. ZipDoctor customers subscribe through the website
and are only required to pay a monthly fee, which is determined based on whether they are an individual, a couple, or a family. ZipDoctor
is currently being sold on a direct-to-consumer basis, with an emphasis on digital marketing and advertising.
Digital
Marketing Initiative:
The ZipDoctor website was originally designed to be marketed and sold primarily using a digital and social
media advertising campaign. Shortly after the website's launch, ZipDoctor began to advertise on Google pay per click (PPC), search
engine optimization (SEO), Facebook and Instagram. Shortly after launching, the Company decided to shift the focus of its marketing to
a direct sales approach, resulting in the formation and launch of EPIQ MD, Inc.
Going
Forward Strategy:
With EPIQ MD, Inc. taking over the sales and marketing of the direct-to-consumer telemedicine platform, ZipDoctor
has changed its business plan to focus on developing customized telemedicine solutions for niche, or specialty care, areas of medicine.
Telemedicine
Platform Provider for Pharmacies.
ZipDoctor is targeting relationships with specialty compound pharmacies seeking both an online
telemedicine platform and a network of doctors to assist in facilitating patient online visits and to streamline the medical intake,
patient demographics, health insurance verifications and overall prescription process. In exchange, ZipDoctor will receive a monthly
fee on a per-patient per month basis for this customized access to the telemedicine platform. The initial focus will be on Texas based
pharmacies, however, if successful in Texas, ZipDoctor plans to expand its customized telemedicine solution to pharmacies across the
United States.
4
Table of Contents
On
August 15, 2021, ZipDoctor entered into a Telemedicine Services Agreement (the "
Services Agreement
") with Murphy RX,
LLC ("
Murphy
"), a Texas-based specialty pharmacy, which has since ceased operations as of January 31, 2022. Pursuant
to the Services Agreement, ZipDoctor agreed to provide Murphy with access to its centralized technology platform, to collect and manage
patient demographics, and access to telemedicine services. Murphy agreed to pay ZipDoctor a monthly fee on a per-patient basis for the
use of the technology platform and for access to primary care telemedicine services. ZipDoctor also agreed to provide continued support
for the ZipDoctor website through the term of the agreement. The Services Agreement is no longer in effect, as Murphy ceased operations
effective as of January 31, 2022.
As
of the date of this prospectus, ZipDoctor has approximately 100 total members subscribed to its subscription-based telemedicine platform
at
www.ZipDoctor.co
. Monthly subscription payments range from $25/month to $45/month, depending on how many family members are
included, and provide members with unlimited, 24/7 access to board certified physicians and licensed mental and behavioral health counselors
and therapists.
EPIQ
MD, INC. – 100% OWNED
On
October 23, 2020, the Company incorporated a wholly-owned subsidiary, EPIQ MD, Inc. ("
EPIQ MD
") in the state of Nevada.
EPIQ MD is a direct-to-consumer, telemedicine and healthcare company targeting Americans who are uninsured or underinsured. The EPIQ
MD service offering is a convergence of primary care telemedicine, preventative care services and wellness programs – under the
EPIQ MD brand and on a single platform. EPIQ MD markets and sells its services direct to end-use consumers, as well as through business-to-business
(B2B) efforts, by focusing on employers in the targeted industries.
Products
& Services
EPIQ
MD's telemedical services revolve around three services (1) primary care, (2) mental health care, and (3) prevention. Using cloud-based
software, EPIQ MD has been able to merge these services under a single platform.
Primary
care with EPIQ MD connects users to board certified doctors and medical professionals who can treat most non-emergency conditions using
telemedicine. Similarly, EPIQ MD's mental health services connect users with licensed therapists and counselors. As for EPIQ MD's
preventive care, the Company is using data driven technologies (wearables and apps), nutritionist and lab services, to help attempt to
mitigate chronic diseases and the risk factors associated with them. In the future, EPIQ MD plans to add in-home medical devices to record
vital information, offering what we believe to be the ambit of services between patient and doctor via the use of EPIQ MD's telemedicine
platform.
5
Table of Contents
EPIQ
MD also provides its subscribers with an option to participate in two premium add-on services, EPIQ LUX and EPIQ Paws. EPIQ LUX provides
subscribers with discounts to ancillary healthcare related services such as laboratory services, dental and vision discount plans, prescription
drug discounts, and imaging services and EPIQ Paws provides subscribers with access to virtual consultations with licensed veterinarians.
As
of the date of this prospectus, EPIQ MD has nominal subscribers as it is expanding its marketing initiatives. However, EPIQ MD is currently
registered to do business and is being marketed in
Alaska, Georgia, Illinois, Texas, Arizona, New
Mexico, Colorado, Louisiana, Mississippi, Alabama, Florida, Nevada and Utah.
To ensure the highest quality control, it plans to
scale up its full-service coverage incrementally to all 50 U.S. states by year-end 2022, funding permitting.
Marketing
Strategy
With
approximately 30 million people uninsured in the United States (according to 2019 Congressional Budget Office estimates) and 45 percent
of U.S. adults between ages of 19 and 64 being inadequately insured (according to a February 2019 Survey Brief by the Commonwealth Fund),
and an estimated 530,000 families turning to bankruptcy each year due to medical expenses (according to a study published in the March
2019 American Public Journal of Health), the Company sees an opportunity to make a positive impact in the lives of these uninsured or
underinsured people. We believe that this is the demographic that the healthcare system has abandoned, ignored and/or left behind and
is what we believe to be a largely underserved group.
To
grow its subscriber base, EPIQ MD has implemented its own direct-to-consumer distribution channel referred to as the "Ambassador
Program". The Ambassador Program is intended to allow social influencers, community leaders and entrepreneurial-minded sales agents
to market and sell EPIQ MD's services across the nation, on a commission-only basis.
Market
Opportunity
As
previously described above, with approximately 30 million people uninsured in the United States and 45 percent of U.S. adults between
ages of 19 and 64 being inadequately insured, EPIQ MD believes that their service offerings will be instrumental in reaching these Americans
and plans to reach this demographic through its own direct-to-consumer distribution channel, or Ambassador Program, and through its commercial
division
that will target small and medium sized businesses (SMB's) and municipalities.
According
to a 2020 study by the Kaiser Family Foundation, a leading industry research firm ("Key Facts About the Uninsured Population"),
the high cost of insurance is one of the main reasons individuals lack coverage (in 2019, 73.7% of uninsured adults said they were uninsured
because the cost of coverage was too high); and, individuals with income below 200% of the Federal Poverty Level (FPL) are at the highest
risk of being uninsured.
6
Table of Contents
We
see a significant opportunity to market to these uninsured and/or underinsured persons, and believe that our low-cost, flat rate, telemedical
services can be an attractive alternative to those persons seeking lower cost health services.
LIFE
GURU, INC. – 51% OWNED
On
May 15, 2020, the Company acquired a 51% interest in Life Guru, Inc., a Delaware corporation ("
Life Guru
"). Life Guru
owns www.LifeGuru.me – a website dedicated to providing an online platform to connect consumers to a variety of mentors, professionals,
life coaches and career coaches. Upon final launch of the platform, it will include functionality enabling: life coaches from around
the world to access and subscribe to the Life Guru platform; and consumers to filter their life coach options by geographic location,
language and even the type of currency they would like to pay with. While Life Guru is free to consumers, it generates revenues by charging
monthly subscription fees to coaches participating on the platform. Further, and depending on the type of subscription plan the life
coach chooses to participate in, Life Guru receives a percentage of the per session fees generated and earned between the consumer and
the life coach.
Since
the LifeGuru.me website was launched around March 2021, Life Guru has been working to optimize the website for mobile and completing
integration with its merchant account provider to automate monthly payouts to coaches. LifeGuru is currently in the process of marketing
and onboarding coaches onto the platform.
Industry
Trends
Life
coaching has been the second fastest growing industry in the world for over ten consecutive years, behind the information technology
sector (according to a May 2016 article posted at Forbes.com). The global Personal Development Industry (including market segments from
holistic approaches, motivational speakers, inspirational websites, personal coaching, and other forms of personal development) was valued
at approximately $38.28 billion in 2019 and is expected to grow at a compound annual growth rate (CAGR) of 5.1% from 2020 to 2027 (according
to a July 2020 report by Grand View Research). Moreover, Life Guru believes that improving social skills and focusing on critical areas
for self-awareness, such as emotions, character traits, habits, individual values, and the psychological need that shapes the day-to-day
behavior of individuals are gaining importance.
Operational,
Technological & Cost Advantages
We
anticipate that coaches that subscribe to the Life Guru platform will benefit from Life Guru's investment in digital marketing
and promotion, enabling them to reach customers and providing increased visibility. Life Guru has developed a proprietary technology
platform for coaching online, as well as proprietary video conferencing capabilities for coaching interactively. Through our existing
marketing partnerships, Life Guru believes it has access to sales tools which allow the effective marketing of coaches across all major
social media platforms, including and most importantly, LinkedIn. LifeGuru.me is mobile-friendly and can run smoothly on many platforms,
making it highly scalable.
7
Table of Contents
Subscriptions
Life
Guru offers free membership for all consumers to gain access to the site and search for life coaches. Life Guru's model is to charge
coaches, and not members, for the use of its services. The Company currently offers three different subscription levels to life coaches,
with varying levels of promotion on the Life Guru site, prominence of search results, and commissions payable. As of the date of this
prospectus, Life Guru has no members and approximately 100 life coaches have signed up to use the platform.
Growth
Objectives
In
addition to marketing Life Guru directly to consumers, Life Guru intends to implement packages to be sold to various businesses and corporations,
which can, in turn, be marketed as a corporate benefit by employers. Life Guru calls this "Life Guru Corporate". A recent
survey of 256 companies by the National Alliance of Healthcare Purchaser Coalitions, a nonprofit employer group, found that 53% of employers
are providing special emotional and mental health programs for their workforce in the wake of the pandemic. Life Guru believes that Life
Guru Corporate represents important potential upside in targeting the business and corporate world, and providing services to employees
on an ongoing basis. Life Guru Corporate can only be developed once the platform has achieved a reputable brand and a substantial amount
of high-quality business coaches are engaged, and Life Guru does not anticipate launching Life Guru Corporate with fewer than 200 life
coaches, provided Life Guru's projected milestones are met.
MANGOCEUTICALS,
INC.
– 80% OWNED
On
October 7, 2021, the Company incorporated Mangoceuticals, Inc. ("
Mangoceuticals
") in the
state of Texas with the intent of focusing on developing, marketing and selling a variety of men's wellness products and services
via a telemedicine platform. To date, the Company has identified men's wellness telemedicine services and products as a growing
sector in the most recent years and especially related to the areas of erectile dysfunction and hair loss products. In this regard, Mangoceuticals
is currently in the process of developing and preparing to market a new brand of erectile dysfunction (ED) products that delivers fast
acting results through a proprietary combination of FDA approved ingredients.
Mangoceuticals
plans to market and sell this new brand of ED products exclusively online and will require the use of a telemedicine visit, a doctor's
prescription and the fulfillment of the prescription by pharmacy licensed in the state in which the customer resides. Mangoceuticals
plans to rely heavily on digital and social media marketing through channels such as Facebook, Instagram, Twitter, Snap Chat and TikTok
and further has plans to use digital marketing with the goal of creating viral marketing campaigns, using social media influencers and
celebrities, funding permitting.
Our
goal is to eventually sell this new brand of ED products nationwide and to use EPIQ Scripts (described below) as its mail order pharmacy
to fulfill the ED prescriptions. Mangoceuticals is currently in the branding and development stage of this ED product and anticipates
a planned and limited launch in the Texas market in the second quarter of 2022 with the intent of expanding its marketing initiatives
at a pace in which Epiq Scripts obtains additional state licenses across the United States.
8
Table of Contents
Subsequent
to incorporation, Mangoceuticals issued 1,000,000 shares of common stock each to Jacob D. Cohen, the Chief Executive Officer of the Company,
and a third party, in consideration for services rendered. As a result, Mangoceuticals is currently 80% owned by the Company.
EPIQ
SCRIPTS, LLC – 51% OWNED
On
January 24, 2022, the Company formed EPIQ Scripts, LLC ("
EPIQ Scripts
") in the state of Texas. EPIQ Scripts has been
established with the intent of operating as a close-door online mail order pharmacy with a specific target and vision to obtain licenses
in all 50 states across the U.S., of which no state licenses have been obtained as of the date of this prospectus. EPIQ Scripts also
plans to seek to become accredited with the most respected and highly recognized authorities in the industry, such as
Utilization
Review Accreditation Commission (
URAC), Legit Script,
Accreditation Commission for Health
Care
(ACHC), and
National Association of Boards of Pharmacy
(NABP) Digital Pharmacy.
EPIQ Scripts also intends to obtain in-network contracts with all major Pharmacy Benefit Managers (PBM) and insurance payors.
Market
Opportunity
It
is anticipated that if licenses, accreditations and in-network contracts are secured in all 50 U.S. states, EPIQ Scripts will be able
to market itself to the many up and coming telemedicine companies that have been on the rise since early 2020. Pursuant to a July 9,
2021 article published by McKinsey & Company, according to a study taken by McKinsey & Company,
in
April 2020, overall telehealth utilization for office visits and outpatient care was 78 times higher than in February 2020. Ev
en
though telemedicine use has now leveled off as in-person visits have returned, McKinsey & Company is still consistently seeing use
that is 38 times higher than pre-pandemic numbers. Furthermore, a majority of Americans have now tried out telehealth. According to an
article published at Sykes.com, a March 2021 survey of 2,000 U.S. adults undertaken by Sykes.com found that by March 2021, more than
61% of such surveyed individuals had made a telehealth/telemedicine appointment, which is a massive increase from just 19.5% a year prior,
according to Sykes. We further believe that telemedicine use is now widespread across demographics.
We
believe the significant increases in demand for telemedicine has created a vacuum for pharmacies that have the capabilities to handle
the prescription volume generated by these platforms. We believe that EPIQ Scripts' planned mail order pharmacy, which is expected
to have advanced API capabilities and infrastructure and be supported with nationwide licenses and accreditations can position itself
to capitalize on the current market opportunity.
EPIQ
Scripts has currently filed with the
Utilization Review Accreditation Commission (URAC) to obtain
its pharmacy accreditation and is in the process of obtaining its first state license in the State of Texas, which it anticipates receiving
in April 2022. Once the Texas state license is obtained, EPIQ Scripts will be able to apply for additional state licenses until it has
obtained all 50 state licenses, with some state licenses easier to obtain and quicker to obtain than others. EPIQ Scripts intends to
have licenses to operate in all 50 states by the first quarter of 2023.
*
* * * * *
9
Table of Contents
The
Company intends to continue to grow its business both organically and through identifying acquisition targets over the next 12 months
in the telemedicine, life coaching and wellness space, funding permitting. As these opportunities arise, the Company will determine the
best method for financing its growth which may include the issuance of additional debt instruments, common stock, preferred stock, or
a combination thereof, any one or more of which may cause significant dilution to existing shareholders.
The
Company requires approximately $5 million to implement its current business strategy for its different subsidiaries and to support potential
growth.
We expect to raise funds in the future through the sale of debt and/or equity in order to allow us to operate for the
next twelve months and may need to raise further additional capital in order to expedite our growth through acquisitions, none of which
are currently planned. There is no assurance that we will be successful in raising such funds and if we do raise funds, this may result
in substantial dilution to current investors.
DISCONTINUED
OPERATIONS:
MEDICAL
SPA AND WELLNESS
The
Company previously operated three wholly-owned subsidiaries that were in the Medical Spa and Wellness Sector (collectively hereinafter
referred to as "
MedSpa
", or "
VISSIA
"), the operations of which were discontinued in October 2020:
1.
VISSIA
    MCKINNEY, LLC (F/K/A NOVOPELLE DIAMOND, LLC) – 100% OWNED
VISSIA
McKinney was a physician supervised, medical spa and wellness clinic that offered a full menu of wellness services including anti-aging,
weight loss and skin rejuvenation treatments and was located at 5000 Collin McKinney Parkway, Suite 150, McKinney, Texas 75070.
2.
VISSIA
    WATERWAY, INC. (F/K/A NOVOPELLE WATERWAY, INC.) – 100% OWNED
VISSIA
McKinney was a physician supervised, medical spa and wellness clinic that offered a full menu of wellness services including anti-aging,
weight loss and skin rejuvenation treatments and was located at 25 Waterway, Suite 150, The Woodlands, Texas.
3.
NOVOPELLE
    TYLER, INC. – 100% OWNED
On
December 3, 2019, the Company formed and organized Novopelle Tyler, Inc. in the State of Texas with the plan to come to terms on a retail
location for a new med spa to be located in Tyler, Texas. The Company no longer intends to open this location and no activity has been
performed under this entity to date.
*
* * * *
10
Table of Contents
As
a result of COVID-19 and 'stay-at-home' and social distancing orders issued in McKinney and The Woodlands, Texas, we had
to close both of our then operational MedSpas, VISSIA McKinney and VISSIA Waterway, Inc., effective March 10, 2020, and which resulted
in both the loss of income and the loss of substantially all of our MedSpa employees, who had to be let go. VISSIA Waterway, Inc. reopened
effective June 21, 2020 and VISSIA McKinney reopened effective August 8, 2020. However, due to the termination of employees associated
with the shutdown we were forced to expend resources to attract, hire and train completely new staff for preparation of the re-launchings.
Notwithstanding the re-openings, customer traffic and demand at our VISSIA Waterway, Inc. and VISSIA McKinney MedSpa locations failed
to rebound to pre-COVID-19 levels due to COVID-19 and the pandemic's effects on the economy, and because we were unable to predict
the length of the pandemic or ultimate outcome thereof, and further due to our limited capital resources, effective on October 25, 2020,
we made the decision to close both our VISSIA Waterway, Inc. and VISSIA McKinney locations. Our former MedSpa operations and assets are
included under discontinued operations in the statement of operations and balance sheet included herein for the year ended December 31,
2021 and for the year ended, December 31, 2020.
4.
CAPITOL
    CITY SOLUTIONS, USA, INC. – 100% OWNED
On
September 17, 2019, the Company formed and organized Capitol City Solutions USA, Inc. ("
CCS
") in the State of Texas
to act as a general contracting and construction company focused on the remodeling, general construction and interior finish of both
the Company's then MedSpa locations (which have since been closed) as well as to market to other commercial real estate projects
within the United States. The Company made the decision to cease any further construction-based operations under CCS in July 2021, in
order to focus on the subsidiaries that better aligned with the purpose of the Company and its ongoing business plan in the telehealth
and wellness space.
5.
LEGEND
    NUTRITION, INC. – 100% OWNED
On
September 23, 2019, the Company formed and organized Legend Nutrition, Inc. ("
Legend Nutrition
") in the State of Texas
to act as a new brand of retail vitamin and supplement stores to be branded and marketed as Legend Nutrition. October 18, 2019, Legend
entered into an Asset Purchase Agreement to acquire all of the assets associated with and related to a retail vitamin, supplements and
nutrition store located in McKinney, Texas and previously identified and doing business as "
Ideal Nutrition.
" Pursuant
to the Asset Purchase Agreement, Legend purchased a variety of assets including software, contracts, bank and merchant accounts, products,
inventory, computers, security systems and other intellectual properties. As Legend Nutrition's lease expired in January 2021,
the Company made the decision to cease its operations to focus on the subsidiaries that better aligned with the purpose of the Company
and its ongoing business plan in the telehealth and wellness space.
11
Table of Contents
Government
Regulation
The
health care industry is subject to extensive federal, state and local laws and regulations relating to licensure, conduct of operations,
ownership of facilities, addition of facilities and services, payment for services and prices for services that are extremely complex
and for which, in many instances, the industry does not have the benefit of significant regulatory or judicial interpretation. We will
also be subject to regulation regarding sale of our products online and solicitation of clients thereby, as well as through our general
contractor business and the licensing and code requirements relating thereto.
COVID-19
Outlook and Discontinued Operations
The
outbreak of the 2019 novel coronavirus disease ("
COVID-19
"), which was declared a global pandemic by the World Health
Organization on March 11, 2020, and the related responses by public health and governmental authorities to contain and combat its outbreak
and spread has severely impacted the U.S. and world economies, the market for health spa services, nutrition supplements and our other
business offerings during the end of the first quarter of 2020, and continuing through the end of 2020 and into 2021. Government mandated
'stay-at-home' and similar orders have to date, and may in the future, prevent us from operating. In late 2020, we made the
decision to discontinue operations of our VISSIA Waterway, Inc. and VISSIA McKinney MedSpa locations, due to declines in customers and
issues staffing such facilities, each as a result of the pandemic. Additionally, our Legend Nutrition store saw a deep decline in sales
due to social distancing orders and decreases in customers who are willing to venture out to brick-and-mortar establishments. Legend
Nutrition's lease was up January 31, 2021, and the Company chose to not renew the lease, closed the store, and will not continue
in this line of business moving forward. We also decided to cease offering construction services around July 2021.
As
of the date of this prospectus, our operations are limited, and consist solely of ZipDoctor, Inc., Life Guru, Inc., EPIQ MD, Inc, Mangoceuticals,
Inc., and EPIQ Scripts, LLC.
Moving
forward, economic recessions, including those brought on by the continued COVID-19 outbreak, geopolitical events, including the current
military conflict between Russia and the Ukraine, inflationary pressures, or other events, may have a negative effect on the demand for
our services and our operating results. Any prolonged disruption to our operations or work force available is likely to have a significant
adverse effect on our results of operations, cash flows and ability to meet continuing debt service requirements. All of the above may
be exacerbated in the future as the COVID-19 outbreak and the governmental responses thereto continues.
Summary
Risk Factors
Our
business is subject to numerous risks and uncertainties, including those in the section entitled "Risk Factors" and elsewhere
in this prospectus. These risks include, but are not limited to, the following:
●
Our
    limited operating history;
12
Table of Contents
●
Our
    need for additional funding to support our operations, repay debt and expand our operations;
●
The
    continuing effects of COVID-19 on our operations and prospects;
●
Impairments
    we may be required to assess in connection with our assets and goodwill as a result of such shutdowns and/or otherwise;
●
Risks
    associated with our telehealth platform, including liability in connection therewith, funding needed to support such operations and
    other risks associated with the operations of the telehealth platform;
●
Risks
    associated with the launch of our new closed door online digital pharmacy, Epiq Scripts, LLC, including liability in connection therewith,
    ability to obtain state licenses, funding needed to support such operations and other risks associated with the operations of an
    online digital pharmacy;
●
Risks
    associated with the development of our new ED product, including liability in connection therewith, funding needed to support such
    operations and other risks associated with the operations of the telehealth platform;
●
The
    ability of Life Guru to sign up enough life coaches to make the commercial launch of such website economic, and the willingness of
    individuals to use such website in the future;
●
Disruptions
    to our operations or liabilities associated with future acquisitions;
●
Our
    ability to continue as a going concern;
●
Our
    dependence on our Chief Executive Officer and director, Jacob D. Cohen, including the lack of independent directors, and related
    party transactions affecting the Company;
●
Competition
    we face;
●
Our
    ability to maintain our varied operations, and service our indebtedness;
●
Material
    weaknesses in our controls and procedures;
●
Our
    ability to obtain and maintain adequate insurance;
●
Legal
    challenges and litigation;
●
Liability
    associated with our contracting operations;
●
The
    terms of Mr. Cohen's employment agreement;
13
Table of Contents
●
Dilution
    caused by the conversion of outstanding notes, conversion of preferred stock, exercise of outstanding warrants, and future fund-raising
    activities;
●
The
    price of, volatility in, and lack of robust trading market for, our common stock; and
●
The
    fact that Mr. Cohen, our Chief Executive Officer, has voting control over the Company.
Penny
Stock Rules
Our
common stock is considered a "
penny stock
", and subject to the requirements of Rule 15g-9, promulgated under the Exchange
Act. "
Penny stock
" is generally defined as any equity security not traded on an exchange or quoted on NASDAQ that
has a market price of less than $5.00 per share. Under such rule, broker-dealers who recommend low-priced securities to persons other
than established customers and accredited investors must satisfy special sales practice requirements, including a requirement that they
make an individualized written suitability determination for the purchaser and receive the purchaser's consent prior to the transaction.
The Securities Enforcement Remedies and Penny Stock Reform Act of 1990, also requires additional disclosure in connection with any trades
involving a stock defined as a penny stock.
The
required penny stock disclosures include the required delivery, prior to any transaction, of a disclosure schedule explaining the penny
stock market and the risks associated with it. Such requirements could severely limit the market liquidity of the securities and the
ability of purchasers to sell their securities in the secondary market. In addition, various state securities laws impose restrictions
on transferring "
penny stocks
" and as a result, investors in the common stock may have their ability to sell their
shares of the common stock impaired.
Corporate
Information
Our
executive offices are located at 7950 Legacy Drive, Suite 400, Plano, Texas 75024 and our telephone number is (469) 963-2644. Our website
address is
https://amihcorp.com
. We do not incorporate information on our website into this prospectus or any supplement to this
prospectus and you should not consider any information on, or that can be accessed through, our website as part of this prospectus or
any supplement to this prospectus (other than those filings with the SEC that we specifically incorporate by reference into this prospectus
or any supplement to this prospectus).
Reverse
Stock Split
We
have applied to list our common stock and certain warrants to purchase common stock which we plan to sell in the future in a public offering,
on the NASDAQ Capital Market; however, our application to uplist our common stock and certain warrants on the NASDAQ Capital Market may
not be approved and our securities may never trade on the NASDAQ Capital Market.
On
July 30, 2021, our board of directors, and on July 30, 2021, stockholders holding a majority of our outstanding voting shares, approved
resolutions authorizing a reverse stock split of the outstanding shares of our common stock in the range from one-for-two (1-for-2) to
one-for-sixty (1-for-60), and provided authority to our board of directors to select the ratio of the reverse stock split in their discretion,
at any time prior to the earlier of July 30, 2022 and the date of our 2022 annual meeting of shareholders. On January 25, 2022, our board
of directors, pursuant to such shareholder authority, approved a one-for-sixty (1-for-60) reverse stock split of the outstanding shares
of our common stock, which is intended to allow us to meet the minimum share price requirement of the NASDAQ Capital Market. Both the
board of directors and Financial Industry Regulatory Authority, Inc. (FINRA) have approved the reverse stock split, which is proposed
in order to increase the trading price of the Company's common stock to a level thought to be sufficient to allow an uplisting
of the Company's common stock on the Nasdaq Capital Market. Notwithstanding the approvals above, the officers of the Company have
not yet moved forward with the reverse stock split, or filed Articles of Amendment in connection therewith with the Secretary of State
of Nevada. The Company currently does not have an estimated date for when the reverse stock split will be made effective.
Because the Company has not formally affected the reverse stock split, none of the outstanding share amounts set forth below have been
adjusted for such board of directors approved reverse stock split. The board of directors reserves the right to adjust the ratio of the
reverse stock split and/or terminate the authority for such reverse stock split in the future.
Additional
Information
Additional
information about us can be obtained from the documents described under "
Where You Can Find More Information.
"
14
Table of Contents
This
Offering
The
selling stockholders named in this prospectus may offer and sell up to
42,666,665
shares of our common stock, par value $0.0001 per share. Our common stock is currently quoted
on
the OTC Markets Group Inc.'s OTCQB Market (the "
OTCQB
") under the trading symbol, "
AMIH.
"
Shares
    of Common Stock Offered by the Selling Stockholders:
42,666,665
    shares of common stock, which represents (a) up to 29,333,333 shares of common stock issuable upon conversion of the principal and
    accrued interest at maturity under the $2,000,000 in Notes, issued by the Company to the selling stockholders between November 22,
    2021 and December 2, 2021, at the option of the holders thereof; and (b) up to 13,333,332 shares of the Company's common stock
    issuable upon exercise of the Warrants, which Notes and which Warrants, are described in greater detail under "
Securities Purchase Agreement
", beginning on page 47.
Shares
    of Common Stock Outstanding Prior to this Offering:
97,286,902
    shares of common stock.
Shares
    of Common Stock Outstanding After this Offering
1
:
139,953,567
    shares of common stock.
Use
    of Proceeds:
We
    will not receive any of the proceeds from the sale or other disposition by the selling stockholders or their transferees of the
    shares of common stock covered hereby. However, to the extent that the Warrants are exercised for cash, we will receive the payment
    of the exercise price in connection with such exercise (see also "
Use of Proceeds
" on page 50
    below).
Risk
    factors:
The
    purchase of our common stock involves a high degree of risk. The common stock offered in this prospectus is for investment purposes
    only and currently only a limited market exists for our common stock. Please refer to the section entitled "
Risk Factors
"
    before making an investment in our common stock.
Trading
    symbol:
Our
    common stock is quoted on the OTCQB under the trading symbol "
AMIH
".
1
Assumes the issuance of all shares of common stock registered in the registration statement, of which this prospectus
forms a part.
15
Table of Contents
In
this prospectus, unless otherwise indicated, the number of shares of our common stock and other capital stock, and the other information
based thereon, is as of April 21, 2022 and excludes:
●
warrants
    to purchase 13,333,332 shares of our common stock at an exercise price of $0.075 (including shares of common stock issuable upon
    exercise of the Warrants);
●
shares
    of common stock issuable upon conversion of $2,000,000 under various convertible promissory notes (including the Notes), with conversion
    prices of $0.075 per share, subject in many cases to adjustments to the conversion prices upon defaults and anti-dilution; and
●
no
    further awards under the Company's equity compensation plans.
Additionally,
unless otherwise stated, all information in this prospectus:
●
reflects
    all currency in United States dollars.
Risk
Factors
You
should be aware that there are substantial risks for an investment in our common stock. You should carefully consider these risk factors,
along with the other information included in this prospectus, before you decide to invest in our common stock.
If
any of the following risks were to occur, such as our business, financial condition, results of operations or other prospects, any of
these could materially affect our likelihood of success. If that happens, the market price of our common stock, if any, could decline,
and prospective investors would lose all or part of their investment in our common stock.
Risks
Related to our Business
Since
we have a limited operating history, it is difficult for potential investors to evaluate our business.
Our
short operating history in the health and wellness industry and mentoring/life coach industry may hinder our ability to successfully
meet our objectives, and makes it difficult for potential investors to evaluate our business or prospective operations. As an early-stage
company, we are subject to all the risks inherent in the financing, expenditures, operations, complications and delays inherent in a
new business. Accordingly, our business and success face risks from uncertainties faced by developing companies in a competitive environment.
There can be no assurance that our efforts will be successful or that we will ultimately be able to attain profitability.
We
may not be able to raise capital when needed, if at all, which would force us to delay, reduce or eliminate our service locations and
product development programs or commercialization efforts and could cause our business to fail.
The
Company intends to continue to grow its business both organically and by identifying acquisition targets over the next twelve months
in the telemedicine, life coaching and wellness space. We may need to raise additional capital in order to expedite our growth through
acquisitions, provided that none are currently planned. Notwithstanding that, we expect to need substantial additional funding to pursue
additional service locations and product development and commercialize our products and services. There are no assurances that future
funding will be available on favorable terms or at all. The failure to fund our operating and capital requirements could have a material
adverse effect on our business, financial condition and results of operations. If we are unable to raise capital when needed or on attractive
terms, we could be forced to delay, reduce or eliminate our expansion of spa locations and development programs or any future commercialization
efforts. Any of these events could significantly harm our business, financial condition and prospects.
16
Table of Contents
Our
business has been materially and adversely disrupted by COVID-19, and the control response measures that state and local governments
have implemented to address it, and may be impacted by other epidemics or pandemics in the future. We have been forced to close our MedSpas
and have closed our nutrition store.
An
epidemic, pandemic or similar serious public health issue, and the measures undertaken by governmental authorities to address it, could
significantly disrupt or prevent us from operating our business in the ordinary course for an extended period, and thereby, and/or along
with any associated economic and/or social instability or distress, have a material adverse impact on our consolidated financial statements.
On
March 11, 2020, the World Health Organization characterized the outbreak of COVID-19 as a global pandemic and recommended containment
and mitigation measures. On March 13, 2020, the United States declared a national emergency concerning the outbreak, and several states
and municipalities have declared public health emergencies. Along with these declarations, there were extraordinary and wide-ranging
actions taken by international, federal, state and local public health and governmental authorities to contain and combat the outbreak
and spread of COVID-19 in regions across the United States and the world, including quarantines, "
stay-at-home
" orders
and similar mandates for many individuals to substantially restrict daily activities and for many businesses to curtail or cease normal
operations.
The
COVID-19 pandemic, and related social distancing requirements, travel bans, stay-at-home orders and closures limited access to our spas
and store and forced us to close our spas and store during the first quarter of 2020 and into the second quarter of 2020 and even though
such stores eventually reopened in June and August 2020, customer traffic and demand at our MedSpa locations failed to rebound to pre-closure
levels due to COVID-19 and the pandemic's effects on the economy, and because we were unable to predict the length of the pandemic
or ultimate outcome thereof, and further due to our limited capital resources, effective in October, 2020, we made the decision to discontinue
operations of both our MedSpa locations.
While
our MedSpas were forced to close during the second and third quarters of 2020. Legend Nutrition was able to remain open as an essential
business, as we sold vitamins and other nutritional supplements. Though the store was able to remain open, the store saw a deep decline
in sales due to social distancing orders and decreases in customers who are willing to venture out to brick-and-mortar establishments.
Legend Nutrition's lease was up January 31, 2021, and the Company chose to not renew the lease, closed the store, and will not
continue in this line of business moving forward.
We
also decided to cease offering construction services around July 2021.
17
Table of Contents
All
of the above has, in turn, not only negatively impacted our operations, financial condition and demand for our services, but our overall
ability to react timely to mitigate the impact of this event. Our 2021 financial results were significantly negatively affected by COVID-19
and the closure of our med spas and nutrition store in connection therewith (both due to governmental orders and separately due to our
lack of operating funds) and our decision to cease our construction services; however, the full effect on our business and operation
as a result of COVID-19 is currently unknown. The outbreak of COVID-19 has caused significant disruptions to the Company's ability
to generate revenues and cash flows, and uncertainty regarding the length of the disruption may adversely impact our ability to raise
additional capital.
As
of the date of this prospectus, our operations are limited, and consist solely of ZipDoctor, Inc., Life Guru, Inc., Mangoceuticals, Inc.,
EPIQ Scripts, LLC, and EPIQ MD, Inc., which have been only minimally affected by COVID-19 as they mainly operate through online platforms.
Should
the COVID-19 public health effort intensify to such an extent that we cannot operate, if there are prolonged government restrictions
on our business and our customers, and/or an extended economic recession or significant inflation, we could be unable to produce revenues
and cash flows sufficient to conduct our business; or service our outstanding debt. Such a circumstance could, among other things, exhaust
our available liquidity (and ability to access liquidity sources) and/or trigger an acceleration to pay a significant portion or all
of our then-outstanding debt obligations, which we may be unable to do.
Our
business may suffer from the severity or longevity of the Coronavirus/COVID-19 global outbreak.
The
demand for our services relies upon, among other things, the ability of our telemedicine platform to provide telemedicine services and
will in the future rely on the operation of our Life Guru website. Economic recessions, including those brought on by the COVID-19 outbreak
may have a negative effect on the demand for our services and our operating results. We have also experienced delays due to the COVID-19
outbreak in receiving products and supplies which we need to operate. All of the above may be exacerbated in the future as the COVID-19
outbreak and the governmental responses thereto continues. All of the above may in the future cause, and have to date caused, a material
adverse effect on our operating results.
We
have recently changed our primary business focus from the operation of MedSpas, a nutrition store and construction services, to telemedicine,
life coaching and wellness.
Customer
traffic and demand at our VISSIA Waterway, Inc. and VISSIA McKinney MedSpa locations which were re-opened after mandatory closures associated
with COVID-19 in June and August 2020, respectively, failed to rebound to pre-closure levels due to COVID-19 and the pandemic's
effects on the economy, and because we were unable to predict the length of the pandemic or ultimate outcome thereof, and further due
to our limited capital resources, effective in October 2020, we made the decision to close both our VISSIA Waterway, Inc. and VISSIA
McKinney MedSpa locations and discontinue operations. Separately, legend Nutrition's lease was up January 31, 2021, and the Company
chose not to renew the lease, closed the store, and not continue in that line of business moving forward. We also decided to cease offering
construction services around July 2021. As such, our current operations consist solely of operations in the telemedicine, life coaching
and wellness industries, which industries we have only a limited history with. Furthermore, the majority of our revenues for the last
two years were generated through our MedSpa, nutrition store and construction services, and as such, our continued ability to generate
revenues and support our operations is unknown.
18
Table of Contents
We
may owe significant amounts to a consultant under the terms of a consulting agreement.
On
March 8, 2021, we entered into a Consulting Agreement with KBHS, LLC ("
KBHS
"), whose Chief Executive Officer is Mr.
Kevin Harrington, who was appointed the sole member of our then newly formed Advisory Committee. Pursuant to the Consulting Agreement,
KBHS agreed to provide consulting services to the Company as the Company's Brand Ambassador, including providing endorsement services
and advising on marketing, promotions, acquisitions, licensing and business development. KBHS also agreed to up to four webinar appearances
on behalf of the Company per year to support the Company's direct sales efforts. The Consulting Agreement has a term of two years,
and can be terminated with ten days prior written notice (subject to applicable cure rights set forth in the Consulting Agreement), in
the event we or KBHS breach any term of the agreement, or we fail to pay any amounts due, become subject to any government regulatory
investigation, certain lawsuits, claims, actions or take certain other actions during the term of the Consulting Agreement. As consideration
for providing the services under the Consulting Agreement, we issued KBHS 1.5 million shares of restricted common stock, which vested
immediately upon issuance, and agreed to pay KBHS $10,000 per month, a 5% finder's fee on any new business introduced or developed
by KBHS and 7.5% of the value of any acquisition or merger created or developed exclusively by KBHS, undertaken by the Company, subject
to applicable laws. In the event we fail to pay any consideration due under the Consulting Agreement, such amount accrues interest at
the rate of 1.5% per month until paid in full.
The
requirement to pay the finder's fees and/or acquisition/merger fee under the agreement could significantly decrease any margin
we would otherwise obtain on any transaction, decrease our cash flows, and could prevent us from completing certain transactions in the
future, all of which could have a material adverse effect on the Company and its securities.
We
have previously suffered impairment losses, may suffer impairment losses in the future, and may be required to record significant additional
charge to earnings.
Due
to COVID-19's effects on the economy, and because we are unable to predict the length of the pandemic or ultimate outcome thereof,
and further due to our limited capital resources, effective on October 25, 2020, we made the decision to close both MedSpa locations,
which are expected to be closed permanently. In accordance with the Generally Accepted Accounting Principles of the United States of
America ("
GAAP
"), we review our assets for impairment when events or changes in circumstances indicate the carrying
value of the asset may not be recoverable. For example, we had an impairment loss of $605,488 primarily attributable to the investment
in Life Guru, and settlement loss of $1,041,445 in connection with the common shares issued for note settlements in 2020. Other than
a settlement loss of $13,805 for the year ended December 31, 2021, we had no impairment loss nor settlement loss in the year ended December
31, 2021. Goodwill of $29,689 associated with Legend Nutrition was impaired in full during the fourth quarter of 2020. We have other
assets, goodwill and equipment on our balance sheet, which may be impaired in the future. Such impairments may have a significant negative
effect on our balance sheet, results of operations and financial results, and could cause the value of our common stock to decline in
value or become worthless.
19
Table of Contents
We
face numerous risks associated with our ZipDoctor and EPIQ MD telehealth platforms which only recently commenced operations.
In
2020, the Company incorporated two wholly-owned subsidiaries, ZipDoctor, Inc. in the state of Texas and EPIQ MD, Inc. in the state of
Nevada.
Zip
Doctor's telemedicine platform does not require the customer to have an existing insurance plan and does not demand or require
any additional copays. ZipDoctor customers subscribe through the website and are only required to pay a low monthly fee, which is determined
based on if they are an individual, a couple, or a family.
EPIQ
MD is a direct-to-consumer, telemedicine and healthcare company targeting Americans who are uninsured or underinsured. The EPIQ MD service
offering is a convergence of primary care telemedicine, preventative care services and wellness programs – under the EPIQ MD brand
and on a single platform.
The
Company launched the ZipDoctor platform in August 2020 and the EPIQ MD platform in September 2021, and has generated nominal subscriptions
and revenues from each platform through their respective soft launch periods. There is no significant operating history upon which to
base any assumption as to the likelihood that either of the ZipDoctor and EPIQ MD telemedicine platforms will prove successful, and we
may never achieve operations or profitable operations through either platform. Each of our telehealth platforms also faces the following
risks, any of which may significantly negatively affect our operations, results of operations, and cash flows and could cause the value
of our common stock to decline in value:
●
Our telehealth platforms could be adversely affected by legal challenges or by actions restricting our ability of our health providers
to provide services in certain jurisdictions;
●
We will be dependent on the relationships of our partners with health care professionals;
●
Evolving government regulations may require increased costs or adversely affect our results of operations;
●
The market for telehealth services is new and if it does not develop as we forecast or develops more slowly than we expect our growth
may be harmed;
●
The market for telehealth services is competitive and we compete with multiple competitors which have more resources and funding than
we have and a more well-known brand name;
●
Economic uncertainty or downturns, particularly as it impacts particular industries, could adversely affect our business and operating
results; and
●
We will be entirely dependent on the infrastructure and operations of our partner to operate our telehealth platforms and such infrastructure
and operations are completely outside of our control.
20
Table of Contents
Our
independent registered public accounting firm has expressed substantial doubt about our ability to continue as a going concern.
Our
historical financial statements have been prepared under the assumption that we will continue as a going concern. Our independent registered
public accounting firm has issued a report on our financial statements for the years ended December 31, 2021 and 2020, that included
an explanatory paragraph referring to our recurring operating losses and expressing substantial doubt in our ability to continue as a
going concern. Our ability to continue as a going concern is dependent upon our ability to obtain additional equity financing or other
capital, attain further operating efficiencies, reduce expenditures, and, ultimately, generate revenue. Our financial statements do not
include any adjustments that might result from the outcome of this uncertainty. However, if adequate funds are not available to us when
we need it, we will be required to curtail our operations which would, in turn, further raise substantial doubt about our ability to
continue as a going concern. The doubt regarding our potential ability to continue as a going concern may adversely affect our ability
to obtain new financing on reasonable terms or at all. Additionally, if we are unable to continue as a going concern, our stockholders
may lose some or all of their investment in the Company.
We
depend heavily on our Chief Executive Officer, and the loss of his services could harm our business.
Our
future business and results of operations depend in significant part upon the continued contributions of our senior management personnel,
particularly our Chief Executive Officer and director, Jacob D. Cohen. If we lose his services or if he fails to perform in his current
position, or if we are not able to attract and retain skilled personnel as needed, our business could suffer. Significant turnover in
our senior management could significantly deplete our institutional knowledge held by our existing senior management team. We depend
on the skills and abilities of these key personnel in managing our operations, product development, marketing and sales aspects of our
business, any part of which could be harmed by turnover in the future.
We
expect to face intense competition, often from companies with greater resources and experience than we have.
The
health, wellness, and mentoring/life coach industries are highly competitive and subject to rapid change. The industries continue to
expand and evolve as an increasing number of competitors and potential competitors enter the market. Many of these competitors and potential
competitors have substantially greater financial, technological, managerial and research and development resources and experience than
we have. Competitors for our products include Teladoc, PlushCare and Sesamecare. Some of these competitors and potential competitors
have more experience than we have in the development of health and wellness services and products. In addition, our services and products
compete with service and product offerings from large and well-established companies that have greater marketing and sales experience
and capabilities than we or our collaboration partners have. If we are unable to compete successfully, we may be unable to grow and sustain
our revenue.
21
Table of Contents
We
are growing the size of our organization, and we may experience difficulties in managing any growth we may achieve.
As
of the date of this prospectus, we have twelve full-time employees (two at the parent/ZipDoctor level, eight at the EPIQ MD level, and
two at the Life Guru level). As our development and commercialization plans and strategies develop, we expect to need additional development,
managerial, operational, sales, marketing, financial, accounting, legal, and other resources. Future growth would impose significant
added responsibilities on members of management. Our management may not be able to accommodate those added responsibilities, and our
failure to do so could prevent us from effectively managing future growth, if any, and successfully growing our company.
We
may expend our limited resources to pursue particular products, services or locations and may fail to capitalize on products, locations
or services that may be more profitable or for which there is a greater likelihood of success.
Because
we have limited financial and managerial resources, we must focus our efforts on particular service programs, products and locations.
As a result, we may forego or delay pursuit of opportunities with other services, products or locations that later prove to have greater
commercial potential. Our resource allocation decisions may cause us to fail to capitalize on viable commercial products or profitable
market opportunities. Any such failure could result in missed opportunities and/or our focus on products, services or locations with
low market potential, which would harm our business and financial condition.
We
engage in transactions with related parties and such transactions present possible conflicts of interest that could have an adverse effect
on us.
We
have entered, and may continue to enter, into transactions with related parties for financing, corporate, business development and operational
services, as detailed herein. Such transactions may not have been entered into on an arm's-length basis, and we may have achieved
more or less favorable terms because such transactions were entered into with our related parties. This could have a material effect
on our business, results of operations and financial condition. The details of certain of these transactions are set forth under "
Certain Relationships and Related Transactions
". Such conflicts could cause an individual in our management to seek to advance his or her
economic interests or the economic interests of certain related parties above ours. Further, the appearance of conflicts of interest
created by related party transactions could impair the confidence of our investors.
22
Table of Contents
We
have identified material weaknesses in our disclosure controls and procedures and internal control over financial reporting. If not remediated,
our failure to establish and maintain effective disclosure controls and procedures and internal control over financial reporting could
result in material misstatements in our financial statements and a failure to meet our reporting and financial obligations, each of which
could have a material adverse effect on our financial condition and the trading price of our common stock.
Maintaining
effective internal control over financial reporting and effective disclosure controls and procedures are necessary for us to produce
reliable financial statements. As reported in our Annual Report on Form 10-K for the year ended December 31, 2021, we have determined
that our disclosure controls and procedures and our internal control over financial reporting were not effective at the reasonable assurance
level, primarily due to a lack of segregation of duties in financial reporting, as of December 31, 2021, and continue to be ineffective.
Separately, management assessed the effectiveness of the Company's internal control over financial reporting as of December 31,
2021 and determined that such internal control over financial reporting was not effective as a result of such assessment; and further
have not been effective since at least March 31, 2016.
A
material weakness is a deficiency, or a combination of deficiencies, in internal control over financial reporting, such that there is
a reasonable possibility that a material misstatement of the Company's annual or interim financial statements will not be prevented
or detected on a timely basis. A control deficiency exists when the design or operation of a control does not allow management or employees,
in the normal course of performing their assigned functions, to prevent or detect misstatements on a timely basis.
We
recognized the following deficiencies that we believe to be material weaknesses as of December 31, 2021: (a) the Company has not fully
designed, implemented or assessed internal controls over financial reporting and due to the Company being a developing company, management's
assessment and conclusion over internal controls were ineffective this year; (b) we recognized the following deficiencies that we believe
to be significant deficiencies: (i) the Company has no formal control process related to the identification and approval of related party
transactions; (ii) we do not have written documentation of our internal control policies and procedures. Written documentation of key
internal controls over financial reporting is a requirement of Section 404 of the Sarbanes-Oxley Act; and (iii) we do not have sufficient
segregation of duties within accounting functions, which is a basic internal control. Due to our size and nature, segregation of all
conflicting duties may not always be possible and may not be economically feasible. However, to the extent possible, the initiation of
transactions, the custody of assets and the recording of transactions should be performed by separate individuals.
We
believe we have taken significant steps during and since the year ended December 31, 2021 to correct certain of our disclosure controls
and procedures and internal controls. These steps include the hiring of a third-party CPA firm to assist the Company in resolving the
financial statement preparation and disclosure issues, the establishment of an Audit Committee (discussed under "Committees of
the Board", below), and the hiring of Dr. Craig Hewitt to serve as our full-time Chief Financial Officer effective on March 30,
2022. Nonetheless, until these elements have been fully integrated into our organization and we have established appropriate controls
and internal processes in consultation with our third-party CPA firm and Audit Committee, there is no assurance that our disclosure controls
and procedures and internal controls will in fact be effective.
23
Table of Contents
Maintaining
effective disclosure controls and procedures and effective internal control over financial reporting are necessary for us to produce
reliable financial statements and the Company is committed to remediating its material weaknesses in such controls as promptly as possible.
However, there can be no assurance as to when these material weaknesses will be remediated or that additional material weaknesses will
not arise in the future. Any failure to remediate the material weaknesses, or the development of new material weaknesses in our internal
control over financial reporting, could result in material misstatements in our financial statements and cause us to fail to meet our
reporting and financial obligations, which in turn could have a material adverse effect on our financial condition and the trading price
of our common stock, and/or result in litigation against us or our management. In addition, even if we are successful in strengthening
our controls and procedures, those controls and procedures may not be adequate to prevent or identify irregularities or facilitate the
fair presentation of our financial statements or our periodic reports filed with the SEC.
The
employment agreement of Mr. Jacob Cohen, our sole officer and director provides for the payment of certain severance payments upon termination.
Mr.
Jacob D. Cohen's employment agreement provides that if he is terminated during the term of such agreement by the Company without
cause (as defined in the agreement) or by Mr. Cohen for good reason (as defined in the agreement), Mr. Cohen is due a severance payment.
That severance payment is equal to the compensation (including bonus) earned through the date of termination and three times (one time
if less than one year remains on the employment agreement)(the "
multiplier
") the base salary in effect on the date
of the termination plus the average bonus received by Mr. Cohen over the prior two years and Mr. Cohen is also to be paid any bonus which
he would have earned at the end of the fiscal year during which the employment is terminated (pro-rated for days worked), and is to be
paid health insurance for Mr. Cohen and his family for 18 months from the date of termination (the "
Severance Payments
").
Also, all equity compensation due to vest in the following 12 months vests immediately. If Mr. Cohen dies while the employment agreement
is in place, or the agreement is terminated due to Mr. Cohen's disability, the Company is required to pay Mr. Cohen's salary
to his beneficiaries for a period of one year following such death, pay the pro-rated amount of any bonus due, and pay 18 months of health
insurance. If a change in control (as defined in the agreement) occurs and Mr. Cohen is terminated up to one year after such change in
control, Mr. Cohen is due the Severance Payments (based on a 3x multiplier) and all unvested equity awards vest immediately. The payment
of severance fees could have a material adverse effect on our cash flows and results of operations.
Risks
relating to our Telehealth Operations
Our
telehealth business could be adversely affected by ongoing legal challenges to our business model or by new state actions restricting
our ability to provide the full range of our services in certain states.
Our
ability to conduct planned business operations in each state is dependent upon the state's treatment of medicine under such state's
laws, and rules and policies governing the practice of physician supervised services, which are subject to changing political, regulatory
and other influences.
24
Table of Contents
Our
use and disclosure of personally identifiable information, including health information, is subject to federal and state privacy and
security regulations, and our failure to comply with those regulations or to adequately secure the information we hold could result in
significant liability or reputational harm and, in turn, a material adverse effect on our client base and revenue.
Numerous
state and federal laws and regulations govern the collection, dissemination, use, privacy, confidentiality, security, availability and
integrity of personally identifiable information, or PII, including protected health information, or PHI. These laws and regulations
include the Health Information Portability and Accountability Act of 1996, as amended by the Health Information Technology for Economic
and Clinical Health Act, or HITECH, and their implementing regulations (referred to collectively as HIPAA). HIPAA establishes a set of
basic national privacy and security standards for the protection of PHI. HIPAA requires us to develop and maintain policies and procedures
with respect to PHI that is used or disclosed, including the adoption of administrative, physical and technical safeguards to protect
such information. HIPAA imposes mandatory penalties for certain violations. Penalties for violations of HIPAA and its implementing regulations
start at $100 per violation and are not to exceed $50,000 per violation, subject to a cap of $1.5 million for violations of the same
standard in a single calendar year. However, a single breach incident can result in violations of multiple standards. HIPAA also authorizes
state attorneys general to file suit on behalf of their residents. Courts are able to award damages, costs and attorneys' fees
related to violations of HIPAA in such cases. While HIPAA does not create a private right of action allowing individuals to sue us in
civil court for violations of HIPAA, its standards have been used as the basis for duty of care in state civil suits such as those for
negligence or recklessness in the misuse or breach of PHI. In addition, HIPAA mandates that the Secretary of Health and Human Services,
or HHS, conduct periodic compliance audits of HIPAA covered entities or business associates for compliance with the HIPAA Privacy and
Security Standards. It also tasks HHS with establishing a methodology whereby harmed individuals who were the victims of breaches of
unsecured PHI may receive a percentage of the Civil Monetary Penalty fine paid by the violator. HIPAA further requires that patients
be notified of any unauthorized acquisition, access, use or disclosure of their unsecured PHI that compromises the privacy or security
of such information, with certain exceptions related to unintentional or inadvertent use or disclosure by employees or authorized individuals.
HIPAA specifies that such notifications must be made "
without unreasonable delay and in no case later than 60 calendar days
after discovery of the breach.
" If a breach affects 500 patients or more, it must be reported to HHS without unreasonable delay,
and HHS will post the name of the breaching entity on its public web site. Breaches affecting 500 patients or more in the same state
or jurisdiction must also be reported to the local media. If a breach involves fewer than 500 people, the covered entity must record
it in a log and notify HHS at least annually.
Numerous
other federal and state laws protect the confidentiality, privacy, availability, integrity and security of PII, including PHI. These
laws in many cases are more restrictive than, and may not be preempted by, the HIPAA rules and may be subject to varying interpretations
by courts and government agencies, creating complex compliance issues for us and our clients and potentially exposing us to additional
expense, adverse publicity and liability.
25
Table of Contents
Because
of the extreme sensitivity of the PII we store and transmit, the security features of our technology platform are very important. If
our security measures are breached or fail, unauthorized persons may be able to obtain access to sensitive client data, including HIPAA-regulated
PHI. As a result, our reputation could be severely damaged, adversely affecting client confidence. In addition, we could face litigation,
damages for contract breach, penalties and regulatory actions for violation of HIPAA and other applicable laws or regulations and significant
costs for remediation, notification to individuals and for measures to prevent future occurrences. Any potential security breach could
also result in increased costs associated with liability for stolen assets or information, repairing system damage that may have been
caused by such breaches, incentives offered to clients in an effort to maintain our business relationships after a breach and implementing
measures to prevent future occurrences, including organizational changes, deploying additional personnel and protection technologies,
training employees and engaging third-party experts and consultants.
The
failure of our 3rd party telemedicine services provider to attract and retain physicians and nurse practitioners in a competitive labor
market could limit our ability to execute our growth strategy, resulting in a slower rate of growth.
Our
wellness business depends on our ability of our 3
rd
party telemedicine services provider to continue to recruit and retain
a sufficient number of qualified licensed doctors and nurses. Although we believe such provider has an effective recruitment process,
there is no assurance that such provider will be able to secure arrangements with sufficient numbers of licensed doctors and nurses or
retain the services of such practitioners. If our provider experiences delays or shortages in obtaining access to qualified physicians
and nurses, we would be unable to expand our services and operations, resulting in reduced revenues.
If
the physicians who are available through our telemedicine operations develop a poor reputation, our operations and future revenues would
suffer.
The
success of our wellness business is dependent upon quality medical services being rendered by the physicians who are provided by our
3
rd
party telemedicine services provider. As the patient-physician relationship involves inherent trust and confidence, any
negative publicity, whether from civil litigation, allegations of criminal misconduct, or forfeiture of medical licenses, with respect
to any physicians made available for our services, and/or our facilities could adversely affect our future results of operations.
If
we fail to comply with government laws and regulations it could have a materially adverse effect on our business.
The
health care industry is subject to extensive federal, state and local laws and regulations relating to licensure, conduct of operations,
ownership of facilities, addition of facilities and services, payment for services and prices for services that are extremely complex
and for which, in many instances, the industry does not have the benefit of significant regulatory or judicial interpretation. We exercise
care in structuring our arrangements with physicians and other referral sources to comply in all material respects with applicable laws.
We will also take such laws into account when planning future centers, marketing and other activities, and expect that our operations
will be in compliance with applicable law. The laws, rules and regulations described above are complex and subject to interpretation.
In the event of a determination that we are in violation of such laws, rules or regulations, or if further changes in the regulatory
framework occur, any such determination or changes could have a material adverse effect on our business. There can be no assurance however
that we will not be found in noncompliance in any particular situation.
26
Table of Contents
We
may not be able to successfully develop, launch and commercialize our planned erectile dysfunction (ED) product or any other potential
future men's wellness products.
We
may not be able to effectively develop and profitably launch and commercialize our planned erectile dysfunction (ED) product or any other
potential future men's wellness products. If we are unable to successfully develop, produce, launch and commercialize our planned
erectile dysfunction (ED) product or any other potential future men's wellness products, our ability to generate product sales
will be severely limited, which will have a material adverse impact on our business, financial condition, and results of operations.
Changes
to our strategic business plan may cause uncertainty regarding the future of our business, and may adversely impact employee hiring and
retention, our stock price, and our revenue, operating results, and financial condition.
Our
recent change in our business focus from operating MedSpas, a nutrition store and construction services, to men's wellness products
and services and telehealth services, life coaching and other wellness services may cause or result in:
●
disruption
    of our business or distraction of our employees and management;
●
difficulty
    in recruiting, hiring, motivating and retaining talented and skilled personnel;
●
stock
    price volatility; and
●
difficulty
    in negotiating, maintaining or consummating business or strategic relationships or transactions.
If
we are unable to mitigate these or other potential risks, our revenue, operating results and financial condition may be adversely impacted.
We
will depend on our partners to manufacture our planned erectile dysfunction (ED) product and other potential future men's wellness
products.
We
will rely on our planned partners for the manufacture of our planned erectile dysfunction (ED) product and any other potential future
men's wellness products and we cannot assure you that they will be successful. This subjects us to a number of risks, including
the following:
●
we
    may not be able to control the commercialization of our products, including the amount, timing and quality of resources that our
    partners may devote to our products;
27
Table of Contents
●
our
    partners may experience financial, regulatory or operational difficulties, which may impair their ability to fulfill their contractual
    obligations;
●
business
    combinations or significant changes in a partner's business strategy may adversely affect a partner's willingness or
    ability to perform their obligations under any arrangement;
●
legal
    disputes or disagreements may occur with one or more of our partners or between our partners and our suppliers or former partners;
    and
●
a
    partner could independently move forward with a competing product developed either independently or in collaboration with others,
    including with one of our competitors.
If
any of our partners fail to fulfill their contractual obligations, our business may be negatively affected and we may receive limited
or no revenues under our agreements with them.
If
we are unable to maintain or enter into agreements with suppliers or our suppliers fail to supply us with our planned erectile dysfunction
(ED) product or any other potential future men's wellness products, we may experience delays in selling our products.
We
cannot guarantee that we will be successful in maintaining or entering into supply agreements on reasonable terms or at all or that we
or our suppliers will be able to obtain or maintain the necessary regulatory approvals or state and federal controlled substances registrations
for current or potential future suppliers in a timely manner or at all. If we are unable to obtain a sufficient quantity of compounds
required to product products, there could be a delay in producing products, which could adversely affect our product sales and operating
results materially, which could significantly harm our business.
We
currently do not have any manufacturing facilities and intend to rely on third parties for the supply of the products, as well as for
the supply of materials. However, we cannot be certain that we or our suppliers will be able to obtain or maintain the necessary regulatory
approvals or registrations for these suppliers in a timely manner or at all.
Our
ability to gain and increase market acceptance and generate revenues will be subject to a variety of risks, many of which are out of
our control.
Our
planned erectile dysfunction (ED) product or any other potential future men's wellness products may not gain or increase market
acceptance among physicians, patients, healthcare payors or the medical community. We believe that the degree of market acceptance and
our ability to generate revenues from such products will depend on a number of factors, including:
●
our
    ability to expand the use of our products through targeted patient and physician education;
●
competition
    and timing of market introduction of competitive products;
28
Table of Contents
●
quality,
    safety and efficacy in the approved setting;
●
prevalence
    and severity of any side effects, including those of the components of our products;
●
emergence
    of previously unknown side effects, including those of the generic components of our products;
●
potential
    or perceived advantages or disadvantages over alternative treatments;
●
the
    convenience and ease of purchasing the product, as perceived by potential patients;
●
strength
    of sales, marketing and distribution support;
●
price,
    both in absolute terms and relative to alternative treatments;
●
the
    effectiveness of any future collaborators' sales and marketing strategies;
●
the
    effect of current and future healthcare laws;
●
availability
    of coverage and reimbursement from government and other third-party payors;
●
recommendations
    for prescribing physicians to complete certain educational programs for prescribing drugs;
●
the
    willingness of patients to pay out-of-pocket in the absence of government or third-party coverage; and
●
product
    labeling, product insert, or new studies or trial requirements of FDA or other regulatory authorities.
Our
future products may fail to achieve market acceptance or generate significant revenue to achieve sustainable profitability. In addition,
our efforts to educate the medical community and third-party payors on the safety and benefits of our drugs may require significant resources
and may not be successful.
If
we become subject to product liability claims, we may be required to pay damages that exceed our insurance coverage, if any.
Our
future products will be subject to risks for product liability claims due to inherent potential side effects. We may be unable to obtain
or maintain product liability coverage. A product liability claim in excess of, or excluded from, our insurance coverage (if any) would
have to be paid out of cash reserves and could have a material adverse effect upon our business, financial condition and results of operations.
Product liability insurance is expensive even with large self-insured retentions or deductibles, difficult to maintain, and current or
increased coverage may not be available on acceptable terms, if at all.
29
Table of Contents
If
we cannot successfully defend ourselves against a product liability claim, we may incur substantial liabilities. Regardless of merit
or eventual outcome, liability claims may result in:
●
injury
    to our reputation;
●
costs
    of defending the claim and/or related litigation;
●
cost
    of any potential adverse verdict;
●
substantial
    monetary awards to patients or other claimants; and
●
the
    inability to commercialize our products.
Damages
awarded in a product liability action could be substantial and could have a negative impact on our financial condition. Whether or not
we were ultimately successful in product liability litigation, such litigation would consume substantial amounts of our financial and
managerial resources, and might result in adverse publicity, all of which would impair our business. In addition, product liability claims
could result in an FDA investigation of the safety or efficacy of our products, our third-party manufacturing processes and facilities,
or our marketing programs. An FDA investigation could also potentially lead to a recall of our future products or more serious enforcement
actions, limitations on the indications for which they may be used, or suspension or withdrawal of approval.
The
markets in which we operate are highly competitive and we may be unable to compete successfully against new entrants or established companies.
Competition
in the pharmaceutical and medical products industries is intense and is characterized by costly and extensive research efforts and rapid
technological progress. Our competitors may develop technologies and products that are more effective than those we are planning to market.
Such developments could render our planned products less competitive or possibly obsolete.
New
developments, including the development of other products and technologies occur in the pharmaceutical and medical technology industries
at a rapid pace. These developments may render our products obsolete or noncompetitive. Compared to us, many of our potential competitors
have substantially greater:
●
research
    and development resources, including personnel and technology;
●
regulatory
    experience;
●
experience
    and expertise in exploitation of intellectual property rights; and
●
access
    to strategic partners and capital resources.
30
Table of Contents
As
a result of these factors, our competitors may develop drugs or products that are more effective, more useful and less costly than ours
and may also be more successful in manufacturing and marketing their products. In addition, our competitors may be more effective in
commercializing their products. We currently outsource our manufacturing and therefore rely on third parties for that competitive expertise.
There can be no assurance that we will be able to develop or contract for these capabilities on acceptable economic terms, or at all.
Marketing
activities for our planned erectile dysfunction (ED) products are subject to continued governmental regulation.
FDA
authorities have the authority to impose significant restrictions on approved products through regulations on advertising, promotional
and distribution activities. If our future products are marketed in contradiction with FDA laws and regulations, FDA may issue warning
letters that require specific remedial measures to be taken, as well as an immediate cessation of the impermissible conduct, resulting
in adverse publicity. FDA may also require that all future promotional materials receive prior agency review and approval before use.
Certain states have also adopted regulations and reporting requirements surrounding the promotion of pharmaceuticals. Failure by us or
any of our collaborators to comply with state requirements may affect our ability to promote or sell future products in certain states.
This, in turn, could have a material adverse impact on our financial results and financial condition and could subject us to significant
liability, including civil and administrative remedies as well as criminal sanctions.
Many
of our competitors in the online mail order pharmacy space are better established and have resources significantly greater than we have,
which may make it difficult to fend off competition.
We
plan to operate as a close-door online mail order pharmacy with a specific target and vision to obtain licenses in all 50 states across
the U.S. We expect to compete with the three largest drug distributors (McKesson, Cardinal Health and AmerisourceBergen), in addition
to other pharmaceutical distributors, buying groups, software products, and various start-up drug companies. Many of these operations
have substantially greater financial and manufacturer-backed resources, longer operating histories, greater name recognition and more
established relationships in the industry than us. In addition, a number of these competitors may combine or form strategic partnerships.
As a result, our competitors may establish a more favorable footing in the pharmaceutical industry with respect to pricing or other factors.
Our failure to compete successfully with any of these companies would have a material adverse effect on our business and the trading
price of our common stock.
Additional
restrictive elements exist within the pharmaceutical channels of distribution. For example, a number of the inventory management systems,
either developed by the distributors or third-party vendors, have been developed to require compliance to these restrictive purchasing
agreements. Management anticipates that other existing and prospective competitors will adopt technologies or business plans similar
to ours or seek other means to develop operations competitive with ours, particularly if our development of large-scale production progresses
as scheduled.
31
Table of Contents
We
may not receive licenses to operate as an online mail order pharmacy.
Our
planned operations as a close-door online mail order pharmacy is subject to among other things, our receipt of regulatory approvals and
licenses in the states in which we plan to operate. Our failure to receive regulatory approval or licenses in the states in which we
hope to operate may prohibit us from operating as a close-door online mail order pharmacy, be costly, require us to comply with costly
rules and regulations, and/or subject us to liability, fines and penalties for non-compliance. We may not be able to receive approvals
or licenses to operate in any states and may not be able to undertake any operations as a close-door online mail order pharmacy. Any
of the above may have an adverse effect on our revenues, operations and cash flow, and may require us to abandon altogether our business
plans.
There
are inherent risks associated with our planned operations within the Pharmaceutical Distribution Market.
There
are inherent risks involved with doing business within the pharmaceutical distribution market, any of which may have a material adverse
effect on our planned operations, cash flow and revenues, including:
●
Improperly
    manufactured products may prove dangerous to the end consumer.
●
Products
    may become adulterated by improper warehousing methods or modes of shipment.
●
Counterfeit
    products or products with fake pedigree papers.
●
Unlicensed
    or unlawful participants in the distribution channel.
●
Risk
    with default and the assumption of credit loss.
●
Regulatory
    risks.
●
Risk
    related to the loss of supply, or the loss of a number of suppliers, or in the delay of obtaining the supply of drugs.
Pedigree
tracking laws and regulations could increase our regulatory burdens.
Congress
and state and federal agencies, including state boards of pharmacy and departments of health and the FDA, have made increased efforts
in the past year to regulate the pharmaceutical distribution system in order to prevent the introduction of counterfeit, adulterated
or mislabeled drugs into the pharmaceutical distribution system (otherwise known as "
pedigree tracking
"). In November
2013, Congress passed (and President Barack Obama signed into law) the Drug Quality and Security Act (the "
DQSA
").
The DQSA establishes federal standards requiring supply-chain stakeholders to participate in an electronic, interoperable, lot-level
prescription drug track-and-trace system. The law also preempts state drug pedigree requirements and establishes new requirements for
drug wholesale distributors and third-party logistics providers, including licensing requirements in states that had not previously licensed
such entities.
32
Table of Contents
In
addition, the Food and Drug Administration Amendments Act of 2007 requires the FDA to establish standards and identify and validate effective
technologies for the purpose of securing the pharmaceutical supply chain against counterfeit drugs. These standards may include track-and-trace
or authentication technologies, such as radio frequency identification devices, 2D data matrix barcodes, and other similar technologies.
On March 26, 2010, the FDA released the Serialized Numerical Identifier (the "
SNI
") guidance for manufacturers who
serialize pharmaceutical packaging. We expect to be able to accommodate these SNI regulations in our distribution operations. The DQSA
and other pedigree tracking laws and regulations have increased the overall regulatory burden and costs associated with our planned drug
distribution operations and may have had a material adverse impact on our results of operations.
It
may be difficult and costly for us to comply with the extensive government regulations to which our business is subject.
Our
operations are subject to extensive regulation by the U.S. federal and state governments. In addition, as we expand our operations, we
may also become subject to the regulations of foreign jurisdictions, as well as additional regulations relating to environmental matters,
transportation of pharmaceutical products, shipping restrictions, and import and export restrictions. We are also required to comply
with various state pricing gouging laws. Our required compliance, or failure to comply with any of the above rules and regulations, may
adversely affect our cash flow, profitability, and growth.
Regulatory
and Reporting Risks
We
are subject to the reporting requirements of federal securities laws, which are expensive and subject us to potential liability.
We
are a public reporting company in the United States and, accordingly, subject to the information and reporting requirements of the Exchange
Act and other federal securities laws, and the compliance obligations of the Sarbanes-Oxley Act. The costs of preparing and filing annual
and quarterly reports, proxy statements and other information with the SEC and furnishing audited reports to stockholders causes our
expenses to be higher than they would be if we remained a privately-held company. We could also be subject to sanctions or deregistration
if we fail to keep up with or run afoul of our reporting obligations.
Our
compliance with the Sarbanes-Oxley Act and SEC rules concerning internal controls is time consuming, difficult and costly.
Because
we are a reporting company with the SEC, we must comply with Sarbanes-Oxley Act and SEC rules concerning internal controls. It is time
consuming, difficult and costly for us to develop and implement the internal controls and reporting procedures required by the Sarbanes-Oxley
Act. In order to expand our operations, we will need to hire additional financial reporting, internal control, and other finance staff
in order to develop and implement appropriate internal controls and reporting procedures.
33
Table of Contents
Risks
Related to Our Common Stock and Securities
Shareholders
who hold unregistered shares of our common stock will be subject to resale restrictions pursuant to Rule 144, if and when available,
due to the fact that we are deemed to be a former "
shell company
".
Pursuant
to Rule 144 of the Securities Act of 1933, as amended ("
Rule 144
"), a "
shell company
" is defined
as a company that has no or nominal operations; and, either no or nominal assets; assets consisting solely of cash and cash equivalents;
or assets consisting of any amount of cash and cash equivalents and nominal other assets. While we do not believe that we are currently
a "
shell company
", we were previously a "
shell company
" and as such are deemed to be a former "
shell
company
" pursuant to Rule 144, and as such, sales of our securities pursuant to Rule 144 may not be able to be made if we are
not subject to Section 13 or 15(d) of the Exchange Act, and have filed all of our required periodic reports for at least the previous
one year period prior to any sale pursuant to Rule 144; and a period of at least twelve months has elapsed from the date "
Form
10 information
" has been filed with the Commission reflecting the Company's status as a non-"
shell company
"
(which Form 10 information was filed by the Company in August 2019). Although to date we have complied with the requirement of Rule 144
as related to "
shell companies
", our status as a former "
shell company
" could prevent us from raising
additional funds, engaging consultants, and using our securities to pay for any acquisitions in the future (although none are currently
planned).
We
have various outstanding convertible notes which are convertible into shares of our common stock at a discount to market.
As
of
the date of this prospectus, and including the Notes
,
we owed approximately $2,648,560 under various convertible promissory notes. The conversion prices of the convertible notes initially
vary from between $0.075 per share (as to the convertible notes issued between November 22 and December 2, 2022), and 25% of the market
value of our common stock (as to our other convertible notes), subject in many cases to adjustments to the conversion prices upon defaults
and anti-dilution and other rights which may result in such conversion prices declining, including in connection with the Notes, discussed
in greater detail below under
"
Securities Purchase Agreement
", beginning on page 47.
As
a result, any conversion of the convertible notes and sale of shares of common stock issuable in connection with the conversion thereof
may cause the value of our common stock to decline in value, as described in greater detail under the Risk Factors below. Notwithstanding
the above, we hope to repay the convertible notes in full before any conversions take place.
The
issuance and sale of common stock upon conversion of the convertible notes may depress the market price of our common stock.
If
sequential conversions of the convertible notes and sales of such converted shares take place, the price of our common stock may decline,
and as a result, the holders of the convertible notes will be entitled to receive an increasing number of shares in connection with conversions,
which shares could then be sold in the market, triggering further price declines and conversions for even larger numbers of shares, to
the detriment of our investors. The shares of common stock which the convertible notes are convertible into may be sold without restriction
pursuant to Rule 144. As a result, the sale of these shares may adversely affect the market price, if any, of our common stock.
34
Table of Contents
In
addition, the common stock issuable upon conversion of the convertible notes may represent overhang that may also adversely affect the
market price of our common stock. Overhang occurs when there is a greater supply of a company's stock in the market than there
is demand for that stock. When this happens the price of the company's stock will decrease, and any additional shares which shareholders
attempt to sell in the market will only further decrease the share price. The convertible notes will be convertible into shares of our
common stock at a discount to market as described above, and such discount to market provides the holders with the ability to sell their
common stock at or below market and still make a profit. In the event of such overhang, the note holders will have an incentive to sell
their common stock as quickly as possible. If the share volume of our common stock cannot absorb the discounted shares, then the value
of our common stock will likely decrease. Notwithstanding the above, we hope to repay the convertible notes in full before any conversions
take place.
The
issuance of common stock upon conversion of our outstanding convertible notes will cause immediate and substantial dilution.
The
issuance of common stock upon conversion of the convertible notes will result in immediate and substantial dilution to the interests
of other stockholders since the holders of the convertible notes may ultimately receive and sell the full number of shares issuable in
connection with the conversion of such convertible notes. Although certain of the convertible notes may not be converted if such conversion
would cause the holders thereof to own more than 4.99% or 9.99% of our outstanding common stock, this restriction does not prevent the
holders of the convertible notes subject to such restrictions from converting some of their holdings, selling those shares, and then
converting the rest of its holdings, while still staying below the 4.99%/9.99% limit. In this way, the holders of the convertible notes
could sell more than any applicable ownership limit while never actually holding more shares than the applicable limits allow. If the
holders of the convertible notes choose to do this, it will cause substantial dilution to the then holders of our common stock.
The
continuously adjustable conversion price feature of the convertible notes could require us to issue a substantially greater number of
shares, which may adversely affect the market price of our common stock and cause dilution to our existing stockholders.
Our
existing stockholders will experience substantial dilution upon any conversion of the convertible notes. The convertible notes are convertible
into shares of common stock at a conversion price equal to a discount to the market value of our common stock as described above. As
a result, the number of shares issuable could prove to be significantly greater in the event of a decrease in the trading price of our
common stock, which decrease would cause substantial dilution to our existing stockholders. As sequential conversions and sales take
place, the price of our common stock may decline, and if so, the holders of the convertible notes would be entitled to receive an increasing
number of shares, which could then be sold, triggering further price declines and conversions for even larger numbers of shares, which
would cause additional dilution to our existing stockholders and would likely cause the value of our common stock to decline.
35
Table of Contents
We
could face significant penalties for our failure to comply with the terms of our outstanding convertible notes.
Our
various convertible notes contain positive and negative covenants and customary events of default including requiring us in many cases
to timely file SEC reports. In the event we fail to timely file our SEC reports in the future, or any other events of defaults occur
under the notes, we could face significant penalties and/or liquidated damages and/or the conversion price of such notes could be adjusted
downward significantly, all of which could have a material adverse effect on our results of operations and financial condition, or cause
any investment in the Company to decline in value or become worthless.
Certain
of our outstanding warrants to purchase shares of common stock contain anti-dilution rights and favored nation rights, and certain of
our securities purchase agreements include favored nations rights.
Total
outstanding warrants to purchase 23,253,332 shares of common stock (of which 9,920,000 were originally granted with exercise prices from
between $0.20 and $0.50 per share), include anti-dilution and favored nations rights. Pursuant to such rights, subject to certain exceptions,
in the event we issued securities below the then exercise price, the exercise price of the warrants is reduced to the lower of such dilutive
issuance or the volume weighted average price (VWAP) of our common stock on the next trading day following the first public disclosure
of such dilutive issuance, subject to certain exceptions which may reduce such exercise price further in certain cases, including the
issuance of units. In connection with the grant of the Warrants, the exercise price of all the outstanding warrants with anti-dilution
rights were reduced to $0.075 per share. The Warrants also include anti-dilution rights which provides for a reduction of the exercise
price to match the price per share of any dilutive issuance made while the Warrant is outstanding (other than in connection with stock
plan issuances and other customary exceptions and the Uplist Offering). If in the future we issue securities at prices less than such
$0.075 exercise price, the exercise price of the warrants may be further reduced to such lower amount. Certain of such warrants also
include favored nations provisions which could be triggered in the future and could materially change the terms of the warrants. In the
event any anti-dilution or favored nations provisions of the warrants are triggered, it may cause the terms of such warrants to be materially
amended in favor of the holders thereof, cause significant dilution to existing shareholders, and otherwise have a material adverse effect
on the Company.
Our
outstanding convertible promissory notes include favored nations rights.
All
of our outstanding convertible promissory notes, including the Notes, include provisions which provide that, so long as such notes are
outstanding, upon any issuance by the Company (or under certain notes, any of its subsidiaries) of any security, or amendment to a security
that was originally issued, with any term that the holder of such note reasonably believes is more favorable to the holder of such security
or with a term in favor of the holder of such security that the holder reasonably believes was not similarly provided to the holder in
such note, then at the option of the holder, such term may become part of the holder's notes. The types of terms contained in another
security that may be more favorable to the holder of such security include, but are not limited to, terms addressing prepayment rate,
interest rates, and original issue discounts. Such favored nations provisions could be triggered in the future and could materially change
the terms of the notes. In the event any favored nations provisions of the notes are triggered, it may cause the terms of such notes
to be materially amended in favor of the holders thereof, cause significant dilution to existing shareholders, and otherwise have a material
adverse effect on the Company.
36
Table of Contents
The
issuance and sale of common stock upon exercise of warrants may cause substantial dilution to existing stockholders and may also depress
the market price of our common stock.
As
of the date of this prospectus, we had a total of 23,253,332 warrants outstanding, of which a) 7,250,000 warrants have an exercise price
of $0.075 per share and mature on January 6, 2026, b) 2,670,000 warrants have an exercise price of $0.075 per share and mature on June
24, 2026, and c) 13,333,332 warrants mature between November 23, 2026 and December 2, 2026 and have an exercise price equal to either
i) in the event of the Company's listing on a national exchange by May 23, 2022, at a price equal to 120% of the offering price
upon uplisting, or ii) $0.075 per share. The warrants contain provisions limiting each holder's ability to exercise the warrants
if such exercise would cause the holder's (or any affiliate of any such holder) holdings in the Company to exceed 9.99% of the
Company's issued and outstanding shares of common stock (4.99% in connection with the Warrants). The ownership limitation does
not prevent such holder from exercising some of the warrants, selling those shares, and then exercising the rest of the warrants, while
still staying below the 9.99% limit (4.99% in connection with the Warrants). In this way, the holders of the warrants could sell more
than this limit while never actually holding more shares than this limit allows. If the holders of the warrants choose to do this, it
will cause substantial dilution to the then holders of our common stock.
If
exercises of the warrants and sales of such shares issuable upon exercise thereof take place, the price of our common stock may decline.
In addition, the common stock issuable upon exercise of the warrants may represent overhang that may also adversely affect the market
price of our common stock. Overhang occurs when there is a greater supply of a company's stock in the market than there is demand
for that stock. When this happens the price of the company's stock will decrease, and any additional shares which shareholders
attempt to sell in the market will only further decrease the share price. If the share volume of our common stock cannot absorb shares
sold by the warrant holders, then the value of our common stock will likely decrease.
The
issuance of common stock upon conversion of the Notes will cause immediate and substantial dilution to existing shareholders.
The
Notes (including accrued and unpaid interest and late fees) making up the $2,000,000 in Notes sold between November 22, 2021 and December
2, 2021 are convertible into shares of the Company's common stock at any time, at the option of the holders thereof, at a rate
equal to $0.075 per share; however, if the Company consummates any offering of common stock or common stock equivalents that results
in the immediate listing for trading of the Company's common stock on a national stock exchange or Nasdaq, which occurs within
220 days from the date the Notes were issued, referred to as an "
Uplist Offering
", the conversion price thereof will
be equal to 80% of the offering price per share of the Company's common stock in such Uplist Offering. Each of the Notes provides
for a reduction of the conversion price to match the price per share of any dilutive issuance made while the Note is outstanding (other
than pursuant to certain customary excepted issuances), provided that no adjustment is required unless the Company fails to consummate
an Uplist Offering on or before 220 calendar days after the issuance date of the Note, provided that if such Uplist Offering is not completed
within such 220 calendar day period, the conversion price is adjusted for any dilutive issuance which occurred during such 220 calendar
day period.
Although the Notes may not be converted by a holder if such conversion would cause
the holder to own more than 4.99% of our outstanding common stock, this restriction does not prevent such holder from converting some
of its holdings, selling those shares, and then converting the rest of its holdings, while still staying below the 4.99% limit. In this
way, the holders of the Notes could sell more than this limit while never actually holding more shares than this limit allows. If the
holders of the Notes choose to do this, it will cause substantial dilution to the then holders of our common stock.
37
Table of Contents
The
issuance and sale of common stock upon conversion of the Notes may depress the market price of our common stock.
If
conversions of the Notes and sales of such converted shares take place, the price of our common stock may decline. In addition, the common
stock issuable upon conversion of the Notes may represent overhang that may also adversely affect the market price of our common stock.
Overhang occurs when there is a greater supply of a company's stock in the market than there is demand for that stock. When this
happens the price of the company's stock will decrease, and any additional shares which shareholders attempt to sell in the market
will only further decrease the share price. If the share volume of our common stock cannot absorb converted shares sold by the holders
of the Notes, then the value of our common stock will likely decrease.
We
currently owe a significant amount of money under our outstanding convertible notes.
As
of the date of this prospectus we owe approximately $2,648,560 under outstanding convertible (including the Notes) and non-convertible
promissory notes. We do not have sufficient funds to repay such notes and if we are unable to raise additional funds in the future to
repay such amounts, which may not be available on favorable terms, if at all, such failure could have a material adverse effect on our
financial condition or results of operations and cause any investment in the Company to decline in value or become worthless.
We
have established preferred stock which can be designated by the Company's Board of Directors without shareholder approval and the
board has established Series A Preferred Stock, which gives the holders majority voting power over the Company.
The
Company has 5,000,000 shares of preferred stock authorized. The shares of preferred stock of the Company may be issued from time to time
in one or more series, each of which shall have a distinctive designation or title as shall be determined by the board of directors of
the Company prior to the issuance of any shares thereof. The preferred stock shall have such voting powers, full or limited, or no voting
powers, and such preferences and relative, participating, optional or other special rights and such qualifications, limitations or restrictions
thereof as adopted by the board of directors. In May 2020, we designated three shares of Series A Preferred Stock. The Series A Preferred
Stock have the right, voting in aggregate, to vote on all shareholder matters equal to sixty percent (60%) of the total vote (the "
Super
Majority Voting Rights
"), so long as such shares are held by directors of the Company. A total of one share of Series A Preferred
Stock is currently outstanding and held by Jacob D. Cohen, our Chief Executive Officer and director, providing him sole voting right
over 60% of our voting shares.
38
Table of Contents
Because
the board of directors is able to designate the powers and preferences of the preferred stock without the vote of a majority of the Company's
shareholders, shareholders of the Company will have no control over what designations and preferences the Company's preferred stock
will have. The issuance of shares of preferred stock or the rights associated therewith, could cause substantial dilution to our existing
shareholders. Additionally, the dilutive effect of any preferred stock which we may issue may be exacerbated given the fact that such
preferred stock may have voting rights and/or other rights or preferences which could provide the preferred shareholders with substantial
voting control over us and/or give those holders the power to prevent or cause a change in control, even if that change in control might
benefit our shareholders (similar to the Series A Preferred Stock). As a result, the issuance of shares of preferred stock may cause
the value of our securities to decrease.
Stockholders
may be diluted significantly through our efforts to obtain financing and satisfy obligations through the issuance of additional shares
of our common stock.
We
have no committed source of financing. Wherever possible, our board of directors will attempt to use non-cash consideration to satisfy
obligations. In many instances, we believe that the non-cash consideration will consist of restricted shares of our common stock. Our
board of directors has authority, without action or vote of the stockholders, to issue all or part of the authorized but unissued shares
of common stock and designate series of preferred stock. In addition, if a trading market develops for our common stock, we may attempt
to raise capital by selling shares of our common stock (or convertible securities), possibly at a discount to market. These actions will
result in dilution of the ownership interests of existing stockholders, may further dilute common stock book value, and that dilution
may be material. Such issuances may also serve to enhance existing management's ability to maintain control of the Company because
the shares may be issued to parties or entities committed to supporting existing management.
Our
stock price may be volatile, which may result in losses to our stockholders.
The
stock markets have experienced significant price and trading volume fluctuations, and the market prices of companies quoted on the OTC
Markets' OTCQB Market, where our shares of common stock are quoted, generally have been very volatile and have experienced sharp
share-price and trading-volume changes. The trading price of our common stock is likely to be volatile and could fluctuate widely in
response to many of the following factors, some of which are beyond our control:
●
variations
    in our operating results;
●
changes
    in expectations of our future financial performance, including financial estimates by securities analysts and investors;
39
Table of Contents
●
changes
    in operating and stock price performance of other companies in our industry;
●
additions
    or departures of key personnel; and
●
future
    sales of our common stock.
Domestic
and international stock markets often experience significant price and volume fluctuations. These fluctuations, as well as general economic
and political conditions unrelated to our performance, may adversely affect the price of our common stock. In particular, following initial
public offerings, the market prices for stocks of companies often reach levels that bear no established relationship to the operating
performance of these companies. These market prices are generally not sustainable and could vary widely. In the past, following periods
of volatility in the market price of a public company's securities, securities class action litigation has often been initiated.
Our
common shares are thinly-traded, and in the future, may continue to be thinly-traded, and you may be unable to sell at or near ask prices
or at all, if you need to sell your shares to raise money or otherwise desire to liquidate such shares.
We
cannot predict the extent to which an active public market for our common stock will develop or be sustained due to a number of factors,
including the fact that we are a small company that is relatively unknown to stock analysts, stock brokers, institutional investors,
and others in the investment community that generate or influence sales volume, and that even if we came to the attention of such persons,
they tend to be risk-averse and would be reluctant to follow an unproven company such as ours or purchase or recommend the purchase of
our shares until such time as we became more seasoned and viable. As a consequence, there may be periods of several days or more when
trading activity in our shares is minimal or non-existent, as compared to a seasoned issuer which has a large and steady volume of trading
activity that will generally support continuous sales without an adverse effect on share price. We cannot give you any assurance that
a broader or more active public trading market for our common stock will develop or be sustained, or that current trading levels will
be sustained. You may be unable to sell your common stock at or above your purchase price if at all, which may result in substantial
losses to you. As a consequence of this lack of liquidity, the trading of relatively small quantities of shares by our stockholders may
disproportionately influence the price of those shares in either direction. The price for our shares could, for example, decline precipitously
in the event that a large number of our common shares are sold on the market without commensurate demand, as compared to a seasoned issuer
that could better absorb those sales without adverse impact on its share price. Secondly, an investment in us is a speculative or "
risky
"
investment due to our lack of revenues or profits to date. As a consequence of this enhanced risk, more risk-adverse investors may, under
the fear of losing all or most of their investment in the event of negative news or lack of progress, be more inclined to sell their
shares on the market more quickly and at greater discounts than would be the case with the stock of a seasoned issuer.
40
Table of Contents
Our
common stock is likely to be subject to penny stock rules, which may make it more difficult for our stockholders to sell their common
stock.
Broker-dealer
practices in connection with transactions in "
penny stocks
" are regulated by certain penny stock rules adopted by
the SEC. Penny stocks generally are equity securities with a price of less than $5.00 per share. The penny stock rules require a broker-dealer,
prior to a purchase or sale of a penny stock not otherwise exempt from the rules, to deliver to the customer a standardized risk disclosure
document that provides information about penny stocks and the risks in the penny stock market. The broker-dealer also must provide the
customer with current bid and offer quotations for the penny stock, the compensation of the broker-dealer and its salesperson in the
transaction, and monthly account statements showing the market value of each penny stock held in the customer's account. In addition,
the penny stock rules generally require that prior to a transaction in a penny stock the broker-dealer make a special written determination
that the penny stock is a suitable investment for the purchaser and receive the purchaser's written agreement to the transaction.
These disclosure requirements may have the effect of reducing the level of trading activity in the secondary market for a stock that
becomes subject to the penny stock rules.
Our
Chief Executive Officer and director holds majority voting control over the Company.
Our
Chief Executive Officer and director, Jacob D. Cohen, beneficially owns 28.7% of our outstanding common stock and also has the ability
to vote in aggregate, a separate 60% of our voting stock pursuant to his ownership of the one outstanding share of Series A Preferred
Stock, which gives him control over approximately 71.5% of our voting securities. As a result, Mr. Cohen has the ability to influence
matters affecting our stockholders and will therefore exercise control in determining the outcome of all corporate transactions or other
matters, including the election of directors, mergers, consolidations, the sale of all or substantially all of our assets, and also the
power to prevent or cause a change in control. Any investor who purchases shares will be a minority stockholder and as such will have
little to no say in the direction of the Company and the election of directors. Additionally, it will be difficult if not impossible
for investors to remove Mr. Cohen as a director, which will mean he will remain in control of who serves as officers of the Company as
well as whether any changes are made in the board of directors. As a potential investor in the Company, you should keep in mind that
even if you own shares of the Company's common stock and wish to vote them at annual or special stockholder meetings, your shares
will likely have little effect on the outcome of corporate decisions. Because Mr. Cohen controls such vote, investors may find it difficult
to replace our management if they disagree with the way our business is being operated. Additionally, the interests of Mr. Cohen may
differ from the interests of the other stockholders and thus result in corporate decisions that are averse to other stockholders.
We
currently have limited operations and may not generate significant revenues or be profitable in the future.
Our
current operations consist solely of ZipDoctor, Inc., Life Guru, Inc., EPIQ MD, Inc., EPIQ Scripts, LLC, and Mangoceuticals, Inc. We
may not be successful in our planned operations in the future and can make no assurances that we will be able to generate significant
revenues in the future, that we will have sufficient funding to support our operations and pay our expenses, or that we will ever become
profitable. In the event we are unable to generate revenues and/or support our operations, we will be forced to curtail and/or abandon
our current business plan and any investment in the Company could become worthless.
41
Table of Contents
Risks
Related to the Planned Reverse Stock Split
On
July 30, 2021, our board of directors, and on July 30, 2021, stockholders holding a majority of our outstanding voting shares, approved
resolutions authorizing a reverse stock split of the outstanding shares of our common stock in the range from one-for-two (1-for-2) to
one-for-sixty (1-for-60), and provided authority to our board of directors to select the ratio of the reverse stock split in their discretion,
at any time prior to the earlier of July 30, 2022 and the date of our 2022 annual meeting of shareholders. On January 25, 2022, our board
of directors, pursuant to such shareholder authority, approved a one-for-sixty (1-for-60) reverse stock split of the outstanding shares
of our common stock, which is intended to allow us to meet the minimum share price requirement of the NASDAQ Capital Market. Both the
board of directors and Financial Industry Regulatory Authority, Inc. (FINRA) have approved the reverse stock split, which is proposed
in order to increase the trading price of the Company's common stock to a level thought to be sufficient to allow an uplisting
of the Company's common stock on the Nasdaq Capital Market. Notwithstanding the approvals above, the officers of the Company have
not yet moved forward with the reverse stock split, or filed Articles of Amendment in connection therewith with the Secretary of State
of Nevada. The Company currently does not have an estimated date for when the reverse stock split will be made effective. Because
the Company has not formally affected the reverse stock split, none of the outstanding share amounts set forth below have been adjusted
for such board of directors approved reverse stock split. The board of directors reserves the right to adjust the ratio of the reverse
stock split and/or terminate the authority for such reverse stock split in the future.
We
anticipate effecting a reverse stock split of our outstanding common stock in the future.
We
expect that the reverse stock split will increase the market price of our common stock while our stock is trading and enable us to meet
the minimum market price requirement of the listing rules of the Nasdaq Capital Market. However, the effect of a reverse stock split
upon the market price of our common stock cannot be predicted with certainty, and the results of reverse stock splits by companies in
similar circumstances have been varied. It is possible that the market price of our common stock following the reverse stock split will
not increase sufficiently for us to be in compliance with the minimum market price requirement of the Nasdaq Capital Market, or if it
does, that such price will be sustained. If we are unable to meet the minimum market price requirement, we may be unable to list our
shares on the Nasdaq Capital Market.
Even
if the market price of our common stock increases sufficiently so that we comply with the minimum market price requirement, we cannot
assure you that we will be able to comply with the other standards that we are required to meet in order to be approved for listing on
the Nasdaq Capital Market or maintain a listing of our common stock on the Nasdaq Capital Market. Our failure to meet these requirements
may result in our common stock being unable to be listed on the Nasdaq Capital Market.
42
Table of Contents
The
reverse stock split may decrease the liquidity of the shares of our common stock.
The
liquidity of the shares of our common stock may be affected adversely by the reverse stock split given the reduced number of shares that
will be outstanding following the reverse stock split. In addition, the reverse stock split may increase the number of stockholders who
own odd lots (less than 100 shares) of our common stock, creating the potential for such stockholders to experience an increase in the
cost of selling their shares and greater difficulty affecting such sales.
The
reverse stock split may not increase our stock price over the long-term.
The
principal purpose of the reverse stock split is to increase the per-share market price of our common stock. It cannot be assured, however,
that the reverse stock split will accomplish this objective for any meaningful period. While it is expected that the reduction in the
number of outstanding shares of common stock will proportionally increase the market price of the Company's common stock, it cannot
be assured that the reverse stock split will increase the market price of our common stock by a multiple of the proposed reverse stock
split ratio, or result in any permanent or sustained increase in the market price of our common stock, which is dependent upon many factors,
including our business and financial performance, general market conditions, and prospects for future success. Thus, while our stock
price might meet the initial and continued listing requirements for The Nasdaq Capital Market initially, it cannot be assured that it
will continue to do so.
General
Risk Factors
We
will continue to incur increased costs as a result of being a reporting company, and given our limited capital resources, such additional
costs may have an adverse impact on our profitability.
We
are an SEC reporting company. The rules and regulations under the Exchange Act require reporting companies to provide periodic reports
with interactive data files, which require that we engage legal, accounting and auditing professionals, and eXtensible Business Reporting
Language (XBRL) and EDGAR (Electronic Data Gathering, Analysis, and Retrieval) service providers. The engagement of such services can
be costly, and we may continue to incur additional losses, which may adversely affect our ability to continue as a going concern. In
addition, the Sarbanes Oxley Act of 2002, as well as a variety of related rules implemented by the SEC, have required changes in corporate
governance practices and generally increased the disclosure requirements of public companies. For example, as a result of being a reporting
company, we are required to file periodic and current reports and other information with the SEC and we have adopted policies regarding
disclosure controls and procedures and regularly evaluate those controls and procedures.
The
additional costs we continue to incur in connection with becoming a reporting company (expected to be approximately a hundred thousand
dollars per year) will continue to further stretch our limited capital resources. Due to our limited resources, we have to allocate resources
away from other productive uses in order to continue to comply with our obligations as an SEC reporting company. Further, there is no
guarantee that we will have sufficient resources to continue to meet our reporting and filing obligations with the SEC as they come due.
43
Table of Contents
Our
acquisitions may expose us to unknown liabilities.
Because
we have acquired, and expect generally to acquire, all (or a majority of) the outstanding securities of certain of our acquisition targets,
our investment in those companies is or will be subject to all of their liabilities other than their respective debts which we paid or
will pay at the time of the acquisitions. If there are unknown liabilities or other obligations, our business could be materially affected.
We may also experience issues relating to internal controls over financial reporting that could affect our ability to comply with the
Sarbanes-Oxley Act, or that could affect our ability to comply with other applicable laws.
We
may have difficulty obtaining future funding sources, if needed, and we may have to accept terms that would adversely affect stockholders.
We
will need to raise funds from additional financing in the future to complete our business plan and may need to raise additional funding
in the future to support our operations. We have no commitments for any financing and any financing commitments may result in dilution
to our existing stockholders. We may have difficulty obtaining additional funding, and we may have to accept terms that would adversely
affect our stockholders. For example, the terms of any future financings may impose restrictions on our right to declare dividends or
on the manner in which we conduct our business. Additionally, we may raise funding by issuing additional convertible notes, which if
converted into shares of our common stock would dilute our then stockholders' interests. Lending institutions or private investors
may impose restrictions on a future decision by us to make capital expenditures, acquisitions or significant asset sales. If we are unable
to raise additional funds, we may be forced to curtail or even abandon our business plan.
If
we make any acquisitions, they may disrupt or have a negative impact on our business.
If
we make acquisitions in the future, funding permitting, which may not be available on favorable terms, if at all, we could have difficulty
integrating the acquired company's assets, personnel and operations with our own. We do not anticipate that any acquisitions or
mergers we may enter into in the future would result in a change of control of the Company. In addition, the key personnel of the acquired
business may not be willing to work for us. We cannot predict the effect expansion may have on our core business. Regardless of whether
we are successful in making an acquisition, the negotiations could disrupt our ongoing business, distract our management and employees
and increase our expenses. In addition to the risks described above, acquisitions are accompanied by a number of inherent risks, including,
without limitation, the following:
●
the
    difficulty of integrating acquired products, services or operations;
●
the
    potential disruption of the ongoing businesses and distraction of our management and the management of acquired companies;
44
Table of Contents
●
difficulties
    in maintaining uniform standards, controls, procedures and policies;
●
the
    potential impairment of relationships with employees and customers as a result of any integration of new management personnel;
●
the
    potential inability or failure to achieve additional sales and enhance our customer base through cross-marketing of the products
    to new and existing customers;
●
the
    effect of any government regulations which relate to the business acquired;
●
potential
    unknown liabilities associated with acquired businesses or product lines, or the need to spend significant amounts to retool, reposition
    or modify the marketing and sales of acquired products or operations, or the defense of any litigation, whether or not successful,
    resulting from actions of the acquired company prior to our acquisition; and
●
potential
    expenses under the labor, environmental and other laws of various jurisdictions.
Our
business could be severely impaired if and to the extent that we are unable to succeed in addressing any of these risks or other problems
encountered in connection with an acquisition, many of which cannot be presently identified. These risks and problems could disrupt our
ongoing business, distract our management and employees, increase our expenses and adversely affect our results of operations.
Current
global financial conditions have been characterized by increased volatility which could negatively impact our business, prospects, liquidity
and financial condition.
Current
global financial conditions and recent market events have been characterized by increased volatility and the resulting tightening of
the credit and capital markets has reduced the amount of available liquidity and overall economic activity. We cannot guaranty that debt
or equity financing, the ability to borrow funds or cash generated by operations will be available or sufficient to meet or satisfy our
initiatives, objectives or requirements. Our inability to access sufficient amounts of capital on terms acceptable to us for our operations
will negatively impact our business, prospects, liquidity and financial condition.
Our
ability to service our indebtedness will depend on our ability to generate cash in the future.
Our
ability to make payments on our indebtedness will depend on our ability to generate cash in the future. Our ability to generate cash
is subject to general economic and market conditions and financial, competitive, legislative, regulatory and other factors that are beyond
our control. Our business may not generate sufficient cash to fund our working capital requirements, capital expenditure, debt service
and other liquidity needs, which could result in our inability to comply with financial and other covenants contained in our debt agreements,
our being unable to repay or pay interest on our indebtedness, and our inability to fund our other liquidity needs. If we are unable
to service our debt obligations, fund our other liquidity needs and maintain compliance with our financial and other covenants, we could
be forced to curtail our operations, our creditors could accelerate our indebtedness and exercise other remedies and we could be required
to pursue one or more alternative strategies, such as selling assets or refinancing or restructuring our indebtedness. However, such
alternatives may not be feasible or adequate.
45
Table of Contents
Our
potential for rapid growth and our entry into new markets make it difficult for us to evaluate our current and future business prospects,
and we may be unable to effectively manage any growth associated with these new markets, which may increase the risk of your investment
and could harm our business, financial condition, results of operations and cash flow.
Our
entry into the rapidly growing health, wellness and mentoring/life coaching market may place a significant strain on our resources and
increase demands on our executive management, personnel and systems, and our operational, administrative and financial resources may
be inadequate. We may also not be able to effectively manage any expanded operations, or achieve planned growth on a timely or profitable
basis, particularly if the number of customers using our technology significantly increases or their demands and needs change as our
business expands. If we are unable to manage expanded operations effectively, we may experience operating inefficiencies, the quality
of our products and services could deteriorate, and our business and results of operations could be materially adversely affected.
If
we are unable to develop and maintain our brand and reputation for our service and product offerings, our business and prospects could
be materially harmed.
Our
business and prospects depend, in part, on developing and then maintaining and strengthening our brand and reputation in the markets
we serve. If problems arise with our products or services, our brand and reputation could be diminished. If we fail to develop, promote
and maintain our brand and reputation successfully, our business and prospects could be materially harmed.
We
may not maintain sufficient insurance coverage for the risks associated with our business operations.
Risks
associated with our business and operations include, but are not limited to, claims for wrongful acts committed by our officers, directors,
and other representatives, the loss of intellectual property rights, the loss of key personnel, risks posed by natural disasters and
risks of lawsuits from customers who are injured from or dissatisfied with our services. Any of these risks may result in significant
losses. We cannot provide any assurance that our insurance coverage is sufficient to cover any losses that we may sustain, or that we
will be able to successfully claim our losses under our insurance policies on a timely basis or at all. If we incur any loss not covered
by our insurance policies, or the compensated amount is significantly less than our actual loss or is not timely paid, our business,
financial condition and results of operations could be materially and adversely affected.
46
Table of Contents
We
do not anticipate paying any cash dividends.
We
presently do not anticipate that we will pay any dividends on any of our capital stock in the foreseeable future. The payment of dividends,
if any, would be contingent upon our revenues and earnings, if any, capital requirements, and general financial condition. The payment
of any dividends will be within the discretion of our board of directors. We presently intend to retain all earnings, if any, to implement
our business plan; accordingly, we do not anticipate the declaration of any dividends in the foreseeable future.
Any
failure to protect our intellectual property rights could impair our ability to protect our technology and our brand.
Our
success depends in part on our ability to enforce our intellectual property and other proprietary rights. We rely upon a combination
of trademark and trade secret laws, as well as license and other contractual provisions, to protect our intellectual property and other
proprietary rights. These laws, procedures and restrictions provide only limited protection and any of our intellectual property rights
may be challenged, invalidated, circumvented, infringed or misappropriated. To the extent that our intellectual property and other proprietary
rights are not adequately protected, third parties may gain access to our proprietary information, develop and market solutions similar
to ours or use trademarks similar to ours, each of which could materially harm our business. The failure to adequately protect our intellectual
property and other proprietary rights could have a material adverse effect on our business, financial condition and results of operations.
For
all of the foregoing reasons and others set forth herein, an investment in our securities in involves a high degree of risk.
Securities
Purchase AgreementS
Between
November 22, 2021 and December 2, 2021, we entered into four separate Securities Purchase Agreements (collectively, the "
Purchase
Agreements
") with four accredited institutional investors (collectively, the "
Investors
"), for the sale
of convertible promissory notes in an aggregate principal amount of $2,000,000 (collectively, the "
Notes
") and warrants
to purchase an aggregate of 13,333,332 shares of the Company's common stock (collectively, the "
Warrants
").
The Purchase Agreements, Notes, and Warrants are collectively referred to as the "
Transaction Documents
"). The Company
and the Investors closed the sale of the Notes and Warrants between November 23, 2021 and December 3, 2021. Gross proceeds of $1,800,000
were raised through the sale of the Notes and Warrants.
J.H.
Darbie & Co., Inc. acted as placement agent for the offering and was paid a total of $188,000 in placement agent fees of which $98,000
was paid in cash and $90,000 was paid in the form of 1,151,678 shares of restricted common stock from the Company.
47
Table of Contents
The
Purchase Agreements
Pursuant
to the Purchase Agreements, the Company was required to use the proceeds of the sale of the Notes for business development and not for
the repayment of any indebtedness owed to officers, directors or employees of the Company or their affiliates (except for certain excepted
payments not to exceed $115,000 under certain of the Purchase Agreements); any loan, credit, or advance to any officers, directors, employees,
or affiliates of the Company; the repayment of any debt issued in corporate finance transactions; any loan to or investment in any other
corporation, partnership, enterprise or other person, except in connection with the Company's currently existing operations; or
in violation or contravention of any applicable law, rule or regulation. The Company is not permitted to enter into any public or private
offering of the Company's securities (including convertible securities) with any other investor that is more favorable in any material
respect than the Investor's rights under the Transaction Documents, unless similar terms are granted to the Investor, and is prohibited
from entering into certain "variable rate transactions" (including the issuance of convertible securities with a conversion
or exercise price that varies with trading prices of the Company's common stock or is contingent upon a future event relating to
the Company's business or the market for its common stock, or any agreement to issue securities at a future determined price) for
as long as the Notes are outstanding. The Company is also required to maintain the listing and trading of its common stock on the principal
securities exchange or trading market where such common stock is listed or traded and timely file all required reports with the Securities
and Exchange Commission under the Exchange Act, with a penalty of 1% of the purchase price of the Notes to be paid on the date of any
reporting failure and every thirty days thereafter until such reporting failure is cured. The Company also granted the Investors piggy-back
registration rights (except in connection with underwritten offerings and other customary exceptions) and agreed to indemnify the Investors
in connection with certain violations of the Exchange Act or the Securities Act, in connection with the piggy-back registration rights.
Each Purchase Agreement includes indemnification obligations of the Company and customary representations and warranties of the Buyers
and the Company regarding the purchase and offer and sale of the Notes.
The
Notes
Each
Note contains a 10% original issue discount, matures one year from its date of issue, and accrues interest at a rate of 10% per annum
(16% upon the occurrence of an event of default). The Notes also included expense reimbursements of the Investors in the aggregate amount
of $30,000. The Notes do not provide for fixed installment payments, but each Note provides that upon the Company's receipt of
cash proceeds from any source, at the Investor's option, the Company will immediately apply up to 50% of such proceeds to repay
all or any portion of the outstanding principal amount and interest then due under such Note (or up to 100% of the proceeds of any offering
of common stock or common stock equivalents that results in the immediate listing for trading of the Company's common stock on
a national stock exchange or Nasdaq, and occurs within 220 days from the date the Notes are issued, referred to as an "
Uplist
Offering
").
The
Notes (including accrued interest thereon) are convertible into shares of the Company's common stock at any time after the occurrence
of an event of default under the Notes, the date that an Uplist Offering has been completed or 10 business days after notice of pre-payment
has been provided to the holders by the Company, at a conversion price equal to $0.075 per share; however, if the Company consummates
any Uplist Offering on or before 220 calendar days from the issuance date of the applicable Note, the conversion price thereof will be
equal to 80% of the offering price per share of the Company's common stock in such Uplist Offering. Each Note contains a requirement
for the Company to reserve a number of shares of common stock equal to the greater of: (i) two times the number of shares of common stock
then issuable upon conversion of such Note or (ii) a fixed number of shares of common stock which equal two times the initial number
of shares issuable upon conversion of the Note. Each Note provides for a reduction of the conversion price to match the price per share
of any dilutive issuance made while the Note is outstanding (other than pursuant to certain customary excepted issuances), provided that
no adjustment is required unless the Company fails to consummate an Uplist Offering on or before 220 calendar days after the issuance
date of the Note, provided that if such Uplist Offering is not completed within such 220 calendar day period, the conversion price is
adjusted for any dilutive issuance which occurred during such 220 calendar day period. The conversion price of the Notes may be adjusted
upon the occurrence of certain events, such as a merger, consolidation, exchange of shares, recapitalization, reorganization, or similar
events.
48
Table of Contents
The
Notes have priority over all unsecured indebtedness of the Company, and while the Notes are outstanding, the Company is prohibited from
incurring any unsecured indebtedness that is senior to or pari passu with the Notes, paying or declaring any dividend or other distribution
on shares of capital stock other than dividends in kind and distributions pursuant to any shareholders' rights plan which is approved
by a majority of the Company's disinterested directors, selling, leasing or otherwise disposing of any significant portion of its
assets outside the ordinary course of business and from lending money, giving credit, making advances to or entering into any transaction
with any person, firm, joint venture or corporation (other than transactions in existence prior to the issuance of the Notes of which
the Investors have been informed in writing prior to closing, transactions with unaffiliated third parties in the ordinary course of
business, transactions with unaffiliated third parties not in excess of $100,000).
The
Notes contain penalties for the Company's failure to timely deliver shares due upon conversion thereof. The Notes contain provisions
limiting each Investor's ability to convert any portion of its individual Note if such conversion would cause the Investor's
(or any affiliate of any such Investor's) holdings in the Company to exceed 4.99% of the Company's issued and outstanding
shares of common stock. The Notes contain customary events of default, which include failure by the Company to maintain a market capitalization
of at least $2,000,000 on any trading day; the suspension, trading halt, or delisting of the Company's common stock on the principal
securities exchange or trading market on which the Company's common stock is listed or traded; final judgments equal to or greater
than $100,000 rendered against the Company; failure to consummate an Uplist Offering within 220 calendar days after the issue date of
each Note; and the Company's failure to comply with the reporting obligations of the Exchange Act. Upon the occurrence of an event
of default, the amount of each Note increases by 125% (including principal and accrued interest) and is immediately due and payable.
The Company has the right to prepay the Notes by paying 110% of the principal and interest thereon at any time (provided we are required
to provide the holders 10 trading days' prior written notice of such repayment), plus $750 per note holder for administrative fees.
49
Table of Contents
The
Warrants
The
Warrants have a term of five years, are exercisable beginning 90 days after the issuance date, and have an exercise price of $0.075 per
share; however, if the Company consummates any Uplist Offering on or before 180 calendar days from the grant date of the Warrants, the
exercise price will be equal to 120% of the offering price per share of the Company's common stock in such Uplist Offering. If
the exercise price is lower than the highest traded price of the Company's common stock during the 150 trading days prior to the
date of exercise and the shares underlying the Warrants are not registered, the Warrants may be exercised via cashless exercise (with
the formula for such cashless exercise being set forth in the Warrants, and based on such highest traded price within the last 150 days).
The exercise price and the number of shares underlying the Warrant will be adjusted to account for any dividend or distribution by the
Company to the holders of its common stock. Each Warrant provides for a reduction of the exercise price to match the price per share
of any dilutive issuance made while the Warrant is outstanding (other than in connection with stock plan issuances and other customary
exceptions). Such reduction of the exercise price will not apply to the Uplist Offering if the Uplist Offering is consummated on or before
180 calendar days after the grant date of the Warrant. The exercise price of the Warrants is subject to customary adjustment upon the
occurrence of certain events, such as a subdivision (by any stock split, stock dividend, recapitalization or otherwise) of the Company's
common stock.
Each
Warrant contains a requirement for the Company to reserve two times the number of shares of common stock issuable upon the exercise of
such Warrant. If the Company undertakes certain fundamental transactions (such as certain mergers, exchanges, or the sale of substantially
all of the Company's assets) while the Warrants are outstanding, the Investors will have the right to receive any consideration
received by the record holders of the Company's common stock as a result of such fundamental transaction and the exercise price
of the Warrants will be adjusted to account for such additional consideration. The Warrants contain provisions limiting each Investor's
ability to exercise the Warrants if such exercise would cause the Investor's (or any affiliate of any such Investor) holdings in
the Company to exceed 4.99% of the Company's issued and outstanding shares of common stock.
Use
of Proceeds
We
are registering the shares of common stock for the benefit of the selling stockholders. We are not selling any securities under this
prospectus and we will not receive any of the proceeds from the sale or other disposition by the selling stockholders or their transferees
of the shares of common stock covered hereby. However, to the extent that the Warrants are exercised for cash, we will receive up to
$1,000,000 (assuming the exercise price of the Warrants, which is subject to adjustment as discussed above, remains at $0.075 per share)
which amount we plan to use for working capital and general corporate purposes. However, the timing and manner of use of the net proceeds
may vary, depending on the amount of actual proceeds received from the exercise of the Warrants, if any, the timing of the receipt of
such proceeds, our rate of growth and other factors. To the extent that any shares of common stock issuable upon exercise of the Warrants
are not registered under an effective registration statement under the Securities Act, such unregistered Warrants or portion thereof
are exercisable on a cashless basis pursuant to the terms of the Warrant agreements.
We
have agreed to pay all costs, expenses and fees relating to registering the shares of our common stock referenced in this prospectus.
The selling stockholders will pay any underwriting discounts and commissions and expenses incurred by the selling stockholders for brokerage,
accounting, tax or legal services or any other expenses incurred by the selling stockholders in disposing of the shares.
See
"
Selling Stockholders
" and "
Plan of Distribution
" described below.
50
Table of Contents
Determination
of Offering Price
The
selling stockholders will offer the shares at the prevailing market prices or privately negotiated price. The offering price of our common
stock does not necessarily bear any relationship to our book value, assets, past operating results, financial condition or any other
established criteria of value. Our common stock may not trade at market prices in excess of the offering price as prices for common stock
in any public market will be determined in the marketplace and may be influenced by many factors, including the depth and liquidity.
Description
of Capital Stock
The
following information describes our common stock and preferred stock, as well as certain provisions of our Articles of Incorporation
and Bylaws, as amended and restated (the "
Bylaws
"). This description is only a summary. You should also refer to our
Articles of Incorporation and Bylaws, which have been filed with the SEC as exhibits to our registration statement, of which this prospectus
forms a part.
Description
of Capital Stock
Our
authorized capital stock consists of 195,000,000 shares of common stock with a $0.0001 par value per share, and 5,000,000 shares of preferred
stock with a $0.0001 par value per share. As of the date of this prospectus, we have designated three shares of Series A Preferred Stock
and 2,000,000 shares of Series B Preferred Stock. As of the date of this prospectus, there are 97,286,902 shares of common stock issued
and outstanding, one share of Series A Preferred Stock issued and outstanding and no shares of Series B Preferred Stock issued and outstanding.
The following is a summary of the material provisions of the common stock and preferred stock provided for in our Articles of Incorporation
and Bylaws. For additional detail about our capital stock, please refer to our Articles of Incorporation and Bylaws.
Common
Stock
Voting
Rights
. Each share of our common stock is entitled to one vote on all stockholder matters. Shares of our common stock do not
possess any cumulative voting rights.
Except
for the election of directors, if a quorum is present, an action on a matter is approved if it receives the affirmative vote of the holders
of a majority of the voting power of the shares of capital stock present in person or represented by proxy at the meeting and entitled
to vote on the matter, unless otherwise required by applicable law, Nevada law, our Articles of Incorporation, as amended or Bylaws,
as amended. The election of directors will be determined by a plurality of the votes cast in respect of the shares present in person
or represented by proxy at the meeting and entitled to vote, meaning that the nominees with the greatest number of votes cast, even if
less than a majority, will be elected. The rights, preferences and privileges of holders of common stock are subject to, and may be impacted
by, the rights of the holders of shares of any series of preferred stock that we have designated, or may designate and issue in the future.
51
Table of Contents
Dividend
Rights
. Each share of our common stock is entitled to equal dividends and distributions per share with respect to the common
stock when, as and if declared by our board of directors, subject to any preferential or other rights of any outstanding preferred stock.
Liquidation
and Dissolution Rights
. Upon liquidation, dissolution or winding up, our common stock will be entitled to receive pro rata on
a share-for-share basis, the assets available for distribution to the stockholders after payment of liabilities and payment of preferential
and other amounts, if any, payable on any outstanding preferred stock.
Fully
Paid Status
.
All outstanding shares of the Company's common stock are validly issued, fully paid and non-assessable.
Other
Matters
. No holder of any shares of our common stock has a preemptive right to subscribe for any of our securities, nor are any
shares of our common stock subject to redemption or convertible into other securities.
Preferred
Stock
On
May 18, 2020, the board of directors of the Company approved the filing of (a) an Amended and Restated Certificate of Designation of
the Company's Series A Preferred Stock (the "
Series A Preferred Stock
" and the "
Series A Designation
");
and (b) an Amended and Restated Certificate of Designation of the Company's Series B Convertible Preferred Stock (the "
Series
B Preferred Stock
" and the "
Series B Designation
"), with the Secretary of State of Nevada, which designations
were filed with, and became effective with, the Secretary of State of Nevada on the same date. The Series A Designation designated three
shares of Series A Preferred Stock and the Series B Designation designated 2,000,000 shares of Series B Preferred Stock.
Series
A Preferred Stock
The
Series A Designation provides for the Series A Preferred Stock to have the following rights:
Dividend
Rights
. The Series A Preferred Stock do not accrue dividends.
Liquidation
Preference
. The Series A Preferred Stock have no liquidation preference.
Conversion
Rights
. The Series A Preferred Stock have no conversion rights.
Voting
Rights
.
For so long as any shares of Series A Preferred Stock remain issued and outstanding, the holders thereof, voting separately
as a class, have the right to vote on all shareholder matters (including, but not limited to at every meeting of the stockholders of
the Company and upon any action taken by stockholders of the Company with or without a meeting) equal to sixty percent (60%) of the total
vote (the "
Total Series A Vote
" and the "
Voting Rights
"). For example, if there are 10,000 shares
of the Company's common stock issued and outstanding at the time of a shareholder vote, the holders of the Series A Preferred Stock,
voting separately as a class, will have the right to vote an aggregate of 15,000 shares, out of a total number of 25,000 shares voting.
52
Table of Contents
Additionally,
so long as Series A Preferred Stock is outstanding, the Company shall not, without the affirmative vote of the holders of at least 66-2/3%
of all outstanding shares of Series A Preferred Stock, voting separately as a class (i) amend, alter or repeal any provision of the Articles
of Incorporation or the Bylaws of the Company so as to adversely affect the designations, preferences, limitations and relative rights
of the Series A Preferred Stock, (ii) effect any reclassification of the Series A Preferred Stock, (iii) designate any additional series
of preferred stock, the designation of which adversely effects the rights, privileges, preferences or limitations of the Series A Preferred
Stock; or (iv) amend, alter or repeal any provision of the Series A Designation (except in connection with certain non-material technical
amendments).
Notwithstanding
the above, no shares of Series A Preferred Stock held by any person who is not a then member of the board of directors of the Company
(each a "
Non-Director Holder
"), shall have any Voting Rights and the Voting Rights of all other shares of Series A
Preferred Stock (including, but not limited to the Total Series A Vote) shall be calculated without regard to, and without taking into
account, the shares of Series A Preferred Stock held by such Non-Director Holder.
Redemption
Right
. The Company has the option in its sole discretion, at any time, with the majority consent or approval of the board of
directors of the Company, to redeem any outstanding shares of Series A Preferred Stock of the Company held by any Non-Director Holder,
by paying the Non-Director Holder(s) a redemption price of $1.00 per share for each such Series A Preferred Stock shares redeemed (the
"
Redemption Amount
", and each a "
Redemption
"). The payment by the Company to the Non-Director Holder
(at such Non-Director Holder's address of record) of the Redemption Amount in connection with a Redemption automatically results
in the cancellation, termination and invalidation of any outstanding Series A Preferred Stock held by a Non-Director Holder or his, her
or its assigns.
Purchase
Right
. In the event the Company is legally prohibited from exercising the redemption right discussed above, any one or more of
the other holders of the Series A Preferred Stock, other than any Non-Director Holder(s) (the "
Director Holders
"),
have the option, exercisable in their sole discretion, to purchase their pro rata share of any shares of Series A Preferred Stock held
by any Non-Director Holder(s) for $1.00 per share of Series A Preferred Stock (the "
Purchase Amount
", and the "
Purchase
").
The payment by the Director Holder(s) of the Series A Preferred Stock to the Non-Director Holder of the Purchase Amount automatically,
and without any required action by the Director Holder(s) or the Non-Director Holder, results in the transfer of the rights to, and ownership
of, such Series A Preferred Stock held by a Non-Director Holder or his, her or its assigns, to the Director Holder(s), pro rata with
their payment of the Purchase Amount.
53
Table of Contents
Protective
Provisions
. Subject to the rights of series of preferred stock which may from time to time come into existence, so long as any
shares of Series A Preferred Stock are outstanding, the Company cannot without first obtaining the approval (by written consent, as provided
by law) of the holders of a majority of the then outstanding shares of Series A Preferred Stock, voting together as a class:
(a)
Issue any additional shares of Series A Preferred Stock after the original issuance of shares of Series A Preferred Stock;
(b)
Increase or decrease the total number of authorized or designated shares of Series A Preferred Stock;
(c)
Effect an exchange, reclassification, or cancellation of all or a part of the Series A Preferred Stock;
(d)
Effect an exchange, or create a right of exchange, of all or part of the shares of another class of shares into shares of Series A Preferred
Stock; or
(e)
Alter or change the rights, preferences or privileges of the shares of Series A Preferred Stock so as to affect adversely the shares
of such series, including the rights set forth in the Series A Designation.
Transfer
Restrictions
. Each holder of Series A Preferred Stock is prohibited from Transferring any shares of Series A Preferred Stock.
"
Transfer
" means directly or indirectly (a) offering for sale, selling, pledging, hypothecating, transferring, assigning
or otherwise disposing of (or enter into any transaction or device that is designed to, or could be expected to, result in the sale,
pledge, hypothecation, transfer, assignment or other disposition at any time) (including, without limitation, by operation of law); or
(b) entering into any swap or other derivatives transaction that transfers to another, in whole or in part, any of the benefits or risks
of ownership of the applicable securities, whether any such transaction is to be settled by delivery of securities or other securities,
in cash or otherwise.
A
total of one share of Series A Preferred Stock is currently outstanding.
Series
B Convertible Preferred Stock
The
Series B Designation provides for the Series B Preferred Stock to have the following rights:
Dividend
Rights
. The Series B Preferred Stock does not accrue any dividends, but the Series B Preferred Stock holders are entitled to
share in dividends paid to the holders of the Company's common stock to the same extent that such holders would have received such
dividends had they converted the Series B Preferred Stock into common stock pursuant to the conversion rights discussed below.
54
Table of Contents
Liquidation
Preference
. In the event of any liquidation, dissolution or winding up of the Company, either voluntary or involuntary (each
a "
Liquidation Event
"), the holders of Series B Preferred Stock are entitled to receive pari passu with any distribution
of any of the assets of the Company to the holders of the Company's common stock, but not prior to any holders of senior securities
(which include holders of capital leases, other preferred stock and debt holders, and banks or others, which hold priority liquidation
preferences over the assets of the Company), which holders of the senior securities have priority to the distribution of any assets of
the Company, an amount per share for each share of Series B Preferred Stock held by them equal to $1.00 per share.
Conversion
Rights
. Each share of Series B Preferred Stock may be converted, at the option of the holder thereof, into that number of shares
of common stock of the Company as equals $1.00 divided by 90% of the average of the volume weighted average prices ("
VWAP
")
of the Company's common, for the five trading days immediately preceding the date the notice of conversion is received, with any
remainder rounded to the hundredths place. Notwithstanding the above, at no time may the Series B Preferred Stock be converted into shares
of our common stock by any holder, if such conversion would result in such holder thereof and its affiliates owning an aggregate of in
excess of 4.999% of the then outstanding shares of our common stock, which amount may be increased to 9.999% on a per holder basis, upon
61 days' prior written notice.
Voting
Rights
. The Series B Preferred Stock have no voting rights on general corporate matters, provided that the Series B Designation
does contain customary protective provisions restricting the Company's ability to undertake any of the following without the approval
of a majority in interest of such shares of Series B Preferred Stock:
(a)
Increase or decrease (other than by redemption or conversion) the total number of authorized shares of Series B Preferred Stock;
(b)
Re-issue any shares of Series B Preferred Stock converted pursuant to the terms of the Series B Designation;
(c)
Issue any shares of Series B Preferred Stock other than pursuant to a specified securities purchase agreement;
(d)
Alter or change the rights, preferences or privileges of the shares of Series B Preferred Stock so as to affect adversely the shares
of such series; or
(e)
Amend or waive any provision of the Company's Articles of Incorporation or Bylaws relative to the Series B Preferred Stock so as
to affect adversely the shares of Series B Preferred Stock in any material respect as compared to holders of other series of shares.
Redemption
Rights
. The Series B Preferred Stock have no redemption rights.
No
shares of Series B Preferred Stock are currently outstanding.
55
Table of Contents
Anti-Takeover
Provisions Under the Nevada Revised Statutes
Business
Combinations
Sections
78.411 to 78.444 of the Nevada revised statutes (the "
NRS
") prohibit a Nevada corporation from engaging in a "
combination
"
with an "
interested stockholder
" for three years following the date that such person becomes an interested stockholder
and places certain restrictions on such combinations even after the expiration of the three-year period. With certain exceptions, an
interested stockholder is a person or group that owns 10% or more of the corporation's outstanding voting power (including stock
with respect to which the person has voting rights and any rights to acquire stock pursuant to an option, warrant, agreement, arrangement,
or understanding or upon the exercise of conversion or exchange rights) or is an affiliate or associate of the corporation and was the
owner of 10% or more of such voting stock at any time within the previous three years.
A
Nevada corporation may elect not to be governed by Sections 78.411 to 78.444 by a provision in its Articles of Incorporation. We do not
have such a provision in our Amended and Restated Articles of Incorporation, as amended, pursuant to which we have elected to opt out
of Sections 78.411 to 78.444; therefore, these sections apply to us.
Control
Shares
Nevada
law also seeks to impede "
unfriendly
" corporate takeovers by providing in Sections 78.378 to 78.3793 of the NRS that
an "
acquiring person
" shall only obtain voting rights in the "
control shares
" purchased by such
person to the extent approved by the other stockholders at a meeting. With certain exceptions, an acquiring person is one who acquires
or offers to acquire a "
controlling interest
" in the corporation, defined as one-fifth or more of the voting power.
Control shares include not only shares acquired or offered to be acquired in connection with the acquisition of a controlling interest,
but also all shares acquired by the acquiring person within the preceding 90 days. The statute covers not only the acquiring person but
also any persons acting in association with the acquiring person. The NRS control share statutes only apply to issuers that have 200
or more stockholders of record, at least 100 of whom have had addresses in Nevada appearing on the stock ledger of the corporation at
all times during the 90 days immediately preceding such date; and whom do business in Nevada directly or through an affiliated corporation.
We do not currently meet these requirements and as such these provisions do not apply to us.
A
Nevada corporation may elect to opt out of the provisions of Sections 78.378 to 78.3793 of the NRS. We do not have a provision in our
Amended and Restated Articles of Incorporation pursuant to which we have elected to opt out of Sections 78.378 to 78.3793; therefore,
these sections do apply to us.
Removal
of Directors
Section
78.335 of the NRS provides that 2/3rds of the voting power of the issued and outstanding shares of the Company are required to remove
a Director from office. As such, it may be more difficult for stockholders to remove Directors due to the fact the NRS requires greater
than majority approval of the stockholders for such removal.
56
Table of Contents
Anti-Takeover
Effects of Our Articles of Incorporation and Bylaws
The
following provisions of our Articles of Incorporation and Bylaws could have the effect of delaying or discouraging another party from
acquiring control of us and could encourage persons seeking to acquire control of us to first negotiate with our board of directors:
●
no
    cumulative voting in the election of directors, which limits the ability of minority stockholders to elect director candidates;
●
the
    right of our board of directors to elect a director to fill a vacancy created by the expansion of the board of directors or the resignation,
    death or removal of a director, with our stockholders only allowed to fill such a vacancy if not filled by the board;
●
the
    super majority voting rights of our Series A Preferred Stock, to the extent such shares are held by members of our board of directors;
●
the
    ability of our board of directors to alter our Bylaws without obtaining stockholder approval; and
●
the
    requirement that a special meeting of stockholders may be called only by the board of directors, the Chairman of the Board, the President
    or a committee of the board of directors duly designated and whose powers and authority include the power to call meetings may call
    special meetings of the Company.
Listing
Our
common stock is traded on the OTCQB Market under the symbol "
AMIH
".
Transfer
Agent and Registrar
The
transfer agent and registrar for our common stock is American Stock Transfer & Trust Company, 6201 15th Ave, Brooklyn, NY 11219.
Its telephone number is (800) 937-5449.
Plan
of Distribution
We
are registering the shares of common stock covered by the registration statement of which this prospectus is a part, which are issuable
to the selling stockholders upon the conversion of Notes and upon the exercise of Warrants, to permit the resale of these shares of common
stock by the selling stockholders from time to time from after the date of this prospectus.
57
Table of Contents
Each
selling stockholder may, from time to time, sell any or all of their shares of common stock covered hereby on the over-the-counter market,
any national securities exchange or quotation service on which the shares of our common stock may be listed or quoted at the time of
sale, in the over-the counter market, in privately negotiated transactions, through the writing of options, whether such options are
listed on an options exchange or otherwise, short sales or in a combination of such transactions. These sales may be at fixed prices,
at prevailing market prices at the time of the sale, at varying prices determined at the time of sale, or privately negotiated prices.
A Selling Stockholder may use any one or more of the following methods when selling shares:
●
ordinary
    brokerage transactions and transactions in which the broker-dealer solicits purchasers;
●
block
    trades in which the broker-dealer will attempt to sell the shares as agent but may position and resell a portion of the block as
    principal to facilitate the transaction;
●
purchases
    by a broker-dealer as principal and resale by the broker-dealer for its account;
●
an
    exchange distribution in accordance with the rules of the applicable exchange;
●
privately
    negotiated transactions;
●
settlement
    of short sales, to the extent permitted by law;
●
in
    transactions through broker-dealers that agree with the selling stockholders to sell a specified number of such shares at a stipulated
    price per share;
●
through
    the writing or settlement of options or other hedging transactions, whether through an options exchange or otherwise;
●
a
    combination of any such methods of sale; or
●
any
    other method permitted pursuant to applicable law.
The
selling stockholders may pledge or grant a security interest in some or all of the shares of common stock owned by them and, if they
default in the performance of their secured obligations, the pledgees or secured parties may offer and sell the shares of common stock
from time to time pursuant to this prospectus.
The
selling stockholders also may transfer and donate the shares of common stock in other circumstances in which case the transferees, donees,
pledgees or other successors in interest will be the selling beneficial owners for purposes of this prospectus.
The
selling stockholders may also sell the shares of common stock under Rule 144 under the Securities Act, if available, rather than under
this prospectus.
Broker-dealers
engaged by the selling stockholders may arrange for other brokers-dealers to participate in sales. Broker-dealers may receive commissions
or discounts from the selling stockholders (or, if any broker-dealer acts as agent for the purchaser of shares, from the purchaser) in
amounts to be negotiated, but, except as set forth in a supplement to this prospectus, in the case of an agency transaction not in excess
of a customary brokerage commission in compliance with FINRA Rule 2440; and in the case of a principal transaction a markup or markdown
in compliance with FINRA IM-2440-1.
58
Table of Contents
The
aggregate proceeds to the selling stockholders from the sale of the common stock offered by them will be the purchase price of the common
stock less discounts or commissions, if any. Each of the selling stockholders reserve the right to accept and, together with their agents
from time to time, to reject, in whole or in part, any proposed purchase of common stock to be made directly or through agents. We will
not receive any of the proceeds from the sale by the selling stockholders of the shares of common stock.
In
connection with the sale of the shares of common stock or interests therein, the selling stockholders may enter into hedging transactions
with broker-dealers or other financial institutions, which may in turn engage in short sales of the shares of common stock in the course
of hedging the positions they assume. The selling stockholders may also sell the shares of common stock short and deliver these securities
to close out their short positions or to return borrowed shares in connection with such short sales, or loan or pledge the shares of
common stock to broker-dealers that in turn may sell these securities. The selling stockholders may also enter into option or other transactions
with broker-dealers or other financial institutions or create one or more derivative securities which require the delivery to such broker-dealer
or other financial institution of shares of common stock offered by this prospectus, which shares such broker-dealer or other financial
institution may resell pursuant to this prospectus (as supplemented or amended to reflect such transaction).
The
selling stockholders and any broker-dealers or agents that are involved in selling the shares of common stock may be deemed to be "
underwriters
"
within the meaning of the Securities Act in connection with such sales. In such event, any commissions received by such selling stockholders,
broker-dealers or agents and any profit on the resale of the shares purchased by them may be deemed to be underwriting commissions or
discounts under the Securities Act. Selling stockholders who are "
underwriters
" within the meaning of Section 2(11)
of the Securities Act will be subject to the prospectus delivery requirements of the Securities Act and may be subject to certain statutory
liabilities of, including but not limited to, Sections 11, 12 and 17 of the Securities Act and Rule 10b-5 under the Exchange Act. Each
selling stockholder has informed us that it is not a registered broker-dealer or an affiliate of a registered broker-dealer.
Under
the securities laws of some states, the shares of common stock may be sold in such states only through registered or licensed brokers
or dealers. In addition, in some states the shares of common stock may not be sold unless such shares have been registered or qualified
for sale in such state or an exemption from registration or qualification is available and is complied with. There can be no assurance
that any selling stockholder will sell any or all of the shares of common stock registered pursuant to the registration statement, of
which this prospectus forms a part.
We
are required to pay certain fees and expenses incurred by us incident to the registration of the shares. We have agreed to indemnify
the selling stockholders against certain losses, claims, damages and liabilities, including liabilities under the Securities Act, and
the selling stockholders may be entitled to contribution. We may be indemnified by the selling stockholders against certain losses, claims,
damages and liabilities, including liabilities under the Securities Act that may arise from any written information furnished to us by
the selling stockholders specifically for use in this prospectus, or we may be entitled to contribution.
59
Table of Contents
The
selling stockholders will be subject to the prospectus delivery requirements of the Securities Act including Rule 172 thereunder unless
an exemption therefrom is available.
Under
applicable rules and regulations under the Exchange Act, any person engaged in the distribution of the shares of common stock may not
simultaneously engage in market making activities with respect to the shares of common stock for the applicable restricted period, as
defined in Regulation M, prior to the commencement of the distribution. In addition, the selling stockholders will be subject to applicable
provisions of the Exchange Act and the rules and regulations thereunder, including Regulation M, which may limit the timing of purchases
and sales of shares of common stock by the selling stockholders or any other person. We will make copies of this prospectus available
to the selling stockholders and have informed them of the need to deliver a copy of this prospectus at or prior to the time of the sale
(including by compliance with Rule 172 under the Securities Act).
To
the extent required, the shares of our common stock to be sold, the names of the selling stockholders, the respective purchase prices
and public offering prices, the names of any agents, dealer or underwriter, any applicable commissions or discounts with respect to a
particular offer will be set forth in an accompanying prospectus supplement or, if appropriate, a post-effective amendment to the registration
statement that includes this prospectus.
The
selling stockholders may not sell any or all of the shares of common stock we registered on behalf of the selling stockholders pursuant
to the registration statement of which this prospectus forms a part.
Once
sold under the registration statement of which this prospectus forms a part, the shares of common stock registered herein will be freely
tradable in the hands of persons other than our affiliates.
Selling
Stockholders
This
prospectus covers the resale from time to time by the selling stockholders identified in the table below of up to 42,666,665 shares of
common stock through this prospectus, including up to 29,333,333 shares of common stock issuable upon conversion of Notes and 13,333,332
shares of common stock issuable upon exercise of outstanding Warrants, each described in greater detail above under "
Securities Purchase Agreement
".
We
are registering the shares to permit the selling stockholders and any of their pledgees, donees, transferees, assignees and successors-in-interest
to, from time to time, sell any or all of the shares through public or private transactions at prevailing market prices, at prices related
to prevailing market prices or at privately negotiated prices of common stock on any stock exchange, market or trading facility on which
the shares are traded or in private transactions when and as they deem appropriate in the manner described in "
Plan of Distribution
".
As of the date of this prospectus, there are 97,286,902 shares of our common stock issued and outstanding.
60
Table of Contents
The
following table sets forth, as of the date of this prospectus, the name of each selling stockholder, the number and percentage of shares
of our common stock beneficially owned by each selling stockholder prior to the offering for resale of the shares under this prospectus,
the number of shares of our common stock beneficially owned by each selling stockholder that may be offered from time to time under this
prospectus, and the number and percentage of shares of our common stock beneficially owned by the selling stockholder after the offering
of the shares (assuming all of the offered shares are sold by the selling stockholder).
There
are no agreements between the Company and any selling stockholder pursuant to which the shares subject to this registration statement
were issued except as discussed above under "
Securities Purchase Agreement
". None of the selling stockholders has ever been
an executive officer or director of the Company or has had a material relationship with us at any time within the past three years unless
disclosed in the footnotes below.
Beneficial
ownership is determined in accordance with the rules of the SEC, and includes any shares of common stock as to which a person has sole
or shared voting power or investment power and any shares of common stock which the person has the right to acquire within sixty (60)
days through the exercise of any option, warrant or right, through conversion of any security or pursuant to the automatic termination
of a power of attorney or revocation of a trust, discretionary account or similar arrangement.
Number of Shares of Common Stock Beneficially Owned Prior to this Offering (1)
Number of Shares of
Beneficial Ownership of Common Stock After Registration Assuming All Shares Are Sold (#)
Name of Selling Stockholder
Number
Percentage
Common Stock Being Offered
Number
Percentage
Mast Hill Fund, L.P. (2)
4,048,335
(10)
4.99
%(10)
16,000,000
(6)
–
–
Blue Lake Partners, LLC (3)
4,048,335
(10)
4.99
%(10)
10,666,666
(7)
–
–
%
Talos Victory Fund, LLC (4)
4,048,335
(10)
4.99
%(10)
10,666,666
(8)
–
–
%
LGH Investments, LLC (5)
4,048,335
(10)
4.99
%(10)
5,333,333
(9)
–
–
%
42,666,665
*
Less than one percent (1%).
#
Assumes the sale of all shares offered herein.
61
Table of Contents
(1)
"
Beneficial ownership
" means that a person, directly or indirectly, has or shares voting or investment power with
respect to a security or has the right to acquire such power within 60 days. The percentage is based upon 97,286,902 shares of our common
stock outstanding as of April 21, 2022.
(2)
Address: 48 Parker Road, Wellesley, MA 02482. Patrick Hassani is the Chief Investment Officer of Mast Hill Fund, L.P. and has voting
and investment power over these securities.
(3)
Address: 3411 Silverside Road, Tatnal Building #104, Wilmington, DE 19810. Craig Kesselman is a managing member of Blue Lake Partners,
LLC. and has voting and investment power over these securities.
(4)
Address: 348 Cambridge Street #101, Woburn, MA 01801. Thomas Silverman is a managing member of Talos Victory Fund, LLC. and has voting
and investment power over these securities.
(5)
Address: 6170 Tiki Ct., San Diego, CA 92130. Lucas Hoppel is a managing member of LGH Investments, LLC. and has voting and investment
power over these securities.
(6)
Represents (1) 5,000,000 shares of common stock issuable upon exercise of Common Stock Purchase Warrants granted to the selling stockholder,
providing such selling stockholders the right to purchase 5,000,000 shares of common stock at an exercise price of $0.075 per share,
subject to adjustment; and (2) up to 11,000,000 shares of common stock of the Company issuable, upon conversion of principal and accrued
interest at maturity pursuant to a $750,000 Note acquired by the selling stockholder on November 22, 2021, at the option of the holder
thereof.
(7)
Represents (1) 3,333,333 shares of common stock issuable upon exercise of Common Stock Purchase Warrants granted to the selling stockholder,
providing such selling stockholders the right to purchase 3,333,333 shares of common stock at an exercise price of $0.075 per share,
subject to adjustment; and (2) up to 7,333,333 shares of common stock of the Company issuable, upon conversion of principal and accrued
interest at maturity pursuant to a $500,000 Note acquired by the selling stockholder on December 2, 2021, at the option of the holder
thereof.
(9)
Represents (1) 3,333,333 shares of common stock issuable upon exercise of Common Stock Purchase Warrants granted to the selling stockholder,
providing such selling stockholders the right to purchase 3,333,333 shares of common stock at an exercise price of $0.075 per share,
subject to adjustment; and (2) up to 7,333,333 shares of common stock of the Company issuable, upon conversion of principal and accrued
interest at maturity pursuant to a $500,000 Note acquired by the selling stockholder on November 30, 2021, at the option of the holder
thereof.
(9)
Represents (1) 1,666,666 shares of common stock issuable upon exercise of Common Stock Purchase Warrants granted to the selling stockholder,
providing such selling stockholders the right to purchase 1,666,666 shares of common stock at an exercise price of $0.075 per share,
subject to adjustment; and (2) up to 3,666,667 shares of common stock of the Company issuable, upon conversion of principal and accrued
interest at maturity pursuant to a $250,000 Note acquired by the selling stockholder on December 1, 2021, at the option of the holder
thereof.
62
Table of Contents
(10)
The Notes and Warrants contain provisions limiting each holder's ability to convert/exercise such security, if such conversion/exercise
would cause the holder's (or any affiliate of any such holder's) holdings in the Company to exceed 4.99% of the Company's
issued and outstanding shares of common stock. As such, the number of shares of common stock beneficially owned prior to this offering
represents 4.99% of the Company's current outstanding shares of common stock.
Certain
Beneficial Owners and Management
The
following table sets forth information regarding the beneficial ownership of our common stock as of April [  ], 2022 (the "
Date
of Determination
") by (i) each Named Executive Officer, as such term is defined in "
Executive and Director Compensation
",
(ii) each member of our board of directors, (iii) each person deemed to be the beneficial owner of more than five percent (5%) of our
common stock or preferred stock, and (iv) all of our executive officers and directors as a group. Unless otherwise indicated, each person
named in the following table is assumed to have sole voting power and investment power with respect to all shares of our stock listed
as owned by such person. The address of each person is deemed to be the address of the Company unless otherwise noted.
Beneficial
ownership is determined in accordance with the rules of the SEC and includes voting and/or investing power with respect to securities.
These rules generally provide that shares of common stock subject to options, warrants or other convertible securities that are currently
exercisable or convertible, or exercisable or convertible within 60 days of the Date of Determination, are deemed to be outstanding and
to be beneficially owned by the person or group holding such options, warrants or other convertible securities for the purpose of computing
the percentage ownership of such person or group, but are not treated as outstanding for the purpose of computing the percentage ownership
of any other person or group. The percentages are based upon 97,286,902 shares of our common stock outstanding as of the Date of Determination.
To
our knowledge, except as indicated in the footnotes to this table and pursuant to applicable community property laws, as of the Date
of Determination, (a) the persons named in the table have sole voting and investment power with respect to all shares of common stock
shown as beneficially owned by them, subject to applicable community property laws; and (b) no person owns more than 5% of our common
or preferred stock. Unless otherwise indicated, the address for each of the officers or directors listed in the table below is 7950 Legacy
Drive, Suite 400, Plano, Texas 75024.
63
Table of Contents
Name and Address of Beneficial Owner
Common Shares Beneficially Owned
Common Ownership Percentage
Series A Preferred Stock Shares Beneficially Owned
Series A Preferred Stock Percentage (1)
Total Voting Percentage (2)
Officers and Directors
Jacob D. Cohen
27,500,000
(3)
28.3
%
1
100
%
71.4
%
Alejandro Rodriguez
4,000,000
(4)
4.1
%
1.7
%
Verdie Bowen
1,500,000
1.5
%
*
Sultan Haroon
-
-
-
-
Maja Matthews
-
-
-
-
Peter "Casey" Jensen
414,112
*
-
*
Dr. Kenny Myers
163,043
*
-
-
*
Lorraine D'Alessio
163,043
*
-
*
Dr. Craig Hewitt
-
-
-
-
*
All officers and directors as a group
33,251,069
34.7
%
1
100
%
73.1
%
Greater than 5% Shareholders
Cavalry Fund I LP (5)
5,023,352
5.0
%
—
—
%
2.1
%
L1 Capital Global Opportunities Master Fund (6)
8,081,267
8.1
%
—
—
%
3.3
%
*
Less than 1%.
(1)
The Series A Preferred Stock have the right, voting in aggregate, to vote on all shareholder matters equal to sixty percent (60%) of
the total vote, so long as such shares are held by directors of the Company.
(2)
Based on 240,983,562 total voting shares, including 97,286,902 shares voted by our common stockholders and 143,696,660 voting shares
voted by our Series A Preferred Stock holder, Mr. Cohen (see also footnote 1).
(3)
The shares of common stock are held in the name of Cohen Enterprises, Inc., which shares Mr. Cohen is deemed to beneficially own due
to his ownership of 100% of Cohen Enterprises and his position as President thereof.
(4)
The shares of common stock are held in the name of Landa Rodriguez Holdings, LLC., which shares Mr. Rodriguez is deemed to beneficially
own due to his control position and majority ownership thereof.
(5)
Address: 82 E. Allendale Rd., Ste 5B, Saddle River, NJ 07458. Cavalry Fund I Management LLC, the investment manager of Cavalry Fund I
LP, has voting and investment power over these securities. Thomas Walsh is the managing member of Cavalry Fund I Management LLC, which
is the general partner of Cavalry Fund I LP. Thomas Walsh disclaims beneficial ownership over these securities. Based solely on the Schedule
13G/A filed by Cavalry Fund I LP on February 4, 2022, which we do not know or have reason to believe is not complete or accurate and
on which we are relying pursuant to applicable SEC regulations.
64
Table of Contents
(6)
Address: 161A Shedden Road, 1 Artillery Court, PO Box 10085, Grand Cayman, Cayman Islands KY1-1001. David Feldman and Joel Arber are
the Directors of L1 Capital Global Opportunities Master Fund Ltd. As such, L1 Capital Global Opportunities Master Fund Ltd, Mr. Feldman
and Mr. Arber may be deemed to beneficially own the shares of the Company held by L1 Capital Global Opportunities Master Fund. To the
extent Mr. Feldman and Mr. Arber are deemed to beneficially own such shares, Mr. Feldman and Mr. Arber disclaim beneficial ownership
of these securities for all other purposes. Based solely on the Schedule 13G/A filed by L1 Capital Global Opportunities Master Fund on
February 14, 2022, which we do not know or have reason to believe is not complete or accurate and on which we are relying pursuant to
applicable SEC regulations.
Change
of Control
The
Company is not aware of any arrangements which may at a subsequent date result in a change of control of the Company.
Dividend
Policy
We
have never paid or declared any cash dividends on our common stock and do not anticipate paying cash dividends in the foreseeable future.
We anticipate that we will retain all of our future earnings for use in the operation of our business and for general corporate purposes.
Any determination to pay dividends in the future will be at the discretion of our board of directors. Accordingly, investors must rely
on sales of their common stock after price appreciation, which may never occur, as the only way to realize any future gains on their
investments.
Legal
Matters
The
validity of the securities offered by this prospectus have been passed upon for us by The Loev Law Firm, PC. David M. Loev, the Managing
Partner of The Loev Law Firm, PC (who is the brother in-law of Jacob Cohen, our Chief Executive Officer), owns 1,000,000 shares of the
Company's common stock. The securities are subject to a lock-up agreement (expiring January 22, 2023), preventing the sale or transfer
of such shares without the written approval of the Company, except to affiliates of the holder, who agree to be bound by the same terms.
Experts
The
audited financial statements of American International Holdings Corp. and its subsidiaries as of December 31, 2021 and 2020, and for
the years then ended, included in this prospectus have been audited by M&K CPAS, PLLC, Houston, Texas, independent registered public
accounting firm, as stated in their report date dated March 29, 2022, which is included herein, and has been so incorporated in reliance
upon the report of such firm given upon their authority as experts in accounting and auditing.
No
expert or counsel named in this prospectus as having prepared or certified any part of this prospectus or having given an opinion upon
the validity of the securities being registered or upon other legal matters in connection with the registration or offering of the common
stock was employed on a contingency basis, or had, or is to receive, any interest, directly or indirectly, in our Company or any of our
parents or subsidiaries, nor was any such person connected with us or any of our parents or subsidiaries, if any, as a promoter, managing
or principal underwriter, voting trustee, director, officer, or employee.
65
Table of Contents
Changes
in and Disagreements with Accountants on Accounting and Financial Disclosure
None.
Description
of Business
The
following discussion should be read in conjunction with our financial statements and the related notes and other financial information
appearing elsewhere in this prospectus.
Overview
The
Company is headquartered in Plano, Texas, and is an investor, developer and asset manager with diversified assets across the healthcare
supply chain. The Company's portfolio encompasses telemedicine and other virtual health platforms, subscriber based primary care
and concierge medicine plans, preventative care solutions and wellness related assets such as mental and behavioral health services,
as well as its own proprietary life coaching platform. The Company provides its various services through direct-to-consumer and business-to-business
distribution channels and is focused on developing, acquiring and bringing to market technologies and solutions that we believe can advance
the quality of life for the global community. Additionally, the Company seeks opportunities to acquire and grow businesses that possess
strong brand values and that can generate long-term sustainable free cash flow and attractive returns in order to maximize value for
all stakeholders.
Corporate
Structure
The
Company currently is the parent to ten subsidiaries, of which seven are wholly-owned subsidiaries and three (3) are majority-owned subsidiaries.
In 2021, the Company ceased operations of five of its ten subsidiaries in order to focus on the subsidiaries that better aligned with
the purpose of the Company and its ongoing business plan.
ZIPDOCTOR,
INC. – 100% OWNED
On
April 28, 2020, the Company incorporated a wholly-owned subsidiary, ZipDoctor, Inc. ("
ZipDoctor
") in the state of
Texas. ZipDoctor launched its online, direct-to-consumer subscription-based telemedicine platform
www.ZipDoctor.co
in the third
quarter of 2020. ZipDoctor provides its customers with unlimited, 24/7 access to board certified physicians and licensed mental and behavioral
health counselors and therapists via a newly developed, monthly subscription-based online telemedicine platform. ZipDoctor's online
telemedicine platform is available to customers across the United States and offers bilingual coverage (English and Spanish), with virtual
visits taking place either via the phone or through a secured video chat platform. ZipDoctor customers subscribe through the website
and are only required to pay a monthly fee, which is determined based on whether they are an individual, a couple, or a family. ZipDoctor
is currently being sold on a direct-to-consumer basis, with an emphasis on digital marketing and advertising.
66
Table of Contents
Digital
Marketing Initiative:
The ZipDoctor website was originally designed to be marketed and sold primarily using a digital and social
media advertising campaign. Shortly after the website's launch, ZipDoctor began to advertise on Google pay per click (PPC), search
engine optimization (SEO), Facebook and Instagram. Shortly after launching, the Company decided to shift the focus of its marketing to
a direct sales approach, resulting in the formation and launch of EPIQ MD, Inc. (discussed below).
Going
Forward Strategy:
With EPIQ MD, Inc. taking over the sales and marketing of the direct-to-consumer telemedicine platform, ZipDoctor
has changed its business plan to focus on developing customized telemedicine solutions for niche, or specialty care, areas of medicine.
Telemedicine
Platform Provider for Pharmacies.
ZipDoctor is targeting relationships with specialty compound pharmacies seeking both an online
telemedicine platform and a network of doctors to assist in facilitating patient online visits and to streamline the medical intake,
patient demographics, health insurance verifications and overall prescription process. In exchange, ZipDoctor expects to receive a monthly
fee on a per-patient per month basis for this customized access to the telemedicine platform. The initial focus is on Texas based pharmacies,
however, if successful in Texas, ZipDoctor plans to expand its customized telemedicine solution to pharmacies across the United States,
funding permitting.
On
August 15, 2021, ZipDoctor entered into a Telemedicine Services Agreement (the "
Services Agreement
") with Murphy RX,
LLC ("
Murphy
"), a Texas-based specialty pharmacy, which has since ceased operations as of January 31, 2022. Pursuant
to the Services Agreement, ZipDoctor agreed to provide Murphy with access to its centralized technology platform, to collect and manage
patient demographics, and access to telemedicine services. Murphy agreed to pay ZipDoctor a monthly fee on a per-patient basis for the
use of the technology platform and for access to primary care telemedicine services. ZipDoctor also agreed to provide continued support
for the ZipDoctor website through the term of the agreement. The Services Agreement is no longer in effect, as Murphy ceased operations
effective as of January 31, 2022.
As
of the date of this prospectus, ZipDoctor has approximately 100 total members subscribed to its subscription-based telemedicine platform
at www.ZipDoctor.co. Monthly subscription payments range from $25/month to $45/month, depending on how many family members are included,
and provide members with unlimited, 24/7 access to board certified physicians and licensed mental and behavioral health counselors and
therapists.
EPIQ
MD, INC. – 100% OWNED
On
October 23, 2020, the Company incorporated a wholly-owned subsidiary, EPIQ MD, Inc. ("EPIQ MD") in the state of Nevada. EPIQ
MD is a direct-to-consumer, telemedicine and healthcare company targeting Americans who are uninsured or underinsured. The EPIQ MD service
offering is a convergence of primary care telemedicine, preventative care services and wellness programs – under the EPIQ MD brand
and on a single platform. EPIQ MD markets and sells its services direct to end-use consumers, as well as through business-to-business
(B2B) efforts, by focusing on employers in the targeted industries.
67
Table of Contents
Products
& Services
EPIQ
MD's telemedical services revolve around three services (1) primary care, (2) mental health care, and (3) prevention. Using cloud-based
software, EPIQ MD has been able to merge these services under a single platform.
Primary
care with EPIQ MD connects users to board certified doctors and medical professionals who can treat most non-emergency conditions using
telemedicine. Similarly, EPIQ MD's mental health services connect users with licensed therapists and counselors. As for EPIQ MD's
preventive care, the Company is using data driven technologies (wearables and apps), nutritionist and lab services, to help attempt to
mitigate chronic diseases and the risk factors associated with them. In the future, funding permitting, EPIQ MD plans to add in-home
medical devices to record vital information, offering what we believe to be the ambit of services between patient and doctor via the
use of EPIQ MD's telemedicine platform.
EPIQ
MD also provides its subscribers with an option to participate in two premium add-on services, EPIQ LUX and EPIQ Paws. EPIQ LUX provides
subscribers with discounts to ancillary healthcare related services such as laboratory services, dental and vision discount plans, prescription
drug discounts, and imaging services and EPIQ Paws provides subscribers with access to virtual consultations with licensed veterinarians.
As
of the date of this prospectus, EPIQ MD has nominal subscribers as it is expanding its marketing initiatives. However, EPIQ MD is currently
registered to do business and is being marketed in
Alaska, Georgia, Illinois, Texas, Arizona, New
Mexico, Colorado, Louisiana, Mississippi, Alabama, Florida, Nevada and Utah.
To ensure the highest quality control, it plans to
scale up its full-service coverage incrementally to all 50 U.S. states by year-end 2022, funding permitting.
Marketing
Strategy
With
approximately 30 million people uninsured in the United States (according to 2019 Congressional Budget Office estimates) and 45 percent
of U.S. adults between ages of 19 and 64 being inadequately insured (according to a February 2019 Survey Brief by the Commonwealth Fund),
and an estimated 530,000 families turning to bankruptcy each year due to medical expenses (according to a study published in the March
2019 American Public Journal of Health), the Company sees an opportunity to make a positive impact in the lives of these uninsured or
underinsured people. We believe that this is the demographic that the healthcare system has abandoned, ignored and/or left behind and
is what we believe to be a largely underserved group.
To
grow its subscriber base, EPIQ MD has implemented its own direct-to-consumer distribution channel referred to as the "Ambassador
Program". The Ambassador Program is intended to allow social influencers, community leaders and entrepreneurial-minded sales agents
to market and sell EPIQ MD's services across the nation, on a commission-only basis.
68
Table of Contents
Market
Opportunity
As
previously described above, with approximately 30 million people uninsured in the United States and 45 percent of U.S. adults between
ages of 19 and 64 being inadequately insured, EPIQ MD believes that their service offerings will be instrumental in reaching these Americans
and plans to reach this demographic through its own direct-to-consumer distribution channel, or Ambassador Program, and through its commercial
division
that will target small and medium sized businesses (SMB's) and municipalities.
According
to a 2020 study by the Kaiser Family Foundation, a leading industry research firm ("Key Facts About the Uninsured Population"),
the high cost of insurance is one of the main reasons individuals lack coverage (in 2019, 73.7% of uninsured adults said they were uninsured
because the cost of coverage was too high); and, individuals with income below 200% of the Federal Poverty Level (FPL) are at the highest
risk of being uninsured.
We
see a significant opportunity to market to these uninsured and/or underinsured persons, and believe that our low-cost, flat rate, telemedical
services can be an attractive alternative to those persons seeking lower cost health services.
LIFE
GURU, INC. – 51% OWNED
On
May 15, 2020, the Company acquired a 51% interest in Life Guru, Inc., a Delaware corporation ("
Life Guru
"). Life Guru
owns www.LifeGuru.me – a website dedicated to providing an online platform to connect consumers to a variety of mentors, professionals,
life coaches and career coaches. Upon final launch of the platform, it will include functionality enabling: life coaches from around
the world to access and subscribe to the Life Guru platform; and consumers to filter their life coach options by geographic location,
language and even the type of currency they would like to pay with. While Life Guru is free to consumers, it generates revenues by charging
monthly subscription fees to coaches participating on the platform. Further, and depending on the type of subscription plan the life
coach chooses to participate in, Life Guru receives a percentage of the per session fees generated and earned between the consumer and
the life coach.
Since
the LifeGuru.me website was launched around March 2021, Life Guru has been working to optimize the website for mobile and completing
integration with its merchant account provider to automate monthly payouts to coaches. LifeGuru is currently in the process of marketing
and onboarding coaches onto the platform.
Industry
Trends
Life
coaching has been the second fastest growing industry in the world for over ten consecutive years, behind the information technology
sector (according to a May 2016 article posted at Forbes.com). The global Personal Development Industry (including market segments from
holistic approaches, motivational speakers, inspirational websites, personal coaching, and other forms of personal development) was valued
at approximately $38.28 billion in 2019 and is expected to grow at a compound annual growth rate (CAGR) of 5.1% from 2020 to 2027 (according
to a July 2020 report by Grand View Research). Moreover, Life Guru believes that improving social skills and focusing on critical areas
for self-awareness, such as emotions, character traits, habits, individual values, and the psychological need that shapes the day-to-day
behavior of individuals are gaining importance.
69
Table of Contents
Operational,
Technological & Cost Advantages
We
anticipate that coaches that subscribe to the Life Guru platform will benefit from Life Guru's investment in digital marketing
and promotion, enabling them to reach customers and providing increased visibility. Life Guru has developed a proprietary technology
platform for coaching online, as well as proprietary video conferencing capabilities for coaching interactively. Through our existing
marketing partnerships, Life Guru believes it has access to sales tools which allow the effective marketing of coaches across all major
social media platforms, including and most importantly, LinkedIn. LifeGuru.me is mobile-friendly and can run smoothly on many platforms,
making it highly scalable.
Subscriptions
Life
Guru offers free membership for all consumers to gain access to the site and search for life coaches. Life Guru's model is to charge
coaches, and not members, for the use of its services. The Company currently offers three different subscription levels to life coaches,
with varying levels of promotion on the Life Guru site, prominence of search results, and commissions payable. As of the date of this
prospectus, Life Guru has no members and approximately 200 total life coaches that have signed up and created profiles on the platform.
Growth
Objectives
In
addition to marketing Life Guru directly to consumers, Life Guru intends to implement packages to be sold to various businesses and corporations,
which can, in turn, be marketed as a corporate benefit by employers. Life Guru calls this "Life Guru Corporate". A recent
survey of 256 companies by the National Alliance of Healthcare Purchaser Coalitions, a nonprofit employer group, found that 53% of employers
are providing special emotional and mental health programs for their workforce in the wake of the pandemic. Life Guru believes that Life
Guru Corporate represents important potential upside in targeting the business and corporate world, and providing services to employees
on an ongoing basis. Life Guru Corporate can only be developed once the platform has achieved a reputable brand and a substantial amount
of high-quality business coaches are engaged, and Life Guru does not anticipate launching Life Guru Corporate with fewer than 200 life
coaches, provided Life Guru's projected milestones are met.
MANGOCEUTICALS,
INC.
– 80% OWNED
On
October 7, 2021, the Company incorporated Mangoceuticals, Inc. ("
Mangoceuticals
") in the
state of Texas with the intent of focusing on developing, marketing and selling a variety of men's wellness products and services
via a telemedicine platform. To date, the Company has identified men's wellness telemedicine services and products as a growing
sector in the most recent years and especially related to the areas of erectile dysfunction and hair loss products. In this regard, Mangoceuticals
is currently in the process of developing and preparing to market a new brand of erectile dysfunction (ED) products that delivers fast
acting results through a proprietary combination of FDA approved ingredients.
70
Table of Contents
Mangoceuticals
plans to market and sell this new brand of ED products exclusively online and will require the use of a telemedicine visit, a doctor's
prescription and the fulfillment of the prescription by pharmacy licensed in the state in which the customer resides. Mangoceuticals
plans to rely heavily on digital and social media marketing through channels such as Facebook, Instagram, Twitter, Snap Chat and TikTok
and further has plans to use digital marketing with the goal of creating viral marketing campaigns, using social media influencers and
celebrities, funding permitting.
Our
goal is to eventually sell this new brand of ED products nationwide and to use EPIQ Scripts (described below) as its mail order pharmacy
to fulfill the ED prescriptions. Mangoceuticals is currently in the branding and development stage of this ED product and anticipates
a planned and limited launch in the Texas market in the second quarter of 2022 with the intent of expanding its marketing initiatives
at a pace in which Epiq Scripts obtains additional state licenses across the United States.
Subsequent
to incorporation, Mangoceuticals issued 1,000,000 shares of common stock each to Jacob D. Cohen, the Chief Executive Officer of the Company,
and a third party, in consideration for services rendered. As a result, Mangoceuticals is currently 80% owned by the Company.
EPIQ
SCRIPTS, LLC – 51% OWNED
On
January 24, 2022, the Company formed EPIQ Scripts, LLC ("
EPIQ Scripts
") in the state of Texas. EPIQ Scripts has been
established with the intent of operating as a close-door online mail order pharmacy with a specific target and vision to obtain licenses
in all 50 states across the U.S., of which no state licenses have been obtained as of the date of this prospectus. EPIQ Scripts also
plans to seek to become accredited with the most respected and highly recognized authorities in the industry, such as
Utilization
Review Accreditation Commission (
URAC), Legit Script,
Accreditation Commission for Health
Care
(ACHC), and
National Association of Boards of Pharmacy
(NABP) Digital Pharmacy.
EPIQ Scripts also intends to obtain in-network contracts with all major Pharmacy Benefit Managers (PBM) and insurance payors.
Market
Opportunity
It
is anticipated that if licenses, accreditations and in-network contracts are secured in all 50 U.S. states, EPIQ Scripts will be able
to market itself to the many up and coming telemedicine companies that have been on the rise since early 2020. Pursuant to a July 9,
2021 article published by McKinsey & Company, according to a study taken by McKinsey & Company,
in
April 2020, overall telehealth utilization for office visits and outpatient care was 78 times higher than in February 2020. Ev
en
though telemedicine use has now leveled off as in-person visits have returned, McKinsey & Company is still consistently seeing use
that is 38 times higher than pre-pandemic numbers. Furthermore, a majority of Americans have now tried out telehealth. According to an
article published at Sykes.com, a March 2021 survey of 2,000 U.S. adults undertaken by Sykes.com found that by March 2021, more than
61% of such surveyed individuals had made a telehealth/telemedicine appointment, which is a massive increase from just 19.5% a year prior,
according to Sykes. We further believe that telemedicine use is now widespread across demographics.
71
Table of Contents
We
believe the significant increases in demand for telemedicine has created a vacuum for pharmacies that have the capabilities to handle
the prescription volume generated by these platforms. We believe that EPIQ Scripts' planned mail order pharmacy, which is expected
to have advanced API capabilities and infrastructure and be supported with nationwide licenses and accreditations can position itself
to capitalize on the current market opportunity.
EPIQ
Scripts has currently filed with the
Utilization Review Accreditation Commission (URAC) to obtain
its pharmacy accreditation and is in the process of obtaining its first state license in the State of Texas, which it anticipates receiving
in April 2022. Once the Texas state license is obtained, EPIQ Scripts will be able to apply for additional state licenses until they
have obtained all 50 state licenses, with some state licenses easier to obtain and quicker to obtain than others. EPIQ Scripts intends
to have licenses to operate in all 50 states by the first quarter of 2023.
*
* * * * *
The
Company intends to continue to grow its business both organically and through identifying acquisition targets over the next 12 months
in the telemedicine, life coaching and wellness space, funding permitting. As these opportunities arise, the Company will determine the
best method for financing its growth which may include the issuance of additional debt instruments, common stock, preferred stock, or
a combination thereof, any one or more of which may cause significant dilution to existing shareholders.
The
Company requires approximately $5 million to implement its current business strategy for its different subsidiaries and to support potential
growth.
We expect to raise funds in the future through the sale of debt and/or equity in order to allow us to operate for the
next twelve months, and may need to raise further additional capital in order to expedite our growth through acquisitions, none of which
are currently planned. There is no assurance that we will be successful in raising such funds and if we do raise funds, this may result
in substantial dilution to current investors.
DISCONTINUED
OPERATIONS:
MEDICAL
SPA AND WELLNESS
The
Company previously operated three wholly-owned subsidiaries that were in the Medical Spa and Wellness Sector (collectively hereinafter
referred to as "
MedSpa
", or "
VISSIA
"), the operations of which were discontinued in October 2020:
1.
VISSIA
    MCKINNEY, LLC (F/K/A NOVOPELLE DIAMOND, LLC) – 100% OWNED
VISSIA
McKinney was a physician supervised, medical spa and wellness clinic that offered a full menu of wellness services including anti-aging,
weight loss and skin rejuvenation treatments and was located at 5000 Collin McKinney Parkway, Suite 150, McKinney, Texas 75070.
72
Table of Contents
2.
VISSIA
    WATERWAY, INC. (F/K/A NOVOPELLE WATERWAY, INC.) – 100% OWNED
VISSIA
McKinney was a physician supervised, medical spa and wellness clinic that offered a full menu of wellness services including anti-aging,
weight loss and skin rejuvenation treatments and was located at 25 Waterway, Suite 150, The Woodlands, Texas.
3.
NOVOPELLE
    TYLER, INC. – 100% OWNED
On
December 3, 2019, the Company formed and organized Novopelle Tyler, Inc. in the State of Texas with the plan to come to terms on a retail
location for a new med spa to be located in Tyler, Texas. The Company no longer intends to open this location and no activity has been
performed under this entity to date.
*
* * * *
As
a result of COVID-19 and 'stay-at-home' and social distancing orders issued in McKinney and The Woodlands, Texas, we had
to close both of our then operational MedSpas, VISSIA McKinney and VISSIA Waterway, Inc., effective March 10, 2020, and which resulted
in both the loss of income and the loss of substantially all of our MedSpa employees, who had to be let go. VISSIA Waterway, Inc. reopened
effective June 21, 2020 and VISSIA McKinney reopened effective August 8, 2020. However, due to the termination of employees associated
with the shutdown we were forced to expend resources to attract, hire and train completely new staff for preparation of the re-launchings.
Notwithstanding the re-openings, customer traffic and demand at our VISSIA Waterway, Inc. and VISSIA McKinney MedSpa locations failed
to rebound to pre-COVID-19 levels due to COVID-19 and the pandemic's effects on the economy, and because we were unable to predict
the length of the pandemic or ultimate outcome thereof, and further due to our limited capital resources, effective on October 25, 2020,
we made the decision to close both our VISSIA Waterway, Inc. and VISSIA McKinney locations. Our former MedSpa operations and assets are
included under discontinued operations in the statement of operations and balance sheet included herein for the year ended December 31,
2021 and for the year ended, December 31, 2020.
4.
CAPITOL
    CITY SOLUTIONS, USA, INC. – 100% OWNED
On
September 17, 2019, the Company formed and organized Capitol City Solutions USA, Inc. ("
CCS
") in the State of Texas
to act as a general contracting and construction company focused on the remodeling, general construction and interior finish of both
the Company's then MedSpa locations (which have since been closed) as well as to market to other commercial real estate projects
within the United States. The Company made the decision to cease any further construction-based operations under CCS in July 2021, in
order to focus on the subsidiaries that better aligned with the purpose of the Company and its ongoing business plan in the telehealth
and wellness space.
73
Table of Contents
5.
LEGEND
    NUTRITION, INC. – 100% OWNED
On
September 23, 2019, the Company formed and organized Legend Nutrition, Inc. ("
Legend Nutrition
") in the State of Texas
to act as a new brand of retail vitamin and supplement stores to be branded and marketed as Legend Nutrition. October 18, 2019, Legend
entered into an Asset Purchase Agreement to acquire all of the assets associated with and related to a retail vitamin, supplements and
nutrition store located in McKinney, Texas and previously identified and doing business as "
Ideal Nutrition.
" Pursuant
to the Asset Purchase Agreement, Legend purchased a variety of assets including software, contracts, bank and merchant accounts, products,
inventory, computers, security systems and other intellectual properties. As Legend Nutrition's lease expired in January 2021,
the Company made the decision to cease its operations to focus on the subsidiaries that better aligned with the purpose of the Company
and its ongoing business plan in the telehealth and wellness space.
Corporate
History
American
International Holdings Corp.
American
International Holdings Corp. was organized in 1986 and is incorporated in Nevada. The Company has undergone several name changes and
changes of control since its incorporation; however, from 2012 until April 2019, the Company had no operations and nominal assets.
Prior
to May 31, 2018, the Company was a 93.2% owned subsidiary of American International Industries, Inc. ("
American
",
"
AMIN
"), a company whose securities are traded on the OTCQB market maintained by OTC Markets under the symbol "
AMIN
".
Effective
on May 31, 2018, the Company issued (a) 4,300,000 shares of restricted common stock to Mr. Daniel Dror (the Company's former Chief
Executive Officer and President (who resigned from such positions effective on May 31, 2018)); (b) 3,800,000 shares of restricted common
stock to Mr. Robert Holden (who was appointed President, Chief Executive Officer and Director of the Company on May 31, 2018 and resigned
on August 20, 2018); (c) 750,000 shares of restricted common stock to Mr. Everett Bassie (who was appointed as Chief Financial Officer,
Secretary, Treasurer and a member of the board of directors of the Company on May 31, 2018, and resigned from all positions with the
Company); (d) 750,000 shares of restricted common stock to Mr. Winfred Fields (a consultant to the Company); and (e) 500,000 shares of
restricted common stock to Mr. Charles R. Zeller (a then director of the Company), each in consideration for services rendered to the
Company.
As
a result of the issuance of the shares in May 2018 as discussed above, a change in control occurred. American International Industries,
Inc. ownership decreased from 93.2% to 6.4%.
74
Table of Contents
On
April 12, 2019, the Company entered into a Share Exchange Agreement (the "
Share Exchange Agreement
") with Novopelle
Diamond, LLC, a Texas limited liability company ("
Novopelle Diamond
" and "
Novopelle
") and certain
unitholders of Novopelle Diamond. Pursuant to the terms of the Share Exchange Agreement, the Company acquired 100% of the issued and
outstanding membership interests of Novopelle Diamond by means of a share exchange with the Novopelle Members in exchange for 18,000,000
newly issued shares of the common stock of the Company (the "
Share Exchange
"). As a result of the Share Exchange,
Novopelle became a 100% owned subsidiary of the Company. The closing of the Share Exchange occurred concurrently with the entry into
the Share Exchange Agreement and resulted in a change of control of the Company. As a result of the Share Exchange, the Company acquired
the business of Novopelle Diamond and all of its assets. Novopelle Diamond is a physician supervised, medical spa and wellness clinic
that offers a full menu of wellness services including anti-aging, weight loss and skin rejuvenation treatments.
The
three unitholders of Novopelle Diamond who received shares pursuant to the Share Exchange Agreement were (1) Jacob D. Cohen; (2) Esteban
Alexander; and (3) Luis Alan Hernandez, who each received six million shares pursuant to the Share Exchange.
Concurrent
with the Share Exchange, the Company entered into individual share exchange agreements and promissory notes with each of Daniel Dror,
Winfred Fields and former directors Everett Bassie and Charles Zeller (the "
AMIH Shareholders
") whereby the AMIH Shareholders
agreed to cancel and exchange a total of 4,900,000 shares of their Company common stock for individual promissory notes with an aggregate
principal amount of $350,000 (the "
Promissory Notes
"). The Promissory Notes had a term of two years and accrue interest
at the rate of 10% per annum (payable at maturity) until paid in full by the Company. The current principal balance of the Promissory
Notes is approximately $110,000 as of the date of this prospectus.
As
a result of the issuance of the shares in the Share Exchange and the cancellation of the shares held by the AMIH Shareholders, control
of the Company changed to (1) Jacob D. Cohen; (2) Esteban Alexander; and (3) Alan Hernandez, who each owned 26% of the Company's
common stock following such transactions.
Also
effective on April 12, 2019, the directors of the Company changed to Mr. Jacob D. Cohen; Mr. Esteban Alexander; and Mr. Alan Hernandez,
who were also each appointed as the Chief Executive Officer and President of the Company (Mr. Cohen); the Chief Operating Officer and
Treasurer (Mr. Alexander); and the Chief Marketing Officer and Secretary (Mr. Hernandez). Mr. Bassie resigned as a member of the board
of directors of the Company and as the Secretary and Treasurer on April 12, 2019, but remained as the Company's Chief Financial
Officer until his passing on May 21, 2020.
On
October 2, 2020, Jacob D. Cohen, the Chief Executive Officer and member of the board of directors of the Company entered into Stock Purchase
Agreements with each of (a) Esteban Alexander, the Chief Operating Officer and member of the board of directors of the Company, and (b)
Luis Alan Hernandez, the Chief Marketing Officer and member of the board of directors of the Company (collectively, the "
Preferred
Holders
" and the "
Stock Purchase Agreements
").
75
Table of Contents
Pursuant
to the Stock Purchase Agreements, Mr. Alexander agreed to sell 7,000,000 shares of common stock of the Company which he held to Mr. Cohen,
which rights to such shares were assigned by Mr. Cohen to Cohen Enterprises, Inc., which entity he controls ("
Cohen Enterprises
"),
in consideration for an aggregate of $1,500 (which was an arbitrary value agreed to by the parties) as well as for the amount of services
provided by Mr. Cohen to the Company; and Mr. Hernandez agreed to sell 4,000,000 shares of common stock of the Company which he held
to Cohen Enterprises, in consideration for an aggregate of $1,000 as well as for the amount of services provided by Mr. Cohen to the
Company. The sales closed on November 5, 2020.
One
of the reasons that Mr. Alexander and Mr. Hernandez agreed to the terms of the Stock Purchase Agreements (including the sale of the shares
of common stock of the Company at below market value), is because (a) each of Mr. Cohen, Mr. Alexander, and Mr. Hernandez were all appointed
as officers and directors of the Company at the same time in April 2019, with the intention that such persons would provide a relatively
equal amount of services to the Company in the roles as officers and directors thereof; (b) since such appointment date Mr. Cohen has
been required to provide a disproportionate amount of services to the Company; and (c) each of Mr. Alexander and Mr. Hernandez desired
to provide additional consideration to Mr. Cohen for such disproportionate level of service.
A
condition to the Stock Purchase Agreements was that each of Mr. Alexander and Mr. Hernandez resign as a member of the board of directors
of the Company by no later than January 15, 2021, which resignations were effective December 15, 2020.
A
further requirement to the terms of the Stock Purchase Agreements was that each of Mr. Alexander and Mr. Hernandez take such actions
necessary and which may be requested from time to time by Mr. Cohen, to affect the cancellation of the one share of Series A Preferred
Stock of the Company held by each of them, for no consideration (including, but not limited to, without the required payment by the Company
of the $1 redemption price described in the designation of such Series A Preferred Stock).
The
shares of Series A Preferred Stock held by Mr. Alexander and Mr. Hernandez were canceled on November 6, 2020. The common shares were
also transferred to Mr. Cohen on November 6, 2020, and as such, a change of control occurred on such date, with Mr. Cohen taking over
voting control of the Company, and serving between December 15, 2020 and October 19, 2021, as the sole officer and director of the Company.
Effective
on October 19, 2021, the Company
appointed Peter "
Casey
" Jensen to fill one
of the vacancies on the Board of Directors, as an independent director. Mr. Jensen was also appointed as the sole member of the Company's
newly established Audit Committee (discussed under "Committees of the Board", below), and to serve as the Chairperson of
the Audit Committee.
Effective
on January 13, 2022, the Company
appointed Ms. Lorraine D'Alessio and Dr. Kenny Myers to
fill two of the vacancies on the Board of Directors, as independent directors. Both Ms. D'Alessio and Dr. Myers were appointed
as members of the Company's Audit Committee upon their appointment to the Board of Directors.
76
Table of Contents
COVID-19
Outlook
The
outbreak of the 2019 novel coronavirus disease ("
COVID-19
"), which was declared a global pandemic by the World Health
Organization on March 11, 2020, and the related responses by public health and governmental authorities to contain and combat its outbreak
and spread has severely impacted the U.S. and world economies, the market for health spa services, nutrition supplements and our other
business offerings during the end of the first quarter of 2020, and continuing through the end of 2020 and into 2021. Government mandated
'stay-at-home' and similar orders have to date, and may in the future, prevent us from operating. As discussed above, we
made the decision to discontinue operations of our VISSIA Waterway, Inc. and VISSIA McKinney MedSpa locations. Additionally, our Legend
Nutrition store saw a deep decline in sales due to social distancing orders and decreases in customers who are willing to venture out
to brick-and-mortar establishments. Legend Nutrition's lease was up January 31, 2021, and the Company chose to not renew the lease,
closed the store, and will not continue in this line of business moving forward. We also decided to cease offering construction services
around July 2021.
As
of the date of this prospectus, our operations are limited, and consist mainly of ZipDoctor, Inc., Life Guru, Inc., EPIQ MD, Inc., EPIQ
Scripts, LLC, and Mangoceuticals, Inc.
Moving
forward, economic recessions, including those brought on by the continued COVID-19 outbreak may have a negative effect on the demand
for our services and our operating results. Any prolonged disruption to our operations or work force available is likely to have a significant
adverse effect on our results of operations, cash flows and ability to meet continuing debt service requirements. All of the above may
be exacerbated in the future as the COVID-19 outbreak and the governmental responses thereto continues.
Employees
As
of the date of this prospectus, we have fifteen full-time employees (two at the parent/ZipDoctor/Mangoceuticals level, nine at the EPIQ
MD level, two at the EPIQ Scripts level, and two at the Life Guru level). Our compensation programs are designed to align the compensation
of our employees with performance and to provide the proper incentives to attract, retain and motivate employees to achieve superior
results. The structure of our compensation programs balances incentives earnings for both short-term and long-term performance such as
incentive bonuses and flexible schedules. The Company believes that its rich culture of inclusion and diversity enables it to create,
develop and fully leverage the strength of its workforce to exceed customer expectation and meet its growth objectives. The Company places
a high value on diversity and inclusion. We also utilize numerous outside consultants. Our future success will depend partially on our
ability to attract, retain and motivate qualified personnel. We are not a party to any collective bargaining agreements and have not
experienced any strikes or work stoppages. We consider our relations with our employees to be satisfactory.
Government
Regulation
The
health care industry is subject to extensive federal, state and local laws and regulations relating to licensure, conduct of operations,
ownership of facilities, addition of facilities and services, payment for services and prices for services that are extremely complex
and for which, in many instances, the industry does not have the benefit of significant regulatory or judicial interpretation. We will
also be subject to regulation regarding sale of our products online and solicitation of clients thereby, as well as through our general
contractor business and the licensing and code requirements relating thereto.
77
Table of Contents
Available
Information
We
are subject to the information and reporting requirements of the Exchange Act, under which we file periodic reports, proxy and information
statements and other information with the Commission. Copies of the reports, proxy statements and other information may be examined without
charge on the Internet at
https://www.sec.gov
.
We
file annual, quarterly, and current reports, proxy statements and other information with the SEC. Our SEC filings are available to the
public over the Internet at the SEC's website at
www.sec.gov
and are available for download, free of charge, soon after
such reports are filed with or furnished to the SEC, on our website at
https://amihcorp.com/investors/
. Copies of documents filed
by us with the SEC are also available from us without charge, upon oral or written request to our Secretary, who can be contacted at
7950 Legacy Drive, Suite 400, Plano, Texas 75024. Our website address is
https://amihcorp.com.
The information on, or that may
be accessed through, our website is not incorporated by reference into this prospectus and should not be considered a part of this prospectus.
Description
of Property
EPIQ
MD, INC.
On
February 24, 2021, EPIQ MD entered into a short term, six-month lease agreement with Venture X to lease and occupy approximately 1,200
square feet of office space at a rate of $3,500 per month located at 7950 Legacy Drive, Suite 400, Plano, Texas 75024 (the
"EPIQ
MD Lease
"). The EPIQ MD Lease commenced on March 1, 2021 and was to expire on August 31, 2021, but was renewed on August 19,
2021 for an additional six-month term with a commencement date of September 1, 2021, and expiration date of February 28, 2022. The EPIQ
MD Lease was renewed for an additional six month period and has an expiration date of August 31, 2022. The EPIQ MD Lease contains an
auto renewal feature unless notice of termination is provided ninety (90) days in advance. The Company has deemed this office space to
serve as its corporate headquarters and believes this space to be adequate for the purposes of our operations.
VISSIA
MCKINNEY, LLC
On
June 11, 2018, VISSIA McKinney, LLC. (f/k/a Novopelle Diamond, LLC) entered into a Lease Agreement with The Shops at Lake Forest, LLC
to lease and occupy approximately 1,400 square feet of commercial retail space located at 5000 Collin McKinney Parkway, Suite 150, McKinney,
Texas 75070, to operate a MedSpa (the "
McKinney Lease Agreement
"). On September 5, 2021, VISSIA McKinney entered into
a Release Agreement with the Landlord, whereby the Landlord agreed to release VISSIA McKinney from its remaining obligations under the
McKinney Lease Agreement in exchange for a total of $22,500, of which $10,000 was paid to the Landlord with furniture and fixtures located
at the leased premises and the remaining $12,500 was paid in cash. Accordingly, VISSIA McKinney has ceased operations at the leased premises
and has no further obligations under the McKinney Lease Agreement as of the date of this prospectus.
78
Table of Contents
VISSIA
WATERWAY, INC.
On
November 6, 2019, VISSIA Waterway, Inc. (f/k/a
Novopelle Waterway
, Inc.) entered into a Lease Agreement with 20 & 25 Waterway
Holdings, LLC (the "
Waterway Landlord
") to lease and occupy approximately 1,254 square feet of commercial retail space
located at 25 Waterway, Suite 150, The Woodlands, Texas to operate a MedSpa (the "
Waterway Lease Agreement
"). On December
31, 2021, Vissia Waterway, LLC entered into a Release Agreement with its landlord for the leased premises located at 25 Waterway Avenue,
The Woodlands, Montgomery County, Texas whereby the landlord agreed to release Vissia Waterway from its remaining obligations under the
lease in exchange for a total of $88,679. Accordingly, VISSIA Waterway has ceased operations at the leased premises and has no further
obligations under the Waterway Lease Agreement as of the date of this prospectus.
CAPITOL
CITY SOLUTIONS USA, INC.
On
January 3, 2020, Capitol City Solutions USA, Inc. ("
CCS
") entered into a Lease Agreement with Asher Park, LLC (the
"CCS Landlord") to lease and occupy approximately 1,516 square feet of commercial office space located at 1043 Asher Way,
Suite 300, Tyler, TX 75703 to be used for CCS's corporate offices and headquarters (the "CCS Lease Agreement"). On
March 9, 2022, CCS and the CCS Landlord mutually agreed to terminate the lease for the leased premises and release CCS from its remaining
obligations under the lease in exchange for a total of $18,523. Accordingly, CCS has ceased operations at the leased premises and has
no further obligations under the CCS Lease Agreement as of the date of this prospectus. Total rental expense related to this location
for the year ended December 31, 2021, was $0. The operating lease right-of-use asset net balance on December 31, 2021, related to this
location was $0, which was impaired in full due to discontinued operations.
EPIQ
SCRIPTS, LLC
On
February 2, 2022, EPIQ Scripts, LLC entered into a Sublease Agreement with Ideal Xtracare, LLC (the "Epiq Scripts Landlord")
to sublease and occupy approximately 3,080 square feet of commercial office space located at 465 W. President George Bush Fwy, Suite
240, Richardson, TX 75080 to be used for Epiq Scripts's corporate offices and pharmacy location (the "Epiq Scripts Sublease
Agreement"). The Epiq Scripts Sublease Agreement had an effective date of February 15, 2022 and a term of seventeen (17) months
and sixteen (16) days, terminating on July 31, 2023. The Epiq Scripts Sublease Agreement has base monthly rent of $4,106.67 and includes
an additional $385 electricity expense reimbursement.
79
Table of Contents
Legal
Proceedings
In
the ordinary course of business, the Company may become a party to lawsuits involving various matters. The impact and outcome of litigation,
if any, is subject to inherent uncertainties, and an adverse result in these or other matters may arise from time to time that may harm
its business. The Company believes the ultimate resolution of any such current proceeding will not have a material adverse effect on
our continued financial position, results of operations or cash flows.
Robert
Holden vs AMIH
On
October 14, 2019, Robert Holden, the Company's former CEO, filed a Petition and Application for Temporary Restraining Order in
the District Court, 152
nd
Judicial District of Harris County, Texas, against the Company stating that the Company is blocking
Mr. Holden's legal right to trade his shares in the open market and further attempting to stake his claim that he maintains his
rights to the 3,800,000 shares he received in connection with his acceptance as CEO of the Company on or around May 31, 2018. The Company
is maintaining the position that Mr. Holden does not have the right to those shares as he was in breach of his obligation to convey a
digital marketing business to the Company and subsequently resigned from the Company shortly thereafter, on or around August 15, 2018
and that he procured the shares through fraud. On November 11, 2019, the Company issued a response with a Motion to Dismiss Under the
Texas Citizen's Participation Act (TCPA) citing that any declaratory judgment and breach of contract claims be dismissed unless
Mr. Holden can, through "
clear and specific evidence
", establish a prima facie case for each essential element of
his claims. After an attempt to remand the case to federal court, the Company filed an amended notice of submission for its TCPA motion
for submission on May 18, 2020, whereby Holden failed to respond to the motion in a timely manner. On May 18, 2020, the Company filed
a response in support of its motion to dismiss under the TCPA, which was denied on June 3, 2020. Immediately thereafter, on June 4, 2020,
the Company filed a notice of accelerated interlocutory appeal to appeal the denial of the motion to dismiss under the TCPA and the trial
court's failure to rule on the Company's objection to the timeliness of Holden's response. The outcome of this action,
and the ultimate outcome of the lawsuit is currently unknown at this time, provided that the Company intends to vehemently defend itself
against the claims made in the lawsuit.
AMIH
vs. Winfred Fields
On
November 11, 2019, the Company filed an original petition and jury demand against Winfred Fields, a shareholder, in the 458
th
Judicial
District Court of Fort Bend County seeking damages related to breach of contract and fraud related charges. The Company executed an exchange
agreement with Mr. Fields on or around April 12, 2019 whereby Mr. Fields was required to tender to the Company a total of 650,000 of
the 750,000 shares of the Company's common stock that Mr. Fields then owned (the "
Exchanged Shares
") in exchange
for a promissory note with a maturity date of April 12, 2021 payable in the amount of $42,500 (the "
Fields Note
").
The Exchange Agreement required that Mr. Fields immediately return the stock certificates for the Exchanged Shares to the Company or
its designated agent for immediate cancellation and for Mr. Fields to retain the remaining 100,000 shares. Mr. Fields agreed in the Exchange
Agreement that these shares would not become unrestricted until such time as Mr. Fields received an opinion of counsel satisfactory to
the Company that the shares were not restricted for trade under SEC regulations. After executing the Exchange Agreement, Mr. Fields—rather
than return the Exchanged Shares or obtain said opinion of counsel—attempted to deposit and trade the Exchanged Shares and the
restricted shares, which was a direct violation of the Exchange Agreement. The Company asserts that Mr. Fields knowingly, willingly and
fraudulently attempted to deposit and trade the Exchanged Shares and is seeking damages and equitable relief. Upon several attempts to
serve Mr. Fields, service was perfected on or around February 3, 2020. On March 2, 2020, Mr. Fields filed a response generally denying
all claims. On May 22, 2020, the Company filed its first request for production and request for disclosure and discovery insisting that
Mr. Fields produce all documentation related to the fraudulent transaction and is awaiting a response to these requested discovery items.
The outcome of this action is currently unknown at this time. In November 2019, the Company recovered 650,000 shares from Mr. Fields
which were cancelled in 2019.
80
Table of Contents
Asher
Park, LLC vs. Novopelle Tyler
On
August 11, 2021, Asher Park, LLC ("Asher Park") filed a petition against the Company and its subsidiary, Novopelle Tyler,
Inc. ("Novopelle Tyler") in the 241
st
Judicial District Court of Smith County, Texas seeking to recover damages
in the amount of $66,651 against that commercial lease and commercial lease guaranty agreement that was signed between the parties on
or around January 8, 2020 to occupy retail premises located at 1058 Asher Way, Suite 100, in Tyler, Texas. As this commercial lease was
executed prior to the COVID-19 pandemic, and due to the uncertainty of the effects on retail establishments during the pandemic, Novopelle
Tyler never officially took possession of the retail premise. On September 23, 2021, the Company and Novopelle Tyler filed an Original
Answer and Affirmative Defense denying the allegations made by Asher Park.
On
January 26, 2022, Novopelle Tyler and the Company entered into a Settlement Agreement & Mutual Release with Asher Park whereby Novopelle
Tyler and the Company agreed to pay Asher Park a total of $35,000 in full and final settlement of all of the Asher Park's claims.
Accordingly, Asher Park, in consideration for the execution of the Settlement Agreement agreed to dismiss the lawsuit against both Novopelle
Tyler and the Company.
Stanley
Tate d/b/a Triangle Cabinets vs. Capitol City Solutions USA, Inc.
On
September 10, 2021, Stanley Tate d/b/a Triangle Cabinets ("Tate"), a materials supplier and subcontractor that was hired
by the Company's subsidiary, Capitol City Solutions USA, Inc. (CCS), filed a petition against the Company, CCS, and CCS's
construction client, PC Gateway, LLC ("PC Gateway") in the 136
th
Judicial District Court of Jefferson County,
Texas seeking payment in the amount of $77,681 for services Tate claimed to provide CCS and PC Gateway. The Company and CCS were not
officially served until on or around October 21, 2021. On October 25, 2021, the Company and CCS filed an Original Answer denying the
allegations made by Tate as Tate had failed to provide the services in which they were hired to perform and demanding strict proof by
a preponderance of credible evidence. On December 29, 2021, Tate dismissed all claims against both the Company and CCS.
81
Table of Contents
Capitol
City Solutions USA, Inc. vs. Peak Living, LLC and PC Gateway, LLC
On
November 1, 2021, the Company's subsidiary, Capitol City Solutions USA, Inc. (CCS), filed a petition against PC Gateway and Peak
Living, LLC ("Peak Living") in the 58
th
Judicial District Court of Jefferson County Texas demanding the payment
of the final invoice as delivered to Peak Living in the amount of $2,069,908 representing the balance as owed to CCS for substantial
supplemental charges (including but not limited to dehumidifiers, various material cost and labor increases, code compliance costs, and
additional profit and overhead). Throughout the term of a project completed by CCS for Peak Living, Peak Living instructed CCS to perform
additional work beyond the original scope of the contracted agreement and fully understood that CCS expected to be compensated at the
fair market value for the additional labor and materials. In addition to seeking actual and statutory damages, CCS is seeking to recover
attorney's fees, prejudgment and post judgement interest, costs of court and has further placed a constitutional lien on the PC
Gateway property, known as Gateway Village, located at 2825 12th Street, Beaumont, Texas, 77705 and which is the subject of the lawsuit.
CCS is currently reviewing and evaluating all of the discovery items received from Peak in connection with the lawsuit.
Market
for Common Equity and Related Stockholder Matters
Market
Information
Our
common stock is quoted on the OTCQB Market maintained by OTC Markets Group Inc. under the symbol "
AMIH
". At present,
there is a very limited market for our common stock. The OTC Market is a network of security dealers who buy and sell stock. The dealers
are connected by a computer network that provides information on current "
bids
" and "
asks
", as
well as volume information. The following table sets forth the range of high and low sales prices for our common stock for each of the
periods indicated as reported by the OTCQB Market. These quotations reflect inter-dealer prices, without retail mark-up, mark-down or
commission and may not necessarily represent actual transactions.
Fiscal 2022
Fiscal 2021
Fiscal 2020
High
Low
High
Low
High
Low
First Quarter ended March 31
$
0.05
0.04
$
0.58
0.14
$
0.75
0.13
Second Quarter ended June 30
(1)
$
0.08
0.04
$
0.23
0.10
$
0.39
0.12
Third Quarter ended September 30
$
—
—
$
0.13
0.05
$
0.33
0.12
Fourth Quarter ended December 31
$
—
—
$
0.12
0.05
$
0.45
0.06
(1)
Through April 21, 2022.
Holders
As
of April 21, 2022, our shares of common stock were held by approximately 253 stockholders of record.
82
Table of Contents
Dividends
We
have never paid any cash dividends on our common stock. We currently anticipate that we will retain all future earnings for use in our
business. Consequently, we do not anticipate paying any cash dividends in the foreseeable future. The payment of dividends in the future
will depend upon our results of operations, as well as our short-term and long-term cash availability, working capital, working capital
needs, and other factors as determined by our board of directors. Currently, except as may be provided by applicable laws, there are
no contractual or other restrictions on our ability to pay dividends if we were to decide to declare and pay them.
Securities
Authorized for Issuance Under Equity Compensation Plans
The
following table sets forth information, as of December 31, 2021, with respect to our compensation plans under which common stock is authorized
for issuance.
Plan Category
Number of securities to be issued upon exercise of outstanding options,
warrants and rights
Weighted-average exercise price of outstanding options,
warrants and rights
Number of securities remaining available for future issuance under equity compensation plans (excluding securities reflected in column (a))
(a)
(b)
(c)
Equity compensation plans approved by security holders
(1)
-
$
-
11,100,000
Equity compensation plans not approved by security holders
(2)
-
-
7,565,000
Total
$
$
18,665,000
(1)
Represents shares available for awards under the Company's
2021 Equity Incentive Plan.
(2)
Represents shares available for awards under the Company's 2019 Stock Option and Incentive Plan.
2019
Stock Option Plan
On
July 5, 2019, the board of directors adopted and approved a 2019 Stock Option and Incentive Plan (the "
Plan
"). The
Plan is intended to promote the interests of the Company by providing eligible persons with the opportunity to acquire a proprietary
interest, or otherwise increase their proprietary interest, in the Company as an incentive for them to remain in the service of the Company.
The maximum number of shares available to be issued under the Plan is currently 10,000,000 shares, subject to adjustments for any stock
splits, stock dividends or other specified adjustments which may take place in the future. The Company has issued 3,535,000 shares of
common stock under the Plan as of the date of this prospectus.
83
Table of Contents
The
Plan is administered by the Company's board of directors. Persons eligible to participate in the Plan must: (i) be a natural person,
(ii) provide bona fide services to the Company, and (iii) provide services to the Company that services are not in connection with the
offer or sale of securities in a capital-raising transaction, and do not directly or indirectly promote or maintain a market for the
registrant's securities. All grants under the Plan are intended to comply with the requirements under Internal Revenue Code Section
409A and activities under the Plan will be administered accordingly.
Options
granted under the Plan are evidenced by agreement between the recipient and the Company, subject to the following general provisions:(i)
a recipient of employee stock option may not exercise any options which would cause him/her/it to hold more than 4.9% of the Company's
issued and outstanding common or voting stock, unless such limitation is waived by providing 61 days' written notice to the Company,
but in no event may exercise options that would cause such recipient to hold more than 9.9% of the Company's issued and outstanding
common or voting stock; and (ii) the term of stock options shall be limited to a maximum of two years, unless otherwise approved by the
board of directors.
2021
Stock Option Plan
Effective
on July 30, 2021, the majority shareholders approved the adoption of the American International Holdings Corp. 2021 Equity Incentive
Plan (the "
2021 Plan
"), which in accordance with Rule 14c-2 of the Exchange Act, became effective on September 13,
2021, forty days after the date the information statement disclosing the adoption of such 2021 Plan was first made available to shareholders.
The
2021 Plan provides an opportunity for any employee, officer, director, or consultant of the Company, subject to limitations provided
by federal or state securities laws, to receive (i) incentive stock options (to eligible employees only); (ii) nonqualified stock options;
(iii) restricted stock; (iv) stock awards; (v) shares in performance of services; or (vi) any combination of the foregoing. In making
such determinations, the Board of Directors may take into account the nature of the services rendered by such person, his or her present
and potential contribution to the Company's success, and such other factors as the Board of Directors in its discretion shall deem
relevant.
Subject
to adjustment in connection with the payment of a stock dividend, a stock split or subdivision or combination of the shares of common
stock, or a reorganization or reclassification of the Company's common stock, the aggregate number of shares of common stock which
may be issued pursuant to awards under the 2021 Plan is the sum of (i) 11,100,000 shares, and (ii) an annual increase on April 1st of
each calendar year, beginning in 2022 and ending in 2031, in each case subject to the approval of the Board of Directors or the compensation
committee of the Company (if any) on or prior to the applicable date, equal to the lesser of (A) five percent (5%) of the total shares
of common stock of the Company outstanding on the last day of the immediately preceding fiscal year; (B) 10,000,000 shares of common
stock; and (C) such smaller number of shares as determined by the Board of Directors or compensation committee of the of the Company
(if any)(the "
Share Limit
"), also known as an "
evergreen
" provision. Notwithstanding the foregoing,
shares added to the Share Limit are available for issuance as incentive stock options only to the extent that making such shares available
for issuance as incentive stock options would not cause any incentive stock option to cease to qualify as such. In the event that the
Board of Directors or the compensation committee (if any) does not take action to affirmatively approve an increase in the Share Limit
on or prior to the applicable date provided for under the plan, the Share Limit remains at its then current level. Notwithstanding the
above, no more than 90,000,000 incentive stock options may be granted pursuant to the terms of the 2021 Plan.
84
Table of Contents
Management's
Discussion and Analysis of Financial Condition and Results of Operations
Introduction
Our
Management's Discussion and Analysis of Financial Condition and Results of Operations (MD&A) is provided in addition to the
accompanying financial statements and notes to assist readers in understanding our results of operations, financial condition, and cash
flows. MD&A is organized as follows:
●
Results
    of Operations
. An analysis of our financial results comparing the years ended December 31, 2021, and 2020.
●
Liquidity
    and Capital Resources
. A discussion of our financial condition, including descriptions of balance sheet information and cash
    flows.
●
Critical
    Accounting Policies and Estimates
. Critical accounting policies and estimates that we believe are important to understanding
    the assumptions and judgments incorporated in our reported financial results and forecasts.
All
references to years relate to the fiscal year ended December 31 of the particular year.
The
following discussion should be read in conjunction with the American International Holdings Corp. financial statements and accompanying
notes included elsewhere in this prospectus.
Results
of Operations
Revenues
We
had revenues of $20,169 and $2,115 for the years ended December 31, 2021 and 2020, respectively. The increase in revenues in 2021 was
due primarily to our change in business strategy. We recognized revenues in accordance with Accounting Standards Codification (ASC) Topic
606. A five-step process has been designed for the individual or pool of contracts to keep financial statements focused on this principle.
Revenues from fixed-price and cost-plus contracts are recognized on the percentage of completion method, whereby revenues on long-term
contracts were recorded on the basis of the Company's estimates of the percentage of completion of contracts based on the ratio
of actual cost incurred to total estimated costs. This cost-to-cost method was used because management considered it to be the best available
measure of progress on these contacts. Revenues from cost-plus-fee contracts were recognized on the basis of costs incurred during the
period plus the fee earned, measured on the cost-to-cost method. Revenues from time-and-material and rate chart contracts were recognized
currently as work is performed. During the year ended December 31, 2021, we recognized revenues of $20,169 in connection with membership
income from ZipDoctor. During the year ended December 31, 2020, we recognized revenues of $2,115.
85
Table of Contents
Cost
of Revenues
We
had cost of revenues of $39,738 and $0 during the years ended December 31, 2021 and 2020, respectively. Cost of revenues include all
direct material, sub-contractor, labor and certain other direct costs, as well as those indirect costs related to contract performance,
such as indirect labor and fringe benefits. Selling, general, and administrative costs are charged to expense as incurred.
Operating
Expenses
General
and administrative expenses were $6,975,654 and $3,711,317 during the years ended December 31, 2021 and 2020, respectively. The increase
in 2021 was due primarily to stock-based compensation in the amount of $4,986,143 (including $4,334,857 in stock issued for services
rendered and $601,852 in stock issued for in process research and development), which totaled $2,860,813 in 2020, stock-and professional
expenses incurred as a public company such as legal expenses in the amount of $242,293 for the year ended December 31, 2021, as compared
to $112,175 for the year ended December 31, 2020, and financial reporting, accounting and auditing compliance expenses in the amount
of $131,608 for the year ended December 31, 2021, as compared to $99,003 for the year ended December 31, 2020.
Other
Expenses
During
the year ended December 31, 2021, and 2020, we incurred interest expense of $184,589 and $219,202, respectively, of which $1,979 and
$3,345, respectively, were recorded as imputed interest in connection with related party loans.
Amortization
of debt discount was $1,958,298 and $777,964 during the years ended December 31, 2021 and 2020, respectively.
We
had a loss of $1,071,028 and a loss of $107,574 during the year ended December 31, 2021 and 2020, respectively, due to change in derivative
liabilities. See also "Note 12 – Derivative Liabilities", in the notes to unconsolidated financial statements included
in "
Index to Financial Statements
", below, for a more detailed discussion of gain (loss) in derivative liabilities
which is non-cash.
86
Table of Contents
We
had a settlement loss for the year ended December 31, 2021 of $16,359 compared to a settlement loss of $1,041,445 for the year ended
December 31, 2020, each in connection with debt settlements that occurred during the respective periods.
We
also had no impairment loss for the year ended December 31, 2021, compared to an impairment loss of $605,488 for the year ended December
31, 2020 in connection with the common shares issued for notes settlement during the applicable period.
Discontinued
operations
Customer
traffic and demand at our VISSIA Waterway, Inc. and VISSIA McKinney MedSpa locations which were re-opened after mandatory closures associated
with COVID-19 in June and August 2020, respectively, failed to rebound to pre-closure levels due to COVID-19 and the pandemic's
effects on the economy, and because we are unable to predict the length of the pandemic or ultimate outcome thereof, and further due
to our limited capital resources, effective in October 2020, we made the decision to close both our VISSIA Waterway, Inc. and VISSIA
McKinney locations and discontinued such operations. As such locations are closed, they are not generating any revenue. The continuing
expenses, without corresponding revenues, may have a significant negative affect on our results of operations and cash flows. Separately,
Legend Nutrition's lease was up January 31, 2021, and the Company chose not to renew the lease, closed the store, and not continue
in that line of business moving forward.
VISSIA
Waterway, Inc., VISSIA McKinney LLC Legend Nutrition and Capitol City Solutions USA, Inc. (collectively referred to as "
Discontinued
Subsidiaries
") have been presented as discontinued operations in the accompanying consolidated financial statements for the
year ended December 31, 2021, and 2020, and are summarized below:
The Years Ended
December 31,
2021
2020
Revenue
$
2,530
$
6,107,106
Cost of revenue
-
5,058,373
Gross profit
2,530
1,048,813
Operating expenses
57,659
1,205,993
Loss from operations
(55,130
)
(157,180
)
Other income (expenses)
299,716
(722,057
)
Net income (loss)
$
244,586
$
(879,237
)
Net
Loss
We
had a net loss of $9,980,911, or $0.14 per share from continuing operations and net income of $244,586 or $0.00 per share from discontinued
operations during the year ended December 31, 2021, for a total net loss of $10,008,362 or $0.14 per share. We had a net loss of $7,339,890,
or $0.18 per share from continuing operations and $879,237 or $0.02 per share from discontinued operations during the year ended December
31, 2020, totaling an aggregate of $7,339,890 or $0.18 per share in total net loss. The increase in net loss in 2021 was primarily attributable
to non-cash expenses in connection with stock-based compensation, amortization of debt discount, the change in derivative values associated
with outstanding convertible debt, settlement loss in connection with the common shares issued for notes settlement, and the decrease
in gross profit and revenues, each as discussed above.
87
Table of Contents
Liquidity
and Capital Resources
As
of December 31, 2021 and 2020, the Company had total assets of $1,213,647 and $38,539, respectively, including $0 and $0 of assets of
discontinued operations, respectively. The main reason for the increase in total assets as of December 31, 2021, compared to December
30, 2020, was due to a $1,184,593 increase in cash, which was mainly due to the proceeds received from the Company's financing
activities and issuances of convertible notes, offset by the $208,984 decrease in assets of discontinued operations.
As
of December 31, 2021 and 2020, the Company had total liabilities of $5,100,557 and $1,656,529, respectively, which consisted of accounts
payable, accrued interest and accrued compensation in the amount of $252,194 and $211,271, respectively, convertible notes payable (net
of discount) and loans payable to related parties and non-related parties (net of discount) in the amounts of $396,419, $75,000 and $123,473
and $74,827, $55,000 and $135,392 as of December 31, 2021 and 2020, respectively, and derivative liabilities of $4,141,272 and $517,366,
respectively. We also had $112,199 and $669,574 of net liabilities related to discontinued operations. The Company had a total stockholders'
deficit of $3,869,111 and $1,391,007 as of December 31, 2021 and 2020, respectively.
During
the year ended December 31, 2021, net cash used in operating activities was $2,211,762, compared to net cash used in operating activities
of $2,153,263 for the year ended December 31, 2020. Negative cash flows during the year ended December 31, 2021, were due primarily to
the net loss of $10,225,497 and change in derivative liabilities of $2,469,697, partially offset by non-cash expenses, including stock-based
compensation of $4,334,857, amortization of debt discount of $1,958,298, derivative expense of $3,540,725, loss on loans settlement of
$58,059, and in process research and development of $601,852 Comparatively, negative cash flows during the year ended December 31, 2020,
were due primarily to the net loss of $6,460,653, partially offset by non-cash expenses, including stock-based compensation of $2,860,813,
amortization of debt discount of $777,965, loss on loans settlement by $1,155,685, and impairment loss of $670,280.
During
the years ended December 31, 2021 and 2020, we had cash provided by investing activities of $10,000 and cash used in investing activities
of $27,392, respectively. The net cash used in investing activities in each year was solely attributable to capital expenditures for
and disposal of property and equipment.
During
the years ended December 31, 2021 and 2020, net cash flows provided by financing activities were $3,386,335 and $947,180, respectively,
primarily attributable to the proceeds from notes payable to related parties and non-related parties during the respective periods. We
had proceeds of $141,928 from related party borrowings and $3,738,999 from non-related party borrowings in the year ended December 31,
2021, compared to proceeds of $0 from related party borrowings and proceeds of $947,750 from non-related party borrowings in the year
ended December 31, 2020. We made repayments of $141,9289 on related party borrowings and repayments of $427,500 on non-related party
borrowings in the year ended December 31, 2021 compared to repayments of $40,000 on non-related party borrowings and repayments of $0
on related party borrowings in the year ended December 31, 2020. We had proceeds of $100,000 from sales of stock in 2021, which was $46,500
in 2020.
88
Table of Contents
We
had cash of $1,209,737 and a working capital deficit of $3,886,910 as of December 31, 2021. On the short-term basis, we will be required
to raise a significant amount of additional funds over the next 12 months to sustain operations and pay outstanding liabilities. On the
long-term basis, we will potentially need to raise capital to grow and develop our business.
Since
December 31, 2019, we have (a) sold 330,250 shares of our common stock in consideration for $146,500 in cash through our Regulation A
offering, which related to the sale of up to 10,800,000 shares of our common stock at a price of $0.50 per share, which has since been
terminated; and (b) issued 36,236,429 shares of our common stock in exchange for the conversion of $2,832,852 in debt.
On
September 27, 2021, October 29, 2021, November 2, 2021, and November 12, 2021, Jacob Cohen, our Chief Executive Officer, advanced the
Company, $50,000, $15,000, $10,000, and $40,000, respectively, which loans are payable upon demand and not bearing interest. This amount
was repaid in November 2021.
It
is likely that we will require significant additional financing within the next 12 months and if we are unable to raise the needed funds
on an acceptable basis, we may be forced to cease or curtail operations.
Additional
information regarding the Company's (a) accrued compensation for related parties can be found in "Note 9 – Accrued
Compensation for Related Parties"; (b) notes payable can be found in "Note 10 – Notes Payable"; (c) related party
loans can be found in "Note 11 – Loans from Related Parties"; derivative liabilities can be found in "Note 12
– Derivative Liabilities"; in the notes to unconsolidated financial statements included in "
Index to Financial Statements
",
below.
Critical
Accounting Policies and Estimates
Our
discussion and analysis of our financial condition and results of operations are based upon our consolidated financial statements, which
have been prepared in accordance with accounting principles generally accepted in the United States. The preparation of these financial
statements requires us to make estimates and judgments that affect the reported amounts of assets, liabilities, revenues and expenses.
See "Note 1 – Summary of Significant Accounting Policies" to the audited financial statements included under "
Index
to Financial Statements
", below.
89
Table of Contents
Revenue
Recognition
The
Company generates its revenue from monthly membership subscriptions. Revenue is recognized at the time of delivery and includes a delivery
fee for each delivery or a subscription fee on a monthly basis for memberships. Under Accounting Standards Update ("ASU")
No. 2014-09 (Topic 606) "Revenue from Contracts with Customers", revenue from contracts with customers is measured based
on the consideration specified in the contract with the customer, and excludes any sales incentives and amounts collected on behalf of
third parties. A performance obligation is a promise in a contract to transfer a distinct good or service to a customer and is the unit
of account under Topic 606. The Company's contracts with its customers do not include multiple performance obligations. The Company
recognizes revenue when a performance obligation is satisfied by transferring control over a product or service to a customer. The amount
of revenue recognized reflects the consideration the Company expects to be entitled to in exchange for such products or services.
The
Company's subsidiaries, EPIQ MD, Inc. and ZipDoctor, Inc. both provide its customers with access to its telemedicine platform where
customers have unlimited access to start a doctor visit 24/7. The customers pay a flat fee per month for use of the platform and is not
dependent on the frequency of the doctor visits. Each doctor visit is included in the monthly subscription fee.
EPIQ
MD: The base monthly subscription fees range from $24.95-$49.95 per month and is dependent on the number of family members included in
the plan. Customers can choose to add additional services, such as Epiq Paws and Epiq Lux, ranging from an additional $4.95-$9.95 per
month.
The
customer gains immediate access to the telemedicine platform upon completing the enrollment process and making the first month's
payment, at which point the Company recognizes the revenue from that customer. Billing commences on the day that the customer is enrolled
for the Company's services and is continued to be billed on the calendar day of each calendar month, in accordance with the original
date of enrollment.
Customer's
may cancel their subscription at any time provided that they provide the Company with thirty (30) days advanced written notice of cancellation
with no cancellation fees charged to the customer. In the event a subscriber provides a notice of cancellation within the membership
period, the customer will be billed on their regular billing date at an amount adjusted to reflect an amount due until the cancellation
date.
For
avoidance of doubt, if a subscriber is billed $29.95 on the 1st of the month and cancels on the 15th, the subscriber will be billed on
the 1st of the following month at a prorated rate through the 15th, or at a rate of $14.97.
ZipDoctor,
Inc: The base monthly subscription fees range from $25.00-$45.00 per month and is dependent on the number of family members included
in the plan. The customer gains immediate access to the telemedicine platform upon completing the enrollment process and making the first
month's payment, at which point the Company recognizes the revenue from that customer. Billing commences on the day that the customer
is enrolled for the Company's services and is continued to be billed on the calendar day of each calendar month, in accordance
with the original date of enrollment.
90
Table of Contents
Customer's
may cancel their subscription at any time provided that they provide the Company with thirty (30) days advanced written notice of cancellation
with no cancellation fees charged to the customer. In the event a subscriber provides a notice of cancellation within the membership
period, the customer will be billed on their regular billing date at an amount adjusted to reflect an amount due until the cancellation
date.
For
avoidance of doubt, if a subscriber is billed $25.00 on the 1st of the month and cancels on the 15th, the subscriber will be billed on
the 1st of the following month at a prorated rate through the 15th, or at a rate of $12.50.
LEGEND
NUTRITION – DISCONTINUED OPERATIONS
The
Company recognizes revenue in according with Accounting Standards Codification (ASC) Topic 606. The underlying principle is that the
Company recognize revenue to depict the transfer of promised goods and services to customers in an amount that they expect to be entitled
to in the exchange for goods and services provided.
The
Company's discontinued subsidiary, Legend Nutrition, Inc., operated a retail store in which it sold nutritional and wellness related
products. Legend's business was solely based on the sale of retail products and did not offer any non-tangible services.
Revenue
for the entire product sold was recognized when the customer purchased and had control of the product, even if the terms included a right
of return. Legend accounted for any discounts and concessions at the time of sale and accounted for returns and refunds when Legend received
the product back in its possession where in some instances, if the product was unused, would be returned to Legend's inventory
or, if used, would be discarded.
Costs
of revenue included the amounts that Legend paid its wholesalers and distributors and recognized the cost of revenue when the products
were sold and transferred to the possession of the customer. The cost of revenue was deducted from Legends open inventory balance upon
sale.
Fair
value of financial instruments
The
Company measures its financial and non-financial assets and liabilities, as well as makes related disclosures, in accordance with FASB
Accounting Standards Codification No. 820, Fair Value Measurement ("
ASC 820
"), which provides guidance with respect
to valuation techniques to be utilized in the determination of fair value of assets and liabilities. Approaches include, (i) the market
approach (comparable market prices), (ii) the income approach (present value of future income or cash flow), and (iii) the cost approach
(cost to replace the service capacity of an asset or replacement cost). ASC 820 utilizes a fair value hierarchy that prioritizes the
inputs to valuation techniques used to measure fair value into three broad levels. The following is a brief description of those three
levels:
Level
1: Observable inputs such as quoted prices (unadjusted) in active markets for identical assets or liabilities.
91
Table of Contents
Level
2: Inputs other than quoted prices that are observable, either directly or indirectly. These include quoted prices for similar assets
or liabilities in active markets and quoted prices for identical or similar assets or liabilities in markets that are not active.
Level
3: Unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions, such as
valuations derived from valuation techniques in which one or more significant inputs or significant value drivers are unobservable.
Our
financial instruments include cash, accounts receivable, other receivable, inventories, accounts payable, accrued liabilities, convertible
note payable, and derivative liabilities.
The
carrying values of the Company's cash, accounts receivable, other receivable, inventories, accounts payable, and accrued liabilities
approximate their fair value due to their short-term nature.
The
Company's convertible notes payable are measured at amortized cost.
The
derivative liabilities are stated at their fair value as a level 3 measurement. The Company used the Lattice Model to determine the fair
values of these derivative liabilities. "
Note 12 – Derivative Liabilities
", to the notes to the financial statements
included herein, under "
Index to Financial Statements
", below, for the Company's assumptions used in determining
the fair value of these financial instruments.
Convertible
note payable
The
Company accounts for convertible notes payable in accordance with the Under Financial Accounting Standard Board ("
FASB
")
Accounting Standards Codification No. 815, Derivatives and Hedging, since the conversion feature is not indexed to the Company's
stock and can't be classified in equity. The Company allocates the proceeds received from convertible notes payable between the
liability component and conversion feature component. The conversion feature that is considered embedded derivative liabilities has been
recorded at their fair value as its fair value can be separated from the convertible note and its conversion is independent of the underlying
note value. The Company has also recorded the resulting discount on debt related to the conversion feature and is amortizing the discount
using the effective interest rate method over the life of the debt instruments.
Derivative
liabilities
The
Company accounts for derivative liabilities in accordance with the FASB Accounting Standards Codification No. 815, Derivatives and Hedging
("
ASC 815
"). ASC 815 requires companies to recognize all derivative liabilities in the balance sheet at fair value,
and marks it to market at each reporting date with the resulting gains or losses shown in the Statement of Operations.
92
Table of Contents
Stock
based compensation
The
Company recognizes compensation costs to employees under FASB Accounting Standards Codification 718 "
Compensation - Stock Compensation
"
("
ASC 718
"). Under ASC 718, companies are required to measure the compensation costs of share-based compensation arrangements
based on the grant-date fair value and recognize the costs in the financial statements over the period during which employees are required
to provide services. Share based compensation arrangements include stock options and warrants. As such, compensation cost is measured
on the date of grant at their fair value. Such compensation amounts, if any, are amortized over the respective vesting periods of the
option grant.
On
July 27, 2018, the inception date, the Company adopted ASU No. 2018-07 "
Compensation - Stock Compensation (Topic 718): Improvements
to Nonemployee Share-Based Payment Accounting.
" These amendments expand the scope of Topic 718, Compensation - Stock Compensation
(which currently only includes share-based payments to employees) to include share-based payments issued to nonemployees for goods or
services. Consequently, the accounting for share-based payments to nonemployees and employees will be substantially aligned.
Off-Balance
Sheet Arrangements
As
of December 31, 2021, we did not have any off-balance sheet arrangements as defined in Item 303(a)(4)(ii) of Regulation S-K promulgated
under the Securities Act of 1934.
93
Table of Contents
Quantitative
and Qualitative Disclosures About Market Risk
Pursuant
to Item 305(e) of Regulation S-K (§ 229.305(e)), the Company is not required to provide the information required by this Item as
it is a "
smaller reporting company,
" as defined by Rule 229.10(f)(1).
Directors,
Executive Officers and Corporate Governance
The
following table sets forth the name, age and position of each director and executive officer of the Company .
Name
Position
Age
Term
    of Office
Jacob
    D. Cohen
CEO,
    President, Director
CEO,
    Director
Mangoceuticals,
    Inc.
43
April
    2019 – Present
Craig
    A. Hewitt
Chief
    Financial Officer
54
March
    2022 – Present
Alejandro
    Rodriguez
CEO
    EPIQ MD, Inc.
47
January
    2021 – Present
Verdie
    Bowen
COO
    EPIQ MD, Inc.
37
January
    2021 – Present
Sultan
    Haroon
Dir.
    of Business Operations, EPIQ Scripts, LLC
28
March
    2022 – Present
Maja
    Matthews
Dir.
    of Business Development,
EPIQ
    Scripts, LLC
44
March
    2022 – Present
Jonathan
    Arango
COO,
    President and Director, Mangoceuticals, Inc.
27
April
    2022 – Present
Peter
    "Casey" Jensen
Director
48
October
    2021 – Present
Lorraine
    D'Alessio
Director
42
January
    2022 – Present
Dr.
    Kenny Myers
Director
55
January
    2022 – Present
Our
directors are elected annually (or as often as we hold meetings of stockholders) and will hold office until our next annual meeting of
the stockholders and until their successors are elected and qualified. Officers will hold their positions at the pleasure of the Board
of Directors, absent any employment agreement. Our officers and directors may receive compensation as determined by us from time to time
by vote of the Board of Directors. Such compensation might be in the form of stock options or other equity. Directors may be reimbursed
by the Company for expenses incurred in attending meetings of the board of directors. Vacancies in the Board are filled by majority vote
of the remaining directors.
The
following is biographical information on the members of our Board of Directors:
94
Table of Contents
Jacob
D. Cohen, Chief Executive Officer, President and Director
Jacob
Cohen is a serial entrepreneur, corporate finance and executive management professional with over 20 years of investment banking and
capital markets experience having started and growing multiple companies in various industry sectors including marketing, advertising,
healthcare, IT and financial services. Prior to joining the Company, Mr. Cohen was the co-founder and managing partner of several boutique
investment bank and strategic advisory firms where he advised both early and later stage companies in raising capital in the form of
debt and/or equity and in both private and public markets.
Prior
to his experiences in investment banking, Mr. Cohen served as the Chief Financial Officer of The Renewed Group, Inc. – a manufacturer,
wholesaler and retailer of eco-friendly and sustainable apparel primarily made from recycled textiles and under the brand name REUSE
JEANS from 2010 through the end of 2013. Further, Mr. Cohen served from 2008 through 2010 as Executive Vice President and Controller
of Metiscan, Inc., a publicly-traded company, and as the President and Chief Executive Officer of one of its subsidiaries, Shoreline
Employment Services, Inc. During his tenure at Metiscan, Mr. Cohen was instrumental in restructuring, reorganizing and operating the
company and its five subsidiaries, and successfully raised over $8 million in equity financing for growth capital. Mr. Cohen also spearheaded
the company's financial audit process and managed its various filings with the SEC.
From
2007 through 2008, Mr. Cohen served as the Chief Operating Officer of Artfest International, which he assisted in taking public at the
end of 2007. Throughout his career, Mr. Cohen was involved in starting many new ventures, including The AdvertEyes Network, a digital
signage advertising company where he served as founder and CEO. Other positions include investment advisor and institutional equity research
analyst for Solomon Advisors and Huberman Financial, securities broker-dealers, from 2003 through 2005, and investment banker for Allegiance
Capital, a middle market investment bank specializing on mergers and acquisitions, from 2005-2007. Mr. Cohen holds a Bachelors of Arts
in International Economics and Finance from Brandeis University in Waltham, MA.
We
believe that Mr. Cohen's extensive background in investment banking, public company management, and corporate finance, make him
a strong addition to, and well qualified to serve on, the board of directors.
Dr.
Craig A. Hewitt, Ph. D, Chief Financial Officer
Dr.
Hewitt, age 54, has served as the Chief Financial Officer of the Company since March 30, 2022. Dr. Hewitt has nearly 20 years of experience
serving in executive management and leadership roles for companies in the health services and business services sectors. Between November
2015 and November 2021, Dr. Hewitt served as Chief Financial Officer of Holston Medical Group, an independent physician group of over
220 primary care physicians, specialists and mid-level providers with over 1,000 employees. Dr. Hewitt was a co-founder of, and Chief
Executive Officer of, Legacy Financial Partners, a business services provider, between 2010 and 2015. From 2005 to 2009, Dr. Hewitt served
as Chief Operating Officer and Interim Chief Executive Officer of Surrex Solutions, a high tech staffing company with over 600 employees
and branch offices in 23 states, while also serving as a member of Surrex's Board of Directors, Audit Committee, and Compensation
Committee. Between 2002 and 2005, Dr. Hewitt served as Chief Financial Officer of Accupoll, Inc., a company engaged in the design, development,
and sale of electronic voting systems and related technologies, where he was also a member Board of Directors, Audit Committee, and Compensation
Committee. From 1999 and 2002, Dr. Hewitt served as Chief Financial Officer of Universal Broadband Networks and from 1995 to 1999, Dr.
Hewitt served as Chief Financial Officer of Compreview, Inc.
95
Table of Contents
In
2021, Dr. Hewitt received his Ph.D in Health Science from Trident University, in Cypress California, where he also earned a Master's
degree in Healthcare in 2017. Dr. Hewitt received a Master's degree in Business Administration from Western Governors University
in Salt Lake City, Utah, in 2015 and a Bachelor's degree in Business Administration from California State University, Fullerton
in 1990.
Alejandro
Rodriguez
,
Chief Executive Officer – EPIQ MD, Inc.
Alejandro
Rodriguez has served as the Chief Executive Officer of EPIQ MD, Inc. since January 2021. Mr. Rodriguez has 15 years of energy experience
and a total of 20 years of business experience at the C-Level across the energy, telecom and information technology industries. Mr. Rodriguez
is a business development and marketing executive that has successfully launched five different companies that were collectively responsible
for nearly $6 billion in sales revenue over the course of his career in the energy industry. This experience includes but is not limited
to the following private companies SYNRG Marketing (Chief Business Officers & Partner) and Utility Choice Electric (VP of Sales &
Marketing) from 2001 through 2003, AmPro Energy (VP if Business Development) from 2003 through 2004, Stream Energy and Ignite (Founder
& Managing Partner) from 2004 through end of 2009. In August 2004, Mr. Rodriguez co-founded and served as Managing Partner of Stream
Energy, a fast-growing retail energy provider that provided electricity and natural gas services to approximately 400,000 customers and
grossed over $2 billion within the first four years of operation.
Upon
his exit from Stream Energy in late 2009, Mr. Rodriguez founded and served as Chairman of NAUP Capital, LP (NAUP Investments, LLC), through
2018. NAUP was an energy holding company and venture development firm with holdings in energy, solar, energy brokerage and energy software
related entities. In his position at NAUP, Mr. Rodriguez founded and grew several companies. Diversegy, LLC and EPIQ Energy, LLC were
among these NAUP projects. Rodriguez served as CEO for these companies and was successful in selling both of these companies to an NYSE
publicly traded energy company (Genie Energy) in December of 2013. Diversegy, LLC is a national energy brokerage company that advises
commercial, industrial and municipal customers regarding their natural gas and power needs.
96
Table of Contents
Between
February of 2016 and August of 2019, Rodriguez served as a fractional Director and then Chief Executive Officer of a micro-cap company
called The Chron Organization, Inc. (DBA: Zen Home Services & Zenergy). During his tenure with this fledgling upstart, Rodriguez
would develop a national smart home service offering that would automate lights, locks and thermostats for homeowners. Rodriguez resigned
in August of 2019 and formed Essential Sustainability Services ("Essential"), where he served as CEO and a board member.
As a result of the Covid-19 pandemic and related shutdowns, Rodriguez, for various personal reasons decided to resign from Essential
as its CEO and to retire from the energy industry altogether to focus on the healthcare industry.
Verdie
Bowen, Chief Operating Officer - EPIQ MD, Inc.
Verdie
Bowen has served as the Chief Operating Officer of EPIQ MD, Inc. since January 2021. Mr. Bowen has spent the past 17 years of his career
focused on information technology, systems and infrastructure development. Over the course of this time period, Verdie Bowen has advised
and consulted with a myriad of Fortune 1000 companies with respect to the design and implementation of various operating systems and
infrastructure assets. In addition to being a well-rounded chief operations executive, Mr. Bowen's foundation for his knowledge
base can be attributed to his expertise in Enterprise and Service Provider Network architecture, WAN Architecture, and Data Center Architecture.
Prior
to his position at EPIQ MD, Inc,, Mr. Bowen served as a solutions architect for General Datatech (GDT) from November 2010 wherein he's
focused on the various business development and design aspects of large IT and Systems-related infrastructure projects for large private
and public sector clientele. Among his flagship clients and projects are the following (not limited to): U.S. Department of Defense's
Biometric Fusion Center, the State of Alaska's first major IP Telephony deployment, which at the time was the 2
nd
largest
Cisco IPT deployment in the world, General Communication's (GCI) ISP core network redesign and implementation, T-Mobile, FiServ,
First Data, US Cellular, HEB, Phillips 66 and Enterprise Partners. From July 2006 to November 2010, Mr. Bowen served as a Lead Engineer
for World Wide Technology, an IT solutions and strategy company.
Mr.
Bowen is certified in various CISCO specialist programs such as Data Center Storage Networking Design, Firewall, Advanced Wireless Field,
IPS, and Wide Area Application Services for System Engineers. Mr. Bowen holds an AAS in Computer Science focusing on Networking Technology
and a BS in Information Technology Engineering from Charter College.
Sultan
Haroon, Director of Business Operations, EPIQ Scripts, LLC
Sultan
Haroon started his successful pharmacy career with American Specialty Pharmacy. Taking his knowledge, experience, and research, Sultan
launched a Pharmacy Consulting Company which connected doctors to ancillary services such as pharmacies, labs, and durable medical equipment
companies. Mr. Haroon later went on to establish Whole Health Kinetix (WHK) which specialized in customizing supplements and healthcare
according to a patient's blood work and DNA. After its successful launch, WHK was acquired by a group of physicians in the Dallas/Ft
Worth metroplex. Sultan then went on to manage, own and operate five Texas Class-A Pharmacies and was also a co-owner of a Class-G Pharmacy.
Mr. Haroon grew the pharmacies to several millions of dollars in revenue until they were ultimately purchased by a large east-coast based
Venture Capital firm.
97
Table of Contents
Maja
Matthews, Director of Business Development, EPIQ Scripts, LLC
Drawing
on her 27 years of experience in health care, Ms. Matthews provides in-depth knowledge in many facets of the Pharmacy/Health Care Industry.
Maja has hands-on experience in management and development of policies & procedures, along with years of experience in credentialing
new pharmacies. This includes State Board, NPI, NCPDP, DEA, URAC, all PBM Contracts, State/Federal Compliance, and out of state licensing.
Ms. Matthews managed and operated five Texas Class-A Pharmacies and was also Co-Owner of a Class-G Pharmacy. Prior to her venturing out
on her own, Maja was District Trainer and Sr. Pharmacy Technician with CVS Pharmacy. She was also Director of Operations and Sr. Technician
at American Specialty Pharmacy (ASP) where she managed and trained hundreds of technicians in the processing of prescriptions, auditing,
and workers compensation. Maja has been a State Certified Pharmacy Technician since 1996.
Peter
"Casey" Jensen, Director
Peter
"Casey" Jensen was appointed as a director of the Company effective October 19, 2021.
Since
September 2019, Mr. Jensen has served as Managing Partner at PHX Global, LLC providing executive management and international business
advisory services. Mr. Jensen worked as a registered investment adviser from December 2018 through October 2019, at Madison Avenue Securities,
LLC/EFC Wealth Management. In February 2013, Mr. Jensen co-founded JPM Capital, a boutique Investment Bank and Strategic Advisory firm,
where he worked until July 2018, and where he assisted in successfully closing over 160 investments in public companies. While serving
as Managing Partner at JPM, Mr. Jensen invested in healthcare start-ups, and he was able to manage investments from seed stage to profitability.
From February 2013 through December 2016, Mr. Jensen served as a partner and investment advisor at Anubis Capital Advisors, Inc.
From
2000 to 2010, Mr. Jensen worked in investor education and owned a stock brokerage where he managed approximately $100 million in assets
for high net worth and institutional investors. Also, during this period, Mr. Jensen formed Trindax Capital, LLC, an investment firm
focused on commodities and commercial real estate, where he served as CEO. In 2010, Mr. Jensen combined his experience in commercial
finance and investments, and entered private equity. Mr. Jensen became a Managing Director Heartland Capital Markets, where he co-managed
a variety of private equity investments in both seed and growth stage companies from February 2010 to January 2013.
In
addition to being a former Registered Investment Adviser, Mr. Jensen has passed Series 3, 7, 24, 63 and 65 FINRA examinations.
98
Table of Contents
The
Board of Directors believes that Mr. Jensen is well qualified to serve on the Board of Directors, and as the sole member and Chairperson
of the Company's Audit Committee, because of his strong background in finance and securities, and consistent success in several
different roles and industries.
Lorraine
D'Alessio, Esq., Director
Lorraine
D'Alessio was appointed as a director of the Company effective January 13, 2022.
Since
2010, Ms. D'Alessio has served as CEO and Managing Partner at D'Alessio Law Group, PLC, a law firm in Beverly Hills, California
which provides immigration and entertainment law services. In that capacity, she has provided counsel to entertainment agencies, unions,
private companies, academic institutions, tech startups, entrepreneurs and enterprises including: Next Models, Food Network, SubPac,
Pepperdine University, ACTRA, New York Film Academy, Plug and Play, Expert Dojo, and 500 Startups.
Ms.
D'Alessio was named the 2017 Leader in Law by the Los Angeles Business Journal and is the recipient of the 2018 Enterprising Woman
Award. Since 2016, Ms. D'Alessio has also served on the board of directors of Artists for Change, a non-profit organization which
focuses on creating high impact film, television, and multimedia projects to inspire individuals, organizations, and communities to bring
about positive social change.
From
2005 to 2007, Ms. D'Alessio served as a policy analyst and advisor for the government of Ontario, Canada.
Ms.
D'Alessio received her Bachelor's degree in International Relations from the University of Toronto in 2005; a Master's
of Public Policy in Public Policy Administration from Queen's University, in Kingston, Ontario in 2006; and a Juris Doctorate degree
from Southwestern Law School in Los Angeles, California in 2010.
The
Board of Directors believes that Ms. D'Alessio is well qualified to serve on the Board of Directors because of her extensive business
knowledge and legal expertise.
Dr.
Kenny Myers, Director
Dr.
Kenny Myers was appointed as a director of the Company effective January 13, 2022.
Since
March 2020, Dr. Myers has served as VP of Business Development for Living Fit Nation, Inc., a corporate wellness provider which designs
and implements customized employee health and wellness programs for corporations around the United States. From March 2012 to February
2020, Dr. Myers worked as VP of Business Development at One Health Medical Systems, LLC, an integrated health services provider, where
he was responsible for overseeing the planning, development and execution of the organization's marketing and advertising initiatives.
From May 1998 to March 2012, Dr. Myers was CEO of Texas Physicians Network, a healthcare management company where he was responsible
for the marketing and management several urgent care centers, medical clinics and other related healthcare facilities.
99
Table of Contents
Dr.
Myers received his Bachelor of Science degree in Microbiology from Oklahoma University in 1989, and a Doctor of Chiropractic Degree from
Parker University in Dallas, Texas in 1996.
The
Board of Directors believes that Dr. Myers is well qualified to serve on the Board of Directors because of his background in the health
services industry and his experience in business marketing and development.
Corporate
Governance
The
Company promotes accountability for adherence to honest and ethical conduct; endeavors to provide full, fair, accurate, timely and understandable
disclosure in reports and documents that the Company files with the SEC and in other public communications made by the Company; and strives
to be compliant with applicable governmental laws, rules and regulations.
Board
Leadership Structure
Our
board of directors has the responsibility for selecting the appropriate leadership structure for the Company. In making leadership structure
determinations, the board of directors considers many factors, including the specific needs of the business and what is in the best interests
of the Company's stockholders. Our Chief Executive Officer, Mr. Cohen, currently serves as Chairman of the board of directors.
The board of directors believes that this leadership structure is the most effective and efficient for the Company at this time. Mr.
Cohen possesses detailed and in-depth knowledge of the issues, opportunities, and challenges facing the Company. The Board believes that
its programs for overseeing risk, as described below, would be effective under a variety of leadership frameworks and therefore do not
materially affect its choice of structure.
Risk
Oversight
Effective
risk oversight is an important priority of the board of directors. Because risks are considered in virtually every business decision,
the board of directors discusses risk throughout the year generally or in connection with specific proposed actions. The board of directors'
approach to risk oversight includes understanding the critical risks in the Company's business and strategy, evaluating the Company's
risk management processes, allocating responsibilities for risk oversight, and fostering an appropriate culture of integrity and compliance
with legal responsibilities. The directors exercise direct oversight of strategic risks to the Company.
100
Table of Contents
Family
Relationships
None
of our directors are related by blood, marriage, or adoption to any other director, executive officer, or other key employees.
Arrangements
between Officers and Directors
To
our knowledge, there is no arrangement or understanding between any of our officers and any other person, including directors, pursuant
to which the officer was selected to serve as an officer.
Other
Directorships
No
directors of the Company are also directors of issuers with a class of securities registered under Section 12 of the Exchange Act (or
which otherwise are required to file periodic reports under the Exchange Act).
Involvement
in Certain Legal Proceedings
None
of our executive officers or directors has been involved in any of the following events during the past ten years:
(1) any
bankruptcy petition filed by or against any business of which such person was a general partner or executive officer either at the time
of the bankruptcy or within two years prior to that time;
(2) any
conviction in a criminal proceeding or being a named subject to a pending criminal proceeding (excluding traffic violations and minor
offenses);
(3) being
subject to any order, judgment, or decree, not subsequently reversed, suspended or vacated, of any court of competent jurisdiction, permanently
or temporarily enjoining, barring, suspending or otherwise limiting his involvement in any type of business, securities or banking activities;
(4) being
found by a court of competent jurisdiction (in a civil action), the SEC or the Commodities Futures Trading Commission to have violated
a federal or state securities or commodities law;
(5) being
the subject of, or a party to, any Federal or State judicial or administrative order, judgment, decree, or finding, not subsequently
reversed, suspended or vacated, relating to an alleged violation of (i) any Federal or State securities or commodities law or regulation;
(ii) any law or regulation respecting financial institutions or insurance companies, including, but not limited to, a temporary or permanent
injunction, order of disgorgement or restitution, civil money penalty or temporary or permanent cease-and-desist order, or removal or
prohibition order, or (iii) any law or regulation prohibiting mail or wire fraud or fraud in connection with any business entity; or
101
Table of Contents
(6) being
the subject of, or a party to, any sanction or order, not subsequently reversed, suspended or vacated, of any self- regulatory organization
(as defined in Section 3(a)(26) of the Exchange Act), any registered entity (as defined in Section (1)(a)(40) of the Commodity Exchange
Act), or any equivalent exchange, association, entity, or organization that has disciplinary authority over its members or persons associated
with a member.
Board
of Directors and Committee Meetings
During
the fiscal years that ended on December 31, 2021 and 2020, the Board held no meetings, but took various actions via written consent of
the board of directors.
Committees
of the Board
Board
Committee Membership
Independent
Audit
Committee
Jacob D. Cohen
(1)
Peter "Casey" Jensen
X
C
Lorraine D'Alessio
X
M
Dr. Kenny Myers
X
M
(1)
Chairman of Board of Directors.
C
- Chairman of Committee.
M
- Member.
Audit
Committee
The
Audit Committee, which is comprised exclusively of an independent director, has been established by the Board to oversee our accounting
and financial reporting processes and the audits of our financial statements.
The
Board has selected the members of the Audit Committee based on the Board's determination that the members are financially literate
(as required by NASDAQ rules) and qualified to monitor the performance of management and the independent auditors and to monitor our
disclosures so that our disclosures fairly present our business, financial condition and results of operations.
The
Board has also determined that Mr. Jensen, is an "
audit committee financial expert
" (as defined in the SEC rules)
because he has the following attributes: (i) an understanding of generally accepted accounting principles in the United States of America
("
GAAP
") and financial statements; (ii) the ability to assess the general application of such principles in connection
with accounting for estimates, accruals and reserves; (iii) experience analyzing and evaluating financial statements that present a breadth
and level of complexity of accounting issues that are generally comparable to the breadth and complexity of issues that can reasonably
be expected to be raised by our financial statements; (iv) an understanding of internal control over financial reporting; and (v) an
understanding of audit committee functions. Mr. Jensen has acquired these attributes as a result of his significant experience serving
on the board of directors of various private and public companies and as an investor and founder of a private equity firm.
102
Table of Contents
The
Audit Committee has the sole authority, at its discretion and at our expense, to retain, compensate, evaluate and terminate our independent
auditors and to review, as it deems appropriate, the scope of our annual audits, our accounting policies and reporting practices, our
system of internal controls, our compliance with policies regarding business conduct and other matters. In addition, the Audit Committee
has the authority, at its discretion and at our expense, to retain special legal, accounting or other advisors to advise the Audit Committee.
Other
Committees
Our
Company currently does not have nominating or compensation committees or committees performing similar functions, nor does our Company
have a written nominating or compensation committee charter. Our directors believe that it is not necessary to have such committees,
at this time, because the functions of such committees can be adequately performed by our board of directors.
Our
Company does not have any defined policy or procedural requirements for stockholders to submit recommendations or nominations for directors.
Our directors believe that, given the stage of our development, a specific nominating policy would be premature and of little assistance
until our business operations develop to a more advanced level. Our Company does not currently have any specific or minimum criteria
for the election of nominees to the board of directors and we do not have any specific process or procedure for evaluating such nominees.
The board of directors will assess all candidates, whether submitted by management or stockholders, and make recommendations for election
or appointment.
Corporate
Governance
The
Company promotes accountability for adherence to honest and ethical conduct and strives to be compliant with applicable governmental
laws, rules and regulations.
Our
Audit Committee is responsible for reviewing and making recommendations concerning the selection of outside auditors, reviewing the scope,
results and effectiveness of the annual audit of the Company's financial statements and other services provided by the Company's
independent public accountants. The Audit Committee reviews the Company's internal accounting controls, practices and policies.
103
Table of Contents
Director
Independence
Our
common stock is currently quoted on the OTCQB Market maintained by OTC Markets. The OTCQB Market does not require us to have independent
members of our board of directors. Notwithstanding that, our board of directors has determined that Peter "Casey" Jensen,
Lorraine D'Alessio, and Dr. Kenny Myers are "independent" pursuant to the rules of the NASDAQ Capital Market.
As
described above, we do not currently have a separately designated nominating or compensation committee.
Stockholder
Communications with the Board
Our
stockholders and other interested parties may communicate with members of the Board by submitting such communications in writing to our
Corporate Secretary at 7950 Legacy Drive, Suite 400, Plano, Texas 75024, who, upon receipt of any communication other than one that is
clearly marked "
Confidential,
" will note the date the communication was received, open the communication, make a copy
of it for our files and promptly forward the communication to the director(s) to whom it is addressed. Upon receipt of any communication
that is clearly marked "
Confidential,
" our Corporate Secretary will not open the communication, but will note the
date the communication was received and promptly forward the communication to the director(s) to whom it is addressed. If the correspondence
is not addressed to any particular Board member or members, the communication will be forwarded to a Board member to bring to the attention
of the Board.
Code
of Ethics
On
June 24, 2020, our board of directors adopted a Code of Ethical Business Conduct ("
Code of Ethics
") that applies to
all of our directors, officers and employees. The Code of Ethics will be available for review in print, without charge, to any stockholder
who requests a copy by writing to us at 7950 Legacy Drive, Suite 400, Plano, Texas 75024, Attention: Investor Relations. Each of our
directors, employees and officers are required to comply with the Code of Ethics.
We
intend to disclose any amendments to our Code of Ethics and any waivers with respect to our Code of Ethics granted to our principal executive
officer, our principal financial officer, or any of our other employees performing similar functions on our website at amihcorp.com within
four business days after the amendment or waiver. In such case, the disclosure regarding the amendment or waiver will remain available
on our website for at least 12 months after the initial disclosure. There have been no waivers granted with respect to our Code of Ethics
to any such officers or employees.
104
Table of Contents
Policy
on Equity Ownership
The
Company does not have a policy on equity ownership at this time. However, as illustrated in "
Certain Beneficial Owners and Management
",
two out of our four current officers and directors are beneficial owners of stock of the Company.
Policy
Against Hedging
The
Company recognizes that hedging against losses in Company shares may disturb the alignment between stockholders and executives that equity
awards are intended to build. Accordingly, the Company discourages 'short sales' of the Company's securities by officers,
directors and employees.
Compensation
Recovery
Under
the Sarbanes–Oxley Act of 2002 (the "
Sarbanes-Oxley Act
"), in the event of misconduct that results in a financial
restatement that would have reduced a previously paid incentive amount, we can recoup those improper payments from our Chief Executive
Officer and Chief Financial Officer. We plan to implement a clawback policy in the future, although we have not yet implemented such
policy.
Advisory
Board
On
March 17, 2021, the Company formed an Advisory Board to provide guidance to the Board of Directors, regarding business development, marketing,
acquisitions and other growth initiatives, and on such other matters as the board of directors may from time-to-time request input and
guidance on. The Advisory Board has no authority to bind the Company or the board of directors on any matters and was formed only to
provide the director(s) non-binding guidance and advice as requested by the Directors from time to time.
On
March 17, 2021, the board of directors appointed Mr. Kevin Harrington to the newly formed Advisory Board. The Advisory Board's
mandate is to provide guidance to the Board of Directors regarding business development, marketing, acquisitions, other strategic initiatives
and other matters as may be requested. As of the date of this report, Mr. Harrington is the sole member of the Company's Advisory
Board.
Whistleblower
Protection Policy
The
Company adopted a Whistleblower Protection Policy ("
Whistleblower Policy
") that applies to all of its directors, officers,
employees, consultants, contractors and agents of the Company. The Whistleblower Policy has been reviewed and approved by the Board.
105
Table of Contents
Executive
and Director Compensation
The
following table sets forth information concerning the compensation of (i) all individuals serving as our principal executive officer
or acting in a similar capacity during the last completed fiscal year ("
PEO
"), regardless of compensation level; (ii)
our two most highly compensated executive officers other than the PEO who were serving as executive officers at the end of the last completed
fiscal year, if any; and (iii) up to two additional individuals for whom disclosure would have been provided pursuant to paragraph (ii)
but for the fact that the individual was not serving as an executive officer at the end of the last completed fiscal year (collectively,
the "
Named Executive Officers
").
Name and Principal Position
Fiscal Year Ended
December 31
Salary ($)(1)
Bonus ($)
Stock Award (s) *
Option Awards *
All Other Compensation(5)
Total
Jacob D. Cohen, President and CEO
2021
$
150,000
—
$
950,000
(4)
—
$
18,000
$
1,118,000
2020
$
120,000
—
$
780,000
(3)
—
—
$
900,000
Alejandro Rodriguez CEO, EPIQ MD, Inc.
2021
$
115,000
—
$
1,520,000
(6)
—
—
$
1,635,000
Verdie Bowen COO, EPIQ MD, Inc.
2021
$
60,000
—
$
570,000
(7)
—
—
$
630,000
Esteban Alexander, Former COO (2)
2020
$
100,000
—
$
780,000
(3)
—
—
$
880,000
Alan Hernandez, Former CMO (2)
2020
$
100,000
—
—
—
—
$
100,000
Does
not include perquisites and other personal benefits, or property, unless the aggregate amount of such compensation is more than $10,000.
No executive officer earned any non-equity incentive plan compensation or nonqualified deferred compensation during the periods reported
above. There have been no changes in the Company's compensation policies since December 31, 2021.
*
The fair value of stock issued for services computed in accordance with Financial Accounting Standards Board Accounting Standards Codification
Topic 718 on the date of grant. The fair value of options granted computed in accordance with Financial Accounting Standards Board Accounting
Standards Codification Topic 718 on the date of grant.
(1) $53,500,
$25,000 and $25,000 has been accrued to each of Messrs. Cohen, Alexander and Hernandez, respectively, which remains unpaid as of the
date of this prospectus.
106
Table of Contents
(2)
On December 15, 2020, (a) Esteban Alexander, the Chief Operating Officer and member of the board of directors of the Company and (b)
Luis Alan Hernandez, the Chief Marketing Officer and member of the board of directors of the Company, each provided notice to the board
of directors of the Company of their resignation from their respective officer and Board positions, effective December 15, 2020.
(3)
Represents the value of 3,000,000 shares of common stock issued on May 22, 2020, valued at $0.26 per share, in consideration for services
rendered.
(4)
Represents the value of 2,500,000 shares of common stock issued on January 22, 2021, valued at $0.38 per share, in consideration for
services rendered.
(5)
Represents an automobile allowance of $1,500 per month pursuant to the terms of Mr. Cohen's employment agreement, dated April 12,
2019.
(6)
Represents the value of 4,000,000 shares of common stock issued on January 22, 2021, valued at $0.38 per share, in consideration for
services rendered.
(7)
Represents the value of 1,500,000 shares of common stock issued on January 22, 2021, valued at $0.38 per share, in consideration for
services rendered.
Employment
Agreements
Employment
Agreement of Jacob D. Cohen, Chief Executive Officer
Concurrent
with the Share Exchange Agreement entered into on April 12, 2019, Jacob D. Cohen ("
Mr. Cohen
" or the "
Executive
")
entered into an Executive Employment Agreement with the Company (the "
Executive Employment Agreement
"). Effective
on January 12, 2022, the Company entered into a new employment agreement with Mr. Cohen, which replaced and superseded the Executive
Employment Agreement (the "
New Employment Agreement
").
The
New Employment Agreement, which provides for Mr. Cohen to continue to serve as the Company's Chief Executive Officer, has a three-year
term expiring January 12, 2025, provided that the New Employment Agreement automatically extends for additional one year terms thereafter
in the event neither party provides the other at least 60 days prior notice of their intention not to renew the terms of the agreement.
The New Employment Agreement also requires the Board, subject to certain exceptions, to nominate Mr. Cohen to serve on the Board at each
stockholders' meeting which occurs during the term of the New Employment Agreement and to serve as the Chairman of the Board.
107
Table of Contents
Pursuant
to the terms of the New Employment Agreement, Mr. Cohen's annual compensation package includes (1) a base salary of $180,000 per
year, subject to automatic $60,000 annual increases beginning December 31, 2022 and on each December 31 thereafter, along with such other
increases as may be determined in the sole discretion of the Board from time to time (the "
Base Salary
"); (2) a yearly
incentive bonus ("
Incentive Bonus
") equal to 10% of the net income of the Company and its current and existing and
subsequently acquired or organized subsidiaries, determined annually on a consolidated basis by the Company's independent accounting
firm; and (3) an award of 5,000,000 restricted shares of the Company's common stock as a signing bonus in consideration of Mr.
Cohen entering into the New Employment Agreement. Mr. Cohen may also receive additional bonuses awarded from time to time in the discretion
of the Board and/or Compensation Committee (if any) in cash, stock or other equity consideration, and the Board of Directors may also
increase Mr. Cohen's salary from time to time, with or without amending the New Employment Agreement, in its discretion. Mr. Cohen
is also paid an automobile allowance of $1,500 per month during the term of the New Employment Agreement and is eligible to participate
in our stock option plan and other benefit plans.
The
agreement prohibits Mr. Cohen from competing against us during the term of the agreement and for a period of twelve months after the
termination of the agreement in any state and any other geographic area in which we or our Subsidiaries provide Restricted Services or
Restricted Products, directly or indirectly, during the twelve months preceding the date of the termination of the agreement. "
Restricted
Services
" means any online, direct-to-consumer subscription-based telemedicine or life-coaching platform, and any other services
that we or our subsidiaries have provided or are researching, developing, performing and/or providing at any time during the two years
immediately preceding the date of termination, or which Mr. Cohen has obtained any trade secret or other confidential information about
at any time during the two years immediately preceding the date of termination of the agreement. "
Restricted Products
"
means pharmaceutical drugs and other healthcare products and any other product, that we or our subsidiaries have provided or are researching,
developing, manufacturing, distributing, purchasing, selling and/or providing at any time during the two years immediately preceding
the date the agreement is terminated, or which Mr. Cohen obtained any trade secret or other confidential information in connection with
at any time during the two years immediately preceding the date of termination of the agreement.
We
may terminate Mr. Cohen's employment (a) for "
cause
" (which is defined to include, a material breach of the
agreement by Mr. Cohen, any act of misappropriation of funds or embezzlement by Mr. Cohen, Mr. Cohen committing any act of fraud, or
Mr. Cohen being indicted of, or pleading guilty or nolo contendere with respect to, theft, fraud, a crime involving moral turpitude,
or a felony under federal or applicable state law); (b) in the event Mr. Cohen suffers a physical or mental disability which renders
him unable to perform his duties and obligations for either 90 consecutive days or 180 days in any 12-month period; (c) for any reason
without "
cause
"; or (d) upon expiration of the initial term of the agreement (or any renewal) upon notice as provided
above. The agreement also automatically terminates upon the death of Mr. Cohen.
108
Table of Contents
Mr.
Cohen may terminate his employment (a) for "
good reason
" (i.e., (i) if his position or duties are modified to such
an extent that his duties are no longer consistent with the position of CEO of the Company, (ii) there has been a material breach by
us of a material term of the agreement or Mr. Cohen reasonably believes that we are violating any law which would have a material adverse
effect on our operations and such violation continues uncured thirty days after such breach and after notice thereof has been provided
to us by Mr. Cohen, (iii) Mr. Cohen's compensation is reduced without his consent, or we fail to pay to Mr. Cohen any compensation
due to him upon five days written notice from Mr. Cohen informing us of such failure, (iv) if the Company's headquarters are relocated
to a location more than thirty-five (35) miles from the Company's current headquarters in Plano, Texas, without his consent, or
(v) if Mr. Cohen is also then serving as a member of the Board and is not re-nominated by the Board to serve as a member of the Board
at any annual meeting of stockholders of the Company; provided, however, prior to any such termination by Mr. Cohen for "
good
reason
", Mr. Cohen must first advise us in writing (within 15 days of the occurrence of such event) and provide us 15 days
to cure (5 days in connection with the reduction of Mr. Cohen's salary or the failure to pay amounts owed to him)); (b) for any
reason without "
good reason
"; and (c) upon expiration of the initial term of the agreement (or any renewal) upon notice
as provided above.
In
the event that Mr. Cohen's employment is terminated for any reason (not including, however, a termination by us for "cause"
or a termination as a result of Mr. Cohen's death or disability) during the twelve month period following a Change of Control (a
"
Change of Control Termination
") or in anticipation of a Change of Control, we are required to pay Mr. Cohen, within
60 days following the later of (i) the date of such Change of Control Termination; and (ii) the date of such Change of Control, a cash
severance payment in a lump sum in an amount equal to 3.0 times the sum of his current base salary and the amount of the last bonus payable
to Mr. Cohen (the "
Change of Control Payment
"), which amount is due within 60 days of the later of (i) the date of
such Change of Control Termination; and (ii) the date of such Change of Control. If Mr. Cohen's employment terminates due to a
Change of Control Termination within six (6) months prior to a Change of Control, it will be deemed to be "in anticipation of a
Change of Control" for all purposes. In addition, in the event of a Change of Control, all of Mr. Cohen's equity-based compensation
immediately vests to Mr. Cohen and any outstanding stock options held by Mr. Cohen can be exercised by Mr. Cohen until the earlier of
(A) one (1) year from the date of termination and (B) the latest date upon which such stock options would have expired by their original
terms under any circumstances, provided that if Mr. Cohen's employment ends in anticipation of a Change of Control and such equity-based
compensation awards or stock options have previously expired pursuant to their terms, the Company is required to pay Mr. Cohen a lump
sum payment, payable on the same date as the Change of Control Payment, equal to the black scholes value of the expired and unexercised
equity compensation awards and stock options held by Mr. Cohen on the date of termination, based on the value of such awards had they
been exercisable through the end of their stated term and had not previously expired. "
Change of Control
" for the
purposes of the agreement means: (a) any person obtaining beneficial ownership representing more than 50% of the total voting power represented
by our then outstanding voting securities without the approval of not fewer than two-thirds of our Board of Directors; (b) a merger or
consolidation of us whether or not approved by our Board of Directors, other than a merger or consolidation that would result in our
voting securities immediately prior thereto continuing to represent at least 50% of the total voting power outstanding immediately after
such merger or consolidation, (c) our stockholders approving a plan of complete liquidation or an agreement for the sale or disposition
by us of all or substantially all of our assets, or (d) as a result of the election of members to our Board of Directors, a majority
of the Board of Directors consists of persons who are not members of the Board of Directors on January 12, 2022, except in the event
that such slate of directors is proposed by a committee of the Board or the Board; provided that if the definition of "
Change
of Control
" in our Stock Incentive Plans or Equity Compensation Plans is more favorable than the definition above, then such
definition shall be controlling.
109
Table of Contents
If
Mr. Cohen's employment is terminated pursuant to his death or disability, (i) all salary, vacation days, and bonuses accrued through
the termination date will be paid to Mr. Cohen's estate or beneficiaries or to Mr. Cohen, as applicable, in cash within 30 days
of the termination date; (ii) 100% of Mr. Cohen's then current annual Base Salary, as in effect on the date the agreement is terminated
(the "
Termination Date
"), will be paid to Mr. Cohen's estate or beneficiaries or to Mr. Cohen, as applicable,
in cash when due under Texas law; (iii) the pro rata amount of any discretionary bonus and performance bonus he would have been due for
the year in which the termination date occurred will be paid to Mr. Cohen's estate or beneficiaries or to Mr. Cohen, as applicable,
at the time when annual bonuses are paid to the Company's other senior executives for that fiscal year; (iv) Mr. Cohen and his
eligible family members will continue to be provided with group health insurance coverage at least equal to that which would have been
provided to them if Mr. Cohen's employment had not been terminated (or at the Company's election, pay the applicable COBRA
premium for such coverage), subject to certain rights which reduce such obligation if Mr. Cohen is covered by health insurance with a
substantially similar level of insurance as prior to the termination; and (v) any vested benefits which Mr. Cohen is required or eligible
to receive as of the termination date under any plan, contract or agreement of the Company and its affiliates will be paid or provided
to Mr. Cohen's estate or beneficiaries or to Mr. Cohen, as applicable, on a timely basis.
If
Mr. Cohen's employment is terminated pursuant to the end of the initial term (or any renewal term), without "
good reason
"
by Mr. Cohen, or by us for "
cause
", Mr. Cohen is entitled to all salary accrued through the termination date and no
other benefits other than as required under the terms of employee benefit plans in which Mr. Cohen was participating as of the termination
date. Additionally, any unvested stock options or equity compensation held by Mr. Cohen immediately terminate and are forfeited (unless
otherwise provided in the applicable award) and any previously vested stock options (or if applicable equity compensation) are subject
to the terms and conditions set forth in the applicable Stock Incentive Plan or Equity Compensation Plan, or award agreement, as such
may describe the rights and obligations upon termination of employment of Mr. Cohen.
110
Table of Contents
If
Mr. Cohen's employment is terminated by Mr. Cohen for "
good reason
", or by us without "
cause
",
(i) Mr. Cohen will be paid, in two lump sum payments, (a) all salary, vacation days, and bonuses accrued through the termination date,
payable when due under Texas law, and (b) an amount, payable within 60 days after the termination date, equal to 3.0 times (the "
Severance
Multiple
") the sum of (1) the Base Salary then in effect plus (2) the average Incentive Bonus and Discretionary Bonus received
by Mr. Cohen for the Company's one or two most recent complete fiscal years, as applicable at the time of the termination (or,
if termination occurs during the first year of employment, a prorated amount), provided that, if less than one year remains in the term
of the agreement after the termination date, the Severance Multiple will be 1.0; (ii) the pro rata amount of any discretionary bonus
and performance bonus he would have been due for the year in which the termination date occurred will be paid to Mr. Cohen at the time
when annual bonuses are paid to the Company's other senior executives for that fiscal year; and (iii) Mr. Cohen and his eligible
family members will continue to be provided with group health insurance coverage at least equal to that which would have been provided
to them if Mr. Cohen's employment had not been terminated (or at the Company's election, pay the applicable COBRA premium
for such coverage), subject to certain rights which reduce such obligation if Mr. Cohen is covered by health insurance with a substantially
similar level of insurance as prior to the termination. Additionally, unvested benefits (whether equity or cash benefits and bonuses)
will vest immediately upon such termination and any outstanding stock options previously granted to Mr. Cohen will vest immediately upon
such termination and will be exercisable until the earlier of (A) one year from the date of termination and (B) the latest date upon
which such stock options would have expired by their original terms under any circumstance. Mr. Cohen will also receive any other benefits
payable under any other benefit plans in which he is entitled to participate through the termination date, subject to and in accordance
with the terms of such plans.
The
agreement contains standard assignment of inventions, indemnification and confidentiality provisions. Further, Mr. Cohen is subject to
non-solicitation covenants during the term of the agreement and for twelve months thereafter. Although Mr. Cohen will be prohibited from
competing with us while he is employed with us, he will only be prohibited from competing for twelve months after his employment with
us ends pursuant to the agreement.
Employment
Agreement of Dr. Craig Hewitt, Chief Financial Officer
On
February 11, 2022, and effective on March 30, 2022, the Company entered into a Confidential Employment Offer Letter and Summary of Terms
and Conditions with Dr. Craig Hewitt (the "
Employment Agreement
").
Pursuant
to the Employment Agreement, Dr. Hewitt agreed to serve as Chief Financial Officer ("
CFO
") of the Company. In his
role as CFO Dr. Hewitt's responsibilities include, but are not limited to, (i) creating, coordinating, and evaluating the financial
programs and supporting information systems of the Company to include budgeting, tax planning, and conservation of assets; (ii) assisting
the Company by providing all information necessary in connection with the Company's becoming listed on NASDAQ; (iii) creating investment
related documentation and presenting to prospective investors for both debt and equity financings; (iv) developing an organizational
chart and layout for the Company; (v) assist in the hiring and development of key individuals across the Company and its subsidiaries;
(vi) directing financial audits and providing recommendations for procedural improvements; (vii) approving and coordinating changes and
improvements in automated financial and management information systems for the Company; (viii) ensuring compliance with local, state,
and federal budgetary reporting requirements; (ix) coordinating the preparation of financial statements, financial reports, tax returns,
special analyses, and information reports; (x) developing and implementing finance, accounting, billing, and auditing procedures; (xi)
establishing and maintaining appropriate internal control safeguards; (xii) interacting with other managers to provide consultative support
to planning initiatives through financial and management information analyses, reports, and recommendations; (xiii) ensuring records
systems are maintained in accordance with generally accepted auditing standards; (xiv) developing and directing the implementation of
strategic business and/or operational plans, projects, programs, and systems; (xv) reviewing, analyzing, and structuring all potential
M&A activity for the Company; (xvi) analyzing cash flow, cost controls, and expenses to guide business leaders; (xvii) analyzing
financial statements to pinpoint potential weak areas; (xviii) establishing and implementing short and long-range departmental goals,
objectives, policies, and operating procedures; (xix) serving on planning and policy-making committees; and (xx) representing the Company
externally to media, government agencies, funding agencies, and the general public.
111
Table of Contents
In
consideration for performing such services, which require that Dr. Hewitt allocate his full business efforts to the Company, the Company
agreed to pay Dr. Hewitt a starting salary of $48,000 per year, which will be increased to $120,000 if and when the Company achieves
a successful uplisting to a national exchange (NASDAQ or NYSE). Additionally, Dr. Hewitt will be eligible to participate in other performance
base incentives, benefits, employee stock option plans of the Company. Dr. Hewitt will initially work remotely from his home in Tennessee,
but may be required to relocate to the Dallas-Fort Worth area upon the Company's common stock being listed on a national exchange.
Dr. Hewitt's employment agreement also contains confidentiality terms and requires Dr. Hewitt to enter into a confidentiality and
non-disclosure agreement with the Company in connection with his employment by the Company. Dr. Hewitt may also receive additional bonuses
awarded from time to time in the discretion of the Board and/or Compensation Committee (if any) in cash, stock or other equity consideration,
and the Board of Directors may also increase Mr. Hewitt's salary from time to time, with or without amending the Employment Agreement,
in its discretion.
Employment
Agreement of Alejandro Rodriguez, Chief Executive Officer of EPIQ MD, Inc.
On
January 21, 2021, we entered into an Executive Employment Agreement with Alejandro Rodriguez, pursuant to which Mr. Rodriguez agreed
to serve as the Chief Executive Officer of EPIQ MD, Inc. ("
EPIQ MD
"), a newly formed wholly-owned Texas subsidiary
of the Company. The agreement has an initial term of three years, beginning on January 1, 2021, provided that the agreement automatically
extends for additional one-year terms thereafter in the event neither party provides the other at least 60 days prior notice of their
intention not to renew the terms of the agreement.
Pursuant
to the terms of the agreement, Mr. Rodriguez's annual compensation package includes annual base compensation of $90,000 for the
first three months, which increases to an annual base salary of $120,000 commencing April 1, 2021, throughout the initial term of this
agreement, provided that the annual salary increases to $240,000 upon Mr. Rodriguez and EPIQ MD achieving the First Performance Benchmarks
(defined below), and increases to $500,000 upon achieving the Second Performance Benchmark (defined below).
112
Table of Contents
The
"
First Performance Benchmarks
" are defined as the (a) launch the EPIQ MD Ambassador Program (defined below); (b) EPIQ
MD enrolling 10,000 active customers; (c) EPIQ MD enrolling 50,000 active customers by May 31, 2022; and (d) EPIQ MD enrolling 100,000
active customers by March 31, 2023. The "
Second Performance Benchmark
" is defined as EPIQ MD enrolling 200,000 active
customers by March 31, 2024. "
Launching of the Ambassador Program
" means the commencement and implementation of the
direct-sales campaign wherein independent contractors will become sales agents of EPIQ MD for the purposes of soliciting and procuring
end-use customers for EPIQ MD's telemedicine services. As of the date of this prospectus, none of the First Performance Benchmarks
or the Second Performance Benchmarks have been achieved.
As
additional consideration pursuant to the agreement, the Company agreed to issue Mr. Rodriguez (a) 4,000,000 shares of restricted common
stock, subject to forfeiture and vesting, of which 2,000,000 shares will vest upon the Launching of the Ambassador Program; 1,200,000
shares will vest upon EPIQ MD reaching the 5,000 active customer mark; and the remaining 800,000 shares will vest upon EPIQ MD reaching
the 10,000 active customer mark, provided that all shares vest if the Company uplists its common stock to a higher trading exchange;
and (b) together with other senior executives of EPIQ MD, up to 33% of the ownership of EPIQ MD, due as follows: 10% if Section (a) of
the First Performance Benchmarks are met; 5% if Section (b) of the First Performance Benchmarks are met; 5% if Section (c) of the First
Performance Benchmarks are met; 5% if Section (d) of the First Performance Benchmarks are met; and 8% if the Second Performance Benchmark
is met, which shares shall vest immediately if EPIQ MD completes a spin-off, up-listing and/or a change of control event.
The
board of directors and/or Compensation Committee (if any) may also authorize bonuses payable to Mr. Rodriguez from time to time in their
discretion, in cash or securities, and the Board of Directors may also increase Mr. Rodriguez's salary from time to time, with
or without amending the employment agreement, in its discretion.
The
agreement prohibits Mr. Rodriguez from competing against us during the term of the agreement and for a period of twelve months after
the termination of the agreement in any state and any other geographic area in which we or our subsidiaries provide Nutraceutical products
or services, directly or indirectly, during the twelve months preceding the date of the termination of the agreement.
We
may terminate Mr. Rodriguez's employment (a) for "
cause
" (which is defined to include, a material breach of
the agreement by Mr. Rodriguez, any act of misappropriation of funds or embezzlement by Mr. Rodriguez, Mr. Rodriguez committing any act
of fraud, or Mr. Rodriguez being indicted of, or pleading guilty or nolo contendere with respect to, theft, fraud, a crime involving
moral turpitude, or a felony under federal or applicable state law); (b) in the event Mr. Rodriguez suffers a physical or mental disability
which renders him unable to perform his duties and obligations for either 90 consecutive days or 180 days in any 12-month period; (c)
for any reason without "
cause
"; or (d) upon expiration of the initial term of the agreement (or any renewal) upon
notice as provided above. The agreement also automatically terminates upon the death of Mr. Rodriguez.
113
Table of Contents
Mr.
Rodriguez may terminate his employment (a) for "
good reason
" (i.e., (i) if his position or duties are modified to
such an extent that his duties are no longer consistent with the position of CEO of EPIQ MD, (ii) there has been a material breach by
us of a material term of the agreement or Mr. Rodriguez reasonably believes that we are violating any law which would have a material
adverse effect on our operations and such violation continues uncured thirty days after such breach and after notice thereof has been
provided to us by Mr. Rodriguez, or (iii) Mr. Rodriguez's compensation is reduced without his consent, or we fail to pay to Mr.
Rodriguez any compensation due to him upon 15 days written notice from Mr. Rodriguez informing us of such failure); provided, however,
prior to any such termination by Mr. Rodriguez for "
good reason
", Mr. Rodriguez must first advise us in writing (within
15 days of the occurrence of such event) and provide us 15 days to cure (15 days in connection with the reduction of Mr. Rodriguez's
salary or the failure to pay amounts owed to him)); (b) for any reason without "
good reason
"; and (c) upon expiration
of the initial term of the agreement (or any renewal) upon notice as provided above.
If
Mr. Rodriguez's employment is terminated by Mr. Rodriguez for "
good reason
", or by us without "
cause
",
Mr. Rodriguez is entitled to continue to receive the salary due pursuant to the terms of the agreement at the rate in effect upon the
termination date for six (6) months and we are required to pay 12 months of Mr. Rodriguez's COBRA expenses.
The
agreement contains standard assignment of inventions, indemnification, confidentiality and arbitration provisions. Further, Mr. Rodriguez
is subject to non-solicitation covenants during the term of the agreement.
Employment
Agreement of Verdie Bowen, President and Chief Operating Officer of EPIQ MD, Inc.
On
January 21, 2021, we entered into an Executive Employment Agreement with Verdie Bowen, pursuant to which Mr. Bowen agreed to serve as
the President and Chief Operating Officer of EPIQ MD. The agreement has an initial term of three years, beginning on January 1, 2021,
provided that the agreement automatically extends for additional one-year terms thereafter in the event neither party provides the other
at least 60 days prior notice of their intention not to renew the terms of the agreement.
Pursuant
to the terms of the agreement, Mr. Bowen's annual compensation package includes base annual compensation of $60,000 for the first
three months, which increases to an annual base salary of $120,000 commencing April 1, 2021 throughout the initial term of this agreement,
provided that the annual increases to $240,000 upon Mr. Bowen and EPIQ MD achieving 10,000 active customers.
114
Table of Contents
As
additional consideration pursuant to the agreement, the Company agreed to issue Mr. Bowen (a) 1,500,000 shares of restricted Company
common stock, subject to forfeiture and vesting, of which 500,000 shares vest upon the Launching of the Ambassador Program; 500,000 vest
upon EPIQ MD reaching the 5,000 active customer mark; and 500,000 vesting upon EPIQ MD reaching the 10,000 active customer mark, provided
that all shares shall vest if the Company's common stock is uplisted to a higher trading exchange; and (b) up to 750,000 shares
of EPIQ MD, upon reaching certain milestones, which vest immediately if EPIQ MD completes a spin-off, up-listing and/or a change of control
event. As of the date of this prospectus, none of these benchmarks have been achieved.
The
board of directors and/or Compensation Committee (if any) may also authorize bonuses payable to Mr. Bowen from time to time in their
discretion, in cash or securities, and the Board of Directors may also increase Mr. Bowen's salary from time to time, with or without
amending the employment agreement, in its discretion.
The
agreement prohibits Mr. Bowen from competing against us during the term of the agreement and for a period of twelve months after the
termination of the agreement in any state and any other geographic area in which we or our subsidiaries provide Nutraceutical products
or services, directly or indirectly, during the twelve months preceding the date of the termination of the agreement.
We
may terminate Mr. Bowen's employment (a) for "
cause
" (which is defined to include, a material breach of the
agreement by Mr. Bowen, any act of misappropriation of funds or embezzlement by Mr. Bowen, Mr. Bowen committing any act of fraud, or
Mr. Bowen being indicted of, or pleading guilty or nolo contendere with respect to, theft, fraud, a crime involving moral turpitude,
or a felony under federal or applicable state law); (b) in the event Mr. Bowen suffers a physical or mental disability which renders
him unable to perform his duties and obligations for either 90 consecutive days or 180 days in any 12-month period; (c) for any reason
without "
cause
"; or (d) upon expiration of the initial term of the agreement (or any renewal) upon notice as provided
above. The agreement also automatically terminates upon the death of Mr. Bowen.
Mr.
Bowen may terminate his employment (a) for "
good reason
" (i.e., (i) if his position or duties are modified to such
an extent that his duties are no longer consistent with the position of President and Chief Operating Officer of EPIQ MD, (ii) there
has been a material breach by us of a material term of the agreement or Mr. Bowen reasonably believes that we are violating any law which
would have a material adverse effect on our operations and such violation continues uncured thirty days after such breach and after notice
thereof has been provided to us by Mr. Bowen, or (iii) Mr. Bowen's compensation is reduced without his consent, or we fail to pay
to Mr. Bowen any compensation due to him upon 15 days written notice from Mr. Bowen informing us of such failure); provided, however,
prior to any such termination by Mr. Bowen for "
good reason
", Mr. Bowen must first advise us in writing (within 15
days of the occurrence of such event) and provide us 15 days to cure (15 days in connection with the reduction of Mr. Bowen's salary
or the failure to pay amounts owed to him)); (b) for any reason without "
good reason
"; and (c) upon expiration of
the initial term of the agreement (or any renewal) upon notice as provided above.
115
Table of Contents
If
Mr. Bowen's employment is terminated by Mr. Bowen for "
good reason
", or by us without "
cause
",
Mr. Bowen is entitled to continue to receive the salary due pursuant to the terms of the agreement at the rate in effect upon the termination
date for six (6) months or otherwise until such obligation ceases and we are required to pay 12 months of Mr. Bowen's COBRA expenses.
The
agreement contains standard assignment of inventions, indemnification, confidentiality and arbitration provisions. Further, Mr. Bowen
is subject to non-solicitation covenants during the term of the agreement.
Employment
Agreements with Maja Matthews and Sultan Haroon of Epiq Scripts, LLC
Effective
on March 4, 2022, EPIQ Scripts entered into employment agreements with Maja Matthews and Sultan Haroon (each an "
Employee
"
or collectively, the "
Employees
").
The
agreements are substantially identical, except that Mr. Matthews' agreement provides for Mr. Matthews to serve as EPIQ Scripts'
Director of Business Development and provides for compensation of $125,000 per year; and Mr. Haroon's agreement provides for him
to serve as EPIQ Scripts' Director of Business Operations and provides for compensation of $100,000 per year.
Each
agreement has a one-year term expiring March 4, 2023, provided that the term of each of the agreements automatically extends on a year-to-year
basis thereafter, in the event neither party provides the other at least 30 days prior notice of their intention not to renew the terms
of the agreement.
The
terms of each agreement are discussed below:
The
agreement prohibits the Employee from competing against us during the term of the agreement and for a period of twelve months after the
termination of the agreement which generally restricts their ability to compete against us in any state and any other geographic area
in which we or our subsidiaries provide services or products or in connection with any confidential information obtained from the Company.
We
may terminate the Employee's employment (a) for "
cause
" (which is defined to include, a material breach of the
agreement by the Employee (subject to a 20 day cure right), any act of misappropriation of funds or embezzlement by the Employee, the
Employee committing any act of fraud, or the Employee being indicted of, or pleading guilty or nolo contendere with respect to, theft,
fraud, a crime involving moral turpitude, or a felony under federal or applicable state law); (b) in the event the Employee suffers a
physical or mental disability which renders him unable to perform his duties and obligations for either 90 consecutive days or 180 days
in any 12-month period; (c) for any reason without "
cause
"; or (d) upon expiration of the initial term of the agreement
(or any renewal) upon notice as provided above. The agreement also automatically terminates upon the death of the Employee.
116
Table of Contents
The
Employee may terminate his employment (a) for "
good reason
", including (i) if there has been a material breach by
the Company of a material term of the agreement or Employee reasonably believes that the Company is violating any law which would have
a material adverse effect on the Company's operations and such violation continues uncured following twenty days after such breach
and after notice thereof has been provided to the Company by the Employee, or (ii) Employee's compensation is reduced without Employee's
consent, or the Company fails to pay to Employee any compensation due to him upon five days written; or (b) for any reason without "
good
reason
"; and (c) upon expiration of the initial term of the agreement (or any renewal) upon notice as provided above.
If
the Employee's employment is terminated pursuant to his death, his disability, by the Company for cause, by the Employee without
"good reason", or the end of the initial term or any renewal term, the Employee is entitled to salary accrued through the
dated of termination and no other benefits other than as required under the terms of employee benefit plans in which Employee was participating
as of the termination date.
If
the Employee's employment is terminated for "good reason" or without cause by the Company, the Employee is entitled
to continue to receive the base salary due under the agreement at the rate in effect upon the termination of the agreement, for four
months following such termination, payable in accordance with the Company's normal payroll practices and policies, as if Employee's
employment had not terminated.
The
agreements contain standard assignment of inventions, indemnification and confidentiality provisions. Further, each Employee is subject
to non-solicitation covenants during the term of the agreement and for twelve months thereafter. Although the Employees will be prohibited
from competing with us while they are employed with us, they will only be prohibited from competing for twelve months after their employment
with us ends pursuant to the agreements.
Consulting
Agreement
On
March 8, 2021, we entered into a Consulting Agreement with KBHS, LLC ("
KBHS
"), whose Chief Executive Officer is Mr.
Kevin Harrington, who has been appointed as the sole member of our Advisory Board.
Pursuant
to the Consulting Agreement, KBHS agreed to provide consulting services to the Company as the Company's Brand Ambassador, including
providing endorsement services and advising on marketing, promotions, acquisitions, licensing and business development. KBHS also agreed
to up to four webinar appearances on behalf of the Company per year to support the Company's direct sales efforts. The Consulting
Agreement has a term of two years, and can be terminated with ten days prior written notice (subject to applicable cure rights set forth
in the Consulting Agreement), in the event we or KBHS breach any term of the agreement, or we fail to pay any amounts due, become subject
to any government regulatory investigation, certain lawsuits, claims, actions or take certain other actions during the term of the Consulting
Agreement.
117
Table of Contents
As
consideration for providing the services under the Consulting Agreement, we agreed to issue KBHS 1.5 million shares of restricted common
stock, which vest immediately upon issuance, to pay KBHS $10,000 per month, and agreed to pay KBHS a 5% finder's fee on any new
business introduced or developed by KBHS and 7.5% of the value of any acquisition or merger created or developed exclusively by KBHS,
undertaken by the Company, subject to applicable laws. In the event we fail to pay any consideration due under the Consulting Agreement,
such amount accrues interest at the rate of 1.5% per month until paid in full. As of the date of this prospectus, no payments have been
made under the Consulting Agreement.
Director
Summary Compensation Table
We
grant our Board members options from time to time as consideration for their services to the Board. Our executive officers are not paid
any consideration for their service to the Board separate from the consideration they are paid as executive officers of the Company,
as shown above.
The
following table sets forth summary information concerning the compensation we paid to non-executive directors during the year ended December
31, 2021:
Name (1)
Fees Earned or Paid in Cash ($)
Option Awards ($)(1)
All Other Compensation ($)
Total ($)
Peter "Casey" Jensen
$
-
$
-
$
-
$
-
*
The table above does not include the amount of any expense reimbursements paid to the above directors. No directors received any Stock
Awards, Non-Equity Incentive Plan Compensation, Change in Pension Value and Nonqualified Deferred Compensation Earnings during the period
presented. Does not include perquisites and other personal benefits, or property, unless the aggregate amount of such compensation is
more than $10,000.
(1)
Represents the fair value of the grant of certain options to purchase shares of our common stock calculated in accordance with Financial
Accounting Standards Board Accounting Standards Codification Topic 718.
Outstanding
Option Equity Awards at 2021 Fiscal Year End
There
were no unvested stock or option awards outstanding at year end held by executive officers.
118
Table of Contents
Certain
Relationships and Related Transactions
Except
as discussed below or otherwise disclosed above under "
Executive and Director Compensation
", which
information is incorporated by reference where applicable in this "
Certain Relationships and Related Transactions
"
section, the following sets forth a summary of all transactions since the beginning of the fiscal year of 2019, or any currently proposed
transaction, in which the Company was to be a participant and the amount involved exceeded or exceeds the lesser of $120,000 or one percent
of the average of the Company's total assets at the fiscal year-end for 2021 and 2020, and in which any related person had or will
have a direct or indirect material interest (other than compensation described above under "
Executive and Director Compensation
").
We believe the terms obtained or consideration that we paid or received, as applicable, in connection with the transactions described
below were comparable to terms available or the amounts that would be paid or received, as applicable, in arm's-length transactions.
Loans
from Related Parties
On
June 21, 2019, the Company issued a promissory note with a principal amount of $40,000 to a related party (the father of the Company's
CEO, Jacob Cohen) in exchange for $40,000 in cash. The promissory note is unsecured, has a maturity date of June 21, 2020 and accrues
interest at the rate of 8% per annum until paid in full by the Company. Furthermore, the Company issued 50,000 shares of the Company's
common stock to the related party investor as further consideration to enter into the loan with the Company. The Company issued 50,000
shares of common stock valued at $0.10 per share or $5,000, which was accounted for as a discount on the note. This note was repaid in
full in March 2020.
On
September 9, 2019, the Company issued a promissory note with a principal amount of $100,000 to a related party (the father of the Company's
CEO, Jacob Cohen) in exchange for $100,000 in cash. The promissory note is unsecured, has a maturity date of September 9, 2020 and accrues
interest at the rate of 8% per annum until paid in full by the Company. Furthermore, the Company issued 100,000 shares of the Company's
common stock to the related party investor as further consideration to enter into the loan with the Company. The Company issued 100,000
shares of common stock valued at $1.00 per share or $100,000, which was accounted for a discount on the note. This note was repaid in
full in August 2020.
Amortization
of the discounts on the note was $30,874 for the 12 months ended December 31, 2019.
As
of December 31, 2021, the short-term note payable to Kemah Development Texas, LP, a company owned by Dror Family Trust, a former related
party totaled $13,473.
On
September 27, 2021, October 29, 2021, November 2, 2021, and November 12, 2021, Jacob Cohen, our Chief Executive Officer, advanced the
Company, $50,000, $15,000, $10,000, and $40,000, respectively, which loans are payable upon demand and not bearing interest. This amount
was repaid in November 2021.
119
Table of Contents
Long-Term
Debt to Related Parties
On
April 12, 2019 the Company entered into individual share exchange agreements and promissory notes with each of Daniel Dror, Winfred Fields
and former directors Everett Bassie (also the former CFO of the Company) and Charles Zeller (the "AMIH Shareholders"), whereby
the AMIH Shareholders agreed to cancel and exchange a total of 5,900,000 shares of their AMIH common stock. The Company issued individual
promissory notes with an aggregate principal balance of $350,000 (the "Promissory Notes") for cancellation of the 5,900,000
shares of common stock. The Promissory Notes have a term of two years and accrue interest at the rate of 10% per annum until paid in
full by the Company. As of December 31, 2019, 4,250,000 shares were returned to Treasury for cancellation, and 1,650,000 shares were
cancelled in 2020. The Company accrued $18,956 and $29,956 of interest on these notes during the years ended December 31, 2020 and 2021,
respectively.
The
Company incurred long term debt in the amount of $37,027 during the year ended December 31, 2019 to purchase equipment used in its operations.
The total purchase price was $37,027, with the Company making a down payment in the amount of $3,000. The note is due in monthly payments
of $1,258.50, including interest at 8%, due in September 2021. Due to the Company's discontinued operations of its MedSpas, the
equipment was returned in the third quarter of 2020. As of December 31, 2020 and 2021, the balance of the note was $0.
At
December 31, 2021, accrued compensation was $103,500, representing $53,500 as owed to Jacob Cohen, the Company's CEO and $25,000
owed to each of Alan Hernandez and Esteban Alexander, the Company's former officers and directors.
Additional
Transactions
On
July 5, 2019, our board of directors adopted and approved our 2019 Stock Option and Incentive Plan. The Plan is intended to promote the
interests of our Company by providing eligible person with the opportunity to acquire a proprietary interest, or otherwise increase their
proprietary interest, in the Company as an incentive for them to remain in the service of the Company. The maximum number of shares available
to be issued under the Plan is currently 10,000,000 shares, subject to adjustments for any stock splits, stock dividends or other specified
adjustments which may take place in the future. The Company issued a total of 2,535,000 shares to eligible persons under the Plan and
recorded a total $2,193,550 as Stock Based Compensation against these issuances for the year ended December 31, 2021.
On
January 13, 2020, and with an effective date of December 31, 2019, the Company sold 100% of its interest in YS Brands to its then current
officers and directors, Jacob Cohen, Alan Hernandez and Esteban Alexander, in consideration of $300 in cash.
120
Table of Contents
On
May 20, 2020, the Company issued one share of its newly designated shares of Series A Preferred Stock (the rights associated with such
Series A Preferred Stock are described in greater detail under "Description of Capital Stock—
Preferred Stock
—
Series
A Preferred Stock
"), to each of the three members of its then board of directors, (1) Jacob D. Cohen, (2) Esteban Alexander
and (3) Alan Hernandez, in consideration for services rendered to the Company as members of the board of directors. Such shares of Series
A Preferred Stock vote in aggregate sixty percent (60%) of the total vote on all shareholder matters, voting separately as a class, as
discussed in greater detail under "
Description of Capital Stock
—
Preferred Stock
—
Series B Convertible
Preferred Stock
". Notwithstanding such voting rights, no change in control of the Company was deemed to have occurred in connection
with the issuance since Messrs. Cohen, Alexander and Hernandez, own in aggregate 68% of the Company's outstanding common stock
and therefore controlled the Company prior to such issuance.
On
October 2, 2020, Jacob D. Cohen, the Chief Executive Officer and member of the board of directors of the Company entered into Stock Purchase
Agreements with each of (a) Esteban Alexander, the Chief Operating Officer and member of the board of directors of the Company, and (b)
Luis Alan Hernandez, the Chief Marketing Officer and member of the board of directors of the Company (collectively, the "
Preferred
Holders
" and the "
Stock Purchase Agreements
").
Pursuant
to the Stock Purchase Agreements, Mr. Alexander agreed to sell 7,000,000 shares of common stock of the Company which he held to Mr. Cohen,
which rights to such shares were assigned by Mr. Cohen to Cohen Enterprises, Inc., which entity he controls ("
Cohen Enterprises
"),
in consideration for an aggregate of $1,500 as well as for the amount of services provided by Mr. Cohen to the Company; and Mr. Hernandez
agreed to sell 4,000,000 shares of common stock of the Company which he held to Cohen Enterprises, in consideration for an aggregate
of $1,000 as well as for the amount of services provided by Mr. Cohen to the Company. The sales closed on November 5, 2020.
One
of the reasons that Mr. Alexander and Mr. Hernandez agreed to the terms of the Stock Purchase Agreements (including the sale of the shares
of common stock of the Company at below market value), is because (a) each of Mr. Cohen, Mr. Alexander, and Mr. Hernandez were all appointed
as officers and directors of the Company at the same time in April 2019, with the intention that such persons would provide a relatively
equal amount of services to the Company in the roles as officers and directors thereof; (b) since such appointment date Mr. Cohen has
been required to provide a disproportionate amount of services to the Company; and (c) each of Mr. Alexander and Mr. Hernandez desired
to provide additional consideration to Mr. Cohen for such disproportionate level of service.
A
condition to the Stock Purchase Agreements was that each of Mr. Alexander and Mr. Hernandez resign as a member of the board of directors
of the Company by no later than January 15, 2021, which resignations were effective December 15, 2020.
121
Table of Contents
A
further requirement to the terms of the Stock Purchase Agreements was that each of Mr. Alexander and Mr. Hernandez take such actions
necessary and which may be requested from time to time by Mr. Cohen, to affect the cancellation of the one share of Series A Preferred
Stock of the Company held by each of them, for no consideration (including, but not limited to, without the required payment by the Company
of the $1 redemption price described in the designation of such Series A Preferred Stock).
The
shares of Series A Preferred Stock held by Mr. Alexander and Mr. Hernandez were canceled on November 6, 2020. The common shares were
also transferred to Mr. Cohen on November 6, 2020, and as such, a change of control occurred on such date, with Mr. Cohen taking over
voting control of the Company.
In
January 2021, the Company issued Mr. Cohen an aggregate of 2.5 million shares of common stock in consideration for services rendered.
On
January 12, 2022, the Company issued an award of 5,000,000 restricted shares of the Company's common stock as a signing bonus in
consideration of Mr. Cohen entering into his new Employment Agreement with the Company.
On
October 7, 2021, the Company incorporated Mangoceuticals, Inc. ("
Mangoceuticals
") in the
state of Texas with the intent of focusing on developing, marketing and selling a variety of men's wellness products and services
via a telemedicine platform. Subsequent to incorporation, Mangoceuticals issued 1,000,000 shares of common stock each to Jacob D. Cohen,
the Chief Executive Officer of the Company, and a third party, in consideration for services rendered. As a result, Mangoceuticals is
currently 80% owned by the Company.
Review,
Approval and Ratification of Related Party Transactions
The
Audit Committee of the Board of Directors of the Company is tasked with reviewing and approving any issues relating to conflicts of interests
and all related party transactions of the Company ("
Related Party Transactions
"). The Audit Committee, in undertaking
such review and will analyze the following factors, in addition to any other factors the Audit Committee deems appropriate, in determining
whether to approve a Related Party Transaction: (1) the fairness of the terms for the Company (including fairness from a financial point
of view); (2) the materiality of the transaction; (3) bids / terms for such transaction from unrelated parties; (4) the structure of
the transaction; (5) the policies, rules and regulations of the U.S. federal and state securities laws; (6) the policies of the Committee;
and (7) interests of each related party in the transaction.
The
Audit Committee will only approve a Related Party Transaction if the Audit Committee determines that the terms of the Related Party Transaction
are beneficial and fair (including fair from a financial point of view) to the Company and are lawful under the laws of the United States.
In the event multiple members of the Audit Committee are deemed a related party, the Related Party Transaction will be considered by
the disinterested members of the Board of Directors in place of the Committee.
122
Table of Contents
In
addition, our Code of Ethics (described above under "
Code of Ethics
"), which is applicable to all of our employees,
officers and directors, requires that all employees, officers and directors avoid any conflict, or the appearance of a conflict, between
an individual's personal interests and our interests.
Where
You Can Find Additional Information
We
will provide without charge to each person, including any beneficial owner, to whom this prospectus is delivered, upon his or her written
or oral request, a copy of any or all of the reports or documents referred to above that have been incorporated by reference into this
prospectus, excluding exhibits to those documents unless they are specifically incorporated by reference into those documents. You may
request a copy of these filings, at no cost, by contacting us at our address at 7950 Legacy Drive, Suite 400, Plano, Texas 75024 or by
email at info@amihcorp.com.
We
file annual, quarterly, and current reports, proxy statements and other information with the SEC. Our SEC filings are available to the
public over the Internet at the SEC's website at
www.sec.gov
and are available for download, free of charge, soon after
such reports are filed with or furnished to the SEC, on our website at
https://amihcorp.com/investors/
. Our website address is
https://amihcorp.com
.
We
do not incorporate information on our website into this prospectus or any supplement to this prospectus and you should not consider any
information on, or that can be accessed through, our website as part of this prospectus or any supplement to this prospectus (other than
those filings with the SEC that we specifically incorporate by reference into this prospectus or any supplement to this prospectus).
123
Table of Contents
Indemnification
of Directors and Officers
As
authorized by
Section 78.751
of the Nevada Revised Statutes, we may indemnify our officers and directors against expenses incurred
by such persons in connection with any threatened, pending or completed action, suit or proceedings, whether civil, criminal, administrative
or investigative, involving such persons in their capacities as officers and directors, so long as such persons acted in good faith and
in a manner which they reasonably believed to be in our best interests. If the legal proceeding, however, is by or in our right, the
director or officer may not be indemnified in respect of any claim, issue or matter as to which he is adjudged to be liable for negligence
or misconduct in the performance of his duty to us unless a court determines otherwise.
Under
Nevada law, corporations may also purchase and maintain insurance or make other financial arrangements on behalf of any person who is
or was a director or officer (or is serving at our request as a director or officer of another corporation) for any liability asserted
against such person and any expenses incurred by him in his capacity as a director or officer. These financial arrangements may include
trust funds, self-insurance programs, guarantees and insurance policies.
Additionally,
our Bylaws, as amended and restated ("
Bylaws
"), state that we shall indemnify every (i) present or former director,
advisory director or officer of us, (ii) any person who while serving in any of the capacities referred to in clause (i) served at our
request as a director, officer, partner, venturer, proprietor, trustee, employee, agent or similar functionary of another foreign or
domestic corporation, partnership, joint venture, trust, employee benefit plan or other enterprise, and (iii) any person nominated or
designated by (or pursuant to authority granted by) the Board of Directors or any committee thereof to serve in any of the capacities
referred to in clauses (i) or (ii) (each an "
Indemnitee
").
Our
Bylaws provide that we shall indemnify an Indemnitee against all judgments, penalties (including excise and similar taxes), fines, amounts
paid in settlement and reasonable expenses actually incurred by the Indemnitee in connection with any proceeding in which he was, is
or is threatened to be named as a defendant or respondent, or in which he was or is a witness without being named a defendant or respondent,
by reason, in whole or in part, of his serving or having served, or having been nominated or designated to serve, if it is determined
that the Indemnitee (a) conducted himself in good faith, (b) reasonably believed, in the case of conduct in his official capacity, that
his conduct was in our best interests and, in all other cases, that his conduct was at least not opposed to our best interests, and (c)
in the case of any criminal proceeding, had no reasonable cause to believe that his conduct was unlawful; provided, however, that in
the event that an Indemnitee is found liable to us or is found liable on the basis that personal benefit was improperly received by the
Indemnitee, the indemnification (i) is limited to reasonable expenses actually incurred by the Indemnitee in connection with the proceeding
and (ii) shall not be made in respect of any proceeding in which the Indemnitee shall have been found liable for willful or intentional
misconduct in the performance of his duty to us.
124
Table of Contents
Except
as provided above, the Bylaws provide that no indemnification shall be made in respect to any proceeding in which such Indemnitee has
been (a) found liable on the basis that personal benefit was improperly received by him, whether or not the benefit resulted from an
action taken in the Indemnitee's official capacity, or (b) found liable to us. The termination of any proceeding by judgment, order,
settlement or conviction, or on a plea of nolo contendere or its equivalent, is not of itself determinative that the Indemnitee did not
meet the requirements set forth in clauses (a) or (b) above. An Indemnitee shall be deemed to have been found liable in respect of any
claim, issue or matter only after the Indemnitee shall have been so adjudged by a court of competent jurisdiction after exhaustion of
all appeals therefrom. Reasonable expenses shall include, without limitation, all court costs and all fees and disbursements of attorneys'
fees for the Indemnitee. The indemnification provided shall be applicable whether or not negligence or gross negligence of the Indemnitee
is alleged or proven.
Neither
our Bylaws nor our Articles of Incorporation include any specific indemnification provisions for our officers or directors against liability
under the Securities Act. Additionally, insofar as indemnification for liabilities arising under the Securities Act may be permitted
to directors, officers and controlling persons of the Company pursuant to the foregoing provisions, or otherwise, the Company has been
advised that in the opinion of the Securities and Exchange Commission such indemnification is against public policy as expressed in the
Securities Act and is, therefore, unenforceable.
125
Table of Contents
INDEX TO FINANCIAL STATEMENTS
Contents
Page(s)
Audited
    Financial Statements for the Years Ended December 2021 and 2020
Report
    of Independent Registered Public Accounting Firm
PCAOB ID NO: 2738
F-2
Consolidated
    Balance Sheets at December 31, 2021 and 2020
F-3
Consolidated
    Statements of Operations for the Years Ended December 31, 2021 and 2020
F-4
Consolidated
    Statements of Stockholders' Equity (Deficit) for the Years Ended December 31, 2021 and 2020
F-5
Consolidated
    Statements of Cash Flows for the Years Ended December 31, 2021 and 2020
F-6
Notes
    to Consolidated Financial Statements
F-7
F-
1
Table of Contents
REPORT
OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
To
the Board of Directors and Stockholders of American International Holdings Corp.,
Opinion
on the Financial Statements
We
have audited the accompanying consolidated balance sheets of American International Holdings Corp. (the Company) as of December 31, 2021
and 2020, and the related consolidated statements of operations, changes in stockholders' deficit, and cash flows for the
two-year period then ended, and the related notes (collectively referred to as the "financial statements").
In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company as of December
31, 2021 and 2020, and the results of its operations and its cash flows for the years then ended in conformity with accounting
principles generally accepted in the United States of America.
Going
Concern
The
accompanying financial statements have been prepared assuming that the Company will continue as a going concern. As discussed in Note
15 to the financial statements, the Company has suffered net losses from continuing and discontinued operations, which raises substantial
doubt about its ability to continue as a going concern. Management's plans regarding those matters are discussed in Note 15. The
financial statements do not include any adjustments that might result from the outcome of this uncertainty.
Basis
for Opinion
These
financial statements are the responsibility of the Company's management. Our responsibility is to express an opinion on the Company's
financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board
(United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities
laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.
We
conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audits to obtain
reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud.
The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting.
As part of our audits, we are required to obtain an understanding of internal control over financial reporting, but not for the purpose
of expressing an opinion on the effectiveness of the Company's internal control over financial reporting. Accordingly, we express
no such opinion.
Our
audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error
or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence
regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles
used and the significant estimates made by management, as well as evaluating the overall presentation of the financial
statements. We believe our audits provide a reasonable basis for our opinion.
Critical
Audit Matters
The
critical audit matter communicated below is a matter arising from the current period audit of the financial statements that were communicated
or required to be communicated to the audit committee and that: (1) relate to accounts or disclosures that are material to the financial
statements and (2) involved our especially challenging, subjective, or complex judgments. The communication of critical audit matters
does not alter in any way our opinion on the financial statements, taken as a whole, and we are not, by communicating the critical audit
matter below, providing separate opinion on the critical audit matter or on the accounts or disclosures to which they relate.
As
discussed in Note 12, the Company borrows funds through the use of convertible notes payable that contain a conversion price that may
be fixed or fluctuates with the stock price.
Auditing
management's estimates of the fair value of the derivative liability involves significant judgements and estimates given the embedded
conversion features of the notes.
To
evaluate the appropriateness of the fluctuation of the conversion price, the embedded conversion feature requires bifurcation from the
host contract and is recorded as a liability subject to market adjustments as of each reporting period. Significant judgment is exercised
by the Company in determining derivative liability values for these convertible note agreements, including the use of a specialist engaged
by management.
We evaluated management's conclusions regarding their derivative liability and reviewed
support for the significant inputs used in the valuation model, as well as assessing the model for reasonableness.
/s/
    M&K CPAS, PLLC
M&K CPAS, PLLC
We
    have served as the Company's auditor since 2015
Houston,
    Texas
March 29,
2022
F-
2
Table of Contents
American
International Holdings Corp.
Consolidated
Balance Sheets
(Audited)
(Audited)
December 31, 2021
December 31, 2020
ASSETS
CURRENT ASSETS:
Cash and equivalents
$
1,209,807
$
25,235
Inventory
3,840
-
Prepayment and deposits
-
3,333
Assets of discontinued operations
-
9,971
TOTAL CURENT ASSETS
1,213,647
38,539
NON-CURRENT ASSETS
Rent deposits
3,599
3,800
Assets of discontinued operations
14,199
223,183
NET NON-CURRENT ASSETS
17,798
226,983
TOTAL ASSETS
$
1,231,445
$
265,522
LIABILITIES AND STOCKHOLDERS' DEFICIT
CURRENT LIABILITIES
Accounts payable and accrued liabilities
$
54,918
$
14,576
Accrued interest payable
93,776
42,195
Accrued compensation - related parties
103,500
154,500
Convertible notes payable, net of debt discount of $
2,479,023
and $
370,923
396,419
74,827
Loans payable to related parties
123,473
13,473
Loans payable
75,000
55,000
Derivative liabilities
4,141,272
517,366
Net liabilities of discontinued operations
112,199
669,574
TOTAL CURRENT LIABILITIES
5,100,557
1,541,511
LONG-TERM LIABILITIES
Convertible notes payable, net of debt discount of $
0
and $
78,482
-
5,018
Long-term debt - related parties
-
110,000
TOTAL LONG-TERM LIABILITIES
-
115,018
TOTAL LIABILITIES
5,100,557
1,656,529
STOCKHOLDERS' DEFICIT
Preferred stock, (par value $
0.0001
,
5,000,000
shares authorized, of which
1
and
1
shares issued and outstanding as of December 31, 2021 and December 31, 2020, respectively)
-
-
Common stock (par value $
.0001
,
195,000,000
shares authorized, of which
84,445,067
and
55,066,855
shares issued and outstanding as of December 31, 2021 and December 31, 2020, respectively)
8,445
5,507
Treasury stock, at cost
(
3,894
)
(
3,894
)
Additional paid in capital
16,666,906
9,167,038
Accumulated deficit
(
20,540,569
)
(
10,559,658
)
TOTAL STOCKHOLDERS' DEFICIT
(
3,869,111
)
(
1,391,007
)
TOTAL LIABILITIES AND STOCKHOLDERS' DEFICIT
$
1,231,445
$
265,522
The
accompanying notes are an integral part of these consolidated audited financial statements.
F-
3
Table of Contents
American
International Holdings Corp.
Consolidated
Statements of Operations
(Audited)
(Audited)
For The Twelve
For The Twelve
Months Ended
Months Ended
December 31, 2021
December 31, 2020
Revenues
Revenues
$
20,169
$
2,115
Cost of revenues
39,738
-
Gross profit (loss)
(
19,569
)
2,115
Operating expenses
General and administrative expenses
6,975,654
3,711,317
Total operating expenses
6,975,654
3,711,317
Income (loss) from operations
(
6,995,223
)
(
3,709,202
)
Other income (expenses)
Amortization of debt discount
(
1,958,298
)
(
777,964
)
Change in derivative liabilities
(
1,071,028
)
(
107,574
)
Forgiveness of Loan
45,500
-
Impairment Loss
-
(
605,488
)
Interest expense
(
184,589
)
(
219,280
)
Settlement loss
(
61,859
)
(
1,041,445
)
Other income
-
300
Total other income (expense)
(
3,230,274
)
(
2,751,451
)
Income (loss) before income taxes
(
10,225,497
)
(
6,460,653
)
Income taxes
-
-
Net (loss) from continuing operations
$
(
10,225,497
)
$
(
6,460,653
)
Discontinued operations:
Income (loss) from discontinued operations
244,586
(
879,237
)
Total discontinued operations
244,586
(
879,237
)
Net loss
$
(
9,980,911
)
$
(
7,339,890
)
Basic income (loss) per share
Continuing operations
$
(
0.14
)
$
(
0.18
)
Discontinued operations
$
0.00
$
(
0.02
)
Diluted income (loss) per share
Continuing operations
$
(
0.14
)
$
(
0.18
)
Discontinued operations
$
0.00
$
(
0.02
)
Weighted average number of shares outstanding
Basic
74,925,101
35,462,109
Diluted
75,311,586
35,456,109
The
accompanying notes are an integral part of these consolidated audited financial statements.
F-
4
Table of Contents
American
International Holdings Corp.
Consolidated
Statement of Changes in Stockholders' Deficit
(Audited)
Preferred
Stock A
Preferred
Stock B
Common Stock
Additional
Paid-in
Common
Stock
Retained
Earnings
Treasury
Total
Stockholders'
Shares
Amount
Shares
Amount
Shares
Amount
Capital
Payable
(Deficit)
Stock
(Deficit)
Balance, December 31, 2019
-
$
-
-
$
-
27,208,356
$
2,721
$
2,186,651
$
25,000
$
(
3,219,768
)
$
(
103,537
)
$
(
1,108,933
)
Imputed interest
-
-
-
-
-
-
3,345
-
-
-
3,345
Reclassification of derivative liabilities due to note conversion
-
-
-
-
-
-
907,551
-
-
-
907,551
Issuance of Series B preferred shares for investment
-
-
500,000
50
-
-
605,438
-
-
-
605,438
Issuance of common shares under private placement
-
-
-
-
131,250
13
71,487
(
25,000
)
-
-
46,500
Cancellation of treasury stock
-
-
-
-
(
1,650,000
)
(
165
)
(
99,478
)
-
-
99,643
-
Issuance of common shares for note settlement
-
-
-
-
18,916,774
1,892
2,632,227
-
-
-
2,634,119
Issuance of shares for services - related parties
1
-
-
-
6,000,000
600
1,559,400
-
-
-
1,560,000
Issuance of shares for services
-
-
-
-
2,377,142
238
1,300,575
-
-
-
1,300,813
Issuance of common shares for Series B preferred shares conversion
-
-
(
500,000
)
(
50
)
2,083,333
208
(
158
)
-
-
-
50
Net (loss)
-
-
-
-
-
-
-
-
(
7,339,890
)
-
(
7,339,890
)
Balance, December 31, 2020
1
$
-
-
$
-
55,066,855
$
5,507
$
9,167,038
$
-
$
(
10,559,658
)
$
(
3,894
)
$
(
1,391,007
)
Preferred
Stock A
Preferred
Stock B
Common Stock
Additional
Paid-in
Common
Stock
Retained
Earnings
Treasury
Total
Stockholders'
Shares
Amount
Shares
Amount
Shares
Amount
Capital
Payable
(Deficit)
Stock
(Deficit)
Balance, December 31, 2020
1
$
-
-
$
-
55,066,855
$
5,507
$
9,167,038
$
-
$
(
10,559,658
)
$
(
3,894
)
$
(
1,391,007
)
Imputed interest
-
-
-
-
-
-
1,979
-
-
-
1,979
Reclassification of derivative liabilities due to note conversion
-
-
-
-
-
-
1,116,122
-
-
-
1,116,122
Issuance
    of Series B preferred shares for In Process Research and Development
-
-
500,000
50
-
-
601,802
-
-
-
601,852
Issuance of common shares for Series B preferred shares conversion
-
-
(
500,000
)
(
50
)
2,057,613
206
(
156
)
-
-
-
-
Issuance of common shares under private placement
-
-
-
-
200,000
20
99,980
-
-
-
100,000
Issuance of common shares for note conversion and settlement
-
-
-
-
12,545,171
1,255
1,227,216
-
-
-
1,228,471
Issuance of shares for services - related parties
-
-
-
-
6,500,000
650
2,510,000
-
-
-
2,510,650
Issuance of shares for services
-
-
-
-
7,366,678
736
1,823,471
-
-
-
1,824,207
Issuance of common shares for debt settlement
-
-
-
-
708,750
71
119,454
-
-
-
119,525
Net income
-
-
-
-
-
-
-
-
(
9,980,911
)
-
(
9,980,911
)
Balance, December 31, 2021
1
$
-
-
$
-
84,445,067
$
8,445
$
16,666,906
$
-
$
(
20,540,569
)
$
(
3,894
)
$
(
3,869,111
)
The
accompanying notes are an integral part of these audited consolidated financial statements.
F-
5
Table of Contents
AMERICAN
INTERNATIONAL HOLDINGS CORP.
Consolidated
Statements of Cash Flows
For the Year Ended
For the Year Ended
December 31, 2021
December 31, 2020
CASH FLOWS FROM OPERATING ACTIVITIES:
Net income (loss)
$
(
10,225,497
)
$
(
6,460,653
)
Net loss from discontinued operations
244,586
$
(
879,237
)
Adjustments to reconcile net income (loss) to net cash (used in) operating activities:
Amortization of debt discount
1,958,298
777,964
Change in derivative liabilities
(
2,469,697
)
107,574
Derivatives expenses
3,540,725
-
Forgiveness of Loan
(
45,500
)
-
Impairment loss
-
670,280
Imputed interest expense
1,979
3,345
Loss on disposal
3,800
-
Loss on loans settlement
58,059
1,155,685
Stock issued for services rendered
4,334,857
2,860,813
Stock issued for in process research and development
601,852
-
(Increase) decrease in operating assets:
Inventory
(
3,840
)
-
Prepaid expenses
3,333
(
3,333
)
Rent Deposit
(
3,599
)
(
3,800
)
(Decrease) increase in operating liabilities:
Accounts payable
40,342
13,389
Accrued interest payable
77,296
213,430
Accrued compensation - related parties
(
5,500
)
96,000
NET CASH (USED IN) OPERATING ACTIVITIES OF CONTINUING OPERATIONS
(
1,888,506
)
(
1,448,542
)
NET CASH (USED IN) OPERATING ACTIVITIES OF DISCONTINUED OPERATIONS
(
323,256
)
(
704,721
)
NET CASH (USED IN) OPERATING ACTIVITIES
(
2,211,762
)
(
2,153,263
)
CASH FLOWS FROM INVESTING ACTIVITIES:
NET CASH (USED IN) INVESTING ACTIVITIES OF CONTINUING OPERATIONS
-
-
NET CASH PROVIDED BY (USED IN) INVESTING ACTIVITIES OF DISCONTINUED OPERATIONS
10,000
(
27,392
)
NET CASH PROVIDED BY (USED IN) INVESTING ACTIVITIES OF DISCONTINUED OPERATIONS
10,000
(
27,392
)
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from borrowings - related parties
141,928
-
(Repayment) to borrowings - related parties
(
141,928
)
-
Proceeds from borrowings
3,738,999
947,750
(Repayment) to borrowings
(
427,500
)
(
40,000
)
Proceeds from sales of stock
100,000
46,500
NET CASH PROVIDED BY FINANCING ACTIVITIES OF CONTINUING OPERATIONS
3,411,499
954,250
NET CASH (USED IN) FINANCING ACTIVITIES OF DISCONTINUED OPERATIONS
(
25,164
)
(
7,070
)
NET CASH PROVIDED BY FINANCING ACTIVITIES
3,386,335
947,180
NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS
1,184,572
(
1,233,475
)
CASH AND CASH EQUIVALENTS:
Beginning of period
25,235
1,258,710
End of period
$
1,209,807
$
25,235
Supplemental disclosure of cash flow information:
Cash paid for income taxes
$
-
$
-
Cash paid for interest
$
106,677
$
2,674
Non-cash transactions:
Cancellation of common shares
$
-
$
99,643
Common shares issued for notes conversion
$
1,228,471
$
1,282,386
Common shares issued for loan settlement
$
111,466
$
86,771
Discounts on convertible notes
$
(
3,756,000
)
$
876,098
Issuance of Series B for Investment
$
-
$
605,488
Lease Inception
$
-
$
348,279
Related party's note settled in shares
$
-
$
109,278
Settlement of derivative liabilities
$
1,116,122
$
907,551
Stock Payable
$
-
$
25,000
The
accompanying notes are an integral part of these audited consolidated financial statements.
F-
6
Table of Contents
AMERICAN
INTERNATIONAL HOLDINGS CORP.
Notes
to Consolidated Financial Statements
Year
Ended December 31, 2021
(Audited)
Note
1 –
Summary of Significant Accounting Policies
Organization,
Ownership and Business
Prior
to May 31, 2018, the Company was a
93.2
% owned subsidiary of American International Industries, Inc. ("
American
" or
"
AMIN
") (OTCQB: AMIN). Effective May 31, 2018, the Company issued
10,100,000
shares of restricted common stock. As
a result of the issuance of the common shares, a change in control occurred. American International Industries, Inc. ownership decreased
from
93.2
% to
6.4
%. No one individual or entity owns at least 50% of the outstanding shares of the Company. Effective April 12, 2019,
the Company changed its business focus to the services of medical spas.
On
April 12, 2019, the Company entered into a Share Exchange Agreement (the "
Agreement
") with Novopelle Diamond, LLC
("
Novopelle
") and all three members of Novopelle, pursuant to which the Company issued
18,000,000
shares of the Company
common stock to the members (three individuals) of Novopelle Diamond, LLC ("
Novopelle
"), a Texas limited company,
to acquire
100
% of the membership interests of Novopelle. The issuance of these shares represents a change in control of the Company.
Concurrent with the issuance, Jacob Cohen, Esteban Alexander and Alan Hernandez, representing the three former members of Novopelle,
were elected to the board of directors and to the office of Chief Executive Officer, Chief Operating Officer and Chief Marketing officer
of the Company, respectively. Everett Bassie and Charles Zeller resigned as board members of the Company. This transaction was treated
as a reverse acquisition for accounting purposes, with the Company remaining the parent company and Novopelle (which has since been renamed
VISSIA McKinney, LLC) becoming a wholly-owned subsidiary of the Company.
On
April 28, 2020, the Company incorporated a wholly-owned subsidiary, ZipDoctor, Inc. ("
ZipDoctor
") in the State of
Texas. ZipDoctor plans to provide its customers with unlimited, 24/7 access to board certified physicians and licensed mental and behavioral
health counselors and therapists via a newly developed, monthly subscription based online telemedicine platform. ZipDoctor was launched
in August 2020 and has generated nominal revenues through the year ended December 31, 2021.
On
May 15, 2020, the Company entered into a Securities Purchase Agreement (the "
SPA
") with Global Career Networks Inc,
a Delaware corporation (the "
GCN
"), the sole owner of Life Guru, Inc., a Delaware corporation ("
Life Guru
").
Pursuant to the SPA, the Company acquired a
51
% interest in Life Guru from GCN. As consideration for the purchase of the 51% ownership
interest in Life Guru, the Company issued to GCN
500,000
shares of its newly designated Series B Convertible Preferred Stock, which had
an agreed upon value of $
500,000
($
1.00
per share), and agreed to issue GCN up to an additional
1,500,000
shares of Series B Convertible
Preferred Stock (with an agreed upon value of $
1,500,000
) upon reaching certain milestones.
Impact
of COVID-19 Pandemic on Consolidated Financial Statements.
The outbreak of the 2019 novel coronavirus disease ("
COVID-19
"),
which was declared a global pandemic by the World Health Organization on March 11, 2020, and the related responses by public health and
governmental authorities to contain and combat its outbreak and spread has severely impacted the U.S. and world economies, the market
for health spa services, nutrition supplements and our other business offerings during the end of the first quarter of 2020, and continuing
through the end of 2020 and into 2021. Government mandated 'stay-at-home' and similar orders have to date, and may in the
future, prevent us from staffing our spas and construction services, and prohibited us from operating. In late 2020, we made the decision
to discontinue operations of our VISSIA Waterway, Inc. and VISSIA McKinney MedSpa locations due to declines in customers and issues staffing
such facilities, each as a result of the pandemic. Additionally, our Legend Nutrition store saw a deep decline in sales due to social
distancing orders and decreases in customers who were willing to venture out to brick-and-mortar establishments during 2020. Legend Nutrition's
lease was up January 31, 2021, and the Company chose to not renew the lease, closed the store, and will not continue in this line of
business moving forward. We also decided to cease offering construction services around July 2021.
F-
7
Table of Contents
As
of the date of this Report, our operations are limited, and consist mainly of ZipDoctor, Inc., Life Guru, Inc., EPIQ Scripts, LLC, EPIQ
MD, Inc. and Mangoceuticals, Inc.
Moving
forward, economic recessions, including those brought on by the continued COVID-19 outbreak may have a negative effect on the demand
for our services and our operating results. Any prolonged disruption to our operations or work force availability is likely to have a
significant adverse effect on our results of operations, cash flows and ability to meet continuing debt service requirements. All of
the above may be exacerbated in the future as the COVID-19 outbreak and the governmental responses thereto continues.
Principles
of Consolidation
The
consolidated financial statements include the accounts of AMIH and its subsidiaries: VISSIA McKinney, LLC (f/k/a Novopelle Diamond, LLC),
VISSIA Waterway, Inc. (f/k/a Novopelle Waterway, Inc.), Legend Nutrition, Inc., Capitol City Solutions USA, Inc. ZipDoctor, Inc., LifeGuru,
Inc., Mangoceuticals, Inc., and EPIQ MD, Inc.
VISSIA
Waterway, Inc., VISSIA McKinney LLC, Capitol City Solutions USA, Inc. and Legend Nutrition, Inc. (collectively referred to as "Discontinued
Subsidiaries") have been presented as discontinued operations in the accompanying consolidated financial statements.
All
significant intercompany transactions and balances have been eliminated in consolidation.
Reclassifications
Certain
reclassifications have been made to amounts in prior periods to conform to the current period presentation. All reclassifications have
been applied consistently to the periods presented.
Cash
Equivalents
Highly
liquid investments with original maturities of three months or less are considered cash equivalents. There are
no
cash equivalents at
December 31, 2021 and December 31, 2020.
The
Company maintains the majority of its cash accounts at a commercial bank. The total cash balance is insured by the Federal Deposit Insurance
Corporation ("FDIC") up to $
250,000
per commercial bank. From time to time, cash in deposit accounts may exceed the FDIC
limits, the excess would be at risk of loss for purposes of the statement of cash flows.
Inventory
Inventory
consists of finished goods purchased, which are valued at the lower of cost or market value, with cost being determined on the first-in,
first-out method. The Company periodically reviews historical sales activity to determine potentially obsolete items and also evaluates
the impact of any anticipated changes in future demand. The Company had $
3,840
and $
0
inventory from continuing operations as of December
31, 2021 and 2020, respectively.
No
allowance was necessary as of December 31, 2021
and 2020.
Net
Loss Per Common Share
We
compute net income (loss) per share in accordance with ASC 260,
Earning per Share
. ASC 260 requires presentation of both basic
and diluted earnings per share (EPS) on the face of the income statement. Basic EPS is computed by dividing net income (loss) available
to common shareholders (numerator) by the weighted average number of shares outstanding (denominator) during the period. Diluted EPS
gives effect to all dilutive potential common shares outstanding during the period using the treasury stock method and convertible preferred
stock using the if-converted method. In computing Diluted EPS, the average stock price for the period is used in determining the number
of shares assumed to be purchased from the exercise of stock options or warrants. Diluted EPS excludes all dilutive potential shares
if their effect is anti-dilutive. The Company issued dilutive securities in the form of convertible notes and warrants during the year
ended December 31, 2021.
F-
8
Table of Contents
Property,
Plant, Equipment, Depreciation, Amortization and Long-Lived Assets
Long-lived
assets include:
Property,
Plant and Equipment – Assets acquired in the normal course of business are recorded at original cost and may be adjusted for any
additional significant improvements after purchase. We depreciate the cost evenly over the assets' estimated useful lives from
the date on which they become fully operational and after taking into account their estimated residual values:
Depreciable life
Residual value
Machinery and Equipment
5 years
0
%
Furniture and fixture
7 years
0
%
Computer and software
3 years
0
%
Upon
retirement or sale, the cost of the assets disposed of and the related accumulated depreciation are removed from the accounts, with any
resultant gain or loss being recognized as a component of other income or expense.
Identifiable
intangible assets – These assets are recorded at acquisition cost. Intangible assets with finite lives are amortized evenly over
their estimated useful lives.
At
least annually, we review all long-lived assets for impairment. When necessary, we record changes for impairments of long-lived assets
for the amount by which the present value of future cash flows, or some other fair value measure, is less than the carrying value of
these assets.
If
the carrying amount of a reporting unit exceeds its fair value, we measure the possible goodwill impairment based upon an allocation
of the estimate of fair value of the reporting unit to all of the underlying assets and liabilities of the reporting unit, including
any previously unrecognized intangible assets (Step Two Analysis). The excess of the fair value of a reporting unit over the amounts
assigned to its assets and liabilities ("carrying amount") is the implied fair value of goodwill.
Goodwill
and indefinite-lived brands are not amortized, but are evaluated for impairment annually or when indicators of a potential impairment
are present. Our impairment testing of goodwill is performed separately from our impairment testing of indefinite-lived intangibles.
The annual evaluation for impairment of goodwill and indefinite-lived intangibles is based on valuation models that incorporate assumptions
and internal projections of expected future cash flows and operating plans. The Company believe such assumptions are also comparable
to those that would be used by other marketplace participants.
Fair
value of financial instruments
The
Company measures its financial and non-financial assets and liabilities, as well as makes related disclosures, in accordance with FASB
Accounting Standards Codification No. 820, Fair Value Measurement ("ASC 820"), which provides guidance with respect to valuation
techniques to be utilized in the determination of fair value of assets and liabilities. Approaches include, (i) the market approach (comparable
market prices), (ii) the income approach (present value of future income or cash flow), and (iii) the cost approach (cost to replace
the service capacity of an asset or replacement cost). ASC 820 utilizes a fair value hierarchy that prioritizes the inputs to valuation
techniques used to measure fair value into three broad levels. The following is a brief description of those three levels:
Level
1: Observable inputs such as quoted prices (unadjusted) in active markets for identical assets or liabilities.
Level
2: Inputs other than quoted prices that are observable, either directly or indirectly. These include quoted prices for similar assets
or liabilities in active markets and quoted prices for identical or similar assets or liabilities in markets that are not active.
Level
3: Unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions, such as
valuations derived from valuation techniques in which one more significant inputs or significant value drivers are unobservable.
F-
9
Table of Contents
Our
financial instruments include cash, inventories, prepayment and deposits, accounts payable, accrued liabilities, accrued interest payable,
accrued compensation, convertible note payable, loans payable, derivative liabilities and billing in excess of costs and estimated earnings.
The
carrying values of the Company's cash, inventories, prepayment and deposits, accounts payable, accrued liabilities, accrued interest
payable, accrued compensation, convertible note payable, short-term loans payable, derivative liabilities and billing in excess of costs
and estimated earnings approximate their fair value due to their short-term nature.
The
Company's convertible note payable are measured at amortized cost.
The
derivative liabilities are stated at their fair value as a level 3 measurement. The Company used the Lattice Model to determine the fair
values of these derivative liabilities. See Note 12 for the Company's assumptions used in determining the fair value of these financial
instruments.
Convertible
notes payable
The
Company accounts for convertible notes payable in accordance with the FASB Accounting Standards Codification No. 815, Derivatives and
Hedging, since the conversion feature is not indexed to the Company's stock and can't be classified in equity. The Company
allocates the proceeds received from convertible notes payable between the liability component and conversion feature component. The
conversion feature that is considered embedded derivative liabilities has been recorded at their fair value as its fair value can be
separated from the convertible note and its conversion is independent of the underlying note value. The Company has also recorded the
resulting discount on debt related to the conversion feature and is amortizing the discount using the effective interest rate method
over the life of the debt instruments.
Derivative
liabilities
The
Company accounts for derivative liabilities in accordance with the FASB Accounting Standards Codification No. 815, Derivatives and Hedging
("ASC 815"). ASC 815 requires companies to recognize all derivative liabilities in the balance sheet at fair value, and marks
it to market at each reporting date with the resulting gains or losses shown in the Statement of Operations.
Management's
Estimates and Assumptions
The
preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates
and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date
of the financial statements, and the reported amounts of revenues and expenses. Actual results could differ from these estimates.
Concentration
and Risks
The
Company's operations are subject to risks including financial, operational, regulatory and other risks including the potential
risk of business failure.
For
the year ended December 31, 2021, the Company had no significant revenue from continuing or discounted operations which were derived
from a single or a few major customers.
F-
10
Table of Contents
Revenue
Recognition
The
Company generates its revenue from monthly membership subscriptions. Revenue is recognized at the time of delivery and includes a delivery
fee for each delivery or a subscription fee on a monthly basis for memberships. Under Accounting Standards Update ("ASU")
No. 2014-09 (Topic 606) "Revenue from Contracts with Customers", revenue from contracts with customers is measured based
on the consideration specified in the contract with the customer, and excludes any sales incentives and amounts collected on behalf of
third parties. A performance obligation is a promise in a contract to transfer a distinct good or service to a customer and is the unit
of account under Topic 606. The Company's contracts with its customers do not include multiple performance obligations. The Company
recognizes revenue when a performance obligation is satisfied by transferring control over a product or service to a customer. The amount
of revenue recognized reflects the consideration the Company expects to be entitled to in exchange for such products or services.
The
Company's subsidiaries, EPIQ MD, Inc. and ZipDoctor, Inc. both provide its customers with access to its telemedicine platform where
customers have unlimited access to start a doctor visit 24/7. The customers pay a flat fee per month for use of the platform and is not
dependent on the frequency of the doctor visits. Each doctor visit is included in the monthly subscription fee.
EPIQ
MD: The base monthly subscription fees range from $
24.95
-$
49.95
per month and is dependent on the number of family members included in
the plan. Customers can choose to add additional services, such as Epiq Paws and Epiq Lux, ranging from an additional $
4.95
-$
9.95
per
month.
The
customer gains immediate access to the telemedicine platform upon completing the enrollment process and making the first month's
payment, at which point the Company recognizes the revenue from that customer. Billing commences on the day that the customer is enrolled
for the Company's services and is continued to be billed on the calendar day of each calendar month, in accordance with the original
date of enrollment.
Customer's
may cancel their subscription at any time provided that they provide the Company with thirty (30) days advanced written notice of cancellation
with no cancellation fees charged to the customer. In the event a subscriber provides a notice of cancellation within the membership
period, the customer will be billed on their regular billing date at an amount adjusted to reflect an amount due until the cancellation
date.
For
avoidance of doubt,
if a subscriber is billed $29.95 on the 1st of the month and cancels on the 15th, the subscriber will be billed on
the 1st of the following month at a prorated rate through the 15th, or at a rate of $14.97
.
ZipDoctor,
Inc
: The base monthly subscription fees range from $
25.00
-$
45.00
per month and is dependent on the number of family members included
in the plan. The customer gains immediate access to the telemedicine platform upon completing the enrollment process and making the first
month's payment, at which point the Company recognizes the revenue from that customer. Billing commences on the day that the customer
is enrolled for the Company's services and is continued to be billed on the calendar day of each calendar month, in accordance
with the original date of enrollment.
Customer's
may cancel their subscription at any time provided that they provide the Company with thirty (30) days advanced written notice of cancellation
with no cancellation fees charged to the customer. In the event a subscriber provides a notice of cancellation within the membership
period, the customer will be billed on their regular billing date at an amount adjusted to reflect an amount due until the cancellation
date.
For
avoidance of doubt,
if a subscriber is billed $25.00 on the 1st of the month and cancels on the 15th, the subscriber will be billed on
the 1st of the following month at a prorated rate through the 15th, or at a rate of $12.50
.
LEGEND
NUTRITION – DISCONTINUED OPERATIONS
The
Company recognizes revenue in according with Accounting Standards Codification (ASC) Topic 606. The underlying principle is that the
Company recognize revenue to depict the transfer of promised goods and services to customers in an amount that they expect to be entitled
to in the exchange for goods and services provided.
The
Company's discontinued subsidiary, Legend Nutrition, Inc., operated a retail store in which it sold nutritional and wellness related
products. Legend's business was solely based on the sale of retail products and did not offer any non-tangible services.
F-
11
Table of Contents
Revenue
for the entire product sold was recognized when the customer purchased and had control of the product, even if the terms included a right
of return. Legend accounted for any discounts and concessions at the time of sale and accounted for returns and refunds when Legend received
the product back in its possession where in some instances, if the product was unused, would be returned to Legend's inventory
or, if used, would be discarded.
Costs
of revenue included the amounts that Legend paid its wholesalers and distributors and recognized the cost of revenue when the products
were sold and transferred to the possession of the customer. The cost of revenue was deducted from Legends open inventory balance upon
sale.
Stock
based compensation
The
Company recognizes compensation costs to employees under FASB Accounting Standards Codification 718 "Compensation - Stock Compensation"
("ASC 718"). Under ASC 718, companies are required to measure the compensation costs of share-based compensation arrangements
based on the grant-date fair value and recognize the costs in the financial statements over the period during which employees are required
to provide services. Share based compensation arrangements include stock options and warrants. As such, compensation cost is measured
on the date of grant at their fair value. Such compensation amounts, if any, are amortized over the respective vesting periods of the
option grant.
On
July 27, 2018, the inception date, the Company adopted ASU No. 2018-07 "Compensation - Stock Compensation (Topic 718): Improvements
to Nonemployee Share-Based Payment Accounting." These amendments expand the scope of Topic 718, Compensation - Stock Compensation
(which currently only includes share-based payments to employees) to include share-based payments issued to nonemployees for goods or
services. Consequently, the accounting for share-based payments to nonemployees and employees will be substantially aligned.
Income
Taxes
The
Company is a taxable entity and recognizes deferred tax assets and liabilities for the future tax consequences attributable to differences
between the financial statement carrying amounts of existing assets and liabilities and their respective tax basis. Deferred tax assets
and liabilities are measured using enacted tax rates expected to be in effect when the temporary differences reverse. The effect on the
deferred tax assets and liabilities of a change in tax rates is recognized in income in the year that includes the enactment date of
the rate change. A valuation allowance is used to reduce deferred tax assets to the amount that is more likely than not to be realized.
Related
Parties
The
Company follows subtopic 850-10 of the FASB Accounting Standards Codification for the identification of related parties and disclosure
of related party transactions.
Pursuant
to Section 850-10-20 the related parties include a. affiliates of the Company; b. Entities for which investments in their equity securities
would be required, absent the election of the fair value option under the Fair Value Option Subsection of Section 825–10–15,
to be accounted for by the equity method by the investing entity; c. trusts for the benefit of employees, such as pension and profit-sharing
trusts that are managed by or under the trusteeship of management; d. principal owners of the Company; e. management of the Company;
f. other parties with which the Company may deal if one party controls or can significantly influence the management or operating policies
of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests; and
g. Other parties that can significantly influence the management or operating policies of the transacting parties or that have an ownership
interest in one of the transacting parties and can significantly influence the other to an extent that one or more of the transacting
parties might be prevented from fully pursuing its own separate interests.
The
consolidated financial statements shall include disclosures of material related party transactions, other than compensation arrangements,
expense allowances, and other similar items in the ordinary course of business. However, disclosure of transactions that are eliminated
in the preparation of consolidated or combined financial statements is not required in those statements. The disclosures shall include:
a. the nature of the relationship(s) involved; b. a description of the transactions, including transactions to which no amounts or nominal
amounts were ascribed, for each of the periods for which income statements are presented, and such other information deemed necessary
to an understanding of the effects of the transactions on the financial statements; c. the dollar amounts of transactions for each of
the periods for which income statements are presented and the effects of any change in the method of establishing the terms from that
used in the preceding period; and d. amounts due from or to related parties as of the date of each balance sheet presented and, if not
otherwise apparent, the terms and manner of settlement. A material related party transaction has been identified in Note 11 in the financial
statements.
F-
12
Table of Contents
Recently
Issued Accounting Pronouncements
From
time to time, new accounting pronouncements are issued by the Financial Accounting Standard Board ("
FASB
") or other
standard setting bodies that are adopted by the Company as of the specified effective date. Unless otherwise discussed, the Company believes
that the effect of recently issued standards that are not yet effective will not have a material effect on its consolidated financial
position or results of operations upon adoption.
In
December 2019, the FASB issued ASU No. 2019-12, "Simplifying the Accounting for Income Taxes (Topic 740)". This standard
simplifies the accounting for income taxes. This standard is effective for fiscal years beginning after December 15, 2020, including
interim periods within those fiscal years. Early adoption is permitted for all entities. The Company adopted ASU 2019-12 effective on
January 1, 2021, and it did not have an effect on the Company's consolidated financial statements.
In
August 2020, the FASB issued ASU 2020-06,
"
Debt – Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives
and Hedging – Contracts in Entity's Own Equity (Subtopic 815 – 40)
"
("
ASU 2020-06
").
ASU 2020-06 simplifies the accounting for certain financial instruments with characteristics of liabilities and equity, including convertible
instruments and contracts on an entity's own equity. The ASU is part of the FASB's simplification initiative, which aims
to reduce unnecessary complexity in U.S. GAAP. The ASU's amendments are effective for fiscal years beginning after December 15,
2023, and interim periods within those fiscal years. The Company is currently evaluating the impact of ASU 2020-06 on its financial statements.
Note
2 –
Property and Equipment
Property
and equipment from continuing operations were as follows at December 31, 2021 and 2020:
December 31,
December 31,
2021
2020
Leasehold improvements
-
-
Furniture & fixtures
-
-
-
-
Less accumulated depreciation and amortization
-
-
Net property and equipment
$
-
$
-
Property
and equipment from discontinued operations were as follows at December 31, 2021 and 2020:
December 31,
December 31,
2021
2020
Leasehold improvements
$
4,262
$
4,262
Furniture & fixtures
18,830
29,902
Equipment
-
-
23,092
118,083
Less accumulated depreciation and amortization
8,823
10,422
Net property and equipment
$
14,199
$
107,661
As
a result of discontinued operations, the leasing equipment of $
67,336
was returned in the first quarter of 2021 and the related liabilities
were released.
F-
13
Table of Contents
Depreciation
and amortization expense from continuing operations for the years ended December 31, 2021 and 2020 was $
0
and
$
0
,
respectively. Depreciation and amortization expense from discontinued operations for the years ended December 31, 2021 and 2020 was $
8,823
and $
10,422
,
respectively.
Note
3 –
Asset Purchase Agreement
On
October 18, 2019, Legend Nutrition, Inc. ("Legend"), a wholly owned subsidiary of the Company entered into an Asset Purchase
Agreement with David Morales (the "Asset Purchase Agreement") to acquire all of the assets associated with and related to
a retail vitamin, supplements and nutrition store located in Mckinney, TX previously doing business as "Ideal Nutrition".
Pursuant to the Asset Purchase Agreement, Legend purchased a variety of assets including software, contracts, bank and merchant accounts,
products, inventory, computers, security systems and other intellectual properties (the "Assets"). For consideration of the
Assets, Legend issued to Mr. Morales a promissory note in the amount of Seventy-Five Thousand US Dollars ($
75,000
) bearing an interest
rate of five percent (
5
%) per annum and with a
maturity date of one year
(the "Promissory Note"). As of December 31, 2020,
the promissory note is fully converted. During 2021, the Company discontinued operation of Legend. The assets acquired pursuant to the
Asset Purchase Agreement, such as property and equipment of $
16,303
and goodwill of $
29,689
, have been fully impaired.
Note
4 –
Goodwill
As
of December 31, 2021, the goodwill in connection with the acquisition of the assets in October 2019 associated with and related to a
retail vitamin, supplements and nutrition store located in McKinney, Texas was $
0
.
Goodwill
is not amortized, but is evaluated for impairment annually or when indicators of a potential impairment are present. The annual evaluation
for impairment of goodwill is based on valuation models that incorporate assumptions and internal projections of expected future cash
flows and operating plans. The Company believes such assumptions are also comparable to those that would be used by other marketplace
participants. The Company determined impairment adjustment was necessary for the year ended December 31, 2020, since the goodwill was
not substantiating a future cash flow. Hence, goodwill of $
29,689
was impaired in full during the fourth quarter of 2020.
Note
5 –
Licensing Agreement
On
June 27
th
, 2019, the Company executed an exclusive license agreement with Novo MedSpa Addison Corp ("
Novo Medspa
")
providing the Company with the exclusive rights to the Novopelle brand and to establish new Novopelle branded MedSpa locations on a worldwide
basis (the "
Exclusive License
"). In consideration for the Exclusive License, the Company paid Novo MedSpa a one-time
cash payment of $
40,000
and issued to Novo MedSpa
250,000
shares of the Company's common stock. The
250,000
shares of the Company's
common stock were valued at $
0.10
per share or $
25,000
.
During
the fourth quarter of 2019, the Company opened a new MedSpa location and paid Novo MedSpa a one-time cash payment of $
30,000
as a new
location fee pursuant to the exclusive license agreement.
On
May 13, 2020, the Company provided Novo Medspa with notice to terminate the June 27, 2019 License Agreement in pursuit of the Company's
desire to establish and develop its own brand and have the flexibility to offer additional products and services that are not currently
available at Novopelle branded locations, which was effective immediately. Accordingly, the license of $
95,000
was impaired in full during
the second quarter of 2020.
Note
6 –
Other assets
On
May 15, 2020, the Company executed a securities purchase agreement with Global Career Networks Inc, a Delaware corporation (the "
Seller
"),
the
sole owner of Life Guru, pursuant to which the Company purchased from the Seller, a 51% interest in the capital stock of Life Guru, representing
an aggregate of 2,040 shares of Life Guru's common stock. LifeGuru owns and operates the LifeGuru.me website which is currently
in development and is anticipated to be fully launched in the second quarter of 2022. In consideration for the purchase,
the Company agreed to issue the Seller
500,000
shares of the Company's Series B Preferred Stock at closing, which occurred on May
15, 2020
. An additional up to
1,500,000
Series B Preferred Stock shares will be issuable
to the Seller upon the following milestones, provided that such milestones are met prior to the earlier of (i) one (1) year after closing;
and (ii) thirty (30) days after the Company has provided the Seller written notice of a breach by the Seller of any provision of the
SPA, which breach has not been reasonably cured within such thirty (30) day period (such earlier date of (i) and (ii), the "
Milestone
Termination Date
"):
(a)
500,000
Series B Preferred Stock shares upon completion of the fully operational LifeGuru.me website;
F-
14
Table of Contents
(b)
500,000
Series B Preferred Stock shares upon such time as 300 coaches have signed up at LifeGuru.me; and
(c)
500,000
Series B Preferred Stock shares upon such time as 1,000 coaches have signed up at LifeGuru.me.
The
fair value of
500,000
shares of the Company's Series B Preferred Stock issued at closing, valued on such grant date was $
605,488
,
which equaled the market price per common share on the grant multiplied by the equivalent number of common shares which would be issuable
upon conversion of Series B Preferred Stock.
The
Company did not recognize any liabilities related to the milestone shares due to the uncertainty surrounding such milestones.
The
51
% owned subsidiary is a consolidated entity which requires the presentation of noncontrolling interest in the consolidated statements
of operations for the year ended December 31, 2021. As there was no activity for the entity as of December 31, 2021, no assets, liabilities
or noncontrolling interest were presented at the period ended December 31, 2020. Since the asset is not substantiating a future cash
flow, the Company determined an impairment adjustment was necessary for the periods presented. Investment in LifeGuru of $
605,488
was
impaired in full during the fourth quarter of 2020.
During
the first quarter of 2021, the Company issued
500,000
Series B Preferred Stock shares for reaching
the first milestone (milestone (a)). The fair value of
500,000
shares of the Company's Series B Preferred
Stock issued at closing, valued on such grant date was $
601,852
,
which equaled the market price per common share on the grant multiplied by the equivalent number of common shares which would be issuable
upon conversion of Series B Preferred Stock. This amount was expensed as in process research and development.
The
Company did not recognize any liabilities related to the milestone shares due to the uncertainty surrounding such milestones.
Since
more than one year has elapsed since closing, the right of the Seller to earn the milestone shares set forth in (b) and (c) above
has expired.
Note
7 –
Capital lease
On
June 17, 2020, the Company entered into an agreement with a vendor to purchase equipment used in its spa operations. Pursuant to the
agreement, the Company agreed to pay a total amount of $
44,722
in 24 installments, or $
1,819
per month plus tax. The outstanding balance
of this capital lease was $
0
as of December 31, 2021. Due to the discontinued operation, the Company returned equipment in the first
quarter of 2021.
On
July 14, 2020, the Company entered into an agreement with a vendor to purchase equipment used in its spa operations. Pursuant to the
agreement, the Company agreed to pay a total amount of $
44,722
in 24 installments, or $
1,819
per month plus tax. The outstanding balance
of this capital lease was $
0
as of December 31, 2021. Due to the discontinued operation, the Company returned equipment in the first
quarter of 2021.
Note
8 –
Operating Right-of-Use Lease Liability
On
January 1, 2019, the Company adopted Accounting Standards Update No. 2016-2, Leases (Topic 842), as amended, which supersedes the lease
accounting guidance under Topic 840, and generally requires lessees to recognize operating and financing lease liabilities and corresponding
right-of-use (ROU) assets on the balance sheet and to provide enhanced disclosure surrounding the amount, timing and uncertainty of cash
flows arising from leasing arrangements.
F-
15
Table of Contents
As
of December 31, 2021, the Company had three (3) leasing agreements subject to Accounting Standards Codification (ASC) 842.
Location
1 – Capitol City Solutions USA, Inc.
On
January 1, 2020, the Company recognized an operating right-of-use asset in the amount of $
113,794
and an operating lease liability in the amount
of $
113,794
in connection with Location 1. The lease term
is sixty-one (
61
)
months and
expires
in January 2025
.
The
following is a schedule, by year, of maturities of lease liabilities as of December 31, 2021:
2022
27,288
2023
27,288
2024
27,288
2025
2,274
Total undiscounted cash flows
84,138
Less imputed interest (
8
%)
(
20,623
)
Present value of lease liability
$
63,515
On
March 9,
2022, Capitol City Solutions USA, Inc.
entered into a Release Agreement with its landlord for the leased premises located at 1043 Asher Way, Suite 300, Tyler, TX 75703 whereby
the landlord agreed to release CCS from its remaining obligations under the lease in exchange for a total of $
18,523
.
Total rental expense related to this location for the year ended December 31, 2021, was $
0
.
The operating lease right-of-use asset net balance on December 31, 2021, related to this location was $
0
,
which was impaired in full due to discontinued operations.
Location
2 – VISSIA Mckinney, LLC
On
January 1, 2019, the Company recognized an operating right-of-use asset in the amount of $
287,206
and an operating lease liability in
the amount of $
294,774
in connection with Location 1. The lease term is eighty-four (
84
) months and expires in November 2025.
The
following is a schedule, by year, of maturities of lease liabilities as of December 31, 2021:
2021
54,951
2022
55,854
2023
56,776
2024
57,715
2025
53,828
Total undiscounted cash flows
279,124
Less imputed interest (
8
%)
(
83,144
)
Present value of lease liability
$
195,980
On
September 5, 2021, Vissia Mckinney, LLC entered into a Release Agreement with its landlord for the leased premises located at 5000 Collin
Mckinney Parkway, Mckinney, Texas 75070 whereby the landlord agreed to release Vissia Mckinney from its remaining obligations under the
lease in exchange for a total of $
22,500
, of which $
10,000
was paid to the landlord with furniture and fixtures located at the property
and the remaining $
12,500
was paid in full with cash. Total rental expense related to this location for the year ended December 31, 2021,
was $
0
. The operating lease right-of-use asset net balance on December 31, 2021, related to this location was $
0
, which was impaired
in full due to discontinued operations.
Location
3 – VISSIA Waterway, Inc.
On
January 1, 2020, the Company recognized an operating right-of-use asset in the amount of $
234,485
and an operating lease liability in
the amount of $
234,485
in connection with Location 2. The lease term is sixty (
60
) months and expires in December 2024.
The
following is a schedule, by year, of maturities of lease liabilities as of December 31, 2020:
2021
55,540
2022
57,206
2023
58,922
2024
60,690
Total undiscounted cash flows
232,358
Less imputed interest (
8
%)
(
49,529
)
Present value of lease liability
$
182,829
On
December 31, 2021, Vissia Waterway, LLC entered into a Release Agreement with its landlord for the leased premises located at 25 Waterway
Avenue, The Woodlands, Montgomery County, Texas whereby the landlord agreed to release Vissia Waterway from its remaining obligations
under the lease in exchange for a total of $
88,679
. Total rental expense related to this location for the year ended December 31, 2021,
was $
0
. The operating lease right-of-use asset net balance on December 31, 2021, related to this location was $
0
, which was impaired
in full due to discontinued operations.
Note
9 –
Accrued Compensation for Related Parties
At
December 31, 2021, accrued compensation was $
103,500
, representing $
53,500
owed to Jacob Cohen, the Company's CEO and $
25,000
owed
to each of Alan Hernandez and Esteban Alexander, the Company's former officers and directors.
F-
16
Table of Contents
Note
10 –
Notes Payable
Notes
payable represents the following at December 31, 2021:
Note payable to an individual dated July 8, 2019 for $
40,000
, with interest at
8
% per annum and due on
July 8, 2020
. The Note is currently past due.
$
40,000
Note payable dated July 7, 2020 for $
50,000
, with interest at
5
% per annum and due on
July 7, 2021
. The Note is unsecured. The Note is currently past due.
50,000
Note payable of $
53,000
dated August 5, 2020 for cash of $
53,000
, with interest at
8
% per annum and due on
November 5, 2021
. The annual interest rate will increase to
22
% if in default. The Note is a convertible promissory note. The conversion price equals
61
% of the lowest daily volume weighted average price (VWAP) for the common stock during the ten (
10
) trading day period prior to the conversion date, representing a discount rate of
39
%. The note, accrued interest and early payment penalty totaling $
70,736
was paid during the three months ended March 31, 2021.
53,000
Less: Repayment
(
53,000
)
-
Note payable of $
105,000
dated August 11, 2020 for cash of $
100,000
, net of original issue discount of $
5,000
, with one-time interest charge of
8
% payable and due on May 11, 2021. The outstanding balance of the Note will be increase by
135
% if in default. The Note is a convertible promissory note. The conversion price equals the lower of $
0.50
per share or
60
% of the lowest daily volume weighted average price (VWAP) for the common stock during the ten (
10
) trading day period prior to the conversion date, representing a discount rate of
40
%. The note and accrued interest totaling $
111,466
was settled by the issuance of
708,750
common shares of the Company and $
50,000
in cash. The note and accrued interest were converted at $
0.1614
per share and settled with additional shares valued at $
0.45
per shares. Accordingly, the Company recorded a loss on loan settlement of $
58,059
during the three months ended March 31, 2021.
$
105,000
Less: Repayment
(
105,000
)
-
Note payable of $
53,000
dated September 14, 2020 for cash of $
53,000
, with interest at
8
% per annum and due on
December 14, 2021
. The annual interest rate will increase to
22
% if in default. The Note is a convertible promissory note. The conversion price equals
61
% of the lowest daily volume weighted average price (VWAP) for the common stock during the ten (
10
) trading day period prior to the conversion date, representing a discount rate of
39
%. The note, accrued interest and early payment penalty totaling $
70,736
was paid during the three months ended March 31, 2021.
$
53,000
Less: Repayment
(
53,000
)
-
Note payable to an unrelated party dated September 11, 2020 for $
4,000
, with no interest and due on demand.
$
4,000
Note payable to an unrelated party dated September 16, 2020 for $
5,000
, with no interest and due on demand.
$
5,000
Note payable of $
56,750
dated October 12, 2020, for cash of $
52,750
, with interest at
8
% per annum and due on
October 12, 2021
. The annual interest rate will increase to
24
% if in default. The Note is a convertible promissory note. The conversion price equals the lessor of $
0.50
per share or
60
% of the lowest daily volume weighted average price (VWAP) for the common stock during the ten (
10
) trading day period prior to the conversion date, representing a discount rate of
40
%. The Note and accrued interest totaling $
56,750
was converted into
760,928
common shares of the Company within the terms of the note during the quarter ended June 30, 2021.
$
56,750
Less: Repayment
(
56,750
)
-
Note payable of $
138,00
dated November 13, 2020 for cash of $
138,000
, with interest at
8
% per annum and due on
November 13, 2021
. The annual interest rate will increase to
18
% if in default. The Note is a convertible promissory note. The conversion price equals
61
% of the lowest daily volume weighted average price (VWAP) for the common stock during the ten (
10
) trading day period prior to the conversion date, representing a discount rate of
39
%. The note, accrued interest and early payment penalty totaling $
183,483
was paid during the three months ended March 31, 2021.
$
138,000
Less: Repayment
(
138,000
)
-
Note payable of $
83,500
dated December 2, 2020 for cash of $
83,500
, with interest at
8
% per annum and due on
March 2, 2022
. The annual interest rate will increase to
22
% if in default. The Note is a convertible promissory note. The conversion price equals
61
% of the lowest daily volume weighted average price (VWAP) for the common stock during the ten (
10
) trading day period prior to the conversion date, representing a discount rate of
39
%. The note, accrued interest and early payment penalty totaling $
104,527
was paid during the three months ended March 31, 2021.
$
83,500
Less: Repayment
(
83,500
)
-
Note payable of $
425,000
dated January 6, 2021 for cash of $
400,000
, with interest at
6
% per annum and due on
January 7, 2022
. The annual interest rate will increase to
15
% if in default. The Note is a convertible promissory note. The conversion price equals the lessor of $
0.50
or
75
% of the lowest daily volume weighted average price (VWAP) for the common stock during the seven (
7
) trading day period prior to the conversion date, representing a discount rate of
25
%. The note and accrued interest totaling $
437,359
was converted into
2,549,999
common shares of the Company within the terms of the note during the quarter ended June 30, 2021.
$
425,000
Less: Conversion
(
425,000
)
-
Note payable of $
425,000
dated January 6, 2021 for cash of $
400,000
, with interest at
6
% per annum and due on
January 7, 2022
. The annual interest rate will increase to
15
% if in default. The Note is a convertible promissory note. The conversion price equals the lessor of $
0.50
or
75
% of the lowest daily volume weighted average price (VWAP) for the common stock during the seven (
7
) trading day period prior to the conversion date, representing a discount rate of
25
%. The note and accrued interest totaling $
437,297
was converted into
3,220,515
common shares of the Company within the terms of the note during the quarter ended June 30, 2021.
$
425,000
Less: Conversion
(
425,000
)
-
Note payable of $
300,000
dated March 30, 2021 for cash of $
282,000
, with interest at
6
% per annum
    and due on
March 30, 2022
. The annual interest rate will increase to
15
% if in default. The Note is a convertible promissory note.
    The conversion price equals the lessor of $
0.2437
or
75
% of the lowest daily volume weighted average price (VWAP) for the common
    stock during the seven (
7
) trading day period prior to the conversion date, representing a discount rate of
25
%.
$
300,000
Note payable of $
300,000
dated March 30, 2021 for cash of $
282,000
, with interest at
6
% per annum
    and due on
March 30, 2022
. The annual interest rate will increase to
15
% if in default. The Note is a convertible promissory note.
    The conversion price equals the lessor of $
0.2437
or
75
% of the lowest daily volume weighted average price (VWAP) for the common
    stock during the seven (
7
) trading day period prior to the conversion date, representing a discount rate of
25
%. A partial conversion
    of the Note and accrued interest totaling $
51,116
was converted into
881,310
common shares of the Company within the terms of the
    note during the quarter ended September 30, 2021.
$
300,000
Less: Conversion
(
50,000
)
250,000
Note payable of $
265,958
dated June 24, 2021 for cash of $
250,000
, with interest at
6
% per annum
    and due on
June 24, 2022
. The annual interest rate will increase to
15
% if in default. The Note is a convertible promissory note.
    The conversion price equals the lessor of $
0.2437
or
75
% of the lowest daily volume weighted average price (VWAP) for the common
    stock during the seven (
7
) trading day period prior to the conversion date, representing a discount rate of
25
%.A partial conversion
    of the Note totaling $
118,668
was converted into
2,390,000
common shares of the Company within the terms of the note during the quarter
    ended September 30, 2021 and fourth quarter ended December 31, 2021.
$
265,958
Less: Conversion
(
118,668
)
147,290
Note payable of $
271,958
dated June 24, 2021 for cash of $
256,000
, with interest at
6
% per annum
    and due on
June 24, 2022
. The annual interest rate will increase to
15
% if in default. The Note is a convertible promissory note.
    The conversion price equals the lessor of $
0.2437
or
75
% of the lowest daily volume weighted average price (VWAP) for the common
    stock during the seven (
7
) trading day period prior to the conversion date, representing a discount rate of
25
%. A partial conversion
    of the Note and accrued interest totaling $
140,000
was converted into
2,742,419
common shares of the Company within the terms of
    the note during the quarter ended September 30, 2021 and fourth quarter ended December 31, 2021.
$
271,958
Less: Conversion
(
133,806
)
138,152
As of December 31, 2021 the Company had a short-term Advance payable in amount of $
50,000
to a unrelated party, with no interest and due on demand.
$
50,000
Less: Repayment
(
50,000
)
-
Note payable of $
750,000
dated November 22, 2021 for cash of $
750,000
, with interest at
10
% per annum and due on
June 24, 2022
. The annual interest rate will increase to
16
% or the maximum amount permitted by law if in default. The Note is a convertible promissory note. The conversion price equals the lessor of $
0.075
or
80
% of the offering price per share of Common Stock at which the Company offers shares of Common Stock in a public offering which results in the Common Stock being uplisted on a national stock exchange or Nasdaq, that occurs within 220 days from the date the Notes are issued (an "Uplist Offering").
$
750,000
Note payable of $
500,000
dated November 30, 2021 for cash of $
500,000
, with interest at
10
% per annum and due on
November 30, 2022
. The annual interest rate will increase to
16
% or the maximum amount permitted by law if in default. The Note is a convertible promissory note. The conversion price equals the lessor of $
0.075
or
80
% of the offering price per share of Common Stock at which the Uplist Offering is made.
$
500,000
Note payable of $
250,000
dated December 1, 2021 for cash of $
250,000
, with interest at
10
% per annum and due on
December 1, 2022
. The annual interest rate will increase to
16
% or the maximum amount permitted by law if in default. The Note is a convertible promissory note. The conversion price equals the lessor of $
0.075
or
80
% of the offering price per share of Common Stock at which the Uplist Offering is made.
$
250,000
Note payable of $
500,000
dated December 2, 2021 for cash of $
5000,000
, with interest at
10
% per annum and due on
December 2, 2022
. The annual interest rate will increase to
16
% or the maximum amount permitted by law if in default. The Note is a convertible promissory note. The conversion price equals the lessor of $
0.075
or
80
% of the offering price per share of Common Stock at which the Uplist Offering is made.
$
500,000
As of December 31, 2021 the Company had a short-term Advance payable in amount of $
20,000
to a unrelated party, with no interest and due on demand.
$
20,000
$
2,950,442
Less: unamortized discount
(
2,479,023
)
Total
$
471,419
Short term convertible notes, net of discount of $
2,479,023
$
396,419
Long-term convertible notes, net of discount of $
0
$
0
Short-term non-convertible notes – continuing operations
$
75,000
Short-term non-convertible notes – discontinued operations
$
4,000
Long-term non-convertible notes
$
0
F-
17
Table of Contents
Note
11 –
Loans from Related Parties
On April 12, 2019, the Company entered into individual share exchange agreements and promissory notes with each of Daniel Dror, Winfred Fields and former Directors Everett Bassie and Charles Zeller (the "
AMIH Shareholders
"), whereby the AMIH Shareholders agreed to cancel and exchange a total of
5,900,000
shares of their AMIH common stock. The Company issued individual promissory notes with an aggregate principal amount of $
350,000
(the "
Promissory Notes
") for cancellation of the
5,900,000
common shares. The Promissory Notes have a term of two years and accrue interest at the rate of
10
% per annum until paid in full by the Company. The Company recorded interest of $
7,506
on these notes during the year ended December 31, 2020. The accrued interest on these notes was $
18,982
as of December 31, 2020. The Note and accrued interest totaling $
280,108
was settled by the issuance of
3,476,495
common shares of the Company. The shares were valued at $
0.31
and $
0.27
per share based on the market price at the settlement date. Accordingly, the Company recorded a loss on loan settlement of $
758,601
during the year ended December 31, 2020.
$
350,000
Less: Conversion
(
240,000
)
110,000
As of December 31, 2021, the Company had a short-term note payable in the amount of $
13,473
to Kemah Development Texas, LP, a company owned by Dror Family Trust, a related party.
13,473
As of December 31, 2021, outstanding loan balances payable to the Company's CEO and board member, Jacob Cohen, were $
50
with no interest and due on demand
50
$
123,523
Less: unamortized discount
0
Total
$
123,523
Long-term loan from related parties
$
0
Short-term loan from related parties – continuing operations
$
123,473
Short-term loan from related parties – discontinued operations
$
50
F-
18
Table of Contents
Note
12–
Derivative Liabilities
Notes
that are convertible at a discount to market are considered embedded derivatives.
Under
Financial Accounting Standard Board ("
FASB
"), U.S. GAAP, Accounting Standards Codification, "
Derivatives
and Hedging
", ASC Topic 815 ("
ASC 815
") requires that all derivative financial instruments be recorded on
the balance sheet at fair value. Fair values for exchange traded securities and derivatives are based on quoted market prices. Where
market prices are not readily available, fair values are determined using market-based pricing models incorporating readily observable
market data and requiring judgment and estimates.
The
Company's convertible note has been evaluated with respect to the terms and conditions of the conversion features contained in
the note to determine whether they represent embedded or freestanding derivative instruments under the provisions of ASC 815. The Company
determined that the conversion features contained in the notes totaled $
1,575,083
and represent a freestanding derivative instrument
that meets the requirements for liability classification under ASC 815. As a result, the fair value of the derivative financial instrument
in the note is reflected in the Company's balance sheet as a liability. The fair value of the derivative financial instrument of
the convertible note was measured using the Lattice Model at the inception date of the note and will do so again on each subsequent balance
sheet date. Any changes in the fair value of the derivative financial instruments are recorded as non-operating, non-cash income or expense
at each balance sheet date. The derivative liabilities will be reclassified into additional paid in capital upon conversion.
The
Convertible Note derivatives were valued as of December 31, 2020, at issuance, at conversion and at December 31, 2021 as set forth in
the table below.
Derivative liabilities as of December 31, 2020
$
517,366
Initial derivative liabilities at new note issuance
7,209,723
Initial loss
(
0
)
Conversion
(
1,116,124
)
Mark to market changes
(
2,469,693
)
Derivative liabilities as of December 31, 2021
$
4,141,272
As
of December 31, 2021, the Company had derivative liabilities of $
4,141,272
, and recorded changes in derivative liabilities in the amount
of $
1,171,028
during the year ended December 31, 2021.
F-
19
Table of Contents
The
following assumptions were used for the valuation of the derivative liability related to the Notes:
-
The
    stock price would fluctuate with the Company's projected volatility;
-
The
    projected volatility curve from an annualized analysis for each valuation period was based on the historical volatility of the Company
    and the term remaining for each note ranged from
116
% through
206
% at issuance, conversion, and quarters ends;
-
The
    Company would not redeem the notes;
-
An
    event of default adjusting the interest rate would occur initially 0% of the time for all notes with increases 1% per month to a
    maximum of 10% with the corresponding penalty
;
-
The
    Company would raise capital quarterly at market, which could trigger a reset event; and
-
The
    Holder would convert the note monthly if the Company was not in default.
The
following assumptions were used for the valuation of the warrant derivative liability related to the Notes:
-
The
    stock price would fluctuate with the Company's projected volatility;
-
The
    projected volatility curve from an annualized analysis for each valuation period was based on the historical volatility of the Company
    and the term remaining for each note ranged from
166
% through
166.9
% at issuance, conversion, and quarters ends.
-
The
    Warrants with the fixed $
0.20
, $
0.35
, and $
0.50
exercise prices are subject to full ratchet reset provisions;
-
The
    Company would raise capital quarterly at market, which could trigger a reset event;
-
The
    cash flows are discounted to net present values using risk free rates; discount rates were based on risk free rates in effect based
    on the remaining term.
-
The
    occurrence of a fundamental transaction by a public company was estimated at 2.5% after 2.5 years and 5% prior to maturity; and
-
The
    Holder would hold the warrant to maturity (
5
-year terms) at which point it could exercise the warrant if the warrant were in the
    money.
Note
13 –
Income Taxes
The
Company has current net operating loss carryforwards in excess of $
20,540,569
as of December 31, 2021, to offset future taxable income,
which expire beginning
2029
.
Deferred
taxes are determined based on the temporary differences between the financial statement and income tax bases of assets and liabilities
as measured by the enacted tax rates, which will be in effect when these differences reverse. The components of deferred income tax assets
are as follows:
December 31, 2021
Deferred Tax Asset:
Net Operating Loss
$
9,980,911
Valuation Allowance
(
9,980,911
)
Net Deferred Asset
$
—
At
December 31, 2021, the Company provided a
100
% valuation allowance for the deferred tax asset because it could not be determined whether
it was more likely than not that the deferred tax asset/(liability) would be realized.
Note
14 –
Capital Stock
Preferred
Stock
The
Company is authorized to issue up to
5,000,000
shares of preferred stock, $
0.0001
par value, of which three shares were designated as
Series A Preferred Stock and
2,000,000
were designated as Series B Preferred stock, the balance of
2,999,997
shares of preferred stock
were undesignated as of December 31, 2021.
F-
20
Table of Contents
The
holders of Series A Preferred Stock have no dividend rights, liquidation preference and conversion rights. As long as any shares of Series
A Preferred Stock remain issued and outstanding, the holders of Series A Preferred Stock have the right to vote on all shareholder matters
equal to sixty percent (60%) of the total vote. At the option of the Company, Series A Preferred Stock is redeemable at $
1.00
per share.
The
holders of Series B Preferred Stock have the same dividend rights as common stockholders on a fully converted basis, are entitled to
receive pari passu with any distribution of any of the assets of the Company to the holders of the Company's common stock, but
not prior to any holders of senior securities. Each share of Series B Preferred Stock may be converted, at the option of the holder thereof,
into that number of shares of common stock of the Company as equals $1.00 divided by 90% of the average of the volume weighted average
prices ("
VWAP
") of the Company's common stock, for the five trading days immediately preceding the date the
notice of conversion is received, subject to the limit of 4.999% of the Company's outstanding shares of common stock. The holders
of Series B Preferred Stock have no voting rights.
On
May 15, 2020, the Company entered into a Securities Purchase Agreement with GCN as described in greater detail in "Note 1 Summary
of Significant Account Policies – Organization, Ownership and Business". Pursuant to the SPA, the Company acquired a 51%
interest in Life Guru from GCN in consideration for
500,000
shares of Series B Convertible Preferred Stock, which had an agreed upon
value of $
500,000
($
1.00
per share), and agreed to issue GCN up to an additional
1,500,000
shares of Series B Convertible Preferred Stock
(with an agreed upon value of $
1,500,000
) upon reaching certain milestones. The fair value of the first
500,000
shares of the Company's
Series B Preferred Stock at grant date was $
605,488
, a result of market price per common share at the grant date times the equivalent
number of common shares after the conversion of Series B Preferred Stock. Such
500,000
initial shares of Series B Preferred Stock were
subsequently converted to common stock in June 2020, as discussed below.
On
May 20, 2020, the Company issued one share of its newly designated shares of Series A Preferred Stock to each of the three members of
its then Board of Directors, (1) Jacob D. Cohen, (2) Esteban Alexander and (3) Luis Alan Hernandez, in consideration for services rendered
to the Company as members of the Board of Directors. Such shares of Series A Preferred Stock vote in aggregate sixty percent (60%) of
the total vote on all shareholder matters, voting separately as a class. Notwithstanding such voting rights, no change in control of
the Company was deemed to have occurred in connection with the issuance since Messrs. Cohen, Alexander and Hernandez, own in aggregate
68% of the Company's outstanding common stock and therefore controlled the Company prior to such issuance
. The shares of Series
A Preferred Stock held by Mr. Alexander and Mr. Hernandez were cancelled on November 6, 2020 pursuant to the Stock Purchase Agreements
dated October 2, 2020, and as such, a change of control occurred on such date, with Mr. Cohen taking over voting control of the Company,
and serving between December 15, 2020 and October 19, 2021, as the sole officer and director of the Company.
During the first quarter of 2021, the Company
issued
500,000
Series B Preferred Stock shares for reaching the first milestone (milestone (a)). The fair value of
500,000
shares of
the Company's Series B Preferred Stock issued at closing, valued on such grant date was $
601,852
, which equaled the market price
per common share on the grant multiplied by the equivalent number of common shares which would be issuable upon conversion of Series
B Preferred Stock. This amount was expensed as in process research and development. The shareholder then elected to convert the Series
B Preferred Stock to
2,057,613
shares of common stock.
As
of December 31, 2021 and December 31, 2020, there was
one
share of Series A Preferred Stock and
no
shares of Series B Preferred Stock
issued and outstanding.
Common
Stock
The
Company is authorized to issue up to
195,000,000
shares of common stock, $
0.0001
par value, of which
84,445,067
shares were issued and
outstanding at December 31, 2021 and
55,066,855
were issued and outstanding at December 31, 2020.
On
January 12, 2021, the Company issued
708,750
common shares and paid $
50,000
to settle a note with an unrelated party, dated August 11,
2020, under the terms and conditions of convertible notes as issued. The Company recorded a loss on loan settlement of $
58,059
.
On
February 2, 2021, the Company issued
200,000
shares of the Company's common stock to a non-related third-party investor in exchange
for $
100,000
in cash.
In
the first quarter of 2021, the Company issued
11,800,000
shares of the Company's common stock in consideration for services performed
by employees and non-employee consultants. The shares were valued at $
4,223,390
based on the market price on the date of agreements.
F-
21
Table of Contents
In
the first quarter of 2021, the Company issued
2,730,548
common shares to investors in exchange for $
502,050
of principal and accrued
interest owed under the terms and conditions of convertible notes as issued.
In
the first quarter of 2021, the Company issued
500,000
shares of Series B Preferred Shares to a third party for services related to research
and development. The shares were subsequently converted into
2,057,613
shares of common stock. The shares were valued at $
601,582
,
under the terms and conditions of agreement.
In
the second quarter of 2021, the Company issued
3,800,894
common shares to investors in exchange for $
416,636
of principal and accrued
interest owed under the terms and conditions of convertible notes as issued.
In
the third quarter of 2021, the Company issued
915,000
shares of the Company's common stock in consideration for services performed
by employees and non-employee consultants. The shares were valued at $
68,609
based on the market price on the date of agreements.
In
the third quarter of 2021, the Company issued
3,049,304
common shares to investors in exchange for $
156,204
of principal and accrued
interest owed under the terms and conditions of convertible notes outstanding.
In
the fourth quarter, the Company issued
1,151,678
shares of the Company's common stock in consideration for services performed by
employees and non-employee consultants. The shares were valued at $
92,293
based on the market price on the date of agreements.
In
the fourth quarter of 2021, the Company issued
2,964,425
common shares to investors in exchange for $
153,580
of principal and accrued
interest owed under the terms and conditions of convertible notes outstanding.
Note
15 –
Going Concern
These
consolidated financial statements have been prepared assuming that the Company will continue as a going concern, which contemplates the
realization of assets and the discharge of liabilities in the normal course of business for the foreseeable future.
As
reflected in the accompanying financial statements, the Company has a net loss from continuing operation of $
10,225,497
and $
6,460,653
for the year ended December 31, 2021 and 2020 respectively, a gain of $
244,586
and a net loss from discontinued operation of $
879,237
for the year ended December 31, 2021 and 2020 respectively, and an accumulated deficit of $
20,540,569
as of December 31, 2021. The ability to continue as a going concern is dependent upon the Company generating profitable operations
in the future and/or to obtain the necessary financing to meet its obligations and repay its liabilities arising from normal
business operations when they come due. These financials do not include any adjustments relating to the recoverability and
reclassification of recorded asset amounts, or amounts and classifications of liabilities that might result from this uncertainty.
There can be no assurance that the Company will become commercially viable without additional financing, the availability and terms
of which are uncertain. If the Company cannot secure necessary capital when needed on commercially reasonable terms, its business,
condition (financial and otherwise) and commercial viability may be harmed. Although management believes that it will be able to
successfully execute its business plan, which includes third party financing and the raising of capital to meet the Company's
future liquidity needs, there can be no assurances in this regard. These matters raise substantial doubt about the Company's
ability to continue as a going concern.
Note
16 –
Commitments and Contingencies
In
the ordinary course of business, the Company may become a party to lawsuits involving various matters. The impact and outcome of litigation,
if any, is subject to inherent uncertainties, and an adverse result in these or other matters may arise from time to time that may harm
its business. The Company believes the ultimate resolution of any such current proceeding will not have a material adverse effect on
our continued financial position, results of operations or cash flows.
F-
22
Table of Contents
On
October 14, 2019, Robert Holden, the Company's former CEO, filed a Petition and Application for Temporary Restraining Order in
the District Court, 152
nd
Judicial District of Harris County, Texas, against the Company stating that the Company is blocking
Mr. Holden's legal right to trade his shares in the open market and further attempting to stake his claim that he maintains his
rights to the
3,800,000
shares he received in connection with his acceptance as CEO of the Company on or around May 31, 2018. The Company
is maintaining the position that Mr. Holden does not have the right to those shares as he was in breach of his obligation to convey a
digital marketing business to the Company and subsequently resigned from the Company shortly thereafter, on or around August 15, 2018
and that he procured the shares through fraud. On November 11, 2019, the Company issued a response with a Motion to Dismiss Under the
Texas Citizen's Participation Act (TCPA) citing that any declaratory judgment and breach of contract claims be dismissed unless
Mr. Holden can, through "
clear and specific evidence
", establish a prima facie case for each essential element of
his claims. After an attempt to remand the case to federal court, the Company filed an amended notice of submission for its TCPA motion
for submission on May 18, 2020, whereby Holden failed to respond to the motion in a timely manner. On May 18, 2020, the Company filed
a response in support of its motion to dismiss under the TCPA, which was denied on June 3, 2020. Immediately thereafter, on June 4, 2020,
the Company filed a notice of accelerated interlocutory appeal to appeal the denial of the motion to dismiss under the TCPA and the trial
court's failure to rule on the Company's objection to the timeliness of Holden's response. The outcome of this action,
and the ultimate outcome of the lawsuit is currently unknown at this time, provided that the Company intends to vehemently defend itself
against the claims made in the lawsuit.
AMIH
vs. Winfred Fields
On
November 11, 2019, the Company filed an Original Petition and Jury Demand in the 458
th
Judicial District Court of Fort Bend
County, Texas against Winfred Fields, a shareholder, in the 458
th
Judicial District Court of Fort Bend County seeking damages
related to breach of contract and fraud related charges. The Company executed an exchange agreement with Mr. Fields on or around April
12, 2019 whereby Mr. Fields was required to tender to the Company a total of
650,000
of the
750,000
shares of the Company's common
stock that Mr. Fields then owned (the "
Exchanged Shares
") in exchange for a promissory note with a maturity date of
April 12, 2021 payable in the amount of $
42,500
(the "
Fields Note
") (see also "Note 11 – Loans from Related
Parties"). The Exchange Agreement required that Mr. Fields immediately return the stock certificates for the Exchanged Shares to
the Company or its designated agent for immediate cancellation and for Mr. Fields to retain the remaining
100,000
shares. Mr. Fields
agreed in the Exchange Agreement that these shares would not become unrestricted until such time as Mr. Fields received an opinion of
counsel satisfactory to the Company that the shares were not restricted for trade under SEC regulations. After executing the Exchange
Agreement, Mr. Fields—rather than return the Exchanged Shares or obtain said opinion of counsel—attempted to deposit and
trade the Exchanged Shares and the restricted shares, which was a direct violation of the Exchange Agreement. The Company asserts that
Mr. Fields knowingly, willingly and fraudulently attempted to deposit and trade the Exchanged Shares and is seeking damages and equitable
relief. Upon several attempts to serve Mr. Fields, service was perfected on or around February 3, 2020. On March 2, 2020, Mr. Fields
filed a response generally denying all claims. On May 22, 2020, the Company filed its first request for production and request for disclosure
and discovery insisting that Mr. Fields produce all documentation related to the fraudulent transaction and is awaiting a response to
these requested discovery items. The outcome of this action is currently unknown at this time. In November 2019, the Company recovered
650,000
shares from Mr. Fields which were cancelled in 2019.
Asher
Park, LLC vs. Novopelle Tyler
On
August 11, 2021, Asher Park, LLC ("Asher Park") filed a petition against the Company and its subsidiary, Novopelle Tyler,
Inc. ("Novopelle Tyler") in the 241
st
Judicial District Court of Smith County, Texas seeking to recover damages
in the amount of $
66,651
against that commercial lease and commercial lease guaranty agreement that was signed between the parties on
or around January 8, 2020 to occupy retail premises located at 1058 Asher Way, Suite 100, in Tyler, Texas. As this commercial lease was
executed prior to the COVID-19 pandemic, and due to the uncertainty of the effects on retail establishments during the pandemic, Novopelle
Tyler never officially took possession of the retail premise. On September 23, 2021, the Company and Novopelle Tyler filed an Original
Answer and Affirmative Defense denying the allegations made by Asher Park.
On
January 26, 2022, Novopelle Tyler and the Company entered into a Settlement Agreement & Mutual Release with Asher Park whereby Novopelle
Tyler and the Company agreed to pay Asher Park a total of $
35,000
in full and final settlement of all of the Asher
Park's claims. Accordingly, Asher Park, in consideration for the execution of the Settlement Agreement agreed to dismiss the lawsuit
against both Novopelle Tyler and the Company.
F-
23
Table of Contents
Stanley Tate d/b/a Triangle Cabinets vs. Capitol
City Solutions USA, Inc.
On September 10, 2021, Stanley Tate d/b/a Triangle
Cabinets ("Tate"), a materials supplier and subcontractor that was hired by the Company's subsidiary, Capitol City Solutions
USA, Inc. (CCS), filed a petition against the Company, CCS, and CCS's construction client, PC Gateway, LLC ("PC Gateway")
in the 136
th
Judicial District Court of Jefferson County, Texas seeking payment in the amount of $
77,681
for services Tate
claimed to provide CCS and PC Gateway. The Company and CCS were not officially served until on or around October 21, 2021. On October
25, 2021, the Company and CCS filed an Original Answer denying the allegations made by Tate as Tate had failed to provide the services
in which they were hired to perform and demanding strict proof by a preponderance of credible evidence.
On December 29, 2021, Tate dismissed all claims against
both the Company and CCS.
Capitol City Solutions USA, Inc. vs. Peak Living,
LLC and PC Gateway, LLC
On November 1, 2021, the Company's subsidiary,
Capitol City Solutions USA, Inc. (CCS), filed a petition against PC Gateway and Peak Living, LLC ("Peak Living") in the 58
th
Judicial District Court of Jefferson County Texas demanding the payment of the final invoice as delivered to Peak Living in the
amount of $
2,069,908
representing the balance as owed to CCS for substantial supplemental charges (including but not limited to dehumidifiers, various
material cost and labor increases, code compliance costs, and additional profit and overhead). Throughout the term of a project completed
by CCS for Peak Living, Peak Living instructed CCS to perform additional work beyond the original scope of the contracted agreement and
fully understood that CCS expected to be compensated at the fair market value for the additional labor and materials. In addition to
seeking actual and statutory damages, CCS is seeking to recover attorney's fees, prejudgment and post judgement interest, costs
of court and has further placed a constitutional lien on the PC Gateway property, known as Gateway Village, located at 2825 12th Street,
Beaumont, Texas, 77705 and which is the subject of the lawsuit. CCS is currently reviewing and evaluating all of the discovery
items received from Peak in connection with the lawsuit.
Note 17 –
Discontinued Operations
During 2020 and 2021, the Company decided to discontinue
the operation of its VISSIA McKinney, VISSIA Waterway, Legend Nutrition and Capitol City Solutions USA, Inc. VISSIA McKinney, VISSIA Waterway,
Legend Nutrition and Capitol City Solutions have been presented as discontinued operations in the accompanying consolidated financial
statements. The operating results for VISSIA McKinney, VISSIA Waterway, Legend Nutrition and Capitol City Solutions have been presented
in the accompanying consolidated statement of operations for the years ended December 31, 2021 and December 31, 2020 as discontinued operations
and are summarized below:
The Years Ended
December 31,
2021
2020
Revenue
$
2,530
$
6,107,106
Cost of revenue
-
5,058,373
Gross profit
2,530
1,048,813
Operating expenses
57,659
1,205,993
Loss from operations
(
55,130
)
(
157,180
)
Other income (expenses)
299,716
(
722,057
)
Net loss
$
244,586
$
(
879,237
)
Note 18 –
Subsequent Events
On January 5, 2022, the Company
issued
1,200,000
shares of common stock to a note holder in exchange for $
50,688
of principal and accrued interest owed under the terms
and conditions of the
6
%
convertible promissory note as issued to FirstFire Global, dated June 24, 2021.
On January 6, 2022, the Company issued
710,227
common
shares to a note holder in exchange for $
30,000
of principal owed under the terms and conditions of that
6
% convertible promissory note
as issued to Quick Capital, LLC, dated June 24, 2021.
On January 12, 2022, the Company issued an award of
5,000,000
restricted shares of the Company's common stock as a signing bonus in consideration of Mr. Cohen entering into the New
Employment Agreement.
On January 27, 2022, the
Company issued
1,260,000
shares of the Company's common stock in consideration for consulting services. The shares were valued at
$
0.0625
per share, or $
78,687
based on the market price on the date of issuance.
On February 2, 2022, the Company issued
3,182,479
shares of common stock to a note holder in exchange for $
124,117
of principal and accrued interest owed under the terms and conditions
of that
6
%
convertible promissory note as issued to L1 Capital, dated March 30, 2021.
F-
24
Table of Contents
42,666,665
SHARES OF COMMON STOCK
PROSPECTUS
______________,
2022
Neither
we nor the selling stockholders have authorized any dealer, salesperson or other person to give any information or to make any representations
not contained in this prospectus or any prospectus supplement. You must not rely on any unauthorized information. This prospectus is
not an offer to sell these securities in any jurisdiction where an offer or sale is not permitted. The information in this prospectus
is current as of the date of this prospectus. You should not assume that this prospectus is accurate as of any other date.
126
Table of Contents
PART
II
INFORMATION
NOT REQUIRED IN PROSPECTUS
ITEM
13. OTHER EXPENSES OF ISSUANCE AND DISTRIBUTION
The
following table sets forth an estimate of the registrant's expenses, other than any sales commissions or discounts, in connection
with the issuance and distribution of the securities being registered hereby. All amounts are estimates except the SEC registration fee.
Securities and Exchange Commission registration fee
$
[  ]
Accounting fees and expenses
1,000.00
*
Legal fees and expenses
[  ]
*
Miscellaneous
[  ]
*
Total
$
[  ]
*
Indicates
    expenses that have been estimated for filing purposes only.
ITEM
14. INDEMNIFICATION OF DIRECTORS AND OFFICERS
As
authorized by
Section 78.751
of the Nevada Revised Statutes, we may indemnify our officers and directors against expenses incurred
by such persons in connection with any threatened, pending or completed action, suit or proceedings, whether civil, criminal, administrative
or investigative, involving such persons in their capacities as officers and directors, so long as such persons acted in good faith and
in a manner which they reasonably believed to be in our best interests. If the legal proceeding, however, is by or in our right, the
director or officer may not be indemnified in respect of any claim, issue or matter as to which he is adjudged to be liable for negligence
or misconduct in the performance of his duty to us unless a court determines otherwise.
Under
Nevada law, corporations may also purchase and maintain insurance or make other financial arrangements on behalf of any person who is
or was a director or officer (or is serving at our request as a director or officer of another corporation) for any liability asserted
against such person and any expenses incurred by him in his capacity as a director or officer. These financial arrangements may include
trust funds, self-insurance programs, guarantees and insurance policies.
Additionally,
our Bylaws, as amended and restated ("
Bylaws
"), state that we shall indemnify every (i) present or former director,
advisory director or officer of us, (ii) any person who while serving in any of the capacities referred to in clause (i) served at our
request as a director, officer, partner, venturer, proprietor, trustee, employee, agent or similar functionary of another foreign or
domestic corporation, partnership, joint venture, trust, employee benefit plan or other enterprise, and (iii) any person nominated or
designated by (or pursuant to authority granted by) the Board of Directors or any committee thereof to serve in any of the capacities
referred to in clauses (i) or (ii) (each an "
Indemnitee
").
II-
1
Table of Contents
Our
Bylaws provide that we shall indemnify an Indemnitee against all judgments, penalties (including excise and similar taxes), fines, amounts
paid in settlement and reasonable expenses actually incurred by the Indemnitee in connection with any proceeding in which he was, is
or is threatened to be named as a defendant or respondent, or in which he was or is a witness without being named a defendant or respondent,
by reason, in whole or in part, of his serving or having served, or having been nominated or designated to serve, if it is determined
that the Indemnitee (a) conducted himself in good faith, (b) reasonably believed, in the case of conduct in his official capacity, that
his conduct was in our best interests and, in all other cases, that his conduct was at least not opposed to our best interests, and (c)
in the case of any criminal proceeding, had no reasonable cause to believe that his conduct was unlawful; provided, however, that in
the event that an Indemnitee is found liable to us or is found liable on the basis that personal benefit was improperly received by the
Indemnitee, the indemnification (i) is limited to reasonable expenses actually incurred by the Indemnitee in connection with the proceeding
and (ii) shall not be made in respect of any proceeding in which the Indemnitee shall have been found liable for willful or intentional
misconduct in the performance of his duty to us.
Except
as provided above, the Bylaws provide that no indemnification shall be made in respect to any proceeding in which such Indemnitee has
been (a) found liable on the basis that personal benefit was improperly received by him, whether or not the benefit resulted from an
action taken in the Indemnitee's official capacity, or (b) found liable to us. The termination of any proceeding by judgment, order,
settlement or conviction, or on a plea of nolo contendere or its equivalent, is not of itself determinative that the Indemnitee did not
meet the requirements set forth in clauses (a) or (b) above. An Indemnitee shall be deemed to have been found liable in respect of any
claim, issue or matter only after the Indemnitee shall have been so adjudged by a court of competent jurisdiction after exhaustion of
all appeals therefrom. Reasonable expenses shall include, without limitation, all court costs and all fees and disbursements of attorneys'
fees for the Indemnitee. The indemnification provided shall be applicable whether or not negligence or gross negligence of the Indemnitee
is alleged or proven.
Neither
our Bylaws nor our Articles of Incorporation include any specific indemnification provisions for our officers or directors against liability
under the Securities Act. Additionally, insofar as indemnification for liabilities arising under the Securities Act may be permitted
to directors, officers and controlling persons of the Company pursuant to the foregoing provisions, or otherwise, the Company has been
advised that in the opinion of the Securities and Exchange Commission such indemnification is against public policy as expressed in the
Securities Act and is, therefore, unenforceable.
II-
2
Table of Contents
ITEM
15. RECENT SALES OF UNREGISTERED SECURITIES
On
April 12, 2019, the Company issued 18,000,000 shares of the Company common stock to the members of Novopelle Diamond, LLC ("
Novopelle
"),
a Texas limited company, to acquire 100% of the membership interests of Novopelle. The three members of Novopelle Diamond who received
shares pursuant to the Share Exchange Agreement were (1) Jacob D. Cohen; (2) Esteban Alexander; and (3) Luis Alan Hernandez, who each
received six million shares pursuant to the Share Exchange.
On
May 3, 2019, the Company issued 100,000 shares of the Company's common stock to a non-related third-party investor in exchange
for $10,000 in cash.
On
June 21, 2019, the Company issued a promissory note with a principal amount of $40,000 to a related party (the father of the Company's
CEO, Jacob D. Cohen) in exchange for $40,000 in cash. The promissory note is unsecured, has a maturity date of June 21, 2020 and accrues
interest at the rate of 8% per annum until paid in full by the Company. Furthermore, the Company issued 50,000 shares of the Company's
restricted common stock to the related party investor as further consideration to enter into the loan with the Company.
On
June 24, 2019, the issued 250,000 shares of the Company's common stock as part consideration of an exclusive licensing agreement.
The shares were valued at $0.10 per share or $25,000 based on recent sales of common stock to the third party.
On
June 27, 2019, the Company executed an exclusive license agreement with Novo MedSpa Addison Corp ("
Novo MedSpa
") providing
the Company with the exclusive rights to the Novopelle brand and to establish new Novopelle branded MedSpa locations on a worldwide basis
(the "
Exclusive License
"). In consideration for the Exclusive License, the Company paid Novo MedSpa a one-time cash
payment of $40,000 and issued to Novo MedSpa 250,000 shares of the Company's restricted common stock.
On
July 8, 2019, the Company issued a convertible promissory note with a principal amount of $40,000 to a non-related third party in exchange
for $40,000 in cash. The promissory note is unsecured, has a maturity date of July 8, 2020 and accrues interest at the rate of 8% per
annum until paid in full by the Company. In the event that the Company filed, and had qualified by the SEC, an offering Statement under
Regulation A ("
Offering Statement
") of the Securities Act in order to sell shares of its common stock, the holder
of the note had the right to convert all or any portion of the principal amount and interest due on the note into shares of common stock
through the Offering Statement during the term of the Offering Statement, which Offering Statement has been qualified.
On
August 23, 2019, the Company issued 100,000 shares of the Company's common stock in consideration for consulting services. The
shares were valued at $1.50 per share or $150,000 based on the market price on the date of issuance.
On
September 9, 2019, the Company issued 100,000 shares of common stock as part consideration of a loan agreement. The shares were valued
at $1.00 per share or $100,000 based on the market price on the date of issuance.
II-
3
Table of Contents
On
October 1, 2019, the Company entered into an Employment Agreement with Jesse L. Dickens, Jr. to serve as the Chief Executive Officer
of the Company's newly formed wholly owned subsidiary, Capitol City Solutions USA, Inc. ("
CCS
"). Pursuant to
the Employment Agreement, Mr. Dickens will receive an annual base salary of $120,000 and shall receive an equity grant in the amount
of 1,000,000 shares of the Company's common stock (the "
Equity Shares
") pursuant to a vesting period of one-year,
of which: 500,000 shares on January 1, 2020, 250,000 shares on May 22, 2020, and 250,000 shares on July 1, 2020.
On
October 11, 2019, the Company issued 10,000 shares of common stock as part consideration of a loan agreement. The shares were valued
at $1.16 per share or $11,600 based on the market price on the date of issuance.
On
November 1, 2019, the Company issued 300,000 shares of the Company's common stock to eligible persons under the Plan.
On
November 11, 2019, the Company issued 30,000 shares of the Company's common stock to eligible persons under the Plan.
On
February 24, 2020, the Company entered into a Securities Purchase Agreement with Adar Alef, LLC, an accredited investor ("
Adar
Alef
"), pursuant to which the Company sold Adar Alef a convertible promissory note in the principal amount of $157,500, representing
a purchase price of $150,000 and an original issue discount of $7,500, in exchange for $150,000 in cash (less $7,500 of Adar Alef's
legal fees as discussed below)(the "
Adar Alef Note
"). The Adar Alef Note accrues interest at a rate of 8% per annum
(24% upon the occurrence of an event of default) and has a maturity date of February 24, 2021. Adar Alef may in its option, convert the
outstanding principal and interest on the Adar Alef Note into shares of our common stock at a conversion price per share equal to 60%
of the lowest daily volume weighted average price ("
VWAP
") of our common stock during the 10 days trading days prior
to, and including, the date of conversion. The 40% discount discussed above is automatically increased to 50% in the event we experience
a depository trust company 'chill' on our common stock. Additionally, in the event that we are not 'current'
in our filings with the Securities and Exchange Commission, six months after the date of the note, the conversion price decreases to
the lowest closing bid price of our common stock during the delinquency period, less the applicable percentage discount discussed above.
The conversion discount, look back period and other terms of the Adar Alef Note are adjustable on a ratchet basis if the Company offers
any more favorable terms to any other note holder after the date of the Adar Alef Note. At no time may the Adar Alef Note be converted
into shares of our common stock if such conversion would result in Adar Alef and its affiliates owning an aggregate of in excess of 4.99%
of the then outstanding shares of our common stock, which amount may be increased to 9.9% upon 60 days' prior written notice.
II-
4
Table of Contents
On
January 13, 2020, the Company executed a Data Delivery and Ancillary Services Agreement with a third party, pursuant to which the Company
issued 357,142 shares of the Company's restricted common stock to the third party in exchange of sector-specific consumer records
and data to be utilized for marketing purposes provided by the third party and the ancillary advisory services such as data cleaning,
data emailing, lead generation campaigns, social media management. The shares were valued at $0.56 per share or $200,000 based on the
market price at the grant date.
On
January 17, 2020, the Company issued 62,500 shares of restricted common stock to an investor in exchange for $25,000 in cash and $25,000
of principal and interest due under that certain convertible promissory note between the Company and the investor dated August 26, 2019.
The Company received cash of $25,000 on November 26, 2019 which was recorded as common stock payable as of December 31, 2019. The shares
issued to the investor are part of the 10,000,000 shares qualified and registered in connection with the Company, Regulation A offering,
in which the Company offered for sale up to 10,000,000 shares of common stock at $0.50 per share (the "
Offering Statement
").
On
January 24, 2020, the Company issued 400,000 shares of the Company's common stock to eligible persons under the Plan. The shares
were valued at $0.30 per share or $120,000.
On
February 28, 2020, the Company issued 160,000 common shares to an investor in exchange for $46,500 in cash, net of offering costs, and
$30,000 of principal and interest due under that certain convertible promissory note between the Company and the investor dated August
26, 2019. The shares issued to the investor are part of the 10,000,000 Shares offered and registered by the Company under the Offering
Statement.
On
March 11, 2020, the Company issued 100,000 shares of the Company's common stock to eligible persons under the Plan. The shares
were valued at $0.40 per share or $40,000.
On
April 1, 2020, the Company issued 40,000 common shares to an investor in exchange for $20,000 of principal and interest due under that
certain convertible promissory note between the Company and the investor dated October 10, 2019.
On
April 2, 2020, the Company issued 40,000 shares of common stock to an investor in exchange for $20,000 of principal and interest due
under that certain convertible promissory note between the Company and the investor dated October 10, 2019. The shares issued to the
investor are part of the 10,000,000 Shares offered and registered by the Company under the Offering Statement.
On
April 20, 2020, the Company entered into a Securities Purchase Agreement with Geneva Roth Remark Holdings, Inc. ("
Geneva Roth
"),
an accredited investor, pursuant to which the Company sold Geneva Roth a convertible promissory note in the principal amount of $88,000
(the "
Geneva Roth Note
"). The Geneva Roth Note accrues interest at a rate of 8% per annum (22% upon the occurrence
of an event of default) and has a maturity date of April 20, 2021. Geneva Roth may in its option, at any time beginning 180 days after
the date of the note, convert the outstanding principal and interest on the Geneva Roth Note into shares of our common stock at a conversion
price per share equal to 61% of the lowest daily volume weighted average price ("
VWAP
") of our common stock during
the 10 days trading days prior to the date of conversion. We agreed to reserve a number of shares of our common stock equal to 6 times
the number of shares of common stock which may be issuable upon conversion of the Geneva Roth Note at all times. At no time may the Geneva
Roth Note be converted into shares of our common stock if such conversion would result in Geneva Roth and its affiliates owning an aggregate
of in excess of 4.99% of the then outstanding shares of our common stock.
II-
5
Table of Contents
On
April 30, 2020, we entered into a Securities Purchase Agreement with FirstFire Global Opportunities Fund, LLC, an accredited investor
("
FirstFire
"), pursuant to which the Company sold FirstFire a convertible promissory note in the principal amount
of $105,000, representing a purchase price of $100,000 and an original issue discount of $5,000 (the "
FirstFire Note
").
The FirstFire Note accrues interest at a rate of 8% per annum (15% upon the occurrence of an event of default) and has a maturity date
of April 30, 2021. FirstFire may in its option, at any time, convert the outstanding principal and interest on the FirstFire Note into
shares of our common stock at a conversion price per share equal to $0.50 per share for the first 180 days that the FirstFire Note is
outstanding and the lower of (a) $0.50 per share; and (b) 60% of the lowest VWAP of our common stock during the 10 days trading days
prior to the date of conversion (the "
Variable Conversion Rate
"), thereafter, subject to adjustment in the case of
certain fundamental transactions. In the event we have a DTC "
Chill
" on our shares, an additional discount of 10%
will apply to the Variable Conversion Rate while that "
Chill
" is in effect. The FirstFire Note includes anti-dilution
protection such that if we, at any time while the note is outstanding, issue any shares or are deemed to have issued any shares at a
price per share less than the applicable conversion price of such FirstFire Note, then FirstFire has the option to reduce such conversion
price to such lower price, subject to certain exceptions. The conversion discount of the Variable Conversion Rate of the FirstFire Note
is adjustable upward by 15% (cumulative for the occurrence of each such event) upon the occurrence of certain events described in the
FirstFire Note including in the event (a) our common stock cannot be delivered via DWAC; (b) we cease to report with the Securities and
Exchange Commission; (c) we fail to maintain DTC eligibility; (d) the conversion price is below $0.01 per share; (e) we do not have sufficient
authorized shares to allow for any conversion; and (f) certain other events described in the FirstFire Note occur. In addition, upon
the occurrence of any events described in the immediately preceding sentence (and after each such event), FirstFire can increase the
amount of the FirstFire Note by $10,000. At no time may the FirstFire Note be converted into shares of our common stock if such conversion
would result in FirstFire and its affiliates owning an aggregate of in excess of 4.99% of the then outstanding shares of our common stock,
which amount may be increased to 9.9% upon 60 days' prior written notice.
On
May 15, 2020, the Company entered into a Securities Purchase Agreement (the "
SPA
") with Global Career Networks Inc,
a Delaware corporation (the "
Seller
"), the sole owner of Life Guru, Inc., a Delaware corporation ("
Life Guru
").
Pursuant to the SPA, the Company acquired a 51% interest in Life Guru from the Seller. Life Guru owns the website www.LifeGuru.me –
a website dedicated to providing an online platform to connect consumers to a variety of mentors, professionals, life coaches and career
coaches, which was under development. As consideration for the purchase of the 51% ownership interest in Life Guru, the Company issued
the Seller 500,000 shares of its newly designated Series B Convertible Preferred Stock, which had an agreed upon value of $500,000 ($1.00
per share), and agreed to issue the Seller up to an additional 1,500,000 shares of Series B Convertible Preferred Stock (with an agreed
upon value of $1,500,000) upon the following milestones, provided that such milestones are met prior to the earlier of (i) May 15, 2021;
and (ii) thirty (30) days after the Company has provided the Seller written notice of a breach by the Seller of any provision of the
SPA, which breach has not been reasonably cured within a thirty (30) day period:
(a)
500,000 Series B Convertible Preferred Stock shares upon completion of the fully operational LifeGuru.me website;
II-
6
Table of Contents
(b)
500,000 Series B Convertible Preferred Stock shares upon such time as 300 coaches have signed up at LifeGuru.me; and
(c)
500,000 Series B Convertible Preferred Stock shares upon such time as 1,000 coaches have signed up at LifeGuru.me.
Each
share of Series B Preferred Stock may be converted, at the option of the holder thereof, into that number of shares of common stock of
the Company as equals $1.00 divided by 90% of the average of the volume weighted average prices of the Company's common, for the
five trading days immediately preceding the date the notice of conversion is received, with any remainder rounded to the hundredths place.
Notwithstanding
the above, at no time may the Series B Preferred Stock be converted into shares of our common stock by any holder, if such conversion
would result in such holder thereof and its affiliates owning an aggregate of in excess of 4.999% of the then outstanding shares of our
common stock, which amount may be increased to 9.999% on a per holder basis, upon 61 days' prior written notice.
On
May 20, 2020, the Company issued one share of its newly designated shares of Series A Preferred Stock, to each of the three members of
its then board of directors, (1) Jacob D. Cohen, (2) Esteban Alexander and (3) Luis Alan Hernandez, in consideration for services rendered
to the Company as members of the board of directors. Such shares of Series A Preferred Stock vote in aggregate sixty percent (60%) of
the total vote on all shareholder matters, voting separately as a class. Notwithstanding such voting rights, no change in control of
the Company was deemed to have occurred in connection with the issuance since Messrs. Cohen, Alexander and Hernandez, owned in aggregate
68% of the Company's outstanding common stock prior to such issuance, and therefore controlled the Company prior to such issuance.
On
May 19, 2020, the Company entered into a Securities Purchase Agreement with Geneva Roth, pursuant to which the Company sold Geneva Roth
a convertible promissory note in the principal amount of $53,000 (the "
Geneva Roth Note #2
"). The Geneva Roth Note
#2 accrues interest at a rate of 8% per annum (22% upon the occurrence of an event of default) and has a maturity date of May 19, 2021.
Geneva Roth may in its option, at any time beginning 180 days after the date of the note, convert the outstanding principal and interest
on the Geneva Roth Note #2 into shares of our common stock at a conversion price per share equal to 61% of the lowest daily volume weighted
average price of our common stock during the 10 days trading days prior to the date of conversion. At no time may the Geneva Roth Note
#2 be converted into shares of our common stock if such conversion would result in Geneva Roth and its affiliates owning an aggregate
of in excess of 4.99% of the then outstanding shares of our common stock.
II-
7
Table of Contents
On
May 22, 2020, (a) in consideration for Mr. Jacob D. Cohen's past services rendered as President and Chief Executive Officer of
the Company, and in further consideration of the liability he has incurred in his capacity as President and Chief Executive Officer of
the Company, and (b) in consideration for Mr. Esteban Alexander's past services rendered as Chief Operating Officer of the Company,
and in further consideration of the liability he has incurred in his capacity as Chief Operating Officer of the Company, the Company
issued Mr. Cohen and Mr. Alexander each a one-time bonus of 3,000,000 shares of the Company's restricted common stock (6,000,000
in total), which shares vested immediately.
On
June 2, 2020, the Company issued 2,083,333 shares of the Company's common stock to Global Career Networks Inc, a Delaware corporation
(the "
GCN
") in connection with the conversion of 500,000 shares of Series B Convertible Preferred stock into common
stock. The shares were valued at $0.24 per share or $500,000.
On
June 4, 2020, the Company issued 50,000 common shares to an investor in exchange for $6,600 of principal and interest due under that
certain convertible promissory note between the Company and the investor dated October 28, 2019.
On
June 8, 2020, the Company issued 125,000 shares of the Company's common stock to eligible persons under the Plan. The shares were
valued at $0.27 per share or $33,750.
On
July 27, 2020, the Company issued 1,030,808 restricted common shares to an investor in exchange for $77,929 of principal and accrued
interest owed under the terms and conditions of that convertible note as issued to Fourth Man, LLC dated October 28, 2019. After this
conversion, the balance owed under the convertible note is $0.
On
July 27, 2020, the Company issued 1,119,309 restricted common shares to an investor in exchange for $84,620 of principal and accrued
interest owed under the terms and conditions of that convertible note as issued to Armada Capital Partners, LLC dated October 28, 2019.
After this conversion, the balance owed under the convertible note is $0.
On
July 27, 2020, the Company issued 1,119,309 restricted common shares to an investor in exchange for $84,620 of principal and accrued
interest owed under the terms and conditions of that convertible note as issued to BHP Capital NY, Inc. dated October 28, 2019. After
this conversion, the balance owed under the convertible note is $0.
II-
8
Table of Contents
On
June 8, 2020, the Company issued 125,000 shares of the Company's common stock to eligible persons under the 2019 Stock Option and
Incentive Plan (the "
Plan
"). The shares were valued at $0.27 per share or $33,750.
On
August 5, 2020, we entered into a Securities Purchase Agreement with Geneva Roth Remark Holdings, Inc., an accredited investor, pursuant
to which the Company sold Geneva Roth a convertible promissory note in the principal amount of $53,000 (the "
Geneva Roth Note
#3
"). The Geneva Roth Note #3 accrues interest at a rate of 8% per annum (22% upon the occurrence of an event of default) and
has a maturity date of November 5, 2021. Geneva Roth may in its option, at any time beginning 180 days after the date of the note, convert
the outstanding principal and interest on the Geneva Roth Note #3 into shares of our common stock at a conversion price per share equal
to 61% of the lowest daily volume weighted average price of our common stock during the 10 days trading days prior to the date of conversion.
We agreed to reserve a number of shares of our common stock equal to the number of shares of common stock which may be issuable upon
conversion of the Geneva Roth Note #3 at all times. At no time may the Geneva Roth Note #3 be converted into shares of our common stock
if such conversion would result in Geneva Roth and its affiliates owning an aggregate of in excess of 4.99% of the then outstanding shares
of our common stock.
On
August 11, 2020, we sold LGH Investments, LLC ("
LGH
") a convertible promissory note in the principal amount of $105,000
(the "
LGH Note
"). The LGH Note included a $5,000 originally issuance discount. The LGH Note accrues interest at a
rate of 8% per annum (22% upon the occurrence of an event of default) and has a maturity date of May 11, 2021. LGH may in its option,
at any time convert the outstanding principal and interest on the LGH Note into shares of our common stock at a conversion price per
share equal to the lesser of (a) $0.50 per share; and (b) 60% of the lowest daily volume weighted average price of the Company's
common stock on the ten trading days prior to the date of conversion. We agreed to reserve a number of shares of our common stock equal
to three times the number of shares of common stock which may be issuable upon conversion of the LGH Note at all times. At no time may
the LGH Note be converted into shares of our common stock if such conversion would result in LGH and its affiliates owning an aggregate
of in excess of 4.99% of the then outstanding shares of our common stock, provided that such percentage automatically increases to 9.99%
if our market capitalization falls below $2.5 million.
On
August 21, 2020, the Company issued 330,689 common shares to an investor in exchange for $25,000 of principal and accrued interest owed
under the terms and conditions of that convertible note as issued to GHS Investments, LLC dated October 10, 2019.
On
August 24, 2020, the Company issued 895,722 common shares to an investor in exchange for $109,278 of principal and accrued interest owed
under the terms and conditions of that promissory note as issued to Isaak Cohen (the father of our Chief Executive Officer and director,
Jacob D. Cohen), dated September 9, 2019. After this conversion, the balance owed under the promissory note is $0.
II-
9
Table of Contents
On
August 26, 2020, the Company issued 242,407 common shares to an investor in exchange for $31,792 of principal and accrued interest owed
under the terms and conditions of that promissory note as issued to Bradley Stewart, dated May 17, 2019. After this conversion, the balance
owed under the promissory note is $0.
On
August 28, 2020, the Company issued 895,722 common shares to settle a Note with an unrelated party. The shares were valued at $0.33 per
share based on the market price at the settlement date.
On
September 8, 2020, the Company issued 330,689 common shares to an investor in exchange for $25,000 of principal and accrued interest
owed under the terms and conditions of that convertible note, dated October 15, 2019. After this conversion, the balance owed under the
convertible note is $33,888.
On
September 14, 2020, the Company entered into a Securities Purchase Agreement with Geneva Roth, pursuant to which the Company sold Geneva
Roth a convertible promissory note in the principal amount of $53,000 (the "
Geneva Roth Note #4
"). The Geneva Roth
Note #4 accrues interest at a rate of 8% per annum (22% upon the occurrence of an event of default) and has a maturity date of December
14, 2021. Geneva Roth may in its option, at any time beginning 180 days after the date of the note, convert the outstanding principal
and interest on the Geneva Roth Note #4 into shares of our common stock at a conversion price per share equal to 61% of the average of
the two lowest daily volume weighted average prices of our common stock during the 10 days trading days prior to the date of conversion.
At no time may the Geneva Roth Note #4 be converted into shares of our common stock if such conversion would result in Geneva Roth and
its affiliates owning an aggregate of in excess of 4.99% of the then outstanding shares of our common stock.
On
October 8, 2020, the Company issued 125,000 shares of the Company's common stock to eligible persons under the Plan. The shares
were valued at $0.27 per share or $33,750.
On
October 12, 2020, the Company issued 136,687 common shares to an investor in exchange for $12,818 of principal and accrued interest owed
under the terms and conditions of that convertible note as issued to Adar Alef, LLC, dated February 24, 2020.
II-
10
Table of Contents
On
October 12, 2020, the Company entered into a Securities Purchase Agreement with Quick Capital LLC an accredited investor ("
Quick
Capital
"), pursuant to which the Company sold Quick Capital a convertible promissory note in the principal amount of $56,750
(the "
Quick Capital Note
") in consideration for a $52,750 payment. The principal amount of the Quick Capital Note
includes an advancement of legal fees equal to Quick Capital of $2,750 and carries a lump-sum interest payment for the entire twelve
(12) months of the note, at eight percent (8%) per annum, equal to $4,000 which was capitalized upon the entry into the note. The Quick
Capital Note has a maturity date of October 12, 2021. Among other requirements, the Securities Purchase Agreement requires us to cause
the par value of our common stock to be reduced below $0.00001, if the closing bid price of our common stock shall ever fall below $0.0001
per share. Upon an event of default, the Quick Capital Note accrues interest at the lesser of 24% per annum and the highest rate provided
by law. Quick Capital may in its option, at any time after the date of the note, convert the outstanding principal and interest on the
Quick Capital Note into shares of our common stock at a conversion price per share equal to the lesser of a) $0.50 per share, b) 60%
(the "
Discount
") of the lowest daily volume weighted average price per share of our common stock during the 10 days
trading days prior to the date of conversion; and c) 60% of the lowest daily VWAP of our common stock during the 10 days trading days
prior to the date of the Quick Capital Note. The conversion price is adjustable downward if within three business days of the date of
any conversion notice, the Company's common stock has a closing bid price 5% or lower than the conversion rate set forth in the
notice of conversion. The Discount decreases by 10% in the event the Company's common stock is not eligible to be delivered via
DWAC and decreases by an additional 15% if the Company's common stock is 'chilled' by the DTC system (while such 'chill
is in place'). Separately, if the Company ceases to be a reporting company or the note cannot be converted into free trading shares
181 days after the date of the note, the Discount decreases by an additional 15%. Quick Capital can deduct $750 from each conversion
amount to cover its deposit fees. The conversion rate is also subject to a favored nations provision (subject to certain exceptions),
allowing Quick Capital to use any more favorable conversion terms of other parties converting securities of the Company. The conversion
rate is also further adjustable in the event of the occurrence of certain major transaction announcements. In the event the conversion
price falls below $0.01 per share at any time, the Discount is lowered to 40% and $15,000 is added to the principal amount of the note.
We are also required to pay certain penalties in the event we fail to timely deliver stock upon conversion of the Quick Capital Note.
At no time may the Quick Capital Note be converted into shares of our common stock if such conversion would result in Quick Capital and
its affiliates owning an aggregate of in excess of 4.99% of the then outstanding shares of our common stock.
On
October 12, 2020, the Company issued 136,687 common shares to an investor in exchange for $12,818 of principal and accrued interest owed
under the terms and conditions of that convertible note as issued to Adar Alef, LLC, dated February 24, 2020.
On
October 19, 2020, the Company issued 323,322 common shares to an investor in exchange for $18,682 of principal and accrued interest owed
under the terms and conditions of that convertible note as issued to Adar Alef, LLC, dated February 24, 2020.
On
October 21, 2020, the Company issued 416,667 common shares to an investor in exchange for $30,000 of principal and accrued interest owed
under the terms and conditions of that convertible note as issued to GHS Investments, LLC, dated October 10, 2020.
On
October 26, 2020, the Company issued 340,716 common shares to an investor in exchange for $20,000 of principal and accrued interest owed
under the terms and conditions of that convertible note as issued to Geneva Roth Remark Holdings, Inc., dated April 20, 2020.
II-
11
Table of Contents
On
November 3, 2020, the Company issued 520,833 common shares to an investor in exchange for $26,000 of principal and accrued interest owed
under the terms and conditions of that convertible note as issued to Adar Alef, LLC, dated February 24, 2020.
On
November 3, 2020, the Company issued 492,126 common shares to an investor in exchange for $20,000 of principal and accrued interest owed
under the terms and conditions of that convertible note as issued to Geneva Roth, dated April 20, 2020.
On
November 9, 2020, the Company issued 688,976 common shares to an investor in exchange for $20,000 of principal and accrued interest owed
under the terms and conditions of that convertible note as issued to Geneva Roth, dated April 20, 2020.
On
November 10, 2020, the Company issued 721,154 common shares to an investor in exchange for $36,000 of principal and accrued interest
owed under the terms and conditions of that convertible note as issued to Adar Alef, LLC, dated February 24, 2020.
On
November 13, 2020, the Company issued 480,769 common shares to an investor in exchange for $24,000 of principal and accrued interest
owed under the terms and conditions of that convertible note as issued to Adar Alef, LLC, dated February 24, 2020.
On
November 22, 2020, the Company issued 480,000 common shares to an investor in exchange for $25,000 of principal and accrued interest
owed under the terms and conditions of that certain convertible note as issued to FirstFire Global Opportunities Fund LLC, dated April
30, 2020.
On
December 2, 2020, the Company entered into a Securities Purchase Agreement with Geneva Roth, pursuant to which the Company sold Geneva
Roth a convertible promissory note in the principal amount of $83,000 (the "
Geneva Roth Note #5
"). The Geneva Roth
Note #5 accrues interest at a rate of 8% per annum (22% upon the occurrence of an event of default) and has a maturity date of March
2, 2022. Geneva Roth may in its option, at any time beginning 180 days after the date of the note, convert the outstanding principal
and interest on the Geneva Roth Note #5 into shares of our common stock at a conversion price per share equal to 61% of the average of
the two lowest daily volume weighted average prices of our common stock during the 10 days trading days prior to the date of conversion.
At no time may the Geneva Roth Note #5 be converted into shares of our common stock if such conversion would result in Geneva Roth and
its affiliates owning an aggregate of in excess of 4.99% of the then outstanding shares of our common stock.
On
December 2, 2020, the Company issued 716,527 common shares to an investor in exchange for $35,769 of principal and accrued interest owed
under the terms and conditions of that convertible note as issued to GHS Investments, LLC, dated October 10, 2020.
II-
12
Table of Contents
On
December 2, 2020, the Company issued 889,054 common shares to an investor in exchange for $40,000 of principal and accrued interest owed
under the terms and conditions of that convertible note as issued to Adar Alef, LLC, dated February 24, 2020.
On
December 2, 2020, the Company issued 622,000 common shares to an investor in exchange for $31,100 of principal and accrued interest owed
under the terms and conditions of that convertible note as issued to GreenTree Financial Group, Inc., dated August 26, 2019.
On
December 2, 2020, the Company issued 1,031,000 common shares to an investor in exchange for $84,200 of principal and accrued interest
owed under the terms and conditions of that convertible note as issued to FirstFire Global Opportunities Fund LLC, dated April 30, 2020.
On
December 12, 2020, the Company issued 2,501,378 common shares to an investor in exchange for $195,108 of principal and accrued interest
owed under the terms and conditions of that promissory note as issued to Daniel Dror, dated April 12, 2019.
On
December 12, 2020, the Company issued 412,580 common shares to an investor in exchange for $35,000 of principal and accrued interest
owed under the terms and conditions of that convertible note as issued to Geneva Roth, dated April 20, 2020.
On
December 18, 2020, the Company issued 297,900 common shares to an investor in exchange for $25,968 of principal and accrued interest
owed under the terms and conditions of that convertible note as issued to Geneva Roth, dated April 20, 2020.
On
December 18, 2020, the Company issued 975,117 common shares to an investor in exchange for $85,000 of principal and accrued interest
owed under the terms and conditions of that promissory note as issued to Daniel Dror, dated April 12, 2019.
On
December 18, 2020, the Company issued 500,000 shares of the Company's common stock in consideration for consulting services. The
shares were valued at $0.08 per share, or $40,000 based on the market price on the date of issuance.
On
December 30, 2020, the Company issued 683,791 common shares to an investor in exchange for $86,217 of principal and accrued interest
owed under the terms and conditions of that convertible note as issued to Geneva Roth, dated May 19, 2020.
On
December 30, 2020, the Company issued 889,979 common shares to an investor in exchange for $72,657 of principal and accrued interest
owed under the terms and conditions of that promissory note as issued to David Morales, dated October 18, 2019.
II-
13
Table of Contents
On
December 30, 2020, the Company issued 376,704 common shares to an investor in exchange for $30,777 of principal and accrued interest
owed under the terms and conditions of that promissory note as issued to Asia Pacific Partners, Inc., dated June 24, 2020.
On
January 6, 2021 (the "
Closing Date
"), the Company closed the transactions contemplated by a Securities Purchase Agreement
dated January 6, 2021 (the "
Purchase Agreement
"), which was entered into with a group of accredited institutional
investors (collectively, the "
Investors
"), for the sale of convertible promissory notes. Pursuant to the Purchase
Agreement, the Company agreed to sell 6% Original Issue Discount Senior Secured Convertible Promissory Notes in an aggregate principal
amount of $1,450,000 (the "
Notes
") and warrants to purchase up to an aggregate of 6,750,000 shares of the Company's
common stock (the "
Warrants
") to the Investors and entered into a Security Agreement, a Guaranty Agreement, a Pledge
Agreement, and a Registration Rights Agreement (the foregoing, collectively with the Purchase Agreement, Notes and Warrant, the "
Transaction
Documents
"). The Purchase Agreement includes indemnification obligations of the Company, requirements for the Company to reserve
three times the number of shares of common stock issuable upon conversion of the Notes and exercise of the Warrants, the right of the
Investors to participate up to 30% in any future equity or debt offering made by the Company in the 12 months after the Closing Date,
a prohibition on the Company selling any shares of common stock or common stock equivalents until 30 days after the Closing Date, subject
to certain exceptions, a one year prohibition on the Company entering into any equity line transaction or variable rate transaction (including
convertible notes with adjustable conversion prices), and a one year prohibition, without the approval of the Investors, of a reverse
or forward stock split.
A
total of $850,000 in Notes (the "
First Tranche Notes
") were sold on the Closing Date, and a total of $600,000 in Notes
(the "
Second Tranche Notes
"), were sold on March 30, 2021. In connection with the sale of the First Tranche Notes,
the Company paid $25,000 of the Investors' legal fees and certain other amounts in expense reimbursements.
The
First Tranche Notes mature on January 7, 2022, and the Second Tranche Notes mature on March 30, 2022, and accrue interest at a rate of
6% per annum (15% upon the occurrence of an event of default) payable to the Investors in cash on a calendar quarterly basis (which changes
to monthly upon the occurrence of an event of default). Each of the Notes contained a 6% original issue discount.
The
First Tranche Notes, Second Tranche Notes and Warrants are described in greater detail in the prospectus which forms a part of this Registration
Statement under Greentree "Securities Purchase Agreement", beginning on page 2.
On
January 12, 2021, the Company issued 708,750 common shares to an investor in exchange for $114,392 of principal and accrued interest
owed under the terms and conditions of that promissory note as issued to LGH Investments, LLC., dated August 11, 2020.
II-
14
Table of Contents
On
January 13, 2021, the Company issued 105,000 shares of the Company's common stock to eligible persons under the Plan. The shares
were valued at $0.40 per share or $40,000.
On
January 21, 2021, the Company agreed to issue 4,000,000 shares of common stock to Mr. Rodriquez under the terms of his employment agreement,
1,500,000 million shares of common stock to Mr. Bowen under the terms of his employment agreement and 1,000,000 shares to the Company's
legal counsel under the terms of the reduced fee agreement. The securities issued to the Company's legal counsel are subject to
a two-year lock-up agreement, preventing the sale or transfer of such shares without the written approval of the Company, except to affiliates
of the holder, who agree to be bound by the same terms.
On
January 22, 2021, Mr. Jacob D. Cohen, as the sole member of the Board of Directors of the Company, approved the issuance to himself,
in consideration for services rendered as the sole officer and director of the Company, of 2,500,000 shares of restricted common stock.
The securities are subject to a two-year lock-up agreement, preventing the sale or transfer of such shares without the written approval
of the Company, except to affiliates of the holder, who agree to be bound by the same terms.
On
January 22, 2021, the Company issued 400,000 shares of the Company's common stock in consideration for consulting services. The
shares were valued at $0.38 per share, or $152,000 based on the market price on the date of issuance.
On
January 22, 2021, the Company issued 200,000 common shares to an investor in exchange for $94,500 in cash, net of offering costs. The
shares issued to the investor are part of the 10,000,000 Shares offered and registered by the Company under the Offering Statement.
On
February 8, 2021, the Company issued 217,640 common shares to an investor in exchange for $50,275 of principal and accrued interest owed
under the terms and conditions of that 6% convertible promissory note as issued to L1 Capital Global Opportunities Master Fund ("
L1
Capital
"), dated January 7, 2021.
On
February 12, 2021, the Company issued 224,921 common shares to an investor in exchange for $50,000 of principal and accrued interest
owed under the terms and conditions of that 6% convertible promissory note as issued to Cavalry Fund 1, LP ("
Cavalry
"),
dated January 7, 2021.
On
February 26, 2021, the Company issued 500,000 shares of the Company's common stock in consideration for consulting services. The
shares were valued at $0.08 per share, or $142,600 based on the market price on the date of issuance.
On
March 5, 2021, the Company issued 409,333 common shares to an investor in exchange for $75,000 of principal and accrued interest owed
under the terms and conditions of that 6% convertible promissory note as issued to Cavalry, dated January 7, 2021.
II-
15
Table of Contents
On
March 8, 2021, the Company issued to GCN an additional 500,000 shares of Series B Convertible Preferred Stock, which had an agreed upon
value of $500,000 ($1.00 per share) in connection with milestones achieved pursuant to a Securities Purchase Agreement as executed with
GCN on May 15, 2020. Immediately upon issuance, GCN elected to convert the 500,000 shares of Series B Convertible Preferred Stock into
2,057,613 shares of the Company's common stock, at a price of $0.24 per share.
On
March 8, 2021, the Company issued 1,500,000 shares of the Company's common stock in consideration for consulting services. The
shares were valued at $0.27 per share, or $405,000 based on the market price on the date of issuance.
On
March 9, 2021, the Company issued 200,000 shares of the Company's common stock in consideration for consulting services. The shares
were valued at $0.22 per share, or $44,000 based on the market price on the date of issuance.
On
March 18, 2021, the Company issued 451,060 common shares to an investor in exchange for $75,000 of principal and accrued interest owed
under the terms and conditions of that 6% convertible promissory note as issued to Cavalry, dated January 7, 2021.
On
March 19, 2021, the Company issued 872,270 common shares to an investor in exchange for $151,175 of principal and accrued interest owed
under the terms and conditions of that 6% convertible promissory note as issued to L1 Capital, dated January 7, 2021.
On
March 22, 2021, the Company issued 100,000 shares of the Company's common stock in consideration for consulting services. The shares
were valued at $0.28 per share, or $28,000 based on the market price on the date of issuance.
On
March 24, 2021, the Company issued 555,324 common shares to an investor in exchange for $100,000 of principal and accrued interest owed
under the terms and conditions of that 6% convertible promissory note as issued to Cavalry, dated January 7, 2021.
On
April 8, 2021, the Company issued 909,361 common shares to an investor in exchange for $129,925 of principal and accrued interest owed
under the terms and conditions of that 6% convertible promissory note as issued to Cavalry, dated January 7, 2021.
On
April 21, 2021, the Company issued 403,769 common shares to an investor in exchange for $50,875 of principal and accrued interest owed
under the terms and conditions of that 6% convertible promissory note as issued to L1 Capital, dated January 7, 2021.
II-
16
Table of Contents
On
April 28, 2021, the Company issued 485,079 common shares to an investor in exchange for $61,120 of principal and accrued interest owed
under the terms and conditions of that 6% convertible promissory note as issued to L1 Capital, dated January 7, 2021.
On
May 3, 2021, the Company issued 760,928 common shares to an investor in exchange for $56,750 of principal and accrued interest owed under
the terms and conditions of that 8% convertible promissory note as issued to Quick Capital, LLC, dated October 20, 2020.
On
June 24, 2021 (the "
Closing Date
"), American International Holdings Corp (the "
Company
", "
we
"
and "
us
") closed the transactions contemplated by a Securities Purchase Agreement dated June 24, 2021 (the "
Purchase
Agreement
"), which was entered into with two accredited institutional investors (collectively, the "
Investors
"),
for the sale of convertible promissory notes.
On
May 25, 2021, the Company issued 538,505 common shares to an investor in exchange for $51,158 of principal and accrued interest owed
under the terms and conditions of that 6% convertible promissory note as issued to L1 Capital, dated January 7, 2021.
On
June 22, 2021, the Company issued 703,252 common shares to an investor in exchange for $66,809 of principal and accrued interest owed
under the terms and conditions of that 6% convertible promissory note as issued to L1 Capital, dated January 7, 2021.
On
June 24, 2021, the
Company
closed the transactions contemplated by a Securities Purchase Agreement dated June 24, 2021 (the "
Purchase
Agreement
"), which was entered into with two accredited institutional investors (collectively, the "
Investors
"),
for the sale of convertible promissory notes.
Pursuant
to the Purchase Agreement, the Company agreed to sell 6% Original Issue Discount Senior Secured Convertible Promissory Notes in an aggregate
principal amount of $537,916 (the "
Notes
") and warrants to purchase up to an aggregate of 2,670,000 shares of the
Company's common stock (the "
Warrants
") to the Investors and entered into a Registration Rights Agreement (the
foregoing, collectively with the Purchase Agreement, Notes and Warrant, the "
Transaction Documents
"). The Purchase
Agreement includes indemnification obligations of the Company, requirements for the Company to reserve three times the number of shares
of common stock issuable upon conversion of the Notes and exercise of the Warrants, the right of the Investors to participate up to 30%
in any future equity or debt offering made by the Company in the 12 months after the Closing Date, a prohibition on the Company selling
any shares of common stock or common stock equivalents until 30 days after the Closing Date, subject to certain exceptions, a one year
prohibition on the Company entering into any equity line transaction or variable rate transaction (including convertible notes with adjustable
conversion prices), and a one year prohibition, without the approval of the Investors, of a reverse or forward stock split. A total of
$537,916 in Notes (the "
Notes
") were sold on the Closing Date.
II-
17
Table of Contents
On
July 6, 2021, the Company issued 165,000 shares of the Company's common stock in consideration for consulting services. The shares
were valued at $0.11 per share, or $18,150 based on the market price on the date of issuance.
On
July 29, 2021, the Company issued 750,000 shares of the Company's common stock in consideration for consulting services. The shares
were valued at $0.10 per share, or $75,000 based on the market price on the date of issuance.
On
August 11, 2021, the Company issued 881,310 common shares to an investor in exchange for $51,116 of principal and accrued interest owed
under the terms and conditions of that 6% convertible promissory note as issued to L1 Capital, dated March 30, 2021.
On
August 23, 2021, the Company issued 490,000 common shares to an investor in exchange for $25,088 of principal and accrued interest owed
under the terms and conditions of that 6% convertible promissory note as issued to FirstFire Global, dated June 24, 2021.
On
September 1, 2021, the Company issued 607,903 common shares to an investor in exchange for $30,000 of principal owed under the terms
and conditions of that 6% convertible promissory note as issued to Quick Capital, LLC, dated June 24, 2021.
On
September 17, 2021, the Company issued 1,070,091 common shares to an investor in exchange for $50,000 of principal owed under the terms
and conditions of that 6% convertible promissory note as issued to Quick Capital, LLC, dated June 24, 2021.
Between
November 22, 2021 and December 2, 2021, we entered into four separate Securities Purchase Agreements with four accredited institutional
investors, for the sale of convertible promissory notes in an aggregate principal amount of $2,000,000 and warrants to purchase an aggregate
of 13,333,332 shares of the Company's common stock. J.H. Darbie & Co., Inc. acted as placement agent for the offering and was
paid a total of $188,000 in placement agent fees of which $98,000 was paid in cash and $90,000 was paid in the form of 1,151,678 shares
of restricted common stock issued by the Company between November 22, 2021 and December 3, 2021.
On
November 29, 2021, the Company issued 476,190 shares of common stock to a note holder in exchange for $30,000 of principal owed under
the terms and conditions of that 6% convertible promissory note as issued to Quick Capital, LLC, dated June 24, 2021.
On
November 30, 2021, the Company issued 600,000 shares of common stock to a note holder in exchange for $37,800 of principal and accrued
interest owed under the terms and conditions of the 6% convertible promissory note as issued to FirstFire Global, dated June 24, 2021.
II-
18
Table of Contents
On
December 7, 2021, the Company issued 588,235 shares of common stock to a note holder in exchange for $30,000 of principal owed under
the terms and conditions of that 6% convertible promissory note as issued to Quick Capital, LLC, dated June 24, 2021.
On
January 5, 2022, the Company issued 1,200,000 shares of common stock to a note holder in exchange for $50,688 of principal and accrued
interest owed under the terms and conditions of the 6% convertible promissory note as issued to FirstFire Global, dated June 24, 2021.
On
January 6, 2022, the Company issued 710,227 common shares to a note holder in exchange for $30,000 of principal owed under the terms
and conditions of that 6% convertible promissory note as issued to Quick Capital, LLC, dated June 24, 2021.
On
January 27, 2022, the Company issued 1,260,000 shares of the Company's restricted common stock in consideration for consulting
services. The shares were valued at $0.0625 per share, or $78,687 based on the market price on the date of issuance.
On
February 2, 2022, the Company issued 3,182,479 shares of common stock to a note holder in exchange for $124,117 of principal and accrued
interest owed under the terms and conditions of that 6% convertible promissory note as issued to L1 Capital, dated March 30, 2021.
On
March 31, 2022, the Company issued 163,043 shares of common stock to Peter Casey Jensen at a price of $.046 per share, or $7,500 based
on the market price on the date of issuance. The shares were issued as consideration for his services as an independent member of the
board of directors for the quarter ended March 31, 2022.
On
March 31, 2022, the Company issued 163,043 shares of common stock to Dr. Kenny Myers at a price of $.046 per share, or $7,500 based on
the market price on the date of issuance. The shares were issued as consideration for his services as an independent member of the board
of directors for the quarter ended March 31, 2022.
On
March 31, 2022, the Company issued 163,043 shares of common stock to Loraine D'Alessio at a price of $.046 per share, or $7,500
based on the market price on the date of issuance. The shares were issued as consideration for her services as an independent member
of the board of directors for the quarter ended March 31, 2022.
On
April 15, 2022, the Company issued 1,000,000 shares of the Company's common stock to eligible persons under the Plan. The shares
were valued at $0.04 per share or $40,000.
*
* * * * * *
II-
19
Table of Contents
The
use of proceeds associated with the above listed sales of unregistered securities was for general working capital purposes.
The
issuances and grants described above, except as otherwise disclosed, or set forth below, were exempt from registration pursuant to Section
4(a)(2), Rule 506 of Regulation D and/or Regulation S of the Securities Act, since the foregoing issuances and grants did not involve
a public offering, the recipients took the securities for investment and not resale, we took take appropriate measures to restrict transfer,
and the recipients were (a) "
accredited investors
"; (b) had access to similar documentation and information as would
be required in a Registration Statement under the Securities Act; (c) were non U.S. persons; and/or (d) were officers or directors of
the Company. The securities are subject to transfer restrictions, and the certificates evidencing the securities contain an appropriate
legend stating that such securities have not been registered under the Securities Act and may not be offered or sold absent registration
or pursuant to an exemption therefrom. The securities were not registered under the Securities Act and such securities may not be offered
or sold in the United States absent registration or an exemption from registration under the Securities Act and any applicable state
securities laws.
We
claim an exemption from registration afforded by Section 3(a)(9) of the Securities Act, for the above conversions, as the securities
were exchanged by the Company with its existing security holders exclusively in transactions where no commission or other remuneration
was paid or given directly or indirectly for soliciting such exchange.
ITEM
16. EXHIBITS
(a)
Exhibits
                                            Pursuant to Item 601 of Regulation S-K:
EXHIBIT
INDEX
Incorporated by Reference
Exhibit No.
Description
Form
File No.
Exhibit
Filing Date
Filed Herewith
2.1
Share Exchange Agreement, dated as of April 12, 2019 by and among American Holdings International Corp., Novopelle Diamond, LLC and the Novopelle Members
8-K
000-50912
2.1
6/7/2019
2.2
Securities Purchase Agreement dated May 15, 2020, by and between American International Holdings Corp., as purchaser and Global Career Networks Inc, as seller, relating to the sale of 51% of Life Guru, Inc.
8-K
000-50912
2.1
5/21/2020
II-
20
Table of Contents
3.1
Articles of Incorporation, as amended
10-K
000-50912
3.1
6/26/2020
3.2
Amended and Restated Certificate of Designations of American International Holdings Corp. Establishing the Designations, Preferences, Limitations and Relative Rights of Its Series A Preferred Stock, filed with the Secretary of State of Nevada on May 18, 2020
8-K
000-50912
3.1
5/21/2020
3.3
Amended and Restated Certificate of Designation of American International Holdings Corp. Establishing the Designation, Preferences, Limitations and Relative Rights of Its Series B Convertible Preferred Stock, filed with the Secretary of State of Nevada on May 18, 2020
8-K
000-50912
3.2
5/21/2020
3.4
Bylaws of Unlimited Coatings Corporation
10-SB/12G
000-50912
3(ii)
8/18/04
4.1
Description of Securities of the Registrant
10-K
000-50912
4.1
3/29/2022
5.1
Opinion and consent of The Loev Law Firm, PC re: the legality of the securities being registered
X
10.1
Exclusive License Agreement, dated as of June 27, 2019 by and among American Holdings International Corp., and Novo MedSpa Addison Corporation
8-K
000-50912
1.1
7/05/2019
10.2***
American Holdings International Corp. 2019 Employee Stock Option Plan, dated July 5, 2019
8-K
000-50912
1.1
7/8/2019
10.3***
Employment Agreement, dated as of October 1, 2019 by and among American Holdings International Corp., and Jesse L. Dickens, Jr.
8-K
000-50912
1.1
10/8/2019
II-
21
Table of Contents
10.4
Asset Purchase Agreement and Promissory Note, dated as of October 18, 2019 by and among Legend Nutrition, Inc. and David Morales.
8-K
000-50912
1.1
11/13/2019
10.5***
Employment Agreement, dated as of October 18, 2019 by and among Legend Nutrition, Inc. and Michael Ladner
8-K
000-50912
1.2
11/13/2019
10.6
Lease Agreement, dated as of November 6, 2019 by and among Novopelle Waterway, Inc. and 20 & 25 Waterway Holdings, LLC
8-K
000-50912
1.1
11/15/2019
10.7
Share Exchange Agreement and Promissory Note, dated as of April 12, 2019, by and between American Holdings International Corp. and Daniel Dror
8-K
000-50912
10.1
6/7/2019
10.8
Share Exchange Agreement and Promissory Note, dated as of April 12, 2019, by and between American Holdings International Corp. and Winfred Fields
8-K
000-50912
10.2
6/7/2019
10.9
Share Exchange Agreement and Promissory Note, dated as of April 12, 2019, by and between American Holdings International Corp. and Everett Bassie
8-K
000-50912
10.3
6/7/2019
10.10
Share Exchange Agreement and Promissory Note, dated as of April 12, 2019, by and between American Holdings International Corp. and Charles Zeller
8-K
000-50912
10.4
6/7/2019
10.11***
Executive Employment Agreement, dated as of April 12, 2019, by and between American Holdings International Corp. and Jacob D. Cohen
8-K
000-50912
10.5
6/7/2019
II-
22
Table of Contents
10.12***
Executive Employment Agreement, dated as of April 12, 2019, by and between American Holdings International Corp. and Esteban Alexander
8-K
000-50912
10.6
6/7/2019
10.13***
Executive Employment Agreement, dated as of April 12, 2019, by and between American Holdings International Corp. and Alan Hernandez
8-K
000-50912
10.7
6/7/2019
10.14***
Financial and Accounting Consulting Agreement, dated as of May 3, 2019, by and between American Holdings International Corp. and Everett Bassie
8-K/A
000-50912
10.8
8/15/2019
10.15***
Sample Stock Option Award and Stock Option Agreement under 2019 Employee Stock Option Plan
S-8
333-232638
4.2
7/12/2020
10.16
$78,750 Convertible Promissory Note dated October 28, 2019 payable to Armada Capital Partners LLC
1-A Pos
024-11080
6.11
12/16/2019
10.17
$78,750 Convertible Promissory Note dated October 28, 2019 payable to Fourth Man LLC
1-A Pos
024-11080
6.11
12/16/2019
10.18
$78,750 Convertible Promissory Note dated October 28, 2019 payable to BHP Capital NY Inc.
1-A Pos
024-11080
6.11
12/16/2019
10.19
Jesse L. Dickens, Jr. employment agreement with Capitol City Solutions USA, Inc. dated October 1, 2019
8-K
024-11080
1.1
10/8/2019
10.20
Legend Nutrition, Inc. Asset Acquisition Agreement and Related Promissory Note dated October 18, 2019
8-K
000-50912
1.1
11/13/2019
10.21***
Employment Agreement between Legend Nutrition, Inc. and Michael Ladner dated October 18, 2019
8-K
000-50912
1.2
11/13/2019
II-
23
Table of Contents
10.22
$75,000 Promissory Note Issued October 11, 2019, evidencing amounts owed to GHS Investments, LLC
1-A Pos
024-11080
6.15
12/16/2019
10.23
Services Agreement and Promissory Note dated August 26, 2019 with Greentree Financial Group, Inc.
1-A Pos
024-11080
6.17
1/9/2019
10.24
$40,000 Promissory Note with Isaak Cohen dated June 21, 2019
1-A Pos
024-11080
6.18
1/9/2019
10.25
$40,000 Promissory Note with Megan Amason dated July 8, 2019
1-A Pos
024-11080
6.19
1/9/2019
10.26
Form of Subscription Agreement for the Company's Regulation A Offering
1-A
024-11080
4.1
9/23/2019
10.27
Securities Purchase Agreement between Adar Alef, LLC and American International Holdings Corp., dated February 24, 2020
8-K
000-50912
10.1
3/4/2020
10.28
Convertible Promissory Note between Adar Alef, LLC and American International Holdings Corp., dated February 24, 2020
8-K
000-50912
10.2
3/4/2020
10.29
Securities Purchase Agreement between Geneva Roth Remark Holdings, Inc. and American International Holdings Corp., dated April 20, 2020
8-K
000-50912
10.1
5/18/2020
10.30
$88,000 Convertible Promissory Note between Geneva Roth Remark Holdings, Inc. and American International Holdings Corp., dated April 20, 2020
8-K
000-50912
10.2
5/18/2020
10.31
Securities Purchase Agreement between FirstFire Global Opportunities Fund LLC and American International Holdings Corp., dated April 30, 2020
8-K
000-50912
10.3
5/18/2020
II-
24
Table of Contents
10.32
$105,000 Convertible Promissory Note between FirstFire Global Opportunities Fund LLC and American International Holdings Corp., dated April 30, 2020
8-K
000-50912
10.4
5/18/2020
10.33
Data Delivery and Ancillary Services Agreement between American International Holdings Corp. and Cicero Transact Group, Inc., dated January 13, 2020
10-Q
000-50912
10.8
7/24/2020
10.34
Securities Purchase Agreement between Geneva Roth Remark Holdings, Inc. and American International Holdings Corp., dated August 5, 2020
10-Q
000-50912
10.9
8/19/2020
10.35
$53,000 Convertible Promissory Note between Geneva Roth Remark Holdings, Inc. and American International Holdings Corp., dated August 5, 2020
10-Q
000-50912
10.10
8/19/2020
10.36
$105,000 Convertible Promissory Note between LGH Investments, LLC and American International Holdings Corp., dated August 11, 2020
10-Q
000-50912
10.11
8/19/2020
10.37
Securities Purchase Agreement between Geneva Roth Remark Holdings, Inc. and American International Holdings Corp., dated September 14, 2020
8-K
000-50912
10.1
10/5/2020
10.38
$53,000 Convertible Promissory Note between Geneva Roth Remark Holdings, Inc. and American International Holdings Corp., dated September 14, 2020
8-K
000-50912
10.2
10/5/2020
10.39
Stock Purchase Agreement dated October 2, 2020, by and between Jacob Cohen and Luis Alan Hernandez
8-K
000-50912
10.1
11/17/2020
10.40
Stock Purchase Agreement dated October 2, 2020, by and between Jacob Cohen and Estaban Alexander
8-K
000-50912
10.2
10/5/2020
II-
25
Table of Contents
10.41
Securities Purchase Agreement between Quick Capital, LLC and American International Holdings Corp., dated October 12, 2020
8-K
000-50912
10.3
11/17/2020
10.42
$56,750 Convertible Promissory Note between Quick Capital, LLC and American International Holdings Corp., dated October 12, 2020
8-K
000-50912
10.4
11/17/2020
10.43
$138,000 Convertible Promissory Note between JSJ Investments, Inc. and American International Holdings Corp., dated November 13, 2020
10-Q
000-50912
10.18
11/20/2020
10.44#
Securities Purchase Agreement dated January 6, 2021, by and between American International Holdings Corp., and the Investors party thereto
8-K
000-50912
10.1
1/12/2021
10.45
Form of 6% Original Issue Discount Secured Convertible Promissory Note dated January 6, 2021, by American International Holdings Corp. in favor of the holders thereof
8-K
000-50912
10.2
1/12/2021
10.46
Form of Warrant to Purchase Common Stock dated January 6, 2021, by American International Holdings Corp. in favor of the holders thereof
8-K
000-50912
10.3
1/12/2021
10.47#
Security Agreement date January 6, 2021, between American International Holdings Corp., VISSIA McKinney, LLC, VISSIA Waterway, Inc., EPIQ MD, Inc., Legend Nutrition, Inc., Life Guru, Inc and ZipDoctor, Inc., and in favor of the debtors named therein and collateral agent set forth therein
8-K
000-50912
10.4
1/12/2021
II-
26
Table of Contents
10.48#
Pledge Agreement dated January 6, 2021, by American International Holdings Corp. in favor of the collateral agent set forth thereof
8-K
000-50912
10.5
1/12/2021
10.49#
Registration Rights Agreement dated January 6, 2021, by American International Holdings Corp. in favor of the investors named thereof
8-K
000-50912
10.6
1/12/2021
10.50#
Subsidiary Guaranty Agreement between American International Holdings Corp., VISSIA McKinney, LLC, VISSIA Waterway, Inc., EPIQ MD, Inc., Legend Nutrition, Inc., Life Guru, Inc and ZipDoctor, Inc., and in favor of the purchasers named therein and collateral agent set forth therein
8-K
000-50912
10.7
1/12/2021
10.51***
January 21, 2021 Employment Agreement between American International Holdings Corp. and Alejandro Rodriquez
8-K
000-50912
10.1
1/26/2021
10.52***
January 21, 2021 Employment Agreement between American International Holdings Corp. and Verdie Bowen
8-K
000-50912
10.2
1/26/2021
10.53
Reduced Fee Agreement between American International Holdings Corp. and The Loev Law Firm, PC dated January 22, 2021
8-K
000-50912
10.3
1/26/2021
10.54
Lock-Up Agreement dated January 22, 2021, between American International Holdings Corp. and the shareholders party thereto
8-K
000-50912
10.4
1/26/2021
10.55
Securities Purchase Agreement dated December 2, 2020, between American International Holdings Corp. and Geneva Roth Remark Holdings, Inc.
8-K/A
000-50912
10.5
1/27/2021
II-
27
Table of Contents
10.56
$83,000 Convertible Promissory Note date dated December 2, 2020, issued by American International Holdings Corp. to Geneva Roth Remark Holdings, Inc.
8-K/A
000-50912
10.6
1/27/2021
10.57
March 8, 2021, Consulting Agreement between American International Holdings Corp. and KBHS, LLC
8-K
000-50912
10.1
3/18/2021
10.58
Form of 6% Original Issue Discount Secured Convertible Promissory Note dated January 6, 2021, by American International Holdings Corp. in favor of the holders thereof
8-K
000-50912
10.3
4/6/2021
10.59#
Securities Purchase Agreement dated June 24, 2021, by and between American International Holdings Corp., and the Investors party thereto
8-K
000-50912
10.1
7/13/2021
10.60
Form of 6% Original Issue Discount Secured Convertible Promissory Note dated June 24, 2021, by American International Holdings Corp. in favor of the holders thereof
8-K
000-50912
10.2
7/13/2021
10.61
Form of Warrant to Purchase Common Stock dated June 24, 2021, by American International Holdings Corp. in favor of the holders thereof
8-K
000-50912
10.3
7/13/2021
10.62#
Registration Rights Agreement dated June 24, 2021, by American International Holdings Corp. in favor of the investors named therein
8-K
000-50912
10.4
7/13/2021
10.63***
American International Holdings Corp. 2021 Equity Incentive Plan
8-K
000-50912
10.1
8/4/2021
II-
28
Table of Contents
10.64
Telemedicine Services Agreement dated August 15, 2021, by and between ZipDoctor, Inc. and Murphy RX, LLC
8-K
000-50912
10.1
8/26/2021
10.65
Form of Securities Purchase Agreement by and between American International Holdings Corp., and each Investor party thereto (November 2021 Offering)
8-K
000-50912
10.1
12/8/2021
10.66
Form of Promissory Note by American International Holdings Corp. in favor of the holders thereof (November 2021 Offering)
8-K
000-50912
10.2
12/8/2021
10.67
Form of Common Stock Purchase Warrant by American International Holdings Corp. in favor of the holders thereof (November 2021 Offering)
8-K
000-50912
10.3
12/8/2021
10.68***
January 12, 2022 Executive Employment Agreement between American International Holdings Corp. and Jacob D. Cohen
8-K
000-50912
10.1
1/18/2022
10.69***
Confidential Employment Offer Letter and Summary of Terms and Conditions dated February 11, 2022, by and between American International Holdings Corp and Craig Hewitt
8-K
000-50912
10.1
2/17/2022
10.70***
Employment Agreement between American International Holdings Corp. and Maja Matthews dated March 4, 2022
8-K
000-50912
10.1
3/08/2022
10.71***
Employment Agreement between American International Holdings Corp. and Sultan Haroon dated March 4, 2022
8-K
000-50912
10.2
3/08/2022
II-
29
Table of Contents
23.1*
Consent of Independent Registered Public Accounting Firm
X
23.2#
Consent of The Loev Law Firm, PC (included in Exhibit 5.1)
24.1*
Power of Attorney (included on signature page)
X
107*
Filing Fee Table
X
*
Filed
    herewith.
***
Indicates
    management contract or compensatory plan or arrangement.
#
Certain schedules and exhibits have been omitted pursuant to Item 601(a)(5) of Regulation S-K. A copy of any omitted schedule or Exhibit
will be furnished supplementally to the Securities and Exchange Commission upon request; provided, however that American International
Holdings Corp. may request confidential treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended, for any
schedule or Exhibit so furnished.
ITEM
17. UNDERTAKINGS
The
undersigned registrant hereby undertakes:
(1)
To file, during any period in which offers or sales are being made, a post-effective amendment to this registration statement to:
(i)
Include any prospectus required by Section 10(a)(3) of the Securities Act;
(ii)
Reflect in the prospectus any facts or events arising after the effective date of the registration statement (or the most recent post-effective
amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in the registration
statement. Notwithstanding the foregoing, any increase or decrease in volume of securities offered (if the total dollar value of securities
offered would not exceed that which was registered) and any deviation from the low or high end of the estimated maximum offering range
may be reflected in the form of prospectus filed with the Commission pursuant to Rule 424(b) if, in the aggregate, the changes in volume
and price represent no more than a 20% change in the maximum aggregate offering price set forth in the "
Calculation of Registration
Fee
" table in the effective registration statement; and
(iii)
Include any material information with respect to the plan of distribution not previously disclosed in the registration statement or any
material change to such information in the registration statement.
(2)
That, for the purpose of determining any liability under the Securities Act of 1933, each such post-effective amendment shall be deemed
to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall
be deemed to be the initial bona fide offering thereof.
II-
30
Table of Contents
(3)
To remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the
termination of the offering.
(4)
That, for the purpose of determining liability under the Securities Act of 1933 to any purchaser each prospectus filed by the registrant
pursuant to Rule 424(b)(3) shall be deemed to be part of the registration statement as of the date the filed prospectus was deemed part
of and included in the registration statement; and each prospectus required to be filed pursuant to Rule 424(b)(2), (b)(5), or (b)(7)
as part of a registration statement in reliance on Rule 430B relating to an offering made pursuant to Rule 415(a)(1)(i), (vii), or (x)
for the purpose of providing the information required by section 10(a) of the Securities Act of 1933 shall be deemed to be part of and
included in the registration statement as of the earlier of the date such form of prospectus is first used after effectiveness or the
date of the first contract of sale of securities in the offering described in the prospectus. As provided in Rule 430B, for liability
purposes of the issuer and any person that is at that date an underwriter, such date shall be deemed to be a new effective date of the
registration statement relating to the securities in the registration statement to which that prospectus relates, and the offering of
such securities at that time shall be deemed to be the initial bona fide offering thereof. Provided, however, that no statement made
in a registration statement or prospectus that is part of the registration statement or made in a document incorporated or deemed incorporated
by reference into the registration statement or prospectus that is part of the registration statement will, as to a purchaser with a
time of contract of sale prior to such effective date, supersede or modify any statement that was made in the registration statement
or prospectus that was part of the registration statement or made in any such document immediately prior to such effective date.
(5)
Insofar as indemnification for liabilities arising under the Securities Act of 1933 may be permitted to directors, officers and controlling
persons of the registrant pursuant to the foregoing provisions, or otherwise, the registrant has been advised that in the opinion of
the Securities and Exchange Commission such indemnification is against public policy as expressed in the Act and is, therefore, unenforceable.
In the event that a claim for indemnification against such liabilities (other than the payment by the registrant of expenses incurred
or paid by a director, officer or controlling person of the registrant in the successful defense of any action, suit or proceeding) is
asserted by such director, officer or controlling person in connection with the securities being registered, the registrant will, unless
in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the
question whether such indemnification by it is against public policy as expressed in the Act and will be governed by the final adjudication
of such issue.
II-
31
Table of Contents
SIGNATURES
Pursuant
to the requirements of the Securities Act of 1933, the registrant has duly caused this registration statement to be signed on its behalf
by the undersigned, thereunto duly authorized, in the city of Plano, State of Texas on the 21
st
day of April 2022.
AMERICAN
    INTERNATIONAL HOLDINGS CORP.
/s/
    Jacob D. Cohen
By:
Jacob
    D. Cohen, Chief Executive Officer, President, Director (Principal Executive Officer)
KNOW
ALL MEN BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints Mr. Jacob D. Cohen with full power
of substitution and authority to act in the absence of the other, as his or her true and lawful attorneys-in-fact and agents, with full
power of substitution and re-substitution for him or her and in his or her name, place and stead, in any and all capacities, to sign
any and all amendments (including post-effective amendments) to this Registration Statement, and to file the same, with all exhibits
thereto, and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact
and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done
in and about the premises, as fully to all intents and purposes as he might or could do in person, hereby ratifying and confirming all
that each of said attorney-in-fact or his substitute or substitutes, may lawfully do or cause to be done by virtue hereof.
Pursuant
to the requirements of the Securities Act of 1933, this Registration Statement has been signed by the following persons in the capacities
and on the dates indicated.
Signature
Title
Date
/s/
    Jacob D. Cohen
Chief
    Executive Officer, President,
April
    21,
2022
Jacob
    D. Cohen
Director
    (Principal Executive Officer)
/s/
    Craig A. Hewitt
Chief
    Financial Officer
April
    21,
2022
Craig
    A. Hewitt
(Principal
    Financial/Accounting Officer)
/s/
    Peter "Casey" Jensen
Director
April
    21,
2022
Peter
                                            "Casey" Jensen
/s/
    Kenny Myers
Director
April
    21,
2022
Kenny
    Myers
/s/
Lorraine D'Alessio
Director
April
    21,
2022
Lorraine
    D'Alessio
II-
32